name,clinical trial,accession number,smiles,categories,unii,cas number,kegg drug,pubchem compound,chemspider,bindingdb,rxnav,chebi,chembl,therapeutic targets database,pharmgkb,zinc
Bivalirudin,phase 4 complete,"DB00006 (BTD00076, EXPT03302, BIOD00076, DB02351)",CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O,"Amino Acids, Peptides, and Proteins / Anticoagulants / Antithrombin Proteins / Antithrombins / Blood and Blood Forming Organs / Enzyme Inhibitors / Hematologic Agents / Peptides / Protease Inhibitors / Proteins / Serine Protease Inhibitors / Serpins / Thrombin Inhibitors",TN9BEX005G,128270-60-0,D03136,16129704.0,10482069.0,50248103.0,60819.0,59173.0,CHEMBL2103749,DAP000542,PA10032,
Leuprolide,phase 4 complete,"DB00007 (BTD00009, BIOD00009)",CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1,"Adrenal Cortex Hormones / Agents Causing Muscle Toxicity / Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Endocrine Therapy / Fertility Agents / Fertility Agents, Female / Gonadotropin Releasing Hormone Receptor Agonist / Gonadotropin Releasing Hormone Receptor Agonists / Gonadotropin-releasing hormone agonist / Gonadotropins / Hormones / Hormones and Related Agents / Hyperglycemia-Associated Agents / Hypothalamic Hormones / Moderate Risk QTc-Prolonging Agents / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Photosensitizing Agents / Pituitary Hormone-Releasing Hormones / Proteins / QTc Prolonging Agents / Reproductive Control Agents",EFY6W0M8TG,53714-56-0,D08113,,571356.0,50369395.0,42375.0,6427.0,CHEMBL1201199,DAP000020,PA450203,
Goserelin,phase 4 complete,"DB00014 (BTD00113, BIOD00113)",CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,"Adrenal Cortex Hormones / Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Drugs that are Mainly Renally Excreted / Endocrine Therapy / Gonadotropin Releasing Hormone Receptor Agonist / Gonadotropin Releasing Hormone Receptor Agonists / Gonadotropin-releasing hormone agonist / Gonadotropins and Antigonadotropins / Hormones / Hormones and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Hypothalamic Hormones / Miscellaneous Therapeutic Agents / Moderate Risk QTc-Prolonging Agents / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary Hormone-Releasing Hormones / Proteins / QTc Prolonging Agents",0F65R8P09N,65807-02-5,D00573,5311128.0,4470656.0,,50610.0,5523.0,CHEMBL1201247,DAP000023,PA164747674,
Gramicidin D,phase 4 complete,"DB00027 (BTD00036, BIOD00036)",CC(C)C[C@@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCCO,"Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Local / Membrane Proteins / P-glycoprotein inhibitors / P-glycoprotein substrates / Peptides / Peptides, Cyclic / Pore Forming Cytotoxic Proteins / Proteins / Throat Preparations",5IE62321P4,1405-97-6,D04369,45267103.0,24623445.0,,5011.0,,CHEMBL557217,DAP001327,PA449808,
Desmopressin,phase 4 complete,"DB00035 (BTD00112, BTD00061, BIOD00112, BIOD00061)",NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O,"Agents that produce hypertension / Amino Acids, Peptides, and Proteins / Antidiuretic Agents / Arginine Vasopressin / Cardiovascular Agents / Coagulants / Drugs that are Mainly Renally Excreted / Factor VIII Activator / Hematologic Agents / Hemostatics / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Increased Coagulation Factor VIII Activity / Increased Coagulation Factor VIII Concentration / Natriuretic Agents / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormones / Pituitary Hormones, Posterior / Posterior Pituitary Lobe Hormones / Proteins / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Vasopressin Analog / Vasopressin and Analogues / Vasopressins",ENR1LLB0FP,16679-58-6,D00291,,4470602.0,50205308.0,3251.0,4450.0,CHEMBL1429,DNC000526,PA449237,
Cetrorelix,phase 4 complete,"DB00050 (BTD00115, APRD00686, BIOD00115)",CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,"Amino Acids, Peptides, and Proteins / Anti-Gonadotropin-Releasing Hormones / Decreased GnRH Secretion / Fertility Agents / Fertility Agents, Female / Gonadotropin Releasing Hormone Receptor Antagonists / Gonadotropin-releasing Hormone Antagonists / Hormone Antagonists / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypothalamic Hormones / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormone-Releasing Hormones / Proteins / Reproductive Control Agents / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",OON1HFZ4BA,120287-85-6,D07665,25074887.0,10482082.0,50369965.0,68147.0,59224.0,CHEMBL1200490,DAP000096,PA164764506,
Vasopressin,phase 4 complete,"DB00067 (BTD00110, BIOD00110, DB09392)",NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(CC2=CC=C(O)C=C2)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O.NC1CSSCC(NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O,"Amino Acids, Peptides, and Proteins / Antidiuretic Agents / Arginine Vasopressin / Arginine Vasopressin, agonists / Arginine Vasopressin, analogs & derivatives / Arginine Vasopressin, antagonists & inhibitors / Cardiovascular Agents / Coagulants / Hematologic Agents / Hemostatics / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Natriuretic Agents / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary / Pituitary Hormones / Pituitary Hormones, Posterior / Proteins / Vasoconstrictor Agents / Vasopressin and Analogues / Vasopressins / Vasopressins, antagonists & inhibitors",Y87Y826H08,11000-17-2,D00101,,10152658.0,,11149.0,,CHEMBL373742,DAP000018,PA451858,
Daptomycin,phase 4 complete,"DB00080 (BTD00111, BIOD00111)",CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=CC=CC=C2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O,"Agents Causing Muscle Toxicity / Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cyclic Lipopeptides / Drugs that are Mainly Renally Excreted / Lipids / Lipopeptide Antibacterial / Lipopeptides / Peptides / Peptides, Cyclic",NWQ5N31VKK,103060-53-3,D01080,16134395.0,10200644.0,,22299.0,600103.0,CHEMBL387675,DAP001328,PA164768820,
Cyclosporine,phase 4 complete,"DB00091 (BTD00003, BIOD00003)",CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,"Agents causing hyperkalemia / Agents Causing Muscle Toxicity / Agents that produce hypertension / Agents that produce neuromuscular block (indirect) / Agents that reduce seizure threshold / Amino Acids, Peptides, and Proteins / Anti-Inflammatory Agents / Antirheumatic Agents / BCRP/ABCG2 Inhibitors / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / Calcineurin Inhibitor Immunosuppressant / Calcineurin Inhibitors / Cyclosporins / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Enzyme Inhibitors / Immunologic Factors / Immunosuppressive Agents / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Neurotoxic agents / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / Ophthalmologicals / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Peptides / Peptides, Cyclic",83HN0GTJ6D,59865-13-3,D00184,5284373.0,4447449.0,50022815.0,3008.0,4031.0,CHEMBL160,DNC001177,PA449167,
Octreotide,phase 4 complete,"DB00104 (BTD00088, BIOD00088)",[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O,"Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Bradycardia-Causing Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Gastrointestinal Agents / Hyperglycemia-Associated Agents / Hypoglycemia-Associated Agents / Hypothalamic Hormones / Miscellaneous Therapeutic Agents / P-glycoprotein substrates / Peptides / Peptides, Cyclic / Pituitary and Hypothalamic Hormones and Analogues / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Somatostatin and Analogues / Somatostatin Receptor Agonists / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",RWM8CCW8GP,83150-76-9,D00442,448601.0,395352.0,50272772.0,7617.0,,CHEMBL1680,DAP000397,PA450678,
Abarelix,phase 4 complete,"DB00106 (BTD00051, BIOD00051)",CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,"Amino Acids, Peptides, and Proteins / Antineoplastic and Immunomodulating Agents / Endocrine Therapy / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Peptides",W486SJ5824,183552-38-7,D02738,16131215.0,10482301.0,50102442.0,301739.0,337298.0,CHEMBL1252,DAP000094,PA164754915,
Pyridoxal phosphate,phase 4 complete,DB00114 (NUTR00045),CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O,"Alimentary Tract and Metabolism / Coenzymes / Diet, Food, and Nutrition / Dietary Supplements / Enzymes and Coenzymes / Food / Food and Beverages / Growth Substances / Micronutrients / Physiological Phenomena / Picolines / Pyridines / Supplements / Vitamin B Complex / Vitamins",F06SGE49M6,54-47-7,D00006,1051.0,1022.0,50118216.0,9004.0,18405.0,CHEMBL82202,DNC001499,PA164749650,ZINC000001532514
CyanocobalaminCommonly known or available as Vitamin B12,phase 4 complete,"DB00115 (NUTR00004, APRD00326, EXPT00965)",C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=NC2=C1C=C(C)C(C)=C2,"Antianemic Preparations / Blood and Blood Forming Organs / Corrinoids / Diet, Food, and Nutrition / Drugs that are Mainly Renally Excreted / Food / Food and Beverages / Growth Substances / Heterocyclic Compounds, Fused-Ring / Iron Preparations / Micronutrients / Vitamin B 12, biosynthesis / Vitamin B Complex / VITAMIN B12 AND FOLIC ACID / Vitamins",P6YC3EG204,68-19-9,D00166,70678590.0,21864832.0,,11248.0,17439.0,CHEMBL2110563,,PA451892,
Ademetionine,phase 4 complete,DB00118 (NUTR00052),C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N,"Alimentary Tract and Metabolism / Amino Acids / Amino Acids and Derivatives / Amino Acids, Essential / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Amino Acids, Sulfur / Carbohydrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Dietary Supplements / Glycosides / Heterocyclic Compounds, Fused-Ring / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / Purine Nucleosides / Purines / Ribonucleosides / Sulfur Compounds / Supplements",7LP2MPO46S,29908-03-0,,34755.0,31982.0,28422.0,9504.0,67040.0,CHEMBL1088977,,PA164754994,
Pyruvic acid,phase 4 complete,"DB00119 (NUTR00050, DB11194)",CC(=O)C(O)=O,Dietary Supplements / Keto Acids / Pyruvates / Supplements,8558G7RUTR,127-17-3,,1060.0,1031.0,19473.0,35161.0,32816.0,CHEMBL1162144,DAP000543,PA164778686,ZINC000001532517
Phenylalanine,phase 4 complete,DB00120 (NUTR00044),N[C@@H](CC1=CC=CC=C1)C(O)=O,"Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Dietary Supplements / Immunosuppressive Agents / Myelosuppressive Agents / Supplements",47E5O17Y3R,63-91-2,D00021,6140.0,5910.0,18073.0,8156.0,17295.0,CHEMBL301523,DAP000807,PA450931,ZINC000000105196
Biotin,phase 4 complete,DB00121 (NUTR00019),[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2,"Alimentary Tract and Metabolism / Coenzymes / Diet, Food, and Nutrition / Dietary Supplements / Enzymes and Coenzymes / Food / Food and Beverages / Growth Substances / Imidazoles / Micronutrients / Physiological Phenomena / Supplements / Vitamin B Complex / Vitamins",6SO6U10H04,58-85-5,D00029,171548.0,149962.0,12.0,1588.0,15956.0,CHEMBL857,,PA448625,ZINC000035024346
Choline,phase 4 complete,DB00122 (NUTR00020),C[N+](C)(C)CCO,Alcohols / Amines / Amino Alcohols / Ammonium Compounds / Analgesics / Antimetabolites / Central Nervous System Agents / Dietary Supplements / Ethanolamines / Gastrointestinal Agents / Hypolipidemic Agents / Lipid Regulating Agents / Lipotropic Agents / Nervous System / Nitrogen Compounds / Nootropic Agents / Noxae / OCT1 inhibitors / OCT1 substrates / OCT2 Inhibitors / OCT2 Substrates / Onium Compounds / Other Nutritional Agents / Quaternary Ammonium Compounds / Salicylic Acid and Derivatives / Supplements / Toxic Actions / Trimethyl Ammonium Compounds / Vitamin B Complex / Vitamins,N91BDP6H0X,62-49-7,D07690,305.0,299.0,50026220.0,2449.0,15354.0,CHEMBL920,,PA448976,ZINC000003079337
L-Lysine,phase 4 complete,"DB00123 (NUTR00037, DB11101)",NCCCC[C@H](N)C(O)=O,"Amino Acids / Amino Acids, Basic / Amino Acids, Diamino / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Dietary Supplements / I.V. Solution Additives / Lysine / Supplements",K3Z4F929H6,56-87-1,D02304,5962.0,5747.0,217367.0,6536.0,18019.0,CHEMBL8085,,PA450280,ZINC000001532522
Ascorbic acidCommonly known or available as Vitamin C,phase 4 complete,"DB00126 (NUTR00001, APRD00084, EXPT00568, DB11167, DB11316, DB11170, DB09541, DB11317)",[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO,"Acids, Acyclic / Alimentary Tract and Metabolism / Antioxidants / Carbohydrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Food / Food and Beverages / Gastrointestinal Acidifying Agents / Genito Urinary System and Sex Hormones / Growth Substances / Gynecological Antiinfectives and Antiseptics / Hydroxy Acids / Micronutrients / Ophthalmologicals / Organic Acids / Physiological Phenomena / Protective Agents / Sensory Organs / Sugar Acids / Urinary Acidifying Agents / Vitamin C and analogues / Vitamins",PQ6CK8PD0R,50-81-7,D00018,54670067.0,10189562.0,50090256.0,1151.0,29073.0,CHEMBL196,DNC000259,PA451898,ZINC000100006770
Aspartic acid,phase 4 complete,"DB00128 (NUTR00016, EXPT01823)",N[C@@H](CC(O)=O)C(O)=O,"Amino Acids / Amino Acids, Acidic / Amino Acids, Dicarboxylic / Amino Acids, Peptides, and Proteins / Dietary Supplements / Excitatory Amino Acids / Supplements",30KYC7MIAI,56-84-8,D00013,5960.0,5745.0,18125.0,1169.0,17053.0,CHEMBL274323,,PA448494,ZINC000000895032
Ornithine,phase 4 complete,DB00129 (NUTR00043),NCCC[C@H](N)C(O)=O,"Alimentary Tract and Metabolism / Amino Acids / Amino Acids, Basic / Amino Acids, Diamino / Amino Acids, Peptides, and Proteins / Bile and Liver Therapy / Dietary Supplements / Liver Therapy / Liver Therapy, Lipotropics / Oligopeptides / Peptides / Supplements",E524N2IXA3,70-26-8,,6262.0,6026.0,,7704.0,15729.0,CHEMBL446143,,PA164783814,ZINC000001532530
L-Glutamine,phase 4 complete,DB00130 (NUTR00026),N[C@@H](CCC(N)=O)C(O)=O,"Alimentary Tract and Metabolism / Amino Acids / Amino Acids and Derivatives / Amino Acids, Basic / Amino Acids, Diamino / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Dietary Supplements / Glutamine / Supplements",0RH81L854J,56-85-9,D00015,5961.0,5746.0,18121.0,4885.0,58359.0,CHEMBL930,,PA10090,ZINC000001532526
Adenosine phosphate,phase 4 complete,"DB00131 (NUTR00011, EXPT00512)",NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1,"Adenine Nucleotides / Carbohydrates / Dietary Supplements / Glycosides / Heterocyclic Compounds, Fused-Ring / Nucleic Acids, Nucleotides, and Nucleosides / Nucleotides / Purine Nucleotides / Purines / Ribonucleotides / Supplements",415SHH325A,61-19-8,D02769,6083.0,5858.0,18137.0,309.0,16027.0,CHEMBL752,DAP001319,PA164744376,ZINC000003860156
alpha-Linolenic acidCommonly known or available as Linolenic acid,phase 4 complete,DB00132 (NUTR00034),CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O,"Diet, Food, and Nutrition / Dietary Fats / Dietary Fats, Unsaturated / Dietary Supplements / Fats / Fatty Acids / Fatty Acids, Essential / Fatty Acids, Omega-3 / Fatty Acids, Unsaturated / Fish Oils / Food / Food and Beverages / Linolenic Acids / Lipids / Oils / Physiological Phenomena / Supplements",0RBV727H71,463-40-1,,5280934.0,4444437.0,50240347.0,52071.0,27432.0,CHEMBL8739,,PA449384,ZINC000003802189
Methionine,phase 4 complete,DB00134 (NUTR00038),CSCC[C@H](N)C(O)=O,"Amino Acids / Amino Acids, Essential / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Amino Acids, Sulfur / Antidotes / Dietary Supplements / Sulfur Compounds / Supplements",AE28F7PNPL,63-68-3,D00019,6137.0,5907.0,50142500.0,6837.0,16643.0,CHEMBL42336,,PA450423,ZINC000001532529
Tyrosine,phase 4 complete,DB00135 (NUTR00059),N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,"Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Dietary Supplements / Supplements",42HK56048U,60-18-4,D00022,6057.0,5833.0,18129.0,10962.0,58315.0,CHEMBL925,DAP000808,PA451822,ZINC000000266964
Calcitriol,phase 4 complete,"DB00136 (NUTR00003, APRD00246, DB05314)",C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,"Alimentary Tract and Metabolism / Antipsoriatics / Antipsoriatics for Topical Use / Bone Density Conservation Agents / Calcium-Regulating Hormones and Agents / Cholestanes / Cholestenes / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Diet, Food, and Nutrition / Food / Food and Beverages / Fused-Ring Compounds / Growth Substances / Lipids / Membrane Lipids / Membrane Transport Modulators / Micronutrients / Misc. Skin and Mucous Membrane Agents / Physiological Phenomena / Secosteroids / Steroids / Sterols / Vitamin D and Analogues / Vitamins / Vitamins (Fat Soluble)",FXC9231JVH,32222-06-3,D00129,5280453.0,4444108.0,50200182.0,1894.0,17823.0,CHEMBL846,DAP000289,PA448717,ZINC000100015048
Lutein,phase 4 complete,"DB00137 (NUTR00036, DB11138)",C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,"Alkenes / Biological Factors / Carotenoids / Cyclohexanes / Cyclohexenes / Cycloparaffins / Dietary Supplements / Hydrocarbons, Acyclic / Pigments, Biological / Polyenes / Supplements / Terpenes / Xanthophylls",X72A60C9MT,127-40-2,,5281243.0,4444655.0,,11359.0,28838.0,CHEMBL173929,,PA164748318,ZINC000008221225
Cystine,phase 4 complete,DB00138 (NUTR00023),N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O,"Acids / Acids, Noncarboxylic / Amino Acids / Amino Acids, Diamino / Amino Acids, Dicarboxylic / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Amino Acids, Sulfur / Anions / Cysteine / Dietary Supplements / Disulfides / Electrolytes / Gases / Hydrogen Sulfide / Ions / Sulfhydryl Compounds / Sulfides / Sulfur Compounds / Supplements",48TCX9A1VT,56-89-3,D03636,67678.0,60997.0,,3036.0,16283.0,CHEMBL590540,,PA449176,ZINC000001532673
Succinic acid,phase 4 complete,DB00139 (NUTR00054),OC(=O)CCC(O)=O,"Acids, Acyclic / Dicarboxylic Acids / Dietary Supplements / OAT3/SLC22A8 Substrates / Succinates / Supplements",AB6MNQ6J6L,110-15-6,,1110.0,1078.0,26121.0,37255.0,15741.0,CHEMBL576,DAP000545,PA164747739,ZINC000000895030
Riboflavin,phase 4 complete,"DB00140 (NUTR00010, APRD00626, EXPT02760, DB09358)",CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1,"Alimentary Tract and Metabolism / Biological Factors / Coenzymes / Dermatologicals / Diet, Food, and Nutrition / Enzymes and Coenzymes / Flavins / Food / Food and Beverages / Growth Substances / Heterocyclic Compounds, Fused-Ring / Micronutrients / OAT1/SLC22A6 inhibitors / Ophthalmologicals / Photosensitizing Agents / Physiological Phenomena / Pigments, Biological / Pteridines / Radiation-Sensitizing Agents / Sensory Organs / Vitamin B Complex / Vitamins",TLM2976OFR,83-88-5,D00050,493570.0,431981.0,50362895.0,9346.0,17015.0,CHEMBL1534,,PA451242,ZINC000002036848
N-Acetylglucosamine,phase 4 complete,DB00141 (NUTR00040),[H]C(=O)[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@H](O)CO,Dietary Supplements / Supplements,V956696549,7512-17-6,,1738118.0,1376695.0,50223349.0,1362871.0,17411.0,CHEMBL447878,DAP000872,PA164752287,ZINC000002077807
Glutamic acid,phase 4 complete,DB00142 (NUTR00027),N[C@@H](CCC(O)=O)C(O)=O,"Acid Preparations / Alimentary Tract and Metabolism / Amino Acids / Amino Acids, Acidic / Amino Acids, Dicarboxylic / Amino Acids, Peptides, and Proteins / Dietary Supplements / Digestives, Incl. Enzymes / Excitatory Amino Acids / Gastrointestinal Acidifying Agents / Gastrointestinal Agents / Glutamates / Supplements",3KX376GY7L,56-86-0,D00007,33032.0,30572.0,17657.0,25916.0,16015.0,CHEMBL575060,DAP000015,PA449776,ZINC000001482113
Glutathione,phase 4 complete,"DB00143 (NUTR00029, EXPT01650)",N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O,"Amino Acids, Peptides, and Proteins / Antidotes / Dietary Supplements / Glutathione, antagonists & inhibitors / Oligopeptides / Peptides / Supplements",GAN16C9B8O,70-18-8,D00014,124886.0,111188.0,50422268.0,4890.0,16856.0,CHEMBL1543,,PA449780,ZINC000003830891
Phosphatidyl serine,phase 4 complete,DB00144 (NUTR00048),CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O,Alcohols / Carbohydrates / Dietary Supplements / Glycerophosphates / Glycerophospholipids / Lipids / Membrane Lipids / Phosphatidic Acids / Phosphatidylserines / Phospholipids / Sugar Alcohols / Sugar Phosphates / Supplements / Triose Sugar Alcohols,394XK0IH40,1446756-47-3,,6323481.0,13628254.0,,89959.0,18303.0,,,PA164768860,ZINC000012484909
Glycine,phase 4 complete,DB00145 (NUTR00028),NCC(O)=O,"Amino Acids / Amino Acids, Peptides, and Proteins / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Dietary Supplements / Glycine Agents / Irrigating Solutions / Neurotransmitter Agents / Supplements",TE7660XO1C,56-40-6,D00011,750.0,730.0,18133.0,4919.0,15428.0,CHEMBL773,DAP000288,PA449789,ZINC000004658552
Calcifediol,phase 4 complete,"DB00146 (NUTR00006, APRD00428)",C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,"Alimentary Tract and Metabolism / Bone Density Conservation Agents / Cholestanes / Cholestenes / Diet, Food, and Nutrition / Food / Food and Beverages / Fused-Ring Compounds / Growth Substances / Lipids / Membrane Lipids / Micronutrients / Physiological Phenomena / Secosteroids / Steroids / Sterols / Vitamin D and Analogues / Vitamins / Vitamins (Fat Soluble)",T0WXW8F54E,19356-17-3,,5283731.0,4446820.0,,1855064.0,17933.0,CHEMBL1040,DAP000290,PA164745614,ZINC000004474414
Creatine,phase 4 complete,DB00148 (NUTR00022),CN(CC(O)=O)C(N)=N,"Amidines / Amino Acids / Amino Acids, Peptides, and Proteins / Dietary Supplements / Guanidines / Supplements",MU72812GK0,57-00-1,,586.0,566.0,50357229.0,2907.0,16919.0,CHEMBL283800,,PA164778930,ZINC000003861770
Tryptophan,phase 4 complete,"DB00150 (NUTR00058, EXPT02064)",N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O,"Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Antidepressive Agents / Antidepressive Agents, Second-Generation / Central Nervous System Agents / Central Nervous System Depressants / Dietary Supplements / Miscellaneous Antidepressants / Nervous System / Psychoanaleptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Supplements / Tryptophan",8DUH1N11BX,73-22-3,D00020,6305.0,6066.0,21974.0,10898.0,16828.0,CHEMBL54976,DAP001316,PA10323,ZINC000000083315
Cysteine,phase 4 complete,"DB00151 (NUTR00018, DB04443, DB09485)",N[C@@H](CS)C(O)=O,"Amino Acids / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Amino Acids, Sulfur / Caloric Agents / Cysteine / Dietary Supplements / Nutritional Support / Sulfhydryl Compounds / Sulfur Compounds / Supplements",K848JZ4886,52-90-4,D00026,5862.0,5653.0,50109609.0,3024.0,17561.0,CHEMBL863,,PA449173,ZINC000000895042
Thiamine,phase 4 complete,"DB00152 (NUTR00009, APRD00552, EXPT03222)",CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N,"Alimentary Tract and Metabolism / Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Micronutrients / OCT1 substrates / OCT2 Inhibitors / Physiological Phenomena / Pyrimidines / Sulfur Compounds / Thiazoles / Vitamin B Complex / Vitamins",4ABT0J945J,70-16-6,D08580,1130.0,1098.0,50373877.0,10454.0,18385.0,CHEMBL1547,DAP000870,PA451652,ZINC000000049153
Ergocalciferol,phase 4 complete,"DB00153 (NUTR00005, APRD00426)",CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,"Alimentary Tract and Metabolism / Bone Density Conservation Agents / Calcium-Regulating Hormones and Agents / Diet, Food, and Nutrition / Food / Food and Beverages / Fused-Ring Compounds / Growth Substances / Lipids / Micronutrients / Physiological Phenomena / Secosteroids / Vitamin D and Analogues / Vitamins / Vitamins (Fat Soluble)",VS041H42XC,50-14-6,D00187,5280793.0,4444351.0,,4018.0,28934.0,CHEMBL1536,DAP000291,PA449484,ZINC000004629876
Citrulline,phase 4 complete,DB00155 (NUTR00021),N[C@@H](CCCNC(N)=O)C(O)=O,"Amino Acids / Amino Acids, Diamino / Amino Acids, Peptides, and Proteins / Dietary Supplements / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / Proteins / Supplements",29VT07BGDA,372-75-8,D07706,9750.0,9367.0,92903.0,2567.0,16349.0,CHEMBL444814,,PA164747225,ZINC000001532614
Threonine,phase 4 complete,DB00156 (NUTR00057),C[C@@H](O)[C@H](N)C(O)=O,"Amino Acids / Amino Acids, Essential / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Dietary Supplements / Supplements / Threonine, antagonists & inhibitors",2ZD004190S,72-19-5,D00041,6288.0,6051.0,,10524.0,16857.0,CHEMBL291747,,PA451673,ZINC000000895103
NADH,phase 4 complete,"DB00157 (NUTR00041, DB01907, EXPT02287, DB03527)",NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O,"Adenine Nucleotides / Carbohydrates / Coenzymes / Dietary Supplements / Enzymes and Coenzymes / Glycosides / Heterocyclic Compounds, Fused-Ring / Nucleic Acids, Nucleotides, and Nucleosides / Nucleotides / Purine Nucleotides / Purines / Ribonucleotides / Supplements",4J24DQ0916,58-68-4,,439153.0,388299.0,,7222.0,16908.0,,DAP001291,PA164755085,ZINC000008215403
Folic acid,phase 4 complete,DB00158 (NUTR00025),NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1,"Antianemic Preparations / Autacoids / BCRP/ABCG2 Substrates / Biological Factors / Diet, Food, and Nutrition / Dietary Supplements / Drugs that are Mainly Renally Excreted / Folic Acid and Derivatives / Food / Food and Beverages / Growth Substances / Hematinics / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Micronutrients / OAT1/SLC22A6 inhibitors / Pteridines / Pterins / Supplements / Vitamin B Complex / VITAMIN B12 AND FOLIC ACID / Vitamins",935E97BOY8,59-30-3,D00070,6037.0,5815.0,50237629.0,4511.0,27470.0,CHEMBL1622,DAP001309,PA449692,ZINC000008577218
Icosapent,phase 4 complete,DB00159 (NUTR00024),CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,"Agents causing hyperkalemia / Agents that produce hypertension / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Autacoids / Biological Factors / Diet, Food, and Nutrition / Dietary Fats / Dietary Fats, Unsaturated / Dietary Supplements / Eicosanoids / Fats / Fatty Acids / Fatty Acids, Omega-3 / Fatty Acids, Unsaturated / Fish Oils / Food / Food and Beverages / Hypolipidemic Agents / Inflammation Mediators / Lipids / Nephrotoxic agents / Non COX-2 selective NSAIDS / Oils / Physiological Phenomena / Supplements",AAN7QOV9EA,10417-94-4,D08061,446284.0,393682.0,50242349.0,90.0,28364.0,CHEMBL460026,DAP000969,PA164746077,ZINC000004474603
Valine,phase 4 complete,DB00161 (NUTR00060),CC(C)[C@H](N)C(O)=O,"Amino Acids / Amino Acids, Branched-Chain / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Dietary Supplements / Valine",HG18B9YRS7,72-18-4,D00039,6287.0,6050.0,,11115.0,16414.0,CHEMBL43068,,PA451843,ZINC000000895099
Vitamin A,phase 4 complete,"DB00162 (NUTR00007, APRD00486)",C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C,"Adjuvants, Immunologic / Alimentary Tract and Metabolism / Alkenes / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anticarcinogenic Agents / Antioxidants / Biological Factors / Carotenoids / Compounds used in a research, industrial, or household setting / Cyclohexanes / Cyclohexenes / Cycloparaffins / Dermatologicals / Diagnostic Agents / Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Immunologic Factors / Micronutrients / Nasal Preparations / Ophthalmologicals / Physiological Phenomena / Pigments, Biological / Polyenes / Protective Agents / Retinoids / Retinoids for Topical Use in Acne / Sensory Organs / Terpenes / Tests for Fat Absorption / Vitamin A / Vitamins / Vitamins (Fat Soluble)",G2SH0XKK91,68-26-8,D00069,445354.0,393012.0,50092056.0,11246.0,17336.0,CHEMBL986,DNC001498,PA451884,ZINC000003831417
Vitamin E,phase 4 complete,"DB00163 (NUTR00061, EXPT03227)",CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C,"Antioxidants / Basic Ointments and Protectants / Benzopyrans / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Diet, Food, and Nutrition / Dietary Supplements / Food / Food and Beverages / Growth Substances / Heterocyclic Compounds, Fused-Ring / Micronutrients / Physiological Phenomena / Protective Agents / Pyrans / Supplements / Vitamin E / Vitamin E, analogs & derivatives / Vitamins / Vitamins (Fat Soluble)",N9PR3490H9,59-02-9,,14985.0,14265.0,,11256.0,18145.0,CHEMBL47,,PA451900,ZINC000004095858
Pyridoxine,phase 4 complete,"DB00165 (NUTR00002, APRD00204)",CC1=C(O)C(CO)=C(CO)C=N1,"Alimentary Tract and Metabolism / Analogs/Derivatives / Antiinfectives for Systemic Use / Antimycobacterials / Diet, Food, and Nutrition / Drugs for Treatment of Tuberculosis / Drugs that are Mainly Renally Excreted / Food / Food and Beverages / Micronutrients / Picolines / Pyridines / Vitamin B Complex / Vitamins",KV2JZ1BI6Z,65-23-6,,1054.0,1025.0,50103505.0,42954.0,16709.0,CHEMBL1364,DAP000869,PA451897,ZINC000000049154
Lipoic acid,phase 4 complete,DB00166 (NUTR00035),OC(=O)CCCC[C@@H]1CCSS1,"Alimentary Tract and Metabolism / Antioxidants / Coenzymes / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Dietary Supplements / Enzymes and Coenzymes / Fatty Acids / Food / Food and Beverages / Growth Substances / Hypoglycemia-Associated Agents / Lipids / Micronutrients / Physiological Phenomena / Protective Agents / Sulfur Compounds / Supplements / Thiophenes / Various Alimentary Tract and Metabolism Products / Vitamin B Complex / Vitamins",VLL71EBS9Z,1200-22-2,D00086,6112.0,5886.0,50106731.0,6417.0,30314.0,CHEMBL134342,,PA164776929,ZINC000001544807
CholecalciferolCommonly known or available as Vitamin D3,phase 4 complete,"DB00169 (NUTR00008, APRD00506)",CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,"Alimentary Tract and Metabolism / Bone Density Conservation Agents / Calcium-Regulating Hormones and Agents / Cholecalciferol, antagonists & inhibitors / Cholestanes / Cholestenes / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diet, Food, and Nutrition / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Food / Food and Beverages / Fused-Ring Compounds / Growth Substances / Lipids / Membrane Lipids / Micronutrients / Musculo-Skeletal System / Physiological Phenomena / Secosteroids / Steroids / Sterols / Vitamin D and Analogues / Vitamins / Vitamins (Fat Soluble)",1C6V77QF41,67-97-0,D00188,5280795.0,4444353.0,50030475.0,1244014.0,28940.0,CHEMBL1042,DAP001273,PA164748138,ZINC000004474460
Menadione,phase 4 complete,DB00170 (NUTR00062),CC1=CC(=O)C2=CC=CC=C2C1=O,"Antifibrinolytic Agents / Blood and Blood Forming Organs / Coagulants / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Diet, Food, and Nutrition / Dietary Supplements / Diterpenes / Fibrin Modulating Agents / Food / Food and Beverages / Growth Substances / Hematologic Agents / Hemostatics / Micronutrients / Naphthalenes / Naphthoquinones / Physiological Phenomena / Phytol / Quinones / Supplements / Terpenes / Vitamin K / Vitamins / Vitamins (Fat Soluble)",723JX6CXY5,58-27-5,D02335,4055.0,3915.0,24778.0,6728.0,28869.0,CHEMBL590,DNC001501,PA450358,ZINC000000001677
Adenine,phase 4 complete,"DB00173 (NUTR00012, EXPT00520)",NC1=C2NC=NC2=NC=N1,"Dietary Supplements / Heterocyclic Compounds, Fused-Ring / Purines / Supplements / UGT1A1 Inhibitors",JAC85A2161,73-24-5,D00034,190.0,185.0,181146.0,290.0,16708.0,CHEMBL226345,DAP000982,PA448048,ZINC000000000882
Asparagine,phase 4 complete,DB00174 (NUTR00015),N[C@@H](CC(N)=O)C(O)=O,"Amino Acids / Amino Acids, Basic / Amino Acids, Diamino / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Dietary Supplements / Supplements",5Z33R5TKO7,70-47-3,,6267.0,6031.0,181137.0,1157.0,58048.0,CHEMBL58832,,PA164776968,ZINC000001532556
Pravastatin,phase 4 complete,DB00175 (APRD00328),[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC,"Agents Causing Muscle Toxicity / Anticholesteremic Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / BSEP/ABCB11 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Noxae / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / Photosensitizing Agents / Toxic Actions",KXO2KT9N0G,81093-37-0,D08410,54687.0,49398.0,20688.0,42463.0,63618.0,CHEMBL1144,DAP000550,PA451089,ZINC000003798763
Fluvoxamine,phase 4 complete,DB00176 (APRD00425),COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F,"Amines / Anti-Anxiety Agents / Antidepressive Agents / Antidepressive Agents, Second-Generation / BSEP/ABCB11 Substrates / Central Nervous System Agents / Central Nervous System Depressants / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strong) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hydroxylamines / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Oximes / P-glycoprotein inhibitors / Psychoanaleptics / Psychotropic Drugs / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / Tranquilizing Agents",O4L1XPO44W,54739-18-3,,3404.0,4481878.0,50028091.0,42355.0,5138.0,CHEMBL814,DNC000897,PA449690,ZINC000003872605
Valsartan,phase 4 complete,DB00177 (APRD00133),CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O,"Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Angiotensin 2 Receptor Blocker / Angiotensin II Antagonists and Calcium Channel Blockers / Angiotensin II Antagonists and Diuretics / Angiotensin II receptor blockers (ARBs) and calcium channel blockers / Angiotensin II receptor blockers (ARBs) and diuretics / Angiotensin II receptor blockers (ARBs), plain / Angiotensin II Type 1 Receptor Blockers / Angiotensin II Type 2 Receptor Blockers / Angiotensin Receptor Antagonists / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hypotensive Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates",80M03YXJ7I,137862-53-4,D00400,60846.0,54833.0,50049186.0,69749.0,9927.0,CHEMBL1069,DAP000363,PA451848,ZINC000003875259
Ramipril,phase 4 complete,DB00178 (APRD00009),[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,"ACE Inhibitors and Calcium Channel Blockers / ACE Inhibitors and Diuretics / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Cholinesterase Inhibitors / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Lipid Modifying Agents / Photosensitizing Agents / Protease Inhibitors",L35JN3I7SJ,87333-19-5,D00421,5362129.0,4514937.0,50084681.0,35296.0,8774.0,CHEMBL1168,DAP000581,PA451223,ZINC000003798757
Masoprocol,phase 4 complete,"DB00179 (APRD01084, DB05900)",C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1,"Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Antioxidants / Benzene Derivatives / Benzyl Compounds / Catechols / Central Nervous System Agents / Compounds used in a research, industrial, or household setting / Cyclooxygenase Inhibitors / Enzyme Inhibitors / Lignans / Lipoxygenase Inhibitors / Peripheral Nervous System Agents / Phenols / Protective Agents / Sensory System Agents",7BO8G1BYQU,27686-84-6,D04862,71398.0,64490.0,22372.0,227239.0,73468.0,CHEMBL313972,DNC001037,PA164746493,ZINC000000012342
Flunisolide,phase 4 complete,DB00180 (APRD00976),[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,"Adrenal Cortex Hormones / Adrenals / Agents to Treat Airway Disease / Anti-Asthmatic Agents / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids for Systemic Use / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Fused-Ring Compounds / Immunosuppressive Agents / Nasal Preparations / Pregnadienes / Pregnanes / Respiratory System Agents / Steroids / Steroids, Fluorinated",78M02AA8KF,3385-03-3,,82153.0,74144.0,,1546428.0,5106.0,CHEMBL1512,DAP001046,PA449661,ZINC000004097305
Baclofen,phase 4 complete,DB00181 (APRD00551),NCC(CC(O)=O)C1=CC=C(Cl)C=C1,"Agents Causing Muscle Toxicity / Amino Acids / Amino Acids, Peptides, and Proteins / Aminobutyrates / Butyrates / Central Nervous System Agents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Agonists / GABA-B Receptor Agonists / Gaba-derivative Skeletal Muscle Relaxants / gamma-Aminobutyric Acid-ergic Agonist / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neurotransmitter Agents",H789N3FKE8,1134-47-0,D00241,2284.0,2197.0,24182.0,1292.0,2972.0,CHEMBL701,DAP000257,PA448533,
Amphetamine,phase 4 complete,DB00182 (APRD00480),CC(N)CC1=CC=CC=C1,"Adrenergic Agents / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Agents that produce hypertension / Agents that reduce seizure threshold / Amines / Amphetamines / Antidepressive Agents / Autonomic Agents / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Catechols / Central Nervous System Agents / Central Nervous System Depressants / Central Nervous System Stimulants / Central Nervous System Stimulation / Centrally Acting Sympathomimetics / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Uptake Inhibitors / Drugs that are Mainly Renally Excreted / Membrane Transport Modulators / Monoamine Oxidase Inhibitors / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Peripheral Nervous System Agents / Phenethylamines / Phenols / Photosensitizing Agents / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sympathomimetics",CK833KGX7E,300-62-9,D07445,3007.0,13852819.0,50005246.0,725.0,132233.0,CHEMBL405,DAP001146,PA448408,
Pentagastrin,phase 4 complete,DB00183 (APRD01172),CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,"Amino Acids, Peptides, and Proteins / Diagnostic Agents / Gastrins / Gastrointestinal Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Pentagastrin, antagonists & inhibitors / Peptide Hormones / Peptides / Proteins / Tests for Gastric Secretion",EF0NX91490,5534-95-2,D01631,9853654.0,8029364.0,50024321.0,7993.0,31974.0,CHEMBL1328,DNC001170,PA450849,ZINC000008214644
Nicotine,phase 4 complete,"DB00184 (APRD00200, EXPT02315, DB09463, DB11303)",CN1CCC[C@H]1C1=CN=CC=C1,"Agents producing tachycardia / Alkaloids / Autonomic Agents / Cholinergic Agents / Cholinergic Agonists / Cholinergic Nicotinic Agonist / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs Used in Addictive Disorders / Drugs Used in Nicotine Dependence / Ganglion Blockers / Ganglionic Stimulants / Miscellaneous Autonomic Drugs / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Nervous System / Neurotransmitter Agents / Nicotine, antagonists & inhibitors / Nicotine, metabolism / Nicotinic Agonists / OCT1 inhibitors / OCT2 Inhibitors / Peripheral Nervous System Agents / Pyridines / Smoking Cessation Agents / Solanaceous Alkaloids",6M3C89ZY6R,54-11-5,D03365,89594.0,80863.0,82070.0,31765.0,17688.0,CHEMBL3,DAP000175,PA450626,ZINC000000391812
Cevimeline,phase 4 complete,DB00185 (APRD00224),CC1O[C@@]2(CS1)CN1CCC2CC1,Autonomic Agents / Cholinergic Agents / Cholinergic Agonists / Cholinergic Receptor Agonist / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Muscarinic Agonists / Nervous System / Neurotransmitter Agents / Parasympathomimetics / Peripheral Nervous System Agents / Sulfur Compounds,K9V0CDQ56E,107233-08-9,D00661,25137844.0,21864737.0,,44281.0,3568.0,,DAP000075,PA164754754,
Lorazepam,phase 4 complete,DB00186 (APRD00116),OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2,"Anti-Anxiety Agents / Anticonvulsants / Antiemetics / Autonomic Agents / Benzazepines / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Benzodiazepinones / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Nervous System / Neurotransmitter Agents / Peripheral Nervous System Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents",O26FZP769L,846-49-1,D00365,3958.0,3821.0,50292627.0,6470.0,6539.0,CHEMBL580,DAP000237,PA450267,
Esmolol,phase 4 complete,DB00187 (APRD00954),COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-1 Receptor Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Beta Blocking Agents, Selective / Beta-Blockers (Beta1 Selective) / Bradycardia-Causing Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Hypotensive Agents / Neurotransmitter Agents / Potential QTc-Prolonging Agents / Propanols / QTc Prolonging Agents",MDY902UXSR,81147-92-4,D07916,59768.0,53916.0,50404796.0,49737.0,88206.0,CHEMBL768,DAP000304,PA449500,
Bortezomib,phase 4 complete,"DB00188 (APRD00828, DB07475)",CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,"Acids / Acids, Noncarboxylic / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Boron Compounds / Boronic Acids / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hepatotoxic Agents / Hypotensive Agents / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / OATP1B3 inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Potential QTc-Prolonging Agents / Proteasome Inhibitors / Pyrazines / QTc Prolonging Agents",69G8BD63PP,179324-69-7,D03150,387447.0,343402.0,50069989.0,358258.0,52717.0,CHEMBL325041,DAP001318,PA10252,ZINC000169746649
Ethchlorvynol,phase 4 complete,DB00189 (APRD00958),CCC(O)(\C=C\Cl)C#C,Alcohols / Central Nervous System Agents / Central Nervous System Depressants / Chlorohydrins / Hypnotics and Sedatives / Nervous System / Psycholeptics,6EIM3851UZ,113-18-8,D00704,5281077.0,4444534.0,,4118.0,4882.0,CHEMBL591,DAP000163,PA164746383,
Carbidopa,phase 4 complete,DB00190 (APRD00160),C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O,Amines / Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Aromatic Amino Acid Decarboxylase Inhibitors / Aromatic L-amino Acid Decarboxylase Inhibitors / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Catecholamines / Catechols / Central Nervous System Agents / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hydrazines / Phenols,KR87B45RGH,28860-95-9,D00558,34359.0,31640.0,50418773.0,2019.0,39585.0,CHEMBL1201236,DAP000592,PA448794,ZINC000019168887
Phentermine,phase 4 complete,DB00191 (APRD00093),CC(C)(N)CC1=CC=CC=C1,"Adrenergic Agents / Agents producing tachycardia / Agents that produce hypertension / Alimentary Tract and Metabolism / Amines / Amphetamines / Anti-Obesity Agents / Antiobesity Preparations, Excl. Diet Products / Appetite Depressants / Appetite Suppression / Autonomic Agents / Central Nervous System Agents / Centrally Acting Antiobesity Products / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Increased Sympathetic Activity / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenethylamines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sympathomimetic Amine Anorectic / Sympathomimetics",C045TQL4WP,122-09-8,D05458,4771.0,4607.0,50246598.0,221138.0,8080.0,CHEMBL1574,DAP000719,PA164748099,ZINC000008403947
Indecainide,phase 4 complete,DB00192 (APRD01032),CC(C)NCCCC1(C(N)=O)C2=CC=CC=C2C2=CC=CC=C12,,3AZF20DM1T,74517-78-5,,52195.0,47194.0,,,135314.0,CHEMBL1201242,DAP000503,PA164754881,ZINC000001855421
Tramadol,phase 4 complete,DB00193 (APRD00028),COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C,Agents producing tachycardia / Agents that reduce seizure threshold / Alcohols / Amines / Analgesics / Anticholinergic Agents / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cyclohexanes / Cyclohexanols / Cycloparaffins / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dimethylamines / Drugs that are Mainly Renally Excreted / Muscarinic Antagonists / Narcotics / Nervous System / NMDA Receptor Antagonists / Opiate Agonists / Opioid Agonist / Opioids / Peripheral Nervous System Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / UGT1A1 Substrates,0NG5TTM63P,27203-92-5,D08623,33741.0,31105.0,50176259.0,10689.0,75725.0,CHEMBL1066,DAP000140,PA451735,ZINC000000000853
Vidarabine,phase 4 complete,"DB00194 (APRD00333, EXPT02753)",NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antimetabolites / Antiviral Agents / Antivirals for Systemic Use / Arabinonucleosides / Carbohydrates / Direct Acting Antivirals / Glycosides / Heterocyclic Compounds, Fused-Ring / Noxae / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors / Ophthalmologicals / Purine Nucleosides / Purines / Ribonucleosides / Sensory Organs / Toxic Actions",3XQD2MEW34,24356-66-9,D00406,21704.0,20400.0,50144936.0,11194.0,45327.0,CHEMBL1090,DAP000642,PA451876,ZINC000000970363
Betaxolol,phase 4 complete,DB00195 (APRD00245),CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-1 Receptor Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antiglaucoma Preparations and Miotics / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Autonomic Agents / Beta Blocking Agents, Selective / Beta-adrenergic Agents / Beta-Blockers (Beta1 Selective) / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Hypotensive Agents / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / Ophthalmologicals / Peripheral Nervous System Agents / Phenoxypropanolamines / Propanolamines / Propanols / QTc Prolonging Agents / Sensory Organs / Sympatholytics",O0ZR1R6RZ2,63659-18-7,,2369.0,2279.0,50405521.0,1520.0,3082.0,CHEMBL423,DAP000305,PA448611,
Fluconazole,phase 4 complete,DB00196 (APRD00327),OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,"14-alpha Demethylase Inhibitors / Agents causing hyperkalemia / Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Antiinfectives for Systemic Use / Antimycotics for Systemic Use / Azole Antifungals / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Imidazole and Triazole Derivatives / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Steroid Synthesis Inhibitors / Triazole Derivatives / Triazoles",8VZV102JFY,86386-73-4,D00322,3365.0,3248.0,25817.0,4450.0,46081.0,CHEMBL106,DAP000628,PA449653,ZINC000000004009
Troglitazone,phase 4 complete,DB00197 (APRD00488),CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O,"Alimentary Tract and Metabolism / Benzopyrans / Blood Glucose Lowering Agents / BSEP/ABCB11 Inhibitors / Chromans / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs Used in Diabetes / Heterocyclic Compounds, Fused-Ring / OATP1B1/SLCO1B1 Inhibitors / Pyrans / Sulfur Compounds / Thiazoles / Thiazolidinediones / UGT1A1 Substrates / UGT1A3 substrates / UGT1A4 substrates / UGT1A6 Inhibitors / UGT1A6 substrate / UGT1A9 Substrates / UGT2B7 substrates",I66ZZ0ZN0E,97322-87-7,D00395,5591.0,5389.0,50088494.0,72610.0,9753.0,CHEMBL408,DAP001337,PA451799,
Oseltamivir,phase 4 complete,DB00198 (APRD01148),CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,Acetamides / Acetates / Amides / Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Neuraminidase Inhibitors / OAT3/SLC22A8 Substrates,20O93L6F9H,196618-13-0,D00900,65028.0,58540.0,5025.0,260101.0,7798.0,CHEMBL1229,DAP000714,PA450721,ZINC000003929508
Erythromycin,phase 4 complete,DB00199 (APRD00953),CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Antiinfectives for Treatment of Acne / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Enzyme Inhibitors / Erythromycin and similars / Erythromycins / Gastrointestinal Agents / Lactones / Macrolide Antimicrobial / Macrolides / Macrolides, Lincosamides and Streptogramins / Moderate Risk QTc-Prolonging Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / OATP1B3 substrates / Ophthalmologicals / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Synthesis Inhibitors / QTc Prolonging Agents",63937KV33D,114-07-8,D00140,12560.0,12041.0,50344942.0,4053.0,42355.0,CHEMBL532,DAP000111,PA449493,ZINC000085534336
Hydroxocobalamin,phase 4 complete,DB00200 (APRD01022),[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H],"Antianemic Preparations / Antidotes / Blood and Blood Forming Organs / Corrinoids / Diet, Food, and Nutrition / Drugs that are Mainly Renally Excreted / Food / Food and Beverages / Growth Substances / Hematinics / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Micronutrients / Nutritional Support / Physiological Phenomena / Vitamin B Complex / VITAMIN B12 AND FOLIC ACID / Vitamins",Q40X8H422O,13422-51-0,D01027,70678542.0,21403074.0,,5514.0,27786.0,CHEMBL2103737,DAP001336,PA164768689,
Caffeine,phase 4 complete,DB00201 (APRD00673),CN1C=NC2=C1C(=O)N(C)C(=O)N2C,"Alkaloids / Anorexigenic Agents & Respiratory and CNS Stimulants / BCRP/ABCG2 Inhibitors / Caffeine and Caffeine Containing Products / Central Nervous System Agents / Central Nervous System Stimulants / Central Nervous System Stimulation / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diagnostic Agents / Drugs for Obstructive Airway Diseases / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotransmitter Agents / Phosphodiesterase Inhibitors / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Purinergic Agents / Purinergic Antagonists / Purines / Purinones / Respiratory and CNS Stimulants / Tests for Gastric Secretion / Tricarboxylic Acids / Xanthine derivatives",3G6A5W338E,58-08-2,D00528,2519.0,2424.0,10849.0,1886.0,27732.0,CHEMBL113,DAP000099,PA448710,ZINC000000001084
Succinylcholine,phase 4 complete,DB00202 (APRD00159),C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,"Acids, Acyclic / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Ammonium Compounds / Central Nervous System Depressants / Choline Derivatives / Cholinesterase substrates / Dicarboxylic Acids / Ethanolamines / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular Depolarizing Agents / Neuromuscular Depolarizing Blockade / Neurotoxic agents / Nitrogen Compounds / Onium Compounds / Peripheral Nervous System Agents / Quaternary Ammonium Compounds / Succinates / Trimethyl Ammonium Compounds",J2R869A8YF,306-40-1,,5314.0,5123.0,50061568.0,10154.0,45652.0,CHEMBL703,DAP001132,PA451522,ZINC000001530820
Sildenafil,phase 4 complete,DB00203 (APRD00556),CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1,"Agents Causing Muscle Toxicity / Amides / Cardiovascular Agents / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs Used in Erectile Dysfunction / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Phosphodiesterase 5 Inhibitors / Piperazines / Purines / Sulfonamides / Sulfones / Sulfur Compounds / Urological Agents / Urologicals / Vasodilating Agents",3M7OB98Y7H,139755-83-2,D08514,5212.0,5023.0,14390.0,136411.0,9139.0,CHEMBL192,DAP000614,PA451346,ZINC000019796168
Dofetilide,phase 4 complete,DB00204 (APRD00367),CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,"Amides / Amines / Antiarrhythmic agents / Antiarrhythmics, Class III / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Ethylamines / Highest Risk QTc-Prolonging Agents / Membrane Transport Modulators / Narrow Therapeutic Index Drugs / OCT2 Substrates / OCT2 substrates with narrow therapeutic index / Potassium Channel Blockers / QTc Prolonging Agents / Sulfones / Sulfur Compounds",R4Z9X1N2ND,115256-11-6,D00647,71329.0,64435.0,50031720.0,49247.0,4681.0,CHEMBL473,DAP000495,PA449389,ZINC000000596731
Pyrimethamine,phase 4 complete,DB00205 (APRD00599),CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1,"Anti-Infective Agents / Antibiotics for Pneumocystis Pneumonia / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Diaminopyrimidines / Enzyme Inhibitors / Folic Acid Antagonists / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Pyrimidines",Z3614QOX8W,58-14-0,D00488,4993.0,4819.0,18512.0,9010.0,8673.0,CHEMBL36,DAP000633,PA451193,ZINC000000057464
Reserpine,phase 4 complete,DB00206 (APRD00472),[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,"Adrenergic Agents / Adrenergic Uptake Inhibitors / Alkaloids / Antiadrenergic Agents, Centrally Acting / Antidepressive Agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Antipsychotic Agents / BSEP/ABCB11 Inhibitors / Cardiovascular Agents / Catecholamine-depleting Sympatholytic / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Decreased Sympathetic Activity / Drugs that are Mainly Renally Excreted / Gastrointestinal Acidifying Agents / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Indole Alkaloids / Indoles / Membrane Transport Modulators / Neurotoxic agents / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / OCT2 Substrates / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Psychotropic Drugs / Secologanin Tryptamine Alkaloids / Tranquilizing Agents",8B1QWR724A,50-55-5,D00197,5770.0,5566.0,50017712.0,9260.0,28487.0,CHEMBL772,DAP000755,PA451236,ZINC000003938746
Azithromycin,phase 4 complete,DB00207 (APRD00397),CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Experimental Unapproved Treatments for COVID-19 / Lactones / Macrolide Antimicrobial / Macrolides / Macrolides, Lincosamides and Streptogramins / Moderate Risk QTc-Prolonging Agents / Ophthalmologicals / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / Polyketides / QTc Prolonging Agents",J2KLZ20U1M,83905-01-5,,447043.0,10482163.0,50373918.0,1299904.0,2955.0,CHEMBL529,DNC001539,PA448519,ZINC000085537026
Ticlopidine,phase 4 complete,DB00208 (APRD01257),ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2,"Antiplatelet agents / Blood and Blood Forming Organs / Cardiovascular Agents / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (moderate) / Cytochrome P-450 CYP2B6 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (moderate) / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (weak) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Platelet Aggregation / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Fibrin Modulating Agents / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / Platelet Aggregation Inhibitors Excl. Heparin / Purinergic Agents / Purinergic Antagonists / Purinergic P2 Receptor Antagonists / Purinergic P2Y Receptor Antagonists / Pyridines / Sulfur Compounds / Thienopyridines / Thiophenes",OM90ZUW7M1,55142-85-3,D08594,5472.0,5273.0,85509.0,10594.0,9588.0,CHEMBL833,DAP000723,PA451686,ZINC000019594599
Trospium,phase 4 complete,DB00209 (APRD00393),[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1,"Acids, Carbocyclic / Agents producing tachycardia / Alimentary Tract and Metabolism / Alkaloids / Anticholinergic Agents / Autonomic Agents / Aza Compounds / Azabicyclo Compounds / Cholinergic Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Diphenylacetic Acids / Drugs for Functional Gastrointestinal Disorders / Drugs for Urinary Frequency and Incontinence / Genito Urinary System and Sex Hormones / Hydroxy Acids / Muscarinic Antagonists / Neurotransmitter Agents / Parasympatholytics / Peripheral Nervous System Agents / Phenylacetates / Tropanes / Urological Agents / Urologicals",T4Y8ORK057,47608-32-2,D01103,5284632.0,10482307.0,,236778.0,145791.0,CHEMBL1888176,DAP000342,PA164748976,ZINC000100016084
Adapalene,phase 4 complete,DB00210 (APRD00780),COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2,Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anti-Inflammatory Agents / Dermatologicals / Misc. Skin and Mucous Membrane Agents / Naphthalenes / Retinoids / Retinoids for Topical Use in Acne,1L4806J2QF,106685-40-9,D01112,60164.0,54244.0,50048280.0,60223.0,31174.0,CHEMBL1265,DAP000115,PA448047,ZINC000003784182
Midodrine,phase 4 complete,DB00211 (APRD01116),COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1,Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic and Dopaminergic Agents / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Autonomic Agents / Bradycardia-Causing Agents / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Ethanolamines / Neurotransmitter Agents / Peripheral Nervous System Agents / Sympathomimetics / Vasoconstrictor Agents,6YE7PBM15H,42794-76-3,D08220,4195.0,4050.0,,6963.0,6933.0,CHEMBL1201212,DAP000229,PA164749381,
Pantoprazole,phase 4 complete,DB00213 (APRD00073),COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1,"2-Pyridinylmethylsulfinylbenzimidazoles / Acid Reducers / Alimentary Tract and Metabolism / Anti-Ulcer Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Benzimidazoles / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Gastric Acid Lowering Agents / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Proton Pump Inhibitors / Proton-pump Inhibitors / Pyridines / Sulfoxides / Sulfur Compounds",D8TST4O562,102625-70-7,D05353,4679.0,4517.0,50241342.0,40790.0,7915.0,CHEMBL1502,DAP000724,PA450774,
Torasemide,phase 4 complete,"DB00214 (APRD00295, APRD00217)",CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1,Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diuretics / High-Ceiling Diuretics / Hyperglycemia-Associated Agents / Hypotensive Agents / Increased Diuresis at Loop of Henle / Membrane Transport Modulators / Natriuretic Agents / Non Potassium Sparing Diuretics / OATP1B1/SLCO1B1 Substrates / Ototoxic agents / Pyridines / Sodium Potassium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds,W31X2H97FB,56211-40-6,D00382,41781.0,38123.0,64107.0,38413.0,9637.0,CHEMBL1148,DAP000745,PA451733,ZINC000000005823
Citalopram,phase 4 complete,DB00215 (APRD00147),CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,"Amines / Antidepressive Agents / Antidepressive Agents, Second-Generation / Benzofurans / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (weak) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Hypoglycemia-Associated Agents / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Nitriles / P-glycoprotein inhibitors / P-glycoprotein substrates / Propylamines / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Vasodilating Agents",0DHU5B8D6V,59729-33-8,D07704,2771.0,2669.0,25870.0,2556.0,77397.0,CHEMBL549,DAP000118,PA449015,
Eletriptan,phase 4 complete,DB00216 (APRD00945),CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2,"Agents that produce hypertension / Amines / Analgesics / Antidepressive Agents / Antimigraine Preparations / Biogenic Amines / Biogenic Monoamines / Central Nervous System Depressants / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Indoles / Nervous System / Neurotransmitter Agents / P-glycoprotein substrates / Selective Serotonin 5-HT1 Receptor Agonists / Selective Serotonin Agonists / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 1b Receptor Agonists / Serotonin 1d Receptor Agonists / Serotonin 5-HT1 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists / Serotonin-1b and Serotonin-1d Receptor Agonist / Triptans",22QOO9B8KI,143322-58-1,D07887,77993.0,70379.0,50103594.0,231049.0,50922.0,CHEMBL1510,DAP000008,PA134687947,ZINC000003823475
Bethanidine,phase 4 complete,DB00217 (APRD00825),CN\C(NCC1=CC=CC=C1)=N/C,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Amidines / Antiadrenergic Agents, Peripherally Acting / Antihypertensive Agents / Autonomic Agents / Cardiovascular Agents / Guanidine Derivatives / Guanidines / Neurotransmitter Agents / Peripheral Nervous System Agents / Sympatholytics",W8S3YM7AUU,55-73-2,D01603,2368.0,2278.0,,1523.0,37937.0,CHEMBL1201260,DAP000047,PA164743235,ZINC000002041046
Moxifloxacin,phase 4 complete,DB00218 (APRD00281),[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Moderate Risk QTc-Prolonging Agents / Ophthalmologicals / QTc Prolonging Agents / Quinolines / Quinolone Antimicrobial / Quinolones / Sensory Organs / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",U188XYD42P,151096-09-2,D08237,152946.0,134802.0,50366824.0,139462.0,63611.0,CHEMBL32,DAP000158,PA450555,ZINC000003826253
Oxyphenonium,phase 4 complete,DB00219 (APRD00189),CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,"Agents producing tachycardia / Alimentary Tract and Metabolism / Amines / Ammonium Compounds / Anticholinergic Agents / Autonomic Agents / Cholinergic Agents / Drugs for Functional Gastrointestinal Disorders / Muscarinic Antagonists / Mydriatics / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Parasympatholytics / Peripheral Nervous System Agents / Quaternary Ammonium Compounds / Synthetic Anticholinergics, Quaternary Ammonium Compounds",D2G5508Y7I,14214-84-7,,5749.0,5547.0,,7818.0,94329.0,CHEMBL1201286,DAP001124,PA164752252,
Nelfinavir,phase 4 complete,DB00220 (APRD00003),[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,"Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BCRP/ABCG2 Inhibitors / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strong) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strong) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / HIV Protease Inhibitors / Hyperglycemia-Associated Agents / Isoquinolines / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / OCT1 inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Potential QTc-Prolonging Agents / Protease Inhibitors / QTc Prolonging Agents / UGT1A1 Inducers",HO3OGH5D7I,159989-64-7,D08259,64143.0,57718.0,518.0,134527.0,7496.0,CHEMBL584,DAP000705,PA450606,ZINC000003833846
Isoetharine,phase 4 complete,DB00221 (APRD00750),CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1,Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Respiratory System Agents,YV0SN3276Q,79490-84-9,D04625,3762.0,3630.0,52083.0,6023.0,6005.0,CHEMBL1201213,DAP000935,PA450103,
Glimepiride,phase 4 complete,DB00222 (APRD00381),CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O,Alimentary Tract and Metabolism / Antiarrhythmic agents / Blood Glucose Lowering Agents / BSEP/ABCB11 Substrates / Cardiovascular Agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs Used in Diabetes / Hypoglycemia-Associated Agents / Immunosuppressive Agents / Sulfones / Sulfonylureas / Sulfur Compounds,6KY687524K,93479-97-1,D00593,3476.0,16740595.0,50237590.0,25789.0,5383.0,CHEMBL1481,DAP000132,PA449761,ZINC000100070954
Diflorasone,phase 4 complete,DB00223 (APRD00921),[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids / Steroids, Fluorinated",T2DHJ9645W,2557-49-5,D07827,71415.0,64505.0,,91311.0,59750.0,CHEMBL1201380,DAP001184,PA164749408,ZINC000005752191
Indinavir,phase 4 complete,DB00224 (APRD00069),CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,Agents Causing Muscle Toxicity / Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (weak) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / HIV Protease Inhibitors / Hyperglycemia-Associated Agents / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Protease Inhibitors / Pyridines / UGT1A1 Inhibitors,9MG78X43ZT,150378-17-9,,5362440.0,4515036.0,517.0,114289.0,44032.0,CHEMBL115,DAP000168,PA449977,ZINC000022448696
Gadodiamide,phase 4 complete,DB00225 (APRD00990),O=C1[O-][Gd+3]234567[O]=C(C[N]2(CC[N]3(CC([O-]4)=O)CC[N]5(CC(=[O]6)NC)CC(=O)[O-]7)C1)NC,"Acetates / Acids, Acyclic / Amines / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Fatty Acids / Fatty Acids, Volatile / Injections, Intravenous / Lipids / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / Miscellaneous Therapeutic Agents / Organometallic Compounds / Paramagnetic Contrast Agent / Paramagnetic Contrast Media / Polyamines",84F6U3J2R6,131410-48-5,,24847884.0,135661.0,,41144.0,37333.0,,,PA164784027,
Guanadrel,phase 4 complete,DB00226 (APRD01006),NC(N)=NCC1COC2(CCCCC2)O1,Adrenergic Antagonists / Amidines / Antihypertensive Agents / Cardiovascular Agents,765C9332T4,40580-59-4,D08029,38521.0,35305.0,,26296.0,5555.0,CHEMBL1037,DAP000059,PA164745308,
Lovastatin,phase 4 complete,DB00227 (APRD00370),[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,Agents Causing Muscle Toxicity / Anticholesteremic Agents / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Modifying Agents / Lipid Regulating Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / P-glycoprotein inhibitors / Photosensitizing Agents / UGT1A1 Substrates / UGT1A3 substrates / UGT2B7 substrates,9LHU78OQFD,75330-75-5,D00359,53232.0,48085.0,34168.0,6472.0,40303.0,CHEMBL503,DAP000551,PA450272,ZINC000003812841
Enflurane,phase 4 complete,DB00228 (APRD00234),FC(F)OC(F)(F)C(F)Cl,"Agents that reduce seizure threshold / Anesthetics / Anesthetics, General / Anesthetics, Inhalation / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Ethers / Methyl Ethers / Nervous System",91I69L5AY5,13838-16-9,D00543,3226.0,3113.0,,3920.0,4792.0,CHEMBL1257,DAP000799,PA449461,
Cefotiam,phase 4 complete,DB00229 (APRD00855),[H][C@]12SCC(CSC3=NN=NN3CCN(C)C)=C(N1C(=O)[C@H]2NC(=O)CC1=CSC(N)=N1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephacetrile / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Second-Generation Cephalosporins / Sulfur Compounds / Thiazines",91W6Z2N718,61622-34-2,D07648,43708.0,39831.0,,2188.0,355510.0,CHEMBL1296,DAP001177,PA164749298,ZINC000003830445
Pregabalin,phase 4 complete,DB00230 (APRD01198),CC(C)C[C@H](CN)CC(O)=O,"Acids, Acyclic / Agents causing angioedema / Amino Acids / Amino Acids, Peptides, and Proteins / Aminobutyrates / Analgesics / Anti-Anxiety Agents / Antiarrhythmic agents / Anticonvulsants / Bradycardia-Causing Agents / Butyrates / Central Nervous System Agents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Miscellaneous Anticonvulsants / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Nervous System / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / Psychotropic Drugs / QTc Prolonging Agents / Sensory System Agents / Tranquilizing Agents / Vasodilating Agents",55JG375S6M,148553-50-8,D02716,5486971.0,4589156.0,50164279.0,187832.0,64356.0,CHEMBL1059,DAP001264,PA164754814,ZINC000000005152
Temazepam,phase 4 complete,DB00231 (APRD00676),CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,"Anti-Anxiety Agents / Benzazepines / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Psychotropic Drugs / Tranquilizing Agents",CHB1QD2QSS,846-50-4,D00370,5391.0,5198.0,50408032.0,10355.0,9435.0,CHEMBL967,DAP000238,PA451608,
Aminosalicylic acid,phase 4 complete,"DB00233 (APRD00749, EXPT00693, DB09367)",NC1=CC(O)=C(C=C1)C(O)=O,"Acids, Carbocyclic / Aminobenzoates / Aminosalicylic Acid and Derivatives / Aminosalicylic Acids / Anti-Bacterial Agents / Anti-Infective Agents / Antiinfectives for Systemic Use / Antimycobacterials / Antituberculosis Agents / Benzene Derivatives / Benzoates / Drugs for Treatment of Tuberculosis / Hydroxy Acids / Hydroxybenzoates / para-Aminobenzoates / Phenols / Salicylates",5B2658E0N2,65-49-6,D00162,4649.0,4488.0,48319.0,7833.0,27565.0,CHEMBL1169,,PA448382,ZINC000000000922
Reboxetine,phase 4 complete,DB00234 (APRD00198),[H][C@@](OC1=CC=CC=C1OCC)(C1=CC=CC=C1)[C@@]1([H])CNCCO1,Adrenergic Agents / Adrenergic Uptake Inhibitors / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Membrane Transport Modulators / Morpholines / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Oxazines / P-glycoprotein inhibitors / Psychoanaleptics / Psychotropic Drugs,947S0YZ36I,71620-89-8,,127151.0,112870.0,,60842.0,135342.0,CHEMBL383921,DAP000720,PA144614921,ZINC000003996032
Milrinone,phase 4 complete,DB00235 (APRD00010),CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1,"Amines / Aminopyridines / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hematologic Agents / Phosphodiesterase 3 Inhibitors / Phosphodiesterase 5 Inhibitors / Phosphodiesterase Inhibitors / Protective Agents / Pyridines / Vasodilating Agents",JU9YAX04C7,78415-72-2,D00417,4197.0,4052.0,15296.0,52769.0,50693.0,CHEMBL189,DAP000150,PA164749171,ZINC000009224016
Pipobroman,phase 4 complete,DB00236 (APRD00693),BrCCC(=O)N1CCN(CC1)C(=O)CCBr,"Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Noxae / Piperazines / Toxic Actions",6Q99RDT97R,54-91-1,D00467,4842.0,4676.0,,8347.0,8242.0,CHEMBL1585,DAP000988,PA164747673,ZINC000001530753
Butabarbital,phase 4 complete,DB00237 (APRD00752),CCC(C)C1(CC)C(=O)NC(=O)NC1=O,Anticholinergic Agents / Anticonvulsants / Barbiturates / Central Nervous System Agents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Hypnotics and Sedatives / Nervous System / Nicotinic Antagonists / Psycholeptics / Pyrimidines / Pyrimidinones,P0078O25A9,125-40-6,D03180,2479.0,2385.0,,477631.0,3228.0,CHEMBL449,DAP000667,PA164743463,
Nevirapine,phase 4 complete,"DB00238 (APRD00705, DB08311)",CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (weak) / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strong) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Hepatotoxic Agents / Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor / Inducers of Drug Clearance / Non-Nucleoside Reverse Transcriptase Inhibitors / Nonnucleoside Reverse Transcriptase Inhibitors / Nucleic Acid Synthesis Inhibitors / OCT1 inhibitors / Pyridines / Reverse Transcriptase Inhibitors,99DK7FVK1H,129618-40-2,D00435,4463.0,4308.0,1434.0,53654.0,63613.0,CHEMBL57,DAP000184,PA450616,ZINC000000004778
Oxiconazole,phase 4 complete,DB00239 (APRD01154),ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1,Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Azole Antifungals / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Imidazole and Triazole Derivatives / Imidazole Derivatives,C668Q9I33J,64211-45-6,D08313,5353853.0,4510239.0,50051844.0,32638.0,7825.0,CHEMBL1262,DAP001204,PA164754742,ZINC000003873295
Alclometasone,phase 4 complete,DB00240 (APRD00783),[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Moderately Potent (Group II) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Ophthalmologicals / Pregnadienes / Pregnadienetriols / Pregnanes / Sensory Organs / Steroids",136H45TB7B,67452-97-5,D07116,5311000.0,4470541.0,,108088.0,53776.0,CHEMBL1201361,DAP000415,PA164747650,ZINC000030691420
Butalbital,phase 4 complete,DB00241 (APRD00266),CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,Anticholinergic Agents / Anticonvulsants / Barbiturates / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Hypnotics and Sedatives / Methemoglobinemia Associated Agents / Nervous System / Nicotinic Antagonists / Psycholeptics / Pyrimidines / Pyrimidinones,KHS0AZ4JVK,77-26-9,D03182,2481.0,2387.0,,19860.0,102524.0,CHEMBL454,DAP000668,PA448695,ZINC000003830347
Cladribine,phase 4 complete,DB00242 (APRD00260),NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1,"2-Chloroadenosine / Agents Causing Muscle Toxicity / Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Carbohydrates / Cardiotoxic antineoplastic agents / Deoxyadenosines / Deoxyribonucleosides / Glycosides / Heterocyclic Compounds, Fused-Ring / Immunologic Factors / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / Purine Analogues / Purine Antimetabolite / Purine Nucleosides / Purines / Ribonucleosides / Selective Immunosuppressants",47M74X9YT5,4291-63-8,D01370,20279.0,19105.0,38920.0,44157.0,567361.0,CHEMBL1619,DAP000565,PA449027,ZINC000003798064
Ranolazine,phase 4 complete,DB00243 (APRD01300),COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1,Acetamides / Antianginal Agents / BSEP/ABCB11 Substrates / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Piperazines / QTc Prolonging Agents / Sodium Channel Blockers / Vasodilating Agents,A6IEZ5M406,95635-55-5,,56959.0,51354.0,50173335.0,35829.0,87690.0,CHEMBL1404,DAP000875,PA164746007,
Mesalazine,phase 4 complete,"DB00244 (APRD01098, DB05376, DB06396)",NC1=CC(C(O)=O)=C(O)C=C1,"Agents causing hyperkalemia / Agents that produce hypertension / Aminosalicylate / Aminosalicylic Acids / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Benzene Derivatives / Hydroxybenzoates / Intestinal Antiinflammatory Agents / Nephrotoxic agents / Non COX-2 selective NSAIDS / Phenols / Salicylates",4Q81I59GXC,89-57-6,D00377,4075.0,3933.0,60918.0,52582.0,6775.0,CHEMBL704,DAP000729,PA450384,ZINC000000001688
Benzatropine,phase 4 complete,DB00245 (APRD00748),[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C,Agents producing tachycardia / Alkaloids / Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Anticholinergic Agents / Aza Compounds / Central Nervous System Agents / Cholinergic Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Uptake Inhibitors / Drugs that are Mainly Renally Excreted / Ethers of Tropine or Tropine Derivatives / Histamine Antagonists / Histamine H1 Antagonists / Histamine Receptor Antagonists / Membrane Transport Modulators / Muscarinic Antagonists / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Tropanes,1NHL2J4X8K,86-13-5,D07511,1201549.0,16736541.0,50366775.0,1424.0,3048.0,CHEMBL1201203,DAP001460,PA448591,ZINC000100036536
Ziprasidone,phase 4 complete,DB00246 (APRD00540),ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1,Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Anticholinergic Agents / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Highest Risk QTc-Prolonging Agents / Histamine Antagonists / Histamine H1 Antagonists / Hyperglycemia-Associated Agents / Indole Derivatives / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1D Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Agonists / Serotonin Receptor Antagonists / Sulfur Compounds / Tranquilizing Agents,6UKA5VEJ6X,146939-27-7,D08687,60854.0,54841.0,50048803.0,115698.0,10119.0,CHEMBL708,DAP000079,PA451974,ZINC000000538550
Methysergide,phase 4 complete,DB00247 (APRD00463),[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO,"Agents that produce hypertension / Alkaloids / Analgesics / Antidepressive Agents / Antimigraine Preparations / Cardiovascular Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Ergolines / Ergot Alkaloids and Derivatives / Heterocyclic Compounds, Fused-Ring / Lysergic Acid / Nervous System / Neurotransmitter Agents / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Vasoconstrictor Agents",XZA9HY6Z98,361-37-5,D02357,6540428.0,5022813.0,50031942.0,6911.0,584020.0,CHEMBL485253,DAP000366,PA164743265,
Cabergoline,phase 4 complete,DB00248 (APRD00836),[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,"Agents that produce hypertension / Alkaloids / Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Antidepressive Agents / Antineoplastic Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Agonists / Ergolines / Ergot Alkaloids and Derivatives / Ergot-derivative Dopamine Receptor Agonists / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotransmitter Agents / P-glycoprotein substrates / Prolactine Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin 5-HT2 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists",LL60K9J05T,81409-90-7,D00987,54746.0,49452.0,50426497.0,47579.0,3286.0,CHEMBL1201087,DAP000251,PA448708,ZINC000003800008
Idoxuridine,phase 4 complete,"DB00249 (APRD00504, EXPT01835, DB03778)",OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Carbohydrates / Deoxyribonucleosides / Deoxyuridine / Dermatologicals / Direct Acting Antivirals / Enzyme Inhibitors / Glycosides / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Analog Antiviral / Nucleosides / Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors / Ophthalmologicals / Pyrimidine Nucleosides / Pyrimidines / Ribonucleosides / Sensory Organs",LGP81V5245,54-42-2,D00342,5905.0,5694.0,50370388.0,5653.0,147675.0,CHEMBL788,DAP000997,PA164781019,ZINC000003834173
Dapsone,phase 4 complete,DB00250 (APRD00345),NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1,Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics for Pneumocystis Pneumonia / Antiinfectives for Systemic Use / Antimalarials / Antimycobacterials / Antiparasitic Agents / Antiprotozoals / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Drugs causing inadvertant photosensitivity / Drugs for Treatment of Lepra / Enzyme Inhibitors / Folic Acid Antagonists / Leprostatic Agents / Methemoglobinemia Associated Agents / Miscellaneous Antimycobacterials / Miscellaneous Local Anti-infectives / Photosensitizing Agents / Sulfones / Sulfur Compounds,8W5C518302,80-08-0,D00592,2955.0,2849.0,50029764.0,3108.0,4325.0,CHEMBL1043,DAP000637,PA449211,ZINC000000006310
Terconazole,phase 4 complete,DB00251 (APRD00659),CC(C)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1,Anti-Infective Agents / Antifungal Agents / Antifungal Agents (Vaginal) / Azole Antifungals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Triazole Derivatives,0KJ2VE664U,67915-31-5,D00888,441383.0,390122.0,50375318.0,37806.0,82980.0,CHEMBL1306,DAP000629,PA164768834,ZINC000003873936
Phenytoin,phase 4 complete,DB00252 (APRD00241),O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,Agents Causing Muscle Toxicity / Anti-epileptic Agent / Anticonvulsants / Central Nervous System Agents / Central Nervous System Depressants / COMT Substrates / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inducers (strong) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (moderate) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strong) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inducers / Cytochrome P-450 CYP3A7 Inducers (weak) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Enzyme Inducing Antiepileptic Drugs / Hydantoins / Imidazoles / Imidazolidines / Inducers of Drug Clearance / Membrane Transport Modulators / Methemoglobinemia Associated Agents / Narrow Therapeutic Index Drugs / Nervous System / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Phenytoin and Prodrugs / Sodium Channel Blockers / Thyroxine-binding globulin substrates / UGT1A1 Inducers / UGT1A1 Substrates / UGT1A4 substrates / UGT1A6 Inhibitors / UGT1A6 substrate / UGT1A9 Inhibitors / UGT1A9 Substrates / Voltage-Gated Sodium Channel Blockers,6158TKW0C5,57-41-0,D00512,1775.0,1710.0,50003655.0,8183.0,8107.0,CHEMBL16,DAP000130,PA450947,ZINC000002510358
Medrysone,phase 4 complete,DB00253 (APRD01091),[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / OAT3/SLC22A8 Substrates / Ophthalmologicals / P-glycoprotein substrates / Pregnanes / Pregnenes / Sensory Organs / Steroids / Thyroxine-binding globulin inhibitors",D2UFC189XF,2668-66-8,D02289,247839.0,216968.0,,29439.0,34829.0,CHEMBL1201173,DAP001048,PA450346,ZINC000003977945
Doxycycline,phase 4 complete,DB00254 (APRD00597),[H][C@@]12[C@@H](C)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O,Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives and Antiseptics for Local Oral Treatment / Antiinfectives for Systemic Use / Antiparasitic Agents / Antiprotozoals / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Naphthacenes / OAT1/SLC22A6 inhibitors / Photosensitizing Agents / Stomatological Preparations / Tetracyclines,334895S862,564-25-0,D07876,54671203.0,10469369.0,50041429.0,1545992.0,50845.0,CHEMBL1433,DAP001371,PA449415,ZINC000016052277
Diethylstilbestrol,phase 4 complete,"DB00255 (APRD00920, EXPT01164)",CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,"Adrenal Cortex Hormones / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / Benzene Derivatives / Benzylidene Compounds / BSEP/ABCB11 Substrates / Carcinogens / COMT Substrates / Contraceptive Agents, Female / Contraceptive Agents, Male / Contraceptives, Postcoital / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Endocrine Therapy / Estrogen Contraceptives / Estrogens / Estrogens, Non-Steroidal / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Noxae / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein substrates / Sex Hormones and Modulators of the Genital System / Stilbenes / Synthetic Estrogens, Plain / Thyroxine-binding globulin inducers / Toxic Actions",731DCA35BT,56-53-1,D00577,3054.0,395306.0,20625.0,3390.0,41922.0,CHEMBL411,DAP001011,PA449307,ZINC000000001290
Lymecycline,phase 4 complete,"DB00256 (APRD00565, EXPT01049)",[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C,Agents that produce neuromuscular block (indirect) / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Naphthacenes / Tetracyclines,7D6EM3S13P,992-21-2,D06884,54707177.0,20121315.0,,6513.0,59040.0,CHEMBL2103929,DAP000881,PA164747190,ZINC000053682936
Clotrimazole,phase 4 complete,DB00257 (APRD00244),ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,"Anti-Infective Agents / Anti-Infective Agents, Local / Antifungal Agents / Antifungal Agents (Vaginal) / Antifungals for Dermatological Use / Antifungals for Topical Use / Antiinfectives and Antiseptics for Local Oral Treatment / Azole Antifungals / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strong) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strong) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (moderate) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A7 Inducers / Cytochrome P-450 CYP3A7 Inducers (strong) / Cytochrome P-450 CYP3A7 Inducers (weak) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Enzyme Inhibitors / Gynecological Antiinfectives and Antiseptics / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Imidazole and Triazole Derivatives / Imidazole Derivatives / Imidazoles / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inducers / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Steroid Synthesis Inhibitors / Stomatological Preparations",G07GZ97H65,23593-75-1,D00282,2812.0,2710.0,31774.0,2623.0,3764.0,CHEMBL104,DAP000138,PA449057,ZINC000003807804
Calcium acetate,phase 4 complete,DB00258 (APRD00839),[Ca++].CC([O-])=O.CC([O-])=O,"Acids / Acids, Acyclic / Acids, Noncarboxylic / Alimentary Tract and Metabolism / Arylsulfonates / Arylsulfonic Acids / Benzene Derivatives / Blood Coagulation Factors / Calcium Salts / Chelating Agents / Compounds used in a research, industrial, or household setting / Drugs for Treatment of Hyperkalemia and Hyperphosphatemia / Fatty Acids / Fatty Acids, Volatile / Lipids / Minerals / Phosphate Binder / Phosphate-removing Agents / Sequestering Agents / Sulfonic Acids / Sulfur Acids / Sulfur Compounds",Y882YXF34X,62-54-4,D00931,6116.0,5890.0,,214342.0,3310.0,CHEMBL1200800,,PA164746897,
Sulfanilamide,phase 4 complete,DB00259 (APRD00438),NC1=CC=C(C=C1)S(N)(=O)=O,Amides / Amines / Aniline Compounds / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Methemoglobinemia Associated Agents / Short-Acting Sulfonamides / Sulfanilamides / Sulfonamide Antibacterial / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds,21240MF57M,63-74-1,D08543,5333.0,5142.0,10857.0,10184.0,45373.0,CHEMBL21,DNC001391,PA451545,ZINC000000002101
Cycloserine,phase 4 complete,"DB00260 (APRD00894, DB03123)",N[C@@H]1CONC1=O,"Amino Acids / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antibiotics, Antitubercular / Antiinfectives for Systemic Use / Antimetabolites / Antimycobacterials / Antituberculosis Agents / Drugs for Treatment of Tuberculosis / Isoxazoles / Neurotoxic agents / Noxae / Oxazoles / Oxazolidinones / Renal Agents / Toxic Actions",95IK5KI84Z,68-41-7,,6234.0,5998.0,50038178.0,3007.0,40009.0,CHEMBL771,DAP001468,PA164764600,ZINC000034676245
Anagrelide,phase 4 complete,DB00261 (APRD00798),ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl,"Agents producing tachycardia / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Antiplatelet agents / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (weak) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Platelet Production / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Phosphodiesterase 3 Inhibitors / Phosphodiesterase Inhibitors / Platelet-reducing Agents / QTc Prolonging Agents / Thrombocytosis / Vasodilating Agents",K9X45X0051,68475-42-3,D07455,2182.0,2097.0,50000334.0,596724.0,142290.0,CHEMBL760,DAP000612,PA164742986,ZINC000003871541
Carmustine,phase 4 complete,DB00262 (APRD00006),ClCCNC(=O)N(CCCl)N=O,"Alkylating Activity / Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nitroso Compounds / Nitrosourea Compounds / Nitrosoureas / Noxae / Toxic Actions",U68WG3173Y,154-93-8,D00254,2578.0,2480.0,50015950.0,2105.0,3423.0,CHEMBL513,DAP000041,PA448810,ZINC000003830387
Sulfisoxazole,phase 4 complete,DB00263 (APRD00595),CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C,Amides / Amines / Aniline Compounds / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Drugs causing inadvertant photosensitivity / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hypoglycemia-Associated Agents / Moderate Risk QTc-Prolonging Agents / Ophthalmologicals / Photosensitizing Agents / QTc Prolonging Agents / Sensory Organs / Short-Acting Sulfonamides / Sulfanilamides / Sulfonamide Antibacterial / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds,740T4C525W,127-69-5,D00450,5344.0,5151.0,50034452.0,10207.0,102484.0,CHEMBL453,DAP001203,PA164748964,ZINC000096006009
Metoprolol,phase 4 complete,DB00264 (APRD00208),COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-1 Receptor Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Beta blocking agents and calcium channel blockers / Beta Blocking Agents and Thiazides / Beta Blocking Agents, Selective / Beta Blocking Agents, Selective, and Thiazides / Beta-Blockers (Beta1 Selective) / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Hypotensive Agents / OCT2 Inhibitors / Photosensitizing Agents / Propanolamines",GEB06NHM23,51384-51-1,D02358,4171.0,4027.0,25756.0,6918.0,6904.0,CHEMBL13,DAP000481,PA450480,
Crotamiton,phase 4 complete,DB00265 (APRD00211),CCN(C(=O)C=CC)C1=CC=CC=C1C,"Agrochemicals / Amines / Aniline Compounds / Benzene Derivatives / Compounds used in a research, industrial, or household setting / Pesticides / Scabicides and Pediculicides / Toxic Actions",2EEH27851Y,483-63-6,D01381,2883.0,599515.0,50240091.0,21766.0,,CHEMBL1200709,,PA164745460,ZINC000000056427
Dicoumarol,phase 4 complete,DB00266 (APRD00761),OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,"4-Hydroxycoumarins / Anticoagulants / Benzopyrans / Blood and Blood Forming Organs / Coumarins / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Enzyme Inhibitors / Fibrinolytic Agents / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / Pyrans / Uncoupling Agents / Vitamin K Antagonists",7QID3E7BG7,66-76-2,D03798,54676038.0,10183330.0,35525.0,1598.0,4513.0,CHEMBL1466,DAP000768,PA449298,ZINC000003869855
Cefmenoxime,phase 4 complete,DB00267 (APRD00851),[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephacetrile / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",KBZ4844CXN,65085-01-0,D01739,9570757.0,7845223.0,,,55490.0,CHEMBL1201224,DAP001178,PA164750569,ZINC000003830413
Ropinirole,phase 4 complete,DB00268 (APRD00302),CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1,"Anti-Dyskinesia Agents / Anti-Parkinson Agents (Dopamine Agonist) / Anti-Parkinson Drugs / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Agonists / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Nervous System / Neurotransmitter Agents / Nonergot-derivative Dopamine Receptor Agonists",030PYR8953,91374-21-9,D08489,5095.0,4916.0,50020680.0,72302.0,8888.0,CHEMBL589,DAP001515,PA164749035,ZINC000000002041
Isradipine,phase 4 complete,DB00270 (APRD00298),COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,Agents causing hyperkalemia / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Bradycardia-Causing Agents / BSEP/ABCB11 Substrates / Calcium Channel Blockers / Calcium Channel Blockers (Dihydropyridine) / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Dihydropyridines / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Membrane Transport Modulators / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,YO1UK1S598,75695-93-1,D00349,3784.0,3652.0,50436176.0,33910.0,6073.0,CHEMBL1648,DAP000134,PA450131,
Diatrizoate,phase 4 complete,DB00271 (APRD00913),CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I,"Acids, Carbocyclic / Alcohols / Amino Sugars / Benzene Derivatives / Benzoates / Carbohydrates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Hexosamines / Iodinated Contrast Agents / Iodobenzoates / Radiographic Contrast Agent / Roentgenography / Sugar Alcohols / Triiodobenzoic Acids / Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media / X-Ray Contrast Activity / X-Ray Contrast Media, Iodinated",5UVC90J1LK,117-96-4,D01013,2140.0,2055.0,62875.0,1546223.0,53691.0,CHEMBL1201220,,PA449281,ZINC000004097476
Betazole,phase 4 complete,DB00272 (APRD00714),NCCC1=CC=NN1,Diagnostic Agents / Gastrointestinal Agents / Histamine Agents / Histamine Agonists / Neurotransmitter Agents / Pyrazoles / Tests for Gastric Secretion,1C065P542O,105-20-4,,7741.0,7455.0,,,59170.0,CHEMBL1201323,DAP001081,PA164784036,ZINC000000001028
Topiramate,phase 4 complete,DB00273 (APRD00237),[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,Anti-Obesity Agents / Anticonvulsants / Carbohydrates / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Drugs that are Mainly Renally Excreted / Enzyme Inducing Antiepileptic Drugs / Fructose / Hexoses / Ketoses / Miscellaneous Anticonvulsants / Monosaccharides / Nervous System / Neuroprotective Agents / P-glycoprotein substrates,0H73WJJ391,97240-79-4,D00537,5284627.0,4447672.0,10887.0,38404.0,63631.0,CHEMBL220492,DAP000137,PA451728,ZINC000095616603
Cefmetazole,phase 4 complete,DB00274 (APRD00852),[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Cephamycins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Second-Generation Cephalosporins / Sulfur Compounds / Thiazines",3J962UJT8H,56796-20-4,D00910,42008.0,38311.0,50350471.0,2182.0,3489.0,CHEMBL1201195,DAP001179,PA164746819,ZINC000003830417
Olmesartan,phase 4 complete,DB00275 (APRD00223),CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O,"Agents Acting on the Renin-Angiotensin System / Agents causing hyperkalemia / Angiotensin 2 Receptor Blocker / Angiotensin II Antagonists and Calcium Channel Blockers / Angiotensin II receptor blockers (ARBs) and calcium channel blockers / Angiotensin II receptor blockers (ARBs) and diuretics / Angiotensin II receptor blockers (ARBs), plain / Angiotensin Receptor Antagonists / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / BSEP/ABCB11 Inhibitors / Cardiovascular Agents / Hypotensive Agents / Imidazoles / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / Tetrazoles",8W1IQP3U10,144689-24-7,D01204,158781.0,139674.0,50241364.0,321064.0,48416.0,CHEMBL1516,DAP001412,PA164742950,ZINC000000538621
Amsacrine,phase 4 complete,DB00276 (APRD00064),COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1,"Acridines / Aminoacridines / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cardiotoxic antineoplastic agents / Compounds used in a research, industrial, or household setting / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Indicators and Reagents / Intercalating Agents / Laboratory Chemicals / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / P-glycoprotein inhibitors",00DPD30SOY,51264-14-3,D02321,2179.0,2094.0,87351.0,739.0,2687.0,CHEMBL43,DAP000046,PA10309,ZINC000003812923
Theophylline,phase 4 complete,"DB00277 (APRD00082, DB09359)",CN1C2=C(NC=N2)C(=O)N(C)C1=O,"Agents that reduce seizure threshold / Alkaloids / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / Neurotransmitter Agents / Peripheral Nervous System Agents / Phosphodiesterase 5 Inhibitors / Phosphodiesterase Inhibitors / Purinergic Agents / Purinergic Antagonists / Purinergic P1 Receptor Antagonists / Purines / Purinones / Respiratory Smooth Muscle Relaxants / Respiratory System Agents / Vasodilating Agents / Xanthine derivatives / Xanthines and Adrenergics",0I55128JYK,58-55-9,D00371,2153.0,2068.0,10847.0,10438.0,28177.0,CHEMBL190,DAP000002,PA451647,ZINC000018043251
Argatroban,phase 4 complete,DB00278 (APRD00105),C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2,Anticoagulants / Antithrombins / Blood and Blood Forming Organs / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Enzyme Inhibitors / Fibrinolytic Agents / Hematologic Agents / Narrow Therapeutic Index Drugs / Piperidines / Protease Inhibitors / Serine Protease Inhibitors / Thrombin Inhibitors,OCY3U280Y3,74863-84-6,,152951.0,83702.0,50038001.0,15202.0,94385.0,CHEMBL1166,DAP000758,PA164745516,
Liothyronine,phase 4 complete,DB00279 (APRD01074),N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O,"Agents used to treat hypothyroidism / Drugs that are Mainly Renally Excreted / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / l-Triiodothyronine / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein inducers / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Thyroid Products / Thyronines / Thyroxine-binding globulin substrates / Triiodothyronine / UGT1A1 Substrates",06LU7C9H1V,6893-02-3,,5920.0,5707.0,18860.0,10814.0,18258.0,CHEMBL1544,DAP000082,PA164778866,ZINC000003830999
Disopyramide,phase 4 complete,DB00280 (APRD00507),CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C,"Agents producing tachycardia / Antiarrhythmic agents / Antiarrhythmics, Class I / Antiarrhythmics, Class Ia / Anticholinergic Agents / Blood Glucose Lowering Agents / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Highest Risk QTc-Prolonging Agents / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Muscarinic Antagonists / OCT1 inhibitors / OCT2 Inhibitors / Pyridines / QTc Prolonging Agents / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers",GFO928U8MQ,3737-09-5,D00303,3114.0,3002.0,50028893.0,3541.0,4657.0,CHEMBL517,DAP000504,PA449373,
Lidocaine,phase 4 complete,"DB00281 (APRD00479, DB05291)",CCN(CC)CC(=O)NC1=C(C)C=CC=C1C,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Agents that reduce seizure threshold / Amides / Amines / Analgesics and Anesthetics / Anesthetics / Anesthetics for Topical Use / Anesthetics, Local / Anilides / Aniline Compounds / Antiarrhythmic agents / Antiarrhythmics, Class I / Antiarrhythmics, Class Ib / Antipruritics and Local Anesthetics / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Cardiac Therapy / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Local Anesthesia / Local Anesthetics (Amide) / Membrane Transport Modulators / Methemoglobinemia Associated Agents / Nervous System / Neuraxial Anesthetics / Ophthalmologicals / Otologicals / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Sensory System Agents / Sodium Channel Blockers / Throat Preparations / Vasoprotectives / Voltage-Gated Sodium Channel Blockers",98PI200987,137-58-6,D00358,3676.0,3548.0,50017662.0,6387.0,6456.0,CHEMBL79,DAP000121,PA450226,ZINC000000020237
Pamidronic acid,phase 4 complete,DB00282 (APRD01161),NCCC(O)(P(O)(O)=O)P(O)(O)=O,Agents Causing Muscle Toxicity / Antineoplastic Agents / Bisphosphonates / Bone Density Conservation Agents / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Musculo-Skeletal System / Nephrotoxic agents / Organophosphonates / Organophosphorus Compounds,OYY3447OMC,40391-99-9,D07281,4674.0,4512.0,12581.0,11473.0,7903.0,CHEMBL834,DAP001416,PA450767,ZINC000003812862
Clemastine,phase 4 complete,DB00283 (APRD00875),CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,"Aminoalkyl Ethers / Anti-Allergic Agents / Antihistamines for Systemic Use / Antihistamines for Topical Use / Antipruritics / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Highest Risk QTc-Prolonging Agents / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Neurotransmitter Agents / Photosensitizing Agents / Pyrrolidines / QTc Prolonging Agents",95QN29S1ID,15686-51-8,D03535,26987.0,25129.0,94606.0,2578.0,3738.0,CHEMBL1626,DAP000322,PA164776997,ZINC000000402830
Acarbose,phase 4 complete,DB00284 (APRD00656),[H]C(=O)[C@H](O)[C@@H](O)[C@]([H])(O[C@@]1([H])O[C@H](CO)[C@@]([H])(O[C@H]2O[C@H](C)[C@@H](N[C@@]3([H])C=C(CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO,Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Enzyme Inhibitors / Glycoside Hydrolase Inhibitors / Hypoglycemia-Associated Agents / Oligosaccharides / Polysaccharides / Trisaccharides,T58MSI464G,56180-94-0,D00216,9811704.0,23264314.0,,16681.0,2376.0,CHEMBL1566,DCL000309,PA448010,ZINC000096309558
Venlafaxine,phase 4 complete,DB00285 (APRD00125),COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,"Agents producing tachycardia / Agents that reduce seizure threshold / Alcohols / Amines / Antidepressive Agents / Antidepressive Agents, Second-Generation / BCRP/ABCG2 Inducers / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cyclohexanes / Cyclohexanols / Cycloparaffins / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Ethylamines / Fatty Alcohols / Hexanols / Hypoglycemia-Associated Agents / Lipids / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Norepinephrine Uptake Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Phenethylamines / Potential QTc-Prolonging Agents / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin and Noradrenaline Reuptake Inhibitors / Serotonin Modulators",GRZ5RCB1QG,93413-69-5,D08670,5656.0,5454.0,82071.0,39786.0,9943.0,CHEMBL637,DAP000054,PA451866,
Conjugated estrogens,phase 4 complete,DB00286 (APRD00396),,"Agents causing angioedema / BCRP/ABCG2 Substrates / COMT Substrates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (weak) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Estradiol Congeners / Estrogens / Estrogens, Conjugated (USP) / Genito Urinary System and Sex Hormones / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Natural and Semisynthetic Estrogens, Plain / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / Sex Hormones and Modulators of the Genital System / Thyroxine-binding globulin inducers",IU5QR144QX,12126-59-9,D04070,,9532.0,,4099.0,8389.0,CHEMBL2106240,DNC001150,PA164754789,
Travoprost,phase 4 complete,DB00287 (APRD01271),CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F,"Antiglaucoma Preparations and Miotics / Antihypertensive Agents / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Inflammation Mediators / Lipids / Ophthalmics / Ophthalmologicals / Prostaglandin analogs reducing intraocular pressure (IOP) / Prostaglandins / Prostaglandins F, Synthetic / Prostaglandins, Synthetic",WJ68R08KX9,157283-68-6,D01964,5282226.0,4445407.0,,283809.0,746859.0,CHEMBL1200799,DAP000274,PA164781371,ZINC000004474682
Amcinonide,phase 4 complete,DB00288 (APRD00788),[H][C@@]12C[C@H]3OC4(CCCC4)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Pregnadienes / Pregnanes / Steroids / Steroids, Fluorinated / Thyroxine-binding globulin inhibitors",423W026MA9,51022-69-6,D01387,443958.0,392009.0,,17652.0,31199.0,CHEMBL1200732,DAP001044,PA164746074,ZINC000003977777
Atomoxetine,phase 4 complete,DB00289 (APRD00614),CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1,"Adrenergic Agents / Agents producing tachycardia / Agents that produce hypertension / Amines / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Membrane Transport Modulators / Miscellaneous Central Nervous System Agents / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Norepinephrine Reuptake Inhibitor / Norepinephrine Uptake Inhibitors / Potential QTc-Prolonging Agents / Propylamines / Psychostimulants, Agents Used for Adhd and Nootropics / QTc Prolonging Agents",ASW034S0B8,83015-26-3,D07473,54841.0,49516.0,50366567.0,38400.0,127342.0,CHEMBL641,DAP000721,PA134688071,ZINC000001842633
Bleomycin,phase 4 complete,"DB00290 (APRD00453, EXPT00718)",[H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O,"Amino Acids, Peptides, and Proteins / Antibiotics, Antineoplastic / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Carbohydrates / Cardiotoxic antineoplastic agents / Cytoprotective Agent / Cytotoxic Antibiotics and Related Substances / Drugs that are Mainly Renally Excreted / Glycoconjugates / Glycopeptides / Immunosuppressive Agents / Narrow Therapeutic Index Drugs / Peptides",40S1VHN69B,11056-06-7,,5360373.0,4514492.0,50122169.0,1622.0,22907.0,CHEMBL403664,DAP000531,PA448645,
Chlorambucil,phase 4 complete,DB00291 (APRD00115),OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl,"Agents that reduce seizure threshold / Alkylating Activity / Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Hydrocarbons, Halogenated / Immunosuppressive Agents / Mustard Compounds / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nitrogen Mustard Analogues / Nitrogen Mustard Compounds / Noxae / Toxic Actions",18D0SL7309,305-03-3,D00266,2708.0,2607.0,50003677.0,2346.0,28830.0,CHEMBL515,DNC001110,PA448926,ZINC000000001115
Etomidate,phase 4 complete,DB00292 (APRD00965),CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1,"Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Central Nervous System Agents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Hypnotics and Sedatives / Imidazoles / Nervous System",Z22628B598,33125-97-2,D00548,667484.0,580864.0,50125935.0,4177.0,4910.0,CHEMBL681,DAP000669,PA164743987,ZINC000000001408
Raltitrexed,phase 4 complete,"DB00293 (APRD00430, EXPT01092)",CN(CC1=CC2=C(NC(C)=NC2=O)C=C1)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,"Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Enzyme Inhibitors / Folic Acid Analogues / Folic Acid Antagonists / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Sulfur Compounds / Thymidylate Synthase, antagonists & inhibitors / Toxic Actions",FCB9EGG971,112887-68-0,D01064,104758.0,94568.0,18795.0,196239.0,5847.0,CHEMBL225071,DAP000759,PA131625240,ZINC000003832372
Etonogestrel,phase 4 complete,DB00294 (APRD00766),[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],"Adrenal Cortex Hormones / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hyperglycemia-Associated Agents / Intravaginal Contraceptives / Norpregnanes / Norpregnenes / Norsteroids / Progesterone Congeners / Progestins / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",304GTH6RNH,54048-10-1,,6917715.0,5292944.0,50423516.0,14584.0,50777.0,CHEMBL1531,DAP000855,PA164771231,ZINC000011680067
Morphine,phase 4 complete,"DB00295 (APRD00215, DB05354)",[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,"Alkaloids / Analgesics / Anesthetics / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / High-risk opioids / Hypotensive Agents / Narcotics / Natural Opium Alkaloids / Nervous System / Neuraxial Anesthetics / Opiate Agonists / Opiate Alkaloids / Opioid Agonist / Opioids / P-glycoprotein substrates / Peripheral Nervous System Agents / Phenanthrenes / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / UGT1A1 Substrates / UGT1A3 substrates / UGT2B7 substrates",76I7G6D29C,57-27-2,D08233,5288826.0,4450907.0,50000092.0,7052.0,17303.0,CHEMBL70,DAP000071,PA450550,ZINC000003812983
Ropivacaine,phase 4 complete,DB00296 (APRD00492),CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,"Amides / Amines / Anesthetics / Anesthetics, Local / Anilides / Aniline Compounds / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Local Anesthesia / Local Anesthetics (Amide) / Nervous System / Neuraxial Anesthetics / Peripheral Nervous System Agents / Sensory System Agents",7IO5LYA57N,84057-95-4,,175805.0,153165.0,50239375.0,35780.0,8890.0,CHEMBL1077896,DAP001230,PA451271,ZINC000000897002
Bupivacaine,phase 4 complete,DB00297 (APRD00247),CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C,"Agents that reduce seizure threshold / Amides / Amines / Anesthetics / Anesthetics, Local / Anilides / Aniline Compounds / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Hypotensive Agents / Local Anesthesia / Local Anesthetics (Amide) / Nervous System / Neuraxial Anesthetics / Peripheral Nervous System Agents / Sensory System Agents",Y8335394RO,38396-39-3,,2474.0,2380.0,50350790.0,1815.0,77431.0,CHEMBL1098,DAP001229,PA135057240,
Dapiprazole,phase 4 complete,DB00298 (APRD00902),CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1,Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antiglaucoma Preparations and Miotics / Antipsychotic Agents / Central Nervous System Agents / Central Nervous System Depressants / Neurotoxic agents / Neurotransmitter Agents / Ophthalmics / Ophthalmologicals / Sensory Organs / Tranquilizing Agents,5RNZ8GJO7K,72822-12-9,D07775,3033538.0,2298190.0,,22298.0,51066.0,CHEMBL1201216,DAP000298,PA164749109,ZINC000000001246
Penciclovir,phase 4 complete,"DB00299 (APRD00041, DB01730)",NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Direct Acting Antivirals / Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor / Heterocyclic Compounds, Fused-Ring / Nucleic Acid Synthesis Inhibitors / Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors / Purines / Purinones / Reverse Transcriptase Inhibitors",359HUE8FJC,39809-25-1,D05407,4725.0,4563.0,50210804.0,59839.0,7956.0,CHEMBL1540,DAP000488,PA450839,ZINC000000001899
Tenofovir disoproxil,phase 4 complete,"DB00300 (APRD01248, DB13426)",[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C,"Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Heterocyclic Compounds, Fused-Ring / Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Nephrotoxic agents / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / Organophosphorus Compounds / P-glycoprotein inhibitors / P-glycoprotein substrates / Purines / Reverse Transcriptase Inhibitors / Tenofovir and prodrugs",F4YU4LON7I,201341-05-1,,5481350.0,4587262.0,77145.0,300195.0,63717.0,CHEMBL1538,DAP001430,PA10204,ZINC000003929022
Flucloxacillin,phase 4 complete,DB00301 (APRD00609),[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1F)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / Beta-Lactamase Resistant Penicillins / beta-Lactams / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillins / Sulfur Compounds",43B2M34G2V,5250-39-5,D04196,21319.0,20037.0,50370590.0,4448.0,5098.0,CHEMBL222645,DAP001163,PA164781042,ZINC000004102187
Tranexamic acid,phase 4 complete,"DB00302 (APRD01270, EXPT00508)",NC[C@H]1CC[C@@H](CC1)C(O)=O,"Acids, Carbocyclic / Amino Acids / Antifibrinolytic Agents / Blood and Blood Forming Organs / Coagulants / Cyclohexanecarboxylic Acids / Cyclohexanes / Cycloparaffins / Decreased Fibrinolysis / Fibrin Modulating Agents / Hematologic Agents / Hemostatics",6T84R30KC1,1197-18-8,D01136,5526.0,10482000.0,50428067.0,10691.0,48669.0,CHEMBL877,DAP000199,PA164750514,ZINC000100071256
Ertapenem,phase 4 complete,DB00303 (APRD00952),[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Carbapenems / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / Penem Antibacterial / Sulfur Compounds",G32F6EID2H,153832-46-3,D07908,150610.0,132758.0,,325642.0,404903.0,CHEMBL1359,DAP000431,PA164777032,ZINC000003918453
Desogestrel,phase 4 complete,DB00304 (APRD00762),[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],"Adrenal Cortex Hormones / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptives, Oral / Contraceptives, Oral, Synthetic / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Norpregnanes / Norpregnenes / Norsteroids / Progestin Contraceptives / Progestins / Progestogens and Estrogens, Sequential Preparations / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids / UGT1A1 Inducers",81K9V7M3A3,54024-22-5,D02367,40973.0,37400.0,50423510.0,22656.0,4453.0,CHEMBL1533,DAP001209,PA449238,ZINC000004097416
Mitomycin,phase 4 complete,DB00305 (APRD00284),[H][C@]12CN3C4=C([C@@H](COC(N)=O)[C@@]3(OC)[C@@]1([H])N2)C(=O)C(N)=C(C)C4=O,"Alkylating Activity / Alkylating Drugs / Antibiotics, Antineoplastic / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Azirines / Cardiotoxic antineoplastic agents / Compounds used in a research, industrial, or household setting / Cross-Linking Reagents / Cytotoxic Antibiotics and Related Substances / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Indicators and Reagents / Indolequinones / Indoles / Mitomycins / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Nucleic Acid Synthesis Inhibitors / Toxic Actions",50SG953SK6,50-07-7,D00208,5746.0,5544.0,50428658.0,632.0,27504.0,CHEMBL105,DAP001402,PA450524,ZINC000030726187
Talbutal,phase 4 complete,DB00306 (APRD01333),CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O,"Anticholinergic Agents / Barbiturates, Plain / Central Nervous System Depressants / Hypnotics and Sedatives / Nervous System / Nicotinic Antagonists / Psycholeptics / Pyrimidines / Pyrimidinones",4YIR8202AX,115-44-6,D06887,8275.0,7976.0,,89810.0,134923.0,CHEMBL1200802,DAP000670,PA164779051,
Bexarotene,phase 4 complete,DB00307 (APRD00114),CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C,"Alkenes / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Biological Factors / Carotenoids / Compounds used in a research, industrial, or household setting / Cyclohexanes / Cyclohexenes / Cycloparaffins / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hydrocarbons, Acyclic / Immunosuppressive Agents / Myelosuppressive Agents / Naphthalenes / Pigments, Biological / Polyenes / Retinoids / Terpenes / Tetrahydronaphthalenes",A61RXM4375,153559-49-0,D03106,82146.0,74139.0,50032675.0,233272.0,50859.0,CHEMBL1023,DAP000276,PA164752250,ZINC000001539579
Ibutilide,phase 4 complete,DB00308 (APRD01025),CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1,"Amides / Antiarrhythmic agents / Antiarrhythmics, Class III / Cardiac Therapy / Cardiovascular Agents / Drugs that are Mainly Renally Excreted / Highest Risk QTc-Prolonging Agents / QTc Prolonging Agents / Sulfones / Sulfur Compounds",2436VX1U9B,122647-31-8,D00648,60753.0,54755.0,50131432.0,41289.0,5856.0,CHEMBL533,DAP000279,PA449958,
Vindesine,phase 4 complete,DB00309 (APRD00392),[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC,"Alkaloids / Antimitotic Agents / Antineoplastic Agents / Antineoplastic Agents, Phytogenic / Antineoplastic and Immunomodulating Agents / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Indole Alkaloids / Indoles / Mitosis Modulators / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Secologanin Tryptamine Alkaloids / Tubulin Modulators / Vinca Alkaloids",RSA8KO39WH,53643-48-4,D01769,40839.0,9818189.0,,11204.0,36373.0,CHEMBL238071,DAP000949,PA10232,ZINC000008214470
Chlorthalidone,phase 4 complete,DB00310 (APRD00127),NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12,"Acids, Carbocyclic / Amides / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzene Derivatives / Benzophenones / Cardiovascular Agents / Diuretics / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Hypotensive Agents / Imides / Increased Diuresis / Isoindoles / Ketones / Low-Ceiling Diuretics and Potassium-Sparing Agents / Low-Ceiling Diuretics, Excl. Thiazides / Membrane Transport Modulators / Natriuretic Agents / Non Potassium Sparing Diuretics / Photosensitizing Agents / Phthalic Acids / Phthalimides / Sodium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds / Thiazide-like Diuretic",Q0MQD1073Q,77-36-1,D00272,2732.0,2631.0,25900.0,2409.0,3654.0,CHEMBL1055,DAP000521,PA448970,
Pentobarbital,phase 4 complete,DB00312 (APRD01174),CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,"Adjuvants, Anesthesia / Anticholinergic Agents / Anticonvulsants / Barbiturates / Barbiturates, Plain / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2A6 Inducers (strong) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Nicotinic Antagonists / Psycholeptics / Pyrimidines / Pyrimidinones",I4744080IR,76-74-4,D00499,4737.0,4575.0,50055935.0,8004.0,7983.0,CHEMBL448,DAP000671,PA450859,
Valproic acid,phase 4 complete,"DB00313 (APRD00256, DB00510, APRD00066)",CCCC(CCC)C(O)=O,"Acids, Acyclic / Anti-epileptic Agent / Anticonvulsants / Antimanic Agents / Antineoplastic Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Fatty Acid Derivatives / Fatty Acids / Fatty Acids, Volatile / GABA Agents / Hepatotoxic Agents / Highest Risk QTc-Prolonging Agents / Histone Deacetylase Inhibitors / Lipids / Methemoglobinemia Associated Agents / Miscellaneous Anticonvulsants / Mood Stabilizer / Narrow Therapeutic Index Drugs / Nervous System / Neurotransmitter Agents / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OAT3/SLC22A8 Substrates with Narrow Therapeutic Index / Pentanoic Acids / Photosensitizing Agents / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Tranquilizing Agents / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT1A1 substrates with narrow therapeutic index / UGT1A3 substrates / UGT1A3 substrates with narrow therapeutic index / UGT1A4 substrates / UGT1A6 substrate / UGT1A6 substrate with narrow therapeutic index / UGT1A9 Substrates / UGT1A9 substrates with narrow therapeutic index / UGT2B7 substrates / UGT2B7 substrates with narrow therapeutic index / Valerates",614OI1Z5WI,99-66-1,D00399,3121.0,3009.0,50003616.0,11118.0,39867.0,CHEMBL109,DNC001659,PA451846,ZINC000003008621
Capreomycin,phase 4 complete,DB00314 (APRD00844),[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O.[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O,"Agents that produce neuromuscular block (indirect) / Amino Acids, Peptides, and Proteins / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics, Antitubercular / Antiinfectives for Systemic Use / Antimycobacterials / Antituberculosis Agents / Drugs for Treatment of Tuberculosis / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Enzyme Inhibitors / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Peptides / Peptides, Cyclic / Protein Synthesis Inhibitors",232HYX66HC,11003-38-6,D00135,3000502.0,2272094.0,,78903.0,3371.0,CHEMBL2303634,DAP000892,PA164746226,
Zolmitriptan,phase 4 complete,DB00315 (APRD00376),CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12,"Agents that produce hypertension / Amines / Analgesics / Antidepressive Agents / Antimigraine Preparations / Biogenic Amines / Biogenic Monoamines / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Indoles / Monoamine Oxidase A Substrates / Nervous System / Neurotransmitter Agents / Oxazoles / Selective Serotonin 5-HT1 Receptor Agonists / Selective Serotonin Agonists / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 1b Receptor Agonists / Serotonin 1d Receptor Agonists / Serotonin 5-HT1 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists / Serotonin-1b and Serotonin-1d Receptor Agonist / Triptans",2FS66TH3YW,139264-17-8,D00415,60857.0,54844.0,50033383.0,135775.0,10124.0,CHEMBL1185,DAP000077,PA451975,ZINC000000015515
Acetaminophen,phase 4 complete,DB00316 (APRD00252),CC(=O)NC1=CC=C(O)C=C1,"Acetaminophen and Prodrugs / Amides / Amines / Analgesics / Analgesics, Non-Narcotic / Anilides / Aniline Compounds / Antipyretics / Central Nervous System Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Methemoglobinemia Associated Agents / Miscellaneous Analgesics and Antipyretics / Nervous System / P-glycoprotein inhibitors / P-glycoprotein substrates / Sensory System Agents / UGT1A1 Substrates / UGT1A6 substrate / UGT1A9 Substrates",362O9ITL9D,103-90-2,D00217,1983.0,1906.0,26197.0,161.0,46195.0,CHEMBL112,DAP001436,PA448015,ZINC000013550868
Gefitinib,phase 4 complete,"DB00317 (APRD00997, DB07998)",COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Kinase Inhibitor / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors / Quinazolines / Tyrosine Kinase Inhibitors",S65743JHBS,184475-35-2,D01977,123631.0,110217.0,5447.0,328134.0,49668.0,CHEMBL939,DAP000657,PA131301952,ZINC000019632614
Codeine,phase 4 complete,"DB00318 (APRD00120, DB09471)",[H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4OC,"Alkaloids / Analgesics / Antitussive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cough and Cold Preparations / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Morphinans / Morphine Derivatives / Narcotics / Natural Opium Alkaloids / Nervous System / OAT1/SLC22A6 inhibitors / OCT1 inhibitors / OCT1 substrates / Opiate Agonists / Opiate Alkaloids / Opioid Agonist / Opioids / Opium Alkaloids and Derivatives / Phenanthrenes / Respiratory System Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / UGT2B7 substrates",UX6OWY2V7J,76-57-3,D03580,5284371.0,4447447.0,50105098.0,1545976.0,16714.0,CHEMBL485,DAP000213,PA449088,ZINC000003806721
Piperacillin,phase 4 complete,DB00319 (APRD00325),[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O,"Agents that produce neuromuscular block (indirect) / Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Drugs that are Mainly Renally Excreted / Extended-spectrum Penicillins / Heterocyclic Compounds, Fused-Ring / Lactams / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Substrates / Penicillin G / Penicillins / Penicillins With Extended Spectrum / Sulfur Compounds",9I628532GX,66258-76-2,D00466,43672.0,39798.0,50240426.0,1546000.0,8232.0,CHEMBL702,DAP001164,PA450975,ZINC000003913937
Dihydroergotamine,phase 4 complete,"DB00320 (APRD00476, DB05743)",[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Alkaloids / Analgesics / Analgesics, Non-Narcotic / Antidepressive Agents / Antimigraine Preparations / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Agonists / Ergot Alkaloids and Derivatives / Ergot-derivative Dopamine Receptor Agonists / Ergotamine Derivative / Ergotamines / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotransmitter Agents / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin 5-HT2 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists / Sympatholytic (Adrenergic Blocking) Agents / Vasoconstrictor Agents",436O5HM03C,511-12-6,,10531.0,10091.0,50295557.0,3418.0,4562.0,CHEMBL1732,DAP000078,PA164743028,ZINC000003978005
Amitriptyline,phase 4 complete,DB00321 (APRD00227),CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Agents that produce hypertension / Agents that reduce seizure threshold / Analgesics / Analgesics, Non-Narcotic / Anticholinergic Agents / Antidepressive Agents / Antidepressive Agents, Tricyclic / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Histamine Antagonists / Histamine H1 Antagonists / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / Muscarinic Antagonists / Neurotoxic agents / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Non-Selective Monoamine Reuptake Inhibitors / P-glycoprotein substrates / Psychotropic Drugs / QTc Prolonging Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Tertiary amine tricyclic antidepressants / Tricyclics and Other Norepinephrine-reuptake Inhibitors / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT1A4 substrates",1806D8D52K,50-48-6,D07448,2160.0,2075.0,50020712.0,704.0,2666.0,CHEMBL629,DNC001466,PA448385,ZINC000000968257
Floxuridine,phase 4 complete,DB00322 (APRD00692),OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O,"Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Carbohydrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strong) / Cytochrome P-450 Enzyme Inhibitors / Deoxyribonucleosides / Deoxyuridine / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Glycosides / Immunosuppressive Agents / Myelosuppressive Agents / Noxae / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / Pyrimidine Analogues / Pyrimidine Nucleosides / Pyrimidines / Ribonucleosides / Thyroxine-binding globulin inducers / Toxic Actions",039LU44I5M,50-91-9,D04197,5790.0,5586.0,50340678.0,4488.0,60761.0,CHEMBL917,DAP001245,PA449652,ZINC000003813010
Tolcapone,phase 4 complete,DB00323 (APRD00445),CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O,Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Benzene Derivatives / Benzophenones / Central Nervous System Agents / Central Nervous System Depressants / COMT Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dopamine Agents / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hypotensive Agents / Ketones / Nervous System / Nitro Compounds / Nitrophenols / Phenols,CIF6334OLY,134308-13-7,D00786,4659569.0,3848682.0,50108877.0,72937.0,63630.0,CHEMBL1324,DAP000607,PA451720,ZINC000035342789
Fluorometholone,phase 4 complete,DB00324 (APRD00980),[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anti-Allergic Agents / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Moderately Potent (Group II) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Ophthalmologicals / Pregnadienediols / Pregnadienes / Pregnanes / Sensory Organs / Steroids / Steroids, Fluorinated / Thyroxine-binding globulin inhibitors / Vasoprotectives",SV0CSG527L,426-13-1,D01367,9878.0,9494.0,50103631.0,4491.0,31625.0,CHEMBL1200600,DAP001047,PA164781355,ZINC000118912517
Nitroprusside,phase 4 complete,DB00325 (APRD01143),O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N,"Acids / Acids, Noncarboxylic / Anions / Antihypertensive Agents / Arteriolar Smooth Muscle, Agents Acting On / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Cyanides / Direct Vasodilators / Drugs that are Mainly Renally Excreted / Electrolytes / Ferric Compounds / Ferricyanides / Hydrogen Cyanide / Hypotensive Agents / Indicators and Reagents / Ions / Iron Compounds / Laboratory Chemicals / Methemoglobinemia Associated Agents / Nitric Oxide Donors / Nitroferricyanide Derivatives / Nitrogen Compounds / Organometallic Compounds / Vasodilating Agents / Vasodilation",169D1260KM,15078-28-1,,11963622.0,21607452.0,50377921.0,7476.0,7596.0,CHEMBL2097081,DNC001351,PA451406,
Calcium glucoheptonate,phase 4 complete,DB00326 (APRD00841),[Ca++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O,"Acids, Acyclic / Alimentary Tract and Metabolism / Calcium Salts / Carbohydrates / Hydroxy Acids / Mineral Supplements / Supplements",L11651398J,29039-00-7,D00934,62859.0,56591.0,,47618.0,3314.0,CHEMBL1237066,,PA164746233,
Hydromorphone,phase 4 complete,DB00327 (APRD01021),[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,"Alkaloids / Analgesics / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / High-risk opioids / Morphinans / Morphine Derivatives / Narcotics / Natural Opium Alkaloids / Nervous System / Opiate Agonists / Opiate Alkaloids / Opioid Agonist / Opioids / Peripheral Nervous System Agents / Phenanthrenes / Semi-synthetic Opioids / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / UGT1A3 substrates / UGT2B7 substrates",Q812464R06,466-99-9,,5284570.0,4447624.0,50241341.0,3423.0,5790.0,CHEMBL398707,DAP000472,PA449918,ZINC000000402954
Indomethacin,phase 4 complete,DB00328 (APRD00109),COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,"Acetic Acid Derivatives and Related Substances / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antigout Preparations / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antirheumatic Agents / BSEP/ABCB11 Substrates / Cardiac Therapy / Cardiovascular Agents / Central Nervous System Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Hypoglycemia-Associated Agents / Immunosuppressive Agents / Indoles / Musculo-Skeletal System / Myelosuppressive Agents / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inhibitors / Ophthalmologicals / Other Nonsteroidal Anti-inflammatory Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / Sensory Organs / Sensory System Agents / Tocolytic Agents / Topical Products for Joint and Muscular Pain / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT1A9 Substrates / UGT2B7 Inhibitors / UGT2B7 substrates",XXE1CET956,53-86-1,D00141,3715.0,3584.0,17638.0,5781.0,49662.0,CHEMBL6,DAP000617,PA449982,ZINC000000601283
Ethambutol,phase 4 complete,DB00330 (APRD00957),CC[C@@H](CO)NCCN[C@@H](CC)CO,Amines / Anti-Bacterial Agents / Anti-Infective Agents / Antiinfectives for Systemic Use / Antimycobacterials / Antituberculosis Agents / Diamines / Drugs for Treatment of Tuberculosis / Drugs that are Mainly Renally Excreted / Ethylenediamines / Polyamines,8G167061QZ,74-55-5,D07925,14052.0,13433.0,50448407.0,4110.0,4877.0,CHEMBL44884,DAP000055,PA164784021,ZINC000019364219
Metformin,phase 4 complete,DB00331 (APRD01099),CN(C)C(=N)NC(N)=N,Alimentary Tract and Metabolism / Amidines / Biguanides / Blood Glucose Lowering Agents / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Guanidines / MATE 1 Substrates / MATE 2 Substrates / MATE substrates / OCT1 substrates / OCT2 Inhibitors / OCT2 Substrates,9100L32L2N,657-24-9,D04966,4091.0,3949.0,50229665.0,6809.0,6801.0,CHEMBL1431,DAP000205,PA450395,ZINC000012859773
Ipratropium,phase 4 complete,DB00332 (APRD00537),[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C,"Adrenergics, Inhalants / Agents producing tachycardia / Agents to Treat Airway Disease / Alkaloids / Anti-Asthmatic Agents / Anticholinergic Agents / Antimuscarinics Antispasmodics / Atropine Derivatives / Autonomic Agents / Aza Compounds / Azabicyclo Compounds / Belladonna Alkaloids / Bronchodilator Agents / Cholinergic Agents / Drugs for Obstructive Airway Diseases / Muscarinic Antagonists / Nasal Preparations / Neurotransmitter Agents / Peripheral Nervous System Agents / Respiratory System Agents / Solanaceous Alkaloids / Tropanes",GR88G0I6UL,60205-81-4,,657308.0,19962157.0,,7213.0,46659.0,CHEMBL1621597,DNC000806,PA450082,
Methadone,phase 4 complete,DB00333 (APRD00485),CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,Analgesics / Anticholinergic Agents / Antidepressive Agents / Antitussive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diphenylpropylamine Derivatives / Drugs that are Mainly Renally Excreted / Drugs Used in Addictive Disorders / Drugs Used in Opioid Dependence / High-risk opioids / Ketones / Moderate Risk QTc-Prolonging Agents / Narcotics / Nervous System / Nicotinic Antagonists / NMDA Receptor Antagonists / Opiate Agonists / Opioid Agonist / Opioids / P-glycoprotein inhibitors / Peripheral Nervous System Agents / QTc Prolonging Agents / Respiratory System Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / Thyroxine-binding globulin inducers,UC6VBE7V1Z,76-99-3,D08195,4095.0,3953.0,82507.0,6813.0,6807.0,CHEMBL651,DAP000267,PA450401,
Olanzapine,phase 4 complete,DB00334 (APRD00138),CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Anticholinergic Agents / Antidepressive Agents / Antiemetics / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Autonomic Agents / Benzazepines / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diazepines, Oxazepines, Thiazepines and Oxepines / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Histamine H2 Antagonists / Hyperglycemia-Associated Agents / Hypotensive Agents / Muscarinic Antagonists / Nervous System / Neurotransmitter Agents / P-glycoprotein substrates / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents / UGT1A4 substrates",N7U69T4SZR,132539-06-1,D00454,4585.0,10442212.0,35254.0,61381.0,7735.0,CHEMBL715,DAP000022,PA450688,ZINC000052957434
Atenolol,phase 4 complete,DB00335 (APRD00172),CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-1 Receptor Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Autonomic Agents / Beta blocking agents and calcium channel blockers / Beta Blocking Agents and Thiazides / Beta Blocking Agents, Selective / Beta Blocking Agents, Selective, and Thiazides / Beta-Blockers (Beta1 Selective) / Bradycardia-Causing Agents / BSEP/ABCB11 Substrates / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Hypotensive Agents / Peripheral Nervous System Agents / QTc shortening agents / Sympatholytics",50VV3VW0TI,29122-68-7,D00235,2249.0,2162.0,25753.0,1202.0,2904.0,CHEMBL24,DAP000482,PA448499,
Nitrofural,phase 4 complete,DB00336 (APRD00050),NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O,"Agents Against Leishmaniasis and Trypanosomiasis / Anti-Infective Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Antiseptics and Disinfectants / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Dermatologicals / Furans / Irrigating Solutions / Medicated Dressings / Medicated Dressings With Antiinfectives / Nitro Compounds / Nitrofuran Derivatives / Nitrofurans / Ophthalmologicals / Otologicals / Sensory Organs",X8XI70B5Z6,59-87-0,D00862,5447130.0,4566720.0,50420350.0,7455.0,,CHEMBL869,,PA164754877,ZINC000000897369
Pimecrolimus,phase 4 complete,DB00337 (APRD01182),[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC,"Agents for Dermatitis, Excluding Corticosteroids / Analgesics / Analgesics, Non-Narcotic / Anti-Bacterial Agents / Anti-Inflammatory Agents / Calcineurin Inhibitor Immunosuppressant / Calcineurin Inhibitors / Central Nervous System Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Enzyme Inhibitors / Immunologic Factors / Immunosuppressive Agents / Lactones / Misc. Skin and Mucous Membrane Agents / Peptidylprolyl Isomerase, antagonists & inhibitors / Peripheral Nervous System Agents / Polyketides / Sensory System Agents",7KYV510875,137071-32-0,,6509979.0,21111755.0,,321952.0,135888.0,CHEMBL1200686,DAP000594,PA164783790,ZINC000085536990
Omeprazole,phase 4 complete,DB00338 (APRD00446),COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C,"2-Pyridinylmethylsulfinylbenzimidazoles / Acid Reducers / Alimentary Tract and Metabolism / Anti-Ulcer Agents / BCRP/ABCG2 Inhibitors / Benzimidazoles / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Enzyme Inhibitors / Gastric Acid Lowering Agents / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / Proton Pump Inhibitors / Proton-pump Inhibitors / Pyridines / Sulfoxides / Sulfur Compounds",KG60484QX9,73590-58-6,D00455,4594.0,4433.0,50241343.0,7646.0,77260.0,CHEMBL1503,DAP000180,PA450704,
Pyrazinamide,phase 4 complete,DB00339 (APRD01206),NC(=O)C1=NC=CN=C1,Anti-Bacterial Agents / Anti-Infective Agents / Antiinfectives for Systemic Use / Antimycobacterials / Antituberculosis Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs for Treatment of Tuberculosis / Drugs that are Mainly Renally Excreted / Hepatotoxic Agents / Photosensitizing Agents / Pyrazines,2KNI5N06TI,98-96-4,D00144,1046.0,1017.0,228814.0,8987.0,45285.0,CHEMBL614,DAP000660,PA451182,ZINC000000002005
Metixene,phase 4 complete,DB00340 (APRD01101),CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1,"Agents producing tachycardia / Anti-Parkinson Drugs / Anticholinergic Agents / Heterocyclic Compounds, Fused-Ring / Muscarinic Antagonists / Nervous System / Sulfur Compounds / Tertiary Amines / Xanthenes",32VY6L26ZW,4969-02-2,D01871,4167.0,4023.0,79211.0,29682.0,51024.0,CHEMBL1201342,DAP000346,PA164783811,
Cetirizine,phase 4 complete,DB00341 (APRD00630),OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,"Anti-Allergic Agents / Antihistamines for Systemic Use / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / P-glycoprotein inhibitors / P-glycoprotein substrates / Piperazine Derivatives / Piperazines / Potential QTc-Prolonging Agents / QTc Prolonging Agents",YO7261ME24,83881-51-0,,2678.0,2577.0,22890.0,20610.0,3561.0,CHEMBL1000,DAP000323,PA448905,
Terfenadine,phase 4 complete,DB00342 (APRD00606),CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,"Anticholinergic Agents / Antihistamines for Systemic Use / Benzene Derivatives / Benzhydryl Compounds / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Highest Risk QTc-Prolonging Agents / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Muscarinic Antagonists / Neurotransmitter Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Piperidines / QTc Prolonging Agents",7BA5G9Y06Q,50679-08-8,D00521,5405.0,5212.0,50017376.0,42330.0,9453.0,CHEMBL17157,DAP000102,PA451619,
Diltiazem,phase 4 complete,DB00343 (APRD00473),COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,"Agents causing hyperkalemia / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzazepines / Benzothiazepine Derivatives / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium Channel Blockers (Nondihydropyridine) / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (moderate) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (moderate) / Cytochrome P-450 CYP3A7 Inhibitors (strong) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Membrane Transport Modulators / Miscellaneous Calcium-channel Blocking Agents / Moderate Risk QTc-Prolonging Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / QTc Prolonging Agents / Selective Calcium Channel Blockers With Direct Cardiac Effects / Vasodilating Agents / Vasoprotectives",EE92BBP03H,42399-41-7,D07845,39186.0,35850.0,50004704.0,3443.0,101278.0,CHEMBL23,DAP001262,PA449334,ZINC000000621893
Protriptyline,phase 4 complete,DB00344 (APRD00441),CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12,"Adrenergic Agents / Adrenergic Uptake Inhibitors / Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Antidepressive Agents, Tricyclic / Benzocycloheptenes / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Dibenzocycloheptenes / Membrane Transport Modulators / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Non-Selective Monoamine Reuptake Inhibitors / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",4NDU154T12,438-60-8,D08447,4976.0,4805.0,50176062.0,8886.0,8597.0,CHEMBL668,DAP000863,PA451168,ZINC000001530764
Aminohippuric acid,phase 4 complete,DB00345 (APRD00792),NC1=CC=C(C=C1)C(=O)NCC(O)=O,"Acids, Carbocyclic / Amides / Aminobenzoates / Aminohippuric Acids / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Diagnostic Agents / Hippurates / Indicators and Reagents / Keto Acids / Laboratory Chemicals / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inhibitors / OCT2 Inhibitors / para-Aminobenzoates / Tests for Renal Function and Ureteral Injuries",Y79XT83BJ9,61-78-9,D06890,2148.0,2063.0,50240008.0,42837.0,104011.0,CHEMBL463,,PA134711723,ZINC000000119344
Alfuzosin,phase 4 complete,DB00346 (APRD00490),COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N(C)CCCNC(=O)C1CCCO1,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs Used in Benign Prostatic Hypertrophy / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / Peripheral alpha-1 blockers / Potential QTc-Prolonging Agents / Prostatic Hyperplasia / QTc Prolonging Agents / Selective Alfa-1-adrenergic Blocking Agents / Urological Agents / Urologicals",90347YTW5F,81403-80-7,D07124,2092.0,2008.0,50033110.0,17300.0,51141.0,CHEMBL709,DCL000664,PA164774795,
Trimethadione,phase 4 complete,DB00347 (APRD00315),CN1C(=O)OC(C)(C)C1=O,Agents causing hyperkalemia / Anti-epileptic Agent / Antiarrhythmic agents / Anticonvulsants / Bradycardia-Causing Agents / Calcium Channel Blockers / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Nervous System / Oxazoles / Oxazolidine Derivatives / Potential QTc-Prolonging Agents / QTc Prolonging Agents,R7GV3H6FQ4,127-48-0,D00392,5576.0,5374.0,50227239.0,10827.0,9727.0,CHEMBL695,DAP001265,PA164744924,ZINC000001530710
Nitisinone,phase 4 complete,DB00348 (APRD01141),[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O,"4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor / 4-Hydroxyphenylpyruvate Dioxygenase, antagonists & inhibitors / Acids, Carbocyclic / Alimentary Tract and Metabolism / Benzene Derivatives / Benzoates / Cyclohexanes / Cycloparaffins / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Hydroxyphenylpyruvate Dioxygenase Inhibitors / Ketones / Other Miscellaneous Therapeutic Agents / Various Alimentary Tract and Metabolism Products",K5BN214699,104206-65-7,,115355.0,103195.0,50088804.0,61805.0,50378.0,CHEMBL1337,DAP000774,PA164777037,ZINC000100014475
Clobazam,phase 4 complete,DB00349 (APRD00307),CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,"Anti-Anxiety Agents / Anticonvulsants / Benzazepines / Benzodiazepines and benzodiazepine derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Agonists / GABA-A Receptor Agonists / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotransmitter Agents / P-glycoprotein substrates / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents",2MRO291B4U,22316-47-8,D01253,2789.0,2687.0,50247888.0,21241.0,31413.0,CHEMBL70418,DAP000672,PA10888,ZINC000000001175
Minoxidil,phase 4 complete,"DB00350 (APRD00086, DB08225)",NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1,"Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Arteriolar Smooth Muscle, Agents Acting On / Arteriolar Vasodilation / Arteriolar Vasodilator / Cardiovascular Agents / Dermatologicals / Direct Vasodilators / Hypotensive Agents / Misc. Skin and Mucous Membrane Agents / Piperidines / Pyrimidine Derivatives / Pyrimidines / UGT1A1 Substrates / Vasodilating Agents",5965120SH1,38304-91-5,D00418,4201.0,10438564.0,50237593.0,6984.0,6942.0,CHEMBL802,DAP000143,PA450521,ZINC000000001735
Megestrol acetate,phase 4 complete,DB00351 (APRD01092),[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,"Adrenal Cortex Hormones / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Appetite Stimulants / Central Nervous System Agents / Central Nervous System Stimulants / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptives, Oral / Contraceptives, Oral, Synthetic / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Endocrine Therapy / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hormones and Related Agents / Hyperglycemia-Associated Agents / Megestrol / P-glycoprotein inhibitors / Pregnadien Derivatives / Pregnadienes / Pregnanes / Progestin Contraceptives / Progestins / Progestogens and Estrogens, Sequential Preparations / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",TJ2M0FR8ES,595-33-5,D00952,11683.0,11192.0,50238674.0,29451.0,6723.0,CHEMBL1201139,DAP000861,PA450351,ZINC000004097467
Tioguanine,phase 4 complete,DB00352 (APRD00290),NC1=NC(=S)C2=C(N1)N=CN2,"Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Myelosuppressive Agents / Noxae / Purine Analogues / Purines / Thiopurine Analogs / Toxic Actions",WIX31ZPX66,154-42-7,D08603,2723601.0,2005804.0,50200099.0,10485.0,9555.0,CHEMBL727,DAP000194,PA451663,ZINC000006382803
Methylergometrine,phase 4 complete,DB00353 (APRD00739),[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,"Agents that produce hypertension / Alkaloids / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Antagonists / Ergolines / Ergonovine / Ergot Alkaloids and Derivatives / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Reproductive Control Agents / Uterotonic agents",W53L6FE61V,113-42-8,D00680,8226.0,7933.0,50330860.0,6883.0,92607.0,CHEMBL1201356,DAP000978,PA450461,ZINC000095619105
Buclizine,phase 4 complete,DB00354 (APRD00723),CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1,Agents producing tachycardia / Anticholinergic Agents / Antihistamines for Systemic Use / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Muscarinic Antagonists / Neurotransmitter Agents / Piperazine Derivatives / Potential QTc-Prolonging Agents / QTc Prolonging Agents,0C94V6X681,82-95-1,D07547,6729.0,6473.0,,59636.0,3205.0,CHEMBL1201271,DAP001076,PA164748223,
Aztreonam,phase 4 complete,"DB00355 (APRD00815, EXPT00605)",C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / Monobactam Antibacterial / Monobactams / Sulfur Compounds",G2B4VE5GH8,78110-38-0,D00240,9568617.0,4674940.0,50240480.0,1272.0,161680.0,CHEMBL158,DAP000117,PA448523,ZINC000003830264
Chlorzoxazone,phase 4 complete,DB00356 (APRD00308),ClC1=CC2=C(OC(=O)N2)C=C1,"Benzoxazoles / Central Nervous System Agents / Central Nervous System Depressants / Centrally-mediated Muscle Relaxation / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Musculo-Skeletal System / Oxazol, Thiazine, and Triazine Derivatives / Peripheral Nervous System Agents",H0DE420U8G,95-25-0,D00771,2733.0,2632.0,50290811.0,2410.0,3655.0,CHEMBL1371,DAP000952,PA448971,ZINC000084843283
Aminoglutethimide,phase 4 complete,DB00357 (APRD00592),CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1,"Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Aromatase Inhibitors / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Endocrine Therapy / Enzyme Inhibitors / Estrogen Antagonists / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Piperidines / Piperidones / Steroid Synthesis Inhibitors",0O54ZQ14I9,125-84-8,D00574,2145.0,2060.0,9460.0,677.0,2654.0,CHEMBL488,DAP000842,PA448375,
Mefloquine,phase 4 complete,DB00358 (APRD00300),OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F,"Agents Causing Muscle Toxicity / Agents that reduce seizure threshold / Aminoquinolines / Anti-Infective Agents / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Cholinesterase Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Methanolquinolines / P-glycoprotein inhibitors / P-glycoprotein substrates / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quinolines",TML814419R,53230-10-7,D04895,4046.0,3906.0,50022889.0,6694.0,63681.0,CHEMBL416956,DAP001310,PA450348,
Sulfadiazine,phase 4 complete,DB00359 (APRD00190),NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1,Amides / Amines / Aniline Compounds / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Antiparasitic Agents / Antiprotozoals / Blood Glucose Lowering Agents / Coccidiostats / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hypoglycemia-Associated Agents / Intermediate-Acting Sulfonamides / Methemoglobinemia Associated Agents / Sulfanilamides / Sulfonamide Antibacterial / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds,0N7609K889,68-35-9,D00587,5215.0,5026.0,50166571.0,10171.0,9328.0,CHEMBL439,DAP001238,PA451539,ZINC000000120319
Sapropterin,phase 4 complete,"DB00360 (APRD01297, EXPT00691, DB02692)",[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O,"Alimentary Tract and Metabolism / Amines / Biological Factors / Breast Cancer Resistance Protein Inhibitors / Coenzymes / Dietary Supplements / Enzymes and Coenzymes / Ethylamines / Heterocyclic Compounds, Fused-Ring / Nitric Oxide Synthase / Other Miscellaneous Therapeutic Agents / P-glycoprotein inhibitors / Phenethylamines / Phenylalanine Hydroxylase Activator / Phenylalanine Hydroxylase Activators / Pigments, Biological / Pteridines / Pterins / Supplements / Various Alimentary Tract and Metabolism Products",EGX657432I,62989-33-7,D08505,44257.0,40270.0,50373697.0,753340.0,59560.0,CHEMBL1201774,DNC000425,PA161990676,ZINC000013585233
Vinorelbine,phase 4 complete,DB00361 (APRD00101),[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC,"Alkaloids / Antimitotic Agents / Antineoplastic Agents / Antineoplastic Agents, Phytogenic / Antineoplastic and Immunomodulating Agents / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Indole Alkaloids / Indoles / Mitosis Modulators / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Neurotoxic agents / Secologanin Tryptamine Alkaloids / Tubulin Modulators / Vinca Alkaloids",Q6C979R91Y,71486-22-1,D08680,44424639.0,4470974.0,,39541.0,480999.0,CHEMBL553025,DAP000765,PA451881,ZINC000085536958
Anidulafungin,phase 4 complete,DB00362 (APRD01301),[H][C@]1(NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C1=O)NC(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,"Amino Acids, Peptides, and Proteins / Anti-Infective Agents / Antifungal Agents / Antiinfectives for Systemic Use / Antimycotics for Systemic Use / Echinocandin Antifungal / Echinocandins / Peptides / Peptides, Cyclic",9HLM53094I,166663-25-8,D03211,166548.0,145752.0,50417554.0,341018.0,55346.0,CHEMBL264241,DAP000546,PA164742938,
Clozapine,phase 4 complete,DB00363 (APRD00470),CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Agents that reduce seizure threshold / Anticholinergic Agents / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diazepines, Oxazepines, Thiazepines and Oxepines / Dibenzazepines / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Antagonists / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Hyperglycemia-Associated Agents / Hypotensive Agents / Moderate Risk QTc-Prolonging Agents / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein substrates / Photosensitizing Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT1D Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents / UGT1A4 substrates",J60AR2IKIC,5786-21-0,D00283,2818.0,10442628.0,50001884.0,2626.0,3766.0,CHEMBL42,DAP000029,PA449061,ZINC000019796155
Sucralfate,phase 4 complete,DB00364 (APRD01238),O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O,Alimentary Tract and Metabolism / Aluminium Compounds / Aluminum Complex / Anti-Ulcer Agents / Carbohydrates / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Drugs that are Mainly Renally Excreted / Gastrointestinal Agents / Glycosides / Metal cations / Metal divalent cations / Organometallic Compounds / Protectants / Sulfur Compounds / Thioglycosides,XX73205DH5,54182-58-0,,70789197.0,32701653.0,,10156.0,,CHEMBL2029132,,PA451524,
Grepafloxacin,phase 4 complete,DB00365 (APRD01003),CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / OAT1/SLC22A6 Substrates / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / QTc Prolonging Agents / Quinolines / Quinolones / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",L1M1U2HC31,119914-60-2,,72474.0,65391.0,50117924.0,83719.0,5543.0,CHEMBL583,DAP001005,PA449812,
Doxylamine,phase 4 complete,DB00366 (APRD00937),CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1,Agents producing tachycardia / Aminoalkyl Ethers / Anticholinergic Agents / Antiemetics / Antihistamines for Systemic Use / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Ethanolamine Derivatives / Gastrointestinal Agents / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine Receptor Antagonists / Muscarinic Antagonists / Neurotransmitter Agents / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents,95QB77JKPL,469-21-6,D02327,3162.0,3050.0,50239996.0,3642.0,51380.0,CHEMBL1004,DAP000859,PA449419,
Levonorgestrel,phase 4 complete,"DB00367 (APRD00754, DB00506, APRD00106)",[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],"Adrenal Cortex Hormones / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptives, Oral / Contraceptives, Oral, Synthetic / Contraceptives, Postcoital / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hyperglycemia-Associated Agents / Inhibit Ovum Fertilization / Norpregnanes / Norpregnenes / Norsteroids / Progestin Contraceptives / Progestin-containing Intrauterine Device / Progestins / Progestogens and Estrogens, Sequential Preparations / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",5W7SIA7YZW,797-63-7,D00950,13109.0,12560.0,50410522.0,6373.0,6443.0,CHEMBL1389,DAP001207,PA450218,ZINC000003814395
Norepinephrine,phase 4 complete,DB00368 (APRD01299),NC[C@H](O)C1=CC(O)=C(O)C=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic and Dopaminergic Agents / Adrenergic beta-1 Receptor Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-3 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Alpha-and Beta-adrenergic Agonists / Amines / Amino Alcohols / Autonomic Agents / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiovascular Agents / Catecholamines / Catechols / COMT Substrates / Epinephrine and similars / Ethanolamines / Neurotransmitter Agents / Norepinephrine, antagonists & inhibitors / OCT1 substrates / OCT2 Inhibitors / OCT2 Substrates / Peripheral Nervous System Agents / Phenols / Sympathomimetics / Vasoconstrictor Agents",X4W3ENH1CV,51-41-2,D00076,439260.0,388394.0,50029051.0,7512.0,18357.0,CHEMBL1437,DNC001034,PA450649,ZINC000000057624
Cidofovir,phase 4 complete,DB00369 (APRD00148),NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1,Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor / Cytosine / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Nephrotoxic agents / Nucleic Acid Synthesis Inhibitors / Nucleosides and Nucleotides / Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / Organophosphonates / Organophosphorus Compounds / Pyrimidines / Pyrimidinones,768M1V522C,113852-37-2,,60613.0,54636.0,31915.0,1546007.0,3696.0,CHEMBL152,DAP001083,PA448997,ZINC000001530600
Mirtazapine,phase 4 complete,DB00370 (APRD00685),CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1,"Adrenergic Agents / Adrenergic alpha-2 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Anti-Anxiety Agents / Antidepressive Agents / Antidepressive Agents, Tetracyclic / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Miscellaneous Antidepressants / Nervous System / Neurotransmitter Agents / Potential QTc-Prolonging Agents / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin 5-HT3 Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Tranquilizing Agents",A051Q2099Q,85650-52-8,D00563,4205.0,4060.0,50115644.0,15996.0,6950.0,CHEMBL654,DAP000010,PA450522,
Meprobamate,phase 4 complete,DB00371 (APRD01095),CCCC(C)(COC(N)=O)COC(N)=O,"Acids, Acyclic / Anti-Anxiety Agents / Carbamates / Central Nervous System Agents / Central Nervous System Depressants / Hypnotics and Sedatives / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Nervous System / Peripheral Nervous System Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents",9I7LNY769Q,57-53-4,D00376,4064.0,3924.0,,6760.0,6761.0,CHEMBL979,DAP001507,PA450377,ZINC000001530701
Thiethylperazine,phase 4 complete,DB00372 (APRD00323),CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1,"Antiemetics / Antihistamines for Systemic Use / Antipsychotic Agents / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs that are Mainly Renally Excreted / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Neurotoxic agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenothiazine Derivatives / Phenothiazines / Piperazines / Sulfur Compounds",8ETK1WAF6R,1420-55-9,D02354,5440.0,5245.0,78436.0,10471.0,9544.0,CHEMBL1378,DAP000315,PA164748882,ZINC000022446674
Timolol,phase 4 complete,"DB00373 (APRD00229, DB08625)",[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1,"Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antiglaucoma Preparations and Miotics / Antihypertensive Agents / Beta Blocking Agents and Thiazides / Beta Blocking Agents, Non-Selective / Beta Blocking Agents, Non-Selective, and Thiazides / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / EENT Drugs, Miscellaneous / Hypotensive Agents / Morpholines / Ophthalmologicals / Oxazines / P-glycoprotein substrates / Potential QTc-Prolonging Agents / Propanolamines / Propanols / QTc Prolonging Agents / Sulfur Compounds / Thiadiazoles / Thiazoles",5JKY92S7BR,26839-75-8,,33624.0,31013.0,50292219.0,10600.0,9599.0,CHEMBL499,DAP000088,PA451690,ZINC000000002176
Treprostinil,phase 4 complete,DB00374 (APRD01272),[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1,"Antihypertensive Agents / Autacoids / Biological Factors / Blood and Blood Forming Organs / Cardiovascular Agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Inflammation Mediators / Lipids / Platelet Aggregation Inhibitors Excl. Heparin / Potential QTc-Prolonging Agents / Prostacyclin Analogues / Prostacycline Vasodilator / Prostaglandins / Prostaglandins I / QTc Prolonging Agents / Vasodilating Agents / Vasodilation",RUM6K67ESG,81846-19-7,,6918140.0,5293353.0,,343048.0,50861.0,CHEMBL1237119,DAP001214,PA164768801,ZINC000003800475
Colestipol,phase 4 complete,DB00375 (APRD00884),,"Amines / Anion Exchange Resins / Bile Acid Sequestrants / Bile-acid Binding Activity / Compounds used in a research, industrial, or household setting / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Macromolecular Substances / Polyamines / Polymers / Sequestering Agents",K50N755924,26658-42-4,,62816.0,56550.0,,2685.0,,CHEMBL1909303,,PA449096,
Trihexyphenidyl,phase 4 complete,DB00376 (APRD00070),OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1,Agents producing tachycardia / Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Anticholinergic Agents / Central Nervous System Agents / Cholinergic Agents / Muscarinic Antagonists / Nervous System / Neurotransmitter Agents / Piperidines / Tertiary Amines,6RC5V8B7PO,144-11-6,D08638,5572.0,5371.0,81462.0,10811.0,9720.0,CHEMBL1490,DAP001532,PA164747026,
Palonosetron,phase 4 complete,DB00377 (APRD00351),[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2,"Alimentary Tract and Metabolism / Antidepressive Agents / Antiemetics / Antiemetics and Antinauseants / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Neurotransmitter Agents / Peripheral Nervous System Agents / Quinuclidines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 3 Receptor Antagonists / Serotonin 5-HT3 Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists",5D06587D6R,135729-56-5,D07175,6337614.0,4892289.0,50417287.0,70561.0,85161.0,CHEMBL1189679,DAP000367,PA10352,ZINC000003795819
Dydrogesterone,phase 4 complete,DB00378 (APRD00941),[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C,"Adrenal Cortex Hormones / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Pregnadien Derivatives / Pregnadienes / Pregnanes / Progestins / Progestogens and Estrogens, Sequential Preparations / Sex Hormones and Modulators of the Genital System / Steroids",90I02KLE8K,152-62-5,D01217,9051.0,8699.0,,3706.0,31527.0,CHEMBL1200853,DAP001205,PA164745443,ZINC000003875998
Mexiletine,phase 4 complete,DB00379 (APRD00242),CC(N)COC1=C(C)C=CC=C1C,"Amines / Antiarrhythmic agents / Antiarrhythmics, Class I / Antiarrhythmics, Class Ib / Benzene Derivatives / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Ethers / Membrane Transport Modulators / Phenols / Phenyl Ethers / Propylamines / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers",1U511HHV4Z,31828-71-4,,4178.0,4034.0,50117271.0,6926.0,6916.0,CHEMBL558,DAP000505,PA450488,
Dexrazoxane,phase 4 complete,"DB00380 (APRD00090, DB02444)",C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,"Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Cytoprotective Agent / Detoxifying Agents for Antineoplastic Treatment / Diketopiperazines / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Immunosuppressive Agents / Miscellaneous Therapeutic Agents / Myelosuppressive Agents / Piperazines / Protective Agents / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",048L81261F,24584-09-6,D03730,71384.0,64479.0,,42736.0,50223.0,CHEMBL1738,DAP000649,PA449259,ZINC000087515509
Amlodipine,phase 4 complete,DB00381 (APRD00520),CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,ACE Inhibitors and Calcium Channel Blockers / Agents causing hyperkalemia / Angiotensin II Antagonists and Calcium Channel Blockers / Angiotensin II receptor blockers (ARBs) and calcium channel blockers / Antianginal Agents / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium Channel Blockers (Dihydropyridine) / Calcium Channel Blockers and Diuretics / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (weak) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Dihydropyridines / Hypotensive Agents / Membrane Transport Modulators / P-glycoprotein inhibitors / P-glycoprotein substrates / Pyridines / QTc Prolonging Agents / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,1J444QC288,88150-42-9,D07450,2162.0,2077.0,50088383.0,17767.0,2668.0,CHEMBL1491,DAP000139,PA448388,
Tacrine,phase 4 complete,DB00382 (APRD00690),NC1=C2CCCCC2=NC2=CC=CC=C12,"Acridines / Agents Causing Muscle Toxicity / Aminoacridines / Anti-Dementia Drugs / Autonomic Agents / Central Nervous System Agents / Cholinergic Agents / Cholinesterase Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotransmitter Agents / Nootropic Agents / P-glycoprotein substrates / Parasympathomimetics / Peripheral Nervous System Agents / Psychoanaleptics",4VX7YNB537,321-64-2,D08555,1935.0,1859.0,8961.0,10318.0,45980.0,CHEMBL95,DAP000558,PA451576,ZINC000019014866
Oxyphencyclimine,phase 4 complete,DB00383 (APRD00399),CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,"Agents producing tachycardia / Alimentary Tract and Metabolism / Anticholinergic Agents / Drugs for Functional Gastrointestinal Disorders / Muscarinic Antagonists / Synthetic Anticholinergics, Esters With Tertiary Amino Group",4V44H1O8XI,125-53-1,D08325,4642.0,4481.0,,32698.0,7868.0,CHEMBL1495,DAP000835,PA164776910,
Triamterene,phase 4 complete,DB00384 (APRD00079),NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1,"Agents causing hyperkalemia / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Decreased Renal K+ Excretion / Diuretics / Drugs causing inadvertant photosensitivity / Epithelial Sodium Channel Blockers / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Increased Diuresis / Membrane Transport Modulators / Natriuretic Agents / Nephrotoxic agents / Photosensitizing Agents / Potassium-Sparing Diuretics / Pteridines / Sodium Channel Blockers",WS821Z52LQ,396-01-0,D00386,5546.0,5345.0,6644.0,10763.0,9671.0,CHEMBL585,DAP000575,PA451752,ZINC000000120286
Valrubicin,phase 4 complete,DB00385 (APRD00662),[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)COC(=O)CCCC)O[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1,Anthracyclines / Anthracyclines and Related Substances / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Carbohydrates / Cytotoxic Antibiotics and Related Substances / Enzyme Inhibitors / Glycosides / Naphthacenes / Topoisomerase II Inhibitors / Topoisomerase Inhibitors,2C6NUM6878,56124-62-0,,454216.0,399974.0,,31435.0,135876.0,CHEMBL1096885,DAP000650,PA164748616,ZINC000049783788
Procyclidine,phase 4 complete,DB00387 (APRD00383),OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1,Agents producing tachycardia / Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Anticholinergic Agents / Central Nervous System Agents / Cholinergic Agents / Muscarinic Antagonists / Nervous System / Neurotransmitter Agents / Pyrrolidines / Tertiary Amines,C6QE1Q1TKR,77-37-2,D08425,4919.0,4750.0,50062598.0,8718.0,8448.0,CHEMBL86715,DAP001110,PA164784001,
Phenylephrine,phase 4 complete,DB00388 (APRD00365),CNC[C@H](O)C1=CC(O)=CC=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic and Dopaminergic Agents / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Autonomic Agents / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Decongestants and Antiallergics / Ethanolamines / Monoamine Oxidase A Substrates / Mydriatics / Mydriatics and Cycloplegics / Nasal Decongestants / Nasal Decongestants for Systemic Use / Nasal Preparations / Neurotransmitter Agents / Ophthalmologicals / Peripheral Nervous System Agents / Protective Agents / Respiratory System Agents / Sensory Organs / Sympathomimetic (Adrenergic) Agents / Sympathomimetics / Sympathomimetics Excl. Antiglaucoma Preparations / Sympathomimetics Used as Decongestants / Sympathomimetics, Plain / Vasoconstrictor Agents",1WS297W6MV,59-42-7,D08365,6041.0,5818.0,50067212.0,8163.0,8093.0,CHEMBL1215,DAP000224,PA450935,ZINC000000113355
Carbimazole,phase 4 complete,DB00389 (APRD00503),CCOC(=O)N1C=CN(C)C1=S,"Agents Causing Muscle Toxicity / Antithyroid agents / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Imidazoles / Sulfur-Containing Imidazole Derivatives / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Thyroid Products",8KQ660G60G,22232-54-8,D07616,31072.0,28829.0,50275889.0,2020.0,617099.0,CHEMBL508102,DAP000762,PA164742970,ZINC000000001091
Digoxin,phase 4 complete,DB00390 (APRD00098),[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1,"Agents causing hyperkalemia / Antiarrhythmic agents / Bradycardia-Causing Agents / BSEP/ABCB11 Substrates / BSEP/ABCB11 Substrates with Narrow Therapeutic Index / Carbohydrates / Cardanolides / Cardenolides / Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Digitalis Glycosides / Digoxin and derivatives / Digoxin, antagonists & inhibitors / Digoxin, immunology / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Fused-Ring Compounds / Glycosides / Narrow Therapeutic Index Drugs / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Potential QTc-Prolonging Agents / Protective Agents / QTc Prolonging Agents",73K4184T59,20830-75-5,D00298,2724385.0,2006532.0,46355.0,3407.0,4551.0,CHEMBL1751,DAP000744,PA449319,ZINC000242548690
Sulpiride,phase 4 complete,DB00391 (APRD00032),CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O,"Acids, Carbocyclic / Amides / Antidepressive Agents / Antidepressive Agents, Second-Generation / Antipsychotic Agents / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Cholinesterase Inhibitors / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Moderate Risk QTc-Prolonging Agents / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Tranquilizing Agents",7MNE9M8287,15676-16-1,D01226,5355.0,5162.0,11638.0,10239.0,32168.0,CHEMBL26,DAP000310,PA164745485,
Profenamine,phase 4 complete,DB00392 (APRD00729),CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12,"Adrenergic Agents / Adrenergic Antagonists / Agents producing tachycardia / Anti-Parkinson Drugs / Anticholinergic Agents / Cholinergic Agents / Cholinesterase Inhibitors / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Muscarinic Antagonists / Nervous System / Neurotransmitter Agents / NMDA Receptor Antagonists / Sulfur Compounds / Tertiary Amines",7WI4P02YN1,522-00-9,D01118,3290.0,3174.0,8958.0,4134.0,313639.0,CHEMBL1206,DAP001119,PA449531,
Nimodipine,phase 4 complete,DB00393 (APRD00612),COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C,Agents causing hyperkalemia / Antiarrhythmic agents / Antihypertensive Agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium Channel Blockers (Dihydropyridine) / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Dihydropyridines / Hypotensive Agents / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / Nicotinic Acids / P-glycoprotein inhibitors / Pyridines / QTc Prolonging Agents / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,57WA9QZ5WH,66085-59-4,D00438,4497.0,4341.0,50101971.0,7426.0,7575.0,CHEMBL1428,DAP000306,PA450633,
Beclomethasone dipropionate,phase 4 complete,"DB00394 (APRD00564, DB11897)",[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Adrenals / Agents to Treat Airway Disease / Alimentary Tract and Metabolism / Anti-Asthmatic Agents / Anti-Inflammatory Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / BCRP/ABCG2 Inhibitors / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids Acting Locally / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Drugs for Obstructive Airway Diseases / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Intestinal Antiinflammatory Agents / Nasal Preparations / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inducers / P-glycoprotein substrates / Pregnadienes / Pregnadienetriols / Pregnanes / Respiratory System Agents / Steroids / Steroids, Chlorinated / Thyroxine-binding globulin inhibitors",5B307S63B2,5534-09-8,D07495,21700.0,20396.0,,1348.0,3002.0,CHEMBL1200500,DAP000416,PA448547,ZINC000003938744
Carisoprodol,phase 4 complete,DB00395 (APRD00417),CCCC(C)(COC(N)=O)COC(=O)NC(C)C,"Carbamates / Carbamic Acid Esters / Central Nervous System Agents / Central Nervous System Depressants / Centrally-mediated Muscle Relaxation / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 Substrates / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Musculo-Skeletal System",21925K482H,78-44-4,D00768,2576.0,2478.0,,2101.0,3419.0,CHEMBL1233,,PA448809,
Progesterone,phase 4 complete,DB00396 (APRD00700),[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"Adrenal Cortex Hormones / BCRP/ABCG2 Inducers / BCRP/ABCG2 Inhibitors / BSEP/ABCB11 Inhibitors / Corpus Luteum Hormones / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inducers / OCT1 inhibitors / OCT2 Inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Pregnanes / Pregnenediones / Pregnenes / Progesterone and Derivatives / Progesterone, antagonists & inhibitors / Progestin-containing Intrauterine Device / Progestins / Sex Hormones and Modulators of the Genital System / Steroids",4G7DS2Q64Y,57-83-0,D00066,5994.0,5773.0,8903.0,8727.0,17026.0,CHEMBL103,DAP000549,PA451123,ZINC000004428529
Phenylpropanolamine,phase 4 complete,"DB00397 (APRD00457, DB09441)",[H][C@@](C)(N)[C@]([H])(O)C1=CC=CC=C1,Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Agents that reduce seizure threshold / Alcohols / Amines / Amino Alcohols / Anti-Obesity Agents / Appetite Depressants / Autonomic Agents / Cardiovascular Agents / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Nasal Decongestants / Nasal Decongestants for Systemic Use / Nasal Preparations / Neurotransmitter Agents / Peripheral Nervous System Agents / Propanolamines / Propanols / Respiratory System Agents / Sympathomimetics / Vasoconstrictor Agents,57B9YG5Y1E,14838-15-4,,26934.0,9875.0,50405613.0,8175.0,80680.0,CHEMBL136560,DNC001144,PA164748965,ZINC000000157545
Sorafenib,phase 4 complete,"DB00398 (APRD01304, DB07438)",CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Benzene Derivatives / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (moderate) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Immunosuppressive Agents / Kinase Inhibitor / Miscellaneous Therapeutic Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nicotinic Acids / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Phenylurea Compounds / Potential QTc-Prolonging Agents / Protein Kinase Inhibitors / Pyridines / QTc Prolonging Agents / Tyrosine Kinase Inhibitors / UGT1A1 Inhibitors / UGT1A9 Inhibitors / UGT1A9 Substrates / UGT1A9 substrates with narrow therapeutic index / Vitamin B Complex / Vitamins,9ZOQ3TZI87,284461-73-0,D08524,216239.0,187440.0,16673.0,495881.0,50924.0,CHEMBL1336,DAP000006,PA7000,ZINC000001493878
Zoledronic acid,phase 4 complete,"DB00399 (APRD01294, DB06286)",OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O,Bisphosphonates / Bone Density Conservation Agents / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Imidazoles / Musculo-Skeletal System / Organophosphonates / Organophosphorus Compounds,70HZ18PH24,118072-93-8,D01968,68740.0,61986.0,12578.0,1546014.0,46557.0,CHEMBL924,DAP001539,PA10235,ZINC000003803652
Griseofulvin,phase 4 complete,DB00400 (APRD01004),COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,"Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Systemic Use / Antifungals for Topical Use / Benzofurans / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Decreased Mitosis / Dermatologicals / Heterocyclic Compounds, Fused-Ring / Microtubule Inhibition / Tubulin Inhibiting Agent",32HRV3E3D5,126-07-8,D00209,441140.0,389934.0,31775.0,5021.0,27779.0,CHEMBL562,DAP000539,PA449814,ZINC000000622123
Nisoldipine,phase 4 complete,DB00401 (APRD00635),COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C,Agents causing hyperkalemia / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium Channel Blockers (Dihydropyridine) / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Decreased Blood Pressure / Dihydropyridine Derivatives / Dihydropyridines / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Membrane Transport Modulators / P-glycoprotein inhibitors / Photosensitizing Agents / Pyridines / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,4I8HAB65SZ,63675-72-9,D00618,4499.0,4343.0,50101963.0,7435.0,76917.0,CHEMBL1726,DAP000595,PA450634,
Eszopiclone,phase 4 complete,DB00402 (APRD00431),CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1,"Benzodiazepine hypnotics and sedatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Hypnotics (Nonbenzodiazepine) / Hypnotics and Sedatives / Miscellaneous Anxiolytics Sedatives and Hypnotics / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Nervous System / Photosensitizing Agents / Piperazines / Psycholeptics / Pyrazines / Pyridines / Zopiclone and prodrugs",UZX80K71OE,138729-47-2,,969472.0,839530.0,26265.0,461016.0,53760.0,CHEMBL1522,DAP000933,PA162630444,ZINC000019632834
Ceruletide,phase 4 complete,DB00403 (APRD00861),[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,"Amino Acids, Peptides, and Proteins / Diagnostic Agents / Oligopeptides / Peptides / Tests for Bile Duct Patency",888Y08971B,17650-98-5,D03442,16129675.0,10481982.0,,,59219.0,CHEMBL1201355,DAP000961,PA164774919,
Alprazolam,phase 4 complete,"DB00404 (APRD00280, DB05925, DB05690)",CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,"Alcohols / Amines / Amino Alcohols / Anti-Anxiety Agents / Benzazepines / Benzene Derivatives / Benzodiazepines and benzodiazepine derivatives / Biogenic Amines / Biogenic Monoamines / Catechols / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Ethanolamines / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Phenols / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents / Triazolobenzodiazepines",YU55MQ3IZY,28981-97-7,D00225,2118.0,2034.0,50001728.0,596.0,2611.0,CHEMBL661,DAP000239,PA448333,ZINC000000000903
Dexbrompheniramine,phase 4 complete,DB00405 (APRD00770),CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1,Antihistamines for Systemic Use / Central Nervous System Depressants / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Neurotransmitter Agents / Potential QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents / Substituted Alkylamines,75T64B71RP,132-21-8,,16960.0,16068.0,,22696.0,59269.0,CHEMBL1201287,DAP001068,PA164746251,ZINC000000000096
Gentian violet cationCommonly known or available as Gentian Violet,phase 4 complete,DB00406 (APRD00998),CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C,"Amines / Aniline Compounds / Anti-Infective Agents / Anti-Infective Agents, Local / Antifungals for Dermatological Use / Antifungals for Topical Use / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Miscellaneous Antifungals",3GVJ31T6YY,7438-46-2,D01046,3468.0,3349.0,50052802.0,1546369.0,77181.0,CHEMBL459265,,PA449755,ZINC000013763987
Ardeparin,phase 4 complete,DB00407 (APRD00803),,Agents causing hyperkalemia / Anticoagulants / Carbohydrates / Cardiovascular Agents / Fibrin Modulating Agents / Glycosaminoglycans / Hematologic Agents / Heparin (Low Molecular Weight) / Heparin and similars / Polysaccharides,VL0L558GCB,9005-49-6,D02980,,,,87866.0,,,DAP000428,PA164754878,
Loxapine,phase 4 complete,DB00408 (APRD00574),CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2,"Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Agents / Central Nervous System Depressants / Diazepines, Oxazepines, Thiazepines and Oxepines / Dibenzoxazepines / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Miscellaneous Antipsychotics / Nervous System / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein inhibitors / Photosensitizing Agents / Psycholeptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents",LER583670J,1977-10-2,D02340,3964.0,3827.0,22871.0,6475.0,50841.0,CHEMBL831,DAP000311,PA450273,ZINC000019796158
Remoxipride,phase 4 complete,DB00409 (APRD00316),CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC,"Acids, Carbocyclic / Amides / Antipsychotic Agents / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Bromobenzoates / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents",0223RD59PE,80125-14-0,,54477.0,49195.0,50026045.0,35350.0,92948.0,CHEMBL22242,DAP000312,PA164749051,ZINC000002021799
Mupirocin,phase 4 complete,DB00410 (APRD00162),C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O,"Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics for Topical Use / Dermatologicals / Enzyme Inhibitors / Epoxy Compounds / Ethers / Ethers, Cyclic / Fatty Acids / Lipids / Nasal Preparations / Protein Synthesis Inhibitors / Pyrans / RNA Synthetase Inhibitor Antibacterial / RNA Synthetase Inhibitors",D0GX863OA5,12650-69-0,D01076,446596.0,393914.0,50290686.0,42372.0,7025.0,CHEMBL719,DAP000711,PA164764568,ZINC000004102194
CarbamoylcholineCommonly known or available as Carbachol,phase 4 complete,"DB00411 (APRD00845, DB02487)",C[N+](C)(C)CCOC(N)=O,"Alcohols / Amines / Amino Alcohols / Ammonium Compounds / Analgesics / Analgesics, Non-Narcotic / Antiglaucoma Preparations and Miotics / Autonomic Agents / Cardiotonic Agents / Cardiovascular Agents / Central Nervous System Agents / Choline Esters / Cholinergic Agents / Cholinergic Agonists / Cholinergic Receptor Agonist / Compounds used in a research, industrial, or household setting / Ethanolamines / Miotics / Nervous System / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Ophthalmologicals / Parasympathomemetic (Cholinergic) Agents / Parasympathomimetics / Peripheral Nervous System Agents / Protective Agents / Quaternary Ammonium Compounds / Sensory Organs / Sensory System Agents / Trimethyl Ammonium Compounds",54Z8M50D6Q,462-58-8,D00524,5831.0,2454.0,50004656.0,1546387.0,3385.0,CHEMBL965,DAP000347,PA448784,ZINC000003079342
Rosiglitazone,phase 4 complete,DB00412 (APRD00403),CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1,Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Hypoglycemia-Associated Agents / OATP1B1/SLCO1B1 Inhibitors / Peroxisome Proliferator Receptor gamma Agonist / Peroxisome Proliferator-activated Receptor Activity / Sulfur Compounds / Thiazoles / Thiazolidinediones / Vasodilating Agents,05V02F2KDG,122320-73-4,D00596,77999.0,70383.0,50030474.0,84108.0,50122.0,CHEMBL121,DAP000271,PA451283,
Pramipexole,phase 4 complete,DB00413 (APRD00156),CCCN[C@H]1CCC2=C(C1)SC(N)=N2,"Anti-Dyskinesia Agents / Anti-Parkinson Agents (Dopamine Agonist) / Anti-Parkinson Drugs / Antioxidants / Benzothiazoles / Central Nervous System Agents / Dopamine Agents / Dopamine Agonists / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Nervous System / Neurotransmitter Agents / Nonergot-derivative Dopamine Receptor Agonists / OCT1 substrates / OCT2 Substrates / Restless Legs Syndrome / Sulfur Compounds / Thiazoles",83619PEU5T,104632-26-0,D00559,119570.0,106770.0,50116766.0,746741.0,8356.0,CHEMBL301265,DAP000019,PA164742949,ZINC000003781664
Acetohexamide,phase 4 complete,DB00414 (APRD00773),CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs Used in Diabetes / Sulfones / Sulfonylureas / Sulfur Compounds,QGC8W08I6I,968-81-0,D00219,1989.0,1912.0,,173.0,28052.0,CHEMBL1589,DAP000922,PA164777011,ZINC000018067894
Ampicillin,phase 4 complete,DB00415 (APRD00320),[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,"Amides / Aminopenicillins / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / Ophthalmologicals / Penicillin G / Penicillins / Penicillins With Extended Spectrum / Sensory Organs / Sulfur Compounds",7C782967RD,69-53-4,D00204,6249.0,6013.0,50350465.0,221058.0,28971.0,CHEMBL174,DAP000432,PA448419,ZINC000003830218
Metocurine iodide,phase 4 complete,DB00416 (APRD01318),[I-].[I-].[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3,"Alkaloids / Amines / Ammonium Compounds / Anticholinergic Agents / Benzylisoquinolines / Central Nervous System Depressants / Drugs, Chinese Herbal / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular-Blocking Agents (Nondepolarizing) / Nicotinic Antagonists / Nitrogen Compounds / Onium Compounds / Peripheral Nervous System Agents / Quaternary Ammonium Compounds / Tetrahydroisoquinolines",O0U0E87X7F,7601-55-0,D00761,24244.0,22666.0,,203206.0,6901.0,CHEMBL1739,DAP000824,PA164749507,
Phenoxymethylpenicillin,phase 4 complete,"DB00417 (APRD00423, DB08415)",[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Aza Compounds / Azabicyclo Compounds / Beta-Lactam Antibacterials / Beta-Lactamase Sensitive Penicillins / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Natural Penicillins / Penicillin G / Penicillins / Sulfur Compounds",Z61I075U2W,87-08-1,D05411,6869.0,6607.0,50370584.0,7984.0,27446.0,CHEMBL615,DAP001165,PA164745442,ZINC000003831282
Secobarbital,phase 4 complete,DB00418 (APRD00497),CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O,"Adjuvants / Adjuvants, Anesthesia / Anticholinergic Agents / Anticonvulsants / Barbiturates / Barbiturates, Plain / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strong) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Nicotinic Antagonists / Psycholeptics / Pyrimidines / Pyrimidinones",1P7H87IN75,76-73-3,D00430,5193.0,5005.0,,9624.0,9073.0,CHEMBL447,DAP000674,PA164784035,
Miglustat,phase 4 complete,DB00419 (APRD01118),CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,Alimentary Tract and Metabolism / Alkaloids / Anti-HIV Agents / Anti-Infective Agents / Carbohydrates / Enzyme Inhibitors / Gaucher Disease / Glucosylceramide Synthase Inhibitor / Glucosylceramide Synthase Inhibitors / Glycoside Hydrolase Inhibitors / Imines / Imino Pyranoses / Imino Sugars / Other Miscellaneous Therapeutic Agents / Piperidines / Various Alimentary Tract and Metabolism Products,ADN3S497AZ,72599-27-0,D05032,51634.0,46764.0,18355.0,402316.0,50381.0,CHEMBL1029,DAP000609,PA10140,ZINC000003794711
Promazine,phase 4 complete,DB00420 (APRD00358),CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Amino Acids / Amino Acids, Branched-Chain / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Anticholinergic Agents / Antidepressive Agents / Antiemetics / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Moderate Risk QTc-Prolonging Agents / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenothiazines / Phenothiazines With Aliphatic Side-Chain / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Tranquilizing Agents",O9M39HTM5W,58-40-2,D08430,4926.0,4757.0,67545.0,8742.0,8459.0,CHEMBL564,DAP000430,PA451126,ZINC000000010402
Spironolactone,phase 4 complete,DB00421 (APRD01234),[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O,"Agents causing hyperkalemia / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / BSEP/ABCB11 Substrates / Cardiovascular Agents / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Diuretics / Fused-Ring Compounds / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypotensive Agents / Lactones / Mineralocorticoid (Aldosterone) Receptor Antagonists / Mineralocorticoid Receptor Antagonists / Natriuretic Agents / P-glycoprotein inducers / Potassium-Sparing Diuretics / Pregnanes / Pregnenes / Steroids",27O7W4T232,52-01-7,D00443,5833.0,5628.0,50228080.0,9997.0,9241.0,CHEMBL1393,DAP000297,PA451483,ZINC000003861599
Methylphenidate,phase 4 complete,DB00422 (APRD00657),COC(=O)C(C1CCCCN1)C1=CC=CC=C1,"Acids, Carbocyclic / Agents that produce hypertension / Agents that reduce seizure threshold / Central Nervous System Agents / Central Nervous System Stimulants / Central Nervous System Stimulation / Centrally Acting Sympathomimetics / Dopamine Agents / Dopamine Uptake Inhibitors / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Membrane Transport Modulators / Methylphenidate and isomer / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Phenylacetates / Piperidines / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Respiratory and CNS Stimulants",207ZZ9QZ49,113-45-1,D04999,4158.0,4015.0,50062912.0,6901.0,84276.0,CHEMBL796,DAP000024,PA450464,
Methocarbamol,phase 4 complete,DB00423 (APRD01102),COC1=C(OCC(O)COC(N)=O)C=CC=C1,"Acids, Acyclic / Benzene Derivatives / Carbamates / Carbamic Acid Esters / Catechols / Central Nervous System Agents / Central Nervous System Depressants / Centrally-mediated Muscle Relaxation / Ethers / Methyl Ethers / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Musculo-Skeletal System / Peripheral Nervous System Agents / Phenols / Phenyl Ethers / Phenylcarbamates",125OD7737X,532-03-6,D00402,4107.0,3964.0,50239995.0,6845.0,77498.0,CHEMBL1201117,,PA164749506,
Hyoscyamine,phase 4 complete,DB00424 (APRD00607),CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1,"Adjuvants, Anesthesia / Agents producing tachycardia / Alimentary Tract and Metabolism / Alkaloids / Anti-Asthmatic Agents / Antiarrhythmic agents / Anticholinergic Agents / Atropine Derivatives / Autonomic Agents / Aza Compounds / Azabicyclo Compounds / Belladonna Alkaloids / Belladonna Alkaloids, Tertiary Amines / Belladonna and Derivatives, Plain / Bronchodilator Agents / Cardiovascular Agents / Central Nervous System Agents / Cholinergic Agents / Drugs for Functional Gastrointestinal Disorders / Muscarinic Antagonists / Mydriatics / Neurotransmitter Agents / Parasympatholytics / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Respiratory System Agents / Solanaceous Alkaloids / Tropanes",PX44XO846X,101-31-5,D00147,154417.0,10246417.0,50239982.0,153970.0,17486.0,CHEMBL1331216,DNC000758,PA164776844,ZINC000100009280
Zolpidem,phase 4 complete,DB00425 (APRD00095),CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1,"Benzodiazepine hypnotics and sedatives / Central Nervous System Agents / Central Nervous System Depressants / Central Nervous System Depression / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / GABA Agents / GABA Agonists / GABA-A Receptor Agonists / gamma-Aminobutyric Acid-ergic Agonist / Hypnotics (Nonbenzodiazepine) / Hypnotics and Sedatives / Miscellaneous Anxiolytics Sedatives and Hypnotics / Nervous System / Neurotransmitter Agents / Psycholeptics / Pyridines / Sleep Aids, Pharmaceutical",7K383OQI23,82626-48-0,,5732.0,5530.0,26266.0,39993.0,10125.0,CHEMBL911,DAP000112,PA451976,ZINC000000003876
Famciclovir,phase 4 complete,DB00426 (APRD00600),CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor / Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor / Heterocyclic Compounds, Fused-Ring / Nucleic Acid Synthesis Inhibitors / Nucleosides and Nucleotides / Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors / Ophthalmologicals / Purines / Sensory Organs",QIC03ANI02,104227-87-4,D00317,3324.0,3207.0,50248001.0,68099.0,4974.0,CHEMBL880,DAP000489,PA449585,ZINC000001530635
Triprolidine,phase 4 complete,DB00427 (APRD00306),CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1,Anti-Allergic Agents / Antihistamines for Systemic Use / Central Nervous System Depressants / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Neurotransmitter Agents / Potential QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents,2L8T9S52QM,486-12-4,D01782,5282443.0,4445597.0,50292411.0,10849.0,84116.0,CHEMBL855,DAP001065,PA451797,ZINC000012503099
Streptozocin,phase 4 complete,DB00428 (APRD00209),CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,"Alkylating Activity / Alkylating Drugs / Antibiotics, Antineoplastic / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Carbohydrates / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Glycosides / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nitroso Compounds / Nitrosourea Compounds / Nitrosoureas / P-glycoprotein inducers",8H27GUR065,18883-66-4,D05932,29327.0,27273.0,,10114.0,9288.0,CHEMBL1603,DAP000984,PA451514,ZINC000003977737
Carboprost tromethamine,phase 4 complete,DB00429 (APRD00847),OCC([NH3+])(CO)CO.CCCCC[C@@](O)(C)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)[O-],"Abortifacient Agents / Abortifacient Agents, Nonsteroidal / Alcohols / Autacoids / Biological Factors / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Genito Urinary System and Sex Hormones / Glycols / Inflammation Mediators / Lipids / Pharmaceutical Preparations / Propylene Glycols / Prostaglandins / Prostaglandins F, Synthetic / Prostaglandins, Synthetic / Reproductive Control Agents / Uterotonic agents",U4526F86FJ,58551-69-2,D00682,45266502.0,26333214.0,,2051.0,3404.0,CHEMBL1237105,DAP001215,PA164754883,
Cefpiramide,phase 4 complete,DB00430 (APRD00856),[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",P936YA152N,70797-11-4,D01904,636405.0,552192.0,,,59213.0,CHEMBL1201204,DAP001157,PA164748136,ZINC000004215257
Lindane,phase 4 complete,DB00431 (APRD01072),Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,"Agents that reduce seizure threshold / Agrochemicals / Antiparasitic Products, Insecticides and Repellents / Chlorine Containing Products / Compounds used in a research, industrial, or household setting / Ectoparasiticides, Incl. Scabicides / Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents / Hydrocarbons, Chlorinated / Hydrocarbons, Halogenated / Insecticides / Pesticides / Toxic Actions",59NEE7PCAB,58-89-9,D00360,727.0,10481896.0,50410525.0,1388.0,32888.0,CHEMBL15891,DAP001036,PA164754914,
Trifluridine,phase 4 complete,DB00432 (APRD01275),OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F,"Anti-Infective Agents / Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Antiviral Agents / Carbohydrates / Deoxyribonucleosides / Drugs that are Mainly Renally Excreted / Glycosides / Immunosuppressive Agents / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Analog Antiviral / Nucleoside Metabolic Inhibitor / Nucleosides / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / Ophthalmologicals / Pyrimidine Analogues / Pyrimidine Nucleosides / Pyrimidines / Sensory Organs / Toxic Actions",RMW9V5RW38,70-00-8,D00391,6256.0,6020.0,50132298.0,10803.0,75179.0,CHEMBL1129,DAP000760,PA451775,ZINC000003842753
Prochlorperazine,phase 4 complete,DB00433 (APRD00624),CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,"Antiemetics / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Moderate Risk QTc-Prolonging Agents / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenothiazines / Phenothiazines With Piperazine Structure / Photosensitizing Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Schizophrenia / Sulfur Compounds / Tranquilizing Agents",YHP6YLT61T,58-38-8,D00493,4917.0,4748.0,78434.0,8704.0,8435.0,CHEMBL728,DAP000373,PA451114,ZINC000019796018
Cyproheptadine,phase 4 complete,DB00434 (APRD00033),CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12,Agents producing tachycardia / Agents that reduce seizure threshold / Anti-Allergic Agents / Anticholinergic Agents / Antidepressive Agents / Antihistamines for Systemic Use / Antipruritics / Benzocycloheptenes / Central Nervous System Depressants / Dermatologicals / Dibenzocycloheptenes / Drugs causing inadvertant photosensitivity / Gastrointestinal Agents / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Miscellaneous Derivatives / Muscarinic Antagonists / Neurotransmitter Agents / Photosensitizing Agents / Piperidines / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / UGT1A3 substrates,2YHB6175DO,129-03-3,,2913.0,2810.0,50017721.0,3013.0,4046.0,CHEMBL516,DAP000103,PA164749366,ZINC000000968264
Nitric Oxide,phase 4 complete,DB00435 (APRD01142),[N]=O,"Anions / Anti-Asthmatic Agents / Antioxidants / Autonomic Agents / Bronchodilator Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Electrolytes / Endothelium-Dependent Relaxing Factors / Free Radical Scavengers / Free Radicals / Gases / Gasotransmitters / Hypotensive Agents / Ions / Methemoglobinemia Associated Agents / Neurotransmitter Agents / Nitrates and Nitrites / Nitric Oxide, antagonists & inhibitors / Nitrogen Compounds / Nitrogen Oxides / Nitroso Compounds / Oxides / Oxygen Compounds / Peripheral Nervous System Agents / Protective Agents / Reactive Nitrogen Species / Respiratory System Agents / Vasodilating Agents / Vasodilation",31C4KY9ESH,10102-43-9,D00074,145068.0,127983.0,,7442.0,16480.0,CHEMBL1200689,DAP001056,PA450635,
Bendroflumethiazide,phase 4 complete,DB00436 (APRD00666),NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F,"Amides / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzothiadiazines / Bradycardia-Causing Agents / Cardiovascular Agents / Diuretics / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Hypotensive Agents / Increased Diuresis / Low-Ceiling Diuretics and Potassium-Sparing Agents / Membrane Transport Modulators / Natriuretic Agents / Sodium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds / Thiazides",5Q52X6ICJI,73-48-3,D00650,2315.0,2225.0,50238678.0,1369.0,3013.0,CHEMBL1684,DAP000188,PA448563,
Allopurinol,phase 4 complete,"DB00437 (APRD00435, DB03027)",OC1=NC=NC2=C1C=NN2,"Antigout Preparations / Antimetabolites / Antioxidants / BCRP/ABCG2 Substrates / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Free Radical Scavengers / Heterocyclic Compounds, Fused-Ring / Musculo-Skeletal System / OAT3/SLC22A8 Substrates / Preparations Inhibiting Uric Acid Production / Protective Agents / Purines / Uricosuric Agents / Xanthine Oxidase Inhibitors",63CZ7GJN5I,315-30-0,D00224,2094.0,2010.0,181133.0,519.0,40279.0,CHEMBL1467,DAP000773,PA448320,ZINC000013298313
Ceftazidime,phase 4 complete,DB00438 (APRD00857),[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephaloridine / Cephalosporins / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",DZR1ENT301,72558-82-8,D07654,5481173.0,4587145.0,50420259.0,1545984.0,3508.0,CHEMBL44354,DAP000433,PA448861,
Cerivastatin,phase 4 complete,DB00439 (APRD00102),COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C,"Agents Causing Muscle Toxicity / Anticholesteremic Agents / BCRP/ABCG2 Substrates / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypolipidemic Agents / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Noxae / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / P-glycoprotein substrates / Toxic Actions / UGT1A1 Substrates",AM91H2KS67,145599-86-6,,446156.0,393588.0,18376.0,596723.0,3558.0,CHEMBL1477,DNC000403,PA448897,ZINC000011330186
Trimethoprim,phase 4 complete,DB00440 (APRD00103),COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC,"Agents causing hyperkalemia / Agents Causing Muscle Toxicity / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antibacterials for Systemic Use / Antibiotics for Pneumocystis Pneumonia / Antiinfectives for Systemic Use / Antimycobacterials / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Folic Acid Antagonists / MATE 1 Inhibitors / MATE 1 Substrates / MATE 2 Inhibitors / MATE 2 Substrates / MATE inhibitors / MATE substrates / OCT2 Inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / Pyrimidines / Renal Agents / SULFONAMIDES AND TRIMETHOPRIM / Trimethoprim and Derivatives",AN164J8Y0X,738-70-5,D00145,5578.0,5376.0,18069.0,10829.0,45924.0,CHEMBL22,DAP000927,PA451788,ZINC000006627681
Gemcitabine,phase 4 complete,DB00441 (APRD00201),NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,"Anti-Infective Agents / Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Carbohydrates / Deoxyribonucleosides / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Glycosides / Immunologic Factors / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Metabolic Inhibitor / Nucleosides / P-glycoprotein substrates / Pyrimidine Analogues / Pyrimidine Nucleosides / Pyrimidines / Radiation-Sensitizing Agents / Ribonucleosides / Ribonucleotide Reductases, antagonists & inhibitors / Toxic Actions",B76N6SBZ8R,95058-81-4,D02368,60750.0,54753.0,,12574.0,175901.0,CHEMBL888,DAP001246,PA449748,ZINC000018279854
Entecavir,phase 4 complete,DB00442 (APRD00948),NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Direct Acting Antivirals / Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Heterocyclic Compounds, Fused-Ring / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / Nucleoside Reverse Transcriptase Inhibitors / Nucleosides and Nucleotides / Purines / Purinones",NNU2O4609D,142217-69-4,D04008,153941.0,135679.0,,1546027.0,473990.0,CHEMBL713,DAP000697,PA164784025,ZINC000003802690
Betamethasone,phase 4 complete,DB00443 (APRD00513),[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Adrenals / Agents Causing Muscle Toxicity / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Alimentary Tract and Metabolism / Anti-Inflammatory Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids Acting Locally / Corticosteroids for Systemic Use / Corticosteroids for Systemic Use, Plain / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (weak) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Drugs for Obstructive Airway Diseases / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Intestinal Antiinflammatory Agents / Nasal Preparations / Ophthalmological and Otological Preparations / Ophthalmologicals / Otologicals / P-glycoprotein substrates / Pregnadienes / Pregnadienetriols / Pregnanes / Respiratory System Agents / Steroids / Steroids, Fluorinated / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Thyroxine-binding globulin inhibitors / Vasoprotectives",9842X06Q6M,378-44-9,D00244,9782.0,9399.0,73823.0,1514.0,3077.0,CHEMBL632,DAP001043,PA164754818,ZINC000003876136
Teniposide,phase 4 complete,DB00444 (APRD00649),[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Carbohydrates / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Glucosides / Glycosides / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Neurotoxic agents / Podophyllotoxin Derivatives / Topoisomerase II Inhibitors / Topoisomerase Inhibitors,957E6438QA,29767-20-2,D02698,452548.0,398606.0,50248198.0,10362.0,,CHEMBL452231,DAP000651,PA451611,ZINC000004099009
Epirubicin,phase 4 complete,DB00445 (APRD00361),COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,"Anthracycline Topoisomerase Inhibitor / Anthracyclines / Anthracyclines and Related Substances / Antibiotics, Antineoplastic / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Carbohydrates / Cardiotoxic antineoplastic agents / Cytotoxic Antibiotics and Related Substances / Enzyme Inhibitors / Glycosides / Hepatotoxic Agents / Immunosuppressive Agents / Myelosuppressive Agents / Naphthacenes / Topoisomerase II Inhibitors / Topoisomerase Inhibitors / UGT2B7 substrates / UGT2B7 substrates with narrow therapeutic index",3Z8479ZZ5X,56420-45-2,,41867.0,38201.0,43839.0,3995.0,47898.0,CHEMBL417,DAP000193,PA449476,ZINC000003938704
Chloramphenicol,phase 4 complete,"DB00446 (APRD00862, EXPT00942)",OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,Alcohols / Amphenicols / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antibiotics for Topical Use / Antiinfectives for Systemic Use / Antiinfectives for Treatment of Acne / Benzene Derivatives / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Glycols / Gynecological Antiinfectives and Antiseptics / Immunosuppressive Agents / Myelosuppressive Agents / Nitro Compounds / Nitrobenzenes / OAT1/SLC22A6 inhibitors / Ophthalmological and Otological Preparations / Ophthalmologicals / Otologicals / Propylene Glycols / Protein Synthesis Inhibitors / Sensory Organs,66974FR9Q1,56-75-7,D00104,5959.0,5744.0,23447.0,2348.0,17698.0,CHEMBL130,DAP001356,PA448927,ZINC000000113382
Loracarbef,phase 4 complete,DB00447 (APRD01077),N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Second-Generation Cephalosporins / Sulfur Compounds / Thiazines",W72I5ZT78Z,76470-66-1,D00916,5284585.0,4447635.0,,28981.0,47544.0,CHEMBL1013,DAP000434,PA164754806,ZINC000001530993
Lansoprazole,phase 4 complete,DB00448 (APRD00077),CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,"Acid Reducers / Alimentary Tract and Metabolism / Anti-Ulcer Agents / BCRP/ABCG2 Inhibitors / Benzimidazoles / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Gastric Acid Lowering Agents / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Inhibition Gastric Acid Secretion / OAT3/SLC22A8 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Proton Pump Inhibitors / Proton-pump Inhibitors / Pyridines / Sulfoxides / Sulfur Compounds",0K5C5T2QPG,103577-45-3,D00355,3883.0,3746.0,47032.0,17128.0,6375.0,CHEMBL480,DAP000725,PA450180,
Dipivefrin,phase 4 complete,DB00449 (APRD00930),CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1,Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic beta-1 Receptor Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-3 Receptor Agonists / Adrenergic beta-Agonists / Alcohols / Amines / Amino Alcohols / Antiglaucoma Preparations and Miotics / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Catecholamines / Catechols / Cholinesterase substrates / Ethanolamines / Mydriatics / Neurotransmitter Agents / Ophthalmics / Ophthalmologicals / Phenols / Sensory Organs / Sympathomimetics in Glaucoma Therapy,8Q1PVL543G,52365-63-6,D02349,3105.0,2994.0,,23410.0,4646.0,CHEMBL1201262,DAP000593,PA449364,
Droperidol,phase 4 complete,DB00450 (APRD00939),FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12,"Adjuvants, Anesthesia / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antiemetics / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Autonomic Agents / Benzimidazoles / Butyrophenone Derivatives / Butyrophenones / Central Nervous System Agents / Central Nervous System Depressants / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Ketones / Miscellaneous Anxiolytics Sedatives and Hypnotics / Moderate Risk QTc-Prolonging Agents / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Tranquilizing Agents",O9U0F09D5X,548-73-2,D00308,3168.0,3056.0,50017705.0,3648.0,4717.0,CHEMBL1108,DAP000412,PA449422,ZINC000019796080
Levothyroxine,phase 4 complete,"DB00451 (APRD00235, EXPT02993)",N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,"Agents used to treat hypothyroidism / Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Narrow Therapeutic Index Drugs / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inducers / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Thyroid Products / Thyroxine-binding globulin substrates / UGT1A1 Substrates / UGT1A1 substrates with narrow therapeutic index",Q51BO43MG4,51-48-9,D08125,5819.0,5614.0,50301375.0,10582.0,18332.0,CHEMBL1624,DAP000083,PA450221,ZINC000003830993
Framycetin,phase 4 complete,DB00452 (APRD00618),NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,Agents that produce neuromuscular block (indirect) / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Carbohydrates / Dermatologicals / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Glycosides / Medicated Dressings / Medicated Dressings With Antiinfectives / Narrow Therapeutic Index Drugs / Nasal Preparations / Nephrotoxic agents / Ophthalmologicals / Sensory Organs,4BOC774388,119-04-0,D05140,8378.0,8075.0,19.0,4556.0,7508.0,CHEMBL184618,DNC001005,PA164743181,ZINC000071928291
Meperidine,phase 4 complete,DB00454 (APRD00074),CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,"Adjuvants / Adjuvants, Anesthesia / Agents that reduce seizure threshold / Analgesics / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / High-risk opioids / Isonipecotic Acids / Narcotics / Nervous System / NMDA Receptor Antagonists / Opiate Agonists / Opioid Agonist / Opioids / P-glycoprotein substrates / Peripheral Nervous System Agents / Phenylpiperidine opioids / Piperidines / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",9E338QE28F,57-42-1,D08343,4058.0,3918.0,50026752.0,6754.0,6754.0,CHEMBL607,DAP000230,PA450369,ZINC000000001681
Loratadine,phase 4 complete,DB00455 (APRD00384),CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,"Anti-Allergic Agents / Antihistamines for Systemic Use / Antipruritics / Benzocycloheptenes / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Dibenzocycloheptenes / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Loratadine and prodrug / Neurotransmitter Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Piperidines / QTc Prolonging Agents",7AJO3BO7QN,79794-75-5,D00364,3957.0,3820.0,22876.0,28889.0,6538.0,CHEMBL998,DAP000101,PA450266,ZINC000000537931
Cefalotin,phase 4 complete,"DB00456 (APRD00859, EXPT00946)",[H][C@@]1(NC(=O)CC2=CC=CS2)C(=O)N2C(C(O)=O)=C(COC(C)=O)CS[C@]12[H],"Agents that reduce seizure threshold / Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephacetrile / Cephalosporins / First-Generation Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Sulfur Compounds / Thiazines",R72LW146E6,153-61-7,D07635,6024.0,5802.0,82898.0,2236.0,124991.0,CHEMBL617,DAP000155,PA448886,ZINC000003830507
Prazosin,phase 4 complete,DB00457 (APRD00020),COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Alpha-Adrenoreceptor Antagonists and Diuretics / Antiadrenergic Agents, Peripherally Acting / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / BCRP/ABCG2 Substrates / Cardiovascular Agents / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / OCT1 inhibitors / OCT1 substrates / OCT2 Substrates / P-glycoprotein inhibitors / P-glycoprotein substrates / Peripheral alpha-1 blockers / Quinazolines / Vasodilating Agents",XM03YJ541D,19216-56-9,D08411,4893.0,4724.0,29568.0,8629.0,8364.0,CHEMBL2,DAP000300,PA451093,ZINC000095616601
Imipramine,phase 4 complete,"DB00458 (APRD00672, DB08002)",CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Agents that produce hypertension / Agents that reduce seizure threshold / Anticholinergic Agents / Antidepressive Agents / Antidepressive Agents, Tricyclic / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dibenzazepines / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Hypotensive Agents / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Non-Selective Monoamine Reuptake Inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Tertiary amine tricyclic antidepressants / Tricyclics and Other Norepinephrine-reuptake Inhibitors",OGG85SX4E4,50-49-7,D08070,3696.0,3568.0,50010859.0,5691.0,47499.0,CHEMBL11,DAP001154,PA449969,ZINC000000020245
Acitretin,phase 4 complete,DB00459 (APRD00778),COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1,"Alkenes / Antipsoriatics / Antipsoriatics for Systemic Use / Biological Factors / Carotenoids / Cyclohexanes / Cyclohexenes / Cycloparaffins / Dermatologicals / Drugs causing inadvertant photosensitivity / Hepatotoxic Agents / Hydrocarbons, Acyclic / Keratolytic Agents / Misc. Skin and Mucous Membrane Agents / Photosensitizing Agents / Pigments, Biological / Polyenes / Retinoids / Retinoids for Treatment of Psoriasis / Terpenes",LCH760E9T7,55079-83-9,D02754,5284513.0,4447573.0,50088429.0,16818.0,50173.0,CHEMBL1131,DAP000743,PA448039,ZINC000003798734
Verteporfin,phase 4 complete,DB00460 (APRD01290),COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C,"Antineovascularisation Agents / Biological Factors / Dermatologicals / EENT Drugs, Miscellaneous / Heterocyclic Compounds, Fused-Ring / Ocular Vascular Disorder Agents / Ophthalmologicals / Photoabsorption / Photoenhancer / Photosensitizing Activity / Photosensitizing Agents / Pigments, Biological / Porphyrins / Radiation-Sensitizing Agents / Sensory Organs",0X9PA28K43,129497-78-5,D01162,5362420.0,4515032.0,,118886.0,,CHEMBL2052016,,PA451871,
Nabumetone,phase 4 complete,DB00461 (APRD01128),COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Butanones / COX-2 Inhibitors / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Ketones / Musculo-Skeletal System / Nephrotoxic agents / Other Nonsteroidal Anti-inflammatory Agents / Photosensitizing Agents / Selective Cyclooxygenase 2 Inhibitors (NSAIDs)",LW0TIW155Z,42924-53-8,D00425,4409.0,4256.0,40128.0,31448.0,7443.0,CHEMBL1070,DAP000735,PA450572,ZINC000000020221
Methscopolamine bromide,phase 4 complete,DB00462 (APRD00314),[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1,Agents producing tachycardia / Anticholinergic Agents / Muscarinic Antagonists,RTN51LK7WL,155-41-9,D00715,23724781.0,26329507.0,,56092.0,6845.0,,DAP001126,PA164784032,
Sodium tetradecyl sulfate,phase 4 complete,DB00464 (APRD00575),[Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O,"Acids / Acids, Noncarboxylic / Alcohols / Alkanes / Alkanesulfonates / Alkanesulfonic Acids / Antivaricose Therapy / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Fatty Alcohols / Hydrocarbons, Acyclic / Lipids / Pharmaceutical Preparations / Pharmaceutical Solutions / Sclerosing Agents for Local Injection / Sclerosing Solutions / Solutions / Sulfonic Acids / Sulfur Acids / Sulfur Compounds / Surface-Active Agents / Vasoprotectives",Q1SUG5KBD6,139-88-8,D06882,23665772.0,8440.0,,9913.0,75273.0,CHEMBL1200354,DAP001276,PA164746759,
Ketorolac,phase 4 complete,DB00465 (APRD01060),OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,"Acetic Acid Derivatives and Related Substances / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Musculo-Skeletal System / Mydriatics / Mydriatics and Cycloplegics / Nephrotoxic agents / Non COX-2 selective NSAIDS / Ophthalmologicals / Other Nonsteroidal Anti-inflammatory Agents / Photosensitizing Agents / Sensory Organs / Sympathomimetics Excl. Antiglaucoma Preparations / UGT2B7 substrates",YZI5105V0L,74103-06-3,,3826.0,3694.0,85511.0,35827.0,76223.0,CHEMBL469,DAP000618,PA450150,
Enoxacin,phase 4 complete,DB00467 (APRD00947),CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strong) / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quinolines / Quinolones / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",325OGW249P,74011-58-8,D00310,3229.0,3116.0,50296358.0,3925.0,157175.0,CHEMBL826,DAP001000,PA449462,ZINC000019594549
Quinine,phase 4 complete,DB00468 (APRD00563),[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12,"Agents that produce neuromuscular block (indirect) / Agents that reduce seizure threshold / Alkaloids / Analgesics / Analgesics, Non-Narcotic / Anti-Infective Agents / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Blood Glucose Lowering Agents / Central Nervous System Agents / Central Nervous System Depressants / Cinchona Alkaloids / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Herbs (Hypotensive Properties) / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Hypoglycemia-Associated Agents / Methanolquinolines / Methemoglobinemia Associated Agents / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / OCT1 substrates / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / QTc Prolonging Agents / Quinolines / Quinuclidines / Sensory System Agents",A7V27PHC7A,130-95-0,,3034034.0,84989.0,50367247.0,9071.0,15854.0,CHEMBL170,DAP000491,PA451213,ZINC000003831404
Tenoxicam,phase 4 complete,DB00469 (APRD00011),CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT3/SLC22A8 Inhibitors / Other Nonsteroidal Anti-inflammatory Agents / Oxicams / Peripheral Nervous System Agents / Sensory System Agents / Sulfur Compounds / Thiazines",Z1R9N0A399,59804-37-4,D01767,54677971.0,10442339.0,92332.0,37790.0,32192.0,CHEMBL302795,DAP000736,PA131890625,ZINC000100006429
Dronabinol,phase 4 complete,DB00470 (APRD00571),[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1,"Agents producing tachycardia / Alimentary Tract and Metabolism / Analgesics / Analgesics, Non-Narcotic / Antiemetics and Antinauseants / BCRP/ABCG2 Inhibitors / Cannabinoid Receptor Agonists / Cannabinoids and similars / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Hallucinogens / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Miscellaneous Antiemetics / Neurotransmitter Agents / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Psychotropic Drugs / Sensory System Agents / Terpenes",7J8897W37S,1972-08-3,D00306,16078.0,15266.0,60994.0,10402.0,66964.0,CHEMBL465,DAP000207,PA449421,ZINC000001530625
Montelukast,phase 4 complete,DB00471 (APRD00434),OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1,"Acids, Acyclic / Agents Causing Muscle Toxicity / Agents to Treat Airway Disease / Anti-Asthmatic Agents / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Fatty Acids / Fatty Acids, Volatile / Heterocyclic Compounds, Fused-Ring / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Leukotriene Antagonists / Leukotriene Modifiers / Lipids / Respiratory System Agents",MHM278SD3E,158966-92-8,D08229,5281040.0,4444507.0,50052024.0,88249.0,50730.0,CHEMBL787,DAP000309,PA450546,ZINC000003831151
Fluoxetine,phase 4 complete,DB00472 (APRD00530),CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,"Agents that reduce seizure threshold / Amines / Anticholinergic Agents / Antidepressive Agents / Antidepressive Agents, Second-Generation / Central Nervous System Agents / Central Nervous System Depressants / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Highest Risk QTc-Prolonging Agents / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Nicotinic Antagonists / P-glycoprotein inhibitors / Propylamines / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Vasodilating Agents",01K63SUP8D,54910-89-3,D00823,3386.0,3269.0,30130.0,4493.0,86990.0,CHEMBL41,DAP000186,PA449673,
Hexylcaine,phase 4 complete,DB00473 (APRD01014),CC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1,Amines / Cyclohexanes / Cycloparaffins,511IU0826Z,532-77-4,,10770.0,10315.0,50225698.0,26879.0,34791.0,CHEMBL1197,DAP000506,PA164746489,
Methohexital,phase 4 complete,DB00474 (APRD00058),CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O,"Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Anticonvulsants / Barbiturates / Barbiturates, Plain / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Hypnotics and Sedatives / Nervous System / Psycholeptics / Pyrimidines / Pyrimidinones",E5B8ND5IPE,151-83-7,D04985,9034.0,8683.0,,6847.0,102216.0,CHEMBL7413,DAP000677,PA164784030,
Chlordiazepoxide,phase 4 complete,DB00475 (APRD00682),CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,"Adjuvants, Anesthesia / Anti-Anxiety Agents / Benzazepines / Benzodiazepines and benzodiazepine derivatives / Carbohydrates / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Cytosine Nucleotides / GABA Agents / GABA Modulators / Glycosides / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Nucleic Acids, Nucleotides, and Nucleosides / Nucleotides / Psycholeptics / Psychotropic Drugs / Pyrimidine Nucleotides / Pyrimidines / Ribonucleotides / Tranquilizing Agents",6RZ6XEZ3CR,58-25-3,D00267,2712.0,10248513.0,50007664.0,2356.0,3611.0,CHEMBL451,DAP000084,PA448932,ZINC000019632917
Duloxetine,phase 4 complete,DB00476 (APRD00060),CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,Agents producing tachycardia / Analgesics / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Nervous System / Neurotransmitter Uptake Inhibitors / Norepinephrine Uptake Inhibitors / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Psychoanaleptics / Psychotropic Drugs / Selective Serotonin Reuptake Inhibitors / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin and Noradrenaline Reuptake Inhibitors / Serotonin Modulators / Sulfur Compounds / Thiophenes,O5TNM5N07U,116539-59-4,,60835.0,54822.0,84745.0,72625.0,36795.0,CHEMBL1175,DAP000494,PA10066,ZINC000001536779
Chlorpromazine,phase 4 complete,DB00477 (APRD00482),CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Agents that reduce seizure threshold / Anticholinergic Agents / Antidepressive Agents / Antiemetics / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Autonomic Agents / BSEP/ABCB11 Inhibitors / Central Nervous System Agents / Central Nervous System Depressants / Cholinesterase Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Hyperglycemia-Associated Agents / Hypotensive Agents / Moderate Risk QTc-Prolonging Agents / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / Phenothiazines / Phenothiazines With Aliphatic Side-Chain / Photosensitizing Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Tranquilizing Agents",U42B7VYA4P,50-53-3,D00270,2726.0,2625.0,50001888.0,2403.0,3647.0,CHEMBL71,DAP000374,PA448964,ZINC000000044027
Rimantadine,phase 4 complete,DB00478 (APRD01219),CC(N)C12CC3CC(CC(C3)C1)C2,Adamantanes / Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Cyclic Amines / Cycloparaffins / Enzyme Inhibitors / Influenza A M2 Protein Inhibitor / M2 Protein Inhibitors / Nucleic Acid Synthesis Inhibitors,0T2EF4JQTU,13392-28-4,D08483,5071.0,4893.0,50216627.0,9386.0,94440.0,CHEMBL959,DAP001087,PA164748038,
Amikacin,phase 4 complete,DB00479 (APRD00550),NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Glycosides / Narrow Therapeutic Index Drugs / Nephrotoxic agents,84319SGC3C,37517-28-5,D02543,37768.0,34635.0,50237603.0,641.0,2637.0,CHEMBL177,DAP000400,PA164744372,ZINC000008214483
Lenalidomide,phase 4 complete,DB00480 (APRD01303),NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,"Acids, Carbocyclic / Angiogenesis Inhibitors / Angiogenesis Modulating Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Drugs that are Mainly Renally Excreted / Growth Inhibitors / Growth Substances / Heterocyclic Compounds, Fused-Ring / Imides / Immunologic Factors / Immunosuppressive Agents / Isoindoles / Myelosuppressive Agents / P-glycoprotein substrates / Phthalic Acids / Phthalimides / Piperidines / Piperidones / Thalidomide Analog",F0P408N6V4,191732-72-6,D04687,216326.0,187515.0,65454.0,342369.0,63791.0,CHEMBL848,DAP001255,PA162363968,
Raloxifene,phase 4 complete,DB00481 (APRD00400),OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,"BCRP/ABCG2 Substrates / Benzene Derivatives / Benzylidene Compounds / Bone Density Conservation Agents / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strong) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Estrogen Agonist-antagonists / Estrogen Agonist/Antagonist / Estrogen Antagonists / Estrogen Receptor Modulators / Genito Urinary System and Sex Hormones / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / Selective Estrogen Receptor Modulators / Sex Hormones and Modulators of the Genital System / Stilbenes / UGT1A1 Substrates",YX9162EO3I,84449-90-1,,5035.0,4859.0,19441.0,72143.0,8772.0,CHEMBL81,DAP000792,PA451221,ZINC000000538275
Celecoxib,phase 4 complete,DB00482 (APRD00373),CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,"Agents causing hyperkalemia / Agents that produce hypertension / Amides / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antineoplastic and Immunomodulating Agents / Antirheumatic Agents / BCRP/ABCG2 Substrates / BSEP/ABCB11 Inhibitors / Central Nervous System Agents / COX-2 Inhibitors / Cyclooxygenase Inhibitors / Cyclooxygenase-2 (COX-2) Inhibitors / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Methemoglobinemia Associated Agents / Musculo-Skeletal System / Nephrotoxic agents / P-glycoprotein substrates / Peripheral Nervous System Agents / Photosensitizing Agents / Pyrazoles / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory System Agents / Sulfonamides / Sulfones / Sulfur Compounds",JCX84Q7J1L,169590-42-5,D00567,2662.0,2562.0,11639.0,140587.0,41423.0,CHEMBL118,DAP000737,PA448871,ZINC000002570895
Gallamine triethiodide,phase 4 complete,DB00483 (APRD00712),[I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC,Agents producing tachycardia / Amines / Ammonium Compounds / Anticholinergic Agents / Central Nervous System Depressants / Cholinergic Agents / Cholinesterase Inhibitors / Muscarinic Antagonists / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular-Blocking Agents (Nondepolarizing) / Neurotransmitter Agents / Nicotinic Antagonists / Nitrogen Compounds / Onium Compounds / Peripheral Nervous System Agents / Quaternary Ammonium Compounds,Q3254X40X2,65-29-2,,6172.0,5937.0,,4639.0,,CHEMBL1200993,DAP001127,PA164745088,
Brimonidine,phase 4 complete,DB00484 (APRD00034),BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Antiglaucoma Preparations and Miotics / Cardiovascular Agents / Central Nervous System Depressants / Dermatologicals / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Misc. Skin and Mucous Membrane Agents / Ophthalmologicals / Quinoxalines / Sensory Organs / Sympathomimetics in Glaucoma Therapy",E6GNX3HHTE,59803-98-4,D07540,2435.0,2341.0,34572.0,134615.0,3175.0,CHEMBL844,DAP000280,PA448665,ZINC000021303210
Dicloxacillin,phase 4 complete,DB00485 (APRD00916),[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / Beta-Lactamase Resistant Penicillins / beta-Lactams / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillins / Sulfur Compounds",COF19H7WBK,3116-76-5,D02348,18381.0,17358.0,50350476.0,3356.0,4511.0,CHEMBL893,DAP000435,PA164749649,ZINC000003978006
Nabilone,phase 4 complete,DB00486 (APRD01127),[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC,Agents producing tachycardia / Alimentary Tract and Metabolism / Antiemetics / Antiemetics and Antinauseants / Autonomic Agents / Cannabinoids and similars / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Drugs causing inadvertant photosensitivity / Gastrointestinal Agents / Hypotensive Agents / Miscellaneous Antiemetics / Peripheral Nervous System Agents / Photosensitizing Agents / Psychotropic Drugs / Terpenes / Tranquilizing Agents,2N4O9L084N,51022-71-0,D05099,5284592.0,4447641.0,50287941.0,31447.0,,CHEMBL947,DAP000067,PA164746998,ZINC000001542930
Pefloxacin,phase 4 complete,DB00487 (APRD00108),CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quinolines / Quinolones / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",2H52Z9F2Q5,70458-92-3,D02306,51081.0,46291.0,57936.0,7960.0,50199.0,CHEMBL267648,DAP001001,PA164742856,ZINC000000001894
Altretamine,phase 4 complete,DB00488 (APRD00652),CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,"Alkylating Activity / Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Toxic Actions / Triazines",Q8BIH59O7H,645-05-6,,2123.0,2038.0,37631.0,5296.0,24564.0,CHEMBL1455,DAP000989,PA164743136,ZINC000000000905
Sotalol,phase 4 complete,DB00489 (APRD01230),CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Autonomic Agents / Beta Blocking Agents and Thiazides / Beta Blocking Agents, Non-Selective / Beta Blocking Agents, Non-Selective, and Thiazides / Bradycardia-Causing Agents / Cardiac Rhythm Alteration / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Ethanolamines / Highest Risk QTc-Prolonging Agents / Hypotensive Agents / Narrow Therapeutic Index Drugs / Neurotransmitter Agents / Peripheral Nervous System Agents / QTc Prolonging Agents / Sympatholytics",A6D97U294I,3930-20-9,,5253.0,5063.0,25762.0,9947.0,63622.0,CHEMBL471,DAP000372,PA451457,
Buspirone,phase 4 complete,DB00490 (APRD00222),O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1,Agents that produce hypertension / Antidepressive Agents / Azaspirodecanedione Derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs that are Mainly Renally Excreted / Miscellaneous Anxiolytics Sedatives and Hypnotics / Nervous System / Neurotransmitter Agents / P-glycoprotein inhibitors / Piperazines / Psycholeptics / Pyrimidines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Spiro Compounds / Tranquilizing Agents,TK65WKS8HL,36505-84-7,D07593,2477.0,2383.0,50001859.0,1827.0,3223.0,CHEMBL49,DAP000031,PA448689,ZINC000001530571
Miglitol,phase 4 complete,DB00491 (APRD01117),OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,Alimentary Tract and Metabolism / Alkaloids / Blood Glucose Lowering Agents / Carbohydrates / Drugs Used in Diabetes / Enzyme Inhibitors / Glycoside Hydrolase Inhibitors / Hypoglycemia-Associated Agents / Imines / Imino Pyranoses / Imino Sugars / Piperidines,0V5436JAQW,72432-03-2,D00625,441314.0,390074.0,50242271.0,30009.0,6935.0,CHEMBL1561,DAP000712,PA164776726,ZINC000004097426
Fosinopril,phase 4 complete,DB00492 (APRD00526),CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C,"ACE Inhibitors and Diuretics / Acids / Acids, Acyclic / Acids, Noncarboxylic / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Amino Acids / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hypotensive Agents / Imines / Imino Acids / Organophosphorus Compounds / Phosphinic Acids / Phosphorus Acids / Phosphorus Compounds / Photosensitizing Agents / Protease Inhibitors",R43D2573WO,98048-97-6,D00622,55891.0,7875352.0,,50166.0,5163.0,CHEMBL3039598,DAP000582,PA449710,ZINC000003977764
Cefotaxime,phase 4 complete,DB00493 (APRD00854),[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,"Agents that reduce seizure threshold / Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephacetrile / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",N2GI8B1GK7,63527-52-6,D07647,5742673.0,4674877.0,,2186.0,204928.0,CHEMBL1730,DAP000146,PA448852,ZINC000004468780
Entacapone,phase 4 complete,DB00494 (APRD00416),CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N,Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Benzene Derivatives / Central Nervous System Agents / Central Nervous System Depressants / COMT Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Dopamine Agents / Enzyme Inhibitors / Nervous System / Phenols / UGT1A9 Substrates,4975G9NM6T,130929-57-6,D00781,5281081.0,4444537.0,50108879.0,60307.0,4798.0,CHEMBL953,DAP000608,PA164748726,ZINC000035342787
Zidovudine,phase 4 complete,DB00495 (APRD00449),CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,"Agents Causing Muscle Toxicity / Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antimetabolites / Antiviral Agents / Antivirals for Systemic Use / BCRP/ABCG2 Substrates / Carbohydrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Deoxyribonucleosides / Dideoxynucleosides / Direct Acting Antivirals / Enzyme Inhibitors / Glycosides / Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Immunosuppressive Agents / Myelosuppressive Agents / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / Nucleoside Reverse Transcriptase Inhibitors / Nucleosides / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / P-glycoprotein substrates / Pyrimidine Nucleosides / Pyrimidines / Reverse Transcriptase Inhibitors / Toxic Actions / UGT1A1 Inducers / UGT1A1 Substrates / UGT2B7 substrates",4B9XT59T7S,30516-87-1,D00413,35370.0,32555.0,50002692.0,11413.0,10110.0,CHEMBL129,DAP000701,PA451954,ZINC000003779042
Darifenacin,phase 4 complete,DB00496 (APRD00903),NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1,"Agents producing tachycardia / Anticholinergic Agents / Cholinergic Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Urinary Frequency and Incontinence / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Muscarinic Antagonists / Neurotransmitter Agents / Urological Agents / Urologicals",APG9819VLM,133099-04-4,D01699,444031.0,392054.0,50109647.0,136198.0,391960.0,CHEMBL1346,DAP001131,PA164774901,ZINC000001996117
Oxycodone,phase 4 complete,DB00497 (APRD00387),COC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5C,"Alkaloids / Analgesics / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Morphinans / Morphine Derivatives / Narcotics / Natural Opium Alkaloids / Nervous System / Opiate Agonists / Opiate Alkaloids / Opioid Agonist / Opioids / Peripheral Nervous System Agents / Phenanthrenes / Semi-synthetic Opioids / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",CD35PMG570,76-42-6,D05312,5284603.0,4447649.0,50370595.0,7804.0,7852.0,CHEMBL656,DAP000283,PA450741,ZINC000000403533
Phenindione,phase 4 complete,DB00498 (APRD00166),O=C1C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1,Anticoagulants / Blood and Blood Forming Organs / Hematologic Agents / Indans / Indenes / Narrow Therapeutic Index Drugs / Vitamin K Antagonists,5M7Y6274ZE,83-12-5,D08354,4760.0,4596.0,50280157.0,8130.0,8066.0,CHEMBL711,DAP000769,PA164784031,ZINC000100004862
Flutamide,phase 4 complete,DB00499 (APRD00984),CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,"Amides / Amines / Androgen Receptor Antagonists / Androgen Receptor Inhibitor / Anilides / Aniline Compounds / Antiandrogens / Antiandrogens, non-steroidal / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Endocrine Therapy / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Methemoglobinemia Associated Agents",76W6J0943E,13311-84-7,D00586,3397.0,3280.0,50131270.0,4508.0,5132.0,CHEMBL806,DAP000301,PA449685,ZINC000003812944
Tolmetin,phase 4 complete,DB00500 (APRD01268),CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1,"Acetic Acid Derivatives and Related Substances / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antirheumatic Agents / Central Nervous System Agents / Cyclooxygenase Inhibitors / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / Peripheral Nervous System Agents / Sensory System Agents / Topical Products for Joint and Muscular Pain",D8K2JPN18B,26171-23-3,,5509.0,5308.0,50295287.0,10636.0,71941.0,CHEMBL1020,DAP000777,PA451721,ZINC000000002191
Cimetidine,phase 4 complete,DB00501 (APRD00568),CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,Acid Reducers / Adjuvants / Agents Causing Muscle Toxicity / Alimentary Tract and Metabolism / Amidines / Anti-Ulcer Agents / BSEP/ABCB11 Inhibitors / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (moderate) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Gastric Acid Lowering Agents / Gastrointestinal Agents / Guanidines / Histamine Agents / Histamine Antagonists / Histamine H2 Antagonists / Imidazoles / MATE 1 Inhibitors / MATE 1 Substrates / MATE 2 Inhibitors / MATE 2 Substrates / MATE inhibitors / MATE substrates / Neurotransmitter Agents / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OCT1 inhibitors / OCT1 substrates / OCT2 Inhibitors / OCT2 Substrates / P-glycoprotein inducers / P-glycoprotein substrates,80061L1WGD,51481-61-9,D00295,2756.0,2654.0,22889.0,2541.0,3699.0,CHEMBL30,DAP000338,PA449001,ZINC000018115268
Haloperidol,phase 4 complete,DB00502 (APRD00538),OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,Agents that reduce seizure threshold / Anti-Dyskinesia Agents / Antiemetics / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Autonomic Agents / Butyrophenone Derivatives / Butyrophenones / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Gastrointestinal Agents / Hyperglycemia-Associated Agents / Ketones / Moderate Risk QTc-Prolonging Agents / Nervous System / Neurotoxic agents / Neurotransmitter Agents / NMDA Receptor Antagonists / P-glycoprotein inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / Photosensitizing Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Tranquilizing Agents / UGT1A9 Substrates,J6292F8L3D,52-86-8,D00136,3559.0,3438.0,21398.0,5093.0,5613.0,CHEMBL54,DAP000313,PA449841,ZINC000000537822
Ritonavir,phase 4 complete,DB00503 (APRD00312),CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,"Acids, Acyclic / Agents Causing Muscle Toxicity / Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Breast Cancer Resistance Protein Inhibitors / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (weak) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (weak) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strong) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strong) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Experimental Unapproved Treatments for COVID-19 / HIV Protease Inhibitors / Hyperglycemia-Associated Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Potential QTc-Prolonging Agents / Protease Inhibitors / QTc Prolonging Agents / Sulfur Compounds / Thiazoles / UDP Glucuronosyltransferases Inducers / UGT1A1 Inducers",O3J8G9O825,155213-67-5,D00427,392622.0,347980.0,520.0,85762.0,45409.0,CHEMBL163,DAP000169,PA451260,ZINC000003944422
Levallorphan,phase 4 complete,DB00504 (APRD00733),[H][C@@]12CCCC[C@@]11CCN(CC=C)[C@@H]2CC2=C1C=C(O)C=C2,"Alkaloids / Central Nervous System Agents / Heterocyclic Compounds, Fused-Ring / Morphinans / Opiate Alkaloids / Opioid Antagonists / Peripheral Nervous System Agents / Phenanthrenes / Sensory System Agents",353613BU4U,152-02-3,,5359371.0,10481920.0,50326673.0,6370.0,6431.0,CHEMBL1254682,DAP000348,PA164749284,ZINC000003875992
Nitazoxanide,phase 4 complete,DB00507 (APRD00558),CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,"Anti-Infective Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Sulfur Compounds",SOA12P041N,55981-09-4,D02486,41684.0,38037.0,50075050.0,31819.0,94807.0,CHEMBL1401,DAP001293,PA164754874,ZINC000003956788
Triflupromazine,phase 4 complete,DB00508 (APRD00465),CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,"Agents producing tachycardia / Anticholinergic Agents / Antidepressive Agents / Antiemetics / Antipsychotic Agents / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Cholinesterase Inhibitors / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Phenothiazines / Phenothiazines With Aliphatic Side-Chain / Psycholeptics / Psychotropic Drugs / Serotonin 5-HT2 Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Tranquilizing Agents",RO16TQF95Y,146-54-3,D00390,5568.0,5367.0,67544.0,10805.0,9711.0,CHEMBL570,DAP000294,PA451773,ZINC000000538507
Dextrothyroxine,phase 4 complete,DB00509 (APRD00911),N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,"Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Lipid Modifying Agents / Lipid Modifying Agents, Plain",4W9K63FION,51-49-0,,8730.0,8402.0,50225220.0,3292.0,30659.0,CHEMBL559,,PA164752444,ZINC000003830994
Acetyldigitoxin,phase 4 complete,DB00511 (APRD01334),[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,"Antiarrhythmic agents / Carbohydrates / Cardanolides / Cardenolides / Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Digitalis Glycosides / Enzyme Inhibitors / Fused-Ring Compounds / Glycosides / Protective Agents / Steroids",0ZV4Q4L2FU,1111-39-3,D06881,5284512.0,4447572.0,,132871.0,53773.0,CHEMBL3545057,DAP000119,PA164746246,ZINC000096006012
Vancomycin,phase 4 complete,"DB00512 (APRD01287, EXPT03217)",CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,"Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antiinfectives for Systemic Use / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Glycoconjugates / Glycopeptide Antibacterials / Glycopeptides / Intestinal Antiinfectives / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Peptides",6Q205EH1VU,1404-90-6,D00212,14969.0,14253.0,50335519.0,11124.0,28001.0,CHEMBL262777,DAP001330,PA451850,
Aminocaproic acid,phase 4 complete,"DB00513 (APRD00791, EXPT00408, EXPT00461, DB04134)",NCCCCCC(O)=O,"Acids, Acyclic / Amino Acids / Amino Acids, Peptides, and Proteins / Aminocaproates / Antifibrinolytic Agents / Blood and Blood Forming Organs / Caproates / Coagulants / Decreased Fibrinolysis / Fatty Acids / Fatty Acids, Volatile / Fibrin Modulating Agents / Hematologic Agents / Hemostatics / Lipids",U6F3787206,60-32-2,D00160,564.0,548.0,50357211.0,99.0,57826.0,CHEMBL1046,DAP000200,PA164774947,ZINC000001529425
Dextromethorphan,phase 4 complete,DB00514 (APRD00655),[H][C@]12CCCC[C@]11CCN(C)[C@H]2CC2=C1C=C(OC)C=C2,"Alkaloids / Anticholinergic Agents / Antidepressive Agents / Antitussive Agents / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cough and Cold Preparations / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Excitatory Amino Acid Agents / Excitatory Amino Acid Antagonists / Heterocyclic Compounds, Fused-Ring / Morphinans / Narcotics / Nervous System / Neurotransmitter Agents / Nicotinic Antagonists / NMDA Receptor Antagonists / Opiate Alkaloids / Opium Alkaloids and Derivatives / Phenanthrenes / Respiratory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / Sigma-1 Agonist / Sigma-1 Receptor Agonists / Uncompetitive N-methyl-D-aspartate Receptor Antagonist / Uncompetitive NMDA Receptor Antagonists",7355X3ROTS,125-71-3,D03742,5360696.0,13109865.0,50366613.0,3289.0,4470.0,CHEMBL52440,DNC000541,PA449273,ZINC000003201907
Cisplatin,phase 4 complete,DB00515 (APRD00359),[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H],"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Cardiotoxic antineoplastic agents / Chlorine Compounds / Cholinesterase Inhibitors / Compounds used in a research, industrial, or household setting / Cross-Linking Reagents / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Immunosuppressive Agents / Indicators and Reagents / Laboratory Chemicals / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Nitrogen Compounds / OCT2 Inhibitors / OCT2 Substrates / OCT2 substrates with narrow therapeutic index / P-glycoprotein substrates / Platinum Compounds / Radiation-Sensitizing Agents",BW0OY6ZTD4,15663-27-1,D00275,2767.0,76401.0,50028111.0,2555.0,27899.0,CHEMBL2068237,DAP000215,PA449014,
Bentoquatam,phase 4 complete,DB00516 (APRD00819),,"Acids / Acids, Noncarboxylic / Aluminium Compounds / Aluminum Silicates / Anions / Dermatologicals / Electrolytes / Ions / Metal cations / Metal divalent cations / Minerals / Oxides / Oxygen Compounds / Silicates / Silicon Compounds",7F465U79Q1,1340-69-8,,,,,134568.0,,CHEMBL1201446,,PA164748098,
Anisotropine methylbromide,phase 4 complete,DB00517 (APRD00800),[Br-].CCCC(CCC)C(=O)O[C@H]1CC2CCC(C1)[N+]2(C)C,Agents producing tachycardia / Alkaloids / Anticholinergic Agents / Aza Compounds / Azabicyclo Compounds / Cholinergic Agents / Muscarinic Antagonists / Neurotransmitter Agents,62M960DHIL,80-50-2,D00232,21867154.0,10611962.0,,17945.0,2739.0,CHEMBL1578,DAP000837,PA164754880,
Albendazole,phase 4 complete,DB00518 (APRD00782),CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,"Acids, Acyclic / Anthelmintics / Anti-Infective Agents / Anticestodal Agents / Antihelminthic / Antimitotic Agents / Antinematodal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiplatyhelmintic Agents / Benzimidazole Derivatives / Benzimidazoles / Carbamates / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strong) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Mitosis Modulators / P-glycoprotein substrates / Tubulin Modulators",F4216019LN,54965-21-8,D00134,2082.0,1998.0,50241293.0,430.0,16664.0,CHEMBL1483,DAP000951,PA164746058,ZINC000017146904
Trandolapril,phase 4 complete,DB00519 (APRD01269),[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O,"ACE Inhibitors and Calcium Channel Blockers / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Protease Inhibitors",1T0N3G9CRC,87679-37-6,D00383,5484727.0,4588590.0,50369775.0,38454.0,9649.0,CHEMBL1519,DAP000583,PA451737,ZINC000001853205
Caspofungin,phase 4 complete,DB00520 (APRD00199),CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,"Amino Acids, Peptides, and Proteins / Anti-Infective Agents / Antifungal Agents / Antiinfectives for Systemic Use / Antimycotics for Systemic Use / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Echinocandin Antifungal / Echinocandins / Enzyme Inhibitors / Lipids / Lipopeptides / OAT1/SLC22A6 inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein inhibitors / Peptides / Peptides, Cyclic",F0XDI6ZL63,162808-62-0,D07626,3035406.0,411774.0,,140108.0,474180.0,CHEMBL499808,DAP000547,PA164743013,
Carteolol,phase 4 complete,DB00521 (APRD00195),CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antiglaucoma Preparations and Miotics / Antihypertensive Agents / Autonomic Agents / Beta Blocking Agents, Non-Selective / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Neurotransmitter Agents / Ophthalmologicals / Peripheral Nervous System Agents / Phenoxypropanolamines / Potential QTc-Prolonging Agents / Propanolamines / Propanols / QTc Prolonging Agents / Quinolines / Quinolones / Sensory Organs / Sympatholytics",8NF31401XG,51781-06-7,D07624,2583.0,2485.0,50040065.0,2116.0,3437.0,CHEMBL839,DAP000065,PA164768736,
Alitretinoin,phase 4 complete,DB00523 (APRD00017),C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O,"Agents for Dermatitis, Excluding Corticosteroids / Alkenes / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Biological Factors / Carotenoids / Cyclohexanes / Cyclohexenes / Cycloparaffins / Dermatologicals / Hydrocarbons, Acyclic / Misc. Skin and Mucous Membrane Agents / P-glycoprotein substrates / Pigments, Biological / Polyenes / Retinoids / Terpenes / Tretinoin / Vitamin A / Vitamins / Vitamins (Fat Soluble)",1UA8E65KDZ,5300-03-8,D02815,449171.0,395778.0,31892.0,81864.0,50648.0,CHEMBL705,DAP000275,PA164746900,ZINC000012661824
Metolazone,phase 4 complete,DB00524 (APRD01109),CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O,"Amides / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Diuretics / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Hypotensive Agents / Increased Diuresis / Low-Ceiling Diuretics and Potassium-Sparing Agents / Low-Ceiling Diuretics, Excl. Thiazides / Membrane Transport Modulators / Natriuretic Agents / Non Potassium Sparing Diuretics / Quinazolines / Quinazolinones / Sodium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds / Thiazide-like Diuretic",TZ7V40X7VX,17560-51-9,D00431,4170.0,4026.0,25899.0,6916.0,64354.0,CHEMBL878,DAP000749,PA164781022,
Tolnaftate,phase 4 complete,DB00525 (APRD01607),CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC=CC(C)=C1,"Acids, Acyclic / Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Carbamates / Dermatologicals / Naphthalenes / Sulfur Compounds / Thiocarbamates",06KB629TKV,2398-96-1,D00381,5510.0,5309.0,39349.0,10637.0,9620.0,CHEMBL83668,DAP001237,PA164752438,ZINC000000057522
Oxaliplatin,phase 4 complete,DB00526 (APRD00186),[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Coordination Complexes / Immunosuppressive Agents / Moderate Risk QTc-Prolonging Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / OCT2 Substrates / OCT2 substrates with narrow therapeutic index / Organometallic Compounds / Platinum Compounds / QTc Prolonging Agents,04ZR38536J,61825-94-3,D01790,6857599.0,8062727.0,,32592.0,31941.0,CHEMBL414804,DAP000062,PA131285527,
Cinchocaine,phase 4 complete,DB00527 (APRD00915),CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Amides / Analgesics and Anesthetics / Anesthetics / Anesthetics for Topical Use / Anesthetics, Local / Antipruritics and Local Anesthetics / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Cell-mediated Immunity / Central Nervous System Agents / Central Nervous System Depressants / Cholinesterase Inhibitors / Dermatologicals / Heterocyclic Compounds, Fused-Ring / Increased Histamine Release / Local Anesthetics (Amide) / Nervous System / Ophthalmologicals / Otologicals / Peripheral Nervous System Agents / Quinolines / Sensory Organs / Sensory System Agents / Standardized Chemical Allergen / Vasoprotectives",L6JW2TJG99,85-79-0,D00733,3025.0,2917.0,48532.0,3339.0,247956.0,CHEMBL1086,DAP000507,PA449286,ZINC000001530939
Lercanidipine,phase 4 complete,DB00528 (APRD00193),COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1,ACE Inhibitors and Calcium Channel Blockers / Agents causing hyperkalemia / Agents Causing Muscle Toxicity / Angiotensin II receptor blockers (ARBs) and calcium channel blockers / Antiarrhythmic agents / Antihypertensive Agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Hypotensive Agents / Membrane Transport Modulators / Pyridines / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,V7XTJ4R0BH,100427-26-7,,65866.0,59276.0,,135056.0,135930.0,CHEMBL250270,DAP001261,PA164769058,
Foscarnet,phase 4 complete,DB00529 (APRD00669),OC(=O)P(O)(O)=O,"Acetates / Acids, Acyclic / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Chelating Activity / Direct Acting Antivirals / Enzyme Inhibitors / Fatty Acids / Fatty Acids, Volatile / Lipids / Nephrotoxic agents / Nucleic Acid Synthesis Inhibitors / OAT1/SLC22A6 inhibitors / Organophosphonates / Organophosphorus Compounds / Phosphonic Acid Derivatives / Potential QTc-Prolonging Agents / Pyrophosphate Analog DNA Polymerase Inhibitor / QTc Prolonging Agents / Reverse Transcriptase Inhibitors",364P9RVW4X,4428-95-9,D00579,3415.0,3297.0,50011181.0,33562.0,127780.0,CHEMBL666,DAP001383,PA449706,ZINC000008101109
Erlotinib,phase 4 complete,DB00530 (APRD00951),COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Kinase Inhibitor / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Protein Kinase Inhibitors / QTc Prolonging Agents / Quinazolines / Tyrosine Kinase Inhibitors / UGT1A1 Inhibitors",J4T82NDH7E,183321-74-6,D07907,176870.0,154044.0,5446.0,337525.0,114785.0,CHEMBL553,DAP001010,PA134687924,ZINC000001546066
Cyclophosphamide,phase 4 complete,DB00531 (APRD00408),ClCCN(CCCl)P1(=O)NCCCO1,"Acids / Acids, Noncarboxylic / Alkylating Activity / Alkylating Drugs / Anions / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Antirheumatic Agents / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Electrolytes / Hydrocarbons, Halogenated / Immunologic Factors / Immunosuppressive Agents / Ions / Methemoglobinemia Associated Agents / Mustard Compounds / Mutagens / Myeloablative Agonists / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Neurotoxic agents / Nitrogen Mustard Analogues / Nitrogen Mustard Compounds / Noxae / Organophosphorus Compounds / Phosphoramide Mustards / Phosphoramides / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds / Toxic Actions",6UXW23996M,50-18-0,D07760,2907.0,2804.0,50237604.0,1545988.0,4027.0,CHEMBL88,DAP000532,PA449165,
Mephenytoin,phase 4 complete,DB00532 (APRD00512),CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1,Anti-epileptic Agent / Anticonvulsants / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Hydantoins / Imidazoles / Imidazolidines / Nervous System / Thyroxine-binding globulin substrates,R420KW629U,50-12-4,D00375,4060.0,3920.0,50103593.0,6757.0,6757.0,CHEMBL861,DAP000508,PA450373,
Rofecoxib,phase 4 complete,DB00533 (APRD00151),CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / COX-2 Inhibitors / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strong) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Peripheral Nervous System Agents / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory System Agents / Sulfur Compounds",0QTW8Z7MCR,162011-90-7,D00568,5090.0,4911.0,22369.0,232158.0,8887.0,CHEMBL122,DAP001338,PA451268,ZINC000000007455
Chlormerodrin,phase 4 complete,DB00534 (APRD00864),COC(CNC(N)=O)C[Hg]Cl,Alkylmercury Compounds / Organomercury Compounds / Organometallic Compounds,99T5TWO621,62-37-3,,25210.0,2615.0,,,59445.0,,DAP000754,PA164748977,
Cefdinir,phase 4 complete,DB00535 (APRD00644),[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Aza Compounds / Azabicyclo Compounds / beta-Lactams / Cephalosporins / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",CI0FAO63WC,91832-40-5,D00917,6915944.0,5291705.0,,25037.0,3485.0,CHEMBL927,DAP000436,PA164768739,ZINC000003927198
Guanidine,phase 4 complete,"DB00536 (APRD01008, EXPT01546)",NC(N)=N,Acetylcholine Releasing Agent / Amidines / Guanidines / Increased Acetylcholine Activity / MATE 1 Substrates / MATE 2 Substrates / MATE substrates / OAT3/SLC22A8 Inhibitors / OCT1 inhibitors / OCT2 Inhibitors,JU58VJ6Y3B,113-00-8,,3520.0,3400.0,50420178.0,50675.0,42820.0,CHEMBL821,,PA164781028,ZINC000008101126
Ciprofloxacin,phase 4 complete,"DB00537 (APRD00424, EXPT00999)",OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O,"Agents Causing Muscle Toxicity / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (moderate) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / MATE 1 Inhibitors / MATE 1 Substrates / MATE 2 Inhibitors / MATE inhibitors / MATE substrates / Moderate Risk QTc-Prolonging Agents / Ophthalmological and Otological Preparations / Ophthalmologicals / Otologicals / P-glycoprotein substrates / Photosensitizing Agents / QTc Prolonging Agents / Quinolines / Quinolone Antimicrobial / Quinolones / Sensory Organs / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",5E8K9I0O4U,85721-33-1,D00186,2764.0,2662.0,21690.0,2551.0,100241.0,CHEMBL8,DAP001360,PA449009,ZINC000000020220
Gadoversetamide,phase 4 complete,DB00538 (APRD00993),[Gd+3].COCCNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NCCOC)CC([O-])=O)CC([O-])=O,"Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Gadolinium-based Contrast Agent / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / Other Diagnostics / Paramagnetic Contrast Agent / Paramagnetic Contrast Media",RLM74T3Z9D,131069-91-5,D01646,444013.0,392041.0,,228833.0,31644.0,CHEMBL1200457,,PA164743703,
Toremifene,phase 4 complete,DB00539 (APRD00391),CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,"Anti-Estrogens / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Benzene Derivatives / Benzylidene Compounds / Bone Density Conservation Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Endocrine Therapy / Estrogen Agonist/Antagonist / Estrogen Receptor Modulators / Highest Risk QTc-Prolonging Agents / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / P-glycoprotein inhibitors / P-glycoprotein substrates / QTc Prolonging Agents / Selective Estrogen Receptor Modulators / Stilbenes",7NFE54O27T,89778-26-7,,3005573.0,2275722.0,58492.0,38409.0,9635.0,CHEMBL1655,DAP000793,PA451731,ZINC000012404516
Nortriptyline,phase 4 complete,DB00540 (APRD00602),CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Agents that produce hypertension / Agents that reduce seizure threshold / Anticholinergic Agents / Antidepressive Agents / Antidepressive Agents, Tricyclic / Benzocycloheptenes / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dibenzocycloheptenes / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Histamine Antagonists / Histamine H1 Antagonists / Membrane Transport Modulators / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Non-Selective Monoamine Reuptake Inhibitors / P-glycoprotein substrates / Potential QTc-Prolonging Agents / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Tricyclics and Other Norepinephrine-reuptake Inhibitors",BL03SY4LXB,72-69-5,D08288,4543.0,4384.0,112777.0,7531.0,7640.0,CHEMBL445,DAP001152,PA450657,ZINC000001530741
Vincristine,phase 4 complete,DB00541 (APRD00495),[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@H]5C[N@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC,"Agents Causing Muscle Toxicity / Alkaloids / Antimitotic Agents / Antineoplastic Agents / Antineoplastic Agents, Phytogenic / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / BSEP/ABCB11 Substrates / BSEP/ABCB11 Substrates with Narrow Therapeutic Index / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Indole Alkaloids / Indoles / Mitosis Modulators / Narrow Therapeutic Index Drugs / Neurotoxic agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Secologanin Tryptamine Alkaloids / Tubulin Modulators / Vinca Alkaloids",5J49Q6B70F,57-22-7,D08679,5978.0,4535015.0,38872.0,11202.0,28445.0,CHEMBL499458,DAP000114,PA451879,ZINC000085537024
Benazepril,phase 4 complete,DB00542 (APRD00063),[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,"ACE Inhibitors and Diuretics / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Decreased Blood Pressure / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Photosensitizing Agents / Protease Inhibitors",UDM7Q7QWP8,86541-75-5,D07499,5362124.0,4514935.0,50021153.0,18867.0,3011.0,CHEMBL838,DAP000584,PA448561,ZINC000003781943
Amoxapine,phase 4 complete,DB00543 (APRD00142),ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Agents that produce hypertension / Agents that reduce seizure threshold / Anticholinergic Agents / Antidepressive Agents / Antidepressive Agents, Tetracyclic / Antidepressive Agents, Tricyclic / Antipsychotic Agents / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dibenzoxazepines / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Membrane Transport Modulators / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Non-Selective Monoamine Reuptake Inhibitors / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists",R63VQ857OT,14028-44-5,D00228,2170.0,2085.0,22870.0,722.0,2675.0,CHEMBL1113,DAP001149,PA448405,ZINC000000000931
Fluorouracil,phase 4 complete,"DB00544 (APRD00516, EXPT03204)",FC1=CNC(=O)NC1=O,Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Fluoropyrimidines / Fluorouracil and prodrugs / Immunologic Factors / Immunosuppressive Agents / Misc. Skin and Mucous Membrane Agents / Moderate Risk QTc-Prolonging Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleoside Metabolic Inhibitor / Photosensitizing Agents / Pyrimidine Analogues / Pyrimidines / Pyrimidinones / QTc Prolonging Agents / Thyroxine-binding globulin inducers / Toxic Actions,U3P01618RT,51-21-8,D00584,3385.0,3268.0,50340677.0,4492.0,46345.0,CHEMBL185,DAP000829,PA128406956,ZINC000038212689
Pyridostigmine,phase 4 complete,DB00545 (APRD00380),CN(C)C(=O)OC1=C[N+](C)=CC=C1,Cholinergic Agents / Cholinesterase Inhibitors / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 Enzyme Inducers / Enzyme Inhibitors / Nervous System / Neurotransmitter Agents / Parasympathomemetic (Cholinergic) Agents / Parasympathomimetics / Pyridines / Pyridinium Compounds,19QM69HH21,155-97-5,D00487,4991.0,4817.0,50313079.0,9000.0,8665.0,CHEMBL1115,DNC001171,PA451185,ZINC000000002009
Desoximetasone,phase 4 complete,DB00547 (APRD00910),[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Pregnadienediols / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids / Steroids, Fluorinated",4E07GXB7AU,382-67-2,,5311067.0,4470604.0,50103622.0,3255.0,691037.0,CHEMBL1766,DAP001185,PA164746011,ZINC000004212854
Azelaic acid,phase 4 complete,"DB00548 (APRD00812, EXPT00598)",OC(=O)CCCCCCCC(O)=O,"Acids, Acyclic / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Decreased Protein Synthesis / Decreased Sebaceous Gland Activity / Dermatologicals / Drugs that are Mainly Renally Excreted / Misc. Skin and Mucous Membrane Agents",F2VW3D43YT,123-99-9,D03034,2266.0,2179.0,,18602.0,48131.0,CHEMBL1238,DAP000889,PA164754850,ZINC000001531036
Zafirlukast,phase 4 complete,DB00549 (APRD00377),COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C,"Agents to Treat Airway Disease / Anti-Asthmatic Agents / Benzene Derivatives / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Leukotriene Antagonists / Leukotriene Modifiers / Respiratory System Agents / Sulfones / Sulfur Compounds",XZ629S5L50,107753-78-6,D00411,5717.0,5515.0,50009073.0,114970.0,10100.0,CHEMBL603,DAP000091,PA451949,ZINC000000896717
Propylthiouracil,phase 4 complete,DB00550 (APRD00297),CCCC1=CC(=O)NC(=S)N1,"Agents Causing Muscle Toxicity / Antimetabolites / Antithyroid agents / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Myelosuppressive Agents / Noxae / Pyrimidines / Pyrimidinones / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Thiouracil / Thiouracils / Thyroid Hormone Synthesis Inhibitor / Thyroid Hormone Synthesis Inhibitors / Thyroid Products / Toxic Actions",721M9407IY,51-52-5,D00562,657298.0,571424.0,50133597.0,8794.0,8502.0,CHEMBL1518,DAP001247,PA451156,ZINC000004640636
Acetohydroxamic acid,phase 4 complete,"DB00551 (APRD00774, EXPT01688)",CC(=O)NO,Amines / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Hydroxy Acids / Hydroxylamines / Urease Inhibitor / Urease Inhibitors / Urologicals,4RZ82L2GY5,546-88-3,D00220,1990.0,1913.0,50099857.0,16728.0,49029.0,CHEMBL734,DAP001277,PA164749213,ZINC000004658603
Pentostatin,phase 4 complete,DB00552 (APRD00202),OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O,"Adenosine Deaminase Inhibitors / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Carbohydrates / Cardiotoxic antineoplastic agents / Coformycin / Deoxyribonucleosides / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Enzyme Inhibitors / Formycins / Glycosides / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Metabolic Inhibitor / Nucleosides / Pyrimidine Nucleosides / Pyrimidines / Ribonucleosides",395575MZO7,53910-25-1,D00155,439693.0,388759.0,22925.0,8011.0,,CHEMBL1580,DAP000566,PA450863,ZINC000003806262
Methoxsalen,phase 4 complete,DB00553 (APRD00157),COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,"Antipsoriatics / Antipsoriatics for Systemic Use / Antipsoriatics for Topical Use / Benzopyrans / Coloring Agents / Compounds used in a research, industrial, or household setting / Cross-Linking Reagents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Drugs that are Mainly Renally Excreted / Furocoumarins / Heterocyclic Compounds, Fused-Ring / Indicators and Reagents / Laboratory Chemicals / Photoabsorption / Photoactivated Radical Generator / Photosensitizing Activity / Photosensitizing Agents / Photosensitizing agents used for phototherapy / Psoralens for Systemic Use / Psoralens for Topical Use / Pyrans / Radiation-Sensitizing Agents",U4VJ29L7BQ,298-81-7,D00139,4114.0,3971.0,50041234.0,6854.0,18358.0,CHEMBL416,DAP000996,PA450433,ZINC000002548959
Piroxicam,phase 4 complete,DB00554 (APRD01187),CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antirheumatic Agents / Central Nervous System Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Ophthalmologicals / Other Nonsteroidal Anti-inflammatory Agents / Oxicams / Peripheral Nervous System Agents / Photosensitizing Agents / Sensory Organs / Sensory System Agents / Sulfur Compounds / Thiazines / Topical Products for Joint and Muscular Pain",13T4O6VMAM,36322-90-4,D00127,54676228.0,10442653.0,85245.0,8356.0,8249.0,CHEMBL527,DAP000181,PA450985,ZINC000051133897
Lamotrigine,phase 4 complete,DB00555 (APRD00570),NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,Agents causing hyperkalemia / Agents producing tachycardia / Anti-epileptic Agent / Antiarrhythmic agents / Anticholinergic Agents / Anticonvulsants / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Membrane Transport Modulators / Miscellaneous Anticonvulsants / Mood Stabilizer / Muscarinic Antagonists / Nervous System / OCT1 substrates / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / Potential QTc-Prolonging Agents / Psychotropic Drugs / QTc Prolonging Agents / Sodium Channel Blockers / Tranquilizing Agents / Triazines / UGT1A1 Inducers / UGT1A1 Substrates / UGT1A3 substrates / UGT1A4 substrates,U3H27498KS,84057-84-1,D00354,3878.0,3741.0,50031299.0,28439.0,6367.0,CHEMBL741,DAP000039,PA450164,ZINC000000013156
Perflutren,phase 4 complete,DB00556 (APRD01177),FC(F)(F)C(F)(F)C(F)(F)F,"Amino Acids, Peptides, and Proteins / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Hydrocarbons, Fluorinated / Hydrocarbons, Halogenated / Microspheres / Moderate Risk QTc-Prolonging Agents / Other Diagnostics / Proteins / QTc Prolonging Agents / Ultrasound Contrast Activity / Ultrasound Contrast Media",CK0N3WH0SR,76-19-7,D01738,6432.0,6192.0,,283753.0,31980.0,CHEMBL1663,,PA164781354,ZINC000008214651
Hydroxyzine,phase 4 complete,DB00557 (APRD00688),OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Anti-Anxiety Agents / Antipruritics / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Diphenylmethane Derivatives / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine Receptor Antagonists / Miscellaneous Anxiolytics Sedatives and Hypnotics / Nervous System / Neurotransmitter Agents / P-glycoprotein substrates / Piperazines / Potential QTc-Prolonging Agents / Psycholeptics / QTc Prolonging Agents,30S50YM8OG,68-88-2,D08054,3658.0,3531.0,22875.0,5553.0,5818.0,CHEMBL896,DAP000324,PA449943,
Zanamivir,phase 4 complete,DB00558 (APRD00378),[H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO,"Acids, Acyclic / Amidines / Amino Sugars / Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Carbohydrates / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Guanidines / Hydroxy Acids / Neuraminic Acids / Neuraminidase Inhibitors / Pyrans / Sialic Acids / Sugar Acids",L6O3XI777I,139110-80-8,D00902,60855.0,54842.0,50330326.0,69722.0,50663.0,CHEMBL222813,DAP000715,PA164740891,ZINC000003918138
Bosentan,phase 4 complete,DB00559 (APRD00829),COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1,Amides / Antihypertensive Agents / Antihypertensives for Pulmonary Arterial Hypertension / BSEP/ABCB11 Inhibitors / Cardiovascular Agents / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (moderate) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Endothelin Receptor Antagonists / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hepatotoxic Agents / OATP1B1/SLCO1B1 Substrates / Pyrimidines / Sulfonamides / Sulfones / Sulfur Compounds / Vasodilating Agents,XUL93R30K2,147536-97-8,D01227,104865.0,94651.0,50061101.0,75207.0,51450.0,CHEMBL957,DNC000341,PA10034,ZINC000001538857
Tigecycline,phase 4 complete,DB00560 (APRD01307),[H][C@@]12CC3=C(C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,Agents that produce neuromuscular block (indirect) / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Enzyme Inhibitors / Glycylcyclines / Naphthacenes / Protein Synthesis Inhibitors / Tetracyclines,70JE2N95KR,220620-09-7,D01079,54686904.0,10482314.0,50247905.0,384455.0,149836.0,CHEMBL376140,DAP000880,PA164746412,ZINC000014879972
Doxapram,phase 4 complete,DB00561 (APRD00935),CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,Agents that produce hypertension / Central Nervous System Agents / Central Nervous System Stimulants / Increased Medullary Respiratory Drive / Pyrrolidines / Pyrrolidinones / Respiratory System Agents,94F3830Q73,309-29-5,D07873,3156.0,3044.0,,3637.0,681848.0,CHEMBL1754,DAP001295,PA164784026,
Benzthiazide,phase 4 complete,DB00562 (APRD00728),NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O,"Amides / Diuretics / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Sodium Chloride Symporter Inhibitors / Stimulants / Sulfonamides / Sulfones / Sulfur Compounds / Thiazides",1TD8J48L61,91-33-8,D00651,2343.0,2253.0,50238676.0,19008.0,3047.0,CHEMBL1201039,DAP000603,PA164776841,ZINC000003871698
Methotrexate,phase 4 complete,DB00563 (APRD00353),CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,"Abortifacient Agents / Abortifacient Agents, Nonsteroidal / Agents Causing Muscle Toxicity / Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Antirheumatic Agents / BCRP/ABCG2 Substrates / Biological Factors / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Dermatologicals / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Folic Acid Analogues / Folic Acid Antagonists / Hepatotoxic Agents / Heterocyclic Compounds, Fused-Ring / Immunologic Factors / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Noxae / Nucleic Acid Synthesis Inhibitors / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / Photosensitizing Agents / Pigments, Biological / Pteridines / Pterins / Reproductive Control Agents / Toxic Actions",YL5FZ2Y5U1,59-05-2,D00142,126941.0,112728.0,66082.0,6851.0,44185.0,CHEMBL34259,DNC000933,PA450428,ZINC000001529323
Carbamazepine,phase 4 complete,DB00564 (APRD00337),NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,"Analgesics / Analgesics, Non-Narcotic / Anticonvulsants / Antimanic Agents / Carboxamide Derivatives / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strong) / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strong) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (moderate) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 CYP3A5 Inducers (strong) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Dibenzazepines / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Enzyme Inducing Antiepileptic Drugs / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Inducers of Drug Clearance / Membrane Transport Modulators / Miscellaneous Anticonvulsants / Mood Stabilizer / Myelosuppressive Agents / P-glycoprotein inducers / P-glycoprotein substrates / Peripheral Nervous System Agents / Psychotropic Drugs / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sodium Channel Blockers / Thyroxine-binding globulin substrates / UGT1A1 Inducers / UGT1A6 inducer / UGT2B7 substrates",33CM23913M,298-46-4,D00252,2554.0,2457.0,50003659.0,2002.0,3387.0,CHEMBL108,DAP000129,PA448785,ZINC000000004785
Cisatracurium,phase 4 complete,DB00565 (APRD00874),COC1=CC2=C(C=C1OC)[C@@H](CC1=CC(OC)=C(OC)C=C1)[N@@+](C)(CCC(=O)OCCCCCOC(=O)CC[N@@+]1(C)CCC3=C(C=C(OC)C(OC)=C3)[C@H]1CC1=CC(OC)=C(OC)C=C1)CC2,"Alkaloids / Anticholinergic Agents / Benzylisoquinolines / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular Nondepolarizing Blockade / Neuromuscular-Blocking Agents (Nondepolarizing) / Nicotinic Antagonists / Peripheral Nervous System Agents",QX62KLI41N,96946-41-7,,62886.0,56615.0,,319864.0,140621.0,CHEMBL1201248,DAP000196,PA164744925,ZINC000238809664
Succimer,phase 4 complete,DB00566 (APRD01236),OC(=O)[C@@H](S)[C@@H](S)C(O)=O,"Acids, Acyclic / Antidotes / Chelating Agents / Compounds used in a research, industrial, or household setting / Dicarboxylic Acids / Lead Chelating Activity / Lead Chelator / Protective Agents / Sequestering Agents / Succinates / Sulfhydryl Compounds / Sulfur Compounds",DX1U2629QE,304-55-2,D00572,2724354.0,2006502.0,50232640.0,3446.0,63623.0,CHEMBL1201073,,PA451521,ZINC000003831475
Cephalexin,phase 4 complete,DB00567 (APRD00250),[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Aza Compounds / Azabicyclo Compounds / beta-Lactams / Cephalosporins / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / First-Generation Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / MATE 1 Substrates / MATE substrates / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Sulfur Compounds / Thiazines",5SFF1W6677,15686-71-2,D00263,27447.0,25541.0,50139896.0,1299782.0,3534.0,CHEMBL1727,DAP000437,PA448883,ZINC000003830500
Cinnarizine,phase 4 complete,DB00568 (APRD00332),C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,Agents causing hyperkalemia / Antiarrhythmic agents / Antivertigo Preparations / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / Nervous System / Neurotransmitter Agents / Piperazines / QTc Prolonging Agents / Vasodilating Agents,3DI2E1X18L,298-57-7,D01295,2761.0,1264793.0,50017657.0,2549.0,31403.0,CHEMBL43064,DAP000325,PA164749342,ZINC000019632891
Fondaparinux,phase 4 complete,"DB00569 (APRD00500, DB11728)",CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O,Anticoagulants / Antithrombins / Blood and Blood Forming Organs / Carbohydrates / Cardiovascular Agents / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Factor Xa Inhibitors / Fibrin Modulating Agents / Fibrinolytic Agents / Hematologic Agents / Miscellaneous Anticoagulants / Oligosaccharides / Polysaccharides / Protease Inhibitors / Serine Protease Inhibitors,J177FOW5JL,104993-28-4,,49852292.0,4445600.0,,,61033.0,CHEMBL1201202,DNC000658,PA164746297,
Vinblastine,phase 4 complete,DB00570 (APRD00708),[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC,"Alkaloids / Antimitotic Agents / Antineoplastic Agents / Antineoplastic Agents, Phytogenic / Antineoplastic and Immunomodulating Agents / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / BSEP/ABCB11 Substrates with Narrow Therapeutic Index / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Indole Alkaloids / Indoles / Mitosis Modulators / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Secologanin Tryptamine Alkaloids / Tubulin Modulators / Vinca Alkaloids",5V9KLZ54CY,865-21-4,,13342.0,12773.0,50012278.0,11198.0,,CHEMBL159,DAP000785,PA451877,ZINC000085432544
Propranolol,phase 4 complete,DB00571 (APRD00194),CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Beta Blocking Agents and Thiazides / Beta Blocking Agents, Non-Selective / Beta Blocking Agents, Non-Selective, and Thiazides / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Moderate Risk QTc-Prolonging Agents / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Naphthalenes / Neurotransmitter Agents / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Phenoxypropanolamines / Propanolamines / Propanols / QTc Prolonging Agents / Vasodilating Agents",9Y8NXQ24VQ,525-66-6,D08443,4946.0,4777.0,25761.0,8787.0,8499.0,CHEMBL27,DAP000089,PA451145,
Atropine,phase 4 complete,"DB00572 (APRD00807, EXPT02427)",CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1,"Adjuvants, Anesthesia / Agents producing tachycardia / Agents that produce hypertension / Alimentary Tract and Metabolism / Alkaloids / Anti-Asthmatic Agents / Antiarrhythmic agents / Anticholinergic Agents / Antimuscarinics Antispasmodics / Atropine Derivatives / Autonomic Agents / Aza Compounds / Azabicyclo Compounds / Belladonna Alkaloids / Belladonna Alkaloids, Tertiary Amines / Belladonna and Derivatives, Plain / Bronchodilator Agents / BSEP/ABCB11 Substrates / Cardiovascular Agents / Central Nervous System Agents / Cholinergic Agents / Drugs for Functional Gastrointestinal Disorders / Moderate Risk QTc-Prolonging Agents / Muscarinic Antagonists / Mydriatics / Mydriatics and Cycloplegics / Neurotransmitter Agents / Ophthalmologicals / Parasympatholytics / Peripheral Nervous System Agents / QTc Prolonging Agents / Respiratory System Agents / Sensory Organs / Solanaceous Alkaloids / Tropanes",7C0697DR9I,51-55-8,D00113,174174.0,10194105.0,50403547.0,1223.0,78734.0,CHEMBL517712,DAP000377,PA448505,
Fenoprofen,phase 4 complete,DB00573 (APRD00970),CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / Cyclooxygenase Inhibitors / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Phenylpropionates / Propionates / Sensory System Agents",RA33EAC7KY,29679-58-1,D00968,3342.0,3225.0,54705.0,4331.0,5004.0,CHEMBL1297,DAP000619,PA449597,
Fenfluramine,phase 4 complete,DB00574 (APRD00319),CCNC(C)CC1=CC=CC(=C1)C(F)(F)F,"Alimentary Tract and Metabolism / Amines / Antidepressive Agents / Antiobesity Preparations, Excl. Diet Products / Central Nervous System Depressants / Centrally Acting Antiobesity Products / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Ethylamines / Membrane Transport Modulators / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Phenethylamines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Agonists / Serotonin Agents / Serotonin Receptor Agonists / Stimulants",2DS058H2CF,458-24-2,D07945,3337.0,3220.0,84738.0,4328.0,5000.0,CHEMBL87493,DAP001478,PA449592,
Clonidine,phase 4 complete,"DB00575 (APRD00174, DB07566)",ClC1=CC=CC(Cl)=C1NC1=NCCN1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Analgesics / Anesthetics / Anesthetics, General / Antiadrenergic Agents, Centrally Acting / Antiglaucoma Preparations and Miotics / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Antimigraine Preparations / Autonomic Agents / Bradycardia-Causing Agents / Cardiovascular Agents / Central alpha-2 Adrenergic Agonist / Central Alpha-agonists / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Hypotensive Agents / Imidazoles / Imidazoline Receptor Agonists / Imidazolines / Nervous System / Neurotransmitter Agents / Ophthalmologicals / P-glycoprotein substrates / Peripheral Nervous System Agents / Sensory Organs / Sensory System Agents / Sympatholytics / Sympathomimetics in Glaucoma Therapy",MN3L5RMN02,4205-90-7,D00281,2803.0,2701.0,14062.0,2599.0,46632.0,CHEMBL134,DAP000231,PA449051,ZINC000000896484
Sulfamethizole,phase 4 complete,DB00576 (APRD00684),CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1,Amides / Amines / Aniline Compounds / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Irrigating Solutions / Ophthalmologicals / Sensory Organs / Short-Acting Sulfonamides / Sulfanilamides / Sulfathiazoles / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds / Thiazoles,25W8454H16,144-82-1,D00870,5328.0,5137.0,50295558.0,10179.0,9331.0,CHEMBL1191,DAP001202,PA164781307,ZINC000000057493
Valaciclovir,phase 4 complete,DB00577 (APRD00697),CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1NC(N)=NC2=O,"Acyclovir and prodrug / Amino Acids / Amino Acids, Branched-Chain / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor / Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor / Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor / Heterocyclic Compounds, Fused-Ring / Nephrotoxic agents / Nucleic Acid Synthesis Inhibitors / Nucleosides and Nucleotides / Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors / OAT3/SLC22A8 Substrates / Prodrugs / Purines / Purinones",MZ1IW7Q79D,124832-26-4,D00398,60773.0,54770.0,50162073.0,73645.0,35854.0,CHEMBL1349,DAP000643,PA451839,ZINC000001530713
Carbenicillin,phase 4 complete,DB00578 (APRD00846),[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(O)=O)C1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / OAT1/SLC22A6 inhibitors / Penicillin G / Penicillins / Penicillins With Extended Spectrum / Sulfur Compounds",G42ZU72N5G,4697-36-3,D07614,20824.0,19599.0,,2015.0,3393.0,CHEMBL1214,DAP000438,PA448788,
Mazindol,phase 4 complete,DB00579 (APRD01085),OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1,"Adrenergic Agents / Adrenergic Uptake Inhibitors / Alimentary Tract and Metabolism / Anorexigenic Agents & Respiratory and Cerebral Stimulants, Miscellaneous / Anorexigenic Agents & Respiratory and CNS Stimulants / Antidepressive Agents / Antiobesity Preparations, Excl. Diet Products / Central Nervous System Agents / Central Nervous System Depressants / Central Nervous System Stimulants / Centrally Acting Antiobesity Products / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Dopamine Agents / Dopamine Uptake Inhibitors / Heterocyclic Compounds, Fused-Ring / Isoindoles / Membrane Transport Modulators / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",C56709M5NH,22232-71-9,D00367,4020.0,3880.0,50005536.0,6664.0,6702.0,CHEMBL781,DAP000722,PA450326,
Valdecoxib,phase 4 complete,"DB00580 (APRD00183, DB07576)",CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O,"Agents causing hyperkalemia / Agents that produce hypertension / Amides / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / COX-2 Inhibitors / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Peripheral Nervous System Agents / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory System Agents / Sulfones / Sulfur Compounds / UGT1A9 Substrates",2919279Q3W,181695-72-7,,119607.0,106796.0,13063.0,278567.0,63634.0,CHEMBL865,DAP001541,PA10226,ZINC000000006694
Lactulose,phase 4 complete,DB00581 (APRD01063),OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,Acidifying Activity / Alimentary Tract and Metabolism / Ammonia Detoxicants / Carbohydrates / Disaccharides / Drugs for Constipation / Gastrointestinal Agents / Laxatives / Osmotic Activity / Osmotic Laxatives / Stimulation Large Intestine Fluid/Electrolyte Secretion,9XH2P2N8EP,4618-18-2,D00352,11333.0,10856.0,50377984.0,6218.0,6359.0,CHEMBL296306,,PA164748762,ZINC000003977952
Voriconazole,phase 4 complete,DB00582 (APRD00543),C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,"14-alpha Demethylase Inhibitors / Anti-Infective Agents / Antifungal Agents / Antiinfectives for Systemic Use / Antimycotics for Systemic Use / Azole Antifungals / Chemically-Induced Disorders / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (moderate) / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (moderate) / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Photosensitizing Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Steroid Synthesis Inhibitors / Triazole Derivatives / Triazoles",JFU09I87TR,137234-62-9,D00578,71616.0,64684.0,50333117.0,121243.0,10023.0,CHEMBL638,DAP001271,PA10233,ZINC000000014864
Levocarnitine,phase 4 complete,DB00583 (APRD01070),C[N+](C)(C)C[C@H](O)CC([O-])=O,Alimentary Tract and Metabolism / Amines / Amino Acids and Derivatives / Ammonium Compounds / Caloric Agents / Carnitine Analog / Dietary Supplements / Drugs that are Mainly Renally Excreted / Nitrogen Compounds / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inhibitors / Onium Compounds / Quaternary Ammonium Compounds / Trimethyl Ammonium Compounds / Vitamin B Complex / Vitamins,0G389FZZ9M,541-15-1,D02176,10917.0,10455.0,50037268.0,2106.0,16347.0,CHEMBL1149,DAP000958,PA450154,
Enalapril,phase 4 complete,DB00584 (APRD00510),CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O,"ACE Inhibitors and Calcium Channel Blockers / ACE Inhibitors and Diuretics / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Agents Causing Muscle Toxicity / Amino Acids, Peptides, and Proteins / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Substrates / Decreased Blood Pressure / Dipeptides / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Hypotensive Agents / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Substrates / Oligopeptides / P-glycoprotein inhibitors / Peptides / Photosensitizing Agents / Protease Inhibitors",69PN84IO1A,75847-73-3,D07892,5388962.0,4534998.0,50017129.0,3827.0,4784.0,CHEMBL578,DAP001374,PA449456,ZINC000003791297
Nizatidine,phase 4 complete,DB00585 (APRD00706),CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O,Acid Reducers / Agents Causing Muscle Toxicity / Alimentary Tract and Metabolism / Anti-Ulcer Agents / Cholinesterase Inhibitors / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Gastric Acid Lowering Agents / Gastrointestinal Agents / Histamine Agents / Histamine Antagonists / Histamine H2 Antagonists / Neurotransmitter Agents / P-glycoprotein substrates / Sulfur Compounds / Thiazoles,P41PML4GHR,76963-41-2,D00440,3033637.0,4356.0,,42319.0,7601.0,CHEMBL3183075,DAP000339,PA164752234,
Diclofenac,phase 4 complete,DB00586 (APRD00527),OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,"Acetic Acid Derivatives and Related Substances / Acids, Carbocyclic / Agents causing angioedema / Agents causing hyperkalemia / Agents that produce hypertension / Amines / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antimigraine Agents, Miscellaneous / Antirheumatic Agents / BSEP/ABCB11 Substrates / Central Nervous System Agents / Cyclooxygenase Inhibitors / Cyclooxygenase-2 (COX-2) Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Prostaglandin Production / Dermatologicals / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Ethylamines / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / Ophthalmologicals / Other Nonsteroidal Anti-inflammatory Agents / P-glycoprotein inducers / Peripheral Nervous System Agents / Phenylacetates / Photosensitizing Agents / Sensory Organs / Sensory System Agents / Topical Products for Joint and Muscular Pain / UGT1A1 Substrates / UGT1A3 substrates / UGT1A9 Substrates / UGT2B7 substrates",144O8QL0L1,15307-86-5,D07816,3033.0,2925.0,13066.0,3355.0,47381.0,CHEMBL139,DAP000620,PA449293,ZINC000000001281
Fluticasone propionate,phase 4 complete,DB00588 (APRD00065),[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Adrenals / Agents to Treat Airway Disease / Androstadienes / Androstanes / Androstenes / Anti-Allergic Agents / Anti-Asthmatic Agents / Anti-Inflammatory Agents / Autonomic Agents / Bronchodilator Agents / Central Nervous System Depressants / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Immunosuppressive Agents / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / Respiratory System Agents / Steroids / Thyroxine-binding globulin inhibitors",O2GMZ0LF5W,80474-14-2,D01708,444036.0,392059.0,50354849.0,50121.0,31441.0,CHEMBL1473,DAP001039,PA449686,ZINC000003920027
Lisuride,phase 4 complete,DB00589 (APRD00636),[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC,"Agents that produce hypertension / Alkaloids / Analgesics / Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Antidepressive Agents / Antimigraine Preparations / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Agonists / Dopamine Antagonists / Ergolines / Ergot Alkaloids and Derivatives / Ergot-derivative Dopamine Receptor Agonists / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotransmitter Agents / Prolactine Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin Agents / Serotonin Receptor Agonists / Serotonin Receptor Antagonists",E0QN3D755O,18016-80-3,D08132,28864.0,26847.0,50056445.0,6446.0,51164.0,CHEMBL157138,DAP000255,PA164749019,ZINC000003831001
Doxazosin,phase 4 complete,DB00590 (APRD00474),COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Antiadrenergic Agents, Peripherally Acting / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Neurotransmitter Agents / OCT1 inhibitors / P-glycoprotein inhibitors / Peripheral alpha-1 blockers / Quinazolines",NW1291F1W8,74191-85-8,D07874,3157.0,3045.0,86731.0,49276.0,4708.0,CHEMBL707,DAP000381,PA449407,
Fluocinolone acetonide,phase 4 complete,DB00591 (APRD00977),[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,"Adrenal Cortex Hormones / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Ophthalmologicals / Otologicals / Pregnadienes / Pregnanes / Steroids / Steroids, Fluorinated / Vasoprotectives",0CD5FD6S2M,67-73-2,D01825,6215.0,5980.0,,4461.0,31623.0,CHEMBL989,DAP000813,PA164754912,ZINC000003977981
Piperazine,phase 4 complete,"DB00592 (APRD00225, DB11514)",C1CNCCN1,"Anthelmintics / Anti-Infective Agents / Antinematodal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Hyperglycemia-Associated Agents / Piperazine and Derivatives / Piperazines",1RTM4PAL0V,110-85-0,D00807,4837.0,13835459.0,,8340.0,28568.0,CHEMBL1412,DAP001418,PA450977,ZINC000005850277
Ethosuximide,phase 4 complete,DB00593 (APRD00318),CCC1(C)CC(=O)NC1=O,Agents causing hyperkalemia / Anti-epileptic Agent / Antiarrhythmic agents / Anticonvulsants / Bradycardia-Causing Agents / Calcium Channel Blockers / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Imides / Nervous System / Potential QTc-Prolonging Agents / Pyrrolidines / Pyrrolidinones / QTc Prolonging Agents / Succinimide Derivatives / Succinimides,5SEH9X1D1D,77-67-8,D00539,3291.0,3175.0,50240424.0,4135.0,4887.0,CHEMBL696,DAP000526,PA449533,
Amiloride,phase 4 complete,"DB00594 (APRD00790, EXPT00514)",NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N,Acid Sensing Ion Channel Blockers / Agents causing hyperkalemia / Cardiovascular Agents / Decreased Renal K+ Excretion / Diuretics / Epithelial Sodium Channel Blockers / Hypotensive Agents / Increased Diuresis / Membrane Transport Modulators / Natriuretic Agents / OCT2 Inhibitors / Potassium-Sparing Diuretics / Pyrazines / Sodium Channel Blockers,7DZO8EB0Z3,2609-46-3,D07447,16231.0,15403.0,16173.0,644.0,2639.0,CHEMBL945,DAP000187,PA448368,ZINC000004340269
Oxytetracycline,phase 4 complete,DB00595 (APRD00019),[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,Agents that produce neuromuscular block (indirect) / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antibiotics for Topical Use / Antiinfectives for Systemic Use / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Naphthacenes / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Ophthalmologicals / Sensory Organs / Tetracyclines,SLF0D9077S,79-57-2,,54675779.0,10482174.0,,7821.0,27701.0,CHEMBL1517,DAP000401,PA450757,ZINC000095626782
Ulobetasol,phase 4 complete,DB00596 (APRD01010),[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Cardiovascular Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Dermatologicals / Fused-Ring Compounds / Immunosuppressive Agents / Pregnadienes / Pregnadienetriols / Pregnanes / Psoriasis / Steroids / Steroids, Fluorinated / Vasoconstrictor Agents",9P6159HM7T,98651-66-2,,5311167.0,4470691.0,,41208.0,,CHEMBL1201360,DAP001186,PA164768832,ZINC000004214603
Gadoteridol,phase 4 complete,DB00597 (APRD00992),[Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,"Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Elements / Lanthanoid Series Elements / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / Metals / Metals, Rare Earth / Other Diagnostics / Paramagnetic Contrast Agent / Paramagnetic Contrast Media",0199MV609F,120066-54-8,D01137,60714.0,54719.0,,25483.0,31643.0,CHEMBL1200593,,PA164746463,
Labetalol,phase 4 complete,DB00598 (APRD01062),CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1,Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Agents producing tachycardia / Alcohols / Alpha and Beta Blocking Agents / Alpha and Beta Blocking Agents and Thiazides / Amides / Amines / Amino Alcohols / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Autonomic Agents / Beta Blocking Agents and Thiazides / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Ethanolamines / Hypotensive Agents / Neurotransmitter Agents / Peripheral alpha-1 blockers / Peripheral Nervous System Agents / Salicylamides / Sympathomimetics / UGT1A1 Substrates / UGT1A9 Substrates / UGT2B7 substrates / Vasodilating Agents,R5H8897N95,36894-69-6,D08106,3869.0,3734.0,25758.0,6185.0,6343.0,CHEMBL429,DAP000038,PA164743150,
Thiopental,phase 4 complete,DB00599 (APRD00660),CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,"Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Anticholinergic Agents / Anticonvulsants / Barbiturates / Barbiturates, Plain / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / GABA Agents / GABA Modulators / Hypnotics and Sedatives / Hypotensive Agents / Narrow Therapeutic Index Drugs / Nervous System / Neurotransmitter Agents / Nicotinic Antagonists / Psycholeptics / Pyrimidines / Pyrimidinones / Thiobarbiturates",JI8Z5M7NA3,76-75-5,,3000715.0,2272258.0,50058058.0,10493.0,102166.0,CHEMBL441,DAP000661,PA451664,
Monobenzone,phase 4 complete,DB00600 (APRD01121),OC1=CC=C(OCC2=CC=CC=C2)C=C1,"alpha-Galactosidase, antagonists & inhibitors / Benzene Derivatives / Depigmenting Activity / Depigmenting Agents / Dermatologicals / Melanin Synthesis Inhibitors / Phenols",9L2KA76MG5,103-16-2,D05072,7638.0,7356.0,50410520.0,17145.0,34380.0,CHEMBL1388,DAP000830,PA164764582,ZINC000000001748
Linezolid,phase 4 complete,"DB00601 (APRD01073, DB08769)",CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,"Acetamides / Acetates / Acids, Acyclic / Agents that produce hypertension / Agents that reduce seizure threshold / Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antidepressive Agents / Antiinfectives for Systemic Use / Central Nervous System Depressants / Enzyme Inhibitors / Fatty Acids / Fatty Acids, Volatile / Immunosuppressive Agents / Lipids / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Monoamine Oxidase Inhibitors / Myelosuppressive Agents / Oxazoles / Oxazolidinone Antibacterial / Oxazolidinones / Protein Synthesis Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",ISQ9I6J12J,165800-03-3,D00947,441401.0,390139.0,50116067.0,190376.0,63607.0,CHEMBL126,DAP000398,PA450233,ZINC000002008866
Ivermectin,phase 4 complete,DB00602 (APRD01058),CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O,"Agents Causing Muscle Toxicity / Agrochemicals / Anthelmintics / Anti-Bacterial Agents / Anti-Infective Agents / Antinematodal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Avermectines / BCRP/ABCG2 Substrates / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Insecticides / Lactones / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Pediculicides / Pesticides / Polyketides / Scabicides and Pediculicides / Toxic Actions",8883YP2R6D,70288-86-7,D00804,46936176.0,30776735.0,,6069.0,,CHEMBL1200633,DAP000261,PA450133,
Medroxyprogesterone acetate,phase 4 complete,DB00603 (APRD00627),[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,"Adrenal Cortex Hormones / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptive Agents, Male / Contraceptives, Oral / Contraceptives, Oral, Synthetic / Corpus Luteum Hormones / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Endocrine Therapy / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydroxyprogesterones / Hyperglycemia-Associated Agents / P-glycoprotein inhibitors / Pregnanes / Pregnen (4) Derivatives / Pregnenediones / Pregnenes / Progesterone and Derivatives / Progesterone Congeners / Progestin Contraceptives / Progestins / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",C2QI4IOI2G,71-58-9,D00951,6279.0,6043.0,50067678.0,1000112.0,6716.0,CHEMBL717,DAP001211,PA450344,ZINC000005029557
Cisapride,phase 4 complete,DB00604 (APRD00454),CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC,"Acids, Carbocyclic / Alimentary Tract and Metabolism / Amides / Aminobenzoates / Anti-Ulcer Agents / Antidepressive Agents / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Central Nervous System Depressants / Chlorobenzoates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (moderate) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Functional Gastrointestinal Disorders / Gastrointestinal Agents / Highest Risk QTc-Prolonging Agents / Neurotransmitter Agents / para-Aminobenzoates / Piperidines / Propulsives / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Receptor Agonists",UVL329170W,81098-60-4,D00274,6917698.0,5292927.0,50005836.0,35255.0,3720.0,CHEMBL560739,DAP000222,PA449011,ZINC000003775140
Sulindac,phase 4 complete,DB00605 (APRD01243),CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O,"Acetic Acid Derivatives and Related Substances / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / Cyclooxygenase Inhibitors / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Indenes / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / Other Nonsteroidal Anti-inflammatory Agents / Peripheral Nervous System Agents / Photosensitizing Agents / Sensory System Agents",184SNS8VUH,38194-50-2,D00120,1548887.0,1265915.0,50012899.0,10237.0,9352.0,CHEMBL15770,DAP000569,PA451565,
Cyclothiazide,phase 4 complete,"DB00606 (APRD00895, EXPT01082)",NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2,"Amides / Antihypertensive Agents / Cardiovascular Agents / Diuretics / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Natriuretic Agents / OAT1/SLC22A6 inhibitors / Receptors, AMPA / Sulfonamides / Sulfones / Sulfur Compounds / Thiazides",P71U09G5BW,2259-96-3,D01256,2910.0,2807.0,50192229.0,22033.0,31448.0,CHEMBL61593,DAP000604,PA449168,
Nafcillin,phase 4 complete,"DB00607 (APRD01130, DB08269)",[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / Beta-Lactamase Resistant Penicillins / beta-Lactams / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (moderate) / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Heterocyclic Compounds, Fused-Ring / Lactams / OAT1/SLC22A6 inhibitors / Penicillins / Sulfur Compounds",4CNZ27M7RV,147-52-4,D08242,8982.0,8634.0,50103525.0,7233.0,7447.0,CHEMBL1443,DAP001166,PA450576,ZINC000003875980
Chloroquine,phase 4 complete,DB00608 (APRD00468),CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,"Agents Causing Muscle Toxicity / Agents that produce neuromuscular block (indirect) / Agents that reduce seizure threshold / alpha-Galactosidase, antagonists & inhibitors / Amebicides / Aminoquinolines / Analgesics / Analgesics, Non-Narcotic / Anti-Infective Agents / Anti-Inflammatory Agents / Antimalarials / Antinematodal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Antirheumatic Agents / Central Nervous System Agents / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Experimental Unapproved Treatments for COVID-19 / Filaricides / Heterocyclic Compounds, Fused-Ring / Methemoglobinemia Associated Agents / Moderate Risk QTc-Prolonging Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / Photosensitizing Agents / QTc Prolonging Agents / Quinolines / Sensory System Agents",886U3H6UFF,54-05-7,D02366,2719.0,2618.0,22985.0,2393.0,3638.0,CHEMBL76,DAP001357,PA448948,
Ethionamide,phase 4 complete,DB00609 (APRD00961),CCC1=NC=CC(=C1)C(N)=S,Anti-Bacterial Agents / Anti-Infective Agents / Antiinfectives for Systemic Use / Antimycobacterials / Antituberculosis Agents / Drugs causing inadvertant photosensitivity / Drugs for Treatment of Tuberculosis / Fatty Acid Synthesis Inhibitors / Hypolipidemic Agents / Isonicotinic Acids / Lipid Regulating Agents / Noxae / Photosensitizing Agents / Pyridines / Thiocarbamide Derivatives / Toxic Actions,OAY8ORS3CQ,536-33-4,D00591,2761171.0,2041901.0,50239976.0,4127.0,4885.0,CHEMBL1441,DAP001141,PA164768738,ZINC000003872520
Metaraminol,phase 4 complete,DB00610 (APRD00555),C[C@H](N)[C@H](O)C1=CC(O)=CC=C1,Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic and Dopaminergic Agents / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Autonomic Agents / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiovascular Agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Propanolamines / Propanols / Sympathomimetics / Vasoconstrictor Agents,818U2PZ2EH,54-49-9,,5906.0,5695.0,50239972.0,6805.0,6794.0,CHEMBL1201319,DAP000225,PA164748761,ZINC000000001695
Butorphanol,phase 4 complete,DB00611 (APRD00835),[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,"Alkaloids / Analgesics / Antitussive Agents / Central Nervous System Agents / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Mixed Agonist / Antagonist Opioids / Morphinan Derivatives / Morphinans / Narcotics / Nervous System / Opiate Alkaloids / Opiate Partial Agonists / Opioid Agonist/Antagonist / Opioid Antagonists / Opioids / Peripheral Nervous System Agents / Phenanthrenes / Respiratory System Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",QV897JC36D,42408-82-2,D00837,6916249.0,16735714.0,50240437.0,1841.0,3242.0,CHEMBL33986,DAP000214,PA164745398,ZINC000003812988
Bisoprolol,phase 4 complete,DB00612 (APRD00257),CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-1 Receptor Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Autonomic Agents / Beta blocking agents and calcium channel blockers / Beta Blocking Agents and Thiazides / Beta Blocking Agents, Selective / Beta Blocking Agents, Selective, and Thiazides / Beta-Blockers (Beta1 Selective) / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Neurotransmitter Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / Phenoxypropanolamines / Propanolamines / Propanols / Sympatholytics",Y41JS2NL6U,66722-44-9,D02342,2405.0,2312.0,25751.0,19484.0,3127.0,CHEMBL645,DAP000483,PA448641,
Amodiaquine,phase 4 complete,DB00613 (APRD00796),CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1,"Aminoquinolines / Anti-Infective Agents / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quinolines",220236ED28,86-42-0,D02922,2165.0,2080.0,50041457.0,720.0,2674.0,CHEMBL682,DAP000699,PA448404,ZINC000000608172
Rifabutin,phase 4 complete,DB00615 (APRD00094),CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics, Antitubercular / Antiinfectives for Systemic Use / Antimycobacterials / Antituberculosis Agents / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (weak) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (moderate) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (weak) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Drugs for Treatment of Tuberculosis / Heterocyclic Compounds, Fused-Ring / Lactams / Lactams, Macrocyclic / P-glycoprotein inducers / Rifamycin Antimycobacterial / Rifamycins",1W306TDA6S,72559-06-9,D00424,6323490.0,10482168.0,50237607.0,55672.0,45367.0,CHEMBL444633,DAP000656,PA451249,ZINC000169621215
Paramethadione,phase 4 complete,DB00617 (APRD00236),CCC1(C)OC(=O)N(C)C1=O,Anticonvulsants / Central Nervous System Depressants / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Nervous System / Oxazolidine Derivatives,Z615FRW64N,115-67-3,D00495,8280.0,7979.0,,32894.0,7921.0,CHEMBL1100,DAP001266,PA164748880,
Demeclocycline,phase 4 complete,DB00618 (APRD00272),[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O,Agents that produce neuromuscular block (indirect) / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antibiotics for Topical Use / Antiinfectives for Systemic Use / Dermatologicals / Drugs causing inadvertant photosensitivity / Naphthacenes / Photosensitizing Agents / Tetracyclines,5R5W9ICI6O,127-33-3,D00290,54680690.0,10482117.0,,3154.0,4392.0,CHEMBL1591,DAP000402,PA164745513,ZINC000100036924
Imatinib,phase 4 complete,"DB00619 (APRD01028, EXPT02967, DB03261)",CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,"Acids, Carbocyclic / Amides / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / BSEP/ABCB11 Substrates / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Highest Risk QTc-Prolonging Agents / Immunosuppressive Agents / Kinase Inhibitor / Myelosuppressive Agents / OCT1 substrates / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / Piperazines / Protein Kinase Inhibitors / Pyrimidines / QTc Prolonging Agents / Tyrosine Kinase Inhibitors",BKJ8M8G5HI,152459-95-5,D01441,5291.0,5101.0,13530.0,282388.0,45783.0,CHEMBL941,DNC001383,PA10804,ZINC000019632618
Triamcinolone,phase 4 complete,DB00620 (APRD00422),[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Adrenals / Agents Causing Muscle Toxicity / Agents to Treat Airway Disease / Alimentary Tract and Metabolism / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids for Local Oral Treatment / Corticosteroids for Systemic Use / Corticosteroids for Systemic Use, Plain / Corticosteroids, Dermatological Preparations / Corticosteroids, Moderately Potent (Group II) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inducers / Cytochrome P-450 CYP3A7 Inducers (strength unknown) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Drugs for Obstructive Airway Diseases / Enzyme Inhibitors / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunologic Factors / Immunosuppressive Agents / Nasal Preparations / Ophthalmologicals / Pregnadienes / Pregnanes / Protein-Lysine 6-Oxidase, antagonists & inhibitors / Sensory Organs / Steroids / Steroids, Fluorinated / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Thyroxine-binding globulin inhibitors / Vasoprotectives",1ZK20VI6TY,124-94-7,D00385,31307.0,29046.0,41132.0,10759.0,9667.0,CHEMBL1451,DAP000417,PA451749,ZINC000003882036
Oxandrolone,phase 4 complete,DB00621 (APRD01151),[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C,"Alimentary Tract and Metabolism / Anabolic Agents / Anabolic Agents for Systemic Use / Anabolic Steroids / Androgens / Androstan Derivatives / Androstanes / Androstanols / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Steroids / Thyroxine-binding globulin inhibitors",7H6TM3CT4L,53-39-4,D00462,5878.0,5667.0,,7779.0,7820.0,CHEMBL1200436,DAP000905,PA164749395,ZINC000003813047
Nicardipine,phase 4 complete,DB00622 (APRD00088),COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1,Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents causing hyperkalemia / Agents producing tachycardia / Antiarrhythmic agents / Anticholinergic Agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Bradycardia-Causing Agents / BSEP/ABCB11 Substrates / Calcium Channel Blockers / Calcium Channel Blockers (Dihydropyridine) / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Dihydropyridines / Hypotensive Agents / Membrane Transport Modulators / Muscarinic Antagonists / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Potential QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,CZ5312222S,55985-32-5,,4474.0,4319.0,50101815.0,7396.0,7550.0,CHEMBL1484,DAP000486,PA450620,
Fluphenazine,phase 4 complete,DB00623 (APRD00633),OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,"Agents that reduce seizure threshold / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Delayed-Action Preparations / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein inhibitors / Phenothiazines / Phenothiazines With Piperazine Structure / Photosensitizing Agents / Prodrugs / Psycholeptics / Psychotropic Drugs / Sulfur Compounds / Tranquilizing Agents",S79426A41Z,69-23-8,D07977,3372.0,3255.0,78433.0,4496.0,5123.0,CHEMBL726,DCL000806,PA449676,ZINC000019203912
Testosterone,phase 4 complete,"DB00624 (APRD00433, DB05720, DB05275)",[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"3-Oxoandrosten (4) Derivatives / Androgens / Androgens and Estrogens / Androstanes / Androstenes / Androstenols / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OAT3/SLC22A8 Inducers / OATP1B3 substrates / P-glycoprotein inhibitors / Sex Hormones and Modulators of the Genital System / Steroids / Testosterone and derivatives / Testosterone Congeners / Thyroxine-binding globulin inhibitors",3XMK78S47O,58-22-0,D00075,6013.0,5791.0,8885.0,10379.0,17347.0,CHEMBL386630,DAP000841,PA451627,ZINC000118912393
Efavirenz,phase 4 complete,"DB00625 (APRD00059, DB07709)",FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,"Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BSEP/ABCB11 Substrates / Central Nervous System Depressants / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (moderate) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (moderate) / Cytochrome P-450 CYP3A7 Inducers / Cytochrome P-450 CYP3A7 Inducers (moderate) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor / Inducers of Drug Clearance / Moderate Risk QTc-Prolonging Agents / Non-Nucleoside Reverse Transcriptase Inhibitors / Nonnucleoside Reverse Transcriptase Inhibitors / Nucleic Acid Synthesis Inhibitors / OCT1 inhibitors / Oxazines / QTc Prolonging Agents / Reverse Transcriptase Inhibitors / UGT1A1 Inducers",JE6H2O27P8,154598-52-4,D00896,64139.0,57715.0,2483.0,195085.0,119486.0,CHEMBL223228,DAP000709,PA449441,ZINC000002020233
Bacitracin,phase 4 complete,DB00626 (APRD00816),CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC,"Acids, Carbocyclic / Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Local / Antibacterials for Systemic Use / Antibiotics for Topical Use / Antiinfectives for Systemic Use / Bacitracins / Benzene Derivatives / Benzoates / Decreased Cell Wall Synthesis & Repair / Dermatologicals / Hydroxy Acids / Hydroxybenzoates / Nephrotoxic agents / Peptides / Peptides, Cyclic / Phenols / Throat Preparations",DDA3RRX0P7,1405-87-4,D00128,10909430.0,9084687.0,,1291.0,35862.0,CHEMBL1200558,DAP000710,PA448531,
Niacin,phase 4 complete,"DB00627 (NUTR00042, APRD00536)",OC(=O)C1=CN=CC=C1,"Agents Causing Muscle Toxicity / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Hyperglycemia-Associated Agents / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Micronutrients / Miscellaneous Antilipemic Agents / Nicotinic Acid and Derivatives / Nicotinic Acids / Noxae / Peripheral Vasodilators / Physiological Phenomena / Pyridines / Thyroxine-binding globulin inhibitors / Toxic Actions / Vasodilating Agents / Vitamin B Complex / Vitamins",2679MF687A,59-67-6,D00049,938.0,913.0,23515.0,7393.0,15940.0,CHEMBL573,,PA450617,ZINC000000001795
Clorazepic acid,phase 4 complete,DB00628 (APRD00881),OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,"Anti-Anxiety Agents / Anticonvulsants / Benzazepines / Benzodiazepines and benzodiazepine derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / Psychotropic Drugs / Tranquilizing Agents",D51WO0G0L4,23887-31-2,D00694,2809.0,2707.0,,235408.0,3761.0,CHEMBL1213252,DAP000240,PA164749297,
Guanabenz,phase 4 complete,DB00629 (APRD00487),NC(N)=NN=CC1=C(Cl)C=CC=C1Cl,Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Amidines / Antihypertensive Agents / Cardiovascular Agents / Central alpha-2 Adrenergic Agonist / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Guanidines / Neurotransmitter Agents,GGD30112WC,5051-62-7,D04375,3517.0,4642445.0,50225293.0,5033.0,5553.0,CHEMBL420,DAP000232,PA164774903,ZINC000000001522
Alendronic acid,phase 4 complete,DB00630 (APRD00561),NCCCC(O)(P(O)(O)=O)P(O)(O)=O,Agents Causing Muscle Toxicity / Bisphosphonates / Bone Density Conservation Agents / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Musculo-Skeletal System / Organophosphonates / Organophosphorus Compounds,X1J18R4W8P,66376-36-1,,2088.0,2004.0,25313.0,236083.0,2567.0,CHEMBL870,DAP000182,PA448082,ZINC000003801919
Clofarabine,phase 4 complete,"DB00631 (APRD00878, DB07554, DB06189)",[H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12,"Adenine Nucleotides / Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Arabinonucleosides / BCRP/ABCG2 Substrates / Carbohydrates / Drugs that are Mainly Renally Excreted / Glycosides / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Immunosuppressive Agents / Myelosuppressive Agents / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Metabolic Inhibitor / Nucleosides / Nucleotides / OAT3/SLC22A8 Substrates / OAT3/SLC22A8 Substrates with Narrow Therapeutic Index / OCT2 substrates with narrow therapeutic index / Purine Analogues / Purine Nucleotides / Purines / Ribonucleotides / Toxic Actions",762RDY0Y2H,123318-82-1,,119182.0,106472.0,,44151.0,681569.0,CHEMBL1750,DAP000849,PA164754863,ZINC000003798247
Docosanol,phase 4 complete,DB00632 (APRD00933),CCCCCCCCCCCCCCCCCCCCCCO,Alcohols / Anti-Infective Agents / Antiviral Agents / Dermatologicals / Lipids,9G1OE216XY,661-19-8,,12620.0,12100.0,50239998.0,594680.0,31000.0,CHEMBL1200453,DAP001249,PA164749211,ZINC000006920384
Dexmedetomidine,phase 4 complete,DB00633 (APRD00578),C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anesthetics / Anesthetics, General / Bradycardia-Causing Agents / Central alpha-2 Adrenergic Agonist / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypnotics and Sedatives / Hypotensive Agents / Imidazoles / Miscellaneous Anxiolytics Sedatives and Hypnotics / Nervous System / Neurotransmitter Agents / Peripheral Nervous System Agents / Psycholeptics / Sensory System Agents",67VB76HONO,113775-47-6,D00514,5311068.0,4470605.0,50085683.0,48937.0,4466.0,CHEMBL778,DAP000233,PA449256,ZINC000004632106
Sulfacetamide,phase 4 complete,DB00634 (APRD00452),CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1,"Amides / Amines / Aniline Compounds / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Local / Anti-Infective Agents, Urinary / Antiinfectives for Treatment of Acne / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Ophthalmologicals / Renal Agents / Sensory Organs / Sulfanilamides / Sulfonamide Antibacterial / Sulfonamides / Sulfones / Sulfur Compounds",4965G3J0F5,144-80-9,D05947,5320.0,5129.0,50316126.0,10169.0,63845.0,CHEMBL455,DAP001191,PA451536,ZINC000005179119
Prednisone,phase 4 complete,DB00635 (APRD00340),[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Adrenals / Alimentary Tract and Metabolism / Anti-Inflammatory Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids Acting Locally / Corticosteroids for Systemic Use / Corticosteroids for Systemic Use, Plain / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Intestinal Antiinflammatory Agents / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Prednisolone and Prodrugs / Pregnadienediols / Pregnadienes / Pregnanes / Steroids / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Thyroxine-binding globulin inhibitors",VB0R961HZT,53-03-2,D00473,5865.0,5656.0,,8640.0,8382.0,CHEMBL635,DAP001041,PA451100,ZINC000003875357
Clofibrate,phase 4 complete,DB00636 (APRD00879),CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,"Acids, Acyclic / Agents Causing Muscle Toxicity / Anticholesteremic Agents / Benzene Derivatives / Butyrates / Clofibric Acid / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Ethers / Fatty Acids / Fatty Acids, Volatile / Fibric Acids / Hypolipidemic Agents / Isobutyrates / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Lipids / Noxae / Phenols / Phenyl Ethers / Thyroxine-binding globulin inducers / Toxic Actions",HPN91K7FU3,637-07-0,D00279,2796.0,2694.0,50085047.0,2594.0,3750.0,CHEMBL565,DAP000262,PA449045,ZINC000000056648
Astemizole,phase 4 complete,DB00637 (APRD00585),COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,"Anti-Allergic Agents / Antihistamines for Systemic Use / Benzimidazoles / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Neurotransmitter Agents / P-glycoprotein inhibitors / QTc Prolonging Agents",7HU6337315,68844-77-9,D00234,2247.0,2160.0,24226.0,42328.0,2896.0,CHEMBL296419,DAP000326,PA448498,ZINC000000601274
Inulin,phase 4 complete,DB00638 (APRD01034),OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(OC[C@@]%12(OC[C@@]%13(OC[C@@]%14(OC[C@@]%15(OC[C@@]%16(OC[C@@]%17(OC[C@@]%18(OC[C@@]%19(OC[C@@]%20(OC[C@@]%21(OC[C@@]%22(OC[C@@]%23(OC[C@@]%24(OC[C@@]%25(OC[C@@]%26(OC[C@@]%27(OC[C@@]%28(OC[C@@]%29(OC[C@@]%30(OC[C@@]%31(OC[C@@]%32(OC[C@@]%33(OC[C@@]%34(OC[C@@]%35(OC[C@@]%36(OC[C@@]%37(O[C@H]%38O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%38O)O[C@H](CO)[C@@H](O)[C@@H]%37O)O[C@H](CO)[C@@H](O)[C@@H]%36O)O[C@H](CO)[C@@H](O)[C@@H]%35O)O[C@H](CO)[C@@H](O)[C@@H]%34O)O[C@H](CO)[C@@H](O)[C@@H]%33O)O[C@H](CO)[C@@H](O)[C@@H]%32O)O[C@H](CO)[C@@H](O)[C@@H]%31O)O[C@H](CO)[C@@H](O)[C@@H]%30O)O[C@H](CO)[C@@H](O)[C@@H]%29O)O[C@H](CO)[C@@H](O)[C@@H]%28O)O[C@H](CO)[C@@H](O)[C@@H]%27O)O[C@H](CO)[C@@H](O)[C@@H]%26O)O[C@H](CO)[C@@H](O)[C@@H]%25O)O[C@H](CO)[C@@H](O)[C@@H]%24O)O[C@H](CO)[C@@H](O)[C@@H]%23O)O[C@H](CO)[C@@H](O)[C@@H]%22O)O[C@H](CO)[C@@H](O)[C@@H]%21O)O[C@H](CO)[C@@H](O)[C@@H]%20O)O[C@H](CO)[C@@H](O)[C@@H]%19O)O[C@H](CO)[C@@H](O)[C@@H]%18O)O[C@H](CO)[C@@H](O)[C@@H]%17O)O[C@H](CO)[C@@H](O)[C@@H]%16O)O[C@H](CO)[C@@H](O)[C@@H]%15O)O[C@H](CO)[C@@H](O)[C@@H]%14O)O[C@H](CO)[C@@H](O)[C@@H]%13O)O[C@H](CO)[C@@H](O)[C@@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O,"Biopolymers / Carbohydrates / Compounds used in a research, industrial, or household setting / Diagnostic Agents / Diet, Food, and Nutrition / Dietary Carbohydrates / Food / Food and Beverages / Fructans / Glucans / Macromolecular Substances / Physiological Phenomena / Polymers / Polysaccharides / Starch / Tests for Renal Function and Ureteral Injuries",JOS53KRJ01,9005-80-5,D00171,24763.0,23149.0,,5924.0,15443.0,CHEMBL1201646,DAP001304,PA450043,
Butoconazole,phase 4 complete,DB00639 (APRD00834),ClC1=CC=C(CCC(CN2C=CN=C2)SC2=C(Cl)C=CC=C2Cl)C=C1,Anti-Infective Agents / Antifungal Agents / Antifungal Agents (Vaginal) / Azole Antifungals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Imidazole Derivatives,0Q771797PH,64872-76-0,D07598,47472.0,43192.0,79206.0,19884.0,3240.0,CHEMBL1295,DAP001267,PA164781353,
Adenosine,phase 4 complete,"DB00640 (APRD00132, DB06639)",NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1,"Adenosine, antagonists & inhibitors / Agents producing tachycardia / Alkenes / Analgesics / Antiarrhythmic agents / Antiarrhythmics, Class V / Biological Factors / Carbohydrates / Cardiac Therapy / Cardiovascular Agents / Central Nervous System Agents / Class IV Antiarrythmics / Cyclohexanes / Cyclohexenes / Cycloparaffins / Enzymes / Enzymes and Coenzymes / Glycosides / Heterocyclic Compounds, Fused-Ring / Hydrocarbons, Acyclic / Miscellaneous Cardiac Drugs / Miscellaneous Therapeutic Agents / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / Oxidoreductases / Peripheral Nervous System Agents / Pigments, Biological / Polyenes / Purine Nucleosides / Purinergic Agents / Purinergic Agonists / Purinergic P1 Receptor Agonists / Purines / QTc Prolonging Agents / Ribonucleosides / Sensory System Agents / Terpenes / Vasodilating Agents",K72T3FS567,58-61-7,D00045,60961.0,54923.0,14487.0,296.0,16335.0,CHEMBL477,DAP000223,PA448049,ZINC000002169830
Simvastatin,phase 4 complete,DB00641 (APRD00104),[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,"Agents Causing Muscle Toxicity / Anticholesteremic Agents / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Naphthalenes / Noxae / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / UGT1A1 Substrates / UGT1A3 substrates / UGT2B7 substrates",AGG2FN16EV,79902-63-9,D00434,54454.0,49179.0,50139181.0,36567.0,9150.0,CHEMBL1064,DAP001519,PA451363,ZINC000003780893
Pemetrexed,phase 4 complete,"DB00642 (APRD00573, EXPT02075)",NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,"Amino Acids / Amino Acids, Acidic / Amino Acids, Dicarboxylic / Amino Acids, Peptides, and Proteins / Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Enzyme Inhibitors / Folic Acid Analogues / Folic Acid Antagonists / Glutamates / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nucleic Acid Synthesis Inhibitors / OAT3/SLC22A8 Substrates / Purines / Purinones",04Q9AIZ7NO,137281-23-3,D07472,446556.0,393879.0,50027656.0,68446.0,63616.0,CHEMBL225072,DCL000320,PA10810,ZINC000001540998
Mebendazole,phase 4 complete,DB00643 (APRD01086),COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1,"Acids, Acyclic / Anthelmintics / Anti-Infective Agents / Antihelminthic / Antimitotic Agents / Antinematodal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Benzimidazole Derivatives / Benzimidazoles / Carbamates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Mitosis Modulators / Tubulin Modulators",81G6I5V05I,31431-39-7,D00368,4030.0,3890.0,50180753.0,6672.0,6704.0,CHEMBL685,DAP000950,PA164776669,ZINC000000121541
Gonadorelin,phase 4 complete,DB00644 (APRD01001),CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,"Adrenal Cortex Hormones / Amino Acids, Peptides, and Proteins / Diagnostic Agents / Gonadotropin-releasing hormone agonist / Gonadotropin-Releasing Hormone, agonists / Gonadotropin-Releasing Hormone, antagonists & inhibitors / Gonadotropins and Antigonadotropins / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypothalamic Hormones / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Function / Pituitary Hormone-Releasing Hormones / Proteins / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Tests for Fertility Disturbances",9O7312W37G,33515-09-2,,36523.0,33562.0,,6384.0,,CHEMBL1981292,DAP001052,PA449801,
Dyclonine,phase 4 complete,DB00645 (APRD00940),CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1,"Anesthetics / Anesthetics, Local / Central Nervous System Agents / Central Nervous System Depressants / Ketones / Nervous System / Peripheral Nervous System Agents / Sensory System Agents / Throat Preparations",078A24Q30O,586-60-7,,3180.0,3068.0,50240047.0,23744.0,4724.0,CHEMBL1201217,DAP000509,PA164748037,ZINC000001530940
Nystatin,phase 4 complete,DB00646 (APRD01146),C[C@H]1O[C@H](OC2CC3O[C@@](O)(CC(O)C3C(O)=O)CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O,"Alimentary Tract and Metabolism / Anti-Infective Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antifungal Agents / Antifungal Agents (Vaginal) / Antifungals for Dermatological Use / Antifungals for Topical Use / Compounds used in a research, industrial, or household setting / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Intestinal Antiinfectives / Ionophores / Lactones / Membrane Transport Modulators / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Polyene Antifungal / Polyenes / Polyketides",BDF1O1C72E,1400-61-9,D00202,11953884.0,10468627.0,,7597.0,473992.0,CHEMBL229383,DAP000879,PA450666,
Dextropropoxyphene,phase 4 complete,DB00647 (APRD00548),CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1,"Acids, Acyclic / Agents that reduce seizure threshold / Analgesics / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diphenylpropylamine Derivatives / Fatty Acids / Fatty Acids, Volatile / High-risk opioids / Lipids / Narcotics / Nervous System / Opioid Agonist / Opioids / Peripheral Nervous System Agents / Propionates / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",S2F83W92TK,469-62-5,D07809,10100.0,9696.0,82269.0,8785.0,51173.0,CHEMBL1213351,DAP000017,PA451142,ZINC000001530769
Mitotane,phase 4 complete,DB00648 (APRD00494),ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl,"Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 Enzyme Inducers / Hydrocarbons, Chlorinated / Hydrocarbons, Halogenated / Narrow Therapeutic Index Drugs / P-glycoprotein inhibitors / Thyroxine-binding globulin inducers",78E4J5IB5J,53-19-0,D00420,4211.0,4066.0,50239991.0,7004.0,6954.0,CHEMBL1670,DAP000033,PA164746157,
Stavudine,phase 4 complete,DB00649 (APRD00440),CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O,"Agents Causing Muscle Toxicity / Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antimetabolites / Antiviral Agents / Antivirals for Systemic Use / Carbohydrates / Deoxyribonucleosides / Dideoxynucleosides / Direct Acting Antivirals / Enzyme Inhibitors / Glycosides / Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Neurotoxic agents / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / Nucleoside Reverse Transcriptase Inhibitors / Nucleosides / OAT1/SLC22A6 Substrates / Pyrimidine Nucleosides / Pyrimidines / Reverse Transcriptase Inhibitors / Toxic Actions",BO9LE4QFZF,3056-17-5,D00445,18283.0,17270.0,50013111.0,59763.0,63581.0,CHEMBL991,DAP000172,PA451494,ZINC000000137884
Leucovorin,phase 4 complete,DB00650 (APRD00698),[H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2,"Antidotes / Biological Factors / Coenzymes / Compounds used in a research, industrial, or household setting / Detoxifying Agents for Antineoplastic Treatment / Diet, Food, and Nutrition / Enzymes and Coenzymes / Folate Analog / Folic Acid and Derivatives / Food / Food and Beverages / Formyltetrahydrofolates / Growth Substances / Heterocyclic Compounds, Fused-Ring / Micronutrients / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Physiological Phenomena / Pigments, Biological / Protective Agents / Pteridines / Pterins / Tetrahydrofolates / Vitamin B Complex / Vitamins",Q573I9DVLP,58-05-9,D07986,6006.0,5784.0,50239970.0,6313.0,15640.0,CHEMBL1679,DAP001244,PA450198,
Dyphylline,phase 4 complete,DB00651 (APRD00769),CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O,"Alkaloids / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cardiovascular Agents / Drugs for Obstructive Airway Diseases / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Peripheral Nervous System Agents / Phosphodiesterase Inhibitors / Purines / Purinones / Respiratory System Agents / Vasodilating Agents / Xanthine derivatives / Xanthines and Adrenergics",263T0E9RR9,479-18-5,D00691,3182.0,3070.0,82016.0,3714.0,4728.0,CHEMBL1752,DAP000596,PA164748027,
Pentazocine,phase 4 complete,DB00652 (APRD01173),C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C,"Adjuvants, Anesthesia / Agents that reduce seizure threshold / Alkaloids / Analgesics / Benzomorphan Derivatives / Benzomorphans / Central Nervous System Agents / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Mixed Agonist / Antagonist Opioids / Morphinans / Narcotics / Nervous System / Opiate Alkaloids / Opiate Partial Agonists / Opioid Antagonists / Opioids / P-glycoprotein substrates / Partial Opioid Agonist/Antagonist / Peripheral Nervous System Agents / Phenanthrenes / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",768DQ5A5AI,359-83-1,D00498,441278.0,390041.0,50001028.0,8001.0,7982.0,CHEMBL560,DAP000356,PA164744326,ZINC000000000596
Magnesium sulfate,phase 4 complete,DB00653 (APRD01080),[Mg++].[O-]S([O-])(=O)=O,"Acids / Acids, Noncarboxylic / Agents causing hyperkalemia / Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Analgesics / Anesthetics / Anions / Antiarrhythmic agents / Anticonvulsants / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Calculi Dissolution Agent / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Dermatologicals / Diagnostic Agents / Drugs for Constipation / Electrolyte Solutions / Electrolytes / I.V. Solution Additives / Ions / Laxatives / Laxatives, magnesium containing / Magnesium Compounds / Magnesium Salts / Membrane Transport Modulators / Metal cations / Metal divalent cations / Mineral Supplements / Miscellaneous Anticonvulsants / Osmotic Laxatives / Paramagnetic Contrast Agent / Peripheral Nervous System Agents / Replacement Preparations / Reproductive Control Agents / Sensory System Agents / Sulfates / Sulfur Acids / Sulfur Compounds / Sulfuric Acids / Tests for Bile Duct Patency / Tocolytic Agents / Vasodilating Agents",ML30MJ2U7I,7487-88-9,D01108,24083.0,22515.0,,1311625.0,32599.0,CHEMBL2021423,DAP000201,PA450302,
Latanoprost,phase 4 complete,DB00654 (APRD01065),CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1,"Antiglaucoma Preparations and Miotics / Antihypertensive Agents / Autacoids / Biological Factors / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Lipids / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Ophthalmologicals / Prostaglandin analogs reducing intraocular pressure (IOP) / Prostaglandins / Prostaglandins F, Synthetic / Prostaglandins, Synthetic / Sensory Organs",6Z5B6HVF6O,130209-82-4,D00356,5311221.0,4470740.0,50240648.0,43611.0,6384.0,CHEMBL1051,DAP001216,PA164774763,ZINC000012468792
Estrone,phase 4 complete,DB00655 (APRD00588),[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,"17-Ketosteroids / Adrenal Cortex Hormones / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Estradiol Congeners / Estranes / Estrenes / Estrogens / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Ketosteroids / Natural and Semisynthetic Estrogens, Plain / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inducers / P-glycoprotein substrates / Sex Hormones and Modulators of the Genital System / Steroids / Thyroxine-binding globulin inducers",2DI9HA706A,53-16-7,D00067,5870.0,5660.0,17289.0,4103.0,17263.0,CHEMBL1405,DAP001020,PA449512,ZINC000013509425
Trazodone,phase 4 complete,DB00656 (APRD00533),ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Agents that reduce seizure threshold / Anti-Anxiety Agents / Antidepressive Agents / Antidepressive Agents, Second-Generation / Antidepressive Agents, Triazolopyridine / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Histamine Antagonists / Histamine H1 Antagonists / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / P-glycoprotein inducers / Peripheral alpha-1 blockers / Piperazines / Potential QTc-Prolonging Agents / Psychoanaleptics / Psychotropic Drugs / Pyridines / Pyridones / QTc Prolonging Agents / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Tranquilizing Agents",YBK48BXK30,19794-93-5,D08626,5533.0,5332.0,50073444.0,10737.0,9654.0,CHEMBL621,DAP000104,PA451744,ZINC000000538483
Mecamylamine,phase 4 complete,DB00657 (APRD00458),CNC1(C)C2CCC(C2)C1(C)C,"Agents that produce neuromuscular block (indirect) / Antiadrenergic Agents, Ganglion-Blocking / Anticholinergic Agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Autonomic Agents / Autonomic Ganglionic Blocker / Cardiovascular Agents / Cholinergic Agents / Decreased Autonomic Ganglionic Activity / Drugs that are Mainly Renally Excreted / Ganglion Blockers / Hypotensive Agents / Monoterpenes / Neurotransmitter Agents / Nicotinic Antagonists / Norbornanes / Peripheral Nervous System Agents / Secondary and Tertiary Amines / Terpenes",6EE945D3OK,60-40-2,,4032.0,3892.0,50061565.0,6673.0,6706.0,CHEMBL267936,DAP000027,PA450334,
Sevelamer,phase 4 complete,DB00658 (APRD01226),NCC=C.ClCC1CO1,"Amines / Bile Acid Sequestrants / Chelating Agents / Compounds used in a research, industrial, or household setting / Drugs for Treatment of Hyperkalemia and Hyperphosphatemia / Lipid Regulating Agents / Phosphate Binder / Phosphate Chelating Activity / Phosphate-removing Agents / Polyamines / Polystyrene Sulfonates / Sequestering Agents",941N5DUU5C,52757-95-6,D01983,3085017.0,2341997.0,,214824.0,,CHEMBL1201798,,PA164781197,
Acamprosate,phase 4 complete,DB00659 (APRD00661),CC(=O)NCCCS(O)(=O)=O,"Acids / Acids, Noncarboxylic / Alcohol Deterrents / Alkanes / Alkanesulfonic Acids / Central Nervous System Agents / Drugs Used in Addictive Disorders / Drugs Used in Alcohol Dependence / Hydrocarbons, Acyclic / Miscellaneous Central Nervous System Agents / Nervous System / Sulfonic Acids / Sulfur Acids / Sulfur Compounds",N4K14YGM3J,77337-76-9,D07058,71158.0,64300.0,,82819.0,51041.0,CHEMBL1201293,DAP000857,PA10344,ZINC000001554588
Metaxalone,phase 4 complete,DB00660 (APRD00514),CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1,"Central Nervous System Depressants / Centrally-mediated Muscle Relaxation / Drugs that are Mainly Renally Excreted / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Oxazoles / Peripheral Nervous System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",1NMA9J598Y,1665-48-1,D00773,15459.0,14709.0,,59078.0,6797.0,CHEMBL1079604,,PA164747189,
Verapamil,phase 4 complete,DB00661 (APRD00335),COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1,ACE Inhibitors and Calcium Channel Blockers / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Amines / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium Channel Blockers (Nondihydropyridine) / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (moderate) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypotensive Agents / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Membrane Transport Modulators / Miscellaneous Calcium-channel Blocking Agents / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / OCT1 substrates / P-glycoprotein inhibitors / P-glycoprotein substrates / Phenylalkylamine Derivatives / Selective Calcium Channel Blockers With Direct Cardiac Effects / Vasodilating Agents / Verapamil and analogues,CJ0O37KU29,52-53-9,D02356,2520.0,2425.0,81939.0,11170.0,77733.0,CHEMBL6966,DAP000040,PA451868,
Trimethobenzamide,phase 4 complete,DB00662 (APRD01277),COC1=CC(=CC(OC)=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1,"Acids, Carbocyclic / Amides / Aminoalkyl Ethers / Antiemetics / Antihistamines for Systemic Use / Autonomic Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Emesis Suppression / Gastrointestinal Agents / Peripheral Nervous System Agents",W2X096QY97,138-56-7,D08643,5577.0,5375.0,,38685.0,27796.0,CHEMBL1201256,,PA164764516,ZINC000000538509
Flumethasone,phase 4 complete,DB00663 (APRD00975),[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Moderately Potent (Group II) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Otologicals / Pregnadienes / Pregnadienetriols / Pregnanes / Sensory Organs / Steroids / Steroids, Fluorinated",LR3CD8SX89,2135-17-3,D04208,16490.0,15632.0,50240002.0,4458.0,34764.0,CHEMBL1201392,DAP000814,PA164749388,ZINC000003983936
Sulfametopyrazine,phase 4 complete,DB00664 (APRD00517),COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1,"Amides / Amines / Aniline Compounds / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Antiparasitic Agents / Antiprotozoals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Long-Acting Sulfonamides / Renal Agents / Sulfanilamides / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds",T6BL4ZC15G,152-47-6,D01216,9047.0,8695.0,,10175.0,32162.0,CHEMBL1525826,DAP001199,PA164747038,ZINC000000002097
Nilutamide,phase 4 complete,DB00665 (APRD00150),CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,"Androgen Receptor Antagonists / Androgen Receptor Inhibitor / Antiandrogens / Antiandrogens, non-steroidal / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Endocrine Therapy / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Imidazoles",51G6I8B902,63612-50-0,D00965,4493.0,4337.0,50135912.0,31805.0,7573.0,CHEMBL1274,DAP000302,PA450632,ZINC000003874498
Nafarelin,phase 4 complete,DB00666 (APRD01129),CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,"Adrenal Cortex Hormones / Agents Causing Muscle Toxicity / Amino Acids, Peptides, and Proteins / Fertility Agents / Fertility Agents, Female / Gonadotropin Releasing Hormone Receptor Agonist / Gonadotropin Releasing Hormone Receptor Agonists / Gonadotropin-releasing hormone agonist / Gonadotropins and Antigonadotropins / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypothalamic Hormones / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormone-Releasing Hormones / Proteins / Reproductive Control Agents / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",1X0094V6JV,76932-56-4,,25077405.0,10482014.0,84707.0,28656.0,,CHEMBL1201309,DAP001051,PA164754805,
Histamine,phase 4 complete,"DB05381 (APRD01015, DB05891, DB11320, DB00667)",NCCC1=CNC=N1,"Adjuvants, Immunologic / Amines / Antineoplastic and Immunomodulating Agents / Autacoids / Biogenic Amines / Biogenic Monoamines / Biological Factors / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diagnostic Agents / Ethylamines / Gastric Function / Histamine Agents / Histamine Agonists / Imidazoles / Inflammation Mediators / Neurotransmitter Agents / OCT1 substrates / OCT2 Inhibitors / OCT2 Substrates / Other Diagnostics / Tests for Gastric Secretion",820484N8I3,51-45-6,D08040,774.0,753.0,50121205.0,5333.0,18295.0,CHEMBL90,,PA449880,ZINC000000388081
Epinephrine,phase 4 complete,"DB00668 (APRD00450, EXPT00496)",CNC[C@H](O)C1=CC(O)=C(O)C=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic and Dopaminergic Agents / Adrenergic beta-1 Receptor Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-3 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Alpha-and Beta-adrenergic Agonists / Amines / Anti-Asthmatic Agents / Antiglaucoma Preparations and Miotics / Autonomic Agents / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Bronchodilator Agents / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiovascular Agents / Catecholamines / Catechols / COMT Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dental Agents / Drugs for Obstructive Airway Diseases / Epinephrine and similars / Hemostatics / Hyperglycemia-Associated Agents / Local Hemostatics / Mydriatics / Nasal Preparations / Neurotransmitter Agents / OCT1 substrates / OCT2 Inhibitors / OCT2 Substrates / Ophthalmologicals / Peripheral Nervous System Agents / Phenols / Respiratory System Agents / Stomatological Preparations / Sympathomimetic (Adrenergic) Agents / Sympathomimetics / Sympathomimetics in Glaucoma Therapy / Sympathomimetics, Plain / Vasoconstrictor Agents",YKH834O4BH,51-43-4,D00095,5816.0,5611.0,44818.0,3992.0,28918.0,CHEMBL679,DAP000066,PA449470,ZINC000000039089
Sumatriptan,phase 4 complete,DB00669 (APRD00379),CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,"Agents that produce hypertension / Amides / Amines / Analgesics / Antidepressive Agents / Antimigraine Preparations / BCRP/ABCG2 Substrates / Biogenic Amines / Biogenic Monoamines / Cardiovascular Agents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Indoles / Monoamine Oxidase A Substrates / Nervous System / Neurotransmitter Agents / OATP1B1/SLCO1B1 Substrates / P-glycoprotein substrates / Selective Serotonin 5-HT1 Receptor Agonists / Selective Serotonin Agonists / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 1b Receptor Agonists / Serotonin 1d Receptor Agonists / Serotonin 5-HT1 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists / Serotonin-1b and Serotonin-1d Receptor Agonist / Sulfonamides / Sulfones / Sulfur Compounds / Triptans / Tryptamines / Vasoconstrictor Agents",8R78F6L9VO,103628-46-2,D00451,5358.0,5165.0,50005835.0,37418.0,10650.0,CHEMBL128,DNC001649,PA451566,ZINC000000014360
Pirenzepine,phase 4 complete,DB00670 (APRD00515),CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,"Agents producing tachycardia / Alimentary Tract and Metabolism / Anti-Ulcer Agents / Anticholinergic Agents / Benzazepines / Benzodiazepinones / Cholinergic Agents / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Muscarinic Antagonists / Neurotransmitter Agents",3G0285N20N,28797-61-7,D08389,4848.0,4682.0,39341.0,8352.0,8247.0,CHEMBL9967,DAP000492,PA10159,ZINC000019632927
Cefixime,phase 4 complete,DB00671 (APRD00583),[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephacetrile / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",XZ7BG04GJX,79350-37-1,D00258,5362065.0,4514923.0,84007.0,25033.0,472657.0,CHEMBL1541,DAP000439,PA164768821,ZINC000004468778
Chlorpropamide,phase 4 complete,DB00672 (APRD00029),CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1,Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Hypoglycemia-Associated Agents / OAT1/SLC22A6 inhibitors / Sulfones / Sulfonylureas / Sulfur Compounds,WTM2C3IL2X,94-20-2,D00271,2727.0,2626.0,50344965.0,2404.0,3650.0,CHEMBL498,DAP000923,PA448966,ZINC000001530599
Aprepitant,phase 4 complete,DB00673 (APRD00100),C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,Alimentary Tract and Metabolism / Antiemetics / Antiemetics and Antinauseants / Aprepitant and Prodrugs / Autonomic Agents / Central Nervous System Agents / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Gastrointestinal Agents / Morpholines / Neurokinin 1 Antagonists / Neurokinin-1 Receptor Antagonists / Neurotransmitter Agents / Oxazines / Peripheral Nervous System Agents / Substance P/Neurokinin-1 Receptor Antagonist,1NF15YR6UY,170729-80-3,D02968,6918365.0,5293568.0,50220136.0,358255.0,499361.0,CHEMBL1471,DNC000952,PA164747039,ZINC000027428713
Galantamine,phase 4 complete,"DB00674 (APRD00206, EXPT01628)",[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3,"Alkaloids / Amaryllidaceae Alkaloids / Anti-Dementia Drugs / Autonomic Agents / Benzazepines / Bradycardia-Causing Agents / Central Nervous System Agents / Cholinergic Agents / Cholinesterase Inhibitors / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotransmitter Agents / Nootropic Agents / P-glycoprotein inhibitors / Parasympathomemetic (Cholinergic) Agents / Parasympathomimetics / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / Psychoanaleptics / QTc Prolonging Agents",0D3Q044KCA,357-70-0,D04292,9651.0,9272.0,10404.0,4637.0,42944.0,CHEMBL659,DAP000559,PA449726,ZINC000000491073
Tamoxifen,phase 4 complete,DB00675 (APRD00123),CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,"Anti-Estrogens / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Benzene Derivatives / Benzylidene Compounds / BSEP/ABCB11 Inhibitors / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (moderate) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Endocrine Therapy / Estrogen Agonist/Antagonist / Estrogen Antagonists / Estrogen Receptor Modulators / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Narrow Therapeutic Index Drugs / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Selective Estrogen Receptor Modulators / Stilbenes / Thyroxine-binding globulin inducers / UGT2B7 substrates / UGT2B7 substrates with narrow therapeutic index",094ZI81Y45,10540-29-1,D08559,2733526.0,2015313.0,20607.0,10324.0,41774.0,CHEMBL83,DAP000108,PA451581,ZINC000001530689
Benzyl benzoate,phase 4 complete,"DB00676 (APRD00821, EXPT00792, DB02775)",O=C(OCC1=CC=CC=C1)C1=CC=CC=C1,"Acaricides / Acids, Carbocyclic / Agrochemicals / Antiparasitic Products, Insecticides and Repellents / Benzene Derivatives / Compounds used in a research, industrial, or household setting / Ectoparasiticides, Incl. Scabicides / Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents / Insecticides / Pesticides / Toxic Actions",N863NB338G,120-51-4,D01138,2345.0,13856959.0,50134035.0,19044.0,41237.0,CHEMBL1239,,PA164748881,ZINC000000001021
Isoflurophate,phase 4 complete,DB00677 (APRD00763),CC(C)OP(F)(=O)OC(C)C,Cholinergic Agents / Cholinesterase Inhibitors / Enzyme Inhibitors / Neurotransmitter Agents / Ophthalmics / Organofluorophosphonates / Organophosphonates / Organophosphorus Compounds / Protease Inhibitors,12UHW9R67N,55-91-4,D00043,5936.0,5723.0,50022772.0,6027.0,17941.0,CHEMBL1025,DAP000896,PA164748933,ZINC000008214587
Losartan,phase 4 complete,DB00678 (APRD00052),CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,"Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Angiotensin 2 Receptor Blocker / Angiotensin II receptor blockers (ARBs) and calcium channel blockers / Angiotensin II receptor blockers (ARBs) and diuretics / Angiotensin II receptor blockers (ARBs), plain / Angiotensin II Type 1 Receptor Blockers / Angiotensin II Type 2 Receptor Blockers / Angiotensin Receptor Antagonists / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzene Derivatives / Biphenyl Compounds / BSEP/ABCB11 Substrates / Cardiovascular Agents / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Hypotensive Agents / Imidazoles / OAT1/SLC22A6 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Tetrazoles / UGT1A1 Substrates / UGT1A3 substrates / UGT2B7 substrates",JMS50MPO89,114798-26-4,D08146,3961.0,3824.0,82258.0,52175.0,6541.0,CHEMBL191,DAP000523,PA450268,ZINC000003873160
Thioridazine,phase 4 complete,DB00679 (APRD00596),CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Hypotensive Agents / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Phenothiazines / Phenothiazines With Piperidine Structure / Photosensitizing Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Tranquilizing Agents",N3D6TG58NI,50-52-2,D00373,5452.0,5253.0,50002338.0,10502.0,9566.0,CHEMBL479,DAP000476,PA451666,
Moricizine,phase 4 complete,DB00680 (APRD01124),CCOC(=O)NC1=CC2=C(SC3=CC=CC=C3N2C(=O)CCN2CCOCC2)C=C1,"Antiarrhythmic agents / Antiarrhythmics, Class I / Antiarrhythmics, Class Ic / Antipsychotic Agents / Cardiac Therapy / Cardiovascular Agents / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Membrane Transport Modulators / Morpholines / Neurotoxic agents / Oxazines / Phenothiazines / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sodium Channel Blockers / Sulfur Compounds / Voltage-Gated Sodium Channel Blockers",2GT1D0TMX1,31883-05-3,D05077,34633.0,31872.0,,40169.0,6997.0,CHEMBL1075,DAP000510,PA164747738,ZINC000019340795
Amphotericin B,phase 4 complete,DB00681 (APRD00797),[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,"Agents Causing Muscle Toxicity / Agents that reduce seizure threshold / Alimentary Tract and Metabolism / Amebicides / Anti-Bacterial Agents / Anti-Infective Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antifungal Agents / Antiinfectives and Antiseptics for Local Oral Treatment / Antiinfectives for Systemic Use / Antimycotics for Systemic Use / Antiparasitic Agents / Antiprotozoals / Biomimetic Materials / Carbohydrates / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Drug Carriers / Drug Delivery Systems / Genito Urinary System and Sex Hormones / Glycosides / Gynecological Antiinfectives and Antiseptics / Hypotensive Agents / Intestinal Antiinfectives / Investigative Techniques / Lactones / Lipid-based Polyene Antifungal / Liposomes / Membranes, Artificial / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Pharmaceutical Preparations / Polyene Antifungal / Polyenes / Polyketides / Stomatological Preparations",7XU7A7DROE,1397-89-3,D00203,5280965.0,10237579.0,,236594.0,2682.0,CHEMBL267345,DAP001322,PA448415,ZINC000253387843
Warfarin,phase 4 complete,DB00682 (APRD00341),CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,"4-Hydroxycoumarins / Agrochemicals / Anticoagulants / Blood and Blood Forming Organs / Compounds used in a research, industrial, or household setting / Coumarins / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (weak) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / Pesticides / Pyrans / Rodenticides / Toxic Actions / Vitamin K Antagonists / Vitamin K Inhibitors",5Q7ZVV76EI,81-81-2,,54678486.0,10442445.0,50343352.0,11289.0,87732.0,CHEMBL1464,DAP000770,PA451906,
Midazolam,phase 4 complete,DB00683 (APRD00680),CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,"Adjuvants, Anesthesia / Anesthetics / Anti-Anxiety Agents / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents / Triazolobenzodiazepines / UGT1A4 substrates",R60L0SM5BC,59467-70-8,D00550,4192.0,4047.0,21363.0,6960.0,6931.0,CHEMBL655,DAP000241,PA450496,ZINC000095626706
Tobramycin,phase 4 complete,DB00684 (APRD00582),NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,Agents that produce neuromuscular block (indirect) / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Glycosides / Narrow Therapeutic Index Drugs / Nebramycin / Nephrotoxic agents / Ophthalmologicals / Sensory Organs,VZ8RRZ51VK,32986-56-4,D00063,36294.0,33377.0,50366778.0,10627.0,28864.0,CHEMBL1747,DAP000110,PA451704,ZINC000008214692
Trovafloxacin,phase 4 complete,DB00685 (APRD01281),[H][C@@]12CN(C[C@]1([H])[C@H]2N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=C(F)C=C(F)C=C1)C(O)=O,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Photosensitizing Agents / QTc Prolonging Agents / Quinolines / Quinolones / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",9F388J00UK,147059-72-1,,62959.0,16736478.0,50146361.0,115552.0,9763.0,CHEMBL428,DAP000652,PA164749184,ZINC000100030989
Pentosan polysulfate,phase 4 complete,DB00686 (APRD01175),O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O,"Acids / Acids, Noncarboxylic / Anticoagulants / Antivaricose Therapy / Carbohydrates / Drugs causing inadvertant photosensitivity / Genito Urinary System and Sex Hormones / Glycosaminoglycans / Hematologic Agents / Miscellaneous Therapeutic Agents / Photosensitizing Agents / Polysaccharides / Sulfur Acids / Sulfur Compounds / Sulfuric Acids / Urologicals / Vasoprotectives",F59P8B75R4,37300-21-3,,37720.0,34595.0,,155046.0,,CHEMBL4073796,DAP001025,PA164774806,ZINC000014879975
Fludrocortisone,phase 4 complete,"DB00687 (APRD00756, DB02478)",[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"11-Hydroxycorticosteroids / 17-Hydroxycorticosteroids / Adrenal Cortex Hormones / Adrenals / Anti-Inflammatory Agents / Corticosteroids / Corticosteroids for Systemic Use / Corticosteroids for Systemic Use, Plain / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydroxycorticosteroids / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Mineralocorticoids / Pregnenes / Steroids / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",U0476M545B,127-31-1,D07967,31378.0,29111.0,,4452.0,50885.0,CHEMBL1201388,DAP001105,PA164743961,ZINC000004097304
Mycophenolate mofetil,phase 4 complete,DB00688 (APRD01602),COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C,"Agents Causing Muscle Toxicity / Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics, Antineoplastic / Antibiotics, Antitubercular / Antimetabolite Immunosuppressant / Antituberculosis Agents / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fatty Acids / Immunologic Factors / Immunosuppressive Agents / IMP Dehydrogenase, antagonists & inhibitors / Lipids / Mycophenolic Acid and Prodrugs / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / UGT1A1 Substrates / UGT1A6 substrate / UGT1A9 Substrates / UGT2B7 substrates",9242ECW6R0,128794-94-5,D00752,5281078.0,4444535.0,50248299.0,68149.0,8764.0,CHEMBL1456,DNC000397,PA450566,ZINC000021297660
Cephaloglycin,phase 4 complete,DB00689 (APRD00858),[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Sulfur Compounds / Thiazines",HD2D469W6U,3577-01-3,D01949,19150.0,18069.0,,,34613.0,CHEMBL1200971,DAP001158,PA164781027,ZINC000003830503
Flurazepam,phase 4 complete,DB00690 (APRD00983),CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F,"Anti-Anxiety Agents / Benzazepines / Benzodiazepines and benzodiazepine derivatives / Benzodiazepinones / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / OCT2 Inhibitors / P-glycoprotein inhibitors / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents",IHP475989U,17617-23-1,D00329,3393.0,3276.0,,4501.0,5128.0,CHEMBL968,DAP000242,PA449681,ZINC000000537752
Moexipril,phase 4 complete,DB00691 (APRD01120),CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O,"ACE Inhibitors and Diuretics / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Isoquinolines / Photosensitizing Agents / Potential QTc-Prolonging Agents / Protease Inhibitors / QTc Prolonging Agents",WT87C52TJZ,103775-10-6,,91270.0,82418.0,50084673.0,30131.0,6960.0,CHEMBL1165,DAP000586,PA164769059,ZINC000003812306
Phentolamine,phase 4 complete,DB00692 (APRD00615),CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1,Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antidotes / Antihypertensive Agents / Cardiovascular Agents / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Imidazoles / Imidazoline Derivatives / Neurotransmitter Agents / Non-selective Alfa-adrenergic Blocking Agents / Peripheral alpha-1 blockers / Peripheral Vasodilators / Sympatholytic (Adrenergic Blocking) Agents / Vasodilating Agents,Z468598HBV,50-60-2,,5775.0,5571.0,31046.0,8153.0,8081.0,CHEMBL597,DAP000299,PA450926,ZINC000000020251
Fluorescein,phase 4 complete,"DB00693 (APRD00979, EXPT01447, DB07777)",OC1=CC=C2C(OC3=CC(O)=CC=C3C22OC(=O)C3=C2C=CC=C3)=C1,"BSEP/ABCB11 Substrates / Coloring Agents / Colouring Agents / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Agents / Diagnostic Dye / Diagnostic Uses of Chemicals / Fluoresceins / Fluorescent Dyes / Heterocyclic Compounds, Fused-Ring / Indicators and Reagents / Laboratory Chemicals / Luminescent Agents / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / Ocular Disorders / Ophthalmologicals / Other Diagnostics / Sensory Organs / Spiro Compounds / Xanthenes",TPY09G7XIR,2321-07-5,D01261,16850.0,15968.0,50237588.0,25138.0,31624.0,CHEMBL1057,,PA164746009,ZINC000003860453
Daunorubicin,phase 4 complete,DB00694 (APRD00521),COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O,"Anthracycline Topoisomerase Inhibitor / Anthracyclines / Anthracyclines and Related Substances / Antibiotics, Antineoplastic / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / BSEP/ABCB11 Substrates / Carbohydrates / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Cytotoxic Antibiotics and Related Substances / Enzyme Inhibitors / Glycosides / Immunosuppressive Agents / Myelosuppressive Agents / Naphthacenes / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",ZS7284E0ZP,20830-81-3,D07776,30323.0,28163.0,32017.0,3109.0,41977.0,CHEMBL178,DNC000517,PA449212,ZINC000003917708
Furosemide,phase 4 complete,"DB00695 (APRD00608, DB07799)",NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O,"Acids, Carbocyclic / Amides / Amines / Aminobenzoates / Aniline Compounds / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzene Derivatives / Benzoates / Cardiovascular Agents / Diuretics / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / High-Ceiling Diuretics / High-Ceiling Diuretics and Potassium-Sparing Agents / Hyperglycemia-Associated Agents / Hypotensive Agents / Increased Diuresis at Loop of Henle / Membrane Transport Modulators / Natriuretic Agents / Nephrotoxic agents / Non Potassium Sparing Diuretics / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Ototoxic agents / Photosensitizing Agents / Sodium Potassium Chloride Symporter Inhibitors / Sulfanilamides / Sulfonamides / Sulfones / Sulfur Compounds / Thyroxine-binding globulin substrates / UGT1A1 Substrates",7LXU5N7ZO5,54-31-9,D00331,3440.0,3322.0,25902.0,4603.0,47426.0,CHEMBL35,DAP000043,PA449719,ZINC000000035804
Ergotamine,phase 4 complete,DB00696 (APRD00677),[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Alkaloids / Analgesics / Analgesics, Non-Narcotic / Antidepressive Agents / Antimigraine Preparations / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Ergot Alkaloids and Derivatives / Ergotamine Derivative / Ergotamines / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotransmitter Agents / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Reproductive Control Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin 5-HT2 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists / Sympatholytic (Adrenergic Blocking) Agents / Uterotonic agents / Vasoconstrictor Agents",PR834Q503T,113-15-5,D07906,8223.0,7930.0,50027065.0,4025.0,64318.0,CHEMBL442,DAP000141,PA164747651,ZINC000052955754
Tizanidine,phase 4 complete,DB00697 (APRD00128),ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Analgesics / Anticonvulsants / Autonomic Agents / Bradycardia-Causing Agents / Central alpha-2 Adrenergic Agonist / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Hypotensive Agents / Imidazoles / Imidazolines / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neurotransmitter Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sensory System Agents",6AI06C00GW,51322-75-9,,5487.0,5287.0,50240671.0,57258.0,63629.0,CHEMBL1079,DAP000234,PA451701,ZINC000019702309
Nitrofurantoin,phase 4 complete,DB00698 (APRD00191),[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O,"Agents causing hyperkalemia / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / BCRP/ABCG2 Substrates / BSEP/ABCB11 Substrates / Drugs that are Mainly Renally Excreted / Furans / Methemoglobinemia Associated Agents / Nitro Compounds / Nitrofuran Antibacterial / Nitrofuran Derivatives / Nitrofurans / P-glycoprotein substrates / Renal Agents / Thyroxine-binding globulin substrates",927AH8112L,67-20-9,D00439,6604200.0,5036498.0,57045.0,235559.0,71415.0,CHEMBL572,DAP000998,PA450640,ZINC000003875368
Nicergoline,phase 4 complete,DB00699 (APRD00617),[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@]1(C[C@@H](COC(=O)C1=CN=CC(Br)=C1)CN2C)OC,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Alkaloids / Cardiovascular Agents / Central Nervous System Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Ergolines / Ergot Alkaloids and Derivatives / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / Nootropic Agents / Peripheral Vasodilators / Vasodilating Agents",JCV8365FWN,27848-84-6,D01290,34040.0,31373.0,,7398.0,31902.0,CHEMBL1372950,DAP000902,PA164743014,ZINC000003873817
Eplerenone,phase 4 complete,DB00700 (APRD00707),[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC,"Agents causing hyperkalemia / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Diuretics / Fused-Ring Compounds / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypotensive Agents / Lactones / Mineralocorticoid (Aldosterone) Receptor Antagonists / Mineralocorticoid Receptor Antagonists / Natriuretic Agents / Potassium-Sparing Diuretics / Pregnanes / Pregnenes / Steroids",6995V82D0B,107724-20-9,D01115,443872.0,10203511.0,50318300.0,298869.0,31547.0,CHEMBL1095097,DAP000085,PA164749044,ZINC000003985982
Amprenavir,phase 4 complete,DB00701 (APRD00605),CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,"Acids, Acyclic / Amides / Amprenavir and Prodrugs / Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antibiotics, Antitubercular / Antiinfectives for Systemic Use / Antituberculosis Agents / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / HIV Protease Inhibitors / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inducers / P-glycoprotein substrates / Protease Inhibitors / Sulfones / Sulfur Compounds",5S0W860XNR,161814-49-9,D00894,65016.0,58532.0,577.0,228656.0,40050.0,CHEMBL116,DAP000170,PA448422,ZINC000003809192
Icodextrin,phase 4 complete,DB00702 (APRD01026),,"Biopolymers / Carbohydrates / Compounds used in a research, industrial, or household setting / Dialysis Solutions / Glucans / Macromolecular Substances / Pharmaceutical Preparations / Pharmaceutical Solutions / Polymers / Polysaccharides / Solutions",2NX48Z0A9G,337376-15-5,,,,,140480.0,,CHEMBL1201472,,PA164743096,
Methazolamide,phase 4 complete,DB00703 (APRD00740),CN1N=C(SC1=NC(C)=O)S(N)(=O)=O,Antiglaucoma Preparations and Miotics / Carbonic Anhydrase Inhibitors / Cardiovascular Agents / Diuretics / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hypotensive Agents / Natriuretic Agents / OAT1/SLC22A6 inhibitors / Ophthalmologicals / Photosensitizing Agents / Sensory Organs / Sulfonamides / Sulfur Compounds / Thiadiazoles / Thiazoles,W733B0S9SD,554-57-4,D00655,4100.0,21122102.0,10881.0,6826.0,94513.0,CHEMBL1335656,DAP000599,PA450413,ZINC000253917094
Naltrexone,phase 4 complete,"DB00704 (APRD00005, DB05067)",[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O,"Agents Causing Muscle Toxicity / Alcohol Deterrents / Alimentary Tract and Metabolism / Alkaloids / Analgesics / Antiobesity Preparations, Excl. Diet Products / Central Nervous System Agents / Centrally Acting Antiobesity Products / Drugs Used in Addictive Disorders / Drugs Used in Alcohol Dependence / Heterocyclic Compounds, Fused-Ring / Morphinans / Narcotics / Natural Opium Alkaloids / Nervous System / Opiate Alkaloids / Opiate Antagonists / Opioid Antagonists / Opioids / Peripheral Nervous System Agents / Phenanthrenes / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / UGT1A1 Substrates",5S6W795CQM,16590-41-3,D05113,5360515.0,4514524.0,60212.0,7243.0,7465.0,CHEMBL19019,DAP000379,PA450588,ZINC000000001773
Delavirdine,phase 4 complete,"DB00705 (APRD00149, DB08563)",CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2,"Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor / Indoles / Non-Nucleoside Reverse Transcriptase Inhibitors / Nonnucleoside Reverse Transcriptase Inhibitors / Nucleic Acid Synthesis Inhibitors / Piperazines / Reverse Transcriptase Inhibitors",DOL5F9JD3E,136817-59-9,,5625.0,5423.0,1944.0,83816.0,119573.0,CHEMBL593,DAP000183,PA449223,ZINC000018516586
Tamsulosin,phase 4 complete,DB00706 (APRD00036),CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O,Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Amides / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Drugs Used in Benign Prostatic Hypertrophy / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hypotensive Agents / Neurotransmitter Agents / Peripheral alpha-1 blockers / Selective Alfa-1-adrenergic Blocking Agents / Sulfonamides / Sulfones / Sulfur Compounds / Urological Agents / Urologicals,G3P28OML5I,106133-20-4,,129211.0,114457.0,50060964.0,77492.0,9398.0,CHEMBL836,DAP000086,PA451583,ZINC000001530694
Porfimer sodium,phase 4 complete,DB00707 (APRD00078),,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Biological Factors / Dermatologicals / Hematoporphyrin Derivative / Hematoporphyrins / Heterocyclic Compounds, Fused-Ring / Photoabsorption / Photoactivated Radical Generator / Photosensitizing Activity / Photosensitizing Agents / Photosensitizing agents used for phototherapy / Pigments, Biological / Porphyrins / Radiation-Sensitizing Agents / Sensitizers Used in Photodynamic/radiation Therapy",Y3834SIK5F,87806-31-3,,,10482043.0,,333848.0,60652.0,,,PA164752658,
Sufentanil,phase 4 complete,"DB00708 (APRD00671, DB05563)",CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1,"Adjuvants, Anesthesia / Agents that produce hypertension / Analgesics / Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Bradycardia-Causing Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fentanyl and fentanyl analogues / High-risk opioids / Hypotensive Agents / Narcotics / Nervous System / Neuraxial Anesthetics / Opiate Agonists / Opioid Agonist / Opioid Anesthetics / Opioids / Opioids, Anilidopiperidine / Peripheral Nervous System Agents / Phenylpiperidine opioids / Piperidines / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",AFE2YW0IIZ,56030-54-7,D05938,41693.0,38043.0,94503.0,56795.0,9316.0,CHEMBL658,DAP000357,PA451527,ZINC000000538386
Lamivudine,phase 4 complete,DB00709 (APRD00681),NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,"Agents Causing Muscle Toxicity / Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BCRP/ABCG2 Substrates / Carbohydrates / Deoxycytidine / Deoxyribonucleosides / Dideoxynucleosides / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Glycosides / Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / Nucleoside Reverse Transcriptase Inhibitors / Nucleosides / OAT1/SLC22A6 Substrates / OCT1 substrates / OCT2 Substrates / P-glycoprotein substrates / Pyrimidine Nucleosides / Pyrimidines / Reverse Transcriptase Inhibitors / Ribonucleosides",2T8Q726O95,134678-17-4,D00353,60825.0,54812.0,50366817.0,68244.0,63577.0,CHEMBL141,DAP000167,PA450163,ZINC000000012346
Ibandronate,phase 4 complete,"DB00710 (APRD00231, DB04635)",CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O,Agents Causing Muscle Toxicity / Bisphosphonates / Bone Density Conservation Agents / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Musculo-Skeletal System / Organophosphonates / Organophosphorus Compounds / Potential QTc-Prolonging Agents / QTc Prolonging Agents,UMD7G2653W,114084-78-5,,60852.0,54839.0,12577.0,115264.0,,CHEMBL997,DAP001022,PA10270,ZINC000001533877
Diethylcarbamazine,phase 4 complete,DB00711 (APRD00918),CCN(CC)C(=O)N1CCN(C)CC1,"Acids, Acyclic / Anthelmintics / Anti-Infective Agents / Antihelminthic / Antinematodal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Carbamates / Cholinesterase Inhibitors / Enzyme Inhibitors / Filaricides / Lipoxygenase Inhibitors / Piperazine and Derivatives / Piperazines",V867Q8X3ZD,90-89-1,D07825,3052.0,2944.0,50024883.0,3384.0,4527.0,CHEMBL684,DAP000914,PA164748883,ZINC000000001288
Flurbiprofen,phase 4 complete,DB00712 (APRD00753),CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1,"Acids, Acyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antirheumatic Agents / Benzene Derivatives / Biphenyl Compounds / Central Nervous System Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Fatty Acids / Fatty Acids, Volatile / Lipids / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / Ophthalmologicals / Other Nonsteroidal Anti-inflammatory Agents / Peripheral Nervous System Agents / Photosensitizing Agents / Propionates / Sensory Organs / Sensory System Agents / Throat Preparations / Topical Products for Joint and Muscular Pain / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT1A3 substrates / UGT1A9 Substrates / UGT2B7 substrates",5GRO578KLP,5104-49-4,D00330,3394.0,3277.0,50074922.0,4502.0,5130.0,CHEMBL563,DAP000621,PA449683,
Oxacillin,phase 4 complete,DB00713 (APRD01149),[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / Beta-Lactamase Resistant Penicillins / beta-Lactams / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillins / Sulfur Compounds",UH95VD7V76,66-79-5,D08307,6196.0,5961.0,50350483.0,7773.0,7809.0,CHEMBL819,DAP000440,PA450725,ZINC000003875439
Apomorphine,phase 4 complete,"DB00714 (APRD00531, DB05816)",[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23,"Alkaloids / Anti-Parkinson Agents (Dopamine Agonist) / Anti-Parkinson Drugs / Antidepressive Agents / Aporphines / Autonomic Agents / Benzylisoquinolines / Central Nervous System Agents / Central Nervous System Depressants / COMT Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Agonists / Drugs Used in Erectile Dysfunction / Emetics / Gastrointestinal Agents / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Isoquinolines / Nervous System / Neurotransmitter Agents / Nonergot-derivative Dopamine Receptor Agonists / Opiate Agonists / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Receptor Antagonists / Urologicals",N21FAR7B4S,58-00-4,D07460,6005.0,5783.0,29644.0,1043.0,48538.0,CHEMBL53,DAP000281,PA164781163,ZINC000000009073
Paroxetine,phase 4 complete,DB00715,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1,"Agents producing tachycardia / Anticholinergic Agents / Antidepressive Agents / Antidepressive Agents, Second-Generation / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Muscarinic Antagonists / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / P-glycoprotein inhibitors / Photosensitizing Agents / Piperidines / Psychoanaleptics / Psychotropic Drugs / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",41VRH5220H,61869-08-7,D02362,43815.0,39888.0,22416.0,32937.0,7936.0,CHEMBL490,DAP001428,PA450801,ZINC000000527386
Nedocromil,phase 4 complete,DB00716 (APRD01137),CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O,"4-Quinolones / Anti-Allergic Agents / Anti-Asthmatic Agents / Anti-Inflammatory Agents / Antiallergic Agents, Excl. Corticosteroids / Decongestants and Antiallergics / Decreased Histamine Release / Drugs for Obstructive Airway Diseases / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Mast Cell Stabilizers / Nasal Preparations / Ophthalmologicals / Quinolines / Quinolones / Respiratory Agents, Miscellaneous / Respiratory System Agents / Sensory Organs",0B535E0BN0,69049-73-6,D05129,50294.0,45608.0,50239990.0,31563.0,7492.0,CHEMBL746,,PA450601,ZINC000003782807
Norethisterone,phase 4 complete,DB00717 (APRD00679),[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],"Adrenal Cortex Hormones / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptives, Oral / Contraceptives, Oral, Synthetic / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Estren Derivatives / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hyperglycemia-Associated Agents / Norpregnenes / Norsteroids / P-glycoprotein inhibitors / Progestin Contraceptives / Progestins / Progestogens and Estrogens, Sequential Preparations / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",T18F433X4S,68-22-4,D00182,6230.0,5994.0,50148732.0,7514.0,7627.0,CHEMBL1162,DAP001212,PA450651,ZINC000085205451
Adefovir dipivoxil,phase 4 complete,DB00718 (APRD00781),CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Direct Acting Antivirals / Enzyme Inhibitors / Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Heterocyclic Compounds, Fused-Ring / Nephrotoxic agents / Nucleic Acid Synthesis Inhibitors / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / Nucleosides and Nucleotides / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / Organophosphorus Compounds / Purines / Reverse Transcriptase Inhibitors",U6Q8Z01514,142340-99-6,D01655,60871.0,54855.0,50248359.0,141400.0,31175.0,CHEMBL922,DNC001135,PA10005,ZINC000003930376
Azatadine,phase 4 complete,DB00719 (APRD00810),CN1CCC(CC1)=C1C2=CC=CC=C2CCC2=C1N=CC=C2,Agents that reduce seizure threshold / Antihistamines for Systemic Use / Benzocycloheptenes / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Dibenzocycloheptenes / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Neurotransmitter Agents / Piperidines / Potential QTc-Prolonging Agents / QTc Prolonging Agents,94Z39NID6C,3964-81-6,,19861.0,18709.0,22868.0,18600.0,2946.0,CHEMBL946,DAP001079,PA164747157,ZINC000000968337
Clodronic acid,phase 4 complete,DB00720 (APRD00639),OP(O)(=O)C(Cl)(Cl)P(O)(O)=O,Bisphosphonates / Bone Density Conservation Agents / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Musculo-Skeletal System / Organophosphonates / Organophosphorus Compounds,0813BZ6866,10596-23-3,,25419.0,23731.0,50216172.0,3350.0,110423.0,CHEMBL12318,DAP000564,PA10239,ZINC000029747100
Procaine,phase 4 complete,"DB00721 (APRD00650, DB05342)",CCN(CC)CCOC(=O)C1=CC=C(N)C=C1,"Acids, Carbocyclic / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Agents that reduce seizure threshold / Aminobenzoates / Anesthetics / Anesthetics, Local / Anticholinergic Agents / Antidepressive Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Cholinesterase Inhibitors / Cholinesterase substrates / Esters of Aminobenzoic Acid / Monoamine Oxidase Inhibitors / Nervous System / Nicotinic Antagonists / NMDA Receptor Antagonists / Ophthalmologicals / para-Aminobenzoates / Peripheral Nervous System Agents / Sensory Organs / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Vasoprotectives",4Z8Y51M438,59-46-1,D08422,4914.0,4745.0,64452.0,8701.0,8430.0,CHEMBL569,DAP000296,PA451110,ZINC000001530757
Lisinopril,phase 4 complete,DB00722 (APRD00560),NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,"ACE Inhibitors and Calcium Channel Blockers / ACE Inhibitors and Diuretics / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Amino Acids, Peptides, and Proteins / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Dipeptides / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hypotensive Agents / Lipid Modifying Agents / Oligopeptides / Peptides / Photosensitizing Agents / Protease Inhibitors / Protective Agents",7Q3P4BS2FD,76547-98-3,D00362,5362119.0,4514933.0,66979.0,1546022.0,43755.0,CHEMBL1237,DAP000587,PA450242,ZINC000003812863
Methoxamine,phase 4 complete,DB00723 (APRD00062),COC1=CC(C(O)C(C)N)=C(OC)C=C1,Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic and Dopaminergic Agents / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Autonomic Agents / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiovascular Agents / Ethylamines / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenethylamines / Propanolamines / Propanols / Sympathomimetics / Vasoconstrictor Agents,HUQ1KC1YLI,390-28-3,D08201,6082.0,5857.0,50026777.0,6853.0,6839.0,CHEMBL524,DAP000796,PA450431,
Imiquimod,phase 4 complete,DB00724 (APRD01030),CC(C)CN1C=NC2=C1C1=C(C=CC=C1)N=C2N,"Adjuvants, Immunologic / Aminoquinolines / Antineoplastic Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Heterocyclic Compounds, Fused-Ring / Immunologic Factors / Immunosuppressive Agents / Increased Cytokine Activity / Increased Cytokine Production / Interferon Inducers / Misc. Skin and Mucous Membrane Agents / Quinolines",P1QW714R7M,99011-02-6,D02500,57469.0,51809.0,50240849.0,59943.0,36704.0,CHEMBL1282,DAP000278,PA449972,ZINC000019632912
Homatropine methylbromide,phase 4 complete,DB00725 (APRD01017),[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1,Agents producing tachycardia / Alimentary Tract and Metabolism / Alkaloids / Anticholinergic Agents / Aza Compounds / Azabicyclo Compounds / Drugs for Functional Gastrointestinal Disorders / Muscarinic Agonists / Muscarinic Antagonists,68JRS2HC1C,80-49-9,D02070,6646.0,6394.0,,1546413.0,50373.0,CHEMBL1200851,DAP000823,PA164749405,
Trimipramine,phase 4 complete,DB00726 (APRD00498),CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Adrenergic Uptake Inhibitors / Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Antidepressive Agents, Tricyclic / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Substrates / Dibenzazepines / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Membrane Transport Modulators / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Non-Selective Monoamine Reuptake Inhibitors / P-glycoprotein substrates / Potential QTc-Prolonging Agents / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Tertiary amine tricyclic antidepressants / Tricyclics and Other Norepinephrine-reuptake Inhibitors",6S082C9NDT,739-71-9,D00394,5584.0,5382.0,50240410.0,10834.0,9738.0,CHEMBL644,DAP001153,PA451791,
Nitroglycerin,phase 4 complete,DB00727 (APRD00153),[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Antianginal Agents / Antihypertensive Agents / Cardiac Therapy / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Explosive Agents / Hypotensive Agents / Methemoglobinemia Associated Agents / Nitrate Vasodilator / Nitrates and Nitrites / Nitro Compounds / Organic Nitrates / Vasodilating Agents / Vasodilation / Vasodilators Used in Cardiac Diseases / Vasoprotectives",G59M7S0WS3,55-63-0,D00515,4510.0,4354.0,,4917.0,28787.0,CHEMBL730,DNC001024,PA450644,ZINC000008214625
Rocuronium,phase 4 complete,DB00728 (APRD01221),[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1,"Agents producing tachycardia / Androstanes / Androstanols / Anticholinergic Agents / Central Nervous System Depressants / Fused-Ring Compounds / Muscarinic Antagonists / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular Nondepolarizing Blockade / Neuromuscular-Blocking Agents (Nondepolarizing) / Nicotinic Antagonists / OCT1 inhibitors / OCT1 substrates / Peripheral Nervous System Agents / Steroids",WRE554RFEZ,143558-00-3,D00765,441290.0,390053.0,,68139.0,8884.0,CHEMBL1201244,DAP000349,PA164754992,ZINC000053229445
Thiabendazole,phase 4 complete,"DB00730 (APRD01252, DB08630)",N1C2=CC=CC=C2N=C1C1=CSC=N1,"Anthelmintics / Anti-Infective Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Antihelminthic / Antinematodal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Benzimidazole Derivatives / Benzimidazoles / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Imidazole and Triazole Derivatives / Sulfur Compounds / Thiazoles",N1Q45E87DT,148-79-8,D00372,5430.0,5237.0,50121347.0,10450.0,45979.0,CHEMBL625,DAP000664,PA164746466,ZINC000000073711
Nateglinide,phase 4 complete,DB00731 (APRD00593),CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O,"Alimentary Tract and Metabolism / Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Blood Glucose Lowering Agents / Cyclohexanes / Cycloparaffins / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Glinide / Hypoglycemia-Associated Agents / OAT1/SLC22A6 inhibitors / Phenylalanine / Potassium Channel Antagonists / UGT1A9 Substrates",41X3PWK4O2,105816-04-4,D01111,5311309.0,10482084.0,50344967.0,274332.0,31897.0,CHEMBL783,DAP000918,PA450600,ZINC000101489663
Atracurium besylate,phase 4 complete,DB00732 (APRD00806),[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2,"Alkaloids / Anticholinergic Agents / Benzylisoquinolines / Central Nervous System Depressants / Cholinergic Agents / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Miscellaneous Skeletal Muscle Relaxants / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular-Blocking Agents (Nondepolarizing) / Neurotransmitter Agents / Nicotinic Antagonists / Peripheral Nervous System Agents",40AX66P76P,64228-81-5,D00758,47320.0,43068.0,50149881.0,1219.0,2915.0,CHEMBL1200527,DAP000105,PA164776840,
Pralidoxime,phase 4 complete,DB00733 (APRD01193),C[N+]1=C(\C=N\O)C=CC=C1,"Amines / Antidotes / Cholinergic Agents / Cholinesterase Reactivators / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Enzyme Reactivators / Hydroxylamines / Neurotransmitter Agents / Oximes / Protective Agents",P7MU9UTP52,6735-59-7,,5353894.0,5193737.0,234367.0,34345.0,8354.0,CHEMBL1420,,PA164744926,ZINC000004577910
Risperidone,phase 4 complete,DB00734 (APRD00187),CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Histamine Antagonists / Histamine H1 Antagonists / Hyperglycemia-Associated Agents / Nervous System / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein substrates / Potential QTc-Prolonging Agents / Psycholeptics / Psychotropic Drugs / Pyrimidines / Pyrimidinones / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT1D Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents,L6UH7ZF8HC,106266-06-2,D00426,5073.0,4895.0,50001885.0,35636.0,8871.0,CHEMBL85,DAP000003,PA451257,ZINC000000538312
Naftifine,phase 4 complete,DB00735 (APRD01131),CN(CC=CC1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12,"Alkenes / Allyl Compounds / Allylamine Antifungal / Amines / Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Dermatologicals / Hydrocarbons, Acyclic",4FB1TON47A,65472-88-0,,73342.0,43344.0,50170647.0,31476.0,7451.0,CHEMBL626,DAP000752,PA164748617,ZINC000001530977
Esomeprazole,phase 4 complete,DB00736 (APRD00363),COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,"2-Pyridinylmethylsulfinylbenzimidazoles / Acid Reducers / Alimentary Tract and Metabolism / Anti-Ulcer Agents / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Benzimidazoles / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Enzyme Inhibitors / Gastric Acid Lowering Agents / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Musculo-Skeletal System / OAT3/SLC22A8 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / Propionates / Proton Pump Inhibitors / Proton-pump Inhibitors / Pyridines / Sulfoxides / Sulfur Compounds",N3PA6559FT,119141-88-7,D07917,9568614.0,7843323.0,,283742.0,50275.0,CHEMBL1201320,DCL000524,PA10075,ZINC000004693574
Meclizine,phase 4 complete,DB00737 (APRD00354),CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1,Anti-Allergic Agents / Antiemetics / Antihistamines for Systemic Use / Antivertigo Preparations / Autonomic Agents / Benzene Derivatives / Benzhydryl Compounds / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Emesis Suppression / Gastrointestinal Agents / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Neurotransmitter Agents / Peripheral Nervous System Agents / Piperazine Derivatives / Piperazines,3L5TQ84570,569-65-3,D08163,4034.0,3894.0,81467.0,6676.0,6709.0,CHEMBL1623,DAP000795,PA450338,
Pentamidine,phase 4 complete,"DB00738 (APRD00303, EXPT02625)",NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1,"Agents Against Leishmaniasis and Trypanosomiasis / Agents causing hyperkalemia / Amidines / Anti-Infective Agents / Antibiotics for Pneumocystis Pneumonia / Antifungal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Benzamidines / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Hyperglycemia-Associated Agents / Hypoglycemia-Associated Agents / Miscellaneous Antiprotozoals / Moderate Risk QTc-Prolonging Agents / Nephrotoxic agents / QTc Prolonging Agents / Trypanocidal Agents",673LC5J4LQ,100-33-4,,4735.0,4573.0,45440.0,7994.0,45081.0,CHEMBL55,DAP000764,PA450850,ZINC000001530775
Hetacillin,phase 4 complete,DB00739 (APRD01012),[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillins / Penicillins With Extended Spectrum / Sulfur Compounds",TN4JSC48CV,3511-16-8,D01074,443387.0,391616.0,,26797.0,5683.0,CHEMBL1201116,DAP001167,PA164746559,ZINC000004102186
Riluzole,phase 4 complete,DB00740 (APRD00145),NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2,"Anticonvulsants / BCRP/ABCG2 Substrates / Benzothiazoles / Central Nervous System Agents / Central Nervous System Depressants / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Excitatory Amino Acid Agents / Excitatory Amino Acid Antagonists / Heterocyclic Compounds, Fused-Ring / Miscellaneous Central Nervous System Agents / Nervous System / Neuroprotective Agents / Neurotransmitter Agents / Protective Agents / Sulfur Compounds / Thiazoles",7LJ087RS6F,1744-22-5,D00775,5070.0,4892.0,30705.0,35623.0,8863.0,CHEMBL744,DAP000527,PA451251,ZINC000000006481
Hydrocortisone,phase 4 complete,"DB00741 (APRD01019, DB07886)",[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"11-Hydroxycorticosteroids / 17-Hydroxycorticosteroids / Adrenal Cortex Hormones / Adrenals / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Alimentary Tract and Metabolism / Anti-Inflammatory Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids Acting Locally / Corticosteroids for Local Oral Treatment / Corticosteroids for Systemic Use / Corticosteroids for Systemic Use, Plain / Corticosteroids, Dermatological Preparations / Corticosteroids, Weak (Group I) / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydrocortisone and derivatives / Hydroxycorticosteroids / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Intestinal Antiinflammatory Agents / Nasal Preparations / OAT3/SLC22A8 Substrates / Ophthalmological and Otological Preparations / Ophthalmologicals / Otologicals / P-glycoprotein inducers / P-glycoprotein substrates / Pregnanes / Pregnenediones / Pregnenes / Sensory Organs / Steroids / Stomatological Preparations / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Vasoprotectives",WI4X0X7BPJ,50-23-7,D00088,5754.0,5551.0,13775.0,5492.0,17650.0,CHEMBL389621,DAP000718,PA449905,ZINC000013540519
Mannitol,phase 4 complete,"DB00742 (APRD01083, EXPT02246)",OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,"Agents causing hyperkalemia / Alcohols / Alimentary Tract and Metabolism / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Carbohydrates / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Cough and Cold Preparations / Diet, Food, and Nutrition / Diuretics / Diuretics, Osmotic / Drugs for Constipation / Drugs that are Mainly Renally Excreted / Expectorants / Flavoring Agents / Food / Food Additives / Food and Beverages / Food Ingredients / Hypotensive Agents / i.v. Solutions / Increased Diuresis / Irrigating Solutions / Kidney Function / Laxatives / Natriuretic Agents / Nephrotoxic agents / Osmotic Activity / Osmotic Laxatives / P-glycoprotein substrates / Pharmaceutic Aids / Pharmaceutical Preparations / Physiological Phenomena / Solutions Producing Osmotic Diuresis / Sugar Alcohols / Sweetening Agents",3OWL53L36A,69-65-8,D00062,6251.0,6015.0,50142798.0,6628.0,16899.0,CHEMBL689,DAP000874,PA450320,ZINC000002041302
Gadobenic acid,phase 4 complete,DB00743 (APRD00989),[Gd+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)C(COCC1=CC=CC=C1)C(O)=O,"Alcohols / Amino Sugars / Carbohydrates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Gadolinium-based Contrast Agent / Hexosamines / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / Moderate Risk QTc-Prolonging Agents / Other Diagnostics / Paramagnetic Contrast Agent / Paramagnetic Contrast Media / QTc Prolonging Agents / Sugar Alcohols",15G12L5X8K,113662-23-0,D08018,131704172.0,94843.0,,692620.0,,CHEMBL1200571,DAP001225,PA164745426,
Zileuton,phase 4 complete,DB00744 (APRD00265),CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1,"Agents to Treat Airway Disease / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Central Nervous System Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Leukotriene Production / Enzyme Inhibitors / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Leukotriene Antagonists / Lipoxygenase Inhibitors / Peripheral Nervous System Agents / Sensory System Agents / UGT1A9 Substrates",V1L22WVE2S,111406-87-2,D00414,60490.0,54531.0,50000541.0,40575.0,10112.0,CHEMBL93,DAP000591,PA451955,
Modafinil,phase 4 complete,DB00745 (APRD00534),NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,"Benzene Derivatives / Benzhydryl Compounds / Central Nervous System Agents / Central Nervous System Stimulants / Central Nervous System Stimulation / Centrally Acting Sympathomimetics / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (moderate) / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (moderate) / Cytochrome P-450 CYP3A5 Inducers (weak) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (weak) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Increased Sympathetic Activity / Nervous System / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Stimulants / Sympathomimetic-like Agent / Wakefulness-Promoting Agents",R3UK8X3U3D,68693-11-8,D01832,4236.0,4088.0,50156055.0,30125.0,77585.0,CHEMBL1373,,PA450530,
Deferoxamine,phase 4 complete,DB00746 (APRD00904),CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,"Amines / Chelating Agents / Compounds used in a research, industrial, or household setting / Heavy Metal Antagonists / Hydroxamic Acids / Hydroxy Acids / Hydroxylamines / Iron Chelating Activity / Iron Chelating Agents / Sequestering Agents / Siderophores",J06Y7MXW4D,70-51-9,D03670,2973.0,2867.0,47715.0,3131.0,4356.0,CHEMBL556,,PA164746490,ZINC000003830635
Scopolamine,phase 4 complete,DB00747 (APRD00616),CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,"Adjuvants / Adjuvants, Anesthesia / Agents producing tachycardia / Alimentary Tract and Metabolism / Alkaloids / Anticholinergic Agents / Antiemetics / Antiemetics and Antinauseants / Antimuscarinics Antispasmodics / Autonomic Agents / Aza Compounds / Azabicyclo Compounds / Belladonna Alkaloids / Central Nervous System Agents / Central Nervous System Depressants / Cholinergic Agents / Gastrointestinal Agents / Hypnotics and Sedatives / Muscarinic Antagonists / Mydriatics / Mydriatics and Cycloplegics / Nervous System / Neurotransmitter Agents / Ophthalmologicals / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Psycholeptics / Scopolamine Derivatives / Sensory Organs / Solanaceous Alkaloids / Tropanes",DL48G20X8X,51-34-3,D00138,3000322.0,10194106.0,50240039.0,9603.0,16794.0,CHEMBL569713,DNC000757,PA451308,ZINC000100037020
Carbinoxamine,phase 4 complete,DB00748 (APRD00765),CN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,Aminoalkyl Ethers / Antihistamines for Systemic Use / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / Photosensitizing Agents / QTc Prolonging Agents,982A7M02H5,486-16-8,,2564.0,2466.0,81464.0,20220.0,3398.0,CHEMBL864,DAP001069,PA164746898,
Etodolac,phase 4 complete,DB00749 (APRD00067),CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,"Acetic Acid Derivatives and Related Substances / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / COX-2 Inhibitors / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Indoleacetic Acids / Indoles / Musculo-Skeletal System / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / Other Nonsteroidal Anti-inflammatory Agents / Peripheral Nervous System Agents / Photosensitizing Agents / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory System Agents / UGT1A3 substrates / UGT1A9 Substrates / UGT2B7 substrates",2M36281008,41340-25-4,D00315,3308.0,3192.0,50016799.0,24605.0,4909.0,CHEMBL622,DAP000778,PA449550,
Prilocaine,phase 4 complete,DB00750 (APRD00180),CCCNC(C)C(=O)NC1=CC=CC=C1C,"Amides / Amines / Anesthetics / Anesthetics, Local / Anilides / Aniline Compounds / Central Nervous System Agents / Central Nervous System Depressants / Local Anesthesia / Local Anesthetics (Amide) / Methemoglobinemia Associated Agents / Nervous System / Peripheral Nervous System Agents / Sensory System Agents",046O35D44R,721-50-6,D00553,4906.0,4737.0,50225477.0,8686.0,8404.0,CHEMBL1194,DAP000511,PA451101,
Epinastine,phase 4 complete,DB00751 (APRD00043),NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21,"Acid Reducers / Antidepressive Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decongestants and Antiallergics / Decreased Histamine Release / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Inhibitors / Histamine H2 Antagonists / Neurotransmitter Agents / Ophthalmics / Ophthalmologicals / P-glycoprotein substrates / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sensory Organs / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists",Q13WX941EF,80012-43-7,D01713,3241.0,3128.0,50131441.0,39684.0,51032.0,CHEMBL1106,DAP001074,PA164764489,
Tranylcypromine,phase 4 complete,DB00752 (APRD00645),NC1CC1C1=CC=CC=C1,"Agents that produce hypertension / Agents that reduce seizure threshold / Amines / Anti-Anxiety Agents / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Hypotensive Agents / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Monoamine Oxidase Inhibitors / Monoamine Oxidase Inhibitors, Non-Selective / Nervous System / Propylamines / Psychoanaleptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / Tranquilizing Agents",3E3V44J4Z9,155-09-9,D08625,5530.0,5329.0,50113851.0,10734.0,131512.0,CHEMBL313833,DAP000081,PA451741,
Isoflurane,phase 4 complete,DB00753 (APRD00212),FC(F)OC(Cl)C(F)(F)F,"Agents that produce hypertension / Agents that reduce seizure threshold / Anesthetics / Anesthetics, General / Anesthetics, Inhalation / Anticholinergic Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Ethers / Hydrocarbons, Halogenated / Hypotensive Agents / Methyl Ethers / Nervous System / Nicotinic Antagonists / Potential QTc-Prolonging Agents / QTc Prolonging Agents",CYS9AKD70P,26675-46-7,D00545,3763.0,3631.0,217353.0,6026.0,6015.0,CHEMBL1256,DAP001033,PA450106,
Ethotoin,phase 4 complete,DB00754 (APRD00962),CCN1C(=O)NC(C1=O)C1=CC=CC=C1,Anti-epileptic Agent / Anticonvulsants / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Decreased Central Nervous System Disorganized Electrical Activity / Hydantoins / Imidazoles / Imidazolidines / Membrane Transport Modulators / Nervous System / Sodium Channel Blockers / Thyroxine-binding globulin substrates / Voltage-Gated Sodium Channel Blockers,46QG38NC4U,86-35-1,D00708,3292.0,3176.0,50239975.0,4136.0,4888.0,CHEMBL1095,DAP000512,PA164768735,
Tretinoin,phase 4 complete,"DB00755 (NUTR00051, APRD00362)",C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O,"Alkenes / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Biological Factors / Cardiotoxic antineoplastic agents / Carotenoids / Cell Stimulants and Proliferants / Cyclohexanes / Cyclohexenes / Cycloparaffins / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Hydrocarbons, Acyclic / Hypotensive Agents / Immunosuppressive Agents / Keratolytic Agents / Pigments, Biological / Polyenes / Retinoids / Retinoids for Topical Use in Acne / Terpenes / Tretinoin / Vitamin A / Vitamins / Vitamins (Fat Soluble)",5688UTC01R,302-79-4,D00094,5538.0,392618.0,31883.0,10753.0,15367.0,CHEMBL38,DNC000117,PA164746900,ZINC000012358651
Hexachlorophene,phase 4 complete,DB00756 (APRD00722),OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl,"Anti-Infective Agents / Anti-Infective Agents, Local / Antiseptics and Disinfectants / Benzene Derivatives / Chlorobenzenes / Chlorophenols / Dermatologicals / Drugs causing inadvertant photosensitivity / Hydrocarbons, Chlorinated / Hydrocarbons, Halogenated / Phenol and Derivatives / Phenols / Photosensitizing Agents",IWW5FV6NK2,70-30-4,D00859,3598.0,3472.0,31712.0,5293.0,5693.0,CHEMBL496,DAP001050,PA449871,ZINC000001530968
Dolasetron,phase 4 complete,DB00757 (APRD00518),[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2,"Alimentary Tract and Metabolism / Antidepressive Agents / Antiemetics / Antiemetics and Antinauseants / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / Peripheral Nervous System Agents / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 3 Receptor Antagonists / Serotonin 5-HT3 Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists",82WI2L7Q6E,115956-12-2,,3033818.0,30845229.0,50451546.0,68091.0,,CHEMBL2368925,DAP000368,PA449390,ZINC000103105084
Clopidogrel,phase 4 complete,DB00758 (APRD00444),[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl,"Antiplatelet agents / Blood and Blood Forming Organs / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (moderate) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Platelet Aggregation / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / OCT1 inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / P2Y12 Platelet Inhibitor / Platelet Aggregation Inhibitors Excl. Heparin / Purinergic Agents / Purinergic Antagonists / Purinergic P2 Receptor Antagonists / Purinergic P2Y Receptor Antagonists / Pyridines / Sulfur Compounds / Thienopyridines / Thiophenes",A74586SNO7,113665-84-2,D00769,60606.0,54632.0,50397662.0,32968.0,37941.0,CHEMBL1771,DAP000178,PA449053,ZINC000034781704
Tetracycline,phase 4 complete,DB00759 (APRD00572),[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,"Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antibiotics for Topical Use / Antiinfectives and Antiseptics for Local Oral Treatment / Antiinfectives for Systemic Use / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Drugs causing inadvertant photosensitivity / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Naphthacenes / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Ophthalmological and Otological Preparations / Ophthalmologicals / Otologicals / Photosensitizing Agents / Protein Synthesis Inhibitors / Sensory Organs / Stomatological Preparations / Tetracycline, antagonists & inhibitors / Tetracyclines",F8VB5M810T,60-54-8,D00201,54675776.0,10257122.0,50237605.0,10395.0,27902.0,CHEMBL1440,DAP001527,PA451640,ZINC000084441937
Meropenem,phase 4 complete,"DB00760 (APRD01097, EXPT02153)",[H][C@]1([C@@H](C)O)C(=O)N2C(C(O)=O)=C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)[C@H](C)[C@]12[H],"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Carbapenems / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / Penem Antibacterial / Sulfur Compounds / Thienamycins",YOP6PX0BAO,96036-03-2,D02222,441130.0,389924.0,50129062.0,1546029.0,43968.0,CHEMBL127,DAP000441,PA164764445,ZINC000003808779
Potassium chloride,phase 4 complete,DB00761 (APRD01322),[Cl-].[K+],"Acids / Acids, Noncarboxylic / Agents causing hyperkalemia / Alimentary Tract and Metabolism / Anions / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Chlorides / Chlorine Compounds / Drugs that are Mainly Renally Excreted / Electrolyte Solutions / Electrolytes / Hemodialysis Solution / I.V. Solution Additives / Ions / Mineral Supplements / Minerals / Potassium Compounds / Potassium Salt / Replacement Preparations",660YQ98I10,7447-40-7,D02060,4873.0,4707.0,,8591.0,32588.0,CHEMBL1200731,DAP000828,PA451055,
Irinotecan,phase 4 complete,DB00762 (APRD00579),CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12,Alkaloids / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Carbohydrates / Cholinesterase substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Disaccharides / Enzyme Inhibitors / Immunosuppressive Agents / Myelosuppressive Agents / OATP1B1/SLCO1B1 Inhibitors / Oligosaccharides / P-glycoprotein substrates / Pharmaceutical Preparations / Polysaccharides / Topoisomerase I Inhibitors / Topoisomerase Inhibitors / UGT1A1 Substrates / UGT1A9 Substrates,7673326042,97682-44-5,D08086,60838.0,54825.0,50128267.0,51499.0,80630.0,CHEMBL481,DAP001339,PA450085,ZINC000001612996
Methimazole,phase 4 complete,DB00763 (APRD00002),CN1C=CNC1=S,"Antithyroid agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (weak) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Imidazoles / Immunosuppressive Agents / Myelosuppressive Agents / Sulfur Compounds / Sulfur-Containing Imidazole Derivatives / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Thyroid Hormone Synthesis Inhibitor / Thyroid Hormone Synthesis Inhibitors / Thyroid Products",554Z48XN5E,60-56-0,D00401,1349907.0,1131173.0,50241361.0,6835.0,50673.0,CHEMBL1515,DNC001429,PA450422,ZINC000001187543
Metyrosine,phase 4 complete,DB00765 (APRD01112),C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O,"Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Antihypertensive Agents / Catecholamine Synthesis Inhibitor / Enzyme Inhibitors / Methyltyrosines / Tyrosine Hydroxylase Inhibitors",DOQ0J0TPF7,672-87-7,D00762,441350.0,390103.0,,266604.0,6912.0,CHEMBL1200862,DAP000471,PA450487,ZINC000000000693
Clavulanic acid,phase 4 complete,DB00766 (APRD00049),[H][C@@]12CC(=O)N1[C@@H](C(O)=O)\C(O2)=C\CO,"Anti-Bacterial Agents / Anti-Infective Agents / beta-Lactamase Inhibitors / beta-Lactams / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Lactams",23521W1S24,58001-44-8,,5280980.0,4444466.0,50021959.0,21216.0,48947.0,CHEMBL777,DAP000948,PA164742987,ZINC000003830569
Olopatadine,phase 4 complete,DB00768 (APRD00310),CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2,"Anti-Allergic Agents / Anti-Inflammatory Agents / Antiallergic Agents, Excl. Corticosteroids / Antihistamine Drugs / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Decongestants and Antiallergics / Decreased Histamine Release / Dibenzoxepins / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Histamine H1 Inhibitors / Mast Cell Stabilizers / Nasal Preparations / Neurotransmitter Agents / Ophthalmologicals / P-glycoprotein substrates / Peripheral Nervous System Agents / QTc Prolonging Agents / Sensory Organs / Sensory System Agents",D27V6190PM,113806-05-6,,5281071.0,4444528.0,50002096.0,135391.0,,CHEMBL1189432,DAP001062,PA450698,ZINC000000001850
Hydrocortamate,phase 4 complete,DB00769 (APRD01018),[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers,Y3N00BK5WK,76-47-1,,84088.0,75860.0,,,50851.0,CHEMBL1201263,DAP001187,PA164745515,ZINC000004213506
Alprostadil,phase 4 complete,DB00770 (APRD00785),CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,"Autacoids / Biological Factors / Cardiac Therapy / Cardiovascular Agents / Drugs Used in Erectile Dysfunction / Eicosanoids / Fatty Acids / Fatty Acids, Monounsaturated / Fatty Acids, Unsaturated / Genito Urinary System and Sex Hormones / Genitourinary Arterial Vasodilation / Hematologic Agents / Inflammation Mediators / Lipids / Miscellaneous Vasodilatating Agents / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / Prostaglandin E1 Agonist / Prostaglandin Receptor Agonists / Prostaglandins / Prostaglandins E / Prostaglandins, Synthetic / Urological Agents / Urologicals / Vasodilating Agents / Venous Vasodilation",F5TD010360,745-65-3,D00180,149351.0,4444306.0,50101853.0,598.0,15544.0,CHEMBL495,DAP001490,PA448334,ZINC000003813088
Clidinium,phase 4 complete,DB00771 (APRD00737),C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,"Acids, Carbocyclic / Agents producing tachycardia / Alimentary Tract and Metabolism / Anticholinergic Agents / Autonomic Agents / Benzilates / Central Nervous System Depressants / Decreased Parasympathetic Acetylcholine Activity / Digestive/GI System Activity Alteration / Diphenylacetic Acids / Drugs for Functional Gastrointestinal Disorders / GI Motility Alteration / Hydroxy Acids / Muscarinic Antagonists / Parasympatholytics / Peripheral Nervous System Agents / Phenylacetates / Quinuclidines",BO76JF850N,7020-55-5,,2784.0,26330531.0,50055977.0,21232.0,3743.0,,DAP001117,PA164781044,
Malathion,phase 4 complete,DB00772 (APRD01081),CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC,"Agrochemicals / Antiparasitic Products, Insecticides and Repellents / Cholinergic Agents / Cholinesterase Inhibitors / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 Substrates / Ectoparasiticides, Incl. Scabicides / Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents / Enzyme Inhibitors / Insecticides / Neurotransmitter Agents / Organophosphates / Organophosphorus Compounds / Organothiophosphates / Organothiophosphorus Compounds / Pesticides / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sulfur Compounds / Toxic Actions",U5N7SU872W,121-75-5,D00534,4004.0,3864.0,85372.0,6606.0,141474.0,CHEMBL1200468,DAP000895,PA164748092,
Etoposide,phase 4 complete,DB00773 (APRD00239),[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O,"Antineoplastic Agents / Antineoplastic Agents, Phytogenic / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Benzene Derivatives / Benzyl Compounds / Carbohydrates / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Glucosides / Glycosides / Immunosuppressive Agents / Lignans / Myelosuppressive Agents / Naphthalenes / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Podophyllotoxin / Podophyllotoxin Derivatives / Tetrahydronaphthalenes / Topoisomerase II Inhibitors / Topoisomerase Inhibitors / UGT1A1 Substrates / UGT1A1 substrates with narrow therapeutic index",6PLQ3CP4P3,33419-42-0,D00125,36462.0,33510.0,50127140.0,4179.0,4911.0,CHEMBL44657,DAP000786,PA449552,ZINC000003938684
Hydroflumethiazide,phase 4 complete,DB00774 (APRD01020),NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F,"Amides / Antihypertensive Agents / Benzothiadiazines / Cardiovascular Agents / Diuretics / Drugs causing inadvertant photosensitivity / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Increased Diuresis / Membrane Transport Modulators / Natriuretic Agents / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Photosensitizing Agents / Sodium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds / Thiazides",501CFL162R,135-09-1,D00654,3647.0,3521.0,25897.0,5495.0,5784.0,CHEMBL1763,DAP000747,PA164752557,ZINC000000897225
Tirofiban,phase 4 complete,DB00775 (APRD00304),CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O,"Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Antiplatelet agents / Blood and Blood Forming Organs / Cardiovascular Agents / Decreased Platelet Aggregation / Drugs that are Mainly Renally Excreted / Fibrin Modulating Agents / Hematologic Agents / Platelet Aggregation Inhibitors Excl. Heparin",GGX234SI5H,144494-65-5,,60947.0,54912.0,50004058.0,73137.0,9605.0,CHEMBL916,DAP000696,PA451698,ZINC000003806104
Oxcarbazepine,phase 4 complete,DB00776 (APRD01308),NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,"Anti-epileptic Agent / Anticonvulsants / Carboxamide Derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Decreased Central Nervous System Disorganized Electrical Activity / Dibenzazepines / Drugs causing inadvertant photosensitivity / Enzyme Inducing Antiepileptic Drugs / Heterocyclic Compounds, Fused-Ring / Membrane Transport Modulators / Miscellaneous Anticonvulsants / Nervous System / P-glycoprotein inducers / P-glycoprotein substrates / Photosensitizing Agents / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers",VZI5B1W380,28721-07-5,D00533,34312.0,31608.0,34179.0,32624.0,7824.0,CHEMBL1068,DAP000528,PA450732,ZINC000000004724
Propiomazine,phase 4 complete,DB00777 (APRD00339),CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Anticholinergic Agents / Antidepressive Agents / Central Nervous System Depressants / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Hypnotics and Sedatives / Muscarinic Antagonists / Nervous System / Psycholeptics / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds",242Z0PM79Y,362-29-8,D02361,4940.0,4771.0,,8770.0,8491.0,CHEMBL1201210,DAP000327,PA164778685,
Roxithromycin,phase 4 complete,DB00778 (APRD01305),CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Erythromycin and similars / Lactones / Macrolides / Macrolides, Lincosamides and Streptogramins / Moderate Risk QTc-Prolonging Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Polyketides / QTc Prolonging Agents",21KOF230FA,80214-83-1,D01710,6915744.0,5291557.0,,9478.0,48935.0,CHEMBL1214185,DAP000885,PA164750505,ZINC000096006016
Nalidixic acid,phase 4 complete,DB00779 (APRD01133),CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2,"4-Quinolones / Agents that reduce seizure threshold / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Moderate Risk QTc-Prolonging Agents / Naphthyridines / OAT1/SLC22A6 inhibitors / Photosensitizing Agents / QTc Prolonging Agents / Quinolines / Quinolones / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",3B91HWA56M,389-08-2,D00183,4421.0,4268.0,21691.0,7240.0,100147.0,CHEMBL5,DAP000817,PA164746384,ZINC000000057421
Phenelzine,phase 4 complete,DB00780 (APRD00099),NNCCC1=CC=CC=C1,"Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hydrazines / Hypotensive Agents / Monoamine Oxidase A Substrates / Monoamine Oxidase Inhibitors / Monoamine Oxidase Inhibitors, Non-Selective / Nervous System / Psychoanaleptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",O408N561GF,51-71-8,D08349,3675.0,3547.0,50105417.0,8123.0,8060.0,CHEMBL1089,DAP000578,PA450903,ZINC000019166991
Polymyxin B,phase 4 complete,DB00781 (APRD01190),[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,"Alimentary Tract and Metabolism / Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antiinfectives for Systemic Use / Antimicrobial Cationic Peptides / Intestinal Antiinfectives / Lipopeptides / Neurotoxic agents / Ophthalmological and Otological Preparations / Ophthalmologicals / Otologicals / Peptides / Peptides, Cyclic / Polymyxin-class Antibacterial / Polymyxins / Pore Forming Cytotoxic Proteins / Proteins / Sensory Organs",J2VZ07J96K,1404-26-8,,,25045120.0,50410807.0,8536.0,,CHEMBL1201283,,,
Propantheline,phase 4 complete,DB00782 (APRD00177),CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12)C(C)C,"Agents producing tachycardia / Alimentary Tract and Metabolism / Amines / Ammonium Compounds / Anti-Ulcer Agents / Anticholinergic Agents / Cholinergic Agents / Drugs for Functional Gastrointestinal Disorders / Drugs that are Mainly Renally Excreted / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Muscarinic Antagonists / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Quaternary Ammonium Compounds / Synthetic Anticholinergics, Quaternary Ammonium Compounds / Xanthenes",1306V2B0Q8,298-50-0,,4934.0,4765.0,,8761.0,8481.0,CHEMBL1180725,DAP001123,PA164746224,ZINC000001530761
Estradiol,phase 4 complete,DB00783 (APRD00311),[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,"Adrenal Cortex Hormones / Androgens and Estrogens / Antiandrogens and Estrogens / BCRP/ABCG2 Inhibitors / COMT Substrates / Contraceptive Agents, Female / Contraceptives, Oral / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Estradiol Congeners / Estradiol, agonists / Estranes / Estrenes / Estrogen Contraceptives / Estrogens / Estrogens, agonists / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Intravaginal Contraceptives / Natural and Semisynthetic Estrogens, Plain / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / Progestogens and Estrogens, Sequential Preparations / Sex Hormones and Modulators of the Genital System / Steroids / Thyroxine-binding globulin inducers / UGT1A1 Substrates",4TI98Z838E,50-28-2,D00105,5757.0,5554.0,17292.0,4083.0,16469.0,CHEMBL135,DAP000854,PA449503,ZINC000013520815
Mefenamic acid,phase 4 complete,DB00784 (APRD00730),CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Amines / Aminobenzoates / Analgesics / Analgesics, Non-Narcotic / Aniline Compounds / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Fenamates / Musculo-Skeletal System / Nephrotoxic agents / ortho-Aminobenzoates / Other Nonsteroidal Anti-inflammatory Agents / Peripheral Nervous System Agents / Photosensitizing Agents / Sensory System Agents / UGT1A9 Inhibitors",367589PJ2C,61-68-7,D00151,4044.0,3904.0,50134036.0,6693.0,6717.0,CHEMBL686,DAP000779,PA450347,ZINC000000020241
Cryptenamine,phase 4 complete,DB00785 (APRD00890),,"Alkaloids / Antihypertensive Agents / Cardiovascular Agents / Cevanes / Heterocyclic Compounds, Fused-Ring / Veratrum Alkaloids",QVO4N8484O,1356-18-9,,,,,42618.0,,,DAP000479,PA164749510,
Acyclovir,phase 4 complete,"DB00787 (APRD00567, EXPT00406, DB05347)",NC1=NC(=O)C2=C(N1)N(COCCO)C=N2,"Acyclovir and prodrug / Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor / Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor / Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor / Heterocyclic Compounds, Fused-Ring / MATE 1 Substrates / MATE 2 Substrates / MATE substrates / Nephrotoxic agents / Nucleic Acid Synthesis Inhibitors / Nucleosides and Nucleotides / Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OCT1 inhibitors / OCT1 substrates / Ophthalmologicals / Purines / Purinones / Sensory Organs",X4HES1O11F,59277-89-3,D00222,2022.0,1945.0,50021776.0,281.0,2453.0,CHEMBL184,DNC000157,PA448045,ZINC000001530555
Naproxen,phase 4 complete,"DB00788 (APRD01135, DB08298)",COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antigout Preparations / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antiinflammatory Products for Vaginal Administration / Antirheumatic Agents / BSEP/ABCB11 Substrates / Central Nervous System Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Musculo-Skeletal System / Naphthaleneacetic Acids / Naphthalenes / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / Other Nonsteroidal Anti-inflammatory Agents / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Photosensitizing Agents / Propionates / Sensory System Agents / Topical Products for Joint and Muscular Pain / UGT1A1 Substrates / UGT1A3 substrates / UGT1A6 substrate / UGT1A9 Substrates / UGT2B7 substrates",57Y76R9ATQ,22204-53-1,D00118,156391.0,137720.0,50339185.0,7258.0,7476.0,CHEMBL154,DAP000968,PA450595,ZINC000000105216
Gadopentetic acid,phase 4 complete,DB00789 (APRD00991),[Gd+3].OC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O,"Acetates / Acids, Acyclic / Amines / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Fatty Acids / Fatty Acids, Volatile / Lipids / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / Miscellaneous Therapeutic Agents / Organometallic Compounds / Paramagnetic Contrast Agent / Paramagnetic Contrast Media / Polyamines",K2I13DR72L,80529-93-7,,55466.0,138549.0,,1546432.0,35778.0,CHEMBL1200431,,PA164748760,
Perindopril,phase 4 complete,DB00790 (APRD01178),[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O,"ACE Inhibitors and Calcium Channel Blockers / ACE Inhibitors and Diuretics / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Cholinesterase Inhibitors / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Indoles / Lipid Modifying Agents / Protease Inhibitors",Y5GMK36KGY,82834-16-0,D03753,107807.0,96956.0,,54552.0,8024.0,CHEMBL1581,DNC001114,PA450877,ZINC000003812867
Uracil mustard,phase 4 complete,DB00791 (APRD00130),ClCCN(CCCl)C1=CNC(=O)NC1=O,"Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Hydrocarbons, Halogenated / Mustard Compounds / Narrow Therapeutic Index Drugs / Nitrogen Mustard Compounds / Nitrosoureas / Noxae / Pyrimidines / Pyrimidinones / Toxic Actions",W7KQ46GJ8U,66-75-1,D06265,6194.0,5959.0,,10996.0,9884.0,CHEMBL1488,DAP000990,PA451830,ZINC000000002235
Tripelennamine,phase 4 complete,DB00792 (APRD00689),CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1,"Amines / Aminopyridines / Anti-Allergic Agents / Antihistamines for Systemic Use / Antihistamines for Topical Use / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Diamines / Ethylenediamine Derivatives / Ethylenediamines / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Neurotransmitter Agents / Polyamines / Pyridines / Substituted Ethylene Diamines",3C5ORO99TY,91-81-6,,5587.0,5385.0,81471.0,10847.0,9741.0,CHEMBL1241,DAP000328,PA164764429,ZINC000019117728
Haloprogin,phase 4 complete,DB00793 (APRD01011),ClC1=CC(Cl)=C(Cl)C=C1OCC#CI,Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Benzene Derivatives / Dermatologicals / Ethers / Phenols,AIU7053OWL,777-11-7,D00339,3561.0,3440.0,50194601.0,26422.0,5614.0,CHEMBL1289,DAP001332,PA164768737,ZINC000001530649
Primidone,phase 4 complete,DB00794 (APRD00549),CCC1(C(=O)NCNC1=O)C1=CC=CC=C1,Anti-epileptic Agent / Anticholinergic Agents / Anticonvulsants / Barbiturates / Barbiturates and Derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP1A2 Inducers (strong) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Enzyme Inducing Antiepileptic Drugs / GABA Agents / GABA Modulators / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Nicotinic Antagonists / Phenobarbital and similars / Psycholeptics / Pyrimidines / Pyrimidinones / UGT1A1 Inducers,13AFD7670Q,125-33-7,D00474,4909.0,4740.0,50248152.0,8691.0,8412.0,CHEMBL856,DAP000678,PA451105,ZINC000000001979
Sulfasalazine,phase 4 complete,"DB00795 (APRD00152, DB08518)",OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1,"Agents causing hyperkalemia / Agents that produce hypertension / Alimentary Tract and Metabolism / Amides / Aminosalicylate / Analgesics / Analgesics, Non-Narcotic / Anti-Infective Agents / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antirheumatic Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Central Nervous System Agents / Gastrointestinal Agents / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Immunosuppressive Agents / Intestinal Antiinflammatory Agents / Methemoglobinemia Associated Agents / Nephrotoxic agents / Non COX-2 selective NSAIDS / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Peripheral Nervous System Agents / Salicylates / Sensory System Agents / Sulfonamides / Sulfones / Sulfur Compounds",3XC8GUZ6CB,599-79-1,D00448,5359476.0,10605946.0,50103596.0,9524.0,9334.0,CHEMBL421,DAP000153,PA451547,ZINC000003831490
Candesartan cilexetil,phase 4 complete,DB00796 (APRD00420),CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1,"Agents Acting on the Renin-Angiotensin System / Agents causing hyperkalemia / Angiotensin 2 Receptor Blocker / Angiotensin II Antagonists and Diuretics / Angiotensin Receptor Antagonists / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzene Derivatives / Cardiovascular Agents / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / P-glycoprotein inhibitors / UGT1A3 substrates",R85M2X0D68,145040-37-5,D00626,2540.0,2444.0,50318907.0,135481.0,3348.0,CHEMBL1014,DAP001442,,
Tolazoline,phase 4 complete,DB00797 (APRD00170),C(C1=NCCN1)C1=CC=CC=C1,Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antihypertensive Agents / Cardiovascular Agents / Hypotensive Agents / Imidazoles / Imidazoline Derivatives / Imidazolines / Musculo-Skeletal System / Neurotransmitter Agents / Peripheral alpha-1 blockers / Peripheral Vasodilators / Topical Products for Joint and Muscular Pain / Vasodilating Agents,CHH9H12AQ3,59-98-3,,5504.0,5303.0,55436.0,10634.0,28502.0,CHEMBL770,DAP000477,PA451716,ZINC000000125006
Gentamicin,phase 4 complete,DB00798 (APRD00214),CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,"Agents that produce neuromuscular block (indirect) / alpha-Galactosidase, antagonists & inhibitors / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antibiotics for Topical Use / Antiinfectives for Systemic Use / Carbohydrates / Dermatologicals / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Enzyme Inhibitors / Gentamicins / Glycosides / Narrow Therapeutic Index Drugs / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / Ophthalmological and Otological Preparations / Ophthalmologicals / Otologicals / Protein Synthesis Inhibitors / Sensory Organs",T6Z9V48IKG,1403-66-3,,3467.0,3348.0,,1596450.0,17833.0,CHEMBL329592,DAP000116,PA449753,
Tazarotene,phase 4 complete,DB00799 (APRD01246),CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1,Antipsoriatics / Antipsoriatics for Topical Use / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Keratolytic Agents / Misc. Skin and Mucous Membrane Agents / Noxae / Prodrugs / Pyridines / Retinoids / Teratogens / Toxic Actions,81BDR9Y8PS,118292-40-3,D01132,5381.0,5188.0,50265951.0,83947.0,32184.0,CHEMBL1657,DAP000462,PA164746821,ZINC000001542199
Fenoldopam,phase 4 complete,DB00800 (APRD00969),OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12,"Adrenergic and Dopaminergic Agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzazepines / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiovascular Agents / Dopamine Agents / Dopamine Agonists / Dopamine D1 Receptor Agonists / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Neurotransmitter Agents / Vasodilating Agents",INU8H2KAWG,67227-56-9,D00613,3341.0,3224.0,60917.0,24853.0,5002.0,CHEMBL588,DAP000254,PA164784034,
Halazepam,phase 4 complete,DB00801 (APRD01009),FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,"Anti-Anxiety Agents / Benzazepines / Benzodiazepines and benzodiazepine derivatives / Central Nervous System Agents / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Nervous System / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents",320YC168LF,23092-17-3,D00338,31640.0,29343.0,50408018.0,26412.0,5603.0,CHEMBL970,DAP000679,PA164746526,ZINC000000537811
Alfentanil,phase 4 complete,DB00802 (APRD00726),CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O,"Agents that produce hypertension / Analgesics / Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Bradycardia-Causing Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Fentanyl and fentanyl analogues / High-risk opioids / Narcotics / Nervous System / Opiate Agonists / Opioid Agonist / Opioid Anesthetics / Opioids / Opioids, Anilidopiperidine / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Phenylpiperidine opioids / Piperidines / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",1N74HM2BS7,71195-58-9,D07122,51263.0,46451.0,83450.0,480.0,2569.0,CHEMBL634,DAP001134,PA448084,ZINC000000601281
Colistin,phase 4 complete,DB00803 (APRD00886),CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C(NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,"Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Amino Acids, Peptides, and Proteins / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antiinfectives for Systemic Use / Antimicrobial Cationic Peptides / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Intestinal Antiinfectives / Lipids / Lipopeptides / Membrane Proteins / Nephrotoxic agents / Peptides / Peptides, Cyclic / Polymyxins / Pore Forming Cytotoxic Proteins / Proteins",Z67X93HJG1,1066-17-7,D02138,131704173.0,,,2709.0,,CHEMBL407135,DAP001324,PA164760862,
Dicyclomine,phase 4 complete,DB00804 (APRD00113),CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1,"Acids, Carbocyclic / Agents producing tachycardia / Alimentary Tract and Metabolism / Anticholinergic Agents / Antimuscarinics Antispasmodics / Autonomic Agents / Cholinergic Agents / Cyclohexanecarboxylic Acids / Cyclohexanes / Cycloparaffins / Drugs for Functional Gastrointestinal Disorders / Drugs that are Mainly Renally Excreted / Muscarinic Antagonists / Neurotransmitter Agents / Parasympatholytics / Peripheral Nervous System Agents / Synthetic Anticholinergics, Esters With Tertiary Amino Group",4KV4X8IF6V,77-19-0,,3042.0,2934.0,50010101.0,3361.0,4514.0,CHEMBL1123,DAP001118,PA164744928,ZINC000001530613
Minaprine,phase 4 complete,DB00805 (APRD00735),CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1,Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Central Nervous System Stimulants / Cholinesterase Inhibitors / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Monoamine Oxidase Inhibitors / Nervous System / Psychoanaleptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists,00U7GX0NLM,25905-77-5,D05039,4199.0,4054.0,50074289.0,30031.0,51038.0,CHEMBL278819,DAP000475,PA164748351,ZINC000019796082
Pentoxifylline,phase 4 complete,DB00806 (APRD00121),CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,"Alkaloids / Antioxidants / Antiplatelet agents / Blood Viscosity Reducer / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Free Radical Scavengers / Hematologic Activity Alteration / Hematologic Agents / Hemorrheologic Agents / Heterocyclic Compounds, Fused-Ring / Peripheral Vasodilators / Phosphodiesterase 5 Inhibitors / Phosphodiesterase Inhibitors / Protective Agents / Purine Derivatives / Purines / Purinones / Radiation-Protective Agents / Vasodilating Agents / Xanthine derivatives",SD6QCT3TSU,6493-05-6,D00501,4740.0,4578.0,10850.0,8013.0,7986.0,CHEMBL628,DAP000048,PA450864,ZINC000001530776
Proparacaine,phase 4 complete,DB00807 (APRD00522),CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC,"Acids, Carbocyclic / Aminobenzoates / Anesthetics / Anesthetics, Local / Benzene Derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Ethers / Hydroxy Acids / Hydroxybenzoate Ethers / Hydroxybenzoates / Isomerism / Local Anesthesia / Ophthalmologicals / para-Aminobenzoates / Peripheral Nervous System Agents / Phenols / Phenyl Ethers / Sensory Organs / Sensory System Agents",B4OB0JHI1X,499-67-2,D08448,4935.0,4766.0,50225500.0,34905.0,8485.0,CHEMBL1196,DAP000513,PA164776849,ZINC000001530762
Indapamide,phase 4 complete,DB00808 (APRD01031),CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O,"Amides / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Diuretics / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Hypotensive Agents / Increased Diuresis / Indoles / Lipid Modifying Agents / Low-Ceiling Diuretics, Excl. Thiazides / Membrane Transport Modulators / Natriuretic Agents / Non Potassium Sparing Diuretics / Photosensitizing Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sodium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds / Thiazide-like Diuretic",F089I0511L,26807-65-8,D00345,3702.0,3574.0,25901.0,5764.0,5893.0,CHEMBL406,DAP000498,PA449975,
Tropicamide,phase 4 complete,DB00809 (APRD00287),CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1,Anticholinergic Agents / Autonomic Agents / Cholinergic Agents / Muscarinic Antagonists / Mydriatics / Mydriatics and Cycloplegics / Neurotransmitter Agents / Ophthalmologicals / Peripheral Nervous System Agents / Pyridines / Sensory Organs,N0A3Z5XTC6,1508-75-4,D00397,5593.0,5391.0,82371.0,10869.0,9757.0,CHEMBL1200604,DAP000345,PA164749389,
Biperiden,phase 4 complete,DB00810 (APRD00725),OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1,Agents producing tachycardia / Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Anticholinergic Agents / Autonomic Agents / Aza Compounds / Azabicyclo Compounds / Central Nervous System Agents / Cholinergic Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Muscarinic Antagonists / Nervous System / Neurotransmitter Agents / Nicotinic Antagonists / Parasympatholytics / Peripheral Nervous System Agents / Piperidines / Tertiary Amines,0FRP6G56LD,514-65-8,D00779,2381.0,2289.0,50240680.0,1589.0,3112.0,CHEMBL1101,DAP001125,PA448626,
Ribavirin,phase 4 complete,"DB00811 (APRD00081, EXPT02825, DB01693)",NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antimetabolites / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / Carbohydrates / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Glycosides / Noxae / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Analog Antiviral / Nucleosides / Nucleosides and Nucleotides / Ribonucleosides / Toxic Actions",49717AWG6K,36791-04-5,D00423,37542.0,34439.0,50154375.0,9344.0,63580.0,CHEMBL1643,DNC001210,PA451241,ZINC000001035331
Phenylbutazone,phase 4 complete,"DB00812 (APRD00409, DB08343)",CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antirheumatic Agents / Butylpyrazolidines / Central Nervous System Agents / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Peripheral Nervous System Agents / Pyrazoles / Pyrazolones / Sensory System Agents / Topical Products for Joint and Muscular Pain",GN5P7K3T8S,50-33-9,D00510,4781.0,4617.0,,8160.0,48574.0,CHEMBL101,DAP000974,PA450932,ZINC000100004227
Fentanyl,phase 4 complete,"DB00813 (APRD00347, DB05853, DB06055, DB06220, DB05564)",CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,"Adjuvants / Adjuvants, Anesthesia / Agents that produce hypertension / Agents that reduce seizure threshold / Analgesics / Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Antidepressive Agents / Bradycardia-Causing Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fentanyl and fentanyl analogues / High-risk opioids / Narcotics / Nervous System / Neuraxial Anesthetics / Opiate Agonists / Opioid Agonist / Opioid Anesthetics / Opioids / Opioids, Anilidopiperidine / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Phenylpiperidine opioids / Piperidines / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",UF599785JZ,437-38-7,D00320,3345.0,3228.0,50008984.0,4337.0,119915.0,CHEMBL596,DAP000072,PA449599,ZINC000002522669
Meloxicam,phase 4 complete,DB00814 (APRD00529),CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / COX-2 Inhibitors / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Musculo-Skeletal System / Nephrotoxic agents / Other Nonsteroidal Anti-inflammatory Agents / Oxicams / Peripheral Nervous System Agents / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory System Agents / Sulfur Compounds / Thiazines / Thiazoles",VG2QF83CGL,71125-38-7,D00969,54677470.0,10442740.0,50056998.0,41493.0,6741.0,CHEMBL599,DAP000971,PA450353,ZINC000013129998
Orciprenaline,phase 4 complete,DB00816 (APRD00210),CC(C)NCC(O)C1=CC(O)=CC(O)=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics for Systemic Use / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Benzene Derivatives / Bronchodilator Agents / Catecholamines / Catechols / Drugs for Obstructive Airway Diseases / Ethanolamines / Neurotransmitter Agents / Non-selective Beta-adrenergic Agonists / Peripheral Nervous System Agents / Phenols / Reproductive Control Agents / Respiratory System Agents / Selective Beta 2-adrenergic Agonists / Sympathomimetics / Tocolytic Agents",53QOG569E0,586-06-1,D00685,4086.0,3944.0,50295572.0,7688.0,83329.0,CHEMBL776,DNC000927,PA450390,
Rosoxacin,phase 4 complete,DB00817 (APRD00369),CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quinolines",3Y1OT3J4NW,40034-42-2,D02305,287180.0,253208.0,,35797.0,131715.0,CHEMBL291157,DAP000929,PA164776843,ZINC000000002042
Propofol,phase 4 complete,"DB00818 (APRD01201, EXPT02558, DB05893)",CC(C)C1=CC=CC(C(C)C)=C1O,"Agents Causing Muscle Toxicity / Agents that produce hypertension / Agents that reduce seizure threshold / Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Benzene Derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hypnotics and Sedatives / Hypotensive Agents / Miscellaneous General Anesthetics / Nervous System / P-glycoprotein inducers / Phenols / Potential QTc-Prolonging Agents / QTc Prolonging Agents / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT1A6 substrate / UGT1A9 Substrates",YI7VU623SF,2078-54-8,D00549,4943.0,4774.0,50058046.0,8782.0,44915.0,CHEMBL526,DAP000662,PA451141,ZINC000000968303
Acetazolamide,phase 4 complete,"DB00819 (APRD00119, EXPT00604)",CC(=O)NC1=NN=C(S1)S(N)(=O)=O,Anticonvulsants / Antiglaucoma Agents / Antiglaucoma Preparations and Miotics / Carbonic Anhydrase Inhibitors / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Diuretics / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Natriuretic Agents / OAT1/SLC22A6 inhibitors / Ophthalmologicals / Photosensitizing Agents / Sensory Organs / Sulfonamides / Sulfur Compounds / Thiadiazoles / Thiazoles,O3FX965V0I,59-66-5,D00218,1986.0,1909.0,10880.0,167.0,27690.0,CHEMBL20,DAP000600,PA448018,ZINC000003813042
Tadalafil,phase 4 complete,DB00820 (APRD00071),[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1,"Antihypertensive Agents / Antihypertensives for Pulmonary Arterial Hypertension / Carbolines / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Drugs Used in Erectile Dysfunction / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Indoles / Phosphodiesterase 5 Inhibitors / Phosphodiesterase Inhibitors / Pyridines / Urological Agents / Urologicals / Vasodilating Agents",742SXX0ICT,171596-29-5,D02008,110635.0,99301.0,14777.0,358263.0,71940.0,CHEMBL779,DAP000615,PA10333,ZINC000003993855
Carprofen,phase 4 complete,DB00821 (APRD00849),CC(C(O)=O)C1=CC2=C(C=C1)C1=C(N2)C=CC(Cl)=C1,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antirheumatic Agents / Central Nervous System Agents / Dermatologicals / Heterocyclic Compounds, Fused-Ring / Indoles / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / Peripheral Nervous System Agents / Photosensitizing Agents / Radiation-Sensitizing Agents / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory System Agents",FFL0D546HO,53716-49-7,,2581.0,2483.0,50097346.0,20343.0,364453.0,CHEMBL1316,DAP000975,PA164781361,
Disulfiram,phase 4 complete,DB00822 (APRD00767),CCN(CC)C(=S)SSC(=S)N(CC)CC,"Acetyl Aldehyde Dehydrogenase Inhibitors / Acids / Acids, Acyclic / Acids, Noncarboxylic / Agents that reduce seizure threshold / Alcohol Deterrents / Aldehyde Dehydrogenase Inhibitor / Anions / Antiparasitic Products, Insecticides and Repellents / BSEP/ABCB11 Substrates / Carbamates / Central Nervous System Agents / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Disulfides / Drugs Used in Addictive Disorders / Drugs Used in Alcohol Dependence / Ectoparasiticides, Incl. Scabicides / Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents / Electrolytes / Enzyme Inhibitors / Gases / Hydrogen Sulfide / Ions / Nervous System / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sulfides / Sulfur Compounds / Sulfur Containing Products / Thiocarbamates",TR3MLJ1UAI,97-77-8,D00131,3117.0,3005.0,50058655.0,3554.0,4659.0,CHEMBL964,DAP000012,PA449376,ZINC000001529266
Ethynodiol diacetate,phase 4 complete,DB00823 (APRD00760),[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H],"Adrenal Cortex Hormones / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptives, Oral / Contraceptives, Oral, Synthetic / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hyperglycemia-Associated Agents / Norpregnanes / Norpregnenes / Norsteroids / Progestin Contraceptives / Progestins / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",62H10A1236,297-76-7,D01294,9270.0,8913.0,50237627.0,4170.0,31580.0,CHEMBL1200624,DAP000856,PA164749157,ZINC000003876023
Enprofylline,phase 4 complete,DB00824 (APRD00273),CCCN1C2=C(NC=N2)C(=O)NC1=O,"Adenosine A2 Receptor Antagonists / Alkaloids / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / Peripheral Nervous System Agents / Purinergic Agents / Purinergic Antagonists / Purinergic P1 Receptor Antagonists / Purines / Purinones / Respiratory System Agents",DT7DT5E518,41078-02-8,D04006,1676.0,1613.0,50001493.0,,126237.0,CHEMBL279898,DAP001375,PA164749350,ZINC000000403567
LevomentholCommonly known or available as Menthol,phase 4 complete,DB00825 (APRD01604),CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,"Agents causing hyperkalemia / Alcohols / Antiarrhythmic agents / Antipruritics / Antipruritics and Local Anesthetics / Basic Lotions and Liniments / Bradycardia-Causing Agents / Calcium Channel Blockers / Cyclohexanes / Cyclohexanols / Cycloparaffins / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dermatologicals / EENT Drugs, Miscellaneous / Fatty Alcohols / Herbs and Natural Products / Hexanols / Lipids / Monoterpenes / Other Analgesics / Other Cold and Cough Preparations / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Terpenes / Vasodilating Agents",BZ1R15MTK7,2216-51-5,D00064,16666.0,15803.0,50318482.0,236388.0,15409.0,CHEMBL470670,DAP000876,PA164776605,ZINC000001482164
Natamycin,phase 4 complete,DB00826 (APRD01136),[H][C@@]12C[C@H](O)C[C@]3(O)C[C@H](O)[C@@H](C(O)=O)[C@]([H])(C[C@@H](O[C@]4([H])O[C@H](C)[C@@H](O)[C@H](N)[C@@H]4O)\C=C\C=C\C=C\C=C\C[C@@H](C)OC(=O)\C=C\[C@@]1([H])O2)O3,"Alimentary Tract and Metabolism / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Local / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Antiinfectives and Antiseptics for Local Oral Treatment / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Intestinal Antiinfectives / Lactones / Ophthalmologicals / Polyene Antifungal / Polyene Antimicrobial / Polyketides / Sensory Organs / Stomatological Preparations",8O0C852CPO,7681-93-8,D00884,5284447.0,10468784.0,50370755.0,7268.0,,CHEMBL1200656,DAP001331,PA164744325,ZINC000008220909
Cinoxacin,phase 4 complete,DB00827 (APRD00873),CCN1N=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Moderate Risk QTc-Prolonging Agents / OAT1/SLC22A6 inhibitors / QTc Prolonging Agents / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",LMK22VUH23,28657-80-9,D00872,2762.0,2660.0,39350.0,2550.0,3716.0,CHEMBL1208,DAP000999,PA449007,ZINC000000032350
Fosfomycin,phase 4 complete,DB00828 (APRD00987),C[C@@H]1O[C@@H]1P(O)(O)=O,"Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Drugs that are Mainly Renally Excreted / Organophosphonates / Organophosphorus Compounds",2N81MY12TE,23155-02-4,D04253,446987.0,394204.0,50024894.0,4550.0,28915.0,CHEMBL1757,DAP000767,PA164748039,ZINC000001530427
Diazepam,phase 4 complete,"DB00829 (APRD00642, DB07699)",CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,"Adjuvants, Anesthesia / Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Anti-Anxiety Agents / Anticonvulsants / Autonomic Agents / Benzazepines / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Benzodiazepinones / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Nervous System / P-glycoprotein substrates / Peripheral Nervous System Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents",Q3JTX2Q7TU,439-14-5,D00293,3016.0,2908.0,50000766.0,3322.0,49575.0,CHEMBL12,DNC000549,PA449283,ZINC000000006427
Phenmetrazine,phase 4 complete,DB00830 (APRD00262),CC1NCCOC1C1=CC=CC=C1,Agents producing tachycardia / Agents that produce hypertension / Anti-Obesity Agents / Appetite Depressants / Autonomic Agents / Central Nervous System Agents / Central Nervous System Stimulants / Morpholines / Oxazines / Peripheral Nervous System Agents / Sympathomimetics,XA501VL3VR,134-49-6,,4762.0,4598.0,,8133.0,8067.0,CHEMBL1201208,DAP000860,PA164747188,
Trifluoperazine,phase 4 complete,"DB00831 (APRD00173, DB08616)",CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antiemetics / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / Phenothiazines / Phenothiazines With Piperazine Structure / Photosensitizing Agents / Psycholeptics / Psychotropic Drugs / Sulfur Compounds / Tranquilizing Agents / UGT1A4 substrates",214IZI85K3,117-89-5,D08636,5566.0,5365.0,79181.0,10800.0,45951.0,CHEMBL422,DAP000034,PA451771,ZINC000019418959
Phensuximide,phase 4 complete,DB00832 (APRD00496),CN1C(=O)CC(C1=O)C1=CC=CC=C1,Anticonvulsants / Central Nervous System Depressants / Imides / Nervous System / Pyrrolidines / Pyrrolidinones / Succinimide Derivatives,6WVL9C355G,86-34-0,D00508,6839.0,6578.0,50240063.0,33309.0,8079.0,CHEMBL797,,PA164771230,
Cefaclor,phase 4 complete,DB00833 (APRD00243),[H][C@]12SCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / BSEP/ABCB11 Substrates / Cephalosporins / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Second-Generation Cephalosporins / Sulfur Compounds / Thiazines",3Z6FS3IK0K,53994-73-3,D00256,51039.0,46260.0,42131.0,1450910.0,3478.0,CHEMBL680,DAP000442,PA164749137,ZINC000003812869
Mifepristone,phase 4 complete,DB00834 (APRD00432),[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H],"Abortifacient Agents / Abortifacient Agents, Steroidal / Adrenal Cortex Hormones / Blood Glucose Lowering Agents / BSEP/ABCB11 Substrates / Contraceptive Agents, Female / Contraceptives, Oral / Contraceptives, Oral, Synthetic / Contraceptives, Postcoital / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Estranes / Estrenes / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Highest Risk QTc-Prolonging Agents / Hormonal Contraceptives for Systemic Use / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypoglycemia-Associated Agents / Luteolytic Agents / Menstruation-Inducing Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / Progestational Hormone Receptor Antagonists / Progesterone Receptor Modulators / Progestin Antagonist / QTc Prolonging Agents / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",320T6RNW1F,84371-65-3,D00585,55245.0,49889.0,50072024.0,6964.0,50692.0,CHEMBL1276308,DAP000090,PA450500,ZINC000003831128
Brompheniramine,phase 4 complete,DB00835 (APRD00832),CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1,Agents producing tachycardia / Anti-Allergic Agents / Anticholinergic Agents / Antihistamines for Systemic Use / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 Substrates / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Muscarinic Antagonists / Neurotransmitter Agents / Photosensitizing Agents / Potential QTc-Prolonging Agents / Propylamine Derivatives / Pyridines / QTc Prolonging Agents / Substituted Alkylamines,H57G17P2FN,86-22-6,D07543,6834.0,6573.0,50017666.0,1767.0,3183.0,CHEMBL811,DAP001066,PA448675,
Loperamide,phase 4 complete,DB00836 (APRD00275),CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1,"Agents causing hyperkalemia / Alimentary Tract and Metabolism / Antiarrhythmic agents / Antidiarrheals / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antipropulsives / Bradycardia-Causing Agents / Calcium Channel Blockers / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Gastrointestinal Agents / Moderate Risk QTc-Prolonging Agents / Opioid Agonist / P-glycoprotein substrates / Piperidines / QTc Prolonging Agents",6X9OC3H4II,53179-11-6,D08144,3955.0,3818.0,50017698.0,6468.0,6532.0,CHEMBL841,DAP000425,PA450262,ZINC000000537928
Clocortolone,phase 4 complete,DB00838 (APRD00877),[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Moderately Potent (Group II) / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Pregnadienediols / Pregnadienes / Pregnanes / Steroids / Steroids, Fluorinated",N8ZUB7XE0H,4828-27-7,D07719,5311052.0,4470589.0,,21249.0,59582.0,,DAP001190,PA164744013,ZINC000021981454
Tolazamide,phase 4 complete,DB00839 (APRD01267),CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1,Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Hypoglycemia-Associated Agents / Sulfones / Sulfonylureas / Sulfur Compounds,9LT1BRO48Q,1156-19-0,D00379,5503.0,5302.0,50240099.0,10633.0,9613.0,CHEMBL817,DAP000919,PA164774902,ZINC000000057512
Hydroxypropyl cellulose,phase 4 complete,DB00840 (APRD01023),,"Artificial Tears / Biopolymers / Carbohydrates / Compounds used in a research, industrial, or household setting / Demulcent / Demulcent Activity / Glucans / Macromolecular Substances / Ophthalmics / Polymers / Polysaccharides",RFW2ET671P,9004-64-2,D01536,,,,27291.0,,CHEMBL1201471,,PA164746492,
Dobutamine,phase 4 complete,DB00841 (APRD00122),CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic and Dopaminergic Agents / Adrenergic beta-1 Receptor Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Amines / Autonomic Agents / Benzene Derivatives / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Catecholamines / Catechols / Compounds used in a research, industrial, or household setting / COMT Substrates / Drugs that are Mainly Renally Excreted / Ethylamines / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenethylamines / Phenols / Protective Agents / Selective Beta 1-adrenergic Agonists / Sympathomimetic (Adrenergic) Agents / Sympathomimetics",3S12J47372,34368-04-2,D03879,36811.0,33786.0,50325274.0,3616.0,4670.0,CHEMBL926,DAP000245,PA449381,
Oxazepam,phase 4 complete,DB00842 (APRD01152),OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,"Anti-Anxiety Agents / Benzazepines / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Benzodiazepinones / Central Nervous System Agents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents / UGT1A9 Substrates / UGT2B7 substrates",6GOW6DWN2A,604-75-1,D00464,4616.0,4455.0,85031.0,7781.0,7823.0,CHEMBL568,DAP000243,PA450731,
Donepezil,phase 4 complete,DB00843 (APRD00039),COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1,"Anti-Dementia Drugs / BCRP/ABCG2 Substrates / Bradycardia-Causing Agents / Central Nervous System Agents / Central Nervous System Depressants / Cholinergic Agents / Cholinesterase Inhibitors / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Indans / Indenes / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Nervous System / Neurotransmitter Agents / Nootropic Agents / Parasympathomemetic (Cholinergic) Agents / Piperidines / Psychoanaleptics / QTc Prolonging Agents",8SSC91326P,120014-06-4,D00670,3152.0,3040.0,8960.0,135447.0,53289.0,CHEMBL502,DAP000560,PA449394,
Nalbuphine,phase 4 complete,DB00844 (APRD01132),O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5,"Alkaloids / Analgesics / Central Nervous System Agents / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Mixed Agonist / Antagonist Opioids / Morphinan Derivatives / Morphinans / Narcotics / Nervous System / Opiate Alkaloids / Opiate Partial Agonists / Opioid Agonist/Antagonist / Opioid Antagonists / Opioids / Peripheral Nervous System Agents / Phenanthrenes / Semi-synthetic Opioids / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",L2T84IQI2K,20594-83-6,D08246,5311304.0,4470813.0,50105085.0,7238.0,7454.0,CHEMBL895,DAP000380,PA164745372,ZINC000003812989
Clofazimine,phase 4 complete,DB00845 (APRD00278),CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1,"Anti-Bacterial Agents / Anti-Infective Agents / Anti-Inflammatory Agents / Antiinfectives for Systemic Use / Antimycobacterials / BCRP/ABCG2 Inhibitors / BSEP/ABCB11 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs for Treatment of Lepra / Heterocyclic Compounds, Fused-Ring / Leprostatic Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Phenazines / Photosensitizing Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents",D959AE5USF,2030-63-9,D00278,2794.0,2692.0,50378783.0,2592.0,3749.0,CHEMBL1292,DAP000789,PA164748759,ZINC000100037101
Flurandrenolide,phase 4 complete,DB00846 (APRD00982),CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Pregnanes / Pregnenediones / Pregnenes / Steroids / Steroids, Fluorinated",8EUL29XUQT,1524-88-5,D00328,15209.0,14475.0,50240003.0,4500.0,5127.0,CHEMBL1201012,DAP000418,PA164750513,ZINC000004097308
Cysteamine,phase 4 complete,DB00847 (APRD00896),NCCS,"Alimentary Tract and Metabolism / Amines / Amino Acids and Derivatives / Cystine Depleting Agents / Cystine Disulfide Reduction / EENT Drugs, Miscellaneous / Ethylamines / Mercaptoethylamines / Ophthalmics / Ophthalmologicals / Other Miscellaneous Therapeutic Agents / Sensory Organs / Sulfhydryl Compounds / Sulfur Compounds",5UX2SD1KE2,60-23-1,D03634,6058.0,5834.0,7968.0,3022.0,17141.0,CHEMBL602,DAP001297,PA449171,ZINC000008034121
Levamisole,phase 4 complete,DB00848 (APRD01067),C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1,"Adjuvants, Immunologic / Anthelmintics / Anti-Infective Agents / Antinematodal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antirheumatic Agents / Imidazoles / Imidazothiazole Derivatives / Immunologic Factors / Levamisole, analogs & derivatives / Sulfur Compounds / Thiazoles",2880D3468G,14769-73-4,D08114,26879.0,25037.0,50241179.0,6371.0,6432.0,CHEMBL1454,DAP000570,PA450205,ZINC000000119839
Methylphenobarbital,phase 4 complete,DB00849 (APRD00047),CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1,Anticholinergic Agents / Anticonvulsants / Barbiturates / Barbiturates and Derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / GABA Agents / GABA Modulators / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Nicotinic Antagonists / Phenobarbital and similars / Psycholeptics / Pyrimidines / Pyrimidinones,5NC67NU76B,115-38-8,D00700,8271.0,7972.0,,6758.0,6758.0,CHEMBL45029,DAP000680,PA450374,
Perphenazine,phase 4 complete,DB00850 (APRD00429),OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,"Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Phenothiazines / Phenothiazines With Piperazine Structure / Photosensitizing Agents / Psycholeptics / Psychotropic Drugs / Sulfur Compounds / Tranquilizing Agents",FTA7XXY4EZ,58-39-9,D00503,4748.0,4586.0,50130273.0,8076.0,8028.0,CHEMBL567,DAP000100,PA450882,ZINC000019228902
Dacarbazine,phase 4 complete,DB00851 (APRD00331),CN(C)\N=N\C1=C(N=CN1)C(N)=O,"Alkylating Activity / Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Imidazoles / Immunosuppressive Agents / Myelosuppressive Agents / Noxae / Toxic Actions / Triazenes",7GR28W0FJI,4342-03-4,D00288,5351166.0,10481959.0,50238687.0,3098.0,4305.0,CHEMBL476,DAP000533,PA449197,ZINC000100019007
Pseudoephedrine,phase 4 complete,DB00852 (APRD00634),CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Alpha-and Beta-adrenergic Agonists / Amines / Amino Alcohols / Amphetamines / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cardiovascular Agents / Ethylamines / Hyperglycemia-Associated Agents / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Nasal Decongestants / Nasal Decongestants for Systemic Use / Nasal Preparations / Norepinephrine Releasing Agent / Peripheral Nervous System Agents / Phenethylamines / Propanolamines / Propanols / Respiratory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sympathomimetic (Adrenergic) Agents / Sympathomimetics / Vasoconstrictor Agents,7CUC9DDI9F,90-82-4,D08449,7028.0,6761.0,,8896.0,51209.0,CHEMBL1590,DAP000195,PA451170,ZINC000000020259
Temozolomide,phase 4 complete,DB00853 (APRD00557),CN1N=NC2=C(N=CN2C1=O)C(N)=O,"Alkylating Activity / Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 Enzyme Inducers / Drugs that are Mainly Renally Excreted / Imidazoles / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Toxic Actions / Triazenes",YF1K15M17Y,85622-93-1,D06067,5394.0,5201.0,50034562.0,37776.0,72564.0,CHEMBL810,DAP000987,PA451609,ZINC000001482184
Levorphanol,phase 4 complete,DB00854 (APRD00764),[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,"Alkaloids / Analgesics / Central Nervous System Agents / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Morphinans / Narcotics / Opiate Alkaloids / Opioid Agonist / Opioids / Peripheral Nervous System Agents / Phenanthrenes / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",27618J1N2X,77-07-6,D08123,5359272.0,16736212.0,50369518.0,6378.0,6444.0,CHEMBL592,DAP000268,PA164744368,ZINC000003812984
Aminolevulinic acid,phase 4 complete,"DB00855 (APRD00793, DB05277)",NCC(=O)CCC(O)=O,"Amino Acids / Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Dermatologicals / Enkephalins / Keto Acids / Levulinic Acids / Misc. Skin and Mucous Membrane Agents / Nerve Tissue Proteins / Neuropeptides / Opioid Peptides / Peptides / Photosensitizing Agents / Photosensitizing agents used for phototherapy / Porphyrin Precursor / Proteins / Radiation-Sensitizing Agents / Sensitizers Used in Photodynamic/radiation Therapy",88755TAZ87,106-60-5,,137.0,134.0,50240386.0,155002.0,17549.0,CHEMBL601,DAP000314,PA10015,ZINC000003782550
Chlorphenesin,phase 4 complete,DB00856 (APRD00867),OCC(O)COC1=CC=C(Cl)C=C1,"Alcohols / Antifungals for Dermatological Use / Antifungals for Topical Use / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Dermatologicals / Glycols / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Peripheral Nervous System Agents / Propylene Glycols",I670DAL4SZ,104-29-0,,7697.0,7411.0,,2399.0,3642.0,CHEMBL388751,,PA164784022,
Terbinafine,phase 4 complete,DB00857 (APRD00508),CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12,Agents Causing Muscle Toxicity / Allylamine Antifungal / Allylamines / Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Systemic Use / Antifungals for Topical Use / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Enzyme Inhibitors / Naphthalenes,G7RIW8S0XP,91161-71-6,D02375,1549008.0,1266005.0,50018518.0,37801.0,9448.0,CHEMBL822,DAP000753,PA451614,ZINC000001530981
Penicillamine,phase 4 complete,DB00859 (APRD01171),[H][C@](N)(C(O)=O)C(C)(C)S,"Agents Causing Muscle Toxicity / Amino Acids / Amino Acids, Peptides, and Proteins / Amino Acids, Sulfur / Antidotes / Antiinflammatory and Antirheumatic Products / Antirheumatic Agents / Chelating Agents / Compounds used in a research, industrial, or household setting / Heavy Metal Antagonists / Immunosuppressive Agents / Musculo-Skeletal System / Myelosuppressive Agents / OATP1B1/SLCO1B1 Substrates / Penicillamine and Similar Agents / Protective Agents / Sequestering Agents / Specific Antirheumatic Agents / Sulfur Compounds",GNN1DV99GX,52-67-5,D00496,5852.0,5643.0,39346.0,7975.0,7959.0,CHEMBL1430,DNC000575,PA450840,ZINC000000114127
Prednisolone,phase 4 complete,DB00860 (APRD00197),[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Adrenals / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Alimentary Tract and Metabolism / Anti-Inflammatory Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antidotes / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids Acting Locally / Corticosteroids for Local Oral Treatment / Corticosteroids for Systemic Use / Corticosteroids for Systemic Use, Plain / Corticosteroids, Dermatological Preparations / Corticosteroids, Weak (Group I) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Intestinal Antiinflammatory Agents / Nasal Preparations / Ophthalmological and Otological Preparations / Ophthalmologicals / Otologicals / P-glycoprotein substrates / Prednisolone and Prodrugs / Pregnadienes / Pregnadienetriols / Pregnanes / Sensory Organs / Steroids / Stomatological Preparations / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Vasoprotectives",9PHQ9Y1OLM,50-24-8,D00472,5755.0,5552.0,19190.0,8638.0,8378.0,CHEMBL131,DAP000419,PA451096,ZINC000003833821
Diflunisal,phase 4 complete,"DB00861 (APRD00922, DB06895)",OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antirheumatic Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Cyclooxygenase Inhibitors / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hydroxy Acids / Hydroxybenzoates / Nephrotoxic agents / Nervous System / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / Other Nonsteroidal Anti-inflammatory Agents / Peripheral Nervous System Agents / Phenols / Photosensitizing Agents / Salicylates / Salicylic Acid and Derivatives / Sensory System Agents / UGT1A9 Inhibitors",7C546U4DEN,22494-42-4,D00130,3059.0,2951.0,50240510.0,3393.0,39669.0,CHEMBL898,DAP000152,PA449313,ZINC000000020243
Vardenafil,phase 4 complete,DB00862 (APRD00699),CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1,Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs Used in Erectile Dysfunction / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Imidazoles / P-glycoprotein inhibitors / P-glycoprotein substrates / Phosphodiesterase 5 Inhibitors / Phosphodiesterase Inhibitors / Piperazines / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Urological Agents / Urologicals / Vasodilating Agents,UCE6F4125H,224785-90-4,D08668,110634.0,99300.0,50088373.0,306674.0,46295.0,CHEMBL1520,DAP000414,PA10229,ZINC000018324776
Ranitidine,phase 4 complete,DB00863 (APRD00254),CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O,Acid Reducers / Agents Causing Muscle Toxicity / Alimentary Tract and Metabolism / Anti-Ulcer Agents / Cholinesterase Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Drugs that are Mainly Renally Excreted / Furans / Gastric Acid Lowering Agents / Gastrointestinal Agents / Histamine Antagonists / Histamine H2 Antagonists / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / OCT1 inhibitors / OCT1 substrates / OCT2 Inhibitors / OCT2 Substrates / P-glycoprotein inhibitors / P-glycoprotein substrates,884KT10YB7,66357-35-5,D00422,3001055.0,4863.0,50103506.0,9143.0,92246.0,CHEMBL1790041,DAP000340,PA451224,
Tacrolimus,phase 4 complete,"DB00864 (APRD00276, EXPT01437)",CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC,"Agents causing hyperkalemia / Agents Causing Muscle Toxicity / Agents for Dermatitis, Excluding Corticosteroids / Anti-Bacterial Agents / Antineoplastic and Immunomodulating Agents / Calcineurin Inhibitor Immunosuppressant / Calcineurin Inhibitors / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Hyperglycemia-Associated Agents / Immunologic Factors / Immunosuppressive Agents / Lactones / Misc. Skin and Mucous Membrane Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nephrotoxic agents / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Photosensitizing Agents / Polyketides / Potential QTc-Prolonging Agents / QTc Prolonging Agents",Y5L2157C4J,104987-11-3,D00107,445643.0,393220.0,50079777.0,235991.0,61049.0,CHEMBL269732,DAP000162,PA451578,ZINC000169289411
Benzphetamine,phase 4 complete,DB00865 (APRD00759),C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1,Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Agents that produce hypertension / Amines / Amphetamines / Antidepressive Agents / Appetite Suppression / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Central Nervous System Stimulants / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Uptake Inhibitors / Ethylamines / Increased Sympathetic Activity / Membrane Transport Modulators / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Peripheral Nervous System Agents / Phenethylamines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sympathomimetic Amine Anorectic / Sympathomimetics,0M3S43XK27,156-08-1,,5311017.0,4470556.0,,1422.0,3044.0,CHEMBL3545985,DAP001147,PA448586,ZINC000000968305
Ritodrine,phase 4 complete,DB00867 (APRD00541),C[C@H](NCCC1=CC=C(O)C=C1)[C@H](O)C1=CC=C(O)C=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Autonomic Agents / Ethylamines / Genito Urinary System and Sex Hormones / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenethylamines / Propanolamines / Propanols / Reproductive Control Agents / Sympathomimetics / Sympathomimetics, Labour Repressants / Tocolytic Agents",I0Q6O6740J,26652-09-5,D02359,33572.0,30971.0,97162.0,9392.0,8872.0,CHEMBL785,DAP000937,PA451258,ZINC000000057480
Benzonatate,phase 4 complete,DB00868 (APRD00629),CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,"Alkanes / Amines / Antitussive Agents / Butanes / Central Nervous System Agents / Cholinesterase substrates / Cough and Cold Preparations / Decreased Tracheobronchial Stretch Receptor Activity / Hydrocarbons, Acyclic / Non-narcotic Antitussive / Respiratory System Agents",5P4DHS6ENR,104-31-4,D00242,7699.0,7413.0,50240086.0,18993.0,3032.0,CHEMBL1374379,DAP000514,PA164745459,ZINC000003830276
Dorzolamide,phase 4 complete,"DB00869 (APRD00577, DB04507)",CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,"Amides / Antiglaucoma Preparations and Miotics / Antihypertensive Agents / Carbonic Anhydrase Inhibitors / Cardiovascular Agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Substrates / Diuretics / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Intraocular Pressure, drug effects / Ophthalmologicals / Sensory Organs / Sulfonamides / Sulfones / Sulfur Compounds",9JDX055TW1,120279-96-1,D07871,5284549.0,4447604.0,10884.0,60207.0,4702.0,CHEMBL218490,DAP000775,PA164748765,ZINC000001530621
Suprofen,phase 4 complete,DB00870 (APRD00230),CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1,"Acids, Carbocyclic / Agents causing hyperkalemia / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Phenylpropionates / Propionates / Sensory System Agents / UGT1A1 Substrates / UGT2B7 substrates",988GU2F9PE,40828-46-4,D00452,5359.0,5166.0,50090676.0,10255.0,9362.0,CHEMBL956,DAP000730,PA451569,
Terbutaline,phase 4 complete,DB00871 (APRD00589),CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics for Systemic Use / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cholinesterase Inhibitors / Drugs for Obstructive Airway Diseases / Drugs that are Mainly Renally Excreted / Ethanolamines / Neurotransmitter Agents / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Reproductive Control Agents / Respiratory System Agents / Selective Beta 2-adrenergic Agonists / Sympathomimetics / Tocolytic Agents",N8ONU3L3PG,23031-25-6,,5403.0,5210.0,25770.0,10368.0,9449.0,CHEMBL1760,DAP000246,PA451616,
Conivaptan,phase 4 complete,DB00872 (APRD01302),CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1,"Antidiuretic Hormone Receptor Antagonists / Cardiovascular Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diuretics / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Natriuretic Agents / P-glycoprotein inhibitors",0NJ98Y462X,210101-16-9,D07748,151171.0,133239.0,85095.0,302285.0,681850.0,CHEMBL1755,DNC001525,PA164742939,ZINC000012503187
Loteprednol,phase 4 complete,DB00873 (APRD01078),[H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Adrenal Cortex Hormones / Androstadienes / Androstanes / Androstenes / Anti-Allergic Agents / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Fused-Ring Compounds / Ophthalmologicals / Sensory Organs / Steroids,Z8CBU6KR16,129260-79-3,,,8041134.0,,237027.0,50848.0,,,,ZINC000030691679
Guaifenesin,phase 4 complete,DB00874 (APRD01005),COC1=CC=CC=C1OCC(O)CO,Benzene Derivatives / Catechols / Cough and Cold Preparations / Ethers / Expectorants / Methyl Ethers / Phenols / Phenyl Ethers / Respiratory System Agents,495W7451VQ,93-14-1,D00337,3516.0,3396.0,50240098.0,5032.0,5551.0,CHEMBL980,,PA449818,
Flupentixol,phase 4 complete,DB00875 (APRD00388),[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Anticholinergic Agents / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Agents / Central Nervous System Depressants / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / Piperazines / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Thioxanthene Derivatives / Thioxanthenes / Tranquilizing Agents / Xanthenes",FA0UYH6QUO,2709-56-0,D01044,5281881.0,4445173.0,79172.0,4495.0,10454.0,CHEMBL54661,DAP000026,PA10268,ZINC000029489118
Eprosartan,phase 4 complete,DB00876 (APRD00950),CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O,"Acids, Acyclic / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Agents Causing Muscle Toxicity / Angiotensin 2 Receptor Blocker / Angiotensin II receptor blockers (ARBs) and diuretics / Angiotensin II receptor blockers (ARBs), plain / Angiotensin II Type 1 Receptor Blockers / Angiotensin Receptor Antagonists / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Hypotensive Agents / Sulfur Compounds",2KH13Z0S0Y,133040-01-4,D04040,5281037.0,4444504.0,50011977.0,83515.0,4814.0,CHEMBL813,DAP001367,PA449481,ZINC000029319828
Sirolimus,phase 4 complete,"DB00877 (APRD00178, DB02439)",[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC,"Agents causing angioedema / Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics, Antineoplastic / Antifungal Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Decreased Immunologic Activity / Hyperglycemia-Associated Agents / Immunologic Factors / Immunosuppressive Agents / Kinase Inhibitor / Lactones / Macrolides / mTOR Inhibitor Immunosuppressant / mTOR Inhibitors / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / OATP1B1/SLCO1B1 Inhibitors / Ophthalmologicals / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Polyketides / Protein Kinase Inhibitors / Selective Immunosuppressants / Sensory Organs / Sirolimus and Prodrugs",W36ZG6FT64,53123-88-9,D00753,5284616.0,10482078.0,36609.0,35302.0,9168.0,CHEMBL413,DNC001197,PA451365,ZINC000169289388
Chlorhexidine,phase 4 complete,DB00878 (APRD00545),ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1,"Alimentary Tract and Metabolism / Amidines / Anti-Infective Agents / Anti-Infective Agents, Local / Antiinfectives and Antiseptics for Local Oral Treatment / Antiseptics and Disinfectants / Biguanides / Biguanides and Amidines / Compounds used in a research, industrial, or household setting / Decreased Cell Wall Integrity / Dental Agents / Dermatologicals / Disinfectants / Guanidines / Household Products / Irrigating Solutions / Medicated Dressings / Medicated Dressings With Antiinfectives / Miscellaneous Anti-infectives / Miscellaneous Local Anti-infectives / Mouthwashes / Ophthalmological and Otological Preparations / Ophthalmologicals / Otologicals / Sensory Organs / Stomatological Preparations / Throat Preparations",R4KO0DY52L,55-56-1,D07668,9552079.0,2612.0,50170723.0,2358.0,3614.0,CHEMBL790,DAP001326,PA164776863,ZINC000014768621
Emtricitabine,phase 4 complete,DB00879 (APRD00226),NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1,"Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Carbohydrates / Deoxycytidine / Deoxyribonucleosides / Dideoxynucleosides / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Glycosides / Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor / MATE 1 Substrates / MATE substrates / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / Nucleoside Reverse Transcriptase Inhibitors / Nucleosides / Pyrimidine Nucleosides / Pyrimidines / Reverse Transcriptase Inhibitors / Ribonucleosides",G70B4ETF4S,143491-57-0,D01199,60877.0,54859.0,50107843.0,276237.0,31536.0,CHEMBL885,DAP001084,PA10069,ZINC000003629271
Chlorothiazide,phase 4 complete,DB00880 (APRD00721),NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1,"Amides / Antihypertensive Agents / Benzothiadiazines / Cardiovascular Agents / Diuretics / Drugs causing inadvertant photosensitivity / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Hypotensive Agents / Increased Diuresis / Membrane Transport Modulators / Natriuretic Agents / OAT1/SLC22A6 inhibitors / Photosensitizing Agents / Sodium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds / Thiazides",77W477J15H,58-94-6,D00519,2720.0,2619.0,39351.0,2396.0,3640.0,CHEMBL842,DAP000605,PA448953,ZINC000003872055
Quinapril,phase 4 complete,DB00881 (APRD00523),CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O,"ACE Inhibitors and Diuretics / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Isoquinolines / OAT3/SLC22A8 Substrates / Protease Inhibitors / Tetrahydroisoquinolines",RJ84Y44811,85441-61-8,D03752,54892.0,49565.0,50368166.0,35208.0,8713.0,CHEMBL1592,DAP000588,PA451205,ZINC000003801163
Clomifene,phase 4 complete,DB00882 (APRD00880),CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1,"Benzene Derivatives / Benzylidene Compounds / Clomiphene / Estrogen Agonist-antagonists / Estrogen Agonist/Antagonist / Estrogen Antagonists / Estrogen Receptor Modulators / Fertility Agents / Fertility Agents, Female / Genito Urinary System and Sex Hormones / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Ovulation Stimulants, Synthetic / P-glycoprotein substrates / Reproductive Control Agents / Selective Estrogen Receptor Modulators / Sex Hormones and Modulators of the Genital System / Stilbenes",1HRS458QU2,911-45-5,D07726,2800.0,2698.0,,2596.0,3752.0,CHEMBL2355051,DAP001013,PA449046,
Isosorbide dinitrate,phase 4 complete,DB00883 (APRD00455),[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Alcohols / Antianginal Agents / Carbohydrates / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Hypotensive Agents / Methemoglobinemia Associated Agents / Nitrate Vasodilator / Nitrates and Nitrites / Nitric Oxide Donors / Organic Nitrates / Sugar Alcohols / Vasodilating Agents / Vasodilation / Vasodilators Used in Cardiac Diseases / Vasoprotectives,IA7306519N,87-33-2,D00516,6883.0,6619.0,,6058.0,6061.0,CHEMBL6622,DAP001057,PA450125,ZINC000018089317
Risedronic acid,phase 4 complete,"DB00884 (APRD00410, DB02782)",OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O,Agents Causing Muscle Toxicity / Bisphosphonates / Bone Density Conservation Agents / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Membrane Transport Modulators / Musculo-Skeletal System / Organophosphonates / Organophosphorus Compounds / Pyridines,KM2Z91756Z,105462-24-6,D08484,5245.0,5055.0,12576.0,55685.0,8869.0,CHEMBL923,DAP000658,PA451255,ZINC000001531009
Pemirolast,phase 4 complete,DB00885 (APRD00394),CC1=CC=CN2C(=O)C(=CN=C12)C1=NNN=N1,Decreased Histamine Release / Histamine Agents / Mast Cell Stabilizers / Neurotransmitter Agents / Ophthalmics / Pyrimidines,2C09NV773M,69372-19-6,D01088,57697.0,51990.0,,19551.0,134936.0,CHEMBL1201198,DAP001064,PA164781018,ZINC000005783214
Bumetanide,phase 4 complete,DB00887 (APRD00294),CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O,"Acids, Carbocyclic / Agents Causing Muscle Toxicity / Amides / Aminobenzoates / Benzene Derivatives / Benzoates / Cardiovascular Agents / Diuretics / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / High-Ceiling Diuretics / High-Ceiling Diuretics and Potassium-Sparing Agents / Hyperglycemia-Associated Agents / Hypotensive Agents / Increased Diuresis at Loop of Henle / Membrane Transport Modulators / meta-Aminobenzoates / Natriuretic Agents / Nephrotoxic agents / Non Potassium Sparing Diuretics / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Photosensitizing Agents / Sodium Potassium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds",0Y2S3XUQ5H,28395-03-1,D00247,2471.0,2377.0,25903.0,1808.0,3213.0,CHEMBL1072,DAP000361,PA448682,ZINC000003813061
Mechlorethamine,phase 4 complete,DB00888 (APRD00249),CN(CCCl)CCCl,"Alkylating Activity / Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Cardiotoxic antineoplastic agents / Cholinesterase Inhibitors / Compounds used in a research, industrial, or household setting / Hydrocarbons, Halogenated / Immunosuppressive Agents / Irritants / Mustard Compounds / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nitrogen Mustard Analogues / Nitrogen Mustard Compounds / Noxae / Poisons / Toxic Actions",50D9XSG0VR,51-75-2,D07671,4033.0,3893.0,200297.0,6674.0,28925.0,CHEMBL427,DAP000790,PA450336,ZINC000002539484
Granisetron,phase 4 complete,DB00889 (APRD01002),CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2,"Alimentary Tract and Metabolism / Antidepressive Agents / Antiemetics / Antiemetics and Antinauseants / Autonomic Agents / Aza Compounds / Azabicyclo Compounds / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Indazoles / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Pyrazoles / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 3 Receptor Antagonists / Serotonin 5-HT3 Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists",WZG3J2MCOL,109889-09-0,D04370,5284566.0,10482033.0,50443668.0,26237.0,5537.0,CHEMBL1290003,DAP000295,PA449809,ZINC000100018854
Dienestrol,phase 4 complete,DB00890 (APRD00917),[H]\C(C)=C(/C(=C(\[H])C)/C1=CC=C(O)C=C1)\C1=CC=C(O)C=C1,"Benzene Derivatives / Estrogens / Estrogens, Non-Steroidal / Genito Urinary System and Sex Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Phenols / Sex Hormones and Modulators of the Genital System / Synthetic Estrogens, Plain",RRW32X4U1F,13029-44-2,D00898,667476.0,580857.0,40491.0,3368.0,4518.0,CHEMBL1018,DAP001015,PA164745534,ZINC000000001283
Sulfapyridine,phase 4 complete,DB00891 (APRD00491),NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,Amides / Amines / Aniline Compounds / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Methemoglobinemia Associated Agents / Short-Acting Sulfonamides / Sulfanilamides / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds,Y5V2N1KE8U,144-83-2,D02434,5336.0,5145.0,39340.0,10188.0,132842.0,CHEMBL700,DAP001200,PA164779050,ZINC000000002105
Oxybuprocaine,phase 4 complete,DB00892 (APRD00817),CCCCOC1=CC(=CC=C1N)C(=O)OCCN(CC)CC,"Acids, Carbocyclic / Aminobenzoates / Anesthetics / Anesthetics for Topical Use / Anesthetics, Local / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Benzene Derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Cholinesterase substrates / Dermatologicals / Ophthalmologicals / para-Aminobenzoates / Peripheral Nervous System Agents / Sensory Organs / Sensory System Agents",AXQ0JYM303,99-43-4,D08319,4633.0,4472.0,50225499.0,18889.0,309594.0,CHEMBL1200,DAP001231,PA164764617,ZINC000002019492
Iron Dextran,phase 4 complete,DB00893 (APRD01053),,"Biopolymers / Carbohydrates / Compounds used in a research, industrial, or household setting / Dextrans / Ferric Compounds / Glucans / Hematinics / Hematologic Agents / Iron Compounds / Macromolecular Substances / Organometallic Compounds / Parenteral Iron Replacement / Phosphate Binder / Polymers / Polysaccharides / Supplements",95HR524N2M,9004-66-4,D02141,,,,5992.0,,CHEMBL1201544,DAP001312,PA164764618,
Testolactone,phase 4 complete,DB00894 (APRD00640),[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)OC(=O)CC[C@@]21[H],"Androstadienes / Androstanes / Androstenes / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Aromatase Inhibitors / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Homosteroids / Steroids",6J9BLA949Q,968-93-4,D00153,13769.0,13172.0,50367848.0,10378.0,9460.0,CHEMBL1571,DAP000624,PA164743056,ZINC000004081771
Benzylpenicilloyl polylysine,phase 4 complete,DB00895 (APRD00822),,"Acetamides / Acetates / Acids, Acyclic / Amides / Anti-Bacterial Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Benzene Derivatives / beta-Lactams / Drug Hypersensitivity / Fatty Acids / Fatty Acids, Volatile / Heterocyclic Compounds, Fused-Ring / Lactams / Lipids / Penicillins / Sulfur Compounds",76479814OY,31855-75-1,,45266800.0,26331550.0,,19079.0,59297.0,CHEMBL1201779,DAP001314,PA164754810,
Rimexolone,phase 4 complete,DB00896 (APRD01220),[H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids for Systemic Use, Plain / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Ophthalmologicals / Pregnanes / Sensory Organs / Steroids / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Thyroxine-binding globulin inhibitors",O7M2E4264D,49697-38-3,D05729,5311412.0,4470902.0,50103606.0,55681.0,135566.0,CHEMBL1200617,DAP000420,PA164752251,ZINC000003945984
Triazolam,phase 4 complete,DB00897 (APRD00313),CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12,"Adjuvants, Anesthesia / Agents Causing Muscle Toxicity / Anti-Anxiety Agents / Benzazepines / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents / Triazolobenzodiazepines",1HM943223R,28911-01-5,D00387,5556.0,5355.0,50001765.0,10767.0,9674.0,CHEMBL646,DAP000244,PA451753,ZINC000000002212
Ethanol,phase 4 complete,DB00898 (APRD00738),CCO,"Agents Causing Muscle Toxicity / Alcohols / Anti-Infective Agents / Anti-Infective Agents, Local / Antidotes / Antiseptics and Disinfectants / Central Nervous System Agents / Central Nervous System Depressants / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (moderate) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Miscellaneous Local Anti-infectives / Miscellaneous Therapeutic Agents / Nerve Depressants / Neurotoxic agents / NMDA Receptor Antagonists / Solvents",3K9958V90M,64-17-5,D00068,702.0,682.0,,448.0,16236.0,CHEMBL545,DAP000681,PA448073,
Remifentanil,phase 4 complete,DB00899 (APRD01216),CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC,"Acids, Acyclic / Agents producing tachycardia / Agents that produce hypertension / Analgesics / Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Bradycardia-Causing Agents / Central Nervous System Agents / Central Nervous System Depressants / Fatty Acids / Fatty Acids, Volatile / Fentanyl and fentanyl analogues / High-risk opioids / Hypnotics and Sedatives / Hypotensive Agents / Lipids / Narcotics / Nervous System / Opiate Agonists / Opioid Agonist / Opioid Anesthetics / Opioids / Opioids, Anilidopiperidine / Peripheral Nervous System Agents / Phenylpiperidine opioids / Piperidines / Propionates / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",P10582JYYK,132875-61-7,D08473,60815.0,54803.0,50012491.0,73032.0,8802.0,CHEMBL1005,DAP000264,PA451232,ZINC000000538283
Didanosine,phase 4 complete,"DB00900 (APRD00240, DB02392)",OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O,"Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antimetabolites / Antiviral Agents / Antivirals for Systemic Use / Carbohydrates / Deoxyribonucleosides / Dideoxynucleosides / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Glycosides / Heterocyclic Compounds, Fused-Ring / Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Neurotoxic agents / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / Nucleoside Reverse Transcriptase Inhibitors / Nucleosides / OAT1/SLC22A6 Substrates / Purine Nucleosides / Purines / Reverse Transcriptase Inhibitors / Ribonucleosides / Toxic Actions",K3GDH6OH08,69655-05-6,D00296,50599.0,45864.0,50404252.0,3364.0,490877.0,CHEMBL1460,DNC000528,PA449301,ZINC000013597823
Methdilazine,phase 4 complete,DB00902 (APRD00713),CN1CCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1,"Agents that reduce seizure threshold / Antihistamines for Systemic Use / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Phenothiazine Derivatives / Sulfur Compounds",4Q13LY9Z8X,1982-37-2,D04979,14677.0,14009.0,81470.0,29648.0,6823.0,CHEMBL1200959,DAP001070,PA164743018,
Etacrynic acid,phase 4 complete,DB00903 (APRD00251),CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1,"Acetates / Acids, Acyclic / Agents that produce neuromuscular block (indirect) / Aryloxyacetic Acid Derivatives / Cardiovascular Agents / Diuretics / Enzyme Inhibitors / Fatty Acids / Fatty Acids, Volatile / Glycolates / High-Ceiling Diuretics / Hydroxy Acids / Hyperglycemia-Associated Agents / Hypotensive Agents / Increased Diuresis at Loop of Henle / Lipids / Natriuretic Agents / Nephrotoxic agents / Non Potassium Sparing Diuretics / OAT1/SLC22A6 inhibitors / Ototoxic agents / Phenoxyacetates / Sodium Potassium Chloride Symporter Inhibitors",M5DP350VZV,58-54-8,D00313,3278.0,3163.0,50186231.0,4109.0,4876.0,CHEMBL456,DAP000748,PA449518,ZINC000000001382
Ondansetron,phase 4 complete,DB00904 (APRD00481),CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2,"Anti-Anxiety Agents / Antidepressive Agents / Antiemetics / Antiemetics and Antinauseants / Carbazoles / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Imidazoles / Indoles / Moderate Risk QTc-Prolonging Agents / Peripheral Nervous System Agents / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 3 Receptor Antagonists / Serotonin 5-HT3 Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists",4AF302ESOS,99614-02-5,D00456,4595.0,4434.0,85330.0,26225.0,7773.0,CHEMBL46,DAP000221,PA450705,
Bimatoprost,phase 4 complete,"DB00905 (APRD00826, DB06863)",CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1,"Amides / Antiglaucoma Preparations and Miotics / Antihypertensive Agents / Autacoids / Biological Factors / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Inflammation Mediators / Lipids / Ophthalmologicals / Prostaglandin analogs reducing intraocular pressure (IOP) / Prostaglandins / Prostaglandins F, Synthetic / Prostaglandins, Synthetic / Sensory Organs",QXS94885MZ,155206-00-1,D02724,5311027.0,4470565.0,220120.0,283810.0,51230.0,CHEMBL1200963,DAP001217,PA164748867,ZINC000004474405
Tiagabine,phase 4 complete,DB00906 (APRD00344),CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1,Anti-epileptic Agent / Anticonvulsants / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Fatty Acid Derivatives / GABA Agents / GABA Uptake Inhibitors / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Nipecotic Acids / Piperidines / UGT1A1 Substrates,Z80I64HMNP,115103-54-3,,60648.0,54661.0,50368628.0,31914.0,9586.0,CHEMBL1027,DAP000164,PA451682,ZINC000003831531
Cocaine,phase 4 complete,DB00907 (APRD00080),[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C,"Agents producing tachycardia / Agents that reduce seizure threshold / Alkaloids / Analgesics and Anesthetics / Anesthetics / Anesthetics, Local / Anticholinergic Agents / Aza Compounds / Azabicyclo Compounds / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cholinesterase substrates / Cocaine, antagonists & inhibitors / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Uptake Inhibitors / Esters of Benzoic Acid / Highest Risk QTc-Prolonging Agents / Local Anesthetics (Ester) / Membrane Transport Modulators / Muscarinic Antagonists / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / OCT2 Inhibitors / Ophthalmologicals / Otologicals / Peripheral Nervous System Agents / QTc Prolonging Agents / Sensory Organs / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Throat Preparations / Tropanes / Vasoconstrictor Agents",I5Y540LHVR,50-36-2,D00110,446220.0,10194104.0,22418.0,2653.0,27958.0,CHEMBL370805,DAP000834,PA449072,ZINC000003875336
Quinidine,phase 4 complete,DB00908 (APRD00136),[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Agents that produce neuromuscular block (indirect) / Agents that reduce seizure threshold / Alkaloids / Anti-Infective Agents / Antiarrhythmic agents / Antiarrhythmics, Class I / Antiarrhythmics, Class Ia / Anticholinergic Agents / Antimalarials / Antiparasitic Agents / Antiprotozoals / Biological Products / Biopolymers / BSEP/ABCB11 Inhibitors / Carbohydrates / Cardiac Therapy / Cardiovascular Agents / Chemically-Induced Disorders / Cholinergic Agents / Cinchona Alkaloids / Complex Mixtures / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strong) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (weak) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Macromolecular Substances / Membrane Transport Modulators / Muscarinic Antagonists / Narrow Therapeutic Index Drugs / Neurotransmitter Agents / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Pharmaceutical Preparations / Photosensitizing Agents / Plant Extracts / Plant Preparations / Polymers / Polysaccharides / QTc Prolonging Agents / Quinolines / Quinuclidines / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers",ITX08688JL,56-54-2,D08458,441074.0,389880.0,50121975.0,9068.0,28593.0,CHEMBL1294,DAP000515,PA451209,ZINC000003831405
Zonisamide,phase 4 complete,DB00909 (APRD00004),NS(=O)(=O)CC1=NOC2=CC=CC=C12,"Agents causing hyperkalemia / Amides / Anti-epileptic Agent / Antiarrhythmic agents / Anticonvulsants / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Carbonic Anhydrase Inhibitors / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Diuretics / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Isoxazoles / Membrane Transport Modulators / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Nervous System / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sulfonamides / Sulfones / Sulfur Compounds / UGT1A1 Substrates",459384H98V,68291-97-4,D00538,5734.0,5532.0,10888.0,39998.0,10127.0,CHEMBL750,DAP000500,PA451978,ZINC000000004321
Paricalcitol,phase 4 complete,DB00910 (APRD01165),[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(C)(C)O,"Anti-Parathyroid Agents / Bone Density Conservation Agents / Calcium Homeostasis / Cholestanes / Cholestenes / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Lipids / Membrane Lipids / Secosteroids / Steroids / Sterols / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / UGT1A4 substrates / Vitamin D and Analogues / Vitamins / Vitamins (Fat Soluble)",6702D36OG5,131918-61-1,D00930,5281104.0,4444552.0,233195.0,73710.0,7931.0,CHEMBL1200622,DAP000211,PA450798,ZINC000013911941
Tinidazole,phase 4 complete,DB00911 (APRD01260),CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O,"Alimentary Tract and Metabolism / Alkylating Drugs / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Antitrichomonal Agents / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Imidazole Derivatives / Imidazoles / Nitro Compounds / Nitroimidazole Antimicrobial / Nitroimidazole Derivatives / Nitroimidazoles / Noxae / Toxic Actions",033KF7V46H,19387-91-8,D01426,5479.0,5279.0,50248360.0,10612.0,63627.0,CHEMBL1220,,PA10813,ZINC000000113446
Repaglinide,phase 4 complete,DB00912 (APRD00439),CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O,"Acids, Acyclic / Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs Used in Diabetes / Glinide / Hypoglycemia-Associated Agents / Meglitinides / OATP1B1/SLCO1B1 Substrates / Potassium Channel Antagonists / Stereoisomerism",668Z8C33LU,135062-02-1,D00594,65981.0,59377.0,50153520.0,73044.0,8805.0,CHEMBL1272,DAP000133,PA451234,ZINC000003798537
Anileridine,phase 4 complete,DB00913 (APRD00741),CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1,"Anesthetics / Anesthetics, General / Nervous System / Opioid Anesthetics / Piperidines",71Q1A3O279,144-14-9,D02941,8944.0,8600.0,,17933.0,61203.0,CHEMBL1201347,DAP001135,PA164768817,ZINC000000608179
Phenformin,phase 4 complete,DB00914 (APRD00511),NC(=N)NC(=N)NCCC1=CC=CC=C1,Alimentary Tract and Metabolism / Amidines / Biguanides / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Drugs Used in Diabetes / Guanidines / OCT1 inhibitors / OCT1 substrates / OCT2 Inhibitors,DD5K7529CE,114-86-3,D08351,8249.0,7953.0,50240908.0,8129.0,8064.0,CHEMBL170988,DAP000206,PA1000,ZINC000005851063
Amantadine,phase 4 complete,DB00915 (APRD00787),NC12CC3CC(CC(C3)C1)C2,"Adamantane Derivatives / Adamantanes / Analgesics / Analgesics, Non-Narcotic / Anti-Dyskinesia Agents / Anti-Infective Agents / Anti-Parkinson Drugs / Anticholinergic Agents / Antiviral Agents / Central Nervous System Agents / Cycloparaffins / Dopamine Agents / Drugs that are Mainly Renally Excreted / Influenza A M2 Protein Inhibitor / M2 Protein Inhibitors / Nervous System / Neurotransmitter Agents / Nicotinic Antagonists / NMDA Receptor Antagonists / OCT1 inhibitors / OCT1 substrates / OCT2 Inhibitors / OCT2 Substrates / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",BF4C9Z1J53,768-94-5,,2130.0,2045.0,50033369.0,620.0,2618.0,CHEMBL660,DAP000781,PA448360,ZINC000000968256
Metronidazole,phase 4 complete,DB00916 (APRD00631),CC1=NC=C(N1CCO)[N+]([O-])=O,"Agents that reduce seizure threshold / Alimentary Tract and Metabolism / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives and Antiseptics for Local Oral Treatment / Antiinfectives for Systemic Use / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Imidazole Derivatives / Imidazoles / Miscellaneous Antiprotozoals / Miscellaneous Local Anti-infectives / Nitro Compounds / Nitroimidazole Antimicrobial / Nitroimidazole Derivatives / Nitroimidazoles / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Stomatological Preparations / UGT1A1 Substrates",140QMO216E,443-48-1,D00409,4173.0,4029.0,50375309.0,6922.0,6909.0,CHEMBL137,DAP000534,PA450484,ZINC000000113442
Dinoprostone,phase 4 complete,DB00917 (APRD00927),CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,"Autacoids / Biological Factors / Dinoprostone, antagonists & inhibitors / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Genito Urinary System and Sex Hormones / Inflammation Mediators / Lipids / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Substrates / OCT1 inhibitors / OCT2 Inhibitors / Prostaglandins / Prostaglandins E / Prostaglandins, Synthetic / Reproductive Control Agents / Uterotonic agents",K7Q1JQR04M,363-24-6,D00079,5280360.0,4444059.0,35847.0,3478.0,15551.0,CHEMBL548,DAP000360,PA449345,ZINC000003830713
Almotriptan,phase 4 complete,DB00918 (APRD00169),CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2,"Agents that produce hypertension / Amines / Analgesics / Antidepressive Agents / Antimigraine Preparations / Biogenic Amines / Biogenic Monoamines / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Indoles / Migraine Disorders / Monoamine Oxidase A Substrates / Nervous System / Neurotransmitter Agents / Selective Serotonin 5-HT1 Receptor Agonists / Selective Serotonin Agonists / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 1b Receptor Agonists / Serotonin 1d Receptor Agonists / Serotonin 5-HT1 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists / Serotonin-1b and Serotonin-1d Receptor Agonist / Triptans",1O4XL5SN61,154323-57-6,,123606.0,110198.0,,279645.0,520985.0,CHEMBL1505,DAP001345,PA10246,ZINC000000018087
Spectinomycin,phase 4 complete,DB00919 (APRD01232),[H][C@@]12O[C@H](C)CC(=O)[C@]1(O)O[C@]1([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]1([H])O2,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Dioxanes / Glycosides / Heterocyclic Compounds, Fused-Ring",93AKI1U6QF,1695-77-8,,15541.0,14785.0,,270.0,9215.0,CHEMBL1167,DAP000403,PA164781342,ZINC000053006806
Ketotifen,phase 4 complete,DB00920 (APRD01061),CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=CC=CC=C12,Anti-Allergic Agents / Antihistamine Drugs / Antihistamines for Systemic Use / Antipruritics / Decongestants and Antiallergics / Dermatologicals / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Inhibitors / Neurotransmitter Agents / Ophthalmologicals / Other Antihistamines / Piperidines / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sensory Organs / Sulfur Compounds / Thiophenes,X49220T18G,34580-13-7,D01332,3827.0,3695.0,94597.0,6146.0,92511.0,CHEMBL534,DAP000329,PA450152,ZINC000000004351
Buprenorphine,phase 4 complete,DB00921 (APRD00670),CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,"Alkaloids / Analgesics / BCRP/ABCG2 Inhibitors / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs Used in Addictive Disorders / Drugs Used in Opioid Dependence / Heterocyclic Compounds, Fused-Ring / Mixed Agonist / Antagonist Opioids / Morphinans / Narcotics / Nervous System / Opiate Agonists / Opiate Alkaloids / Opiate Partial Agonists / Opioid Antagonists / Opioids / Oripavine Derivatives / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Phenanthrenes / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / UGT1A1 Substrates / UGT1A9 Substrates",40D3SCR4GZ,52485-79-7,D07132,644073.0,559124.0,50026603.0,1819.0,3216.0,CHEMBL560511,DAP001353,PA448685,ZINC000001319780
Levosimendan,phase 4 complete,DB00922 (APRD01296),C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1,"Antiarrhythmic agents / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Enzyme Inhibitors / Hydrazines / Hydrazones / Hypotensive Agents / Moderate Risk QTc-Prolonging Agents / Phosphodiesterase 3 Inhibitors / Phosphodiesterase Inhibitors / Protective Agents / Pyridazines / QTc Prolonging Agents / Vasodilating Agents",C6T4514L4E,141505-33-1,D04720,3033825.0,2298414.0,,73107.0,50567.0,CHEMBL2051955,DAP000797,PA164749138,ZINC000003915645
Ceforanide,phase 4 complete,DB00923 (APRD00853),[H][C@]12SCC(CSC3=NN=NN3CC(O)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1CN)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Second-Generation Cephalosporins / Sulfur Compounds / Thiazines",8M1YF8951V,60925-61-3,D00259,43507.0,39656.0,,20486.0,3495.0,CHEMBL1201046,DAP001175,PA164746057,ZINC000003830434
Cyclobenzaprine,phase 4 complete,DB00924 (APRD00213),CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12,"Agents that reduce seizure threshold / Antidepressive Agents / Benzocycloheptenes / Central Nervous System Agents / Central Nervous System Depressants / Centrally-mediated Muscle Relaxation / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dibenzocycloheptenes / Drugs causing inadvertant photosensitivity / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Musculo-Skeletal System / Neurotoxic agents / Photosensitizing Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents / UGT1A4 substrates",69O5WQQ5TI,303-53-7,D07758,2895.0,2792.0,112774.0,21949.0,3996.0,CHEMBL669,DAP000891,PA449160,ZINC000000968263
Phenoxybenzamine,phase 4 complete,DB00925 (APRD00651),CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1,Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Amines / Antihypertensive Agents / Cardiovascular Agents / Ethylamines / Hypotensive Agents / Neurotransmitter Agents / OCT1 inhibitors / OCT2 Inhibitors / Peripheral alpha-1 blockers / Peripheral Vasodilators / Vasodilating Agents,0TTZ664R7Z,59-96-1,,4768.0,4604.0,50017679.0,8149.0,8077.0,CHEMBL753,DAP000478,PA450919,
Famotidine,phase 4 complete,DB00927 (APRD00296),NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1,Acid Reducers / Alimentary Tract and Metabolism / Anti-Ulcer Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Gastric Acid Lowering Agents / Gastrointestinal Agents / Histamine Agents / Histamine Antagonists / Histamine H2 Antagonists / MATE 1 Inhibitors / MATE inhibitors / Neurotransmitter Agents / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OCT2 Inhibitors / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sulfur Compounds / Thiazoles,5QZO15J2Z8,76824-35-6,D00318,3325.0,3208.0,50036754.0,4278.0,4975.0,CHEMBL902,DAP000341,PA449586,ZINC000001530636
Azacitidine,phase 4 complete,DB00928 (APRD00809),NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,"Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Aza Compounds / Carbohydrates / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Glycosides / Immunosuppressive Agents / Myelosuppressive Agents / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Metabolic Inhibitor / Nucleosides / Pyrimidine Analogues / Pyrimidine Nucleosides / Pyrimidines / Ribonucleosides / Toxic Actions",M801H13NRU,320-67-2,D03021,9444.0,9072.0,50424715.0,1251.0,2038.0,CHEMBL1489,DAP000640,PA451996,ZINC000003861768
Misoprostol,phase 4 complete,"DB00929 (APRD00037, DB05379)",CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,"Abortifacient Agents / Abortifacient Agents, Nonsteroidal / Alimentary Tract and Metabolism / Anti-Ulcer Agents / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Autacoids / Biological Factors / Drugs causing inadvertant photosensitivity / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Gastrointestinal Agents / Genito Urinary System and Sex Hormones / Inflammation Mediators / Lipids / Musculo-Skeletal System / Photosensitizing Agents / Propionates / Prostaglandin E1 Analog / Prostaglandins / Prostaglandins E, Synthetic / Prostaglandins, Synthetic / Reproductive Control Agents / Uterotonic agents",0E43V0BB57,59122-46-2,D00419,5282381.0,4445541.0,85606.0,42331.0,63610.0,CHEMBL606,DAP000358,PA450523,
Colesevelam,phase 4 complete,DB00930 (APRD00883),,"Alkenes / Allyl Compounds / Allylamine / Amines / Anticholesteremic Agents / Bile Acid Sequestrants / Bile-acid Binding Activity / Hydrocarbons, Acyclic / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Noxae / Toxic Actions",1XU104G55N,182815-43-6,,,,,141626.0,,,,PA449095,
Metacycline,phase 4 complete,DB00931 (APRD00137),[H][C@@]12[C@@H](O)[C@]3([H])C(=C)C4=C(C(O)=CC=C4)C(=O)C3=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,Agents that produce neuromuscular block (indirect) / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Naphthacenes / Tetracyclines,IR235I7C5P,914-00-1,D04972,54675785.0,10468596.0,50046500.0,6812.0,6805.0,CHEMBL249837,DAP000883,PA164750512,ZINC000085650610
Tipranavir,phase 4 complete,DB00932 (APRD01306),[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O,Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Drugs causing inadvertant photosensitivity / Hepatotoxic Agents / HIV Protease Inhibitors / Hyperglycemia-Associated Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / Protease Inhibitors / Pyrans / UGT1A1 Inducers,ZZT404XD09,174484-41-4,,54682461.0,10482313.0,558.0,190548.0,63628.0,CHEMBL222559,DAP001085,PA163522473,ZINC000100016058
Mesoridazine,phase 4 complete,DB00933 (APRD00610),CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,"Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Moderate Risk QTc-Prolonging Agents / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Phenothiazines / Phenothiazines With Piperidine Structure / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Tranquilizing Agents",5XE4NWM740,5588-33-0,D02671,4078.0,3936.0,50131440.0,6779.0,6780.0,CHEMBL1088,DAP000252,PA450386,
Maprotiline,phase 4 complete,DB00934 (APRD00747),CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21,"Adrenergic Agents / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Agents that reduce seizure threshold / Anthracenes / Anticholinergic Agents / Antidepressive Agents / Antidepressive Agents, Second-Generation / Antidepressive Agents, Tetracyclic / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Histamine Antagonists / Histamine H1 Antagonists / Membrane Transport Modulators / Muscarinic Antagonists / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Non-Selective Monoamine Reuptake Inhibitors / Potential QTc-Prolonging Agents / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / Tricyclics and Other Norepinephrine-reuptake Inhibitors",2U1W68TROF,10262-69-8,D02566,4011.0,3871.0,35228.0,6646.0,6690.0,CHEMBL21731,DAP001150,PA450322,ZINC000001530688
Oxymetazoline,phase 4 complete,DB00935 (APRD01158),CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Autonomic Agents / Cardiovascular Agents / Decongestants and Antiallergics / Imidazoles / Increased Sympathetic Activity / Nasal Decongestants / Nasal Preparations / Neurotransmitter Agents / Ophthalmologicals / Peripheral Nervous System Agents / Respiratory System Agents / Sensory Organs / Sympathomimetics / Sympathomimetics Used as Decongestants / Sympathomimetics, Plain / Vasoconstriction / Vasoconstrictor Agents",8VLN5B44ZY,1491-59-4,,4636.0,4475.0,30712.0,7812.0,7862.0,CHEMBL762,DAP000235,PA164748840,ZINC000000057435
Salicylic acid,phase 4 complete,"DB00936 (APRD01605, DB01398)",OC(=O)C1=CC=CC=C1O,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Infective Agents / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Benzene Derivatives / Benzoates / Central Nervous System Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Enzyme Inhibitors / Hydroxy Acids / Hydroxybenzoates / Keratolytic Agents / Nephrotoxic agents / Nervous System / Nitrogen Binding Agent / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Ophthalmologicals / Peripheral Nervous System Agents / Phenols / Salicylates / Salicylic Acid and Derivatives / Sclerosing Solutions / Sensory Organs / Sensory System Agents",O414PZ4LPZ,69-72-7,D00097,338.0,331.0,26193.0,9525.0,16914.0,CHEMBL424,DAP000731,PA451299,ZINC000000001554
Diethylpropion,phase 4 complete,DB00937 (APRD00919),CCN(CC)C(C)C(=O)C1=CC=CC=C1,"Agents producing tachycardia / Agents that produce hypertension / Alimentary Tract and Metabolism / Amines / Amphetamines / Anti-Obesity Agents / Antiobesity Preparations, Excl. Diet Products / Appetite Depressants / Appetite Suppression / Central Nervous System Depressants / Centrally Acting Antiobesity Products / Ethylamines / Increased Sympathetic Activity / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Stimulants / Sympathomimetic Amine Anorectic / Sympathomimetics",Q94YYU22B8,90-84-6,D07444,7029.0,6762.0,,3389.0,4530.0,CHEMBL1194666,DAP001452,PA164778098,
Salmeterol,phase 4 complete,DB00938 (APRD00277),OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics, Inhalants / Agents Causing Muscle Toxicity / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Ethanolamines / Ethylamines / Neurotransmitter Agents / OCT1 inhibitors / OCT1 substrates / OCT2 Inhibitors / Peripheral Nervous System Agents / Phenethylamines / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Respiratory System Agents / Selective Beta 2-adrenergic Agonists / Sympathomimetic (Adrenergic) Agents",2I4BC502BT,89365-50-4,D05792,5152.0,4968.0,25771.0,36117.0,64064.0,CHEMBL1263,DAP000947,PA451300,
Meclofenamic acid,phase 4 complete,DB00939 (APRD01090),CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Amines / Aminobenzoates / Analgesics / Analgesics, Non-Narcotic / Aniline Compounds / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antirheumatic Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Cyclooxygenase Inhibitors / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Fenamates / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / ortho-Aminobenzoates / Peripheral Nervous System Agents / Sensory System Agents / Thyroxine-binding globulin substrates / Topical Products for Joint and Muscular Pain",48I5LU4ZWD,644-62-2,D02341,4037.0,3897.0,22971.0,6678.0,6710.0,CHEMBL509,DNC000919,PA450341,ZINC000000001655
Methantheline,phase 4 complete,DB00940 (APRD00751),CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12,"Acid Reducers / Agents producing tachycardia / Alimentary Tract and Metabolism / Amines / Ammonium Compounds / Anticholinergic Agents / Cholinergic Agents / Drugs for Functional Gastrointestinal Disorders / Gastric Acid Lowering Agents / Histamine Antagonists / Histamine H2 Antagonists / Muscarinic Antagonists / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Quaternary Ammonium Compounds / Synthetic Anticholinergics, Quaternary Ammonium Compounds",36EI79TX7I,5818-17-7,,4097.0,3955.0,,6821.0,6817.0,CHEMBL1201264,DAP001109,PA164747037,ZINC000001530932
Hexafluronium,phase 4 complete,DB00941 (APRD01013),C[N+](C)(CCCCCC[N+](C)(C)C1C2=C(C=CC=C2)C2=C1C=CC=C2)C1C2=C(C=CC=C2)C2=C1C=CC=C2,"Amines / Ammonium Compounds / Anticholinergic Agents / Bis-Trimethylammonium Compounds / Central Nervous System Depressants / Cholinergic Agents / Cholinesterase Inhibitors / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neurotransmitter Agents / Nicotinic Antagonists / Nitrogen Compounds / Onium Compounds / Quaternary Ammonium Compounds",55W5L6G81R,4844-10-4,D04435,3601.0,3475.0,,26826.0,135804.0,CHEMBL1201349,DAP000963,PA164743020,ZINC000001566899
Cycrimine,phase 4 complete,DB00942 (APRD00731),OC(CCN1CCCCC1)(C1CCCC1)C1=CC=CC=C1,Agents producing tachycardia / Anticholinergic Agents / Muscarinic Antagonists,543567RFQQ,77-39-4,,2911.0,2808.0,,22037.0,59692.0,CHEMBL1201227,DAP001120,PA164749387,
Zalcitabine,phase 4 complete,DB00943 (APRD00562),NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,"Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antimetabolites / Antiviral Agents / Antivirals for Systemic Use / Carbohydrates / Deoxycytidine / Deoxyribonucleosides / Dideoxynucleosides / Direct Acting Antivirals / Enzyme Inhibitors / Glycosides / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / Nucleoside Reverse Transcriptase Inhibitors / Nucleosides / OAT1/SLC22A6 Substrates / Pyrimidine Nucleosides / Pyrimidines / Reverse Transcriptase Inhibitors / Ribonucleosides / Toxic Actions",6L3XT8CB3I,7481-89-2,D00412,24066.0,22498.0,50145605.0,3363.0,10101.0,CHEMBL853,DNC000527,PA451950,ZINC000000039906
Demecarium,phase 4 complete,DB00944 (APRD00905),CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,Amines / Ammonium Compounds / Antiglaucoma Preparations and Miotics / Cholinergic Agents / Cholinesterase Inhibitors / Enzyme Inhibitors / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Ophthalmologicals / Parasympathomimetics / Sensory Organs,ILP8XJ8R5K,16505-84-3,D00667,5966.0,5751.0,,107771.0,59719.0,CHEMBL1201229,DAP000894,PA164745610,ZINC000003875376
Acetylsalicylic acidCommonly known or available as Aspirin,phase 4 complete,"DB00945 (APRD00264, EXPT00475)",CC(=O)OC1=CC=CC=C1C(O)=O,"Acids, Carbocyclic / Agents causing angioedema / Agents causing hyperkalemia / Agents that produce hypertension / Alimentary Tract and Metabolism / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Anticoagulants / Antiinflammatory and Antirheumatic Products / Antiplatelet agents / Antipyretics / Benzene Derivatives / Blood and Blood Forming Organs / Cardiovascular Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Decreased Platelet Aggregation / Decreased Prostaglandin Production / Drugs that are Mainly Renally Excreted / Hematologic Agents / Hydroxybenzoates / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / P-glycoprotein inducers / P-glycoprotein substrates / Peripheral Nervous System Agents / Platelet Aggregation Inhibitors Excl. Heparin / Salicylates / Salicylic Acid and Derivatives / Sensory System Agents / Stomatological Preparations / UGT1A6 substrate",R16CO5Y76E,50-78-2,D00109,2244.0,2157.0,22360.0,1191.0,15365.0,CHEMBL25,DAP000843,PA448497,ZINC000000000053
Phenprocoumon,phase 4 complete,DB00946 (APRD00228),CCC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,"4-Hydroxycoumarins / Anticoagulants / Benzopyrans / Blood and Blood Forming Organs / Coumarins / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / Pyrans / Vitamin K Antagonists / Vitamin K Inhibitors",Q08SIO485D,435-97-2,D05457,54680692.0,10441592.0,768.0,8150.0,50438.0,CHEMBL1465,DAP000771,PA450921,
Fulvestrant,phase 4 complete,DB00947 (APRD00654),[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H],"Anti-Estrogens / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Endocrine Therapy / Estradiol Congeners / Estranes / Estrenes / Estrogen Antagonists / Estrogen Receptor Antagonists / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Selective Estrogen Receptor Modulators / Steroids / UGT1A1 Substrates",22X328QOC4,129453-61-8,D01161,17756771.0,94553.0,50238741.0,282357.0,31638.0,CHEMBL1358,DAP000319,PA164747170,
Mezlocillin,phase 4 complete,DB00948 (APRD01113),[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillin G / Penicillins / Penicillins With Extended Spectrum / Sulfur Compounds",OH2O403D1G,51481-65-3,D05021,656511.0,570894.0,,6927.0,6919.0,CHEMBL1731,DAP001180,PA164750540,ZINC000003831120
Felbamate,phase 4 complete,DB00949 (APRD00505),NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,"Acids, Acyclic / Alcohols / Anti-epileptic Agent / Anticonvulsants / Carbamates / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Excitatory Amino Acid Agents / Excitatory Amino Acid Antagonists / Glycols / Nervous System / Neurotransmitter Agents / NMDA Receptor Antagonists / Phenylcarbamates / Potential QTc-Prolonging Agents / Propylene Glycols / QTc Prolonging Agents",X72RBB02N8,25451-15-4,D00536,3331.0,3214.0,50088430.0,24812.0,4995.0,CHEMBL1094,DAP000093,PA449590,ZINC000001530803
Fexofenadine,phase 4 complete,DB00950 (APRD00349),CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,"Anti-Allergic Agents / Antihistamines for Systemic Use / Benzene Derivatives / Benzhydryl Compounds / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Neurotransmitter Agents / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / Piperidines",E6582LOH6V,83799-24-0,D07958,3348.0,3231.0,22874.0,87636.0,5050.0,CHEMBL914,DAP000330,PA449621,
Isoniazid,phase 4 complete,"DB00951 (APRD01055, EXPT01940)",NNC(=O)C1=CC=NC=C1,Agents Causing Muscle Toxicity / Agents that reduce seizure threshold / Anti-Bacterial Agents / Anti-Infective Agents / Antiinfectives for Systemic Use / Antimycobacterials / Antituberculosis Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (moderate) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Treatment of Tuberculosis / Drugs that are Mainly Renally Excreted / Fatty Acid Synthesis Inhibitors / Hepatotoxic Agents / Hydrazides / Hydrazines / Hypolipidemic Agents / Isonicotinic Acids / Lipid Regulating Agents / Noxae / Pyridines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Toxic Actions,V83O1VOZ8L,54-85-3,D00346,3767.0,3635.0,50336507.0,6038.0,6030.0,CHEMBL64,DAP000011,PA450112,ZINC000000001590
Naratriptan,phase 4 complete,DB00952 (APRD00220),CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1,"Agents that produce hypertension / Amines / Analgesics / Antidepressive Agents / Antimigraine Preparations / Biogenic Amines / Biogenic Monoamines / Cardiovascular Agents / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Indoles / Monoamine Oxidase A Substrates / Nervous System / Neurotransmitter Agents / Selective Serotonin 5-HT1 Receptor Agonists / Selective Serotonin Agonists / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 1b Receptor Agonists / Serotonin 1d Receptor Agonists / Serotonin 5-HT1 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists / Serotonin-1b and Serotonin-1d Receptor Agonist / Triptans / Vasoconstrictor Agents",QX3KXL1ZA2,121679-13-8,D08255,4440.0,4287.0,50073682.0,141366.0,7478.0,CHEMBL1278,DAP000890,PA450597,ZINC000000004076
Rizatriptan,phase 4 complete,DB00953 (APRD00008),CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2,"Agents that produce hypertension / Amines / Analgesics / Antidepressive Agents / Antimigraine Preparations / Biogenic Amines / Biogenic Monoamines / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Indoles / Migraine Disorders / Monoamine Oxidase A Substrates / Nervous System / Neurotransmitter Agents / Selective Serotonin 5-HT1 Receptor Agonists / Selective Serotonin Agonists / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 1b Receptor Agonists / Serotonin 1d Receptor Agonists / Serotonin 5-HT1 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists / Serotonin-1b and Serotonin-1d Receptor Agonist / Triptans",51086HBW8G,144034-80-0,D00675,5078.0,4900.0,50033437.0,88014.0,48273.0,CHEMBL905,DAP000220,PA451264,ZINC000000005895
Netilmicin,phase 4 complete,DB00955 (APRD00232),CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O,Agents that produce neuromuscular block (indirect) / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Enzyme Inhibitors / Gentamicins / Glycosides / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Ophthalmologicals / Protein Synthesis Inhibitors / Sensory Organs,4O5J85GJJB,56391-56-1,D08268,441306.0,20152952.0,,7337.0,7528.0,CHEMBL1572,DAP000404,PA164754913,ZINC000052981502
Hydrocodone,phase 4 complete,"DB00956 (APRD00591, DB09475)",[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,"Alkaloids / Analgesics / Antitussive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cough and Cold Preparations / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Morphinans / Morphine Derivatives / Narcotics / Opiate Alkaloids / Opioid Agonist / Opioids / Opium Alkaloids and Derivatives / Peripheral Nervous System Agents / Respiratory System Agents / Semi-synthetic Opioids / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",6YKS4Y3WQ7,125-29-1,D08045,5284569.0,4447623.0,50386689.0,5489.0,5779.0,CHEMBL1457,DAP000253,PA449900,ZINC000001280665
Norgestimate,phase 4 complete,DB00957 (APRD00569),[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O,"Adrenal Cortex Hormones / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptives, Oral / Contraceptives, Oral, Synthetic / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hyperglycemia-Associated Agents / Norpregnanes / Norpregnenes / Norsteroids / P-glycoprotein inhibitors / Progestin Contraceptives / Progestins / Progestogens and Estrogens, Sequential Preparations / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids / UGT1A1 Substrates",C291HFX4DY,35189-28-7,D05209,6540478.0,5022837.0,,31994.0,50815.0,CHEMBL1200934,DAP001210,PA164744346,ZINC000003938695
Carboplatin,phase 4 complete,DB00958 (APRD00466),[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H],"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Compounds used in a research, industrial, or household setting / Cross-Linking Reagents / Drugs that are Mainly Renally Excreted / Immunosuppressive Agents / Indicators and Reagents / Laboratory Chemicals / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Organometallic Compounds / Platinum Compounds",BG3F62OND5,41575-94-4,D01363,38904.0,8514637.0,,40048.0,31355.0,CHEMBL1351,DAP000535,PA448803,
Methylprednisolone,phase 4 complete,DB00959 (APRD00342),[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Adrenals / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anti-Inflammatory Agents / Antiemetics / Antineoplastic Agents / Autonomic Agents / Central Nervous System Agents / Compounds used in a research, industrial, or household setting / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids for Systemic Use / Corticosteroids for Systemic Use, Plain / Corticosteroids, Dermatological Preparations / Corticosteroids, Weak (Group I) / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Experimental Unapproved Treatments for COVID-19 / Fused-Ring Compounds / Gastrointestinal Agents / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Neuroprotective Agents / Ophthalmologicals / P-glycoprotein inducers / P-glycoprotein substrates / Peripheral Nervous System Agents / Pregnadienes / Pregnadienetriols / Pregnanes / Protective Agents / Sensory Organs / Steroids / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",X4W7ZR7023,83-43-2,D00407,6741.0,6485.0,50103616.0,6902.0,6888.0,CHEMBL650,DAP001040,PA450466,ZINC000003875560
Pindolol,phase 4 complete,DB00960 (APRD00678),CC(C)NCC(O)COC1=CC=CC2=C1C=CN2,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antidepressive Agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Beta Blocking Agents, Non-Selective / Bradycardia-Causing Agents / Cardiovascular Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Neurotransmitter Agents / Phenoxypropanolamines / Propanolamines / Propanols / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Vasodilating Agents",BJ4HF6IU1D,13523-86-9,D00513,4828.0,4662.0,50019443.0,8332.0,8214.0,CHEMBL500,DAP000025,PA450966,
Mepivacaine,phase 4 complete,DB00961 (APRD01094),CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C,"Amides / Anesthetics / Anesthetics, Local / Central Nervous System Agents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Local Anesthesia / Local Anesthetics (Amide) / Nervous System / Peripheral Nervous System Agents / Piperidines / Sensory System Agents",B6E06QE59J,96-88-8,D08181,4062.0,3922.0,50417964.0,6759.0,6759.0,CHEMBL1087,DAP001232,PA164748741,
Zaleplon,phase 4 complete,DB00962 (APRD00411),CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N,"Acetates / Acids, Acyclic / Amides / Anticonvulsants / Benzodiazepine hypnotics and sedatives / Central Nervous System Agents / Central Nervous System Depressants / Central Nervous System Depression / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fatty Acids / Fatty Acids, Volatile / GABA Agents / GABA Agonists / GABA Modulators / GABA-A Receptor Agonists / gamma-Aminobutyric Acid A Receptor Agonist / Hypnotics (Nonbenzodiazepine) / Hypnotics and Sedatives / Lipids / Miscellaneous Anxiolytics Sedatives and Hypnotics / Nervous System / Neurotransmitter Agents / Psycholeptics",S62U433RMH,151319-34-5,D00530,5719.0,5517.0,86521.0,74667.0,10102.0,CHEMBL1521,DAP000266,PA451952,ZINC000000006300
Bromfenac,phase 4 complete,DB00963 (APRD00831),NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1,"Agents causing hyperkalemia / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antirheumatic Agents / Benzene Derivatives / Central Nervous System Agents / Cyclooxygenase Inhibitors / Hydrocarbons, Brominated / Hydrocarbons, Halogenated / Ketones / Nephrotoxic agents / Ophthalmologicals / Peripheral Nervous System Agents / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory Organs / Sensory System Agents",864P0921DW,91714-94-2,D07541,60726.0,54730.0,50248104.0,19737.0,240107.0,CHEMBL1077,DAP000732,PA448670,ZINC000002570817
Apraclonidine,phase 4 complete,DB00964 (APRD00012),NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Antiglaucoma Preparations and Miotics / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / EENT Drugs, Miscellaneous / Hypotensive Agents / Imidazoles / Imidazolines / Neurotransmitter Agents / Ophthalmics / Ophthalmologicals / Sensory Organs / Sympathomimetics in Glaucoma Therapy",843CEN85DI,66711-21-5,,2216.0,2130.0,50021812.0,14845.0,2788.0,CHEMBL647,DAP000236,PA164748866,ZINC000000020231
Ethiodized oil,phase 4 complete,DB00965 (APRD00960),,"Biological Products / Complex Mixtures / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Iodinated Contrast Agents / Iodized Oil / Lipids / Oils / Plant Oils / Plant Preparations / Radiographic Contrast Agent / Roentgenography / X-Ray Contrast Activity",KZW0R0686Q,8008-53-5,D04082,,,,4125.0,,CHEMBL1201458,,PA164768833,
Telmisartan,phase 4 complete,DB00966 (APRD01247),CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O,"Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Angiotensin 2 Receptor Blocker / Angiotensin II receptor blockers (ARBs) and calcium channel blockers / Angiotensin II receptor blockers (ARBs) and diuretics / Angiotensin II receptor blockers (ARBs), plain / Angiotensin II Type 1 Receptor Blockers / Angiotensin II Type 2 Receptor Blockers / Angiotensin Receptor Antagonists / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / BCRP/ABCG2 Inhibitors / Benzene Derivatives / Benzimidazoles / Biphenyl Compounds / BSEP/ABCB11 Substrates / Cardiovascular Agents / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / P-glycoprotein inhibitors / UGT1A3 substrates",U5SYW473RQ,144701-48-4,D00627,65999.0,59391.0,50043280.0,73494.0,9434.0,CHEMBL1017,DAP000766,PA451605,ZINC000001530886
Desloratadine,phase 4 complete,DB00967 (APRD00324),ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1,"Anticholinergic Agents / Antihistamines for Systemic Use / Benzocycloheptenes / Central Nervous System Depressants / Cholinergic Agents / Dibenzocycloheptenes / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Loratadine and prodrug / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / P-glycoprotein inhibitors / Piperidines / QTc Prolonging Agents",FVF865388R,100643-71-8,D03693,124087.0,110575.0,50073179.0,275635.0,291342.0,CHEMBL1172,DAP000331,PA164776964,ZINC000000001261
Methyldopa,phase 4 complete,DB00968 (APRD01106),C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents Causing Muscle Toxicity / Amines / Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Aromatic L-amino Acid Decarboxylase Inhibitors / Autonomic Agents / Benzene Derivatives / Bradycardia-Causing Agents / Cardiovascular Agents / Catecholamines / Catechols / Central alpha-2 Adrenergic Agonist / Central Alpha-agonists / COMT Substrates / Dihydroxyphenylalanine / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hypotensive Agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenols / Phenylalanine / Sympatholytics",M4R0H12F6M,555-30-6,D08205,38853.0,35562.0,48449.0,1545996.0,61058.0,CHEMBL459,DAP000226,PA450453,ZINC000000020255
Alosetron,phase 4 complete,DB00969 (APRD00580),CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2,"Alimentary Tract and Metabolism / Antidepressive Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (moderate) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Functional Gastrointestinal Disorders / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Indoles / Neurotransmitter Agents / Pyridines / Serotonin 3 Receptor Antagonists / Serotonin 5-HT3 Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists",13Z9HTH115,122852-42-0,D07129,2099.0,2015.0,50014558.0,85248.0,253342.0,CHEMBL1110,DAP000369,PA164745502,ZINC000013537284
Dactinomycin,phase 4 complete,DB00970 (APRD00124),[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C,"Actinomycin / Actinomycines / Amino Acids, Peptides, and Proteins / Anti-Infective Agents / Antibiotics, Antineoplastic / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Cytotoxic Antibiotics and Related Substances / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Myelosuppressive Agents / Nucleic Acid Synthesis Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Peptides / Peptides, Cyclic / Protein Synthesis Inhibitors",1CC1JFE158,50-76-0,D00214,457193.0,10482167.0,43866.0,3100.0,27666.0,CHEMBL1554,DNC000380,PA151917012,
Selenium Sulfide,phase 4 complete,DB00971 (APRD01323),S=[Se]=S,Antifungals for Dermatological Use / Antifungals for Topical Use / Dermatologicals / Selenium Compounds,Z69D9E381Q,7488-56-4,,24087.0,22519.0,,36345.0,135934.0,CHEMBL1200680,,PA164771240,
Azelastine,phase 4 complete,DB00972 (APRD00813),CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O,"Anti-Allergic Agents / Antiallergic Agents, Excl. Corticosteroids / Antihistamines for Systemic Use / Autonomic Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decongestants and Antiallergics / Enzyme Inhibitors / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Nasal Preparations / Neurotransmitter Agents / Ophthalmologicals / P-glycoprotein inhibitors / Pyridazines / Respiratory System Agents / Sensory Organs",ZQI909440X,58581-89-8,D07483,2267.0,2180.0,50341448.0,18603.0,2950.0,CHEMBL639,DNC000270,PA448517,
Ezetimibe,phase 4 complete,DB00973 (APRD00619),[H][C@]1(CC[C@H](O)C2=CC=C(F)C=C2)C(=O)N(C2=CC=C(F)C=C2)[C@]1([H])C1=CC=C(O)C=C1,"Anticholesteremic Agents / Azetines / BCRP/ABCG2 Substrates / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Decreased Cholesterol Absorption / Dietary Cholesterol Absorption Inhibitor / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / OATP1B1/SLCO1B1 Substrates / P-glycoprotein substrates / UGT1A1 Substrates / UGT1A3 substrates / UGT2B7 substrates",EOR26LQQ24,163222-33-1,D01966,150311.0,132493.0,50371521.0,341248.0,49040.0,CHEMBL1138,DAP000717,PA10816,ZINC000003810860
Edetic acid,phase 4 complete,DB00974 (APRD01327),OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O,"Acetates / Acids, Acyclic / Amines / Anticoagulants / Calcium Chelating Activity / Calcium Chelating Agents / Chelating Agents / Compounds used in a research, industrial, or household setting / Decreased Coagulation Factor Activity / Diamines / Diet, Food, and Nutrition / Ethylenediamines / Fatty Acids / Fatty Acids, Volatile / Food / Food Additives / Food and Beverages / Food Ingredients / Heavy Metal Antagonists / Hematologic Agents / Lead Chelating Activity / Lead Chelator / Physiological Phenomena / Polyamines / Sequestering Agents",9G34HU7RV0,60-00-4,D00052,6049.0,5826.0,50330325.0,1370600.0,42191.0,CHEMBL858,DNC000594,PA449439,ZINC000019364242
Dipyridamole,phase 4 complete,DB00975 (APRD00360),OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1,Anticoagulants / Antiplatelet agents / Blood and Blood Forming Organs / BSEP/ABCB11 Substrates / Cardiovascular Agents / Decreased Platelet Aggregation / Enzyme Inhibitors / Hematologic Agents / Hypotensive Agents / Miscellaneous Vasodilatating Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Phosphodiesterase 5 Inhibitors / Phosphodiesterase Inhibitors / Platelet Aggregation Inhibitors Excl. Heparin / Pyrimidines / Vasodilating Agents,64ALC7F90C,58-32-2,D00302,3108.0,2997.0,23620.0,3521.0,4653.0,CHEMBL932,DNC001625,PA449367,ZINC000000643046
Telithromycin,phase 4 complete,DB00976 (APRD00483),[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Erythromycin and similars / Ketolide Antibacterial / Ketolides / Lactones / Macrolides / Macrolides, Lincosamides and Streptogramins / Moderate Risk QTc-Prolonging Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Polyketides / Protein Synthesis Inhibitors / QTc Prolonging Agents / RNA, Ribosomal, 23S",KI8H7H19WL,191114-48-4,D01078,3002190.0,2273373.0,50378137.0,274786.0,29688.0,CHEMBL1136,DAP000109,PA10202,ZINC000009574770
Ethinylestradiol,phase 4 complete,DB00977 (APRD00691),[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,"Adrenal Cortex Hormones / Antineoplastic and Immunomodulating Agents / BSEP/ABCB11 inducers / BSEP/ABCB11 Inhibitors / COMT Substrates / Contraceptive Agents, Female / Contraceptives, Oral / Contraceptives, Postcoital / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Endocrine Therapy / Estradiol Congeners / Estrogen Contraceptives / Estrogenic Steroids, Alkylated / Estrogens / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Natural and Semisynthetic Estrogens, Plain / Norpregnanes / Norpregnatrienes / Norsteroids / P-glycoprotein substrates / Progestogens and Estrogens, Sequential Preparations / Sex Hormones and Modulators of the Genital System / Steroids / Thyroxine-binding globulin inducers / UGT1A1 Inducers / UGT1A1 Substrates / UGT1A4 substrates / UGT1A9 Substrates / UGT2B7 substrates",423D2T571U,57-63-6,D00554,5991.0,5770.0,50187243.0,4124.0,4903.0,CHEMBL691,DAP001018,PA449527,ZINC000003812897
Lomefloxacin,phase 4 complete,DB00978 (APRD01076),CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Moderate Risk QTc-Prolonging Agents / Ophthalmologicals / Photosensitizing Agents / QTc Prolonging Agents / Quinolines / Quinolones / Sensory Organs / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",L6BR2WJD8V,98079-51-7,D02318,3948.0,3811.0,50417952.0,28872.0,116278.0,CHEMBL561,DAP000653,PA164749165,
Cyclopentolate,phase 4 complete,DB00979 (APRD00893),CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,"Acids, Carbocyclic / Anticholinergic Agents / Autonomic Agents / Cholinergic Agents / Cholinesterase substrates / Muscarinic Antagonists / Mydriatics / Mydriatics and Cycloplegics / Neurotransmitter Agents / Ophthalmologicals / Parasympatholytics / Peripheral Nervous System Agents / Phenylacetates / Sensory Organs",I76F4SHP7J,512-15-2,,2905.0,2802.0,82375.0,3001.0,4024.0,CHEMBL1201338,DAP001111,PA164743019,
Ramelteon,phase 4 complete,DB00980 (APRD01213),CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2,Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypnotics and Sedatives / Melatonin Receptor Agonists / Nervous System / Psycholeptics,901AS54I69,196597-26-9,,208902.0,181000.0,50118470.0,596205.0,109549.0,CHEMBL1218,DAP000070,PA164744896,ZINC000003960338
Physostigmine,phase 4 complete,DB00981 (APRD00406),[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C,"Acids, Acyclic / Alkaloids / Antidotes / Antiglaucoma Preparations and Miotics / Autonomic Agents / Carbamates / Cholinergic Agents / Cholinesterase Inhibitors / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Indole Alkaloids / Indoles / Miotics / Neurotransmitter Agents / Ophthalmologicals / Parasympathomimetics / Peripheral Nervous System Agents / Phenylcarbamates / Sensory Organs",9U1VM840SP,57-47-6,D00196,5983.0,5763.0,50222010.0,8299.0,27953.0,CHEMBL94,DAP000561,PA450957,ZINC000091689892
Isotretinoin,phase 4 complete,DB00982 (APRD00140),C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O,"Agents Causing Muscle Toxicity / Alkenes / Anti-Acne Preparations / Anti-Acne Preparations for Systemic Use / Anti-Acne Preparations for Topical Use / Biological Factors / Carotenoids / Cyclohexanes / Cyclohexenes / Cycloparaffins / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Hydrocarbons, Acyclic / Misc. Skin and Mucous Membrane Agents / Narrow Therapeutic Index Drugs / Noxae / Photosensitizing Agents / Pigments, Biological / Polyenes / Retinoids / Retinoids for Topical Use in Acne / Retinoids for Treatment of Acne / Teratogens / Terpenes / Toxic Actions",EH28UP18IF,4759-48-2,D00348,5282379.0,4445539.0,50031459.0,6064.0,6067.0,CHEMBL547,DAP000009,PA450128,ZINC000003792789
Formoterol,phase 4 complete,DB00983 (APRD00641),COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Ethanolamines / OCT1 inhibitors / OCT1 substrates / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Respiratory System Agents / Selective Beta 2-adrenergic Agonists / UGT1A9 Substrates / UGT2B7 substrates",5ZZ84GCW8B,73573-87-2,D07990,3410.0,3292.0,86453.0,25255.0,63082.0,CHEMBL1256786,DAP000247,PA134687907,
Nandrolone phenpropionate,phase 4 complete,DB00984 (APRD00134),[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],"Anabolic Agents / Androgens / Estranes / Estrenes / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Nandrolone and esters / Steroids / Testosterone Congeners / Thyroxine-binding globulin inhibitors",KF7Z9K2T3W,62-90-8,D00956,229455.0,199761.0,,31495.0,7468.0,CHEMBL1200412,DAP000903,PA164746281,ZINC000003881613
Dimenhydrinate,phase 4 complete,DB00985 (APRD00924),CN1C2=C(N=C(Cl)N2)C(=O)N(C)C1=O.CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,"Alkaloids / Amines / Antiemetics / Autonomic Agents / Benzene Derivatives / Benzhydryl Compounds / Central Nervous System Agents / Central Nervous System Depressants / Ethanolamine Derivatives / Ethylamines / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Pharmaceutical Preparations / Purines / Purinones / QTc Prolonging Agents",JB937PER5C,523-87-5,D00520,441281.0,10210.0,,3444.0,94848.0,CHEMBL1200406,DAP000333,PA449338,
Glycopyrronium,phase 4 complete,"DB00986 (APRD01000, DB06583)",C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1,"Adjuvants, Anesthesia / Adrenergics, Inhalants / Agents producing tachycardia / Alimentary Tract and Metabolism / Amines / Ammonium Compounds / Anticholinergic Agents / Antimuscarinics Antispasmodics / Central Nervous System Agents / Cholinergic Agents / Drugs for Functional Gastrointestinal Disorders / Drugs for Obstructive Airway Diseases / Muscarinic Antagonists / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Pyrrolidines / Quaternary Ammonium Compounds / Synthetic Anticholinergics, Quaternary Ammonium Compounds",A14FB57V1D,740028-90-4,D00540,9933193.0,3374.0,50417445.0,1546438.0,94449.0,CHEMBL1201335,DAP001116,PA164754882,
Cytarabine,phase 4 complete,DB00987 (APRD00499),NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,"Agents Causing Muscle Toxicity / Anti-Infective Agents / Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Arabinonucleosides / Carbohydrates / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Glycosides / Immunologic Factors / Immunosuppressive Agents / Myelosuppressive Agents / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Metabolic Inhibitor / Nucleosides / OCT1 substrates / Pyrimidine Analogues / Pyrimidine Nucleosides / Pyrimidines / Ribonucleosides / Toxic Actions",04079A1RDZ,147-94-4,D00168,6253.0,6017.0,50087289.0,3041.0,28680.0,CHEMBL803,DNC001551,PA449177,ZINC000003795098
Dopamine,phase 4 complete,DB00988 (APRD00085),NCCC1=CC(O)=C(O)C=C1,"Adrenergic and Dopaminergic Agents / Agents producing tachycardia / Agents that produce hypertension / Amines / Autonomic Agents / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Catecholamines / Catechols / Compounds used in a research, industrial, or household setting / COMT Substrates / Dopamine Agents / Dopamine, metabolism / Drugs that are Mainly Renally Excreted / Monoamine Oxidase A Substrates / Neurotransmitter Agents / OCT1 substrates / OCT2 Inhibitors / OCT2 Substrates / Peripheral Nervous System Agents / Phenols / Protective Agents / Selective Beta 1-adrenergic Agonists / Sympathomimetics",VTD58H1Z2X,51-61-6,D07870,681.0,661.0,55121.0,3628.0,18243.0,CHEMBL59,DAP000212,PA449396,ZINC000000033882
Rivastigmine,phase 4 complete,DB00989 (APRD00321),CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,"Acids, Acyclic / Anti-Dementia Drugs / Bradycardia-Causing Agents / Carbamates / Central Nervous System Agents / Cholinergic Agents / Cholinesterase Inhibitors / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Nervous System / Neuroprotective Agents / Neurotransmitter Agents / Parasympathomemetic (Cholinergic) Agents / Phenylcarbamates / Protective Agents / Psychoanaleptics",PKI06M3IW0,123441-03-2,D03822,77991.0,70377.0,10620.0,183379.0,8874.0,CHEMBL636,DAP000149,PA451262,ZINC000000004413
Exemestane,phase 4 complete,DB00990 (APRD00144),[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C,"Androstanes / Androstenes / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Aromatase Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Endocrine Therapy / Enzyme Inhibitors / Estrogen Antagonists / Fused-Ring Compounds / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Steroid Synthesis Inhibitors / Steroids",NY22HMQ4BX,107868-30-4,D00963,60198.0,54278.0,50398447.0,258494.0,4953.0,CHEMBL1200374,DAP000625,PA449563,ZINC000003973334
Oxaprozin,phase 4 complete,DB00991 (APRD00030),OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1,"Acids, Acyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / Cyclooxygenase Inhibitors / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Fatty Acids / Fatty Acids, Volatile / Lipids / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Other Nonsteroidal Anti-inflammatory Agents / Oxazoles / Peripheral Nervous System Agents / Photosensitizing Agents / Propionates / Sensory System Agents",MHJ80W9LRB,21256-18-8,D00463,4614.0,4453.0,50002861.0,32613.0,7822.0,CHEMBL1071,DAP000622,PA450730,ZINC000049643479
Methyl aminolevulinate,phase 4 complete,DB00992 (APRD01105),COC(=O)CCC(=O)CN,"Amino Acids / Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Dermatologicals / Keto Acids / Levulinic Acids / Misc. Skin and Mucous Membrane Agents / Photochemotherapy / Photosensitizing Agents / Photosensitizing agents used for phototherapy / Porphyrin Precursor / Radiation-Sensitizing Agents / Sensitizers Used in Photodynamic/radiation Therapy",585NM85KYM,33320-16-0,D08204,157922.0,138950.0,,337068.0,724125.0,CHEMBL1096562,DAP001024,PA164784028,ZINC000001909090
Azathioprine,phase 4 complete,DB00993 (APRD00811),CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O,"Antimetabolites / Antineoplastic and Immunomodulating Agents / Antirheumatic Agents / Carbohydrates / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Glycosides / Heterocyclic Compounds, Fused-Ring / Immunologic Factors / Immunosuppressive Agents / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / P-glycoprotein substrates / Purine Antimetabolite / Purines / Sulfhydryl Compounds / Sulfur Compounds / Thionucleosides / Thiopurine Analogs / Toxic Actions",MRK240IY2L,446-86-6,D00238,2265.0,2178.0,50373919.0,1256.0,2948.0,CHEMBL1542,DAP000782,PA448515,ZINC000004258316
Neomycin,phase 4 complete,DB00994 (APRD00013),,"Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antibiotics for Topical Use / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antiinfectives and Antiseptics for Local Oral Treatment / Antiinfectives for Systemic Use / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Carbohydrates / Dermatologicals / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Enzyme Inhibitors / Glycosides / Intestinal Antiinfectives / Irrigating Solutions / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Neurotoxic agents / Ophthalmological and Otological Preparations / Ophthalmologicals / Otologicals / Ototoxic agents / Protein Synthesis Inhibitors / Sensory Organs / Stomatological Preparations / Throat Preparations",I16QD7X297,1404-04-2,D08260,,,,7299.0,7507.0,,DAP000036,PA450608,
Auranofin,phase 4 complete,DB00995 (APRD00808),CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O,Antiinflammatory and Antirheumatic Products / Antirheumatic Agents / Drugs that are Mainly Renally Excreted / Gold Compounds / Gold Preparations / Musculo-Skeletal System / Organogold Compounds / Organometallic Compounds / Specific Antirheumatic Agents,3H04W2810V,34031-32-8,D00237,70788951.0,5293650.0,50153291.0,1227.0,2922.0,CHEMBL1366,DAP000757,PA448510,
Gabapentin,phase 4 complete,DB00996 (APRD00015),NCC1(CC(O)=O)CCCCC1,"Acids, Acyclic / Acids, Carbocyclic / Amines / Amino Acids / Amino Acids, Peptides, and Proteins / Aminobutyrates / Analgesics / Anti-epileptic Agent / Anticonvulsants / Butyrates / Central Nervous System Agents / Central Nervous System Depressants / Cyclohexanecarboxylic Acids / Cyclohexanes / Cycloparaffins / Decreased Central Nervous System Disorganized Electrical Activity / Drugs causing inadvertant photosensitivity / Gabapentin and Prodrugs / Miscellaneous Anticonvulsants / Nervous System / Neurotransmitter Agents / Peripheral Nervous System Agents / Photosensitizing Agents / Psychotropic Drugs / Sensory System Agents / Tranquilizing Agents",6CW7F3G59X,60142-96-3,D00332,3446.0,3328.0,50080153.0,25480.0,42797.0,CHEMBL940,DNC000670,PA449720,ZINC000000004949
Doxorubicin,phase 4 complete,"DB00997 (APRD00185, DB05331, DB05847)",COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,"Anthracycline Topoisomerase Inhibitor / Anthracyclines / Anthracyclines and Related Substances / Antibiotics, Antineoplastic / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / BSEP/ABCB11 Substrates / BSEP/ABCB11 Substrates with Narrow Therapeutic Index / Carbohydrates / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Cytotoxic Antibiotics and Related Substances / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Glycosides / Immunosuppressive Agents / Myelosuppressive Agents / Naphthacenes / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Photosensitizing Agents / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",80168379AG,23214-92-8,D03899,31703.0,29400.0,32022.0,3639.0,28748.0,CHEMBL53463,DNC000163,PA449412,ZINC000003918087
Frovatriptan,phase 4 complete,DB00998 (APRD00270),CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O,"Agents that produce hypertension / Amines / Analgesics / Antidepressive Agents / Antimigraine Preparations / Biogenic Amines / Biogenic Monoamines / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Indoles / Migraine Disorders / Nervous System / Neurotransmitter Agents / Selective Serotonin 5-HT1 Receptor Agonists / Selective Serotonin Agonists / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 1b Receptor Agonists / Serotonin 1d Receptor Agonists / Serotonin 5-HT1 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists / Serotonin-1b and Serotonin-1d Receptor Agonist / Triptans",H82Q2D5WA7,158747-02-5,D07997,77992.0,70378.0,50073689.0,228783.0,134991.0,CHEMBL1279,DAP000063,PA164754891,ZINC000000018635
Hydrochlorothiazide,phase 4 complete,DB00999 (APRD00092),NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,"Amides / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzothiadiazines / Cardiovascular Agents / Diuretics / Drugs causing inadvertant photosensitivity / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Hypotensive Agents / Increased Diuresis / Low-Ceiling Diuretics and Potassium-Sparing Agents / Membrane Transport Modulators / Natriuretic Agents / Nephrotoxic agents / Non Potassium Sparing Diuretics / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Substrates / Photosensitizing Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sodium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds / Thiazides",0J48LPH2TH,58-93-5,D00340,3639.0,3513.0,13076.0,5487.0,5778.0,CHEMBL435,DAP000750,PA449899,ZINC000000896569
Cyclacillin,phase 4 complete,DB01000 (APRD00892),[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillins / Sulfur Compounds",72ZJ154X86,3485-14-1,D01334,19003.0,17941.0,50350474.0,2968.0,31444.0,CHEMBL1200356,DAP001159,PA164743456,ZINC000003830609
Salbutamol,phase 4 complete,DB01001 (APRD00553),CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Drugs for Obstructive Airway Diseases / Drugs that are Mainly Renally Excreted / Ethanolamines / Peripheral Nervous System Agents / Phenethylamines / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Reproductive Control Agents / Respiratory System Agents / Selective Beta 2-adrenergic Agonists / Sympathomimetic (Adrenergic) Agents / Tocolytic Agents",QF8SVZ843E,18559-94-9,D02147,2083.0,1999.0,25769.0,435.0,2549.0,CHEMBL714,DNC000873,PA448068,
Levobupivacaine,phase 4 complete,DB01002 (APRD00110),CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,"Amides / Amines / Anesthetics / Anesthetics, Local / Anilides / Aniline Compounds / Central Nervous System Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Nervous System / Neuraxial Anesthetics / Peripheral Nervous System Agents / Sensory System Agents",A5H73K9U3W,27262-47-1,D08116,92253.0,83289.0,50417951.0,259453.0,6149.0,CHEMBL1201193,DAP001233,PA164754741,ZINC000001530812
Cromoglicic acid,phase 4 complete,DB01003 (APRD00336),OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O,"Adrenergics, Inhalants / Agents for Dermatitis, Excluding Corticosteroids / Alimentary Tract and Metabolism / Anti-Allergic Agents / Anti-Asthmatic Agents / Antiallergic Agents, Excl. Corticosteroids / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Benzopyrans / Chromones / Cromolyn Sodium / Decongestants and Antiallergics / Decreased Histamine Release / Dermatologicals / Drugs causing inadvertant photosensitivity / Drugs for Obstructive Airway Diseases / Heterocyclic Compounds, Fused-Ring / Intestinal Antiinflammatory Agents / Mast Cell Stabilizers / Mast-cell Stabilizers / Nasal Preparations / Ophthalmologicals / Photosensitizing Agents / Pyrans / Respiratory System Agents / Sensory Organs",Y0TK0FS77W,16110-51-3,D07753,2882.0,2779.0,50440033.0,2921.0,59773.0,CHEMBL428880,DAP000819,PA449138,ZINC000001530788
Ganciclovir,phase 4 complete,"DB01004 (APRD00263, EXPT01540)",NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,"Agents Causing Muscle Toxicity / Agents that reduce seizure threshold / Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Ganciclovir / Ganciclovir and prodrug / Heterocyclic Compounds, Fused-Ring / MATE 1 Substrates / MATE 2 Substrates / MATE substrates / Nucleic Acid Synthesis Inhibitors / Nucleoside Analog Antiviral / Nucleosides and Nucleotides / Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OCT1 inhibitors / OCT1 substrates / Ophthalmologicals / Purines / Purinones / Sensory Organs",P9G3CKZ4P5,82410-32-0,D00333,3454.0,3336.0,85707.0,4678.0,465284.0,CHEMBL182,DAP000645,PA449733,ZINC000000001505
Hydroxyurea,phase 4 complete,DB01005 (APRD00023),NC(=O)NO,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Antisickling Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Hematologic Agents / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nucleic Acid Synthesis Inhibitors,X6Q56QN5QC,127-07-1,D00341,3657.0,3530.0,50017811.0,5552.0,44423.0,CHEMBL467,DAP000739,PA449942,ZINC000008034120
Letrozole,phase 4 complete,DB01006 (APRD01066),N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N,"Agents Causing Muscle Toxicity / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Aromatase Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strong) / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Endocrine Therapy / Enzyme Inhibitors / Estrogen Antagonists / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Nitriles / P-glycoprotein substrates / Steroid Synthesis Inhibitors / Triazoles / UGT2B7 substrates",7LKK855W8I,112809-51-5,D00964,3902.0,3765.0,13061.0,72965.0,6413.0,CHEMBL1444,DAP000626,PA450196,ZINC000003778874
Tioconazole,phase 4 complete,DB01007 (APRD01262),ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1,"14-alpha Demethylase Inhibitors / Anti-Infective Agents / Antifungal Agents / Antifungal Agents (Vaginal) / Antifungals for Dermatological Use / Antifungals for Topical Use / Azole Antifungals / Chemically-Induced Disorders / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Imidazole and Triazole Derivatives / Imidazole Derivatives / Steroid Synthesis Inhibitors",S57Y5X1117,65899-73-2,D00890,5482.0,5282.0,50370218.0,38298.0,77898.0,CHEMBL1200438,DAP001268,PA164746156,
Busulfan,phase 4 complete,DB01008 (APRD00664),CS(=O)(=O)OCCCCOS(C)(=O)=O,"Acids / Acids, Noncarboxylic / Alcohols / Alkanes / Alkanesulfonates / Alkanesulfonic Acids / Alkylating Activity / Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Butylene Glycols / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Glycols / Hydrocarbons, Acyclic / Immunologic Factors / Immunosuppressive Agents / Mesylates / Myeloablative Agonists / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Sulfonic Acids / Sulfur Acids / Sulfur Compounds / Toxic Actions",G1LN9045DK,55-98-1,D00248,2478.0,2384.0,50237623.0,1828.0,28901.0,CHEMBL820,,PA448691,ZINC000001530572
Ketoprofen,phase 4 complete,"DB01009 (APRD01059, DB05823, DB05335)",CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antirheumatic Agents / Central Nervous System Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Other Nonsteroidal Anti-inflammatory Agents / Peripheral Nervous System Agents / Phenylpropionates / Photosensitizing Agents / Propionates / Sensory System Agents / Topical Products for Joint and Muscular Pain / UGT1A1 Substrates",90Y4QC304K,22071-15-4,D00132,3825.0,3693.0,50022271.0,6142.0,6128.0,CHEMBL571,DAP000623,PA450149,
Edrophonium,phase 4 complete,DB01010 (APRD00944),CC[N+](C)(C)C1=CC(O)=CC=C1,"Amines / Ammonium Compounds / Antidotes / Cholinergic Agents / Cholinesterase Inhibitors / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Phenylammonium Compounds / Protective Agents / Quaternary Ammonium Compounds",70FP3JLY7N,312-48-1,,3202.0,3090.0,120262.0,3752.0,251408.0,CHEMBL1104,DAP000562,PA449437,ZINC000000001341
Metyrapone,phase 4 complete,"DB01011 (APRD01111, EXPT02271)",CC(C)(C(=O)C1=CN=CC=C1)C1=CC=CN=C1,Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Diagnostic Agents / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Noxae / Pyridines / Steroid Synthesis Inhibitors / Tests for Pituitary Function / Toxic Actions,ZS9KD92H6V,54-36-4,D00410,4174.0,4030.0,50028166.0,6923.0,44241.0,CHEMBL934,DAP000424,PA450486,ZINC000000001728
Cinacalcet,phase 4 complete,DB01012 (APRD00872),C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12,"Anti-Parathyroid Agents / Calcimimetic Agents / Calcium Homeostasis / Calcium-Regulating Hormones and Agents / Calcium-sensing Receptor Agonist / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Increased Calcium-sensing Receptor Sensitivity / Naphthalenes / Other Miscellaneous Therapeutic Agents / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",UAZ6V7728S,226256-56-0,D03504,156419.0,137743.0,50416875.0,407990.0,48390.0,CHEMBL1201284,DAP000256,PA164776671,ZINC000001550499
Clobetasol propionate,phase 4 complete,DB01013 (APRD00876),[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroids / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids / Steroids, Fluorinated / Thyroxine-binding globulin inhibitors",779619577M,25122-46-7,D01272,32798.0,30399.0,39347.0,21245.0,31414.0,CHEMBL1159650,DAP001183,PA164744375,ZINC000003977767
Balsalazide,phase 4 complete,DB01014 (APRD00141),OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Alimentary Tract and Metabolism / Aminobenzoates / Aminosalicylate / Aminosalicylic Acids / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Colitis, Ulcerative / Gastrointestinal Agents / Hydrazines / Hydroxy Acids / Hydroxybenzoates / Inflammatory Bowel Diseases / Intestinal Antiinflammatory Agents / meta-Aminobenzoates / Nephrotoxic agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Phenols / Prodrugs / Salicylates / Sensory System Agents",P80AL8J7ZP,80573-04-2,D07488,6335412.0,10662422.0,,18747.0,267413.0,CHEMBL1201346,DAP000733,PA448536,ZINC000003952881
Sulfamethoxazole,phase 4 complete,DB01015 (APRD00076),CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1,Agents causing hyperkalemia / Agents Causing Muscle Toxicity / Amines / Aniline Compounds / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antibiotics for Pneumocystis Pneumonia / Antiinfectives for Systemic Use / Antimycobacterials / Blood Glucose Lowering Agents / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs for Treatment of Tuberculosis / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hypoglycemia-Associated Agents / Intermediate-Acting Sulfonamides / Methemoglobinemia Associated Agents / Photosensitizing Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sulfanilamides / Sulfonamide Antibacterial / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds,JE42381TNV,723-46-6,D00447,5329.0,5138.0,50029770.0,10180.0,9332.0,CHEMBL443,DNC001393,PA451544,ZINC000000089763
Glyburide,phase 4 complete,DB01016 (APRD00233),COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,Alimentary Tract and Metabolism / BCRP/ABCG2 Substrates / Blood Glucose Lowering Agents / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs Used in Diabetes / Hypoglycemia-Associated Agents / OAT1/SLC22A6 inhibitors / P-glycoprotein inhibitors / Photosensitizing Agents / Sulfones / Sulfonylureas / Sulfur Compounds,SX6K58TVWC,10238-21-8,D00336,3488.0,3368.0,50012957.0,4815.0,5441.0,CHEMBL472,DAP000037,PA449782,ZINC000000537805
Minocycline,phase 4 complete,DB01017 (APRD00547),[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,Agents Causing Muscle Toxicity / Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives and Antiseptics for Local Oral Treatment / Antiinfectives for Systemic Use / Drugs causing inadvertant photosensitivity / Naphthacenes / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Photosensitizing Agents / Stomatological Preparations / Tetracyclines,FYY3R43WGO,10118-90-8,D05045,54675783.0,16735907.0,50103599.0,6980.0,50694.0,CHEMBL1434,DAP000405,PA450519,ZINC000014879992
Guanfacine,phase 4 complete,DB01018 (APRD00075),NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Amidines / Antiadrenergic Agents, Centrally Acting / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Bradycardia-Causing Agents / Cardiovascular Agents / Central alpha-2 Adrenergic Agonist / Central Alpha-agonists / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Guanidines / Hypotensive Agents / Imidazoline Receptor Agonists / MATE 1 Inhibitors / MATE inhibitors / Neurotransmitter Agents / OCT1 inhibitors / OCT1 substrates / OCT2 Substrates",30OMY4G3MK,29110-47-2,D08031,3519.0,3399.0,81984.0,40114.0,5558.0,CHEMBL862,DAP000900,PA449825,ZINC000003872738
Bethanechol,phase 4 complete,DB01019 (APRD00051),CC(C[N+](C)(C)C)OC(N)=O,"Acids, Acyclic / Amines / Ammonium Compounds / Autonomic Agents / Bethanechol Compounds / Carbamates / Choline Esters / Cholinergic Agents / Cholinergic Agonists / Muscarinic Agonists / Nervous System / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Parasympathomemetic (Cholinergic) Agents / Parasympathomimetics / Peripheral Nervous System Agents / Quaternary Ammonium Compounds / Trimethyl Ammonium Compounds",004F72P8F4,674-38-4,,2370.0,2280.0,39342.0,19257.0,3084.0,CHEMBL1482,DAP000263,PA448613,
Isosorbide mononitrate,phase 4 complete,DB01020 (APRD00528),[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O,Alcohols / Antianginal Agents / Carbohydrates / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Substrates / Delayed-Action Preparations / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Methemoglobinemia Associated Agents / Nitrate Vasodilator / Nitrates and Nitrites / Nitric Oxide Donors / Organic Nitrates / Sugar Alcohols / Vasodilating Agents / Vasodilation / Vasodilators Used in Cardiac Diseases,LX1OH63030,16051-77-7,D00630,27661.0,25736.0,,28004.0,6062.0,CHEMBL1311,DAP001058,PA450126,ZINC000001849548
Trichlormethiazide,phase 4 complete,DB01021 (APRD00031),NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl,"Amides / Antihypertensive Agents / Benzothiadiazines / Cardiovascular Agents / Diuretics / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Low-Ceiling Diuretics and Potassium-Sparing Agents / Membrane Transport Modulators / Natriuretic Agents / Sodium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds / Thiazides",Q58C92TUN0,133-67-5,D00658,5560.0,5359.0,26998.0,10772.0,9683.0,CHEMBL1054,DAP000035,PA164752426,
PhylloquinoneCommonly known or available as Vitamin K1,phase 4 complete,"DB01022 (APRD00464, DB09528)",CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O,"Blood and Blood Forming Organs / Coagulants / Diet, Food, and Nutrition / Diterpenes / Drugs that are Mainly Renally Excreted / Fibrin Modulating Agents / Food / Food and Beverages / Growth Substances / Hematologic Agents / Hemostatics / Increased Prothrombin Activity / Micronutrients / Naphthalenes / Naphthoquinones / Physiological Phenomena / Phytol / Quinones / Reversed Anticoagulation Activity / Terpenes / Vitamin K / Vitamins / Vitamins (Fat Soluble) / Warfarin Reversal Agent",S5Z3U87QHF,84-80-0,D00148,5284607.0,4447652.0,24782.0,11258.0,18067.0,CHEMBL1550,DNC001500,PA450961,ZINC000003831332
Felodipine,phase 4 complete,DB01023 (APRD00374),CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC,ACE Inhibitors and Calcium Channel Blockers / Agents causing hyperkalemia / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Beta blocking agents and calcium channel blockers / Bradycardia-Causing Agents / BSEP/ABCB11 Substrates / Calcium Channel Blockers / Calcium Channel Blockers (Dihydropyridine) / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Dihydropyridines / Hypotensive Agents / Membrane Transport Modulators / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,OL961R6O2C,72509-76-3,D00319,3333.0,3216.0,189379.0,4316.0,585948.0,CHEMBL1480,DAP000487,PA449591,
Mycophenolic acid,phase 4 complete,"DB01024 (APRD01603, EXPT02208)",COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C,"Acids, Acyclic / Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics, Antineoplastic / Antibiotics, Antitubercular / Antimetabolite Immunosuppressant / Antineoplastic and Immunomodulating Agents / Antituberculosis Agents / Caproates / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Fatty Acids / Fatty Acids, Volatile / Immunosuppressive Agents / Lipids / Mycophenolic Acid and Prodrugs / Narrow Therapeutic Index Drugs / Selective Immunosuppressants / UGT1A1 Substrates / UGT1A1 substrates with narrow therapeutic index / UGT1A6 substrate / UGT1A6 substrate with narrow therapeutic index / UGT1A9 Substrates / UGT1A9 substrates with narrow therapeutic index / UGT2B7 substrates / UGT2B7 substrates with narrow therapeutic index",HU9DX48N0T,24280-93-1,,446541.0,393865.0,19264.0,265323.0,168396.0,CHEMBL866,DAP000784,PA164748728,ZINC000000001758
Amlexanox,phase 4 complete,DB01025 (APRD00795),CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1,Alimentary Tract and Metabolism / Amines / Anti-Allergic Agents / Decreased Histamine Release / Drugs for Obstructive Airway Diseases / Ophthalmic Solutions / Pyridines / Stomatological Preparations,BRL1C2459K,68302-57-8,D01828,2161.0,2076.0,357857.0,46307.0,31205.0,CHEMBL1096,DAP000321,PA164745310,ZINC000000000928
Ketoconazole,phase 4 complete,DB01026 (APRD00401),CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,14-alpha Demethylase Inhibitors / Agents causing hyperkalemia / Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Antiinfectives for Systemic Use / Antimycotics for Systemic Use / Azole Antifungals / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (moderate) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (moderate) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strong) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strong) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Gynecological Antiinfectives and Antiseptics / Hepatotoxic Agents / Imidazole and Triazole Derivatives / Imidazole Derivatives / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / Piperazines / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Steroid Synthesis Inhibitors / UGT1A1 Inhibitors / UGT2B7 Inhibitors,R9400W927I,65277-42-1,D00351,3823.0,3691.0,151585.0,6135.0,48339.0,CHEMBL157101,DAP000630,PA450146,
Methoxyflurane,phase 4 complete,DB01028 (APRD00744),COC(F)(F)C(Cl)Cl,"Agents that produce hypertension / Analgesics / Anesthetics / Anesthetics, General / Anesthetics, Inhalation / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Ethers / Ethyl Ethers / Methyl Ethers / Miscellaneous Analgesics and Antipyretics / Nervous System",30905R8O7B,76-38-0,D00544,4116.0,3973.0,,6857.0,6843.0,CHEMBL1341,DAP000682,PA450434,ZINC000000896988
Irbesartan,phase 4 complete,DB01029 (APRD00413),CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,"Agents Acting on the Renin-Angiotensin System / Agents causing hyperkalemia / Angiotensin 2 Receptor Blocker / Angiotensin II receptor blockers (ARBs) and calcium channel blockers / Angiotensin II receptor blockers (ARBs) and diuretics / Angiotensin II receptor blockers (ARBs), plain / Angiotensin II Type 2 Receptor Blockers / Angiotensin Receptor Antagonists / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzene Derivatives / Biphenyl Compounds / Cardiovascular Agents / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hypotensive Agents / Spiro Compounds / Tetrazoles / UGT1A3 substrates",J0E2756Z7N,138402-11-6,D00523,3749.0,3618.0,50042235.0,83818.0,5959.0,CHEMBL1513,DAP000364,PA450084,ZINC000003872931
Topotecan,phase 4 complete,DB01030 (APRD00687),CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O,Alkaloids / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Immunosuppressive Agents / MATE 1 Inhibitors / MATE 1 Substrates / MATE 1 Substrates with a Narrow Therapeutic Index / MATE 2 Substrates / MATE 2 Substrates with a Narrow Therapeutic Index / MATE inhibitors / MATE substrates / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Topoisomerase I Inhibitors / Topoisomerase Inhibitors,7M7YKX2N15,123948-87-8,D08618,60700.0,54705.0,50034026.0,57308.0,63632.0,CHEMBL84,DAP000648,PA451729,ZINC000001611274
Ethinamate,phase 4 complete,DB01031 (APRD00959),NC(=O)OC1(CCCCC1)C#C,"Acids, Acyclic",IAN371PP48,126-52-3,D00703,3284.0,3169.0,,24474.0,4884.0,CHEMBL1576,DAP000606,PA164745394,ZINC000000001385
Probenecid,phase 4 complete,DB01032 (APRD00167),CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O,"Adjuvants, Pharmaceutic / Amides / Antigout Preparations / Antirheumatic Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Musculo-Skeletal System / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OCT1 inhibitors / OCT2 Inhibitors / Pharmaceutic Aids / Pharmaceutical Preparations / Preparations Increasing Uric Acid Excretion / Renal Agents / Sulfonamides / Sulfones / Sulfur Compounds / UGT1A1 Inhibitors / Uricosuric Agents",PO572Z7917,57-66-9,D00475,4911.0,4742.0,50206509.0,8698.0,8426.0,CHEMBL897,DAP001292,PA451106,ZINC000000001982
Mercaptopurine,phase 4 complete,DB01033 (APRD01096),S=C1N=CNC2=C1NC=N2,"Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Drugs for Obstructive Airway Diseases / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Immunologic Factors / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleoside Metabolic Inhibitor / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Purine Analogues / Purines / Sulfhydryl Compounds / Sulfur Compounds / Thiopurine Analogs / Toxic Actions / Xanthine derivatives",PKK6MUZ20G,50-44-2,D04931,667490.0,580869.0,50423778.0,103.0,94796.0,CHEMBL1425,DAP000147,PA450379,ZINC000004658290
Procainamide,phase 4 complete,DB01035 (APRD00509),CCN(CC)CCNC(=O)C1=CC=C(N)C=C1,"Acids, Carbocyclic / Agents Causing Muscle Toxicity / Agents that produce neuromuscular block (indirect) / Amides / Aminobenzoates / Antiarrhythmic agents / Antiarrhythmics, Class I / Antiarrhythmics, Class Ia / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Cardiac Therapy / Cardiovascular Agents / Cholinesterase Inhibitors / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Highest Risk QTc-Prolonging Agents / MATE 1 Substrates / MATE 1 Substrates with a Narrow Therapeutic Index / MATE 2 Substrates / MATE 2 Substrates with a Narrow Therapeutic Index / MATE substrates / Membrane Transport Modulators / Narrow Therapeutic Index Drugs / OCT1 inhibitors / OCT2 Inhibitors / OCT2 substrates with narrow therapeutic index / para-Aminobenzoates / QTc Prolonging Agents / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers",L39WTC366D,51-06-9,,4913.0,4744.0,39344.0,8700.0,8428.0,CHEMBL640,DAP000516,PA451108,ZINC000001530756
Tolterodine,phase 4 complete,DB01036 (APRD00146),CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C,Agents producing tachycardia / Alcohols / Amines / Amino Alcohols / Anticholinergic Agents / Benzene Derivatives / Benzhydryl Compounds / Cholinergic Agents / Cresols / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Urinary Frequency and Incontinence / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Genitourinary Smooth Muscle Relaxants / Muscarinic Antagonists / Neurotransmitter Agents / Phenols / Potential QTc-Prolonging Agents / Propanolamines / Propanols / QTc Prolonging Agents / Urological Agents / Urologicals,WHE7A56U7K,124937-51-5,D00646,443879.0,391967.0,50165008.0,119565.0,9622.0,CHEMBL1382,DAP000376,PA164746757,ZINC000000968336
Selegiline,phase 4 complete,DB01037 (APRD00525),C[C@H](CC1=CC=CC=C1)N(C)CC#C,"Agents that produce hypertension / Agents that reduce seizure threshold / Amines / Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Enzyme Inhibitors / Ethylamines / Hypotensive Agents / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Monoamine Oxidase B Inhibitors / Monoamine Oxidase Inhibitors / Nervous System / Neuroprotective Agents / P-glycoprotein inhibitors / Phenethylamines / Protective Agents / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",2K1V7GP655,14611-51-9,D03731,26757.0,24930.0,15579.0,9639.0,9086.0,CHEMBL972,DAP000579,PA451316,ZINC000019632633
Fenofibrate,phase 4 complete,"DB01039 (APRD00405, DB09545)",CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,"Acids, Acyclic / Agents Causing Muscle Toxicity / Benzene Derivatives / Benzophenones / BSEP/ABCB11 Substrates / Butyrates / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Ethers / Fatty Acids / Fatty Acids, Volatile / Fibric Acids / Fribic Acid Derivatives / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Isobutyrates / Ketones / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Lipids / Noxae / P-glycoprotein inhibitors / Peroxisome Proliferator Receptor alpha Agonist / Peroxisome Proliferator-activated Receptor alpha Agonists / Phenols / Phenyl Ethers / Toxic Actions / UGT1A9 Substrates",U202363UOS,49562-28-9,D00565,3339.0,3222.0,50085042.0,8703.0,5001.0,CHEMBL672,DAP000270,PA449594,ZINC000000584092
Thalidomide,phase 4 complete,DB01041 (APRD01251),O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12,"Acids, Carbocyclic / Angiogenesis Inhibitors / Angiogenesis Modulating Agents / Anti-Bacterial Agents / Anti-Infective Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cardiotoxic antineoplastic agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Immunologically Active Molecule Activity / Drugs causing inadvertant photosensitivity / Growth Inhibitors / Growth Substances / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Imides / Immunologic Factors / Immunomodulatory Agents / Immunosuppressive Agents / Isoindoles / Leprostatic Agents / Myelosuppressive Agents / Noxae / Photosensitizing Agents / Phthalic Acids / Phthalimides / Piperidines / Piperidones / Teratogens / Toxic Actions",4Z8R6ORS6L,50-35-1,D00754,5426.0,5233.0,50070114.0,10432.0,74947.0,CHEMBL468,DAP000865,PA451644,
Melphalan,phase 4 complete,DB01042 (APRD00118),N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O,"Alkylating Activity / Alkylating Drugs / Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Hydrocarbons, Halogenated / Immunologic Factors / Immunosuppressive Agents / Mustard Compounds / Myeloablative Agonists / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nitrogen Mustard Analogues / Nitrogen Mustard Compounds / Noxae / Phenylalanine / Toxic Actions",Q41OR9510P,148-82-3,D00369,460612.0,405297.0,50025837.0,6718.0,28876.0,CHEMBL852,DAP000791,PA450354,ZINC000000001673
Memantine,phase 4 complete,DB01043 (APRD00221),CC12CC3CC(C)(C1)CC(N)(C3)C2,Anti-Dementia Drugs / Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Central Nervous System Agents / Cholinesterase Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (weak) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Dopamine Agents / Drugs that are Mainly Renally Excreted / Excitatory Amino Acid Antagonists / Miscellaneous Central Nervous System Agents / N-methyl-D-aspartate Receptor Antagonist / Nervous System / Neurotransmitter Agents / NMDA Receptor Antagonists / OCT2 Substrates / Psychoanaleptics,W8O17SJF3T,19982-08-2,D08174,4054.0,3914.0,50062599.0,6719.0,64312.0,CHEMBL807,DAP000493,PA10364,
Gatifloxacin,phase 4 complete,DB01044 (APRD00996),COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Hypoglycemia-Associated Agents / Ophthalmic Solutions / Ophthalmologicals / Pharmaceutical Preparations / Pharmaceutical Solutions / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quinolines / Quinolone Antimicrobial / Quinolones / Sensory Organs / Solutions / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",81485Y3A9A,112811-59-3,D08011,5379.0,5186.0,50117914.0,1546025.0,5280.0,CHEMBL31,DAP001387,PA449738,
Rifampicin,phase 4 complete,"DB01045 (APRD00207, EXPT02777)",CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics, Antitubercular / Antiinfectives for Systemic Use / Antimycobacterials / Antituberculosis Agents / BSEP/ABCB11 Inhibitors / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (moderate) / Cytochrome P-450 CYP1A2 Inducers (strong) / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2A6 Inducers (moderate) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (moderate) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (moderate) / Cytochrome P-450 CYP2C19 Inducers (strong) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strong) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (moderate) / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strong) / Cytochrome P-450 CYP3A7 Inducers / Cytochrome P-450 CYP3A7 Inducers (strong) / Cytochrome P-450 CYP3A7 Inducers (weak) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Treatment of Tuberculosis / Enzyme Inhibitors / Hepatotoxic Agents / Heterocyclic Compounds, Fused-Ring / Lactams / Lactams, Macrocyclic / Leprostatic Agents / Narrow Therapeutic Index Drugs / Nucleic Acid Synthesis Inhibitors / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / OATP1B3 substrates / P-glycoprotein inducers / Rifamycin Antibacterial / Rifamycins / UGT1A1 Inducers / UGT1A9 Inducers / UGT1A9 Inhibitors",VJT6J7R4TR,13292-46-1,D00211,5381226.0,10468813.0,50370232.0,9384.0,71365.0,CHEMBL374478,DNC000965,PA451250,ZINC000169621223
Lubiprostone,phase 4 complete,DB01046 (APRD01298),[H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC,"Alimentary Tract and Metabolism / Autacoids / Biological Factors / Chloride Channel Agonists / Drugs for Constipation / Drugs that are Mainly Renally Excreted / Eicosanoids / Fatty Acids / Fatty Acids, Monounsaturated / Fatty Acids, Unsaturated / Inflammation Mediators / Laxatives / Lipids / Membrane Transport Modulators / Miscellaneous GI Drugs / Prostaglandins E",7662KG2R6K,136790-76-6,D04790,157920.0,138948.0,,623033.0,,CHEMBL1201134,DAP000208,PA164777012,ZINC000004217732
Fluocinonide,phase 4 complete,DB01047 (APRD00978),[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O,"Adrenal Cortex Hormones / Anti-Allergic Agents / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Pregnadienes / Pregnanes / Steroids / Steroids, Fluorinated / Thyroxine-binding globulin inhibitors",2W4A77YPAN,356-12-7,D00325,9642.0,9265.0,,4462.0,5109.0,CHEMBL1501,DAP000421,PA449664,ZINC000003977978
Abacavir,phase 4 complete,DB01048 (APRD00216),NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1,"Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Carbohydrates / Deoxyribonucleosides / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Glycosides / Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / Nucleoside Reverse Transcriptase Inhibitors / Nucleosides / Reverse Transcriptase Inhibitors / UGT1A1 Substrates",WR2TIP26VS,136470-78-5,D07057,441300.0,390063.0,50366816.0,190521.0,421707.0,CHEMBL1380,DAP000704,PA448004,ZINC000002015928
Ergoloid mesylate,phase 4 complete,"DB01049 (APRD00711, DB01287)",,"Adrenergic Agents / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Alkaloids / Antidepressive Agents / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dihydroergotoxine / Dopamine Agents / Dopamine Agonists / Ergot Alkaloids and Derivatives / Ergot-derivative Dopamine Receptor Agonists / Ergotamines / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / Nootropic Agents / Peripheral Vasodilators / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / Sympatholytic (Adrenergic Blocking) Agents / Vasodilating Agents",X3S33EX3KW,8067-24-1,D02268,,60600935.0,,4024.0,34706.0,,DAP000901,PA164752439,
Ibuprofen,phase 4 complete,DB01050 (APRD00372),CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,"Acids, Carbocyclic / Agents causing angioedema / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antiinflammatory Products for Vaginal Administration / Antirheumatic Agents / Central Nervous System Agents / COX-1 Inhibitors / COX-2 Inhibitors / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Experimental Unapproved Treatments for COVID-19 / Nephrotoxic agents / Nervous System / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Other Nonsteroidal Anti-inflammatory Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / Phenylpropionates / Propionates / Sensory System Agents / Throat Preparations / Topical Products for Joint and Muscular Pain / UGT1A1 Substrates / UGT1A3 substrates / UGT1A9 Substrates / UGT2B7 substrates",WK2XYI10QM,15687-27-1,D00126,3672.0,3544.0,50009859.0,5640.0,5855.0,CHEMBL521,DAP000780,PA449957,
Novobiocin,phase 4 complete,DB01051 (APRD00694),CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=C(C)C3=C(C=C2)C(O)=C(NC(=O)C2=CC=C(O)C(CC=C(C)C)=C2)C(=O)O3)OC1(C)C,"Aminocoumarins / Anti-Bacterial Agents / Anti-Infective Agents / BCRP/ABCG2 Inhibitors / Benzopyrans / Carbohydrates / Coumarins / Enzyme Inhibitors / Glycosides / Heterocyclic Compounds, Fused-Ring / Nucleic Acid Synthesis Inhibitors / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Pyrans",17EC19951N,303-81-1,,54675769.0,10226117.0,50226181.0,7538.0,28368.0,CHEMBL36506,DAP001002,PA164768819,ZINC000014879999
Benzylpenicillin,phase 4 complete,"DB01053 (APRD00646, DB11612)",[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / Beta-Lactamase Sensitive Penicillins / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Natural Penicillins / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Substrates / Ophthalmologicals / Penicillin G / Penicillins / Sensory Organs / Sulfur Compounds",Q42T66VG0C,61-33-6,D02336,5904.0,5693.0,50022787.0,7980.0,18208.0,CHEMBL29,DNC001109,PA450842,ZINC000003871701
Nitrendipine,phase 4 complete,DB01054 (APRD00421),CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC,ACE Inhibitors and Calcium Channel Blockers / Agents causing hyperkalemia / Antiarrhythmic agents / Antihypertensive Agents / Bradycardia-Causing Agents / BSEP/ABCB11 Substrates / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Dihydropyridines / Hypotensive Agents / Membrane Transport Modulators / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,9B627AW319,39562-70-4,D00629,4507.0,4351.0,50237611.0,7441.0,7582.0,CHEMBL475534,DAP001263,PA146096020,
Tocainide,phase 4 complete,DB01056 (APRD01266),CC(N)C(=O)NC1=C(C)C=CC=C1C,"Amides / Amines / Anilides / Aniline Compounds / Antiarrhythmic agents / Antiarrhythmics, Class I / Antiarrhythmics, Class Ib / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (weak) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Membrane Transport Modulators / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers",27DXO59SAN,41708-72-9,D06172,38945.0,35632.0,50092595.0,42359.0,9611.0,CHEMBL1762,DAP000517,PA451706,
Echothiophate,phase 4 complete,DB01057 (APRD00942),CCOP(=O)(OCC)SCC[N+](C)(C)C,Antiglaucoma Preparations and Miotics / Autonomic Agents / Cholinergic Agents / Cholinesterase Inhibitors / Enzyme Inhibitors / Miotics / Neurotransmitter Agents / Ophthalmologicals / Organophosphates / Organophosphorus Compounds / Organothiophosphates / Organothiophosphorus Compounds / Parasympathomimetics / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sensory Organs / Sulfur Compounds,0F350BVT6S,6736-03-4,D02193,10548.0,10108.0,,89778.0,4753.0,CHEMBL1201341,DAP000962,PA164743139,ZINC000001530628
Praziquantel,phase 4 complete,"DB01058 (APRD01196, EXPT02728)",O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,"Anthelmintics / Anti-Infective Agents / Antihelminthic / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antitrematodals / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Quinoline Derivatives and Related Substances",6490C9U457,55268-74-1,D00471,4891.0,4722.0,74574.0,8628.0,91583.0,CHEMBL976,DAP000695,PA164764583,
Norfloxacin,phase 4 complete,DB01059 (APRD00469),CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1,"Agents Causing Muscle Toxicity / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / OAT1/SLC22A6 inhibitors / Ophthalmologicals / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quinolines / Quinolone Antimicrobial / Quinolones / Sensory Organs / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",N0F8P22L1P,70458-96-7,D00210,4539.0,4380.0,50045000.0,7517.0,100246.0,CHEMBL9,DAP000654,PA450654,ZINC000000003742
Amoxicillin,phase 4 complete,DB01060 (APRD00248),[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,"Alimentary Tract and Metabolism / Amides / Aminopenicillins / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / OAT1/SLC22A6 inhibitors / Penicillin G / Penicillins / Penicillins With Extended Spectrum / Sulfur Compounds",9EM05410Q9,26787-78-0,D07452,33613.0,31006.0,50350464.0,1297882.0,2676.0,CHEMBL1082,DAP000443,PA448406,ZINC000003830215
Azlocillin,phase 4 complete,DB01061 (APRD00814),[H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1,"Agents that reduce seizure threshold / Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillin G / Penicillins / Penicillins With Extended Spectrum / Sulfur Compounds",HUM6H389W0,37091-66-0,D02339,6479523.0,4980416.0,,1266.0,2956.0,CHEMBL1537,DAP001169,PA164749135,ZINC000003830261
Oxybutynin,phase 4 complete,DB01062 (APRD00427),CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,"Acids, Carbocyclic / Agents producing tachycardia / Anticholinergic Agents / Autonomic Agents / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Urinary Frequency and Incontinence / Genito Urinary System and Sex Hormones / Hydroxy Acids / Muscarinic Antagonists / Neurotransmitter Agents / Parasympatholytics / Peripheral Nervous System Agents / Urological Agents / Urologicals",K9P6MC7092,5633-20-5,D00465,4634.0,4473.0,50165019.0,32675.0,7856.0,CHEMBL1231,DAP001128,PA164746030,
Acetophenazine,phase 4 complete,DB01063 (APRD00462),CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,"Antipsychotic Agents / Central Nervous System Depressants / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotoxic agents / Phenothiazines / Phenothiazines With Piperazine Structure / Psycholeptics / Sulfur Compounds",8620H6K4QH,2751-68-0,,17676.0,16708.0,82475.0,16735.0,2401.0,CHEMBL1085,DAP000844,PA164781360,ZINC000022446634
Isoprenaline,phase 4 complete,DB01064 (APRD00182),CC(C)NCC(O)C1=CC(O)=C(O)C=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic and Dopaminergic Agents / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics for Systemic Use / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Benzene Derivatives / Bronchodilator Agents / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Catecholamines / Catechols / Compounds used in a research, industrial, or household setting / Drugs for Obstructive Airway Diseases / Ethanolamines / Neurotransmitter Agents / Non-selective Beta-adrenergic Agonists / Peripheral Nervous System Agents / Phenols / Protective Agents / Respiratory System Agents / Sympathomimetics",L628TT009W,7683-59-2,,3779.0,3647.0,25392.0,6054.0,64317.0,CHEMBL434,DNC000819,PA450121,
Melatonin,phase 4 complete,"DB01065 (APRD00742, DB08189)",COC1=CC2=C(NC=C2CCNC(C)=O)C=C1,"Amines / Antioxidants / Biogenic Amines / Biogenic Monoamines / Central Nervous System Agents / Central Nervous System Depressants / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypnotics and Sedatives / Indoles / Melatonin Receptor Agonists / Melatonin, agonists / Melatonin, antagonists & inhibitors / Nervous System / OAT3/SLC22A8 Inhibitors / Protective Agents / Psycholeptics / Tryptamines",JL5DK93RCL,73-31-4,D08170,896.0,872.0,9019.0,6711.0,16796.0,CHEMBL45,DAP000429,PA164752558,ZINC000000057060
Cefditoren,phase 4 complete,DB01066 (APRD00850),[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",81QS09V3YW,104145-95-1,D01628,9870843.0,8046534.0,,83682.0,59343.0,CHEMBL1743,DAP000444,PA164747187,ZINC000004215234
Glipizide,phase 4 complete,DB01067 (APRD00436),CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Hypoglycemia-Associated Agents / Sulfones / Sulfonylureas / Sulfur Compounds / UGT1A1 Substrates,X7WDT95N5C,29094-61-9,D00335,3478.0,3359.0,50012956.0,4821.0,5384.0,CHEMBL1073,DAP000920,PA449762,ZINC000000537795
Clonazepam,phase 4 complete,DB01068 (APRD00054),[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,"Anticonvulsants / Benzazepines / Benzodiazepines and benzodiazepine derivatives / Benzodiazepinones / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Nervous System",5PE9FDE8GB,1622-61-3,D00280,2802.0,2700.0,50019213.0,2598.0,3756.0,CHEMBL452,DAP000259,PA449050,ZINC000003813003
Promethazine,phase 4 complete,DB01069 (APRD00601),CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C,"Acid Reducers / Agents producing tachycardia / Agents that reduce seizure threshold / Amines / Anti-Allergic Agents / Anticholinergic Agents / Antidepressive Agents / Antidotes / Antihistamines for Systemic Use / Antihistamines for Topical Use / Antipruritics / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Antipsychotic Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H2 Antagonists / Miscellaneous Anxiolytics Sedatives and Hypnotics / Muscarinic Antagonists / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein inhibitors / Phenothiazine Derivatives / Phenothiazines / Photosensitizing Agents / Potential QTc-Prolonging Agents / Propylamines / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / Sulfur Compounds",FF28EJQ494,60-87-7,D00494,4927.0,4758.0,50017696.0,8745.0,8461.0,CHEMBL643,DAP000334,PA451128,
Dihydrotachysterol,phase 4 complete,DB01070 (APRD00143),CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C,"Alimentary Tract and Metabolism / Bone Density Conservation Agents / Cholestanes / Cholestenes / Diet, Food, and Nutrition / Food / Food and Beverages / Fused-Ring Compounds / Growth Substances / Lipids / Membrane Lipids / Micronutrients / Physiological Phenomena / Secosteroids / Steroids / Sterols / Vitamin D and Analogues / Vitamins / Vitamins (Fat Soluble)",R5LM3H112R,67-96-9,D00299,5311071.0,4470607.0,,3429.0,4591.0,CHEMBL2356023,DAP000365,PA164744345,ZINC000004212953
Atazanavir,phase 4 complete,DB01072 (APRD00804),COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,"Amino Acids, Peptides, and Proteins / Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / HIV Protease Inhibitors / Hyperglycemia-Associated Agents / Nephrotoxic agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Oligopeptides / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Peptides / Potential QTc-Prolonging Agents / Protease Inhibitors / Pyridines / QTc Prolonging Agents / UDP Glucuronosyltransferases Inhibitors / UGT1A1 Inhibitors",QZU4H47A3S,198904-31-3,D07471,148192.0,130642.0,13934.0,343047.0,37924.0,CHEMBL1163,DNC000332,PA10251,ZINC000003941496
Fludarabine,phase 4 complete,DB01073 (APRD00594),NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,"Adenine Nucleotides / Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Arabinonucleosides / Arabinonucleotides / Carbohydrates / Cardiotoxic antineoplastic agents / DNA (Cytosine-5-)-Methyltransferases, antagonists & inhibitors / Enzyme Inhibitors / Glycosides / Heterocyclic Compounds, Fused-Ring / Immunologic Factors / Immunosuppressive Agents / Myeloablative Agonists / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Metabolic Inhibitor / Nucleosides / Nucleotides / Purine Analogues / Purine Nucleosides / Purine Nucleotides / Purines / Ribonucleosides / Ribonucleotides / Toxic Actions",P2K93U8740,21679-14-1,D01907,657237.0,571392.0,68391.0,24698.0,94701.0,CHEMBL1568,DAP000567,PA449655,ZINC000004216238
Perhexiline,phase 4 complete,DB01074 (APRD00107),C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1,Agents causing hyperkalemia / Antiarrhythmic agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Membrane Transport Modulators / Non-Selective Calcium Channel Blockers / Piperidines / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Vasodilating Agents,KU65374X44,6621-47-2,,4746.0,4584.0,61402.0,8050.0,35553.0,CHEMBL75880,DAP000957,PA130150436,
Diphenhydramine,phase 4 complete,"DB01075 (APRD00587, DB06975)",CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,"Agents producing tachycardia / Amines / Aminoalkyl Ethers / Anesthetics / Anesthetics, Local / Anti-Allergic Agents / Anticholinergic Agents / Antiemetics / Antihistamines for Systemic Use / Antihistamines for Topical Use / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Benzene Derivatives / Benzhydryl Compounds / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Drugs causing inadvertant photosensitivity / Ethanolamine Derivatives / Ethylamines / First Generation Antihistamines / Gastrointestinal Agents / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Hypnotics and Sedatives / Muscarinic Antagonists / OCT2 Inhibitors / Photosensitizing Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sleep Aids, Pharmaceutical",8GTS82S83M,58-73-1,D00300,3100.0,2989.0,50017674.0,3498.0,4636.0,CHEMBL657,DAP000490,PA449349,ZINC000000020244
Atorvastatin,phase 4 complete,DB01076 (APRD00055),CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,"Agents Causing Muscle Toxicity / Anticholesteremic Agents / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Fatty Acids / Heptanoic Acids / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Lipids / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein inhibitors / P-glycoprotein substrates / Toxic Actions / UGT1A1 Substrates / UGT1A3 substrates",A0JWA85V8F,134523-00-5,D07474,60823.0,54810.0,22164.0,1483793.0,39548.0,CHEMBL1487,DAP000553,PA448500,ZINC000003920719
Etidronic acid,phase 4 complete,DB01077 (APRD00964),CC(O)(P(O)(O)=O)P(O)(O)=O,Bisphosphonates / Bone Density Conservation Agents / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Musculo-Skeletal System / Organophosphonates / Organophosphorus Compounds,M2F465ROXU,2809-21-4,D02373,3305.0,3189.0,50115102.0,1356715.0,4907.0,CHEMBL871,DNC000629,PA449548,ZINC000003830813
Deslanoside,phase 4 complete,DB01078 (APRD00909),C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,"Antiarrhythmic agents / Carbohydrates / Cardanolides / Cardenolides / Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Digitalis Glycosides / Enzyme Inhibitors / Fused-Ring Compounds / Glycosides / Lanatosides / Protective Agents / Steroids",YGY317RK75,17598-65-1,D01240,28620.0,26618.0,,3248.0,31468.0,CHEMBL1614,DAP000464,PA164747478,ZINC000253668332
Tegaserod,phase 4 complete,DB01079 (APRD00096),CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2,"Alimentary Tract and Metabolism / Antidepressive Agents / BCRP/ABCG2 Substrates / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Constipation / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Laxatives / P-glycoprotein substrates / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists",458VC51857,145158-71-0,D06056,5362436.0,10609889.0,79022.0,139778.0,51043.0,CHEMBL76370,DAP001526,PA130413154,ZINC000001545565
Vigabatrin,phase 4 complete,DB01080 (APRD00282),NC(CCC(O)=O)C=C,"Acids, Acyclic / Aminobutyrates / Anti-epileptic Agent / Anticonvulsants / Butyrates / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Enzyme Inhibitors / Fatty Acid Derivatives / Fatty Acids / GABA Agents / Lipids / Miscellaneous Anticonvulsants / Nervous System / Neurotransmitter Agents",GR120KRT6K,68506-86-5,D00535,5665.0,5463.0,50118886.0,14851.0,63638.0,CHEMBL89598,DAP000557,PA10231,
Diphenoxylate,phase 4 complete,DB01081 (APRD00366),CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1,"Alimentary Tract and Metabolism / Analgesics / Antidiarrheals / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antipropulsives / Central Nervous System Agents / Central Nervous System Depressants / Gastrointestinal Agents / Isonipecotic Acids / Opioids / Peripheral Nervous System Agents / Piperidines / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",73312P173G,915-30-0,D00301,13505.0,12919.0,50401672.0,3500.0,4639.0,CHEMBL1201294,DAP001136,PA164746539,ZINC000003830716
Streptomycin,phase 4 complete,DB01082 (APRD00412),CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O,"Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antiinfectives for Systemic Use / Antimycobacterials / Carbohydrates / Drugs for Treatment of Tuberculosis / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Enzyme Inhibitors / Glycosides / Intestinal Antiinfectives / Narrow Therapeutic Index Drugs / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / Protein Synthesis Inhibitors / Streptomycins",Y45QSO73OB,57-92-1,,19649.0,18508.0,50103513.0,10109.0,17076.0,CHEMBL372795,DAP000144,PA451512,ZINC000008214681
Orlistat,phase 4 complete,DB01083 (APRD00255),CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,"Alimentary Tract and Metabolism / Anti-Obesity Agents / Antiobesity Preparations, Excl. Diet Products / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Enzyme Inhibitors / Intestinal Lipase Inhibitor / Lactones / Lipase Inhibitors / Lipid Regulating Agents / Miscellaneous GI Drugs / Peripherally Acting Antiobesity Products",95M8R751W8,96829-58-2,,3034010.0,2298564.0,24567.0,37925.0,94686.0,CHEMBL175247,DAP000053,PA164776864,ZINC000008214635
Emedastine,phase 4 complete,DB01084 (APRD00946),CCOCCN1C(=NC2=CC=CC=C12)N1CCCN(C)CC1,"Anti-Allergic Agents / Decongestants and Antiallergics / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Inhibitors / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / Ophthalmologicals / QTc Prolonging Agents / Sensory Organs",9J1H7Y9OJV,87233-61-2,D07890,3219.0,3106.0,50019624.0,28144.0,4779.0,CHEMBL594,DAP001067,PA164751802,ZINC000001530912
Pilocarpine,phase 4 complete,DB01085 (APRD00382),CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O,Alkaloids / Antiglaucoma Preparations and Miotics / Autonomic Agents / Cholinergic Agents / Cholinergic Agonists / Cholinergic Receptor Agonist / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Miotics / Muscarinic Agonists / Nervous System / Neurotransmitter Agents / Ophthalmologicals / Parasympathomemetic (Cholinergic) Agents / Parasympathomimetics / Peripheral Nervous System Agents / Sensory Organs,01MI4Q9DI3,92-13-7,D00525,5910.0,5699.0,50008072.0,8328.0,8207.0,CHEMBL550,DAP001113,PA450962,ZINC000000075008
Benzocaine,phase 4 complete,DB01086 (APRD00539),CCOC(=O)C1=CC=C(N)C=C1,"Acids, Carbocyclic / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Aminobenzoates / Anesthetics / Anesthetics for Topical Use / Anesthetics, Local / Antipruritics and Local Anesthetics / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Benzene Derivatives / Benzoates / Cell-mediated Immunity / Central Nervous System Agents / Central Nervous System Depressants / Dermatologicals / Esters of Aminobenzoic Acid / Increased Histamine Release / Local Anesthetics (Ester) / Methemoglobinemia Associated Agents / Nervous System / P-glycoprotein inhibitors / para-Aminobenzoates / Peripheral Nervous System Agents / Sensory System Agents / Standardized Chemical Allergen / Throat Preparations / Vasoprotectives",U3RSY48JW5,94-09-7,D00552,2337.0,13854242.0,197282.0,1399.0,116735.0,CHEMBL278172,DAP001234,PA448576,ZINC000012358719
Primaquine,phase 4 complete,DB01087 (APRD00604),COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1,"Aminoquinolines / Anti-Infective Agents / Antibiotics for Pneumocystis Pneumonia / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Methemoglobinemia Associated Agents / Moderate Risk QTc-Prolonging Agents / P-glycoprotein inhibitors / QTc Prolonging Agents / Quinolines",MVR3634GX1,90-34-6,,4908.0,4739.0,71542.0,8687.0,8405.0,CHEMBL506,DAP000216,PA451103,
Iloprost,phase 4 complete,DB01088 (APRD01027),[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O,"Agents Causing Muscle Toxicity / Anticoagulants / Antiplatelet agents / Autacoids / Biological Factors / Blood and Blood Forming Organs / Cardiovascular Agents / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Fibrinolytic Agents / Hematologic Agents / Hypotensive Agents / Inflammation Mediators / Lipids / Platelet Aggregation Inhibitors Excl. Heparin / Prostacyclin Analogues / Prostaglandins / Prostaglandins, Synthetic / Vasodilating Agents",JED5K35YGL,78919-13-8,,5311181.0,4470703.0,23954.0,40138.0,63916.0,CHEMBL494,DAP000273,PA164746843,
Deserpidine,phase 4 complete,DB01089 (APRD00906),[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2,"Alkaloids / Antiadrenergic Agents, Centrally Acting / Antihypertensive Agents / Catecholamine-depleting Sympatholytic / Decreased Sympathetic Activity / Heterocyclic Compounds, Fused-Ring / Indole Alkaloids / Indoles / Secologanin Tryptamine Alkaloids",9016E3VB47,131-01-1,D08194,8550.0,8232.0,,62174.0,27478.0,CHEMBL1200515,DAP000909,PA164742966,ZINC000004097186
Pentolinium,phase 4 complete,DB01090 (APRD00038),C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,Anticholinergic Agents / Antihypertensive Agents / Autonomic Agents / Cardiovascular Agents / Cholinergic Agents / Ganglion Blockers / Neurotransmitter Agents / Nicotinic Antagonists / Peripheral Nervous System Agents / Pyrrolidines,ULL76WPU5X,144-44-5,,5850.0,5641.0,50084945.0,,347401.0,CHEMBL1271,DAP001144,PA164777033,ZINC000002041380
Butenafine,phase 4 complete,DB01091 (APRD00833),CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12,Amines / Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Benzene Derivatives / Benzyl Compounds / Benzylamine Antifungal / Benzylamines / Dermatologicals,91Y494NL0X,101828-21-1,D07596,2484.0,2390.0,50436713.0,47461.0,3238.0,CHEMBL990,DAP001236,PA164745478,ZINC000001530975
Ouabain,phase 4 complete,DB01092 (APRD00135),[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,"Carbohydrates / Cardanolides / Cardenolides / Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Enzyme Inhibitors / Fused-Ring Compounds / Glycosides / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / Protective Agents / Steroids / Strophanthins / Strophanthus Glycosides",5ACL011P69,630-60-4,D00112,439501.0,388599.0,50286739.0,7762.0,472805.0,CHEMBL222863,DAP000465,PA163522138,ZINC000008143614
Dimethyl sulfoxide,phase 4 complete,"DB01093 (APRD00925, EXPT01231)",CS(C)=O,"Antioxidants / Compounds used in a research, industrial, or household setting / Cryoprotective Agents / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Free Radical Scavengers / Genito Urinary System and Sex Hormones / Miscellaneous Therapeutic Agents / Musculo-Skeletal System / Protective Agents / Solvents / Sulfoxides / Sulfur Compounds / Topical Products for Joint and Muscular Pain / Urologicals",YOW8V9698H,67-68-5,D01043,679.0,659.0,50026472.0,3455.0,28262.0,CHEMBL504,,PA449342,ZINC000005224188
Fluvastatin,phase 4 complete,DB01095 (APRD00346),CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12,"Agents Causing Muscle Toxicity / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Fatty Acids / Heptanoic Acids / Heterocyclic Compounds, Fused-Ring / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Indoles / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Lipids / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / UGT1A1 Substrates / UGT1A3 substrates / UGT2B7 substrates",4L066368AS,93957-54-1,D07983,1548972.0,1265982.0,50248235.0,41127.0,5136.0,CHEMBL350239,DAP000554,PA449688,ZINC000001530639
Oxamniquine,phase 4 complete,DB01096 (APRD01150),CC(C)NCC1CCC2=CC(CO)=C(C=C2N1)[N+]([O-])=O,"Anthelmintics / Anti-Infective Agents / Antihelminthic / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiplatyhelmintic Agents / Antitrematodals / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Hydroxyquinolines / Nitro Compounds / Nitroquinolines / Quinoline Derivatives and Related Substances / Quinolines / Schistosomicides",0O977R722D,21738-42-1,D00460,4612.0,4451.0,,7778.0,78416.0,CHEMBL847,DAP000992,PA164748782,
Leflunomide,phase 4 complete,DB01097 (APRD00205),CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Adjuvants / Agents Causing Muscle Toxicity / Antineoplastic and Immunomodulating Agents / Antirheumatic Agents / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Disease-modifying Antirheumatic Agents / Enzyme Inhibitors / Immunologic Factors / Immunosuppressive Agents / Isoxazoles / Selective Immunosuppressants,G162GK9U4W,75706-12-6,D00749,3899.0,3762.0,50054601.0,27169.0,6402.0,CHEMBL960,DAP000636,PA450192,ZINC000000004840
Rosuvastatin,phase 4 complete,DB01098 (APRD00546),CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O,"Agents Causing Muscle Toxicity / Alimentary Tract and Metabolism / Amides / Anticholesteremic Agents / BCRP/ABCG2 Substrates / Benzene Derivatives / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs Used in Diabetes / Enzyme Inhibitors / Fluorobenzenes / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hydrocarbons, Fluorinated / Hydrocarbons, Halogenated / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Noxae / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / Pyrimidines / Sulfonamides / Sulfones / Sulfur Compounds / Toxic Actions",413KH5ZJ73,287714-41-4,D08492,446157.0,393589.0,18372.0,301542.0,38545.0,CHEMBL1496,DAP000555,PA134308647,ZINC000001535101
Flucytosine,phase 4 complete,DB01099 (APRD00299),NC1=C(F)C=NC(=O)N1,Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Antiinfectives for Systemic Use / Antimetabolites / Antimycotics for Systemic Use / Cytosine / Dermatologicals / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Fluorouracil and prodrugs / Immunosuppressive Agents / Myelosuppressive Agents / Noxae / Nucleoside Analog Antifungal / Photosensitizing Agents / Pyrimidines / Pyrimidinones / Toxic Actions,D83282DT06,2022-85-7,D00323,3366.0,3249.0,50248003.0,4451.0,5100.0,CHEMBL1463,DAP001542,PA449654,ZINC000000896546
Pimozide,phase 4 complete,DB01100 (APRD00218),FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1,"Agents that reduce seizure threshold / Anti-Dyskinesia Agents / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Benzimidazoles / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diphenylbutylpiperidine Derivatives / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Miscellaneous Antipsychotics / Narrow Therapeutic Index Drugs / Nervous System / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein inhibitors / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Tranquilizing Agents",1HIZ4DL86F,2062-78-4,D00560,16362.0,15520.0,50334150.0,8331.0,8212.0,CHEMBL1423,DAP000316,PA450965,ZINC000004175630
Capecitabine,phase 4 complete,DB01101 (APRD00203),CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,"Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Carbohydrates / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strong) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Deoxycytidine / Deoxyribonucleosides / Drugs that are Mainly Renally Excreted / Fluoropyrimidines / Fluorouracil and prodrugs / Glycosides / Immunosuppressive Agents / Myelosuppressive Agents / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Metabolic Inhibitor / Nucleosides / Pyrimidine Analogues / Pyrimidine Nucleosides / Pyrimidines / Pyrimidinones / Ribonucleosides / Toxic Actions",6804DJ8Z9U,154361-50-9,D01223,60953.0,54916.0,,194000.0,31348.0,CHEMBL1773,DAP000761,PA448771,ZINC000003806413
Arbutamine,phase 4 complete,DB01102 (APRD00802),O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic and Dopaminergic Agents / Adrenergic beta-1 Receptor Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-3 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Amines / Benzene Derivatives / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Catechols / Compounds used in a research, industrial, or household setting / Neurotransmitter Agents / Phenols / Protective Agents",B07L15YAEV,128470-16-6,D02976,60789.0,54785.0,,61609.0,50580.0,CHEMBL1201251,DAP000936,PA164747979,
Sertraline,phase 4 complete,"DB01104 (APRD00175, DB08567)",CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12,Agents that reduce seizure threshold / Amines / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (moderate) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Monoamine Oxidase A Substrates / Naphthalenes / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / P-glycoprotein inhibitors / Photosensitizing Agents / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators,QUC7NX6WMB,79617-96-2,D02360,68617.0,61881.0,79021.0,36437.0,9123.0,CHEMBL809,DAP000051,PA451333,ZINC000001853550
Sibutramine,phase 4 complete,DB01105 (APRD00456),CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1,"Agents producing tachycardia / Alimentary Tract and Metabolism / Anti-Obesity Agents / Antidepressive Agents / Antiobesity Preparations, Excl. Diet Products / Appetite Depressants / Appetite Suppression / Central Nervous System Agents / Central Nervous System Depressants / Centrally Acting Antiobesity Products / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cycloparaffins / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dopamine Uptake Inhibitors / Drugs that are Mainly Renally Excreted / Norepinephrine Uptake Inhibitors / Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic / Psychotropic Drugs / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin and Noradrenaline Reuptake Inhibitors / Serotonin Modulators / Stimulants",WV5EC51866,106650-56-0,D08513,5210.0,5021.0,84742.0,36514.0,9137.0,CHEMBL1419,DCL000881,PA451344,
Levocabastine,phase 4 complete,DB01106 (APRD01069),C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1,"Anti-Allergic Agents / Antiallergic Agents, Excl. Corticosteroids / Central Nervous System Depressants / Decongestants and Antiallergics / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Nasal Preparations / Neurotransmitter Agents / Ophthalmologicals / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sensory Organs",H68BP06S81,79516-68-0,D01717,54385.0,16736421.0,50019405.0,28627.0,135679.0,CHEMBL1615438,DAP000335,PA164742988,ZINC000100089496
Methyprylon,phase 4 complete,DB01107 (APRD00734),CCC1(CC)C(=O)NCC(C)C1=O,Central Nervous System Depressants / Hypnotics and Sedatives / Nervous System / Piperidinedione Derivatives / Piperidines / Psycholeptics,CUT48I42ON,125-64-4,D01150,4162.0,4018.0,,6910.0,31837.0,CHEMBL1200790,DAP000683,PA164746748,
Trilostane,phase 4 complete,DB01108 (APRD01276),[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,"3-Hydroxysteroid Dehydrogenases, antagonists & inhibitors / Abortifacient Agents / Abortifacient Agents, Steroidal / Adrenal Cortex Hormones / Androstanes / Androstanols / Antiadrenal Preparations / Anticorticosteroids / Antineoplastic Agents / Corticosteroids / Corticosteroids for Systemic Use / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Narrow Therapeutic Index Drugs / Oxidative Phosphorylation Coupling Factors / Reproductive Control Agents / Steroids / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Testosterone Congeners",L0FPV48Q5R,13647-35-3,D01180,656583.0,570949.0,,38668.0,32260.0,CHEMBL1200907,DAP000148,PA164748507,ZINC000100038546
Heparin,phase 4 complete,DB01109 (APRD00056),,Agents causing hyperkalemia / Anticoagulants / Antivaricose Therapy / Blood and Blood Forming Organs / Carbohydrates / Cardiovascular Agents / Fibrin Modulating Agents / Glycosaminoglycans / Hematologic Agents / Heparin and similars / Heparin Group / Heparins or Heparinoids for Topical Use / Miscellaneous Therapeutic Agents / Narrow Therapeutic Index Drugs / Ophthalmologicals / Polysaccharides / Sensory Organs / Thyroxine-binding globulin substrates / Vasoprotectives,T2410KM04A,9005-49-6,,,,,5224.0,28304.0,CHEMBL1909300,DAP000189,PA449855,
Miconazole,phase 4 complete,DB01110 (APRD01115),ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,"14-alpha Demethylase Inhibitors / Anti-Infective Agents / Antifungal Agents / Antifungal Agents (Vaginal) / Antifungals for Dermatological Use / Antifungals for Topical Use / Antiinfectives and Antiseptics for Local Oral Treatment / Azole Antifungals / Chemically-Induced Disorders / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strong) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Imidazole and Triazole Derivatives / Imidazole Derivatives / Imidazoles / Intestinal Antiinfectives / Otologicals / P-glycoprotein inhibitors / Sensory Organs / Steroid Synthesis Inhibitors / Stomatological Preparations / Vaginal Creams, Foams, and Jellies",7NNO0D7S5M,22916-47-8,D00882,4189.0,4044.0,31772.0,6932.0,82892.0,CHEMBL91,DAP000154,PA450494,
Colistimethate,phase 4 complete,DB01111 (APRD00885),CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS([O-])(=O)=O)NC1=O)C(C)O,"Agents that produce neuromuscular block (indirect) / Amino Acids, Peptides, and Proteins / Antimicrobial Cationic Peptides / Lipids / Lipopeptides / Membrane Proteins / Nephrotoxic agents / Peptides / Peptides, Cyclic / Polymyxin-class Antibacterial / Polymyxins / Pore Forming Cytotoxic Proteins / Proteins",DL2R53P963,12705-41-8,,70789202.0,26329515.0,,2708.0,59662.0,,DAP001329,PA164749509,
Cefuroxime,phase 4 complete,DB01112 (APRD00285),[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Ophthalmologicals / Second-Generation Cephalosporins / Sensory Organs / Sulfur Compounds / Thiazines",O1R9FJ93ED,55268-75-2,D00262,5479529.0,4586393.0,50422689.0,2194.0,3515.0,CHEMBL1436,DAP000445,PA448868,ZINC000003871978
Papaverine,phase 4 complete,"DB01113 (APRD00628, DB07725)",COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1,"Alimentary Tract and Metabolism / Alkaloids / Benzylisoquinolines / Cardiovascular Agents / Drugs for Functional Gastrointestinal Disorders / Drugs Used in Erectile Dysfunction / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Isoquinolines / Miscellaneous Vasodilatating Agents / Moderate Risk QTc-Prolonging Agents / Opiate Alkaloids / Papaverine and Derivatives / Phosphodiesterase Inhibitors / QTc Prolonging Agents / Urological Agents / Urologicals / Vasodilating Agents",DAA13NKG2Q,58-74-2,D07425,4680.0,4518.0,14754.0,7895.0,28241.0,CHEMBL19224,DAP000959,PA164745550,ZINC000000056555
Chlorpheniramine,phase 4 complete,"DB01114 (APRD00001, DB09440)",CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,Anti-Allergic Agents / Antidepressive Agents / Antihistamines for Systemic Use / Antipruritics / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / OCT1 inhibitors / OCT2 Inhibitors / Propylamine Derivatives / Pyridines / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / Substituted Alkylamines,3U6IO1965U,132-22-9,D07398,2725.0,2624.0,35938.0,2400.0,52010.0,CHEMBL505,DAP000336,PA448960,
Nifedipine,phase 4 complete,DB01115 (APRD00590),COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC,Adrenal Cortex Hormones / Agents causing hyperkalemia / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Beta blocking agents and calcium channel blockers / Bradycardia-Causing Agents / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / Calcium Channel Blockers / Calcium Channel Blockers (Dihydropyridine) / Calcium Channel Blockers and Diuretics / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Dihydropyridines / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Pyridines / QTc Prolonging Agents / Reproductive Control Agents / Selective Calcium Channel Blockers With Mainly Vascular Effects / Tocolytic Agents / Vasodilating Agents,I9ZF7L6G2L,21829-25-4,D00437,4485.0,4330.0,50101817.0,7417.0,7565.0,CHEMBL193,DAP000529,PA450631,ZINC000085205448
Trimethaphan,phase 4 complete,DB01116 (APRD00044),O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1,"Adjuvants, Anesthesia / Antiadrenergic Agents, Ganglion-Blocking / Anticholinergic Agents / Antihypertensive Agents / Autonomic Agents / Cardiovascular Agents / Central Nervous System Agents / Cholinergic Agents / Cholinesterase substrates / Ganglion Blockers / Imidazoles / Neurotransmitter Agents / Nicotinic Antagonists / Peripheral Nervous System Agents / Sulfonium Derivatives / Vasodilating Agents",6G8X656T45,7187-66-8,,23576.0,22044.0,82545.0,10828.0,9728.0,CHEMBL1201329,DAP001143,PA451784,
Atovaquone,phase 4 complete,DB01117 (APRD00805),OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O,"Anti-Infective Agents / Antibiotics for Pneumocystis Pneumonia / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Miscellaneous Antiprotozoals / Naphthalenes / Naphthoquinones / P-glycoprotein inhibitors / Quinones",Y883P1Z2LT,95233-18-4,D00236,74989.0,10482034.0,16301.0,60212.0,575568.0,CHEMBL1450,DAP000156,PA448502,ZINC000116473771
Amiodarone,phase 4 complete,DB01118 (APRD00288),CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,"Agents causing hyperkalemia / Agents Causing Muscle Toxicity / alpha-Galactosidase, antagonists & inhibitors / Antiarrhythmic agents / Antiarrhythmics, Class III / Benzofurans / Bradycardia-Causing Agents / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / BSEP/ABCB11 Substrates with Narrow Therapeutic Index / Calcium Channel Blockers / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (moderate) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Hypotensive Agents / Membrane Transport Modulators / Narrow Therapeutic Index Drugs / OCT2 Inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / Photosensitizing Agents / Potassium Channel Blockers / QTc Prolonging Agents / Sodium Channel Blockers / Vasodilating Agents",N3RQ532IUT,1951-25-3,D02910,2157.0,2072.0,18957.0,703.0,2663.0,CHEMBL633,DAP000496,PA448383,ZINC000003830212
Diazoxide,phase 4 complete,DB01119 (APRD00914),CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2,"Amides / Antihypertensive Agents / Arteriolar Smooth Muscle, Agents Acting On / Benzothiadiazines / Cardiovascular Agents / Direct Vasodilators / Diuretics / Drugs for Treatment of Hypoglycemia / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Hypotensive Agents / Sulfonamides / Sulfones / Sulfur Compounds / Thiazide Derivatives / Vasodilating Agents",O5CB12L4FN,364-98-7,D00294,3019.0,2911.0,86248.0,3327.0,4495.0,CHEMBL181,DAP000956,PA449285,ZINC000003872277
Gliclazide,phase 4 complete,DB01120 (APRD00460),CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1,Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs Used in Diabetes / Hypoglycemia-Associated Agents / Sulfones / Sulfonylureas / Sulfur Compounds,G4PX8C4HKV,21187-98-4,D01599,3475.0,3356.0,50103512.0,4816.0,31654.0,CHEMBL427216,DAP000522,PA10892,
Phenacemide,phase 4 complete,DB01121 (APRD00089),NC(=O)NC(=O)CC1=CC=CC=C1,"Acetamides / Acetates / Acids, Acyclic / Amides / Anticonvulsants / Benzene Derivatives / Central Nervous System Depressants / Fatty Acids / Fatty Acids, Volatile / Lipids / Nervous System",PAI7J52V09,63-98-9,D00504,4753.0,4589.0,50240044.0,33253.0,8049.0,CHEMBL918,DAP000501,PA164745309,ZINC000000001916
Ambenonium,phase 4 complete,DB01122 (APRD00771),CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC1=CC=CC=C1Cl,Amines / Ammonium Compounds / Autonomic Agents / Benzylammonium Compounds / Cholinergic Agents / Cholinesterase Inhibitors / Enzyme Inhibitors / Nervous System / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Parasympathomimetics / Peripheral Nervous System Agents / Quaternary Ammonium Compounds,L16PUN799N,7648-98-8,,2131.0,2046.0,50262988.0,623.0,2627.0,CHEMBL1652,DAP000893,PA164764601,ZINC000003995599
Proflavine,phase 4 complete,DB01123 (APRD00535),NC1=CC2=NC3=C(C=CC(N)=C3)C=C2C=C1,"Acridines / Aminoacridines / Anti-Infective Agents / Anti-Infective Agents, Local / Heterocyclic Compounds, Fused-Ring",CY3RNB3K4T,92-62-6,,7099.0,6832.0,12590.0,8723.0,8452.0,CHEMBL55400,DAP000995,PA164748742,ZINC000003775644
Tolbutamide,phase 4 complete,DB01124 (APRD00267),CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1,Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diagnostic Agents / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Hypoglycemia-Associated Agents / OAT1/SLC22A6 inhibitors / Sulfones / Sulfonylureas / Sulfur Compounds / Tests for Diabetes,982XCM1FOI,64-77-7,D00380,5505.0,5304.0,50027886.0,10635.0,27999.0,CHEMBL782,DAP000136,PA451718,ZINC000001530703
Anisindione,phase 4 complete,DB01125 (APRD00799),COC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O,Indans / Indenes,S747T1ERAJ,117-37-3,D07457,2197.0,2112.0,50280155.0,17941.0,133809.0,CHEMBL712,DAP001274,PA164746467,ZINC000100015486
Dutasteride,phase 4 complete,DB01126 (APRD00385),[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F,"5-alpha Reductase Inhibitors / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Azasteroids / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs Used in Benign Prostatic Hypertrophy / Enzyme Inhibitors / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Steroid Synthesis Inhibitors / Steroids / Urologicals",O0J6XJN02I,164656-23-9,D03820,6918296.0,5293502.0,50340481.0,228790.0,521033.0,CHEMBL1200969,DAP000044,PA164749300,ZINC000003932831
Econazole,phase 4 complete,DB01127 (APRD00943),ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,"14-alpha Demethylase Inhibitors / Anti-Infective Agents / Antifungal Agents / Antifungal Agents (Vaginal) / Antifungals for Dermatological Use / Antifungals for Topical Use / Azole Antifungals / Chemically-Induced Disorders / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Imidazole and Triazole Derivatives / Imidazole Derivatives / Imidazoles / P-glycoprotein inhibitors / Steroid Synthesis Inhibitors",6Z1Y2V4A7M,27220-47-9,D03936,3198.0,3086.0,31773.0,3743.0,82873.0,CHEMBL808,DAP001269,PA164746010,
Bicalutamide,phase 4 complete,"DB01128 (APRD00042, DB06284)",CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F,"Amides / Amines / Androgen Receptor Antagonists / Androgen Receptor Inhibitor / Aniline Compounds / Antiandrogens / Antiandrogens, non-steroidal / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Benzene Derivatives / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Endocrine Therapy / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Narrow Therapeutic Index Drugs / P-glycoprotein inhibitors / Sulfones / Sulfur Compounds",A0Z3NAU9DP,90357-06-5,D00961,2375.0,2284.0,18525.0,83008.0,144093.0,CHEMBL409,DAP000092,PA164746255,
Rabeprazole,phase 4 complete,DB01129 (APRD01212),COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1,"2-Pyridinylmethylsulfinylbenzimidazoles / Acetates / Acid Reducers / Acids, Acyclic / Alimentary Tract and Metabolism / Anti-Ulcer Agents / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / BCRP/ABCG2 Inhibitors / Benzimidazoles / Butylpyrazolidines / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Fatty Acids / Fatty Acids, Volatile / Gastric Acid Lowering Agents / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Hydroxy Acids / Lipids / Musculo-Skeletal System / Proton Pump Inhibitors / Proton-pump Inhibitors / Pyrazoles / Pyrazolones / Pyridines / Sulfoxides / Sulfur Compounds / Topical Products for Joint and Muscular Pain",32828355LL,117976-89-3,D08463,5029.0,4853.0,50070209.0,114979.0,8768.0,CHEMBL1219,DAP000727,PA451216,
Prednicarbate,phase 4 complete,DB01130 (APRD01197),[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids",V901LV1K7D,73771-04-7,,6714002.0,5145991.0,,34369.0,135791.0,CHEMBL1200386,DAP001189,PA164749394,ZINC000003938652
Proguanil,phase 4 complete,DB01131 (APRD00188),CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1,"Amidines / Anti-Infective Agents / Antimalarials / Antimetabolites / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Biguanides / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Folic Acid Antagonists / Guanidines / Noxae / Toxic Actions",S61K3P7B2V,500-92-5,,4923.0,4754.0,50227829.0,2382.0,8455.0,CHEMBL1377,DAP000634,PA451124,ZINC000095452610
Pioglitazone,phase 4 complete,DB01132 (APRD00653),CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs Used in Diabetes / Hypoglycemia-Associated Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Peroxisome Proliferator Receptor gamma Agonist / Peroxisome Proliferator-activated Receptor Activity / Sulfur Compounds / Thiazoles / Thiazolidinediones,X4OV71U42S,111025-46-8,D08378,4829.0,4663.0,50103521.0,33738.0,8228.0,CHEMBL595,DAP000272,PA450970,
Tiludronic acid,phase 4 complete,DB01133 (APRD01259),OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O,"Bisphosphonates / Bone Density Conservation Agents / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Drugs that are Mainly Renally Excreted / Musculo-Skeletal System / Organophosphonates / Organophosphorus Compounds / Phospholipases A, antagonists & inhibitors",6PNS59HP4Y,89987-06-4,,60937.0,54905.0,50442524.0,57230.0,9598.0,CHEMBL1350,,PA451688,ZINC000001531010
DoxacuriumCommonly known or available as Doxacurium chloride,phase 4 complete,"DB01135 (APRD00934, DB01334)",COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC,"Anticholinergic Agents / Central Nervous System Depressants / Cholinesterase substrates / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Muscarinic Antagonists / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular-Blocking Agents (Nondepolarizing) / Nicotinic Antagonists / Peripheral Nervous System Agents",P40015Y3WW,106791-39-3,D00760,5284551.0,54249.0,,23651.0,59819.0,CHEMBL1237123,DAP000350,PA164744927,
Carvedilol,phase 4 complete,DB01136 (APRD00091),COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Adrenergic beta-1 Receptor Antagonists / Adrenergic beta-Antagonists / Adrenergic beta2-Antagonists / Agents causing hyperkalemia / Alcohols / Alpha and Beta Blocking Agents / Amines / Amino Alcohols / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Antioxidants / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Carbazoles / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Indoles / Membrane Transport Modulators / Neurotransmitter Agents / P-glycoprotein inhibitors / Propanolamines / Propanols / Protective Agents / UGT1A1 Substrates / UGT2B7 substrates / Vasodilating Agents",0K47UL67F2,72956-09-3,D00255,2585.0,2487.0,25759.0,20352.0,3441.0,CHEMBL723,DAP000135,PA448817,
Levofloxacin,phase 4 complete,"DB01137 (APRD00477, DB06085)",C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1,"Alimentary Tract and Metabolism / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / MATE 1 Inhibitors / MATE 1 Substrates / MATE 2 Inhibitors / MATE inhibitors / MATE substrates / Moderate Risk QTc-Prolonging Agents / OAT1/SLC22A6 Substrates / OCT1 inhibitors / OCT2 Inhibitors / Ophthalmologicals / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / QTc Prolonging Agents / Quinolines / Quinolone Antimicrobial / Quinolones / Renal Agents / Sensory Organs / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",RIX4E89Y14,100986-85-4,D08120,149096.0,131410.0,50366826.0,82122.0,63598.0,CHEMBL33,DAP000160,PA450214,ZINC000000538273
Sulfinpyrazone,phase 4 complete,DB01138 (APRD00620),O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1,Antigout Preparations / Antiplatelet agents / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Musculo-Skeletal System / Preparations Increasing Uric Acid Excretion / Pyrazoles / Pyrazolones / Renal Agents / Uricosuric Agents,V6OFU47K3W,57-96-5,D00449,5342.0,5149.0,50237626.0,10205.0,9342.0,CHEMBL832,DAP000794,PA451550,
Cefapirin,phase 4 complete,DB01139 (APRD00860),[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC1=CC=NC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephacetrile / Cephalosporins / First-Generation Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Sulfur Compounds / Thiazines",89B59H32VN,21593-23-7,,30699.0,28486.0,50370592.0,2238.0,554446.0,CHEMBL1599,DAP001160,PA164749340,ZINC000003830511
Cefadroxil,phase 4 complete,DB01140 (APRD00196),[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Drugs that are Mainly Renally Excreted / First-Generation Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Sulfur Compounds / Thiazines",Q525PA8JJB,50370-12-2,D00257,47965.0,43630.0,50350467.0,1545975.0,3479.0,CHEMBL1644,DAP000446,PA448835,ZINC000003830391
Micafungin,phase 4 complete,DB01141 (APRD01114),CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O,"Amino Acids, Peptides, and Proteins / Anti-Infective Agents / Antifungal Agents / Antiinfectives for Systemic Use / Antimycotics for Systemic Use / COMT Substrates / Echinocandin Antifungal / Echinocandins / Lipids / Lipopeptides / Peptides / Peptides, Cyclic",R10H71BSWG,235114-32-6,D02465,477468.0,419105.0,,325887.0,600520.0,CHEMBL457547,DAP000548,PA164781026,
Doxepin,phase 4 complete,DB01142 (APRD00398),[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12,"Acid Reducers / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Agents that reduce seizure threshold / Anticholinergic Agents / Antidepressive Agents / Antidepressive Agents, Tricyclic / Antipruritics and Local Anesthetics / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Dibenzoxepins / Dopamine Antagonists / Drugs that are Mainly Renally Excreted / Ethers, Cyclic / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H2 Antagonists / Hypnotics and Sedatives / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Non-Selective Monoamine Reuptake Inhibitors / P-glycoprotein substrates / Potential QTc-Prolonging Agents / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Sleep Aids, Pharmaceutical / Tertiary amine tricyclic antidepressants / Tricyclics and Other Norepinephrine-reuptake Inhibitors",5ASJ6HUZ7D,1668-19-5,D07875,667468.0,3046.0,50225488.0,3638.0,4710.0,CHEMBL1628227,DAP000177,PA449409,
Amifostine,phase 4 complete,DB01143 (APRD00021),NCCCNCCSP(O)(O)=O,"Compounds used in a research, industrial, or household setting / Cytoprotective Agent / Detoxifying Agents for Antineoplastic Treatment / Free Radical Scavenging Activity / Hypotensive Agents / Organophosphates / Organophosphorus Compounds / Organothiophosphates / Organothiophosphorus Compounds / Protective Agents / Radiation-Protective Agents / Sulfur Compounds",ILA426L95O,20537-88-6,,2141.0,2056.0,,1545987.0,2636.0,CHEMBL1006,,PA448365,ZINC000021992285
Diclofenamide,phase 4 complete,"DB01144 (APRD00131, DB07948)",NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O,Amides / Antiglaucoma Preparations and Miotics / Carbonic Anhydrase Inhibitors / Diuretics / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hypotensive Agents / Ophthalmics / Ophthalmologicals / Sensory Organs / Sulfonamides / Sulfones / Sulfur Compounds,VVJ6673MHY,120-97-8,D00518,3038.0,2930.0,10883.0,3353.0,101085.0,CHEMBL17,DAP000601,PA164745512,ZINC000000896918
Sulfoxone,phase 4 complete,DB01145 (APRD00704),OS(=O)CNC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1,Antiinfectives for Systemic Use / Antimycobacterials / Drugs for Treatment of Lepra / Sulfones / Sulfur Compounds,0G3C18OH4D,144-76-3,,5351.0,5158.0,,,135651.0,CHEMBL1570,DAP001192,PA164776911,ZINC000018268128
Diphenylpyraline,phase 4 complete,DB01146 (APRD00719),CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1,Aminoalkyl Ethers / Antihistamines for Systemic Use / Histamine Antagonists / Histamine H1 Antagonists,33361OE3AV,147-20-6,D07862,3103.0,2992.0,50241333.0,23386.0,59788.0,CHEMBL1492,DAP001071,PA164746377,ZINC000000056643
Cloxacillin,phase 4 complete,"DB01147 (APRD00882, EXPT01068)",[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / Beta-Lactamase Resistant Penicillins / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / OAT1/SLC22A6 inhibitors / Penicillinase-resistant Penicillins / Penicillins / Sulfur Compounds",O6X5QGC2VB,61-72-3,,6098.0,5873.0,50022788.0,2625.0,49566.0,CHEMBL891,DAP001161,PA449059,ZINC000003875417
Flavoxate,phase 4 complete,DB01148 (APRD00972),CC1=C(OC2=C(C=CC=C2C(=O)OCCN2CCCCC2)C1=O)C1=CC=CC=C1,"Agents producing tachycardia / Anticholinergic Agents / Autonomic Agents / Benzopyrans / Chromones / Drugs for Urinary Frequency and Incontinence / Drugs that are Mainly Renally Excreted / Flavones / Flavonoids / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Muscarinic Antagonists / Parasympatholytics / Peripheral Nervous System Agents / Pyrans / Urological Agents / Urologicals",3E74Y80MEY,15301-69-6,,3354.0,3237.0,,4440.0,5088.0,CHEMBL1493,DAP001114,PA164781386,ZINC000000608382
Nefazodone,phase 4 complete,DB01149 (APRD00402),CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Analgesics / Antidepressive Agents / Antidepressive Agents, Second-Generation / Antidepressive Agents, Triazolopyridine / BSEP/ABCB11 Substrates / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / OATP1B3 inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / Psychoanaleptics / Psychotropic Drugs / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin and Noradrenaline Reuptake Inhibitors / Serotonin Modulators / Serotonin Receptor Antagonists",59H4FCV1TF,83366-66-9,D08257,4449.0,4294.0,50069447.0,31565.0,7494.0,CHEMBL623,DAP000042,PA450603,ZINC000000538065
Cefprozil,phase 4 complete,DB01150 (APRD00461),[H][C@]12SCC(C=CC)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Second-Generation Cephalosporins / Sulfur Compounds / Thiazines",S1SDI2FJIY,92665-29-7,,5281006.0,4444481.0,,1546020.0,3506.0,CHEMBL276568,DAP000447,PA164746342,ZINC000003776970
Desipramine,phase 4 complete,"DB01151 (APRD00022, DB07682)",CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12,"Adrenergic Agents / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Agents that produce hypertension / Agents that reduce seizure threshold / Anticholinergic Agents / Antidepressive Agents / Antidepressive Agents, Tricyclic / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dibenzazepines / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Membrane Transport Modulators / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Non-Selective Monoamine Reuptake Inhibitors / OCT1 inhibitors / OCT2 Inhibitors / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Tricyclics and Other Norepinephrine-reuptake Inhibitors",TG537D343B,50-47-5,D07791,2995.0,2888.0,35229.0,3247.0,47781.0,CHEMBL72,DAP001151,PA449233,ZINC000001530611
Candicidin,phase 4 complete,DB01152 (APRD00843),CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC(=O)CC(O)C(C(O)CC(OC2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1,Anti-Bacterial Agents / Anti-Infective Agents / Antifungal Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Lactones / Macrolides / Polyketides,48N2IYJ202,1403-17-4,D03347,,8255412.0,,,3349.0,CHEMBL1200647,DAP001325,PA164754911,
Sertaconazole,phase 4 complete,DB01153 (APRD00305),ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl,Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Azole Antifungals / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Imidazole and Triazole Derivatives / Imidazole Derivatives / Sulfur Compounds,72W71I16EG,99592-32-2,,65863.0,59273.0,50051842.0,36435.0,83682.0,CHEMBL1201196,DAP001270,PA164748328,
Thiamylal,phase 4 complete,DB01154 (APRD00154),CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O,"Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Anticonvulsants / Barbiturates / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / GABA Agents / GABA Modulators / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Psycholeptics / Pyrimidines / Pyrimidinones / Thiobarbiturates",01T23W89FR,77-27-0,D06106,3032285.0,2297298.0,,10464.0,9536.0,CHEMBL440,DAP000684,PA164746997,
Gemifloxacin,phase 4 complete,DB01155 (APRD00053),CO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Moderate Risk QTc-Prolonging Agents / Naphthyridines / QTc Prolonging Agents / Quinolines / Quinolone Antimicrobial / Quinolones / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",OKR68Y0E4T,175463-14-6,D08012,9571107.0,7845573.0,50178917.0,138099.0,101853.0,CHEMBL430,DAP000851,PA10088,
Bupropion,phase 4 complete,DB01156 (APRD00621),CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,"Agents that reduce seizure threshold / Aminoketone / Antidepressive Agents / Antiobesity Preparations, Excl. Diet Products / Central Nervous System Agents / Central Nervous System Depressants / Centrally Acting Antiobesity Products / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Uptake Inhibitors / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Increased Dopamine Activity / Increased Norepinephrine Activity / Ketones / Miscellaneous Antidepressants / Nervous System / Neurotransmitter Uptake Inhibitors / Norepinephrine Uptake Inhibitors / OCT2 Inhibitors / Photosensitizing Agents / Psychoanaleptics / Psychotropic Drugs / Smoking Cessation Agents",01ZG3TPX31,34911-55-2,D07591,444.0,431.0,50048392.0,42347.0,3219.0,CHEMBL894,DAP000052,PA448687,
Trimetrexate,phase 4 complete,DB01157 (APRD00268),COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC,"Acids, Acyclic / Acids, Aldehydic / Anti-Infective Agents / Antimetabolites / Antineoplastic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Carbohydrates / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Folic Acid Antagonists / Hepatotoxic Agents / Heterocyclic Compounds, Fused-Ring / Hydroxy Acids / Narrow Therapeutic Index Drugs / Noxae / Pharmaceutical Preparations / Quinazolines / Sugar Acids / Toxic Actions / Uronic Acids",UPN4ITI8T4,52128-35-5,D06238,5583.0,5381.0,18268.0,42333.0,9737.0,CHEMBL119,DAP000635,PA451790,ZINC000000598852
Bretylium,phase 4 complete,DB01158 (APRD00830),CC[N+](C)(C)CC1=CC=CC=C1Br,"Adrenergic Agents / Adrenergic Antagonists / Amines / Ammonium Compounds / Antiarrhythmic agents / Antiarrhythmics, Class III / Antihypertensive Agents / Benzylammonium Compounds / Bradycardia-Causing Agents / Bretylium Compounds / Cardiac Therapy / Cardiovascular Agents / Hypotensive Agents / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quaternary Ammonium Compounds",RZR75EQ2KJ,59-41-6,D00645,2431.0,2337.0,50239966.0,19685.0,3172.0,CHEMBL1199080,DAP000939,PA448662,ZINC000000001041
Halothane,phase 4 complete,"DB01159 (APRD00598, EXPT01754, DB02330)",[H]C(Cl)(Br)C(F)(F)F,"Agents that produce hypertension / Anesthetics / Anesthetics, General / Anesthetics, Inhalation / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Hydrocarbons, Halogenated / Hypotensive Agents / Nervous System / NMDA Receptor Antagonists",UQT9G45D1P,151-67-7,D00542,3562.0,3441.0,50112212.0,5095.0,5615.0,CHEMBL931,DAP000692,PA449845,
Dinoprost tromethamine,phase 4 complete,DB01160 (APRD00926),NC(CO)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,"Abortifacient Agents / Abortifacient Agents, Nonsteroidal / Angiography / Autacoids / Biological Factors / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Inflammation Mediators / Lipids / Prostaglandins / Prostaglandins F / Reproductive Control Agents / Uterotonic agents",CT6BBQ5A68,38562-01-5,D01352,5282415.0,4445570.0,,23321.0,31502.0,CHEMBL1200896,DAP000826,PA164781385,
Chloroprocaine,phase 4 complete,DB01161 (APRD00404),CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1,"Acids, Carbocyclic / Aminobenzoates / Anesthetics / Anesthetics, Local / Anticholinergic Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Cholinesterase substrates / Ester Local Anesthetic / Esters of Aminobenzoic Acid / Local Anesthesia / Nervous System / Nicotinic Antagonists / NMDA Receptor Antagonists / para-Aminobenzoates / Peripheral Nervous System Agents / Sensory System Agents",5YVB0POT2H,133-16-4,D07678,8612.0,8293.0,50239963.0,20859.0,3636.0,CHEMBL1179047,DAP000131,PA448946,ZINC000001530938
Terazosin,phase 4 complete,DB01162 (APRD00667),COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Drugs Used in Benign Prostatic Hypertrophy / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Neurotransmitter Agents / P-glycoprotein inhibitors / Peripheral alpha-1 blockers / Quinazolines / Urological Agents / Urologicals",8L5014XET7,63590-64-7,D08569,5401.0,5208.0,50033111.0,37798.0,9445.0,CHEMBL611,DAP000371,PA451612,
Calcium chloride,phase 4 complete,DB01164 (APRD00840),[Cl-].[Cl-].[Ca++],"Acidifiers / Acids / Acids, Noncarboxylic / Alimentary Tract and Metabolism / Anions / Blood and Blood Forming Organs / Blood Coagulation Factors / Blood Substitutes and Perfusion Solutions / Calcium Compounds / Calcium Salts / Chlorides / Chlorine Compounds / Electrolyte Solutions / Electrolytes / Genito Urinary System and Sex Hormones / Hemodialysis Solution / I.V. Solution Additives / Ions / Mineral Supplements / Phosphate Binder / Replacement Preparations / Supplements / Urologicals",OFM21057LP,10043-52-4,,5284359.0,23237.0,,1667640.0,3312.0,CHEMBL1200668,,PA448729,
Ofloxacin,phase 4 complete,DB01165 (APRD00502),CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1,"Agents Causing Muscle Toxicity / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / BSEP/ABCB11 Substrates / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Moderate Risk QTc-Prolonging Agents / OAT1/SLC22A6 inhibitors / Ophthalmologicals / Otologicals / QTc Prolonging Agents / Quinolines / Quinolone Antimicrobial / Quinolones / Renal Agents / Sensory Organs / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",A4P49JAZ9H,82419-36-1,D00453,4583.0,4422.0,50045004.0,7623.0,7731.0,CHEMBL4,DAP000655,PA450684,
Cilostazol,phase 4 complete,DB01166 (APRD00155),O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2,"Agents producing tachycardia / Anti-Asthmatic Agents / Antiplatelet agents / Autonomic Agents / Blood and Blood Forming Organs / Bronchodilator Agents / Cardiovascular Agents / Central Nervous System Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Fibrin Modulating Agents / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Neuroprotective Agents / Peripheral Nervous System Agents / Phosphodiesterase 3 Inhibitors / Phosphodiesterase Inhibitors / Platelet Aggregation Inhibitors Excl. Heparin / Potential QTc-Prolonging Agents / Protective Agents / QTc Prolonging Agents / Quinolines / Respiratory System Agents / Tetrazoles / Vasodilating Agents",N7Z035406B,73963-72-1,D01896,2754.0,2652.0,50225508.0,21107.0,31401.0,CHEMBL799,DAP000191,PA164746334,ZINC000001552174
Itraconazole,phase 4 complete,DB01167 (APRD00040),CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,"14-alpha Demethylase Inhibitors / Agents causing hyperkalemia / Anti-Infective Agents / Antifungal Agents / Antiinfectives for Systemic Use / Antimycotics for Systemic Use / Azole Antifungals / Breast Cancer Resistance Protein Inhibitors / Chemically-Induced Disorders / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strong) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strong) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strong) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / P-glycoprotein inhibitors / Photosensitizing Agents / Piperazines / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Steroid Synthesis Inhibitors / Triazole Derivatives / Triazoles",304NUG5GF4,84625-61-6,D00350,55283.0,49927.0,50127138.0,28031.0,6076.0,CHEMBL22587,DAP000631,PA450132,
Procarbazine,phase 4 complete,DB01168 (APRD00695),CNNCC1=CC=C(C=C1)C(=O)NC(C)C,"Acids, Carbocyclic / Agents Causing Muscle Toxicity / Alkylating Activity / Alkylating Drugs / Amides / Antidepressive Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Central Nervous System Depressants / Immunosuppressive Agents / Methylhydrazines / Monoamine Oxidase Inhibitors / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",35S93Y190K,671-16-9,D08423,4915.0,4746.0,,8702.0,71417.0,CHEMBL1321,DAP000986,PA451112,ZINC000019166988
Arsenic trioxide,phase 4 complete,DB01169 (APRD00171),O=[As]O[As]=O,Anions / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Arsenicals / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Electrolytes / Highest Risk QTc-Prolonging Agents / Hyperglycemia-Associated Agents / Hypotensive Agents / Immunosuppressive Agents / Ions / Myelosuppressive Agents / Organometallic Compounds / Oxides / Oxygen Compounds / P-glycoprotein substrates / QTc Prolonging Agents,S7V92P67HO,1327-53-3,D02106,261004.0,229103.0,,18330.0,,CHEMBL1200978,DNC000255,PA448486,
Guanethidine,phase 4 complete,DB01170 (APRD01007),NC(N)=NCCN1CCCCCCC1,"Adrenergic Agents / Adrenergic Antagonists / Amidines / Antiadrenergic Agents, Peripherally Acting / Antiglaucoma Preparations and Miotics / Antihypertensive Agents / Autonomic Agents / Cardiovascular Agents / Catecholamine-depleting Sympatholytic / Drugs that are Mainly Renally Excreted / Gastrointestinal Acidifying Agents / Guanidine Derivatives / Guanidine Derivatives and Diuretics / Guanidines / Neurotransmitter Agents / Ophthalmologicals / Peripheral Nervous System Agents / Sensory Organs / Sympatholytics",ZTI6C33Q2Q,55-65-2,D02237,3518.0,3398.0,50239969.0,5036.0,5557.0,CHEMBL765,DAP000124,PA449823,ZINC000001530648
Moclobemide,phase 4 complete,DB01171 (APRD00603),ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1,"Acids, Carbocyclic / Agents that produce hypertension / Agents that reduce seizure threshold / Amides / Antidepressive Agents / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Chlorobenzoates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Monoamine Oxidase A Inhibitors / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Monoamine Oxidase Inhibitors / Nervous System / Psychoanaleptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",PJ0Y7AZB63,71320-77-9,D02561,4235.0,4087.0,15613.0,30121.0,83531.0,CHEMBL86304,DAP000576,PA452615,ZINC000019606670
Kanamycin,phase 4 complete,DB01172 (APRD00026),NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,"Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antiinfectives for Systemic Use / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Enzyme Inhibitors / Glycosides / Intestinal Antiinfectives / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Ophthalmologicals / Protein Synthesis Inhibitors / Sensory Organs",EQK9Q303C5,59-01-8,,6032.0,5810.0,50031282.0,6099.0,17630.0,CHEMBL1384,DNC000201,PA450137,ZINC000008214590
Orphenadrine,phase 4 complete,DB01173 (APRD00097),CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C,"Agents producing tachycardia / Amines / Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Anticholinergic Agents / Autonomic Agents / Benzene Derivatives / Benzhydryl Compounds / Central Nervous System Agents / Central Nervous System Depressants / Centrally-mediated Muscle Relaxation / Chemically-Induced Disorders / Cholinergic Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Ethers, Chemically Close to Antihistamines / Ethylamines / Histamine Antagonists / Histamine H1 Antagonists / Miscellaneous Skeletal Muscle Relaxants / Muscarinic Antagonists / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Musculo-Skeletal System / Nervous System / Neurotransmitter Agents / NMDA Receptor Antagonists / Parasympatholytics / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents",AL805O9OG9,83-98-7,D08305,4601.0,4440.0,50062614.0,7715.0,7789.0,CHEMBL900,DAP000858,PA450715,
Phenobarbital,phase 4 complete,DB01174 (APRD00184),CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1,Anticholinergic Agents / Anticonvulsants / Barbiturates / Barbiturates and Derivatives / BSEP/ABCB11 inducers / Central Nervous System Agents / Central Nervous System Depressants / Chemically-Induced Disorders / Cytochrome P-450 2C18 Inducers / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strong) / Cytochrome P-450 CYP2C18 Inducers (strength unknown) / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers (strong) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP2E1 Inducers (weak) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strong) / Cytochrome P-450 CYP3A7 Inducers / Cytochrome P-450 CYP3A7 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Enzyme Inducing Antiepileptic Drugs / Excitatory Amino Acid Agents / Excitatory Amino Acid Antagonists / GABA Agents / GABA Modulators / Hypnotics and Sedatives / Methemoglobinemia Associated Agents / Narrow Therapeutic Index Drugs / Nervous System / Neurotransmitter Agents / Nicotinic Antagonists / P-glycoprotein inducers / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Phenobarbital and similars / Psycholeptics / Pyrimidines / Pyrimidinones / UGT1A1 Inducers / UGT2B7 inducers,YQE403BP4D,50-06-6,D00506,4763.0,4599.0,50021437.0,8134.0,8069.0,CHEMBL40,DAP000061,PA450911,ZINC000095588079
Escitalopram,phase 4 complete,DB01175 (APRD00683),CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,"Amines / Anticholinergic Agents / Antidepressive Agents / Antidepressive Agents, Second-Generation / Benzofurans / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Muscarinic Antagonists / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Nitriles / P-glycoprotein substrates / Photosensitizing Agents / Propylamines / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",4O4S742ANY,128196-01-0,,146570.0,129277.0,50302225.0,321988.0,36791.0,CHEMBL1508,DAP000741,PA10074,ZINC000003800706
Cyclizine,phase 4 complete,DB01176 (APRD00061),CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,Antiemetics / Antihistamines for Systemic Use / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Gastrointestinal Agents / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Neurotransmitter Agents / Peripheral Nervous System Agents / Piperazine Derivatives / Piperazines / Potential QTc-Prolonging Agents / QTc Prolonging Agents,QRW9FCR9P2,82-92-8,D03621,6726.0,6470.0,,2977.0,3994.0,CHEMBL648,DAP000337,PA164742937,ZINC000019156872
Idarubicin,phase 4 complete,DB01177 (APRD00126),C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O,"Anthracycline Topoisomerase Inhibitor / Anthracyclines / Anthracyclines and Related Substances / Antibiotics, Antineoplastic / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Carbohydrates / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Cytotoxic Antibiotics and Related Substances / Enzyme Inhibitors / Glycosides / Immunosuppressive Agents / Myelosuppressive Agents / Naphthacenes / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",ZRP63D75JW,58957-92-9,,42890.0,39117.0,58490.0,5650.0,42068.0,CHEMBL1117,DAP000050,PA449961,ZINC000003920266
Chlormezanone,phase 4 complete,DB01178 (APRD00865),CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O,"Anti-Anxiety Agents / Central Nervous System Agents / Central Nervous System Depressants / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Oxazol, Thiazine, and Triazine Derivatives / Peripheral Nervous System Agents / Psychotropic Drugs / Sulfur Compounds / Thiazines / Tranquilizing Agents",GP568V9G19,80-77-3,D00268,2717.0,2616.0,,2373.0,3619.0,CHEMBL1200714,DAP001252,PA448939,
Podofilox,phase 4 complete,"DB01179 (APRD01189, DB08417)",[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(OC)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@H]2O,"Antimitotic Agents / Antineoplastic Agents, Phytogenic / Antiviral Agents / Benzene Derivatives / Benzyl Compounds / Decreased Mitosis / Dermatologicals / Keratolytic Agents / Lignans / Misc. Skin and Mucous Membrane Agents / Mitosis Modulators / Naphthalenes / Tetrahydronaphthalenes / Tubulin Modulators",L36H50F353,518-28-5,,10607.0,10162.0,50035218.0,8463.0,50305.0,CHEMBL61,DNC001139,PA450993,ZINC000003861806
Rescinnamine,phase 4 complete,DB01180 (APRD00112),[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,"Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Agents that produce hypertension / Alkaloids / Angiotensin-Converting Enzyme Inhibitors / Antiadrenergic Agents, Centrally Acting / Antihypertensive Agents / Heterocyclic Compounds, Fused-Ring / Indole Alkaloids / Indoles / Secologanin Tryptamine Alkaloids",Q6W1F7DJ2D,24815-24-5,D00198,32681.0,4444446.0,,9259.0,28572.0,CHEMBL1668,DAP000910,PA164768818,ZINC000004097185
Ifosfamide,phase 4 complete,DB01181 (APRD00007),ClCCNP1(=O)OCCCN1CCCl,"Acids / Acids, Noncarboxylic / Alkylating Activity / Alkylating Drugs / Anions / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Electrolytes / Hydrocarbons, Halogenated / Immunosuppressive Agents / Ions / Methemoglobinemia Associated Agents / Mustard Compounds / Myelosuppressive Agents / Nitrogen Mustard Analogues / Nitrogen Mustard Compounds / Noxae / Organophosphorus Compounds / Oxazines / Phosphoramide Mustards / Phosphoramides / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds / Toxic Actions",UM20QQM95Y,3778-73-2,D00343,3690.0,3562.0,189358.0,5657.0,5864.0,CHEMBL1024,DAP000537,PA449964,
Propafenone,phase 4 complete,DB01182 (APRD00261),CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1,"Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Agents that produce hypertension / Antiarrhythmic agents / Antiarrhythmics, Class I / Antiarrhythmics, Class Ic / Bradycardia-Causing Agents / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Ketones / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / P-glycoprotein inhibitors / Propiophenones / QTc Prolonging Agents / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers",68IQX3T69U,54063-53-5,D08435,4932.0,4763.0,50067133.0,8754.0,63619.0,CHEMBL631,DAP000497,PA451131,
Naloxone,phase 4 complete,DB01183 (APRD00025),OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,"Alimentary Tract and Metabolism / Alkaloids / Analgesics / Antidotes / Central Nervous System Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 Enzyme Inhibitors / Drugs for Constipation / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Morphinans / Narcotics / Natural Opium Alkaloids / Nervous System / Opiate Alkaloids / Opiate Antagonists / Opioid Antagonists / P-glycoprotein substrates / Peripheral Nervous System Agents / Peripheral Opioid Receptor Antagonists / Phenanthrenes / Sensory System Agents / UGT1A1 Substrates",36B82AMQ7N,465-65-6,D08249,5284596.0,4447644.0,54795.0,7242.0,7459.0,CHEMBL80,DAP000097,PA450586,ZINC000000389747
Domperidone,phase 4 complete,DB01184 (APRD00418),ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2,"Alimentary Tract and Metabolism / Antiemetics / Autonomic Agents / Benzimidazoles / Central Nervous System Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs for Functional Gastrointestinal Disorders / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Neurotransmitter Agents / P-glycoprotein substrates / Peripheral Nervous System Agents / Piperidines / Prokinetic Agents / Propulsives / QTc Prolonging Agents",5587267Z69,57808-66-9,D01745,3151.0,3039.0,50241107.0,3626.0,31515.0,CHEMBL219916,DAP001368,PA134711056,ZINC000004175569
Fluoxymesterone,phase 4 complete,DB01185 (APRD00981),[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"3-Oxoandrosten (4) Derivatives / Anabolic Agents / Androgens / Androstanes / Androstenediols / Androstenes / Androstenols / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Sex Hormones and Modulators of the Genital System / Steroids / Steroids, Fluorinated",9JU12S4YFY,76-43-7,D00327,6446.0,6205.0,18189.0,4494.0,5120.0,CHEMBL1445,DAP000904,PA164744518,ZINC000003875484
Pergolide,phase 4 complete,DB01186 (APRD00663),[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC,"Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alkaloids / Anti-Parkinson Drugs / Antidepressive Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dopamine Agents / Dopamine Agonists / Ergolines / Ergot Alkaloids and Derivatives / Ergot-derivative Dopamine Receptor Agonists / Ergot-derived Dopamine Receptor Agonist / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotransmitter Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Agonists / Serotonin Agents / Serotonin Receptor Agonists",24MJ822NZ9,66104-22-1,,47811.0,43503.0,50028421.0,8047.0,63617.0,CHEMBL531,DAP000069,PA450873,ZINC000003786466
Iophendylate,phase 4 complete,"DB01187 (APRD01312, DB13498)",CCOC(=O)CCCCCCCCC(C)C1=CC=CC=C1I,"Benzene Derivatives / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Hydrocarbons, Halogenated / Hydrocarbons, Iodinated / Iodobenzenes / Non-Watersoluble X-Ray Contrast Media / X-Ray Contrast Media, Iodinated",6V3I57K9UL,99-79-6,,3037234.0,2301035.0,,5968.0,,CHEMBL951,,PA164743143,
Ciclopirox,phase 4 complete,DB01188 (APRD00871),CC1=CC(=O)N(O)C(=C1)C1CCCCC1,"Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Cyclohexanes / Cycloparaffins / Decreased DNA Replication / Decreased Protein Synthesis / Decreased RNA Replication / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hydroxypyridones / Protein Synthesis Inhibitors / Pyridines / Pyridones / Vaginal Creams, Foams, and Jellies",19W019ZDRJ,29342-05-0,D03488,2749.0,2647.0,66087.0,21090.0,453011.0,CHEMBL1413,DAP000466,PA164747060,ZINC000000001145
Desflurane,phase 4 complete,DB01189 (APRD00907),FC(F)OC(F)C(F)(F)F,"Agents that produce hypertension / Anesthetics / Anesthetics, General / Anesthetics, Inhalation / Central Nervous System Agents / Central Nervous System Depressants / Ethers / Ethyl Ethers / Hydrocarbons, Fluorinated / Hydrocarbons, Halogenated / Hypotensive Agents / Methyl Ethers / Nervous System / Potential QTc-Prolonging Agents / QTc Prolonging Agents",CRS35BZ94Q,57041-67-5,D00546,42113.0,38403.0,,27340.0,4445.0,CHEMBL1200733,DAP000693,PA164749136,
Clindamycin,phase 4 complete,DB01190 (APRD00566),CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,"Agents that produce neuromuscular block (indirect) / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antibiotics for Pneumocystis Pneumonia / Antiinfectives for Systemic Use / Antiinfectives for Treatment of Acne / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Sebaceous Gland Activity / Dermatologicals / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Glycosides / Gynecological Antiinfectives and Antiseptics / Lincomycins / Lincosamide Antibacterial / Lincosamides / Macrolides, Lincosamides and Streptogramins / Narrow Therapeutic Index Drugs / Neurotoxic agents / P-glycoprotein substrates / Protein Synthesis Inhibitors / Pyrrolidines",3U02EL437C,18323-44-9,D00277,446598.0,27005.0,,2582.0,3745.0,CHEMBL376185,DAP000409,PA449035,
Dexfenfluramine,phase 4 complete,DB01191 (APRD00648),CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F,"Alimentary Tract and Metabolism / Amines / Antiobesity Preparations, Excl. Diet Products / Centrally Acting Antiobesity Products / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Ethylamines / Neurotransmitter Agents / Phenethylamines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",E35R3G56OV,3239-44-9,D07805,66265.0,59646.0,85596.0,3268.0,439329.0,CHEMBL248702,DAP001224,PA164747936,ZINC000000000294
Oxymorphone,phase 4 complete,DB01192 (APRD00158),[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O,"Adjuvants / Adjuvants, Anesthesia / Alkaloids / Analgesics / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / High-risk opioids / Morphinans / Morphine Derivatives / Narcotics / Opiate Agonists / Opiate Alkaloids / Opioid Agonist / Opioids / Peripheral Nervous System Agents / Phenanthrenes / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",9VXA968E0C,76-41-5,D08323,5284604.0,4447650.0,50001707.0,7814.0,7865.0,CHEMBL963,DAP001138,PA450748,ZINC000003875483
Acebutolol,phase 4 complete,DB01193 (APRD00772),CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(=C1)C(C)=O,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-1 Receptor Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Autonomic Agents / Beta Blocking Agents and Thiazides / Beta Blocking Agents, Selective / Beta Blocking Agents, Selective, and Thiazides / Beta-Blockers (Beta1 Selective) / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hypotensive Agents / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / P-glycoprotein substrates / Peripheral Nervous System Agents / Phenoxypropanolamines / Propanolamines / Propanols / QTc Prolonging Agents / Sympathomimetics",67P356D8GH,37517-30-9,D02338,1978.0,1901.0,25755.0,149.0,2379.0,CHEMBL642,DAP000484,PA448011,
Brinzolamide,phase 4 complete,DB01194 (APRD00475),CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,Amides / Antiglaucoma Preparations and Miotics / Carbonic Anhydrase Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Diuretics / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Ophthalmics / Ophthalmologicals / Sensory Organs / Sulfonamides / Sulfones / Sulfur Compounds,9451Z89515,138890-62-7,D00652,68844.0,62077.0,10885.0,194881.0,3176.0,CHEMBL220491,DAP000602,PA164744929,ZINC000003953037
Flecainide,phase 4 complete,DB01195 (APRD00129),FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1,"Antiarrhythmic agents / Antiarrhythmics, Class I / Antiarrhythmics, Class Ic / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / MATE 1 Inhibitors / MATE 1 Substrates / MATE inhibitors / MATE substrates / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / Narrow Therapeutic Index Drugs / P-glycoprotein substrates / Piperidines / QTc Prolonging Agents / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers",K94FTS1806,54143-55-4,D07962,3356.0,3239.0,50131434.0,4441.0,75984.0,CHEMBL652,DAP000518,PA449646,
Estramustine,phase 4 complete,DB01196 (APRD00625),[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H],"Alkylating Activity / Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Estradiol Congeners / Estranes / Estrenes / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydrocarbons, Halogenated / Immunosuppressive Agents / Mustard Compounds / Nitrogen Mustard Compounds / Noxae / P-glycoprotein inhibitors / Steroids / Toxic Actions",35LT29625A,2998-57-4,D04066,259331.0,227635.0,50333646.0,4089.0,4868.0,CHEMBL1575,DAP001307,PA449507,ZINC000004099032
Captopril,phase 4 complete,DB01197 (APRD00164),C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,"ACE Inhibitors and Diuretics / Acids, Acyclic / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Agents Causing Muscle Toxicity / Amino Acids / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Hypotensive Agents / Imines / Imino Acids / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / P-glycoprotein inhibitors / Photosensitizing Agents / Protease Inhibitors",9G64RSX1XD,62571-86-2,D00251,44093.0,40130.0,21642.0,1998.0,3380.0,CHEMBL1560,DAP000589,PA448780,ZINC000000057001
Zopiclone,phase 4 complete,DB01198 (APRD00356),CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1,Aza Compounds / Benzodiazepine hypnotics and sedatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Hypnotics (Nonbenzodiazepine) / Hypnotics and Sedatives / Methemoglobinemia Associated Agents / Miscellaneous Anxiolytics Sedatives and Hypnotics / Nervous System / Photosensitizing Agents / Psycholeptics / Sleep Initiation and Maintenance Disorders / Zopiclone and prodrugs,03A5ORL08Q,43200-80-2,D01372,5735.0,5533.0,50054136.0,40001.0,32315.0,CHEMBL135400,DAP000427,PA10236,
Tubocurarine,phase 4 complete,DB01199 (APRD00176),[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3,"Alkaloids / Amines / Ammonium Compounds / Anticholinergic Agents / Benzylisoquinolines / Central Nervous System Depressants / Cholinergic Agents / Cholinesterase Inhibitors / Cholinesterase substrates / Curare Alkaloids / Ganglion Blockers / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular-Blocking Agents (Nondepolarizing) / Neurotoxic agents / Neurotransmitter Agents / Nicotinic Antagonists / Nitrogen Compounds / OCT1 substrates / Onium Compounds / Peripheral Nervous System Agents / Quaternary Ammonium Compounds / Tetrahydroisoquinolines",W9YXS298BM,57-95-4,,6000.0,5778.0,50366799.0,10917.0,9774.0,CHEMBL339427,DAP000351,PA451811,ZINC000003978083
Bromocriptine,phase 4 complete,DB01200 (APRD00622),[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C,"Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Alkaloids / Anti-Dyskinesia Agents / Anti-Parkinson Agents (Dopamine Agonist) / Anti-Parkinson Drugs / Antidepressive Agents / Blood Glucose Lowering Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Agonists / Ergolines / Ergot Alkaloids and Derivatives / Ergot-derivative Dopamine Receptor Agonists / Ergotamines / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypotensive Agents / Nervous System / Neurotransmitter Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Prolactine Inhibitors / Serotonin 5-HT2 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists",3A64E3G5ZO,25614-03-3,D03165,31101.0,28858.0,81993.0,1760.0,3181.0,CHEMBL493,DAP001462,PA448671,ZINC000053683151
Rifapentine,phase 4 complete,DB01201 (APRD01217),CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics, Antitubercular / Antiinfectives for Systemic Use / Antimycobacterials / Antituberculosis Agents / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strong) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Drugs for Treatment of Tuberculosis / Heterocyclic Compounds, Fused-Ring / Lactams / Lactams, Macrocyclic / Leprostatic Agents / Rifamycin Antimycobacterial / Rifamycins",XJM390A33U,61379-65-5,D00879,6323497.0,10482075.0,,35617.0,45304.0,CHEMBL1660,DAP000426,PA164783809,ZINC000169621228
Levetiracetam,phase 4 complete,DB01202 (APRD01068),CC[C@H](N1CCCC1=O)C(N)=O,Acetamides / Amides / Anticonvulsants / Central Nervous System Agents / Central Nervous System Depressants / Decreased Central Nervous System Disorganized Electrical Activity / Miscellaneous Anticonvulsants / Nervous System / P-glycoprotein substrates / Pyrrolidines / Pyrrolidinones,44YRR34555,102767-28-2,D00709,5284583.0,4447633.0,50422542.0,114477.0,6437.0,CHEMBL1286,DAP000502,PA450206,ZINC000001547851
Nadolol,phase 4 complete,DB01203 (APRD00301),CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Autonomic Agents / Beta Blocking Agents and Thiazides / Beta Blocking Agents, Non-Selective / Beta Blocking Agents, Non-Selective, and Thiazides / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Hypotensive Agents / MATE 1 Substrates / MATE 2 Substrates / MATE substrates / Neurotransmitter Agents / P-glycoprotein substrates / Peripheral Nervous System Agents / Phenoxypropanolamines / Photosensitizing Agents / Propanolamines / Propanols / Sympatholytics",FEN504330V,42200-33-9,D00432,39147.0,35815.0,25766.0,7226.0,7444.0,CHEMBL649,DAP000122,PA450573,
Mitoxantrone,phase 4 complete,DB01204 (APRD00371),OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O,Analgesics / Anthracenes / Anthracyclines and Related Substances / Anthraquinones / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Cardiotoxic antineoplastic agents / Central Nervous System Agents / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Cytotoxic Antibiotics and Related Substances / Enzyme Inhibitors / Immunosuppressive Agents / Myelosuppressive Agents / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Peripheral Nervous System Agents / Quinones / Sensory System Agents / Topoisomerase II Inhibitors / Topoisomerase Inhibitors,BZ114NVM5P,65271-80-9,D08224,4212.0,4067.0,67690.0,7005.0,50729.0,CHEMBL58,DAP000057,PA450526,ZINC000003794794
Flumazenil,phase 4 complete,DB01205 (APRD00974),CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1,"Antidotes / Benzazepines / Benzodiazepine Antagonist / Benzodiazepinones / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Miscellaneous Central Nervous System Agents / Neurotransmitter Agents / Protective Agents",40P7XK9392,78755-81-4,D00697,3373.0,3256.0,26263.0,4457.0,5103.0,CHEMBL407,DAP000685,PA449659,ZINC000000001464
Lomustine,phase 4 complete,DB01206 (APRD00292),ClCCN(N=O)C(=O)NC1CCCCC1,"Alkylating Activity / Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nitroso Compounds / Nitrosourea Compounds / Nitrosoureas / Noxae / Toxic Actions",7BRF0Z81KG,13010-47-4,D00363,3950.0,3813.0,50247919.0,6466.0,6520.0,CHEMBL514,DAP000991,PA164749407,ZINC000003831006
Sparfloxacin,phase 4 complete,DB01208 (APRD01231),C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Antituberculosis Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / P-glycoprotein substrates / QTc Prolonging Agents / Quinolines / Quinolones / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",Q90AGA787L,110871-86-8,D00590,60464.0,54517.0,50366822.0,18469.0,9212.0,CHEMBL850,DAP000161,PA451472,ZINC000000538362
Dezocine,phase 4 complete,DB01209 (APRD00912),[H][C@@]12CC3=CC=C(O)C=C3[C@@](C)(CCCCC1)[C@H]2N,Analgesics / Central Nervous System Agents / Central Nervous System Depressants / Naphthalenes / Narcotics / Nervous System / Opioid Antagonists / Opioids / Peripheral Nervous System Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome,VHX8K5SV4X,53648-55-8,D00838,3033053.0,2297867.0,50276568.0,22713.0,4474.0,CHEMBL1685,DAP001100,PA164746059,
Levobunolol,phase 4 complete,DB01210 (APRD00165),CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O,Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiglaucoma Preparations and Miotics / Autonomic Agents / Beta-adrenergic Agents / Bradycardia-Causing Agents / Bunolol / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Hypotensive Agents / Naphthalenes / Neurotransmitter Agents / Ophthalmologicals / Peripheral Nervous System Agents / Phenoxypropanolamines / Propanolamines / Propanols / Sensory Organs / Sympatholytics / Tetrahydronaphthalenes,G6317AOI7K,47141-42-4,,39468.0,36089.0,,1813.0,6438.0,CHEMBL1201237,DAP000303,PA164747027,ZINC000003830339
Clarithromycin,phase 4 complete,DB01211 (APRD00181),[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC,"Alimentary Tract and Metabolism / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / BSEP/ABCB11 Substrates / Chemically-Induced Disorders / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strong) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Enzyme Inhibitors / Erythromycin and similars / Lactones / Macrolide Antimicrobial / Macrolides / Macrolides, Lincosamides and Streptogramins / Moderate Risk QTc-Prolonging Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Other Macrolides / P-glycoprotein inhibitors / P-glycoprotein substrates / Polyketides / Protein Synthesis Inhibitors / QTc Prolonging Agents",H1250JIK0A,81103-11-9,D00276,84029.0,10342604.0,50404044.0,21212.0,3732.0,CHEMBL1741,DAP000410,PA449028,ZINC000085534098
Ceftriaxone,phase 4 complete,DB01212 (APRD00395),[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephacetrile / Cephalosporins / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / P-glycoprotein inhibitors / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",75J73V1629,73384-59-5,D07659,5479530.0,4586394.0,50103601.0,2193.0,29007.0,CHEMBL161,DAP000145,PA448866,ZINC000028467879
Fomepizole,phase 4 complete,DB01213 (APRD00985),CC1=CNN=C1,"Antidotes / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Protective Agents / Pyrazoles",83LCM6L2BY,7554-65-6,D00707,3406.0,3289.0,50226186.0,15226.0,5141.0,CHEMBL1308,DAP000568,PA449697,ZINC000000897288
Metipranolol,phase 4 complete,DB01214 (APRD00668),CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antiglaucoma Preparations and Miotics / Antihypertensive Agents / Autonomic Agents / Beta Blocking Agents and Thiazides / Beta Blocking Agents, Non-Selective, and Thiazides / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Hypotensive Agents / Neurotransmitter Agents / Ophthalmologicals / Peripheral Nervous System Agents / Phenoxypropanolamines / Propanolamines / Propanols / Sensory Organs / Sympatholytics",X39AL81KEB,22664-55-7,D02374,31477.0,29193.0,,10824.0,6897.0,CHEMBL1291,DAP000480,PA164748727,
Estazolam,phase 4 complete,DB01215 (APRD00955),ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1,"Anti-Anxiety Agents / Anticonvulsants / Benzazepines / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Photosensitizing Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents / Triazolobenzodiazepines",36S3EQV54C,29975-16-4,D00311,3261.0,3146.0,50240450.0,4077.0,4858.0,CHEMBL285674,DAP000930,PA449502,ZINC000000001370
Finasteride,phase 4 complete,"DB01216 (APRD00632, DB07774)",[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C,"5-alpha Reductase Inhibitors / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Androstanes / Androstenes / Azasteroids / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Drugs Used in Benign Prostatic Hypertrophy / Enzyme Inhibitors / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Misc. Skin and Mucous Membrane Agents / Steroid Synthesis Inhibitors / Steroids / Urological Agents / Urologicals",57GNO57U7G,98319-26-7,D00321,57363.0,51714.0,50334788.0,25025.0,5062.0,CHEMBL710,DAP000045,PA449627,ZINC000003782599
Anastrozole,phase 4 complete,DB01217 (APRD00016),CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N,"Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Aromatase Inhibitors / Cardiotoxic antineoplastic agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Endocrine Therapy / Enzyme Inhibitors / Estrogen Antagonists / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Nitriles / P-glycoprotein substrates / Steroid Synthesis Inhibitors / Triazoles / UGT1A3 substrates / UGT1A4 substrates / UGT2B7 substrates",2Z07MYW1AZ,120511-73-1,D00960,2187.0,2102.0,10015.0,84857.0,2704.0,CHEMBL1399,DAP000627,PA448432,ZINC000000000941
Halofantrine,phase 4 complete,DB01218 (APRD00419),CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C2C=C(Cl)C=C(Cl)C2=C1)C(F)(F)F,"Agents that reduce seizure threshold / Anti-Infective Agents / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Highest Risk QTc-Prolonging Agents / QTc Prolonging Agents",Q2OS4303HZ,69756-53-2,,37393.0,34303.0,79214.0,50749.0,94392.0,CHEMBL1107,DAP000953,PA449839,
Dantrolene,phase 4 complete,DB01219 (APRD00901),[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O,"Agents causing hyperkalemia / Agents that produce neuromuscular block (indirect) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Substrates / Dantrolene and Derivatives / Decreased Striated Muscle Contraction / Decreased Striated Muscle Tone / Direct-acting Skeletal Muscle Relaxants / Hepatotoxic Agents / Hydantoins / Imidazoles / Imidazolidines / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Peripheral Nervous System Agents / Thyroxine-binding globulin substrates",F64QU97QCR,7261-97-4,D02347,6914273.0,5290202.0,50198767.0,3105.0,4317.0,CHEMBL1201288,DNC001623,PA449208,ZINC000002568036
Rifaximin,phase 4 complete,DB01220 (APRD01218),CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O,"Alimentary Tract and Metabolism / Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics for Topical Use / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strong) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Intestinal Antiinfectives / Lactams / Lactams, Macrocyclic / Rifamycin Antibacterial / Rifamycins",L36O5T016N,80621-81-4,D02554,6436173.0,10482302.0,50347620.0,35619.0,75246.0,CHEMBL1617,DAP001006,PA164752443,ZINC000169621200
Ketamine,phase 4 complete,DB01221 (APRD00493),CNC1(CCCCC1=O)C1=CC=CC=C1Cl,"Agents producing tachycardia / Amino Acids / Amino Acids, Acidic / Amino Acids, Dicarboxylic / Amino Acids, Peptides, and Proteins / Analgesics / Anesthetics / Anesthetics, Dissociative / Anesthetics, General / Anesthetics, Intravenous / Central Nervous System Agents / Central Nervous System Depressants / Cholinesterase Inhibitors / Cyclohexanes / Cycloparaffins / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Excitatory Amino Acid Agents / Excitatory Amino Acid Agonists / Excitatory Amino Acid Antagonists / Excitatory Amino Acids / Miscellaneous General Anesthetics / N-Methylaspartate, agonists / N-Methylaspartate, antagonists & inhibitors / Nervous System / Neurotransmitter Agents / NMDA Receptor Antagonists / Peripheral Nervous System Agents / Sensory System Agents / Vasodilating Agents",690G0D6V8H,6740-88-1,D08098,3821.0,3689.0,50044140.0,6130.0,6121.0,CHEMBL742,DAP001148,PA450144,
Budesonide,phase 4 complete,DB01222 (APRD00442),[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Adrenals / Agents to Treat Airway Disease / Alimentary Tract and Metabolism / Anti-Asthmatic Agents / Anti-Inflammatory Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Autonomic Agents / Bronchodilator Agents / BSEP/ABCB11 Substrates / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids Acting Locally / Corticosteroids for Systemic Use / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (moderate) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Drugs for Obstructive Airway Diseases / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Intestinal Antiinflammatory Agents / Nasal Preparations / OAT3/SLC22A8 Substrates / P-glycoprotein substrates / Peripheral Nervous System Agents / Pregnanes / Pregnenediones / Pregnenes / Respiratory System Agents / Steroids",Q3OKS62Q6X,51333-22-3,D00246,5281004.0,4444479.0,50354850.0,19831.0,3207.0,CHEMBL1370,DAP000320,PA448681,
Aminophylline,phase 4 complete,DB01223 (APRD00329),NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O,"Agents that reduce seizure threshold / Alkaloids / Amines / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Diamines / Drugs for Obstructive Airway Diseases / Enzyme Inhibitors / Ethylenediamines / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / Neurotransmitter Agents / Peripheral Nervous System Agents / Pharmaceutical Preparations / Phosphodiesterase Inhibitors / Polyamines / Protective Agents / Purinergic Agents / Purinergic Antagonists / Purinergic P1 Receptor Antagonists / Purines / Purinones / Respiratory Smooth Muscle Relaxants / Respiratory System Agents / Xanthine derivatives / Xanthines and Adrenergics",27Y3KJK423,317-34-0,D00227,9433.0,9062.0,,689.0,2659.0,CHEMBL1370561,DAP000613,PA164781029,
Quetiapine,phase 4 complete,DB01224 (APRD00675),OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Anticholinergic Agents / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Azepines / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Diazepines, Oxazepines, Thiazepines and Oxepines / Dibenzothiazepines / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Hyperglycemia-Associated Agents / Hypotensive Agents / Moderate Risk QTc-Prolonging Agents / Muscarinic Antagonists / Nervous System / P-glycoprotein substrates / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Thiazepines / Thiepins / Tranquilizing Agents",BGL0JSY5SI,111974-69-7,D08456,5002.0,4827.0,50095890.0,51272.0,8707.0,CHEMBL716,DAP000001,PA451201,ZINC000019632628
Enoxaparin,phase 4 complete,DB01225 (APRD00068),,Agents causing hyperkalemia / Anticoagulants / Blood and Blood Forming Organs / Carbohydrates / Cardiovascular Agents / Fibrin Modulating Agents / Glycosaminoglycans / Hematologic Agents / Heparin (Low Molecular Weight) / Heparin and similars / Heparin Group / Polysaccharides,E47C0NF7LV,9005-49-6,D07510,,751.0,,67108.0,,CHEMBL1201685,DAP000616,PA449463,
Mivacurium,phase 4 complete,DB01226 (APRD01119),COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC,"Agents producing tachycardia / Anticholinergic Agents / Central Nervous System Depressants / Cholinergic Agents / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Muscarinic Antagonists / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular-Blocking Agents (Nondepolarizing) / Nicotinic Antagonists / Peripheral Nervous System Agents",77D66S9Q93,133814-19-4,,5281042.0,4444509.0,,30077.0,6958.0,CHEMBL1182833,DAP000716,PA450528,ZINC000150338702
Levacetylmethadol,phase 4 complete,DB01227 (APRD00745),CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,Analgesics / Anticholinergic Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Drugs Used in Addictive Disorders / Drugs Used in Opioid Dependence / Ketones / Moderate Risk QTc-Prolonging Agents / Narcotics / Nervous System / Nicotinic Antagonists / Opioids / Peripheral Nervous System Agents / QTc Prolonging Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome,R3B637Y991,1477-40-3,D04716,15130.0,14401.0,,237005.0,6441.0,CHEMBL1514,DAP001139,PA450215,ZINC000001530967
Encainide,phase 4 complete,DB01228 (APRD00613),COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C,"Amides / Amines / Anilides / Aniline Compounds / Antiarrhythmic agents / Antiarrhythmics, Class I / Antiarrhythmics, Class Ic / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Membrane Transport Modulators / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers",SY3J0147NB,66778-36-7,D07894,48041.0,43697.0,,42368.0,4788.0,CHEMBL315838,DAP000519,PA449459,
Paclitaxel,phase 4 complete,"DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)",[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,"Agents Causing Muscle Toxicity / Antimitotic Agents / Antineoplastic Agents / Antineoplastic Agents, Phytogenic / Antineoplastic and Immunomodulating Agents / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / BSEP/ABCB11 Substrates with Narrow Therapeutic Index / Cardiotoxic antineoplastic agents / Cyclodecanes / Cycloparaffins / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Diterpenes / Hypotensive Agents / Immunosuppressive Agents / Microtubule Inhibition / Microtubule Inhibitors / Mitosis Modulators / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Neurotoxic agents / OATP1B3 substrates / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Taxane Derivatives / Taxoids / Terpenes / Tubulin Modulators",P88XT4IS4D,33069-62-4,D00491,36314.0,10368587.0,50001839.0,56946.0,45863.0,CHEMBL428647,DNC001411,PA450761,ZINC000096006020
Pemoline,phase 4 complete,DB01230 (APRD01169),NC1=NC(=O)C(O1)C1=CC=CC=C1,"Central Nervous System Agents / Central Nervous System Stimulants / Centrally Acting Sympathomimetics / Nervous System / Oxazoles / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics",7GAQ2332NK,2152-34-3,D00744,4723.0,4561.0,,7966.0,7953.0,CHEMBL1177,,PA450836,
Diphenidol,phase 4 complete,DB01231 (APRD00929),OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,Agents producing tachycardia / Anticholinergic Agents / Antiemetics / Autonomic Agents / Central Nervous System Agents / Emesis Suppression / Gastrointestinal Agents / Muscarinic Antagonists / Peripheral Nervous System Agents,NQO8R319LY,972-02-1,D03858,3055.0,2947.0,50225701.0,23370.0,4638.0,CHEMBL936,DAP001133,PA164746037,ZINC000000968266
Saquinavir,phase 4 complete,DB01232 (APRD00623),[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,"Agents Causing Muscle Toxicity / Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BCRP/ABCG2 Inhibitors / BSEP/ABCB11 Substrates / Chemically-Induced Disorders / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors (strong) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Inhibitors (strong) / Cytochrome P-450 CYP3A7 Inhibitors (weak) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / HIV Protease Inhibitors / Hyperglycemia-Associated Agents / Isoquinolines / Moderate Risk QTc-Prolonging Agents / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Protease Inhibitors / QTc Prolonging Agents / Quinolines",L3JE09KZ2F,127779-20-8,D00429,441243.0,390016.0,519.0,83395.0,63621.0,CHEMBL114,DAP000171,PA451305,ZINC000003914596
Metoclopramide,phase 4 complete,DB01233 (APRD00665),CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC,"Acids, Carbocyclic / Agents Causing Muscle Toxicity / Alimentary Tract and Metabolism / Amides / Aminobenzoates / Antiemetics / Autonomic Agents / Benzamides and benzamide derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Chlorobenzoates / Cholinesterase Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs for Functional Gastrointestinal Disorders / Drugs that are Mainly Renally Excreted / Gastrointestinal Agents / Hydroxybenzoates / Methemoglobinemia Associated Agents / Neurotransmitter Agents / P-glycoprotein substrates / para-Aminobenzoates / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / Prokinetic Agents / Propulsives / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",L4YEB44I46,364-62-5,D00726,4168.0,4024.0,48320.0,6915.0,107736.0,CHEMBL86,DAP000530,PA450475,ZINC000001530716
Dexamethasone,phase 4 complete,DB01234 (APRD00674),[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Adrenals / Agents Causing Muscle Toxicity / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Alimentary Tract and Metabolism / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anti-Inflammatory Agents / Antiemetics / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Autonomic Agents / BCRP/ABCG2 Inhibitors / BSEP/ABCB11 inducers / Central Nervous System Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids for Local Oral Treatment / Corticosteroids for Systemic Use / Corticosteroids for Systemic Use, Plain / Corticosteroids, Dermatological Preparations / Corticosteroids, Moderately Potent (Group II) / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (moderate) / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (moderate) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inducers / Cytochrome P-450 CYP3A7 Inducers (strength unknown) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Experimental Unapproved Treatments for COVID-19 / Fused-Ring Compounds / Gastrointestinal Agents / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Inducers of Drug Clearance / Nasal Preparations / OAT3/SLC22A8 Substrates / Ophthalmological and Otological Preparations / Ophthalmologicals / Otologicals / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / Pregnadienes / Pregnadienetriols / Pregnanes / Sensory Organs / Steroids / Steroids, Fluorinated / Stomatological Preparations / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Vasoprotectives",7S5I7G3JQL,50-02-2,D00292,5743.0,5541.0,18207.0,3264.0,41879.0,CHEMBL384467,DAP000007,PA449247,ZINC000003875332
Levodopa,phase 4 complete,"DB01235 (APRD00309, EXPT01107)",N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O,"Amines / Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Anti-Dyskinesia Agents / Anti-Parkinson Agents (Dopamine Agonist) / Anti-Parkinson Drugs / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Catecholamines / Catechols / Central Nervous System Agents / Central Nervous System Depressants / Dihydroxyphenylalanine / Dopa and Dopa Derivatives / Dopamine Agents / Hypotensive Agents / Levodopa, antagonists & inhibitors / Nervous System / Neurotransmitter Agents / Phenols / Phenylalanine / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",46627O600J,59-92-7,D00059,6047.0,5824.0,60928.0,6375.0,15765.0,CHEMBL1009,DAP000209,PA450213,ZINC000000895199
Sevoflurane,phase 4 complete,DB01236 (APRD00219),FCOC(C(F)(F)F)C(F)(F)F,"Agents that produce hypertension / Anesthetics / Anesthetics, General / Anesthetics, Inhalation / Antiplatelet agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Ethers / Hematologic Agents / Hydrocarbons, Fluorinated / Hydrocarbons, Halogenated / Hypotensive Agents / Methyl Ethers / Nervous System / Potential QTc-Prolonging Agents / QTc Prolonging Agents",38LVP0K73A,28523-86-6,D00547,5206.0,5017.0,,36453.0,9130.0,CHEMBL1200694,DAP000694,PA451341,ZINC000001530810
Bromodiphenhydramine,phase 4 complete,DB01237 (APRD00710),CN(C)CCOC(C1=CC=CC=C1)C1=CC=C(Br)C=C1,Amines / Aminoalkyl Ethers / Antihistamines for Systemic Use / Benzene Derivatives / Benzhydryl Compounds / Ethylamines / Histamine Antagonists / Histamine H1 Antagonists,T032BI7727,118-23-0,,2444.0,2350.0,81465.0,19759.0,59177.0,CHEMBL1201245,DAP001072,PA164760854,
Aripiprazole,phase 4 complete,DB01238 (APRD00638),ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Anticholinergic Agents / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Aripiprazole and prodrugs / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Agonists / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Hyperglycemia-Associated Agents / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Piperazines / Potential QTc-Prolonging Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / QTc shortening agents / Quinolines / Quinolones / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1D Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Agonists / Serotonin Receptor Antagonists / Tranquilizing Agents",82VFR53I78,129722-12-9,D01164,60795.0,54790.0,50130293.0,89013.0,31236.0,CHEMBL1112,DAP000076,PA10026,ZINC000001851149
Chlorprothixene,phase 4 complete,DB01239 (APRD00718),CN(C)CC\C=C1\C2=CC=CC=C2SC2=CC=C(Cl)C=C12,"Agents producing tachycardia / Anticholinergic Agents / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Agents / Central Nervous System Depressants / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Thioxanthene Derivatives / Thioxanthenes / Tranquilizing Agents / Xanthenes",9S7OD60EWP,113-59-7,D00790,667466.0,580849.0,50240514.0,2406.0,50931.0,CHEMBL908,DAP000833,PA164781400,ZINC000000001137
Epoprostenol,phase 4 complete,DB01240 (APRD00949),[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O,"Anticoagulants / Antihypertensive Agents / Antiplatelet agents / Autacoids / Biological Factors / Blood and Blood Forming Organs / Cardiovascular Agents / Drugs that are Mainly Renally Excreted / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Hematologic Agents / Hypotensive Agents / Inflammation Mediators / Lipids / Platelet Aggregation Inhibitors Excl. Heparin / Prostacyclin Analogues / Prostacycline Vasodilator / Prostaglandins / Prostaglandins I / Vasodilating Agents / Vasodilation",DCR9Z582X0,35121-78-9,D00106,5280427.0,4445566.0,,8814.0,15552.0,CHEMBL1139,DAP001213,PA449479,ZINC000003813078
Gemfibrozil,phase 4 complete,DB01241 (APRD00293),CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,"Acids, Acyclic / Agents Causing Muscle Toxicity / Benzene Derivatives / Butyrates / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Ethers / Fatty Acids / Fatty Acids, Volatile / Fibric Acids / Fribic Acid Derivatives / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Isobutyrates / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Lipids / Noxae / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Pentanoic Acids / Peroxisome Proliferator Receptor alpha Agonist / Peroxisome Proliferator-activated Receptor alpha Agonists / Phenols / Phenyl Ethers / Photosensitizing Agents / Toxic Actions / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT1A3 Inhibitors / UGT1A3 substrates / UGT1A9 Substrates / UGT2B7 substrates / Valerates",Q8X02027X3,25812-30-0,D00334,3463.0,3345.0,50110590.0,4719.0,5296.0,CHEMBL457,DAP000210,PA449750,ZINC000001530641
Clomipramine,phase 4 complete,"DB01242 (APRD00253, DB07600)",CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2,"Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Antidepressive Agents, Tricyclic / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dibenzazepines / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Non-Selective Monoamine Reuptake Inhibitors / P-glycoprotein inhibitors / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Tertiary amine tricyclic antidepressants / Tricyclics and Other Norepinephrine-reuptake Inhibitors",NUV44L116D,303-49-1,D00811,2801.0,2699.0,77970.0,2597.0,47780.0,CHEMBL415,DAP000742,PA449048,ZINC000000020248
Chloroxine,phase 4 complete,DB01243 (APRD00866),OC1=C(Cl)C=C(Cl)C2=C1N=CC=C2,"Anti-Bacterial Agents / Anti-Infective Agents / Antifungal Agents / Heterocyclic Compounds, Fused-Ring / Hydroxyquinolines / Quinolines",2I8BD50I8B,773-76-2,D03472,2722.0,2621.0,32147.0,20875.0,59477.0,CHEMBL1200596,,PA164754879,ZINC000000001131
Bepridil,phase 4 complete,DB01244 (APRD00727),CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,Agents causing hyperkalemia / Antiarrhythmic agents / Antihypertensive Agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Highest Risk QTc-Prolonging Agents / Hypotensive Agents / Membrane Transport Modulators / Non-Selective Calcium Channel Blockers / P-glycoprotein inhibitors / Phenylalkylamine Derivatives / Pyrrolidines / QTc Prolonging Agents / Vasodilating Agents,755BO701MA,64706-54-3,D07520,2351.0,2261.0,78577.0,1436.0,3061.0,CHEMBL1008,DAP000525,PA164754755,
Decamethonium,phase 4 complete,DB01245 (APRD00696),C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,Amines / Ammonium Compounds / Bis-Trimethylammonium Compounds / Central Nervous System Depressants / Cholinesterase Inhibitors / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular Depolarizing Agents / Neurotoxic agents / Nitrogen Compounds / Onium Compounds / Peripheral Nervous System Agents / Quaternary Ammonium Compounds,C1CG1S3T2W,156-74-1,,2968.0,2862.0,50060582.0,,41934.0,CHEMBL1190,DAP000378,PA164747980,ZINC000001532339
Alimemazine,phase 4 complete,DB01246 (APRD00258),CC(CN(C)C)CN1C2=CC=CC=C2SC2=CC=CC=C12,"Antihistamines for Systemic Use / Antipruritics / Antipsychotic Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 Enzyme Inducers / Dermatologicals / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Neurotoxic agents / Neurotransmitter Agents / Phenothiazine Derivatives / Phenothiazines / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sulfur Compounds",76H78MJJ52,84-96-8,D07125,5574.0,5373.0,50062261.0,10825.0,9725.0,CHEMBL829,DAP001077,PA164744009,
Isocarboxazid,phase 4 complete,DB01247 (APRD00701),CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1,"Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Hypotensive Agents / Isoxazoles / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Monoamine Oxidase Inhibitors / Monoamine Oxidase Inhibitors, Non-Selective / Nervous System / Photosensitizing Agents / Psychoanaleptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",34237V843T,59-63-2,D02580,3759.0,3628.0,163692.0,6011.0,93635.0,CHEMBL1201168,DAP000577,PA450101,ZINC000000001587
Docetaxel,phase 4 complete,DB01248 (APRD00932),[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,Agents Causing Muscle Toxicity / Antimitotic Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Cardiotoxic antineoplastic agents / Cyclodecanes / Cycloparaffins / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diterpenes / Hepatotoxic Agents / Immunosuppressive Agents / Microtubule Inhibition / Microtubule Inhibitors / Mitosis Modulators / Myelosuppressive Agents / OATP1B3 substrates / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Taxane Derivatives / Taxoids / Terpenes / Tubulin Modulators,699121PHCA,114977-28-5,D02165,148124.0,130581.0,36351.0,1299922.0,4672.0,CHEMBL92,DAP000590,PA449383,ZINC000085537053
Iodixanol,phase 4 complete,DB01249,CC(=O)N(CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Iodinated Contrast Agents / Iodobenzoates / Radiographic Contrast Agent / Roentgenography / Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media / X-Ray Contrast Activity / X-Ray Contrast Media, Iodinated",HW8W27HTXX,92339-11-2,D01474,3724.0,3593.0,,27729.0,31705.0,CHEMBL1200507,,PA164783998,
Olsalazine,phase 4 complete,DB01250,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Alimentary Tract and Metabolism / Aminosalicylate / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Gastrointestinal Agents / Hydroxy Acids / Hydroxybenzoates / Intestinal Antiinflammatory Agents / Nephrotoxic agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Phenols / Salicylates / Sensory System Agents",ULS5I8J03O,15722-48-2,D00727,6003770.0,10642377.0,,32385.0,,CHEMBL425,,PA450700,ZINC000003812865
Gliquidone,phase 4 complete,DB01251,COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O,Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs Used in Diabetes / Sulfones / Sulfonylureas / Sulfur Compounds,C7C2QDD75P,33342-05-1,D02430,91610.0,82719.0,50248247.0,25793.0,93416.0,CHEMBL383634,DAP000924,PA164744895,ZINC000001482077
Ergometrine,phase 4 complete,DB01253,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO,"Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alkaloids / Antidepressive Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Ergolines / Ergot Alkaloids and Derivatives / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / P-glycoprotein inhibitors / Reproductive Control Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / Uterotonic agents",WH41D8433D,60-79-7,D07905,443884.0,391970.0,50390991.0,4021.0,4822.0,CHEMBL119443,DAP000227,PA449487,ZINC000053174604
Dasatinib,phase 4 complete,DB01254,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Immunosuppressive Agents / Kinase Inhibitor / Myelosuppressive Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Photosensitizing Agents / Potential QTc-Prolonging Agents / Protein Kinase Inhibitors / Pyrimidines / QTc Prolonging Agents / Sulfur Compounds / Thiazoles / Tyrosine Kinase Inhibitors,X78UG0A0RN,302962-49-8,D03658,3062316.0,2323020.0,13216.0,1546019.0,49375.0,CHEMBL1421,DAP000004,PA162372878,ZINC000003986735
Lisdexamfetamine,phase 4 complete,DB01255,C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN,"Agents producing tachycardia / Agents that produce hypertension / Amines / Amphetamines / Central Nervous System Agents / Central Nervous System Stimulants / Central Nervous System Stimulation / Centrally Acting Sympathomimetics / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Uptake Inhibitors / Ethylamines / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Phenethylamines / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sympathomimetics",H645GUL8KJ,608137-32-2,,11597698.0,9772458.0,,700810.0,135925.0,CHEMBL1201222,DAP000571,PA164748975,ZINC000011680943
Retapamulin,phase 4 complete,DB01256,[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C,Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics for Topical Use / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Pleuromutilin Antibacterial / Terpenes,4MG6O8991R,224452-66-8,,6918462.0,25064484.0,,642274.0,,CHEMBL1658,DAP000886,PA164749341,ZINC000100013500
Aliskiren,phase 4 complete,DB09026 (DB01258),COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1,"Acids, Acyclic / Agents Acting on the Renin-Angiotensin System / Agents causing hyperkalemia / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzene Derivatives / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dicarboxylic Acids / Ethers / Hypotensive Agents / Methyl Ethers / P-glycoprotein substrates / Renin-Inhibitors",502FWN4Q32,173334-57-1,D03208,5493444.0,4591452.0,17950.0,325646.0,601027.0,CHEMBL1639,,PA143487910,ZINC000004393164
Lapatinib,phase 4 complete,DB01259 (DB02584),CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Hepatotoxic Agents / Heterocyclic Compounds, Fused-Ring / Kinase Inhibitor / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / Protein Kinase Inhibitors / QTc Prolonging Agents / Quinazolines / Tyrosine Kinase Inhibitors",0VUA21238F,231277-92-2,D04024,208908.0,181006.0,5445.0,480167.0,49603.0,CHEMBL554,DCL000344,PA152241907,ZINC000001550477
Desonide,phase 4 complete,DB01260,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Moderately Potent (Group II) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Immunosuppressive Agents / Ophthalmologicals / Pregnadienes / Pregnadienetriols / Pregnanes / Sensory Organs / Steroids",J280872D1O,638-94-8,D03696,5311066.0,4470603.0,,3254.0,204734.0,CHEMBL1201109,DAP001188,PA164776996,ZINC000004212851
Sitagliptin,phase 4 complete,DB01261 (DB07214),N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F,"Agents causing angioedema / Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / DPP-IV Inhibitors / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Enzyme Inhibitors / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypoglycemia-Associated Agents / Incretins / OAT3/SLC22A8 Substrates / P-glycoprotein substrates / Protease Inhibitors / Triazoles",QFP0P1DV7Z,486460-32-6,D08516,4369359.0,3571948.0,11162.0,593411.0,40237.0,CHEMBL1422,DAP000639,PA164748978,ZINC000001489478
Decitabine,phase 4 complete,DB01262,NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1,"Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Aza Compounds / Carbohydrates / Enzyme Inhibitors / Glycosides / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Metabolic Inhibitor / Nucleosides / Pyrimidine Analogues / Pyrimidine Nucleosides / Pyrimidines / Ribonucleosides / Toxic Actions",776B62CQ27,2353-33-5,D03665,451668.0,397844.0,96274.0,15657.0,50131.0,CHEMBL1201129,DAP000641,PA164749631,ZINC000016929327
Posaconazole,phase 4 complete,DB01263,[H][C@@](C)(O)[C@]([H])(CC)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@]2([H])CO[C@](CN3C=NC=N3)(C2)C2=C(F)C=C(F)C=C2)C=C1,"14-alpha Demethylase Inhibitors / Anti-Infective Agents / Antifungal Agents / Antiinfectives for Systemic Use / Antimycotics for Systemic Use / Antiparasitic Agents / Antiprotozoals / Azole Antifungals / Chemically-Induced Disorders / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / P-glycoprotein inhibitors / P-glycoprotein substrates / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Steroid Synthesis Inhibitors / Triazole Derivatives / Trypanocidal Agents",6TK1G07BHZ,171228-49-2,D02555,468595.0,411709.0,50181473.0,282446.0,64355.0,CHEMBL1397,DAP001101,PA151958574,ZINC000003938482
Darunavir,phase 4 complete,DB01264 (EXPT00002),[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,Amides / Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Carbamates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Experimental Unapproved Treatments for COVID-19 / Furans / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / HIV Protease Inhibitors / Hyperglycemia-Associated Agents / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / Protease Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds,YO603Y8113,206361-99-1,D03656,213039.0,184733.0,8125.0,460132.0,367163.0,CHEMBL1323,DAP001086,PA163522472,ZINC000003955219
Telbivudine,phase 4 complete,DB01265,CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Carbohydrates / Deoxyribonucleosides / Direct Acting Antivirals / Enzyme Inhibitors / Glycosides / Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / Nucleoside Reverse Transcriptase Inhibitors / Nucleosides / Nucleosides and Nucleotides / Pyrimidine Nucleosides / Pyrimidines",2OC4HKD3SF,3424-98-4,D06675,159269.0,140081.0,50088372.0,474128.0,63624.0,CHEMBL374731,DAP000698,PA164760861,ZINC000000002159
Sinecatechins,phase 4 complete,DB01266,,Antiviral Agents / Dermatologicals,T432289GYZ,188265-33-0,,,,,753346.0,,,,PA164749508,
Paliperidone,phase 4 complete,DB01267,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1,Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs that are Mainly Renally Excreted / Highest Risk QTc-Prolonging Agents / Hyperglycemia-Associated Agents / Isoxazoles / Nervous System / Neurotoxic agents / Neurotransmitter Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Psycholeptics / Psychotropic Drugs / Pyrimidines / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT1D Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents,838F01T721,144598-75-4,D05339,115237.0,103109.0,50252513.0,679314.0,83804.0,CHEMBL1621,DAP000847,PA163518919,
Sunitinib,phase 4 complete,DB01268 (DB07417),CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,"Angiogenesis Inhibitors / Angiogenesis Modulating Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / Blood Glucose Lowering Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Growth Inhibitors / Growth Substances / Hepatotoxic Agents / Heterocyclic Compounds, Fused-Ring / Hypoglycemia-Associated Agents / Immunosuppressive Agents / Indoles / Kinase Inhibitor / Narrow Therapeutic Index Drugs / P-glycoprotein inhibitors / P-glycoprotein substrates / Potential QTc-Prolonging Agents / Protein Kinase Inhibitors / QTc Prolonging Agents / Tyrosine Kinase Inhibitors",V99T50803M,557795-19-4,D06402,5329102.0,4486264.0,4814.0,357977.0,38940.0,CHEMBL535,DCL000646,PA162372840,ZINC000003964325
Varenicline,phase 4 complete,DB01273,C1C2CNCC1C1=C2C=C2N=CC=NC2=C1,"Benzazepines / Cholinergic Agents / Cholinergic Agonists / Drugs that are Mainly Renally Excreted / Drugs Used in Addictive Disorders / Drugs Used in Nicotine Dependence / Heterocyclic Compounds, Fused-Ring / Miscellaneous Autonomic Drugs / Nervous System / Neurotransmitter Agents / Nicotinic Agonists / OCT2 Inhibitors / OCT2 Substrates / Partial Cholinergic Nicotinic Agonist / Partial Cholinergic Nicotinic Agonists / Quinoxalines / Smoking Cessation Agents",W6HS99O8ZO,249296-44-4,,5310966.0,148958.0,50166908.0,591622.0,84500.0,CHEMBL1396,DAP001535,PA164781343,ZINC000001481833
Arformoterol,phase 4 complete,DB01274,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1,Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Ethanolamines / Neurotransmitter Agents / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Respiratory System Agents,F91H02EBWT,67346-49-0,D07463,3083544.0,2340731.0,50151720.0,304962.0,408174.0,CHEMBL1363,DAP000943,PA164743977,ZINC000002599970
Hydralazine,phase 4 complete,DB01275,NNC1=NN=CC2=CC=CC=C12,"Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Arteriolar Smooth Muscle, Agents Acting On / Arteriolar Vasodilation / Arteriolar Vasodilator / Cardiovascular Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Direct Vasodilators / Drugs that are Mainly Renally Excreted / Hydrazinophthalazine Derivatives / Hydrazinophthalazine Derivatives and Diuretics / Hypotensive Agents / Phthalazines / Pyridazines / Vasodilating Agents",26NAK24LS8,86-54-4,D08044,3637.0,3511.0,81461.0,5470.0,5775.0,CHEMBL276832,DAP000728,PA449894,ZINC000012360535
Pramlintide,phase 4 complete,DB01278,[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@]([H])(NC(=O)[C@H](C)NC(=O)[C@@]([H])(NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O,"Alimentary Tract and Metabolism / Amino Acids, Peptides, and Proteins / Amylin Agonists / Amylin Analog / Amyloid / Amyloidogenic Proteins / Blood Glucose Lowering Agents / Drugs Used in Diabetes / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypoglycemia-Associated Agents / Macromolecular Substances / Multiprotein Complexes / Pancreatic Hormones / Peptide Hormones / Peptides / Proteins",D3FM8FA78T,151126-32-8,D05595,,44241191.0,,139953.0,135922.0,CHEMBL2103758,DCL000936,PA164781394,
Nelarabine,phase 4 complete,DB01280,COC1=NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,"Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Carbohydrates / Glycosides / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nucleic Acid Synthesis Inhibitors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleoside Metabolic Inhibitor / Nucleosides / Purine Analogues",60158CV180,121032-29-9,D05134,3011155.0,2280207.0,,274771.0,63612.0,CHEMBL1201112,DAP000985,PA164752425,ZINC000003823492
Carbetocin,phase 4 complete,DB01282,[H][C@]1(NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)CC,"Amino Acids, Peptides, and Proteins / Delayed-Action Preparations / Drug Delivery Systems / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypotensive Agents / Investigative Techniques / Oxytocin and Analogues / Peptide Hormones / Peptides / Pharmaceutical Preparations / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormones / Pituitary Hormones, Posterior / Posterior Pituitary Lobe Hormones / Reproductive Control Agents / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Uterotonic agents",88TWF8015Y,37025-55-1,D07229,16681432.0,16736854.0,50044677.0,,59204.0,CHEMBL3301668,DAP000269,PA164743086,ZINC000150338703
Lumiracoxib,phase 4 complete,DB01283,CC1=CC=C(NC2=C(Cl)C=CC=C2F)C(CC(O)=O)=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / COX-2 Inhibitors / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Peripheral Nervous System Agents / Phenylacetates / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory System Agents / UGT1A9 Substrates",V91T9204HU,220991-20-8,D03714,151166.0,133236.0,50207446.0,,73044.0,CHEMBL404108,DAP000970,PA164769031,ZINC000000007563
Tetracosactide,phase 4 complete,DB01284,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O,"Adrenals / Adrenocortical Insufficiency / Adrenocorticotropic Hormone / Amino Acids, Peptides, and Proteins / Anterior Pituitary Lobe Hormones and Analogues / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Melanocortins / Nerve Tissue Proteins / Neuropeptides / Peptide Hormones / Peptides / Pituitary / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormones / Pituitary Hormones, Anterior / Pro-Opiomelanocortin / Protein Precursors / Proteins / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",72YY86EA29,16960-16-0,D00284,16133751.0,10481947.0,50017180.0,2890.0,3901.0,CHEMBL2103784,DAP000284,PA164749052,
Fenoterol,phase 4 complete,DB01288,CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics for Systemic Use / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Anticholinergic Agents / Autonomic Agents / Benzene Derivatives / Bronchodilator Agents / Catechols / Drugs for Obstructive Airway Diseases / Ethanolamines / Genito Urinary System and Sex Hormones / Metaproterenol / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenols / Reproductive Control Agents / Respiratory System Agents / Selective Beta 2-adrenergic Agonists / Sympathomimetics / Sympathomimetics, Labour Repressants / Tocolytic Agents",22M9P70OQ9,13392-18-2,D04157,3343.0,3226.0,50131281.0,4333.0,149226.0,CHEMBL32800,DAP000946,PA10079,
Pirbuterol,phase 4 complete,DB01291,CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics for Systemic Use / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Drugs for Obstructive Airway Diseases / Neurotransmitter Agents / Peripheral Nervous System Agents / Protective Agents / Respiratory System Agents / Selective Beta 2-adrenergic Agonists",OG645J8RVW,38677-81-5,,4845.0,4679.0,,33767.0,8245.0,CHEMBL1094966,DAP000249,PA450983,
Bismuth subsalicylate,phase 4 complete,DB01294 (DB01402),O[Bi]1OC(=O)C2=CC=CC=C2O1,"Acids, Carbocyclic / Antacids and Adsorbents / Antidiarrheals / Benzene Derivatives / Benzoates / Bismuth containing drugs / Elements / Elements, Radioactive / Gastrointestinal Agents / Helicobacter Infections / Hydroxy Acids / Hydroxybenzoates / Isotopes / Metals / Metals, Heavy / Neurotoxic agents / Phenols / Radioisotopes / Salicylates",62TEY51RR1,14882-18-9,D00728,16682734.0,17215772.0,,19478.0,261649.0,CHEMBL1120,,PA164774805,
Glucosamine,phase 4 complete,DB01296 (EXPT01563),N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O,"Amino Sugars / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Carbohydrates / Hexosamines / Musculo-Skeletal System",N08U5BOQ1K,3416-24-8,D04334,439213.0,388352.0,,4845.0,47977.0,CHEMBL493287,DAP001097,PA164747613,
Practolol,phase 4 complete,DB01297,CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1,"Acetanilides / Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-1 Receptor Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amides / Amines / Amino Alcohols / Anilides / Aniline Compounds / Antiarrhythmic agents / Antihypertensive Agents / Beta Blocking Agents, Selective / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Neurotransmitter Agents / Phenoxypropanolamines / Propanolamines / Propanols",SUG9176GRW,6673-35-4,D05587,4883.0,4715.0,25749.0,8620.0,258351.0,CHEMBL6995,DAP000940,PA164752820,
Sulfacytine,phase 4 complete,DB01298,CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O,Amides / Amines / Aniline Compounds / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Sulfonamides / Sulfones / Sulfur Compounds,T795873AJP,17784-12-2,,5322.0,5131.0,,78902.0,135230.0,CHEMBL1201056,DAP001201,PA164754808,ZINC000000002092
Sulfadoxine,phase 4 complete,DB01299,COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1OC,"Amides / Amines / Aniline Compounds / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antimalarials / Antiparasitic Agents / Antiprotozoals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Long-Acting Sulfonamides / Renal Agents / Sulfanilamides / Sulfonamides / Sulfones / Sulfur Compounds",88463U4SM5,2447-57-6,D00580,17134.0,16218.0,50238671.0,10173.0,9329.0,CHEMBL1539,DAP000638,PA451540,ZINC000000002094
Rolitetracycline,phase 4 complete,DB01301,[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCN1CCCC1)=C(O)[C@H]2N(C)C,Agents that produce neuromuscular block (indirect) / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Naphthacenes / Tetracyclines,GH9IW85221,751-97-3,D02282,54682938.0,21111754.0,,9462.0,63334.0,CHEMBL1237046,DAP000884,PA164779049,ZINC000014880004
Oxtriphylline,phase 4 complete,DB01303,C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O,"Alcohols / Alkaloids / Amines / Amino Alcohols / Ammonium Compounds / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Ethanolamines / Heterocyclic Compounds, Fused-Ring / Nitrogen Compounds / Onium Compounds / Peripheral Nervous System Agents / Purines / Purinones / Quaternary Ammonium Compounds / Respiratory Smooth Muscle Relaxants / Respiratory System Agents / Trimethyl Ammonium Compounds / Xanthine derivatives / Xanthines and Adrenergics",3K045XR58X,4499-40-5,D02017,656652.0,25044543.0,,20976.0,,CHEMBL1200434,DAP000868,PA164748137,
Fosamprenavir,phase 4 complete,DB01319,CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,"Acids, Acyclic / Amides / Amprenavir and Prodrugs / Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / HIV Protease Inhibitors / Hyperglycemia-Associated Agents / Organophosphorus Compounds / Protease Inhibitors / Sulfones / Sulfur Compounds",WOU1621EEG,226700-79-4,D02497,131536.0,116245.0,,358262.0,82941.0,CHEMBL1664,DAP000707,PA10084,ZINC000003941829
Fosphenytoin,phase 4 complete,DB01320,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,Anti-epileptic Agent / Anticonvulsants / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strong) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Enzyme Inducing Antiepileptic Drugs / Hydantoins / Imidazoles / Imidazolidines / Membrane Transport Modulators / Narrow Therapeutic Index Drugs / Nervous System / Phenytoin and Prodrugs / Prodrugs / Sodium Channel Blockers / Thyroxine-binding globulin substrates / UGT1A6 Inhibitors / UGT1A9 Inhibitors,B4SF212641,93390-81-9,D07993,56339.0,50839.0,,72236.0,5165.0,CHEMBL1201336,DAP000520,PA164746820,ZINC000001530922
Kava,phase 4 complete,DB01322,COC1=CC(=O)OC(C1)\C=C\C1=CCCC=C1,,BOW48C81XP,9000-38-8,,5281052.0,4444512.0,,285228.0,,,,,
St. John's Wort,phase 4 complete,DB01323,,Antidepressive Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Herbs and Natural Products / Hyperglycemia-Associated Agents / Nervous System / P-glycoprotein inducers / Psychoanaleptics / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome,UFH8805FKA,84082-80-4,,,,,1310069.0,,,,PA164924486,
Polythiazide,phase 4 complete,DB01324,CN1C(CSCC(F)(F)F)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O,"Amides / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzothiadiazines / Cardiovascular Agents / Diuretics / Drugs causing inadvertant photosensitivity / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Increased Diuresis / Membrane Transport Modulators / Natriuretic Agents / OAT3/SLC22A8 Substrates / Photosensitizing Agents / Sodium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds / Thiazides",36780APV5N,346-18-9,D00657,4870.0,4704.0,,8565.0,8327.0,CHEMBL1587,DAP000751,PA164748763,
Quinethazone,phase 4 complete,DB01325,CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O,"Amides / Cardiovascular Agents / Diuretics / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Low-Ceiling Diuretics, Excl. Thiazides / Membrane Transport Modulators / Natriuretic Agents / Sodium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds",455E0S048W,73-49-4,D00461,6307.0,6068.0,25898.0,59743.0,8717.0,CHEMBL1532,DAP000955,PA164760863,
Cefamandole,phase 4 complete,DB01326,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Second-Generation Cephalosporins / Sulfur Compounds / Thiazines",5CKP8C2LLI,34444-01-4,D02344,456255.0,401748.0,50350468.0,2178.0,3480.0,CHEMBL1146,DAP000448,PA448837,ZINC000003830394
Cefazolin,phase 4 complete,DB01327,[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / First-Generation Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Sulfur Compounds / Thiazines",IHS69L0Y4T,25953-19-9,D02299,33255.0,30723.0,50370587.0,2180.0,474053.0,CHEMBL1435,DAP000449,PA448839,ZINC000003830405
Cefonicid,phase 4 complete,DB01328,[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Second-Generation Cephalosporins / Sulfur Compounds / Thiazines",6532B86WFG,61270-58-4,D07644,43594.0,39734.0,,2183.0,3491.0,CHEMBL1601,DAP001173,PA164743021,ZINC000003830428
Cefoperazone,phase 4 complete,DB01329,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",7U75I1278D,62893-19-0,,44185.0,40206.0,50390999.0,2184.0,3493.0,CHEMBL507674,DAP000450,PA448849,ZINC000003830432
Cefotetan,phase 4 complete,DB01330,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Cephamycins / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Second-Generation Cephalosporins / Sulfur Compounds / Tetrazoles / Thiazines",48SPP0PA9Q,69712-56-7,D00260,53025.0,47904.0,80643.0,2187.0,3499.0,CHEMBL474579,DAP000451,PA164784033,
Cefoxitin,phase 4 complete,DB01331 (EXPT00897),[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Cephamycins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Second-Generation Cephalosporins / Sulfur Compounds / Thiazines",6OEV9DX57Y,35607-66-0,D02345,441199.0,389981.0,50335563.0,2189.0,209807.0,CHEMBL996,DAP000452,PA448856,ZINC000003830449
Ceftizoxime,phase 4 complete,DB01332,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephacetrile / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",C43C467DPE,68401-81-0,,6533629.0,5018818.0,237182.0,2192.0,553473.0,CHEMBL528,DAP000453,PA164748758,ZINC000003830477
Cefradine,phase 4 complete,DB01333,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CCC=CC1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Drugs that are Mainly Renally Excreted / First-Generation Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / MATE 1 Substrates / MATE substrates / Nephrotoxic agents / OAT1/SLC22A6 inhibitors / Sulfur Compounds / Thiazines",9YA6SX5S4D,38821-53-3,D00264,38103.0,34933.0,50370585.0,2239.0,3547.0,CHEMBL1604,DAP000454,PA448890,ZINC000003830515
Metocurine,phase 4 complete,DB01336,[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3,"Agents producing tachycardia / Alkaloids / Amines / Ammonium Compounds / Anticholinergic Agents / Benzylisoquinolines / Central Nervous System Depressants / Curare Alkaloids / Drugs, Chinese Herbal / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Muscarinic Antagonists / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular-Blocking Agents (Nondepolarizing) / Nicotinic Antagonists / Nitrogen Compounds / Onium Compounds / Peripheral Nervous System Agents / Quaternary Ammonium Compounds / Tetrahydroisoquinolines",V0M92G2U26,5152-30-7,,21233.0,19961.0,50237609.0,29950.0,6900.0,CHEMBL1259,DAP000352,PA164749507,ZINC000004097448
Pancuronium,phase 4 complete,DB01337,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1,"Agents producing tachycardia / Androstanes / Androstanols / Anticholinergic Agents / Central Nervous System Depressants / Cholinergic Agents / Cholinesterase Inhibitors / Fused-Ring Compounds / Muscarinic Antagonists / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular Nondepolarizing Blockade / Neuromuscular-Blocking Agents (Nondepolarizing) / Neurotransmitter Agents / Nicotinic Antagonists / OCT1 inhibitors / OCT1 substrates / Peripheral Nervous System Agents / Steroids",J76UF062FS,16974-53-1,,441289.0,390052.0,,7883.0,7907.0,CHEMBL185073,DAP000123,PA450771,ZINC000004097383
Pipecuronium,phase 4 complete,DB01338,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1,"Agents producing tachycardia / Anticholinergic Agents / Central Nervous System Depressants / Cholinergic Agents / Cholinesterase Inhibitors / Muscarinic Antagonists / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular-Blocking Agents (Nondepolarizing) / Neurotransmitter Agents / Nicotinic Antagonists / Peripheral Nervous System Agents / Piperazines",1N3O74HM92,68399-58-6,,50192.0,45517.0,,33742.0,8230.0,CHEMBL1201206,DAP000353,PA164764567,ZINC000003938681
Vecuronium,phase 4 complete,DB01339,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1,"Androstanes / Androstanols / Anticholinergic Agents / Central Nervous System Depressants / Cholinergic Agents / Fused-Ring Compounds / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular Nondepolarizing Blockade / Neuromuscular-Blocking Agents (Nondepolarizing) / Neurotransmitter Agents / Nicotinic Antagonists / P-glycoprotein substrates / Peripheral Nervous System Agents / Steroids",5438723848,86029-43-8,,39765.0,36358.0,50424713.0,71535.0,9939.0,CHEMBL1201219,DAP000354,PA164748865,ZINC000004097404
Cilazapril,phase 4 complete,DB01340,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O,ACE Inhibitors and Diuretics / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Enzyme Inhibitors / Hypotensive Agents / P-glycoprotein inhibitors / Protease Inhibitors / Pyridazines,8Q9454114Q,88768-40-5,D07699,56330.0,50831.0,,21102.0,3698.0,CHEMBL515606,DAP000912,PA164748302,ZINC000003781951
Tolevamer,phase 4 complete,DB01344 (DB06658),,"Acids / Acids, Noncarboxylic / Benzene Derivatives / Benzylidene Compounds / Cation Exchange Resins / Chelating Agents / Compounds used in a research, industrial, or household setting / Drugs for Treatment of Hyperkalemia and Hyperphosphatemia / Ion Exchange Resins / Laboratory Chemicals / Macromolecular Substances / Plastics / Polymers / Polystyrene Sulfonates / Potassium Binder / Potassium Ion Exchange Activity / Potassium-removing Agents / Sequestering Agents / Styrene / Styrenes / Sulfur Acids / Sulfur Compounds",ZSL2FB6GXN,28210-41-5,,,,,1546436.0,53278.0,,,PA164749386,
Potassium cation,phase 4 complete,DB01345,[K+],Agents causing hyperkalemia / Diuretics / Drugs that are Mainly Renally Excreted / Increased Large Intestinal Motility / Inhibition Large Intestine Fluid/Electrolyte Absorption / Minerals / Osmotic Activity / Potassium Salt / Replacement Preparations,295O53K152,24203-36-9,D08403,5462222.0,791.0,,1318915.0,29103.0,,,PA451047,
Quinidine barbiturate,phase 4 complete,DB01346,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C,,,,,53461739.0,26329517.0,,,,,DAP000915,PA164783957,
Spirapril,phase 4 complete,DB01348,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2,"Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Amino Acids, Peptides, and Proteins / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Cardiovascular Agents / Dipeptides / Enzyme Inhibitors / Oligopeptides / Peptides / Protease Inhibitors",96U2K78I3V,83647-97-6,D08529,5311447.0,4470933.0,50017124.0,36908.0,135756.0,CHEMBL431,DAP000911,PA164776913,ZINC000004217459
Amobarbital,phase 4 complete,DB01351,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O,"Anticholinergic Agents / Anticonvulsants / Barbiturates / Barbiturates, Plain / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / GABA Agents / GABA Modulators / Hypnotics and Sedatives / Nervous System / Neurotransmitter Agents / Nicotinic Antagonists / Psycholeptics / Pyrimidines / Pyrimidinones",GWH6IJ239E,57-43-2,D00555,2164.0,2079.0,,719.0,2673.0,CHEMBL267894,DAP000686,PA448401,ZINC000004811698
Butobarbital,phase 4 complete,DB01353,CCCCC1(CC)C(=O)NC(=O)NC1=O,"Anticholinergic Agents / Barbiturates, Plain / Central Nervous System Agents / Central Nervous System Depressants / Hypnotics and Sedatives / Nervous System / Nicotinic Antagonists / Psycholeptics / Pyrimidines / Pyrimidinones",OHZ8QAW6YC,77-28-1,D02618,6473.0,6229.0,,19874.0,134884.0,CHEMBL404422,DAP000687,PA164748035,ZINC000005514900
Mestranol,phase 4 complete,DB01357,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3,"Adrenal Cortex Hormones / Contraceptive Agents, Female / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Estradiol Congeners / Estrogen Contraceptives / Estrogenic Steroids, Alkylated / Estrogens / Ethinyl Estradiol / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Norpregnanes / Norpregnatrienes / Norsteroids / Steroids / Thyroxine-binding globulin inducers",B2V233XGE7,72-33-3,D00575,6291.0,6054.0,,6782.0,6784.0,CHEMBL1201151,DAP001014,PA450388,ZINC000003815424
Penbutolol,phase 4 complete,DB01359,CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antidepressive Agents / Antihypertensive Agents / Beta Blocking Agents, Non-Selective / Bradycardia-Causing Agents / Cardiovascular Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Neurotransmitter Agents / Phenoxypropanolamines / Propanolamines / Propanols / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists",78W62V43DY,38363-40-5,D08074,37464.0,34369.0,,7973.0,7954.0,CHEMBL1290,DAP000938,PA164749474,ZINC000000001898
Troleandomycin,phase 4 complete,DB13179 (DB01361),CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strong) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strong) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Lactones / Macrolides / Macrolides, Lincosamides and Streptogramins / P-glycoprotein inhibitors / Polyketides",C4DZ64560D,2751-09-9,D01322,202225.0,16707.0,50370258.0,10864.0,45735.0,CHEMBL564085,DAP000411,PA127840611,ZINC000169307271
Iohexol,phase 4 complete,DB01362,CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,"Acids, Carbocyclic / Agents that reduce seizure threshold / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Iodinated Contrast Agents / Iodobenzoates / Radiographic Contrast Agent / Roentgenography / Triiodobenzoic Acids / Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media / X-Ray Contrast Activity / X-Ray Contrast Media, Iodinated",4419T9MX03,66108-95-0,D01817,3730.0,3599.0,,5956.0,31709.0,CHEMBL1200455,,PA450061,
Ephedrine,phase 4 complete,DB01364,CN[C@@H](C)[C@H](O)C1=CC=CC=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-Agonists / Adrenergic and Dopaminergic Agents / Adrenergic beta-Agonists / Adrenergics for Systemic Use / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Alimentary Tract and Metabolism / Alpha-and Beta-adrenergic Agonists / Amines / Amino Alcohols / Antidepressive Agents / Antiobesity Preparations, Excl. Diet Products / Autonomic Agents / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Central Nervous System Stimulants / Centrally Acting Antiobesity Products / Cholinesterase substrates / Drugs for Obstructive Airway Diseases / Epinephrine and similars / Ethylamines / Herbs and Natural Products / Increased Norepinephrine Activity / Mydriatics and Cycloplegics / Nasal Preparations / Neurotransmitter Agents / Norepinephrine Releasing Agent / Ophthalmologicals / Peripheral Nervous System Agents / Phenethylamines / Propanolamines / Propanols / Sensory Organs / Sympathomimetic (Adrenergic) Agents / Sympathomimetics / Sympathomimetics Excl. Antiglaucoma Preparations / Sympathomimetics, Plain / Vasoconstrictor Agents",GN83C131XS,299-42-3,D00124,9294.0,8935.0,,3966.0,15407.0,CHEMBL211456,DAP000228,PA449466,ZINC000000074836
Mephentermine,phase 4 complete,DB01365,CNC(C)(C)CC1=CC=CC=C1,Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic and Dopaminergic Agents / Agents producing tachycardia / Agents that produce hypertension / Amines / Amphetamines / Autonomic Agents / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiovascular Agents / Ethylamines / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenethylamines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sympathomimetics / Vasoconstrictor Agents,TEZ91L71V4,100-92-5,D08180,3677.0,3549.0,81455.0,6756.0,6755.0,CHEMBL1201234,DAP000898,PA164745533,ZINC000008132748
Procaterol,phase 4 complete,DB01366,CC[C@H](NC(C)C)[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics for Systemic Use / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Drugs for Obstructive Airway Diseases / Ethanolamines / Heterocyclic Compounds, Fused-Ring / Hydroxyquinolines / Neurotransmitter Agents / Peripheral Nervous System Agents / Quinolines / Respiratory System Agents / Selective Beta 2-adrenergic Agonists / Sympathomimetics",X7I3EMM5K0,72332-33-3,,688561.0,599984.0,50167071.0,34530.0,,CHEMBL1478530,DAP000944,PA164748908,ZINC000019632692
Rasagiline,phase 4 complete,DB01367 (EXPT02758),C#CCN[C@@H]1CCC2=CC=CC=C12,"Agents that produce hypertension / Agents that reduce seizure threshold / Anti-Parkinson Drugs / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hypotensive Agents / Indenes / Monoamine Oxidase B Inhibitors / Monoamine Oxidase Inhibitors / Nervous System / Neuroprotective Agents / Protective Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",003N66TS6T,136236-51-6,D08469,3052776.0,2314553.0,10989.0,134748.0,63620.0,CHEMBL887,DAP001107,PA164764584,ZINC000019875504
Quinupristin,phase 4 complete,DB01369,[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1,"Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Peptides / Peptides, Cyclic / Streptogramin Antibacterial / Streptogramins",23OW28RS7P,120138-50-3,D00852,5388937.0,4470884.0,,229367.0,,CHEMBL1200649,DAP001288,PA164749647,ZINC000150338707
Aluminium,phase 4 complete,DB01370 (DB11314),[Al],"Aluminium Compounds / Aluminum and magnesium containing antacids / Antacids / Elements / Gastric Acid Lowering Agents / Metal cations / Metal divalent cations / Metals / Metals, Light",CPD4NFA903,7429-90-5,,5359268.0,4514248.0,,1311504.0,28984.0,,DAP000467,PA164760864,
Magnesium oxide,phase 4 complete,DB01377,[O--].[Mg++],"Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Aluminum and magnesium containing antacids / Anions / Antacids / Calculi Dissolution Agent / Drugs for Acid Related Disorders / Drugs for Constipation / Electrolytes / Gastric Acid Lowering Agents / Gastrointestinal Agents / Ions / Laxatives / Laxatives, magnesium containing / Magnesium Compounds / Magnesium Salts / Metal cations / Metal divalent cations / Mineral Supplements / Minerals / Osmotic Laxatives / Oxides / Oxygen Compounds",3A3U0GI71G,1309-48-4,D01167,14792.0,5254017.0,,6582.0,31794.0,CHEMBL1200572,,PA450298,
Magnesium cation,phase 4 complete,DB01378,[Mg++],"Agents that produce neuromuscular block (indirect) / Calculi Dissolution Agent / Increased Large Intestinal Motility / Inhibition Large Intestine Fluid/Electrolyte Absorption / Inhibition Small Intestine Fluid/Electrolyte Absorption / Laxatives / Magnesium Ion Exchange Activity / Minerals / Osmotic Activity / Osmotic Laxatives / Polyvalent cation containing laxatives, antacids, oral supplements / Stimulation Large Intestine Fluid/Electrolyte Secretion",T6V3LHY838,22537-22-0,,888.0,865.0,15.0,1426853.0,18420.0,,DCL000876,PA164712884,
Cortisone acetate,phase 4 complete,DB01380,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"17-Hydroxycorticosteroids / Adrenal Cortex Hormones / Adrenals / Anti-Inflammatory Agents / Corticosteroids / Corticosteroids for Systemic Use / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydroxycorticosteroids / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Pregnanes / Pregnenes / Steroids",883WKN7W8X,50-04-4,D00973,5745.0,5543.0,50455157.0,21655.0,3897.0,CHEMBL1650,,PA449130,ZINC000003875334
Glymidine,phase 4 complete,DB01382,COCCOC1=CN=C(NS(=O)(=O)C2=CC=CC=C2)N=C1,Alimentary Tract and Metabolism / Amides / Blood Glucose Lowering Agents / Drugs Used in Diabetes / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Sulfonamides / Sulfones / Sulfur Compounds,4C5I4BQZ8F,339-44-6,,9565.0,9190.0,,102848.0,146188.0,CHEMBL1697838,DAP000921,PA164748839,ZINC000002040778
Sodium bicarbonate,phase 4 complete,DB01390,[Na+].OC([O-])=O,"Acids / Acids, Noncarboxylic / Alkalies / Anions / Antacids / Antacids and Adsorbents / Bicarbonates / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Carbon Compounds, Inorganic / Carbonates / Carbonic Acid / Electrolyte Solutions / Electrolytes / Gastric Acid Lowering Agents / Hemodialysis Solution / I.V. Solution Additives / Ions / Irrigating Solutions / Radiographic Contrast Agent / Salt Solutions / Sodium Compounds / Urinary Alkalinisers",8MDF5V39QO,144-55-8,D01203,516892.0,8609.0,,36676.0,32139.0,CHEMBL1353,DAP000128,PA451375,
Yohimbine,phase 4 complete,DB01392,[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2,"Adrenergic Agents / Adrenergic alpha-2 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Alkaloids / Antidepressive Agents / Autonomic Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs Used in Erectile Dysfunction / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Indole Alkaloids / Indoles / Mydriatics / Neurotransmitter Agents / Other Miscellaneous Therapeutic Agents / P-glycoprotein inhibitors / Peripheral Nervous System Agents / Secologanin Tryptamine Alkaloids / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1D Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Urological Agents / Urologicals",2Y49VWD90Q,146-48-5,,8969.0,8622.0,50203564.0,220982.0,10093.0,CHEMBL15245,DAP000087,PA451946,ZINC000003860825
Bezafibrate,phase 4 complete,DB01393 (DB08380),CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O,"Acids, Acyclic / Acids, Carbocyclic / Agents Causing Muscle Toxicity / Amides / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Butyrates / Chlorobenzoates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Ethers / Fatty Acids / Fatty Acids, Volatile / Fibric Acids / Fribic Acid Derivatives / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Isobutyrates / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Lipids / Noxae / OATP1B1/SLCO1B1 Inhibitors / Phenols / Phenyl Ethers / Toxic Actions",Y9449Q51XH,41859-67-0,D01366,39042.0,35728.0,28701.0,1525.0,47612.0,CHEMBL264374,DAP001182,PA162364313,ZINC000003956919
Colchicine,phase 4 complete,DB01394,COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O,Agents Causing Muscle Toxicity / Alkaloids / Antigout Preparations / Antimitotic Agents / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Immunosuppressive Agents / Mitosis Modulators / Musculo-Skeletal System / P-glycoprotein inducers / P-glycoprotein substrates / Preparations With No Effect on Uric Acid Metabolism / Tubulin Modulators,SML2Y3J35T,64-86-8,D00570,2833.0,2731.0,,2683.0,23359.0,CHEMBL87,DAP001254,PA449092,
Drospirenone,phase 4 complete,DB01395,[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21,"Adrenal Cortex Hormones / Agents causing hyperkalemia / Androstanes / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptives, Oral / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Diuretics / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Mineralocorticoid Receptor Antagonists / Natriuretic Agents / Progesterone Congeners / Progestin Contraceptives / Progestins / Sex Hormones and Modulators of the Genital System / Steroids",N295J34A25,67392-87-4,D03917,68873.0,62105.0,150275.0,11636.0,50838.0,CHEMBL1509,DAP001206,PA164749409,ZINC000003927200
Digitoxin,phase 4 complete,DB01396,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,"Antiarrhythmic agents / Carbohydrates / Cardanolides / Cardenolides / Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Digitalis Glycosides / Enzyme Inhibitors / Fused-Ring Compounds / Glycosides / Narrow Therapeutic Index Drugs / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Potential QTc-Prolonging Agents / Protective Agents / QTc Prolonging Agents / Steroids",E90NZP2L9U,71-63-6,D00297,441207.0,389987.0,46356.0,3403.0,28544.0,CHEMBL254219,DAP000120,PA449316,ZINC000095862733
Salsalate,phase 4 complete,DB01399,OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antirheumatic Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Hydroxy Acids / Hydroxybenzoates / Nephrotoxic agents / Nervous System / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Phenols / Salicylic Acid and Derivatives / Sensory System Agents",V9MO595C9I,552-94-3,D00428,5161.0,4977.0,85244.0,36108.0,9014.0,CHEMBL154111,DAP000734,PA164745462,ZINC000000002062
Neostigmine,phase 4 complete,DB01400,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C,Amines / Ammonium Compounds / Antiglaucoma Preparations and Miotics / Autonomic Agents / Cholinergic Agents / Cholinesterase Inhibitors / Enzyme Inhibitors / Nervous System / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Ophthalmologicals / Parasympathomemetic (Cholinergic) Agents / Parasympathomimetics / Peripheral Nervous System Agents / Phenylammonium Compounds / Quaternary Ammonium Compounds / Sensory Organs,3982TWQ96G,59-99-4,D08261,4456.0,4301.0,50022775.0,7315.0,7514.0,CHEMBL278020,DAP000563,PA450611,ZINC000000001792
Choline magnesium trisalicylate,phase 4 complete,DB01401,[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Ammonium Compounds / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antirheumatic Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Ethanolamines / Hydroxy Acids / Hydroxybenzoates / Nephrotoxic agents / Nitrogen Compounds / Non COX-2 selective NSAIDS / Onium Compounds / Peripheral Nervous System Agents / Phenols / Quaternary Ammonium Compounds / Sensory System Agents / Trimethyl Ammonium Compounds",DJJ95FJP1H,64425-90-7,,54682045.0,10642393.0,,215799.0,,,,PA164749164,
Methotrimeprazine,phase 4 complete,DB01403,COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anticholinergic Agents / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Hyperglycemia-Associated Agents / Muscarinic Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenothiazines / Phenothiazines With Aliphatic Side-Chain / Photosensitizing Agents / Potential QTc-Prolonging Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Tranquilizing Agents",9G0LAW7ATQ,60-99-1,D00403,72287.0,65239.0,50418049.0,6852.0,6838.0,CHEMBL1764,,PA164743234,ZINC000000020246
Ginseng,phase 4 complete,DB01404,,Herbs and Natural Products,,50647-08-0,,,,,325526.0,,,,PA164781150,
Danazol,phase 4 complete,DB01406,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3,"Androgens / Antigonadotropins and Similar Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 Enzyme Inhibitors / Estrogen Antagonists / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Pregnadienes / Pregnanes / Sex Hormones and Modulators of the Genital System / Steroids / Thyroxine-binding globulin inhibitors",N29QWW3BUO,17230-88-5,D00289,28417.0,26436.0,50423541.0,3102.0,4315.0,CHEMBL1479,DAP001017,PA164749056,ZINC000003881958
Clenbuterol,phase 4 complete,DB01407,CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics for Systemic Use / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Alcohols / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Drugs for Obstructive Airway Diseases / Ethanolamines / Neurotransmitter Agents / Peripheral Nervous System Agents / Respiratory System Agents / Selective Beta 2-adrenergic Agonists / Sympathomimetics",XTZ6AXU7KN,37148-27-9,,2783.0,2681.0,27958.0,2580.0,174690.0,CHEMBL49080,DAP000945,PA164745640,
Tiotropium,phase 4 complete,DB01409,[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1,"Adrenergics, Inhalants / Agents producing tachycardia / Agents to Treat Airway Disease / Alkaloids / Anti-Asthmatic Agents / Anticholinergic Agents / Antimuscarinics Antispasmodics / Autonomic Agents / Aza Compounds / Azabicyclo Compounds / Bronchodilator Agents / Cholinergic Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Drugs that are Mainly Renally Excreted / Muscarinic Antagonists / Neurotransmitter Agents / Parasympatholytics / Peripheral Nervous System Agents / Respiratory System Agents / Scopolamine Derivatives / Tropanes",0EB439235F,186691-13-4,,5487427.0,19618474.0,50239981.0,69120.0,90960.0,CHEMBL1900528,DAP000344,PA164769056,ZINC000100008319
Ciclesonide,phase 4 complete,DB01410,[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C,"Adrenal Cortex Hormones / Adrenals / Agents to Treat Airway Disease / Anti-Allergic Agents / Corticosteroids / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Nasal Preparations / Pregnanes / Pregnenes / Steroids / Thyroxine-binding globulin inhibitors",S59502J185,126544-47-6,D01703,6918155.0,5293368.0,,274964.0,31397.0,CHEMBL2040682,DAP000423,PA164781399,ZINC000003915154
Cefepime,phase 4 complete,DB01413,CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Fourth-Generation Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Sulfur Compounds / Thiazines",807PW4VQE3,88040-23-7,D02376,5479537.0,4586395.0,50350470.0,20481.0,478164.0,CHEMBL186,DAP000455,PA164754876,
Ceftibuten,phase 4 complete,DB01415,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",IW71N46B4Y,97519-39-6,D00922,5282242.0,4445419.0,50370586.0,20492.0,3510.0,CHEMBL1605,DAP000456,PA164744555,ZINC000003871967
Cefpodoxime,phase 4 complete,DB01416,[H][C@]12SCC(COC)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephacetrile / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Prodrugs / Sulfur Compounds / Thiazines / Third-Generation Cephalosporins",7R4F94TVGY,80210-62-4,D07650,6335986.0,4891496.0,50292251.0,20489.0,3504.0,CHEMBL1672,DAP000457,PA164746385,ZINC000003830453
Acenocoumarol,phase 4 complete,DB01418,CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O,"4-Hydroxycoumarins / Anticoagulants / Benzopyrans / Blood and Blood Forming Organs / Coumarins / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / P-glycoprotein substrates / Pyrans / Vitamin K Antagonists",I6WP63U32H,152-72-7,D07064,54676537.0,10443441.0,,154.0,53766.0,CHEMBL397420,DAP000772,PA452632,
Antrafenine,phase 4 complete,DB01419,FC(F)(F)C1=CC(=CC=C1)N1CCN(CCOC(=O)C2=CC=CC=C2NC2=C3C=CC(=CC3=NC=C2)C(F)(F)F)CC1,"Agents causing hyperkalemia / Agents that produce hypertension / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Nephrotoxic agents / Non COX-2 selective NSAIDS",21FS93Y6OE,55300-29-3,,68723.0,61973.0,,,135841.0,CHEMBL345524,,PA164784000,ZINC000053073961
Testosterone propionate,phase 4 complete,DB01420 (DBSALT001032),[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"Androgens / Androstanes / Androstenes / Androstenols / COMT Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / P-glycoprotein substrates / Steroids / Testosterone and derivatives / Testosterone Congeners / Thyroxine-binding globulin inhibitors / UGT1A1 Inducers",WI93Z9138A,57-85-2,D00959,5995.0,5774.0,50215709.0,10382.0,9466.0,CHEMBL1170,,PA164751373,ZINC000000490791
Paromomycin,phase 4 complete,DB01421,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,"Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Amebicides / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antiparasitic Agents / Antiprotozoals / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Glycosides / Intestinal Antiinfectives / Narrow Therapeutic Index Drugs / Nephrotoxic agents",61JJC8N5ZK,7542-37-2,,165580.0,145115.0,50240054.0,7934.0,7934.0,CHEMBL370143,DAP000407,PA164784023,ZINC000060183170
Aminophenazone,phase 4 complete,DB01424,CN(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Nephrotoxic agents / Nervous System / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / Pyrazoles / Pyrazolones",01704YP3MO,58-15-1,D00556,6009.0,5787.0,74258.0,695.0,160246.0,CHEMBL288470,,PA164748135,ZINC000000057115
Ajmaline,phase 4 complete,DB01426,CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=CC=CC=C5[C@]44C[C@@H](C2[C@H]4O)N3[C@@H]1O,"Ajmaline and derivatives / Alkaloids / Antiarrhythmic agents / Antiarrhythmics, Class I / Antiarrhythmics, Class Ia / Antiarrhythmics, Class Ic / Cardiac Therapy / Cardiovascular Agents / Heterocyclic Compounds, Fused-Ring / Indole Alkaloids / Indoles / Membrane Transport Modulators / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Secologanin Tryptamine Alkaloids / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers",1PON08459R,4360-12-7,D00199,441080.0,10145712.0,,423.0,28462.0,CHEMBL2357792,,PA164776839,
Amrinone,phase 4 complete,DB01427,NC1=CC(=CNC1=O)C1=CC=NC=C1,"Amines / Aminopyridines / Calcium-Regulating Hormones and Agents / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Membrane Transport Modulators / Phosphodiesterase 3 Inhibitors / Phosphodiesterase Inhibitors / Protective Agents / Pyridines / Vasodilating Agents",JUT23379TN,60719-84-8,D00231,3698.0,3570.0,34651.0,738.0,2686.0,CHEMBL12856,DAP001392,PA164746803,ZINC000008673078
Oxybenzone,phase 4 complete,DB01428,COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1,"Benzene Derivatives / Compounds used in a research, industrial, or household setting / Cosmetics / Dermatologicals / Drugs that are Mainly Renally Excreted / Household Products / Ketones / Protective Agents / Radiation-Protective Agents / Sunscreen Agents",95OOS7VE0Y,131-57-7,D05309,4632.0,4471.0,50253134.0,32673.0,34283.0,CHEMBL1625,,PA164742933,ZINC000000136138
Almitrine,phase 4 complete,DB01430,FC1=CC=C(C=C1)C(N1CCN(CC1)C1=NC(NCC=C)=NC(NCC=C)=N1)C1=CC=C(F)C=C1,"Alkaloids / Central Nervous System Agents / Compounds used in a research, industrial, or household setting / Heterocyclic Compounds, Fused-Ring / Indole Alkaloids / Indoles / Neuroprotective Agents / Pharmaceutical Preparations / Piperazines / Protective Agents / Respiratory System Agents / Secologanin Tryptamine Alkaloids / Triazines",9A1222NBG4,27469-53-0,D07126,33887.0,31235.0,,528.0,53778.0,CHEMBL1183717,DAP000468,PA164750492,ZINC000004214772
Cholestyramine,phase 4 complete,DB01432,,"Anion Exchange Resins / Anticholesteremic Agents / Benzene Derivatives / Benzylidene Compounds / Bile Acid Sequestrants / Bile-acid Binding Activity / Compounds used in a research, industrial, or household setting / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Ion Exchange Resins / Laboratory Chemicals / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Macromolecular Substances / Noxae / Plastics / Polymers / Polystyrenes / Styrene / Styrenes / Toxic Actions",4B33BGI082,11041-12-6,,,,,2447.0,,CHEMBL1201625,,PA448974,
Antipyrine,phase 4 complete,DB01435,CN1N(C(=O)C=C1C)C1=CC=CC=C1,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics and Anesthetics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Central Nervous System Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Methemoglobinemia Associated Agents / Nephrotoxic agents / Nervous System / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / Otologicals / Peripheral Nervous System Agents / Pyrazoles / Pyrazolones / Sensory Organs / Sensory System Agents",T3CHA1B51H,60-80-0,D01776,2206.0,2121.0,50103600.0,1001.0,31225.0,CHEMBL277474,DNC001118,PA448453,ZINC000000061044
Alfacalcidol,phase 4 complete,DB01436,CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,Alimentary Tract and Metabolism / Bone Density Conservation Agents / Cholestanes / Cholestenes / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Fused-Ring Compounds / Lipids / Membrane Lipids / Musculo-Skeletal System / Secosteroids / Steroids / Sterols / Vitamin D and Analogues / Vitamins / Vitamins (Fat Soluble),URQ2517572,41294-56-8,D01518,5282181.0,4445376.0,,12062.0,31186.0,CHEMBL1601669,,PA164746469,ZINC000012484965
Glutethimide,phase 4 complete,DB01437,CCC1(CCC(=O)NC1=O)C1=CC=CC=C1,Central Nervous System Agents / Central Nervous System Depressants / Hypnotics and Sedatives / Nervous System / Piperidinedione Derivatives / Piperidines / Piperidones / Psycholeptics,C8I4BVN78E,77-21-4,D00532,3487.0,3367.0,,4903.0,5439.0,CHEMBL1102,DAP001305,PA164749505,
Phenazopyridine,phase 4 complete,DB01438,NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1,Amines / Aminopyridines / Antipruritics and Local Anesthetics / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Methemoglobinemia Associated Agents / Nephrotoxic agents / Pyridines / Urologicals,K2J09EMJ52,94-78-0,D08346,4756.0,4592.0,50420356.0,8120.0,71416.0,CHEMBL1242,,PA164746899,ZINC000095483532
gamma-Hydroxybutyric acid,phase 4 complete,DB01440,OCCCC(O)=O,"Acids, Acyclic / Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Butyrates / Central Nervous System Depressants / Central Nervous System Depression / Decreased Central Nervous System Organized Electrical Activity / Fatty Acids / Fatty Acids, Volatile / Hydroxy Acids / Lipids",30IW36W5B2,591-81-1,,3037032.0,9984.0,50023575.0,1546380.0,30830.0,CHEMBL1342,DAP001522,PA10819,ZINC000001532805
Diamorphine,phase 4 complete,DB01452,[H][C@@]12C=C[C@H](OC(C)=O)[C@@H]3OC4=C(OC(C)=O)C=CC5=C4[C@]13CCN(C)[C@@H]2C5,"Alkaloids / Analgesics / Central Nervous System Agents / Central Nervous System Depressants / Drugs Used in Addictive Disorders / Drugs Used in Opioid Dependence / Heroin, agonists / Heterocyclic Compounds, Fused-Ring / Morphinans / Morphine Derivatives / Narcotics / Nervous System / Opiate Alkaloids / Opioids / Peripheral Nervous System Agents / Phenanthrenes / Sensory System Agents / Thyroxine-binding globulin inducers",70D95007SX,561-27-3,D07286,5462328.0,4575379.0,,3304.0,27808.0,CHEMBL459324,,PA452619,ZINC000004097183
Dichloralphenazone,phase 4 complete,DB01495,OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1,Alcohols / Central Nervous System Depressants / Ethylene Glycols / Glycols / Hypnotics and Sedatives / Nervous System / Psycholeptics / Pyrazoles / Pyrazolones,YYX637R279,480-30-8,,10188.0,9776.0,,22892.0,,CHEMBL1697834,,,
Difenoxin,phase 4 complete,DB01501,OC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1,"Alimentary Tract and Metabolism / Antidiarrheals / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antipropulsives / Central Nervous System Depressants / Isonipecotic Acids / Piperidines",3ZZ5BJ9F2Q,28782-42-5,D03809,34328.0,31620.0,,23024.0,4534.0,CHEMBL1201321,,,ZINC000000601317
Flunitrazepam,phase 4 complete,DB01544,CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F,"Anti-Anxiety Agents / Benzazepines / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Benzodiazepinones / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Nervous System / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents / UGT1A1 Inhibitors / UGT1A3 Inhibitors / UGT2B7 Inhibitors",620X0222FQ,1622-62-4,D01230,3380.0,3263.0,25878.0,4460.0,31622.0,CHEMBL13280,DAP000931,PA164781320,ZINC000003812994
Dihydrocodeine,phase 4 complete,DB01551,[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])CC[C@@H]2O)=CC=C3OC,"Alkaloids / Analgesics / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Morphinans / Morphine Derivatives / Narcotics / Natural Opium Alkaloids / Nervous System / Opiate Alkaloids / Opioid Agonist / Opioids / Peripheral Nervous System Agents / Phenanthrenes / Semi-synthetic Opioids / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",N9I9HDB855,125-28-0,D01481,5284543.0,4447600.0,,23088.0,135276.0,CHEMBL1595,,PA449322,ZINC000004215736
Bromazepam,phase 4 complete,DB01558,BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1,"Anti-Anxiety Agents / Benzazepines / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Benzodiazepinones / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Nervous System / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents",X015L14V0O,1812-30-2,D01245,2441.0,2347.0,,1749.0,31302.0,CHEMBL277062,DAP001035,PA10035,ZINC000000001051
Clotiazepam,phase 4 complete,DB01559,CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl,Anti-Anxiety Agents / Benzodiazepines and benzodiazepine derivatives / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Nervous System / Psycholeptics,ZCN055599V,33671-46-4,D01328,2811.0,2709.0,,2622.0,31425.0,CHEMBL1697737,DAP000932,PA164752437,ZINC000000001207
Chloral hydrate,phase 4 complete,DB01563,OC(O)C(Cl)(Cl)Cl,Alcohols / Central Nervous System Agents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Ethylene Glycols / Glycols / Hypnotics and Sedatives / Miscellaneous Anxiolytics Sedatives and Hypnotics / Nervous System / Psycholeptics,418M5916WG,302-17-0,D00265,2707.0,2606.0,,2344.0,28142.0,CHEMBL455917,,PA448925,ZINC000003872049
Attapulgite,phase 4 complete,DB01574,[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[Si+4].[O-][H].[H]O[H].[H]O[H].[H]O[H].[H]O[H],"Alimentary Tract and Metabolism / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antidotes / Compounds used in a research, industrial, or household setting / Intestinal Adsorbents / Protective Agents",U6V729APAM,12174-11-7,,73415752.0,32701176.0,,133050.0,,,,PA164781017,
Kaolin,phase 4 complete,DB01575,O.O.[Al+3].[Al+3].[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-],"Acids / Acids, Noncarboxylic / Alimentary Tract and Metabolism / Aluminium Compounds / Aluminum Silicates / Anions / Antidiarrheals / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Electrolytes / Gastrointestinal Agents / Intestinal Adsorbents / Ions / Metal cations / Metal divalent cations / Minerals / Oxides / Oxygen Compounds / Silicates / Silicon Compounds",24H4NWX5CO,1332-58-7,,92024769.0,21241417.0,,6102.0,,,,PA10457,
Dextroamphetamine,phase 4 complete,DB01576,C[C@H](N)CC1=CC=CC=C1,"Agents producing tachycardia / Agents that produce hypertension / Amines / Amphetamines / Central Nervous System Agents / Central Nervous System Stimulants / Central Nervous System Stimulation / Centrally Acting Sympathomimetics / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Uptake Inhibitors / Ethylamines / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Phenethylamines / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sympathomimetics",TZ47U051FI,51-64-9,D03740,5826.0,5621.0,50022723.0,3288.0,4469.0,CHEMBL612,DAP001470,PA449269,ZINC000006021033
Metamfetamine,phase 4 complete,DB01577,CN[C@@H](C)CC1=CC=CC=C1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Agents that produce hypertension / Amines / Amphetamine Anorectic / Amphetamines / Antidepressive Agents / Appetite Suppression / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Central Nervous System Stimulants / Central Nervous System Stimulation / Centrally Acting Sympathomimetics / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Uptake Inhibitors / Drugs that are Mainly Renally Excreted / Ethylamines / Increased Sympathetic Activity / Membrane Transport Modulators / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Peripheral Nervous System Agents / Phenethylamines / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sympathomimetics",44RAL3456C,537-46-2,,10836.0,10379.0,50359499.0,6816.0,6809.0,CHEMBL1201201,DAP001496,PA450403,ZINC000006021043
Phendimetrazine,phase 4 complete,DB01579,C[C@H]1[C@@H](OCCN1C)C1=CC=CC=C1,Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Appetite Suppression / Central Nervous System Agents / Central Nervous System Stimulants / Increased Sympathetic Activity / Oxazines / Sympathomimetic Amine Anorectic,AB2794W8KV,634-03-7,D08347,30487.0,28295.0,,33272.0,8059.0,CHEMBL1615439,DAP000574,PA450902,ZINC000022010387
Oxprenolol,phase 4 complete,DB01580,CC(C)NCC(O)COC1=CC=CC=C1OCC=C,"Adrenergic Agents / Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Anti-Anxiety Agents / Antiarrhythmic agents / Antihypertensive Agents / Autonomic Agents / Beta Blocking Agents and Thiazides / Beta Blocking Agents, Non-Selective / Beta Blocking Agents, Non-Selective, and Thiazides / Bradycardia-Causing Agents / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hypotensive Agents / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / OCT2 Inhibitors / Peripheral Nervous System Agents / Phenoxypropanolamines / Propanolamines / Propanols / QTc Prolonging Agents / Sympatholytics / Tranquilizing Agents / Vasodilating Agents",519MXN9YZR,6452-71-7,,4631.0,4470.0,50240370.0,7801.0,91704.0,CHEMBL546,DAP000485,PA10284,
Sulfamerazine,phase 4 complete,DB01581,CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1,Amides / Amines / Aniline Compounds / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Long-Acting Sulfonamides / Sulfanilamides / Sulfonamide Antibacterial / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds,UR1SAB295F,127-79-7,D02435,5325.0,5134.0,50238672.0,10176.0,102130.0,CHEMBL438,DAP001240,PA164776842,ZINC000000057501
Sulfamethazine,phase 4 complete,DB01582,CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1,Amides / Amines / Aniline Compounds / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Short-Acting Sulfonamides / Sulfanilamides / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds,48U51W007F,57-68-1,,5327.0,5136.0,50238670.0,10178.0,102265.0,CHEMBL446,DAP001241,PA451542,ZINC000000057494
Liotrix,phase 4 complete,DB01583,[Na+].[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C([O-])=O.N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O,"Agents used to treat hypothyroidism / Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / l-Triiodothyronine / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein inducers / Pharmaceutical Preparations / Thyroid Products / Thyronines / Thyroxine-binding globulin substrates",YW8HJ0N26X,8065-29-0,D00361,71371.0,64467.0,,,6485.0,,,PA164748036,
Ursodeoxycholic acid,phase 4 complete,DB01586,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,Alimentary Tract and Metabolism / Bile Acid Preparations / Bile acids and derivatives / Bile Acids and Salts / Bile and Liver Therapy / Bile Therapy / BSEP/ABCB11 inducers / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / Cholagogues and Choleretics / Cholanes / Cholelitholytic Agents / Cholic Acids / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Fused-Ring Compounds / Gastrointestinal Agents / Steroids,724L30Y2QR,128-13-2,D00734,31401.0,29131.0,53721.0,11065.0,9907.0,CHEMBL1551,DNC000420,PA451837,ZINC000003914809
Ketazolam,phase 4 complete,DB01587,CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1,"Anti-Anxiety Agents / Benzazepines / Benzodiazepines and benzodiazepine derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Nervous System / P-glycoprotein substrates / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents",92A214MD7Y,27223-35-4,,33746.0,31110.0,,28181.0,135556.0,CHEMBL2104356,,PA164749385,
Prazepam,phase 4 complete,DB01588,ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1,"Anti-Anxiety Agents / Benzazepines / Benzodiazepines and benzodiazepine derivatives / Benzodiazepinones / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents",Q30VCC064M,2955-38-6,D00470,4890.0,4721.0,,8627.0,8362.0,CHEMBL969,DAP000689,PA164776668,ZINC000000001971
Quazepam,phase 4 complete,DB01589,FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2,"Benzazepines / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Nervous System / Psycholeptics",JF8V0828ZI,36735-22-5,D00457,4999.0,4825.0,,35185.0,8694.0,CHEMBL1200472,DAP000690,PA164744373,ZINC000000538266
Everolimus,phase 4 complete,DB01590,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,Anti-Bacterial Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Immunologic Activity / Hyperglycemia-Associated Agents / Immunologic Factors / Immunosuppressive Agents / Kinase Inhibitor / Lactones / Macrolides / mTOR Inhibitor Immunosuppressant / mTOR Inhibitors / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Polyketides / Protein Kinase Inhibitors / Selective Immunosuppressants,9HW64Q8G6G,159351-69-6,D02714,6442177.0,21106307.0,50088378.0,141704.0,68478.0,CHEMBL1908360,DAP001223,PA164746311,ZINC000169677008
Solifenacin,phase 4 complete,DB01591 (APRD00168),O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1,"Agents producing tachycardia / Agents that produce hypertension / Anticholinergic Agents / Cholinergic Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Urinary Frequency and Incontinence / Drugs Used in Benign Prostatic Hypertrophy / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Muscarinic Antagonists / Neurotransmitter Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quinuclidines / Tetrahydroisoquinolines / Urological Agents / Urologicals",A8910SQJ1U,242478-37-1,D08522,154059.0,135771.0,50370682.0,322167.0,135530.0,CHEMBL1734,DAP001129,PA164783810,ZINC000003936683
Iron,phase 4 complete,DB01592,[Fe],"Alimentary Tract and Metabolism / Antianemia Drugs / Antianemic Preparations / Blood and Blood Forming Organs / Diet, Food, and Nutrition / Elements / Food / Food and Beverages / Growth Substances / Iron Compounds / Iron Preparations / Metals / Metals, Heavy / Micronutrients / Minerals / Organometallic Compounds / Physiological Phenomena / Supplements / Trace Elements / Transition Elements",E1UOL152H7,7439-89-6,,23925.0,22368.0,,262150.0,18248.0,,DAP001313,PA450087,
Zinc,phase 4 complete,DB01593,[Zn],"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Copper Absorption Inhibitor / Diet, Food, and Nutrition / Elements / Food / Food and Beverages / Growth Substances / Laxatives / Metal cations / Metal divalent cations / Metals / Metals, Heavy / Micronutrients / Minerals / Physiological Phenomena / Replacement Preparations / Trace Elements / Transition Elements / Vasoprotectives / Zinc Compounds",J41CSQ7QDS,7440-66-6,,23994.0,22430.0,50259154.0,11416.0,30185.0,CHEMBL1201279,,PA451956,
Nitrazepam,phase 4 complete,DB01595,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1,"Anti-Anxiety Agents / Anticonvulsants / Benzazepines / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Benzodiazepinones / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Nervous System / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents",9CLV70W7HS,146-22-5,D00531,4506.0,4350.0,50020856.0,7440.0,7581.0,CHEMBL13209,DAP000691,PA10242,ZINC000004311748
Cilastatin,phase 4 complete,DB01597 (EXPT00918),CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O,Cycloparaffins / Cyclopropanes / Dipeptidase Inhibitors / Enzyme Inhibitors / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / Protease Inhibitors / Renal Dehydropeptidase Inhibitor,141A6AMN38,82009-34-5,D07698,6435415.0,4940183.0,50367502.0,2540.0,3697.0,CHEMBL766,DAP000632,PA448998,ZINC000004095696
Imipenem,phase 4 complete,DB01598,[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,"Agents that reduce seizure threshold / Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Carbapenems / Heterocyclic Compounds, Fused-Ring / Lactams / Neurotoxic agents / Penem Antibacterial / Sulfur Compounds / Thienamycins",Q20IM7HE75,64221-86-9,,104838.0,94631.0,50049708.0,1545986.0,471744.0,CHEMBL148,DAP000459,PA449968,ZINC000004097225
Probucol,phase 4 complete,DB01599,CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C,"Anticholesteremic Agents / Antioxidants / Benzene Derivatives / Compounds used in a research, industrial, or household setting / Hypolipidemic Agents / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Moderate Risk QTc-Prolonging Agents / Noxae / Phenols / Protective Agents / QTc Prolonging Agents / Toxic Actions",P3CTH044XJ,23288-49-5,D00476,4912.0,4743.0,50007260.0,8699.0,8427.0,CHEMBL608,DAP000916,PA451107,ZINC000001530755
Tiaprofenic acid,phase 4 complete,DB01600,CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1,"Acids, Acyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / Fatty Acids / Fatty Acids, Volatile / Lipids / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Other Nonsteroidal Anti-inflammatory Agents / Peripheral Nervous System Agents / Photosensitizing Agents / Propionates / Prostaglandin Antagonists / Sensory System Agents",1LS1T6R34C,33005-95-7,,5468.0,5269.0,223313.0,38253.0,32221.0,CHEMBL365795,DAP000973,PA164764503,
Lopinavir,phase 4 complete,DB01601 (EXPT00388),CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BSEP/ABCB11 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Experimental Unapproved Treatments for COVID-19 / HIV Protease Inhibitors / Hyperglycemia-Associated Agents / Nephrotoxic agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Organic Anion Transporting Polypeptide 1B1 Inhibitors / P-glycoprotein inducers / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / Protease Inhibitors / Pyrimidinones / QTc Prolonging Agents,2494G1JF75,192725-17-0,D01425,92727.0,83706.0,50180655.0,195088.0,31781.0,CHEMBL729,DAP000708,PA450264,ZINC000003951740
Bacampicillin,phase 4 complete,DB01602,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OC(C)OC(=O)OCC,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillin G / Penicillins / Penicillins With Extended Spectrum / Sulfur Compounds",8GM2J22278,50972-17-3,,441397.0,390135.0,,18687.0,2968.0,CHEMBL1583,DAP001162,PA164745461,
Meticillin,phase 4 complete,DB01603,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / Beta-Lactamase Resistant Penicillins / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillins / Sulfur Compounds",Q91FH1328A,61-32-5,,6087.0,5862.0,50103523.0,2181306.0,6827.0,CHEMBL575,DAP001170,PA164777034,ZINC000003831070
Pivampicillin,phase 4 complete,DB01604,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OCOC(=O)C(C)(C)C,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillin G / Penicillins / Penicillins With Extended Spectrum / Sulfur Compounds",0HLM346LL7,33817-20-8,,33478.0,30899.0,,8372.0,8255.0,CHEMBL3182343,DAP001171,PA164776912,ZINC000034967244
Pivmecillinam,phase 4 complete,DB01605,[H]C(=N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@]12[H])N1CCCCCC1,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillins / Penicillins With Extended Spectrum / Renal Agents / Sulfur Compounds",1WAM1OQ30B,32886-97-8,D02889,115163.0,16735658.0,,627.0,51210.0,CHEMBL1616433,DAP001174,PA164750167,
Tazobactam,phase 4 complete,DB01606 (EXPT03012),[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O,"Amides / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Aza Compounds / Azabicyclo Compounds / Beta-Lactam Antibacterials / beta-Lactamase Inhibitors / beta-Lactams / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Lactams / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / Sulfones / Sulfur Compounds",SE10G96M8W,89786-04-9,D00660,123630.0,110216.0,50053173.0,37617.0,9421.0,CHEMBL404,DAP000926,PA164764504,ZINC000003787060
Ticarcillin,phase 4 complete,DB01607,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](C(O)=O)C1=CSC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillins / Penicillins With Extended Spectrum / Sulfur Compounds",F93UJX4SWT,34787-01-4,,36921.0,33876.0,50103522.0,10591.0,9587.0,CHEMBL1449,DAP000458,PA451684,ZINC000003831540
Periciazine,phase 4 complete,DB01608,OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Depressants / Dopamine Antagonists / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotoxic agents / Phenothiazines / Phenothiazines With Piperidine Structure / Psycholeptics / Sulfur Compounds",3405M6FD73,2622-26-6,D01485,4747.0,4585.0,50346422.0,8766.0,31981.0,CHEMBL251940,DAP000413,PA164781043,ZINC000000538159
Deferasirox,phase 4 complete,DB01609,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Chelating Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Heavy Metal Antagonists / Iron Chelating Activity / Iron Chelating Agents / Sequestering Agents / Triazoles / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT1A3 Inhibitors / UGT1A9 Inhibitors",V8G4MOF2V9,201530-41-8,D03669,5493381.0,10770206.0,50088376.0,614373.0,49005.0,CHEMBL550348,,PA164760843,ZINC000001481815
Valganciclovir,phase 4 complete,DB01610,CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O,"Agents that reduce seizure threshold / Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Ganciclovir / Ganciclovir and prodrug / Heterocyclic Compounds, Fused-Ring / Nucleic Acid Synthesis Inhibitors / Nucleoside Analog Antiviral / Nucleosides and Nucleotides / Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors / Purines / Purinones",GCU97FKN3R,175865-60-8,D02495,64147.0,57721.0,,275891.0,63635.0,CHEMBL1201314,DAP000646,PA10227,
Hydroxychloroquine,phase 4 complete,DB01611,CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1,"Aminoquinolines / Anti-Infective Agents / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Antirheumatic Agents / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / P-glycoprotein inhibitors / Photosensitizing Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quinolines",4QWG6N8QKH,118-42-3,D08050,3652.0,3526.0,,5521.0,5801.0,CHEMBL1535,DAP000878,PA164777036,
Amyl Nitrite,phase 4 complete,DB01612,CCCCCON=O,"Acids / Acids, Noncarboxylic / Anions / Antianginal Agents / Antidotes / Cardiovascular Agents / Electrolytes / Hypotensive Agents / Ions / Methemoglobinemia Associated Agents / Nitrites / Nitrogen Compounds / Organic Nitrates / Vasodilating Agents",H2HUX79FYK,8017-89-8,D00517,10026.0,9632.0,,742.0,55344.0,CHEMBL3188202,,PA164750570,ZINC000020230701
Erythrityl tetranitrate,phase 4 complete,DB01613,[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O,"Acids / Acids, Noncarboxylic / Alcohols / Anions / Antianginal Agents / Carbohydrates / Cardiac Therapy / Cardiovascular Agents / Electrolytes / Erythritol / Ions / Nitrates / Nitric Acid / Nitrogen Compounds / Organic Nitrates / Sugar Alcohols / Vasodilating Agents / Vasodilators Used in Cardiac Diseases",35X333P19D,7297-25-8,,5284553.0,4447608.0,,4040.0,60072.0,CHEMBL2107583,DAP001060,PA164746528,ZINC000018178475
Alverine,phase 4 complete,DB01616,CCN(CCCC1=CC=CC=C1)CCCC1=CC=CC=C1,Alimentary Tract and Metabolism / Amines / Antidepressive Agents / Autonomic Agents / Central Nervous System Depressants / Drugs for Functional Gastrointestinal Disorders / Parasympatholytics / Peripheral Nervous System Agents / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists,46TIR1560O,150-59-4,D07440,3678.0,3550.0,37636.0,17627.0,518413.0,CHEMBL253371,,PA164764505,ZINC000001481966
Molindone,phase 4 complete,DB01618,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2,"Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Agents / Central Nervous System Depressants / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Indole Derivatives / Indoles / Nervous System / Neurotoxic agents / Psycholeptics / Psychotropic Drugs / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents",RT3Y3QMF8N,7416-34-4,D08226,23897.0,22342.0,50130290.0,7019.0,6965.0,CHEMBL460,DAP000979,PA164746756,
Phenindamine,phase 4 complete,DB01619,CN1CCC2=C(C1)C(C1=CC=CC=C21)C1=CC=CC=C1,Antihistamines for Systemic Use / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Neurotransmitter Agents,772BQ8KSST,82-88-2,D08353,11291.0,10817.0,50089147.0,33283.0,8065.0,CHEMBL278398,DAP001073,PA164750491,
Pheniramine,phase 4 complete,DB01620,CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1,"Anti-Allergic Agents / Antihistamines for Systemic Use / Antihistamines for Topical Use / Antipruritics / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Dermatologicals / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Potential QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents",134FM9ZZ6M,86-21-5,,4761.0,4597.0,50017656.0,8132.0,91591.0,CHEMBL1193,DAP001063,PA164744506,
Pipotiazine,phase 4 complete,DB01621,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CCO)CC2)C=C1,"Antidepressive Agents / Antipsychotic Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Nervous System / Neurotoxic agents / Phenothiazines / Phenothiazines With Piperidine Structure / Photosensitizing Agents / Psycholeptics / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds",L903J9JPYV,39860-99-6,D08385,62867.0,56598.0,81798.0,8348.0,,CHEMBL398880,,PA10158,ZINC000003813024
Thiothixene,phase 4 complete,DB01623,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1,"Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Photosensitizing Agents / Potential QTc-Prolonging Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Thioxanthene Derivatives / Thioxanthenes / Tranquilizing Agents / Xanthenes",7318FJ13YJ,3313-26-6,D00374,941651.0,819430.0,78576.0,10510.0,9571.0,CHEMBL1201,DAP000318,PA451669,ZINC000030690433
Zuclopenthixol,phase 4 complete,"DB01624 (DB08919, DB08920)",OCCN1CCN(CC\C=C2\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (First Generation [Typical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Histamine Antagonists / Histamine H1 Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Thioxanthene Derivatives / Thioxanthenes / Tranquilizing Agents / Xanthenes",47ISU063SG,53772-83-1,D03556,5311507.0,4470984.0,79209.0,114176.0,51364.0,CHEMBL53904,DAP000845,PA452629,ZINC000000601293
Isopropamide,phase 4 complete,DB01625,CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C,"Agents producing tachycardia / Alimentary Tract and Metabolism / Amines / Ammonium Compounds / Anticholinergic Agents / Drugs for Functional Gastrointestinal Disorders / Muscarinic Antagonists / Nitrogen Compounds / Onium Compounds / Synthetic Anticholinergics, Quaternary Ammonium Compounds",8B9I31H724,7492-32-2,,3775.0,3643.0,82074.0,89784.0,6043.0,CHEMBL1201232,,PA164781398,ZINC000001530668
Pargyline,phase 4 complete,DB01626,CN(CC#C)CC1=CC=CC=C1,Agents that produce hypertension / Agents that reduce seizure threshold / Amines / Antidepressive Agents / Antihypertensive Agents / Benzene Derivatives / Benzyl Compounds / Benzylamines / Cardiovascular Agents / Central Nervous System Depressants / Enzyme Inhibitors / MAO Inhibitors and Diuretics / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Monoamine Oxidase Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome,9MV14S8G3E,555-57-7,D08453,4688.0,4526.0,50172756.0,7930.0,7930.0,CHEMBL673,DAP000580,PA450797,ZINC000053084618
Lincomycin,phase 4 complete,DB01627,[H][C@]1(C[C@@H](CCC)CN1C)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,"Agents that produce neuromuscular block (indirect) / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Enzyme Inhibitors / Glycosides / Lincosamides / Macrolides, Lincosamides and Streptogramins / Neurotoxic agents / Protein Synthesis Inhibitors / Pyrrolidines",BOD072YW0F,154-21-2,D00223,3000540.0,2272112.0,50335522.0,6398.0,6472.0,CHEMBL1447,DAP000839,PA164749212,ZINC000003982483
Etoricoxib,phase 4 complete,DB01628 (DB07166),CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / COX-2 Inhibitors / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Peripheral Nervous System Agents / Pyridines / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory System Agents / Sulfones / Sulfur Compounds",WRX4NFY03R,202409-33-4,D03710,123619.0,110209.0,50072064.0,307296.0,6339.0,CHEMBL416146,DAP000738,PA164776853,ZINC000000579472
5-O-phosphono-alpha-D-ribofuranosyl diphosphate,phase 4 complete,DB01632 (EXPT02663),O[C@H]1[C@@H](O)[C@@H](OP(O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O,Carbohydrates / Pentosephosphates / Sugar Phosphates,,13270-65-0,,7339.0,7062.0,25315.0,,17111.0,,,,ZINC000008215630
Sorbitol,phase 4 complete,"DB01638 (EXPT02939, DB09391)",OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,"Alcohols / Alimentary Tract and Metabolism / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Carbohydrates / Compounds used in a research, industrial, or household setting / Diagnostic Agents / Diet, Food, and Nutrition / Drugs for Constipation / Drugs that are Mainly Renally Excreted / Enemas / Flavoring Agents / Food / Food Additives / Food and Beverages / Food Ingredients / Gastrointestinal Agents / Indicators and Reagents / Irrigating Solutions / Laboratory Chemicals / Laxatives / Osmotic Laxatives / Pharmaceutic Aids / Pharmaceutical Preparations / Physiological Phenomena / Sugar Alcohols / Sweetening Agents / Tests for Bile Duct Patency",506T60A25R,50-70-4,D00096,5780.0,5576.0,,9945.0,17924.0,CHEMBL1682,,PA451455,ZINC000018279893
Roflumilast,phase 4 complete,DB01656 (EXPT02802),FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl,"Acids, Carbocyclic / Agents to Treat Airway Disease / Amides / Amines / Benzene Derivatives / Benzoates / Cycloparaffins / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Drugs that are Mainly Renally Excreted / Phosphodiesterase 4 Inhibitors / Phosphodiesterase Inhibitors / Pyridines",0P6C6ZOP5U,162401-32-3,D05744,449193.0,395793.0,14774.0,1091836.0,47657.0,CHEMBL193240,,PA165948052,ZINC000000592419
Rutin,phase 4 complete,DB01698 (EXPT02824),C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,"Benzopyrans / Capillary Stabilizing Agents / Chromones / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Flavonoids / Flavonols / Heterocyclic Compounds, Fused-Ring / Pyrans / Vasoprotectives",5G06TVY3R7,153-18-4,,5280805.0,4444362.0,,9500.0,28527.0,CHEMBL226335,,PA451291,ZINC000004096846
Prasterone,phase 4 complete,"DB01708 (EXPT00519, DB06593)",[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C,"17-Ketosteroids / Adjuvants, Immunologic / Adrenal Cortex Hormones / Alimentary Tract and Metabolism / Anabolic Agents for Systemic Use / Anabolic Steroids / Androgens and Estrogens / Androstan Derivatives / Androstanes / Androstenes / Androstenols / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunologic Factors / Ketosteroids / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / Sex Hormones and Modulators of the Genital System / Steroids / Testosterone Congeners",459AG36T1B,53-43-0,D08409,5881.0,5670.0,50223368.0,3143.0,28689.0,CHEMBL90593,DNC001146,PA451993,ZINC000003807917
Cetrimonium,phase 4 complete,"DB01718 (EXPT00048, DB13159)",CCCCCCCCCCCCCCCC[N+](C)(C)C,"Amines / Ammonium Compounds / Anti-Infective Agents / Anti-Infective Agents, Local / Antiseptics and Disinfectants / Cetrimonium Compounds / Compounds used in a research, industrial, or household setting / Dermatologicals / Medicated Shampoos / Miscellaneous Local Anti-infectives / Nitrogen Compounds / Onium Compounds / Quaternary Ammonium Compounds / Throat Preparations / Trimethyl Ammonium Compounds",Z7FF1XKL7A,6899-10-1,D03454,2681.0,2580.0,58941.0,20614.0,39561.0,CHEMBL1183605,,,ZINC000006846023
Camphor,phase 4 complete,DB01744 (EXPT00827),[H][C@@]12CC[C@@](C)(C(=O)C1)C2(C)C,"Anti-Infective Agents / Anti-Infective Agents, Local / Antipruritics and Local Anesthetics / Basic Lotions and Liniments / Biological Products / Bornanes / Cardiac Therapy / Complex Mixtures / Ketones / Monoterpenes / Norbornanes / Pharmaceutical Preparations / Plant Extracts / Plant Preparations / Terpenes",N20HL7Q941,464-49-3,D06392,159055.0,139902.0,36263.0,1298738.0,15396.0,CHEMBL504760,,PA448759,ZINC000000967520
Dalfopristin,phase 4 complete,DB01764 (EXPT01246),CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC(=CO1)C2=O,"Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Peptides / Peptides, Cyclic / Streptogramin Antibacterial / Streptogramins",R9M4FJE48E,112362-50-2,D00853,6323289.0,16736919.0,,229369.0,,CHEMBL1200937,DAP001294,PA164746234,ZINC000003917540
Pantothenic acid,phase 4 complete,DB01783 (EXPT02501),CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O,"Alanine / Alimentary Tract and Metabolism / Amino Acids / Amino Acids, Peptides, and Proteins / Blood Coagulation Factors / Cicatrizants / Dermatologicals / Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Imides / Micronutrients / Physiological Phenomena / Preparations for Treatment of Wounds and Ulcers / Vitamin B Complex / Vitamins",19F5HK2737,79-83-4,D07413,988.0,6361.0,50240040.0,7891.0,46905.0,CHEMBL1594,,,ZINC000005356910
Propylene glycol,phase 4 complete,"DB01839 (EXPT02572, DB11078)",CC(O)CO,"Alcohols / Compounds used in a research, industrial, or household setting / Drug Delivery Systems / Glycols / Pegylated agents / Pharmaceutic Aids / Pharmaceutical Preparations / Pharmaceutical Vehicles / Propylene Glycols / Solvents",6DC9Q167V3,57-55-6,D00078,1030.0,13835224.0,,34693.0,16997.0,CHEMBL286398,,,
D-glucose,phase 4 complete,"DB01914 (EXPT01609, DB11280)",[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O,"Carbohydrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Flavoring Agents / Food / Food Additives / Food and Beverages / Food Ingredients / Glucose / Hexoses / Monosaccharides / Pharmaceutic Aids / Pharmaceutical Preparations / Physiological Phenomena / Sweetening Agents",5SL0G7R0OK,50-99-7,,107526.0,96749.0,,349730.0,42758.0,,,,ZINC000100009383
Huperzine A,phase 4 complete,"DB04864 (EXPT01795, DB01928, DB05510)",[H][C@@]12CC3=C(C=CC(=O)N3)[C@@](N)(CC(C)=C1)\C2=C\C,"Central Nervous System Agents / Cholinergic Agents / Cholinesterase Inhibitors / Compounds used in a research, industrial, or household setting / Enzyme Inhibitors / Neuroprotective Agents / Neurotransmitter Agents / Protective Agents / Terpenes",0111871I23,102518-79-6,,854026.0,16736021.0,50199522.0,2267703.0,78330.0,CHEMBL395280,,,ZINC000009411213
Taurine,phase 4 complete,"DB01956 (EXPT03010, DB11103)",NCCS(O)(=O)=O,"Acids / Acids, Noncarboxylic / Alkanes / Alkanesulfonic Acids / Hydrocarbons, Acyclic / Sulfonic Acids / Sulfur Acids / Sulfur Compounds",1EQV5MLY3D,107-35-7,D00047,1123.0,1091.0,50357220.0,10337.0,507393.0,CHEMBL239243,,PA451590,ZINC000003809490
Cocarboxylase,phase 4 complete,"DB01987 (EXPT03031, EXPT03093)",CC1=C(CCO[P@](O)(=O)O[P@](O)([O-])=O)SC=[N+]1CC1=CN=C(C)N=C1N,"Coenzymes / Diet, Food, and Nutrition / Enzymes and Coenzymes / Food / Food and Beverages / Growth Substances / Micronutrients / Physiological Phenomena / Pyrimidines / Sulfur Compounds / Thiazoles / Vitamin B Complex / Vitamins",Q57971654Y,136-08-3,,5431.0,5238.0,,10459.0,45931.0,CHEMBL1236235,,,
Phenylbutyric acid,phase 4 complete,"DB06819 (EXPT00947, DB02000, DB12600)",OC(=O)CCCC1=CC=CC=C1,"Acids, Carbocyclic / Alimentary Tract and Metabolism / Ammonium Ion Binding Activity / Antineoplastic Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Nitrogen Binding Agent / Urea Cycle Disorder Agents / Various Alimentary Tract and Metabolism Products",7WY7YBI87E,1821-12-1,D05868,4775.0,4611.0,,1546447.0,41500.0,CHEMBL1469,,,ZINC000000056568
Flufenamic acid,phase 4 complete,DB02266 (EXPT01442),OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F,"Acids, Carbocyclic / Amines / Aminobenzoates / Aniline Compounds / Anti-Inflammatory Agents / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Benzene Derivatives / Benzoates / Fenamates / Musculo-Skeletal System / OAT1/SLC22A6 inhibitors / ortho-Aminobenzoates",60GCX7Y6BH,530-78-9,D01581,3371.0,3254.0,17636.0,4453.0,42638.0,CHEMBL23588,,PA166049190,ZINC000000086535
Calcipotriol,phase 4 complete,DB02300 (EXPT02131),O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1,Antipsoriatics / Antipsoriatics for Topical Use / Cholestanes / Cholestenes / Dermatologicals / Fused-Ring Compounds / Lipids / Membrane Lipids / Misc. Skin and Mucous Membrane Agents / Secosteroids / Steroids / Sterols / Vitamin D and Analogues / Vitamins / Vitamins (Fat Soluble),143NQ3779B,112965-21-6,D01125,5288783.0,4450880.0,50369964.0,29365.0,50749.0,CHEMBL1200666,DAP000292,PA448714,ZINC000003921872
Isopropyl alcohol,phase 4 complete,"DB02325 (EXPT01912, DB04402)",CC(C)O,"Alcohols / Antiseptics and Disinfectants / Compounds used in a research, industrial, or household setting / Dermatologicals / Miscellaneous Local Anti-infectives / Propanols / Solvents",ND2M416302,67-63-0,D00137,3776.0,3644.0,,797541.0,17824.0,CHEMBL582,,PA450117,ZINC000000901159
Aminobenzoic acid,phase 4 complete,DB02362 (EXPT02486),NC1=CC=C(C=C1)C(O)=O,"4-Aminobenzoic Acid / Acids, Carbocyclic / Aminobenzoates / Benzene Derivatives / Benzoates / Dermatologicals / Emollients and Protectives / para-Aminobenzoates / Protectives Against UV-Radiation / Protectives Against UV-Radiation for Topical Use / Sunscreen Agents / Vitamin B Complex / Vitamins",TL2TJE8QTX,150-13-0,D02456,978.0,953.0,50145829.0,74.0,30753.0,CHEMBL542,,,ZINC000000000920
Carbocisteine,phase 4 complete,"DB04339 (EXPT00835, DB02476)",N[C@@H](CSCC(O)=O)C(O)=O,Cough and Cold Preparations / Expectorants,740J2QX53R,638-23-3,D00175,193653.0,168055.0,50213735.0,2023.0,16163.0,CHEMBL396416,,,ZINC000001529732
Thymol,phase 4 complete,DB02513 (EXPT01913),CC(C)C1=CC=C(C)C=C1O,"Anti-Infective Agents / Anti-Infective Agents, Local / Antifungal Agents / Benzene Derivatives / Monoterpenes / Terpenes",3J50XA376E,89-83-8,D01039,6989.0,21105998.0,50240432.0,10553.0,27607.0,CHEMBL29411,,,ZINC000000967597
gamma-Aminobutyric acid,phase 4 complete,"DB02530 (EXPT00402, DB08850)",NCCCC(O)=O,"Acids, Acyclic / Amino Acids / Amino Acids, Peptides, and Proteins / Aminobutyrates / Butyrates / Fatty Acids / Fatty Acids, Volatile / GABA Agents / Lipids / Neurotransmitter Agents",2ACZ6IPC6I,56-12-2,D00058,119.0,116.0,24183.0,4617.0,59888.0,CHEMBL96,,,ZINC000001532620
Vorinostat,phase 4 complete,DB02546 (EXPT02902),ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,Amides / Amines / Anilides / Aniline Compounds / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Enzyme Inhibitors / Histone Deacetylase Inhibitors / Hydroxamic Acids / Hydroxy Acids / Hydroxylamines / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Potential QTc-Prolonging Agents / QTc Prolonging Agents,58IFB293JI,149647-78-9,D06320,5311.0,5120.0,19149.0,194337.0,45716.0,CHEMBL98,DAP001082,PA164748224,ZINC000001543873
Terlipressin,phase 4 complete,DB02638 (EXPT03310),NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,"Amino Acids, Peptides, and Proteins / Cardiovascular Agents / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Moderate Risk QTc-Prolonging Agents / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormones / Pituitary Hormones, Posterior / Posterior Pituitary Lobe Hormones / Proteins / QTc Prolonging Agents / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Vasoconstrictor Agents / Vasopressin and Analogues / Vasopressins",7Z5X49W53P,14636-12-5,,72081.0,65067.0,,57048.0,135905.0,CHEMBL2135460,DAP000058,PA164781020,
Cholic Acid,phase 4 complete,DB02659 (EXPT00906),[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C,Alimentary Tract and Metabolism / Bile Acid Preparations / Bile acids and derivatives / Bile Acids and Salts / Bile and Liver Therapy / Bile Therapy / BSEP/ABCB11 inducers / BSEP/ABCB11 Inhibitors / BSEP/ABCB11 Substrates / Cholanes / Cholic Acids / Fused-Ring Compounds / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inducers / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein inducers / Steroids,G1JO7801AE,81-25-4,D10699,221493.0,192176.0,21680.0,1440856.0,16359.0,CHEMBL205596,,PA166160055,ZINC000006858022
Nicotinamide,phase 4 complete,DB02701 (EXPT02307),NC(=O)C1=CC=CN=C1,"Alimentary Tract and Metabolism / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Micronutrients / Nicotinic Acids / Physiological Phenomena / Pyridines / Vitamin B Complex / Vitamins",25X51I8RD4,98-92-0,D00036,936.0,911.0,27507.0,7405.0,17154.0,CHEMBL1140,DAP001410,,ZINC000000005878
Fusidic acid,phase 4 complete,DB02703 (EXPT01507),[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C(O)=O,Agents Causing Muscle Toxicity / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antibiotics for Topical Use / Antiinfectives for Systemic Use / BCRP/ABCG2 Inhibitors / BSEP/ABCB11 Inhibitors / Cholestadienes / Cholestadienols / Cholestanes / Cholestenes / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Enzyme Inhibitors / Fused-Ring Compounds / Lipids / Medicated Dressings / Medicated Dressings With Antiinfectives / Membrane Lipids / OATP1B1/SLCO1B1 Inhibitors / Ophthalmologicals / Other Miscellaneous Antibacterial Agents / Protein Synthesis Inhibitors / Sensory Organs / Steroid Antibacterials / Steroids / Sterols / UGT1A1 Substrates,59XE10C19C,6990-06-3,D04281,3000226.0,2271900.0,58924.0,113608.0,29013.0,CHEMBL374975,DAP001008,PA164749648,ZINC000008143796
Sucrose,phase 4 complete,DB02772 (EXPT02977),OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,"Carbohydrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Disaccharides / Flavoring Agents / Food / Food Additives / Food and Beverages / Food Ingredients / Oligosaccharides / Pharmaceutic Aids / Pharmaceutical Preparations / Physiological Phenomena / Polysaccharides / Sweetening Agents",C151H8M554,57-50-1,D00025,5988.0,5768.0,50108105.0,10159.0,17992.0,CHEMBL253582,,PA451525,ZINC000004217475
Pregnenolone,phase 4 complete,DB02789 (EXPT02608),[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C,"Adrenal Cortex Hormones / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydroxycorticosteroids / Pregnanes / Pregnenes / Progesterone Congeners / Steroids",73R90F7MQ8,145-13-1,D00143,8955.0,8611.0,50375319.0,114052.0,16581.0,CHEMBL253363,DNC001147,,ZINC000003861150
D-Methionine,phase 4 complete,DB02893 (EXPT02150),CSCC[C@@H](N)C(O)=O,,868496F25R,348-67-4,,84815.0,76512.0,,,57932.0,CHEMBL1234268,,,ZINC000001532766
Piretanide,phase 4 complete,DB02925 (EXPT03308),NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O,Amides / Cardiovascular Agents / Diuretics / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / High-Ceiling Diuretics / Membrane Transport Modulators / Natriuretic Agents / Sodium Potassium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds,DQ6KK6GV93,55837-27-9,D01634,4849.0,4683.0,50240046.0,33770.0,32015.0,CHEMBL349803,DNC001127,,ZINC000003812930
Oxitriptan,phase 4 complete,DB02959 (EXPT01780),N[C@@H](CC1=CNC2=C1C=C(O)C=C2)C(O)=O,"Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Antidepressive Agents / Antidepressive Agents, Second-Generation / Central Nervous System Agents / Central Nervous System Depressants / Nervous System / Psychoanaleptics / Psychotropic Drugs / Tryptophan",C1LJO185Q9,4350-09-8,D07339,439280.0,388413.0,50403163.0,94.0,58266.0,CHEMBL350221,,,ZINC000000895330
Lauric acid,phase 4 complete,"DB03017 (EXPT01112, EXPT02006)",CCCCCCCCCCCC(O)=O,Fatty Acids / Lipids,1160N9NU9U,143-07-7,,3893.0,3756.0,50180948.0,1363435.0,30805.0,CHEMBL108766,,,ZINC000001529498
Glycolic acid,phase 4 complete,"DB03085 (EXPT01629, DB11307)",OCC(O)=O,"Acetates / Acids, Acyclic / Dermatologicals / Fatty Acids / Fatty Acids, Volatile / Hydroxy Acids / Keratolytic Agents / Lipids",0WT12SX38S,79-14-1,,757.0,737.0,,70603.0,17497.0,CHEMBL252557,,,ZINC000004658557
Pidolic acid,phase 4 complete,DB03088 (EXPT00247),OC(=O)[C@@H]1CCC(=O)N1,"Acids, Acyclic / Alimentary Tract and Metabolism / Amino Acids / Amino Acids, Acidic / Amino Acids, Cyclic / Amino Acids, Dicarboxylic / Amino Acids, Peptides, and Proteins / Glutamates / Imines / Imino Acids / Mineral Supplements / Pyrrolidines / Pyrrolidinones",SZB83O1W42,98-79-3,,7405.0,7127.0,,9036.0,18183.0,CHEMBL397976,,,ZINC000003598263
Acetylcholine,phase 4 complete,DB03128 (EXPT00412),CC(=O)OCC[N+](C)(C)C,Amines / Antiglaucoma Preparations and Miotics / Biogenic Amines / Cardiovascular Agents / Cholinergic Agents / Cholinergic Agonists / Cholinergic Receptor Agonist / Miotics / Neurotransmitter Agents / OCT1 substrates / Ophthalmologicals / Parasympathomimetics / Sensory Organs / Vasodilating Agents,N9YNS0M02X,51-84-3,,187.0,182.0,10759.0,194.0,15355.0,CHEMBL667,,PA448031,ZINC000003079336
Flavin adenine dinucleotide,phase 4 complete,DB03147 (EXPT01391),CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO[P@](O)(=O)O[P@@](O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC3=C1N=CN=C3N)C1=NC(=O)NC(=O)C1=N2,"Adenine Nucleotides / Biological Factors / Carbohydrates / Coenzymes / Enzymes and Coenzymes / Flavins / Glycosides / Heterocyclic Compounds, Fused-Ring / Nucleic Acids, Nucleotides, and Nucleosides / Nucleotides / Pigments, Biological / Pteridines / Purine Nucleotides / Purines / Ribonucleotides / Vitamin B Complex / Vitamins",ZC44YTI8KK,146-14-5,D00005,643975.0,559059.0,,1314412.0,16238.0,CHEMBL1232653,,,ZINC000008215434
Acetic acid,phase 4 complete,"DB03166 (EXPT00423, DB04184)",CC(O)=O,"Acetates / Acids, Acyclic / Anti-Bacterial Agents / Anti-Infective Agents / Compounds used in a research, industrial, or household setting / Fatty Acids / Fatty Acids, Volatile / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Indicators and Reagents / Laboratory Chemicals / Lipids / Organic Acids / Otologicals / Sensory Organs",Q40Q9N063P,64-19-7,D00010,176.0,171.0,50074329.0,168.0,15366.0,CHEMBL539,,PA448021,ZINC000005224164
Propyl alcohol,phase 4 complete,DB03175 (EXPT02630),CCCO,Alcohols / Antiseptics and Disinfectants / Dermatologicals / Propanols,96F264O9SV,71-23-8,,1031.0,1004.0,,1362872.0,28831.0,CHEMBL14687,,,ZINC000000895969
Stearic acid,phase 4 complete,DB03193 (EXPT02965),CCCCCCCCCCCCCCCCCC(O)=O,Fatty Acids / Lipids,4ELV7Z65AP,57-11-4,D00119,5281.0,5091.0,50240485.0,1310551.0,28842.0,CHEMBL46403,,,ZINC000004978673
Oteracil,phase 4 complete,DB03209 (EXPT02456),OC(=O)C1=NC(=O)NC(=O)N1,Triazines,5VT6420TIG,937-13-3,D06399,4604.0,4443.0,,,30863.0,CHEMBL181932,,,ZINC000013514753
Flavin mononucleotide,phase 4 complete,DB03247 (EXPT01458),CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)C1=NC(=O)NC(=O)C1=N2,"Biological Factors / Carbohydrates / Coenzymes / Diet, Food, and Nutrition / Enzymes and Coenzymes / Flavins / Food / Food and Beverages / Glycosides / Growth Substances / Heterocyclic Compounds, Fused-Ring / Micronutrients / Nucleic Acids, Nucleotides, and Nucleosides / Nucleotides / Physiological Phenomena / Pigments, Biological / Pteridines / Ribonucleotides / Vitamin B Complex / Vitamins",7N464URE7E,146-17-8,,643976.0,559060.0,50421345.0,,17621.0,CHEMBL1201794,,,ZINC000003831425
Phenol,phase 4 complete,DB03255 (EXPT01917),OC1=CC=CC=C1,"Anesthetics / Anesthetics, Local / Anti-Infective Agents / Anti-Infective Agents, Local / Antiseptics and Disinfectants / Antivaricose Therapy / Benzene Derivatives / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Dermatologicals / Disinfectants / Histamine Antagonists / Miscellaneous Therapeutic Agents / Nervous System / Pharmaceutical Preparations / Pharmaceutical Solutions / Phenol and Derivatives / Phenols / Sclerosing Agents for Local Injection / Sclerosing Solutions / Solutions / Throat Preparations / Vasoprotectives",339NCG44TV,108-95-2,D00033,996.0,971.0,26187.0,33290.0,15882.0,CHEMBL14060,,PA450913,ZINC000005133329
Glutathione disulfide,phase 4 complete,"DB03310 (EXPT01575, DB09544)",N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O,"Amino Acids, Peptides, and Proteins / Oligopeptides / Peptides",ULW86O013H,27025-41-8,D00031,65359.0,58835.0,225231.0,25953.0,17858.0,CHEMBL1372,,,ZINC000003870129
Brivudine,phase 4 complete,"DB03312 (EXPT00783, DB05041)",OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Carbohydrates / Deoxyribonucleosides / Deoxyuridine / Direct Acting Antivirals / Glycosides / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors / Pyrimidine Nucleosides / Pyrimidines / Ribonucleosides",2M3055079H,69304-47-8,,446727.0,394011.0,,59161.0,,CHEMBL31634,,,ZINC000003653378
Oxyphenbutazone,phase 4 complete,DB03585 (EXPT02440),CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antirheumatic Agents / Butylpyrazolidines / Central Nervous System Agents / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / OAT1/SLC22A6 inhibitors / Ophthalmologicals / Other Nonsteroidal Anti-inflammatory Agents / Peripheral Nervous System Agents / Pyrazoles / Pyrazolones / Sensory Organs / Sensory System Agents / Topical Products for Joint and Muscular Pain",A7D84513GV,129-20-4,,4641.0,4480.0,200298.0,7816.0,76258.0,CHEMBL1228,,PA450750,
Mecobalamin,phase 4 complete,DB03614 (EXPT00979),C1(CC[C@@]2([C@@H](CC(N)=O)[C@@]3([C@@]4([N+]5=C([C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C(C)=C4[N+]6=C(C=C7[N+]8=C([C@H](C7(C)C)CCC(N)=O)C(C)=C2N3[Co-3]568([N+]2=CN([C@H]3O[C@@H]([C@@H](OP(O[C@@H](CN1)C)([O-])=O)[C@H]3O)CO)C1=CC(C)=C(C=C21)C)C)[C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C)[H])C)=O,"Antianemic Preparations / Blood and Blood Forming Organs / Corrinoids / Heterocyclic Compounds, Fused-Ring / Vitamin B Complex / VITAMIN B12 AND FOLIC ACID / Vitamins",BR1SN1JS2W,13422-55-4,D03246,71306319.0,28534328.0,,29421.0,28115.0,CHEMBL2448537,,,
Ribostamycin,phase 4 complete,DB03615 (EXPT02786),[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2N)O[C@H](CO)[C@@H](O)[C@H]1O,Agents that produce neuromuscular block (indirect) / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Glycosides / Narrow Therapeutic Index Drugs / Nephrotoxic agents,2Q5JOU7T53,25546-65-0,D08478,33042.0,30581.0,,,45257.0,CHEMBL221572,DNC001211,,ZINC000053255716
Deoxycholic acid,phase 4 complete,"DB03619 (EXPT01194, DB07690)",[H][C@@]12CC[C@H]([C@H](C)CCC(O)=O)[C@@]1(C)[C@@H](O)C[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C,Bile Acids and Salts / BSEP/ABCB11 inducers / Cholagogues and Choleretics / Cholanes / Cholic Acids / Cytolytic Agent / Decreased Cell Membrane Integrity / Dermatologicals / Fused-Ring Compounds / Gastrointestinal Agents / Other Miscellaneous Therapeutic Agents / Steroids,005990WHZZ,83-44-3,,222528.0,193196.0,50375599.0,3194.0,28834.0,CHEMBL406393,,,ZINC000003914810
Peramivir,phase 4 complete,"DB06614 (EXPT00645, DB03655)",[H][C@@]1([C@@H](NC(C)=O)C(CC)CC)[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O,"Amidines / Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cycloparaffins / Direct Acting Antivirals / Enzyme Inhibitors / Neuraminidase Inhibitors / Neuraminidase, antagonists & inhibitors",9ZS94HQO3B,330600-85-6,,154234.0,135903.0,5024.0,619693.0,85202.0,CHEMBL139367,,,ZINC000003981610
Tromethamine,phase 4 complete,DB03754 (EXPT03072),NC(CO)(CO)CO,"Alcohols / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Buffers / Compounds used in a research, industrial, or household setting / Drug Delivery Systems / Excipients / Glycols / I.V. Solution Additives / i.v. Solutions / Laboratory Chemicals / Pharmaceutic Aids / Pharmaceutical Preparations / Pharmaceutical Vehicles / Propylene Glycols / Solutions Affecting the Electrolyte Balance",023C2WHX2V,77-86-1,D00396,6503.0,6257.0,,10865.0,9754.0,CHEMBL1200391,,,ZINC000000896695
Doconexent,phase 4 complete,"DB03756 (EXPT01798, DB11070)",CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O,"Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diet, Food, and Nutrition / Dietary Fats / Dietary Fats, Unsaturated / Fats / Fatty Acids / Fatty Acids, Omega-3 / Fatty Acids, Unsaturated / Fish Oils / Food / Food and Beverages / Lipids / Oils / Physiological Phenomena",ZAD9OKH9JC,6217-54-5,,445580.0,393183.0,50210259.0,1006469.0,28125.0,CHEMBL367149,,,ZINC000004474564
Propanoic acid,phase 4 complete,DB03766 (EXPT02641),CCC(O)=O,"Acids, Acyclic / Anti-Infective Agents / Fatty Acids / Fatty Acids, Volatile / Lipids / Ophthalmologicals / Sensory Organs",JHU490RVYR,79-09-4,D02310,1032.0,1005.0,50082199.0,34658.0,30768.0,CHEMBL14021,,,ZINC000006050663
Febuxostat,phase 4 complete,DB04854 (DB03786),CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N,Antigout Preparations / Antirheumatic Agents / Drugs causing inadvertant photosensitivity / Musculo-Skeletal System / Photosensitizing Agents / Preparations Inhibiting Uric Acid Production / Sulfur Compounds / Thiazoles / Xanthine Oxidase Inhibitors,101V0R1N2E,144060-53-7,D01206,134018.0,118173.0,50320491.0,73689.0,31596.0,CHEMBL1164729,,PA165958521,ZINC000000005423
Benzoic acid,phase 4 complete,DB03793 (EXPT00675),OC(=O)C1=CC=CC=C1,"Acids, Carbocyclic / Alimentary Tract and Metabolism / Ammonium Ion Binding Activity / Anti-Infective Agents / Antifungal Agents / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Diagnostic Agents / Diet, Food, and Nutrition / Food / Food Additives / Food and Beverages / Food Ingredients / Food Preservatives / Nitrogen Binding Agent / OAT3/SLC22A8 Inhibitors / Physiological Phenomena / Tests for Gastric Secretion / Urea Cycle Disorder Agents / Various Alimentary Tract and Metabolism Products",8SKN0B0MIM,65-85-0,D00038,243.0,238.0,197302.0,18989.0,30746.0,CHEMBL541,,PA448578,ZINC000000001011
Palmitic Acid,phase 4 complete,"DB03796 (EXPT01393, EXPT02607)",CCCCCCCCCCCCCCCC(O)=O,Enzyme Inhibitors / Fatty Acids / Lipids / Palmitic Acids,2V16EO95H1,57-10-3,D05341,985.0,960.0,50152850.0,1370621.0,15756.0,CHEMBL82293,,,ZINC000006072466
Teriflunomide,phase 4 complete,"DB08880 (EXPT00364, DB03805)",C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,"Acids, Acyclic / Amines / Analgesics / Analgesics, Non-Narcotic / Aniline Compounds / Anti-Inflammatory Agents / Antineoplastic and Immunomodulating Agents / Antirheumatic Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Benzene Derivatives / Butyrates / Central Nervous System Agents / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP1A2 Inducers (weak) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Dihydroorotate Dehydrogenase Inhibitors / Fatty Acids / Fatty Acids, Volatile / Hepatotoxic Agents / Hydroxy Acids / Immunologic Factors / Immunomodulatory Agents / Immunosuppressive Agents / Lipids / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / Peripheral Nervous System Agents / Pyrimidine Synthesis Inhibitor / Selective Immunosuppressants / Sensory System Agents",1C058IKG3B,163451-81-8,D10172,54684141.0,16737143.0,50018011.0,1310520.0,68540.0,CHEMBL973,,,ZINC000013512456
Formaldehyde,phase 4 complete,DB03843 (EXPT01444),[H]C([H])=O,"Aldehydes / Anti-Infective Agents / Anti-Infective Agents, Local / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Disinfectants / Fixatives / Increased Histamine Release / Macromolecular Substances / Standardized Chemical Allergen",1HG84L3525,50-00-0,D00017,712.0,692.0,,314636.0,16842.0,CHEMBL1255,,PA449703,
Urea,phase 4 complete,DB03904 (EXPT03203),NC(N)=O,"Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Carbamide products / Dermatologicals / Diuretics, Osmotic / Emollients and Protectives / i.v. Solutions / Keratolytic Agents / Solutions Producing Osmotic Diuresis",8W8T17847W,57-13-6,D00023,1176.0,1143.0,24961.0,11002.0,16199.0,CHEMBL985,,PA451831,ZINC000008214514
D-Serine,phase 4 complete,DB03929 (EXPT01275),N[C@H](CO)C(O)=O,,1K77H2Z9B1,312-84-5,,71077.0,64231.0,23167.0,1742747.0,16523.0,CHEMBL285123,DCL000784,,ZINC000000895342
Ergosterol,phase 4 complete,DB04038 (EXPT01357),CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,"Cholestanes / Cholestenes / Diet, Food, and Nutrition / Food / Food and Beverages / Fused-Ring Compounds / Growth Substances / Micronutrients / Physiological Phenomena / Provitamins / Steroids / Vitamins",Z30RAY509F,57-87-4,,444679.0,392539.0,50378884.0,,16933.0,CHEMBL1232562,,,ZINC000004084618
Glycerin,phase 4 complete,"DB09462 (EXPT01027, DB04077)",OCC(O)CO,"Alcohols / Alimentary Tract and Metabolism / Basic Ointments and Protectants / Carbohydrates / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Cryoprotective Agents / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Drugs for Constipation / Enemas / Increased Histamine Release / Increased IgG Production / Irrigating Solutions / Laxatives / Non-Standardized Chemical Allergen / Osmotic Laxatives / Other Cold and Cough Preparations / Other Diagnostics / Protective Agents / Solvents / Sugar Alcohols / Triose Sugar Alcohols",PDC6A3C0OX,56-81-5,D00028,753.0,733.0,,4910.0,17754.0,CHEMBL692,,PA449783,ZINC000000895048
Berberine,phase 4 complete,DB04115 (EXPT00672),COC1=CC=C2C=C3C4=CC5=C(OCO5)C=C4CC[N+]3=CC2=C1OC,"Alkaloids / Benzylisoquinolines / Berberine Alkaloids / Heterocyclic Compounds, Fused-Ring / Isoquinolines",0I8Y3P32UF,2086-83-1,D00092,2353.0,2263.0,50203126.0,1437.0,16118.0,CHEMBL295124,DNC000385,PA165860812,ZINC000003779067
Pyrophosphoric acid,phase 4 complete,"DB04160 (EXPT01258, DB11055)",OP(O)(=O)OP(O)(O)=O,"Acids / Acids, Noncarboxylic / Anions / Electrolytes / Ions / Phosphate salts / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds / Polyphosphates",4E862E7GRQ,2466-09-3,,1023.0,996.0,50147591.0,1546425.0,29888.0,CHEMBL1160571,,,ZINC000006827695
Fructose,phase 4 complete,DB04173 (EXPT01495),OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O,"Carbohydrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Flavoring Agents / Food / Food Additives / Food and Beverages / Food Ingredients / Fructose / General Nutrients / Hexoses / Ketoses / Monosaccharides / Pharmaceutic Aids / Pharmaceutical Preparations / Physiological Phenomena / Sweetening Agents",WR469VI1J3,,,439553.0,388644.0,,4570.0,43703.0,,,PA449716,
Dequalinium,phase 4 complete,"DB04209 (EXPT01162, DB11615)",CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2,"Anti-Infective Agents / Anti-Infective Agents, Local / Antiseptics and Disinfectants / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Miscellaneous Anti-infectives / Quinoline Derivatives / Quinolines / Quinolinium Compounds / Throat Preparations",E7QC7V26B8,6707-58-0,,2993.0,2886.0,50048403.0,3226.0,41872.0,CHEMBL333826,,,ZINC000001655706
Didecyldimethylammonium,phase 4 complete,"DB04221 (EXPT00009, DB11287)",CCCCCCCCCC[N+](C)(C)CCCCCCCCCC,Amines / Ammonium Compounds / Antiseptics and Disinfectants / Dermatologicals / Nitrogen Compounds / Onium Compounds / Quaternary Ammonium Compounds,Z7F472XQPA,20256-56-8,,16958.0,16067.0,,1425983.0,,CHEMBL1182247,,,ZINC000014881137
Oleic Acid,phase 4 complete,DB04224 (EXPT02430),CCCCCCCC\C=C\CCCCCCCC(O)=O,"Fatty Acids / Fatty Acids, Monounsaturated / Fatty Acids, Unsaturated / Lipids / Oleic Acids",4837010H8C,112-80-1,D02315,637517.0,553123.0,50250904.0,7631.0,27997.0,CHEMBL460657,,,ZINC000008217338
Citric acid,phase 4 complete,DB04272 (EXPT00922),OC(=O)CC(O)(CC(O)=O)C(O)=O,"Acid Preparations / Acidifying Activity / Acids, Acyclic / Alimentary Tract and Metabolism / Calcium Chelating Activity / Calcium Chelating Agents / Calculi Dissolution Agent / Chelating Agents / Citrates / Compounds used in a research, industrial, or household setting / Decreased Coagulation Factor Activity / Digestives, Incl. Enzymes / Hematologic Agents / Sequestering Agents / Tricarboxylic Acids / Urinary Acidifying Agents / Urinary Alkalinisers",XF417D3PSL,77-92-9,D00037,311.0,305.0,14672.0,21183.0,30769.0,CHEMBL1261,,PA449021,ZINC000000895081
Citicoline,phase 4 complete,"DB12153 (EXPT00867, DB04290)",C[N+](C)(C)CCOP([O-])(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(N)=NC1=O,"Alcohols / Amines / Amino Alcohols / Ammonium Compounds / Carbohydrates / Central Nervous System Agents / Cytidine Diphosphate / Cytosine Nucleotides / Ethanolamines / Glycosides / Nervous System / Nitrogen Compounds / Nootropic Agents / Nucleic Acids, Nucleotides, and Nucleosides / Nucleotides / Onium Compounds / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Pyrimidine Nucleotides / Pyrimidines / Quaternary Ammonium Compounds / Ribonucleotides / Trimethyl Ammonium Compounds",536BQ2JVC7,987-78-0,D00057,,13207.0,,997602.0,16436.0,CHEMBL1231700,,,
Taurocholic acid,phase 4 complete,DB04348 (EXPT03023),[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCCS(O)(=O)=O,"Acids / Acids, Noncarboxylic / Alkanes / Alkanesulfonic Acids / BCRP/ABCG2 Inhibitors / Bile Acids and Salts / BSEP/ABCB11 inducers / BSEP/ABCB11 Substrates / Cholagogues and Choleretics / Cholanes / Cholic Acids / Compounds used in a research, industrial, or household setting / Detergents / Fused-Ring Compounds / Gastrointestinal Agents / Household Products / Hydrocarbons, Acyclic / OAT1/SLC22A6 inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inducers / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein inhibitors / P-glycoprotein substrates / Steroids / Sulfonic Acids / Sulfur Acids / Sulfur Compounds / Surface-Active Agents",5E090O0G3Z,81-24-3,,6675.0,6423.0,50375594.0,,28865.0,CHEMBL224867,,,ZINC000008214684
Lactic acid,phase 4 complete,"DB04398 (EXPT01996, DB09294)",CC(O)C(O)=O,Basic Ointments and Protectants / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hydroxy Acids / Lactates / Miscellaneous Local Anti-infectives / Organic Acids,3B8D35Y7S4,50-21-5,D00111,612.0,592.0,23233.0,1314409.0,78320.0,CHEMBL1200559,,,
Lactose,phase 4 complete,DB04465 (EXPT02005),OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O,"Carbohydrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Disaccharides / Flavoring Agents / Food / Food Additives / Food and Beverages / Food Ingredients / Oligosaccharides / Pharmaceutic Aids / Pharmaceutical Preparations / Physiological Phenomena / Polysaccharides / Sweetening Agents",3SY5LH9PMK,63-42-3,D00046,440995.0,389820.0,,6211.0,17716.0,,,PA450161,
Polyethylene glycol 400,phase 4 complete,"DB11077 (EXPT02541, DB04535)",,"Alcohols / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / EENT Drugs, Miscellaneous / Ethylene Glycols / Glycols / Macromolecular Substances / P-glycoprotein inhibitors / Pegylated agents / Polymers",B697894SGQ,25322-68-3,,,,,8514.0,,,,,
Cholesterol,phase 4 complete,DB04540 (EXPT00945),[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C,BCRP/ABCG2 Inducers / Cholestanes / Cholestenes / Fused-Ring Compounds / Lipids / Membrane Lipids / P-glycoprotein inhibitors / Steroids / Sterols,97C5T2UQ7J,57-88-5,D00040,5997.0,5775.0,20192.0,2438.0,16113.0,CHEMBL112570,,,ZINC000003875383
Gluconolactone,phase 4 complete,DB04564 (EXPT02023),OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O,"Acids, Acyclic / Calculi Dissolution Agent / Carbohydrates / Hydroxy Acids / Irrigation / Sugar Acids",WQ29KQ9POT,90-80-2,D04332,7027.0,6760.0,50366565.0,25842.0,16217.0,CHEMBL1200829,,,ZINC000002539702
Latamoxef,phase 4 complete,DB04570,[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)OC)C(O)=O,"Acids / Acids, Noncarboxylic / Amides / Anions / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Electrolytes / Gases / Heterocyclic Compounds, Fused-Ring / Hydrogen Sulfide / Ions / Lactams / Nephrotoxic agents / Sulfides / Sulfur Compounds / Third-Generation Cephalosporins",VUF6C936Z3,64952-97-2,D08109,47499.0,43215.0,50370589.0,7069.0,599928.0,CHEMBL74632,DAP001181,PA164743144,
Trioxsalen,phase 4 complete,DB04571,CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1,"Antipsoriatics / Antipsoriatics for Systemic Use / Antipsoriatics for Topical Use / Benzopyrans / Coumarins / Dermatologicals / Furocoumarins / Heterocyclic Compounds, Fused-Ring / Photosensitizing Agents / Photosensitizing agents used for phototherapy / Psoralens for Systemic Use / Psoralens for Topical Use / Pyrans / Radiation-Sensitizing Agents",Y6UY8OV51T,3902-71-4,D01034,5585.0,5383.0,50240033.0,10844.0,28329.0,CHEMBL1475,,PA164747186,ZINC000000002226
Thiotepa,phase 4 complete,DB04572,S=P(N1CC1)(N1CC1)N1CC1,"Acids / Acids, Noncarboxylic / Alkylating Activity / Alkylating Drugs / Anions / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Aziridines / Azirines / Cholinesterase Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (moderate) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Electrolytes / Ethylene Imines / Immunologic Factors / Immunosuppressive Agents / Ions / Myeloablative Agonists / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Organophosphorus Compounds / Phosphoramides / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds / Toxic Actions / Triethylenephosphoramide",905Z5W3GKH,52-24-4,D00583,5453.0,5254.0,50418086.0,10473.0,9570.0,CHEMBL671,,PA451668,ZINC000001530867
Estriol,phase 4 complete,"DB04573 (EXPT01361, DB05375)",[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,"Estradiol Congeners / Estranes / Estrenes / Estrogens / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Natural and Semisynthetic Estrogens, Plain / P-glycoprotein inducers / P-glycoprotein substrates / Sex Hormones and Modulators of the Genital System / Steroids / Thyroxine-binding globulin inducers",FB33469R8E,50-27-1,D00185,5756.0,5553.0,50410506.0,4094.0,27974.0,CHEMBL193482,DAP001019,PA164769104,ZINC000003815418
Estrone sulfate,phase 4 complete,DB04574,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OS(O)(=O)=O)C=C3,"17-Ketosteroids / Adrenal Cortex Hormones / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Estradiol Congeners / Estranes / Estrenes / Estrogens / Estrogens, Conjugated (USP) / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Ketosteroids / MATE 1 Substrates / MATE 2 Substrates / MATE substrates / Reproductive Control Agents / Steroids / Thyroxine-binding globulin inducers",QTL48N278K,481-97-0,,3001028.0,2272513.0,50366524.0,,17474.0,CHEMBL494753,,PA165958342,ZINC000003876186
Quinestrol,phase 4 complete,DB04575,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC1CCCC1)C=C3,"Estradiol Congeners / Estrogenic Steroids, Alkylated / Estrogens / Ethinyl Estradiol / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Norpregnanes / Norpregnatrienes / Norsteroids / Steroids / Thyroxine-binding globulin inducers",JR0N7XD5GZ,152-43-2,D00576,9046.0,8694.0,,9066.0,8716.0,CHEMBL1201165,DAP001016,PA164749042,ZINC000003875993
Carboxin,phase 4 complete,DB04657,CC1=C(SCCO1)C(=O)NC1=CC=CC=C1,"Agrochemicals / Amides / Amines / Anilides / Aniline Compounds / Compounds used in a research, industrial, or household setting / Fungicides, Industrial / Oxathiins / Pesticides / Toxic Actions",5A8K850HDE,5234-68-4,,21307.0,20027.0,,,3405.0,CHEMBL1231667,,,ZINC000000043478
Hesperidin,phase 4 complete,DB04703,COC1=CC=C(C=C1O)[C@@H]1CC(=O)C2=C(O1)C=C(O[C@@H]1O[C@H](CO[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]1O)C=C2O,"Benzopyrans / Chromones / Flavanones / Flavonoids / Heterocyclic Compounds, Fused-Ring / Pyrans",E750O06Y6O,520-26-3,D01038,10621.0,10176.0,61776.0,5281.0,28775.0,CHEMBL449317,,PA449867,ZINC000008143568
Iodipamide,phase 4 complete,DB04711,OC(=O)C1=C(I)C(NC(=O)CCCCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C(I)C=C1I,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Iodinated Contrast Agents / Iodobenzoates / Radiographic Contrast Agent / Roentgenography / Triiodobenzoic Acids / Watersoluble, Hepatotropic X-Ray Contrast Media / X-Ray Contrast Activity / X-Ray Contrast Media, Iodinated",TKQ858A3VW,606-17-7,D01774,3739.0,3608.0,,5936.0,31176.0,CHEMBL1165268,DAP001226,PA164745532,
Nimesulide,phase 4 complete,DB04743,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O,"Agents causing hyperkalemia / Agents that produce hypertension / Amides / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiarrhythmic agents / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antiplatelet agents / Antirheumatic Agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Central Nervous System Agents / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Peripheral Nervous System Agents / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory System Agents / Sulfones / Sulfur Compounds / Topical Products for Joint and Muscular Pain",V4TKW1454M,51803-78-2,D01049,4495.0,4339.0,50056999.0,53694.0,44445.0,CHEMBL56367,DPR000079,PA137179528,ZINC000004617749
Bifonazole,phase 4 complete,DB04794,C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1,Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Azole Antifungals / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Imidazole and Triazole Derivatives,QYJ305Z91O,60628-96-8,,2378.0,2287.0,50128548.0,19295.0,78692.0,CHEMBL277535,DAP000877,PA164746464,
Benoxaprofen,phase 4 complete,DB04812,CC(C(O)=O)C1=CC2=C(OC(=N2)C2=CC=C(Cl)C=C2)C=C1,"Acids, Acyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / Dermatologicals / Enzyme Inhibitors / Fatty Acids / Fatty Acids, Volatile / Lipids / Lipoxygenase Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Peripheral Nervous System Agents / Propionates / Sensory System Agents",17SZX404IM,51234-28-7,D03080,39941.0,36518.0,50088388.0,,76114.0,CHEMBL340978,DCL000338,PA166049178,
Bithionol,phase 4 complete,DB04813,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl,"Anthelmintics / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anti-Infective Agents / Anti-Infective Agents, Local / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiplatyhelmintic Agents / Antitrematodals / Benzene Derivatives / Dermatologicals / Phenols / Preparations Containing Sulfur",AMT77LS62O,97-18-7,D00802,2406.0,2313.0,36880.0,,3131.0,CHEMBL290106,,,ZINC000000608213
Clioquinol,phase 4 complete,DB04815,OC1=C(I)C=C(Cl)C2=C1N=CC=C2,"Anti-Infective Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Antiseptics and Disinfectants / Cell-mediated Immunity / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hydroxyquinoline Derivatives / Hydroxyquinolines / Increased Histamine Release / Medicated Dressings / Medicated Dressings With Antiinfectives / Miscellaneous Antifungals / Otologicals / Quinoline Derivatives / Quinolines / Sensory Organs / Standardized Chemical Allergen",7BHQ856EJ5,130-26-7,,2788.0,2686.0,32188.0,5942.0,74460.0,CHEMBL497,,PA449039,ZINC000006409735
Dantron,phase 4 complete,DB04816,OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O,Alimentary Tract and Metabolism / Anthracenes / Contact Laxatives / Drugs for Constipation / Enemas / Gastrointestinal Agents / Laxatives / Mutagens / Noxae / Quinones / Toxic Actions,Z4XE6IBF3V,117-10-2,D07107,2950.0,2845.0,11316.0,22293.0,3682.0,CHEMBL53418,,PA449206,ZINC000003860369
Metamizole,phase 4 complete,DB04817,CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1,"Agents causing hyperkalemia / Agents that produce hypertension / Aminopyrine / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antipyretics / Central Nervous System Agents / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Nephrotoxic agents / Nervous System / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Pyrazoles / Pyrazolones / Sensory System Agents",934T64RMNJ,50567-35-6,D08188,522325.0,3000.0,235671.0,,62088.0,CHEMBL461522,DNC000568,PA166128206,ZINC000001782155
Nialamide,phase 4 complete,DB04820,O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1,"Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Enzyme Inhibitors / Isonicotinic Acids / Monoamine Oxidase Inhibitors / Monoamine Oxidase Inhibitors, Non-Selective / Nervous System / Psychoanaleptics / Psychotropic Drugs / Pyridines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",T2Q0RYM725,51-12-7,,4472.0,4317.0,163693.0,7394.0,94510.0,CHEMBL1256841,,,ZINC000001713761
Nomifensine,phase 4 complete,DB04821,CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2,"Antidepressive Agents / Central Nervous System Depressants / Dopamine Agents / Dopamine Uptake Inhibitors / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Psychoanaleptics",1LGS5JRP31,24526-64-5,,4528.0,4371.0,50005548.0,7500.0,116225.0,CHEMBL273575,DCL000339,,
Oxeladin,phase 4 complete,DB04822,CCN(CC)CCOCCOC(=O)C(CC)(CC)C1=CC=CC=C1,"Acids, Carbocyclic / Antitussive Agents / Central Nervous System Agents / Cough and Cold Preparations / Respiratory System Agents",SNC1080T5Y,468-61-1,,4619.0,4458.0,,32626.0,135424.0,CHEMBL1500276,,,ZINC000003874580
Phenolphthalein,phase 4 complete,DB04824,OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1,"Alimentary Tract and Metabolism / Benzene Derivatives / Compounds used in a research, industrial, or household setting / Contact Laxatives / Drugs for Constipation / Indicators and Reagents / Laboratory Chemicals / Laxatives / Phenolphthaleins / Phenols",6QK969R2IF,77-09-8,D05456,4764.0,4600.0,50077844.0,155122.0,34914.0,CHEMBL63857,,PA450915,ZINC000003831317
Prenylamine,phase 4 complete,DB04825,CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1,"Adrenergic Agents / Agents causing hyperkalemia / Amines / Antiarrhythmic agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Calmodulin, antagonists & inhibitors / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Ethylamines / Hydroxy Acids / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / Phenethylamines / QTc Prolonging Agents / Vasodilating Agents / Vasodilators Used in Cardiac Diseases",K2OH82Z000,390-64-7,D02383,9801.0,9418.0,50017723.0,8674.0,8397.0,CHEMBL24072,,,
Thenalidine,phase 4 complete,DB04826,CN1CCC(CC1)N(CC1=CC=CS1)C1=CC=CC=C1,"Antihistamines for Systemic Use / Antihistamines for Topical Use / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Dermatologicals",6U94N2D00F,86-12-4,,27901.0,25957.0,,,135187.0,CHEMBL2105458,,,ZINC000000002146
Urethane,phase 4 complete,DB04827,CCOC(N)=O,"Acids, Acyclic / Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Antineoplastic Agents / Carbamates / Carcinogens / Central Nervous System Agents / Central Nervous System Depressants / Noxae / Toxic Actions",3IN71E75Z5,51-79-6,,5641.0,5439.0,50239974.0,1420982.0,17967.0,CHEMBL462547,,,ZINC000000901020
Zimelidine,phase 4 complete,DB04832,CN(C)C\C=C(\C1=CC=C(Br)C=C1)C1=CC=CN=C1,Antidepressive Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / P-glycoprotein inhibitors / Psychoanaleptics / Pyridines / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators,3J928617DW,56775-88-3,,41987.0,4517305.0,50020706.0,,135357.0,CHEMBL37744,,,ZINC000008099545
Rapacuronium,phase 4 complete,DB04834,[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1,Agents producing tachycardia / Androstanes / Androstanols / Anticholinergic Agents / Central Nervous System Depressants / Fused-Ring Compounds / Muscarinic Antagonists / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular-Blocking Agents (Nondepolarizing) / Peripheral Nervous System Agents / Steroids,GG1LBM463S,465499-11-0,,5311399.0,4470890.0,,262100.0,135845.0,CHEMBL1201352,,PA451227,ZINC000003943562
Maraviroc,phase 4 complete,DB04835,CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1,Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / CCR5 Co-receptor Antagonist / CCR5 Receptor Antagonists / Cyclohexanes / Cycloparaffins / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Direct Acting Antivirals / Hepatotoxic Agents / HIV Fusion Inhibitors / Triazoles / Viral Fusion Protein Inhibitors,MD6P741W8A,376348-65-1,,3002977.0,20078004.0,50334986.0,620216.0,63608.0,CHEMBL1201187,DNC001487,PA164768835,ZINC000100003902
Clofedanol,phase 4 complete,DB04837,CN(C)CCC(O)(C1=CC=CC=C1)C1=CC=CC=C1Cl,Alcohols / Amines / Amino Alcohols / Antitussive Agents / Cough and Cold Preparations / Histamine Antagonists / Histamine H1 Antagonists / Propanols,42C50P12AP,791-35-5,,2795.0,2693.0,,21254.0,135207.0,CHEMBL1201313,DAP001080,PA164748134,
Cyclandelate,phase 4 complete,DB04838,CC1CC(CC(C)(C)C1)OC(=O)C(O)C1=CC=CC=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Antiarrhythmic agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Hydroxy Acids / Mandelic Acids / Peripheral Vasodilators / Vasodilating Agents",4139O1OAY2,456-59-7,,2893.0,2790.0,50239973.0,2970.0,3988.0,CHEMBL1480987,,PA164748026,
Cyproterone acetate,phase 4 complete,DB04839,[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H],"Adrenal Cortex Hormones / Antiandrogens / Antiandrogens and Estrogens / Antineoplastic Agents / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptive Agents, Male / Contraceptives, Oral / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Other Miscellaneous Therapeutic Agents / Pregnadienes / Pregnanes / Progestin Contraceptives / Progestins / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids / Steroids, Chlorinated",4KM2BN5JHF,427-51-0,D01368,9880.0,9496.0,50094569.0,22054.0,50743.0,CHEMBL139835,DAP000906,PA10049,ZINC000003814423
Debrisoquine,phase 4 complete,DB04840,NC(=N)N1CCC2=CC=CC=C2C1,"Adrenergic Agents / Antiadrenergic Agents, Peripherally Acting / Antihypertensive Agents / Autonomic Agents / Cardiovascular Agents / Catecholamines / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Guanidine Derivatives / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Neurotransmitter Agents / P-glycoprotein substrates / Peripheral Nervous System Agents / Sympatholytics",X31CDK040E,1131-64-2,,2966.0,2860.0,50122613.0,3118.0,34665.0,CHEMBL169901,DAP000125,PA452616,ZINC000003594299
Flunarizine,phase 4 complete,DB04841,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1,"Agents causing hyperkalemia / Antiarrhythmic agents / Anticonvulsants / Antimigraine Agents, Miscellaneous / Antivertigo Preparations / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Piperazine Derivatives / Piperazines / Vasodilating Agents",R7PLA2DM0J,52468-60-7,D01303,941361.0,819216.0,50017702.0,4459.0,135652.0,CHEMBL30008,DAP000142,PA164776636,ZINC000019360739
Fluspirilene,phase 4 complete,DB04842,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1,Agents causing hyperkalemia / Antiarrhythmic agents / Antidepressive Agents / Antipsychotic Agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Diphenylbutylpiperidine Derivatives / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Imidazoles / Moderate Risk QTc-Prolonging Agents / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Piperidines / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Spiro Compounds / Tranquilizing Agents,C5QA4GLR9M,1841-19-6,D02629,3396.0,3279.0,26948.0,4507.0,93369.0,CHEMBL46516,DAP000980,PA162565878,ZINC000000537755
Mepenzolate,phase 4 complete,DB04843,C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,"Acids, Carbocyclic / Agents producing tachycardia / Alimentary Tract and Metabolism / Anticholinergic Agents / Diphenylacetic Acids / Drugs for Functional Gastrointestinal Disorders / Hydroxy Acids / Muscarinic Antagonists / Phenylacetates / Synthetic Anticholinergics, Quaternary Ammonium Compounds",ONW3LB39P7,25990-43-6,,4057.0,3917.0,50377964.0,107770.0,94411.0,CHEMBL524004,DAP001115,PA164746250,
Tetrabenazine,phase 4 complete,DB04844,COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1,"Adrenergic Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Membrane Transport Modulators / Miscellaneous Central Nervous System Agents / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / QTc Prolonging Agents / Quinolizines / Vesicular Monoamine Transporter 2 Inhibitor / Vesicular Monoamine Transporter 2 Inhibitors",Z9O08YRN8O,58-46-8,D08575,6018.0,5796.0,50017701.0,10390.0,64028.0,CHEMBL117785,DAP000756,PA140222719,
Ixabepilone,phase 4 complete,DB04845,[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1,Anti-Bacterial Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Cytotoxic Antibiotics and Related Substances / Immunosuppressive Agents / Lactones / Macrolides / Microtubule Inhibition / Microtubule Inhibitors / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Polyketides / Tubulin Modulators,K27005NP0A,219989-84-1,D04645,6445540.0,20145579.0,,337523.0,63605.0,CHEMBL1201752,,PA165958343,ZINC000003993846
Celiprolol,phase 4 complete,DB04846,CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O,"Adrenergic Agents / Adrenergic Agonists / Adrenergic Antagonists / Adrenergic beta-1 Receptor Antagonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-3 Receptor Agonists / Adrenergic beta-Agonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antihypertensive Agents / Autonomic Agents / Benzene Derivatives / Beta Blocking Agents, Selective / Beta-Blockers (Beta1 Selective) / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenoxypropanolamines / Phenylurea Compounds / Potential QTc-Prolonging Agents / Propanolamines / Propanols / QTc Prolonging Agents / Sympathomimetics / Vasodilating Agents",DRB57K47QC,56980-93-9,D07660,2663.0,2563.0,,20498.0,94461.0,CHEMBL27810,,,
Dronedarone,phase 4 complete,DB04855,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antiarrhythmic agents / Antiarrhythmics, Class III / Benzofurans / Bradycardia-Causing Agents / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / OCT1 inhibitors / OCT2 Inhibitors / P-glycoprotein inhibitors / Photosensitizing Agents / QTc Prolonging Agents",JQZ1L091Y2,141626-36-0,D02537,208898.0,180996.0,50151864.0,233698.0,50659.0,CHEMBL184412,,PA153619853,ZINC000049933061
Nebivolol,phase 4 complete,DB04861,OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2,"Adrenergic Agents / Adrenergic Agonists / Adrenergic Antagonists / Adrenergic beta-1 Receptor Agonists / Adrenergic beta-Agonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Benzopyrans / Beta blocking agents and calcium channel blockers / Beta Blocking Agents and Thiazides / Beta Blocking Agents, Selective / Beta Blocking Agents, Selective, and Thiazides / Beta-Blockers (Beta1 Selective) / Bradycardia-Causing Agents / Cardiovascular Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Ethanolamines / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Neurotransmitter Agents / Pyrans / Vasodilating Agents",030Y90569U,118457-14-0,D05127,71301.0,64421.0,84735.0,31555.0,64019.0,CHEMBL434394,DAP000942,PA151958426,
Omacetaxine mepesuccinate,phase 4 complete,DB04865,[H][C@@]1(OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@]23CCCN2CCC2=CC4=C(OCO4)C=C2[C@]13[H],"Alkaloids / Antineoplastic Agents / Antineoplastic Agents, Phytogenic / Antineoplastic and Immunomodulating Agents / Benzazepines / Enzyme Inhibitors / Harringtonines / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / Protein Synthesis Inhibitors",6FG8041S5B,26833-87-4,D08956,285033.0,251215.0,,27100.0,71019.0,CHEMBL46286,,,ZINC000026011099
Nilotinib,phase 4 complete,DB04868,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Highest Risk QTc-Prolonging Agents / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Kinase Inhibitor / Myelosuppressive Agents / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Photosensitizing Agents / Protein Kinase Inhibitors / QTc Prolonging Agents / Tyrosine Kinase Inhibitors / UGT1A1 Inhibitors,F41401512X,641571-10-0,D08953,644241.0,559260.0,50237710.0,662281.0,52172.0,CHEMBL255863,,PA165958345,ZINC000006716957
Lorcaserin,phase 4 complete,DB04871,C[C@H]1CNCCC2=CC=C(Cl)C=C12,"Alimentary Tract and Metabolism / Antidepressive Agents / Antiobesity Preparations, Excl. Diet Products / Central Nervous System Depressants / Centrally Acting Antiobesity Products / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 2c Receptor Agonists / Serotonin 5-HT2 Receptor Agonists / Serotonin 5-HT2C Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists",637E494O0Z,616202-92-7,D06613,11658860.0,9833595.0,50161646.0,1300701.0,65353.0,CHEMBL360328,,,ZINC000006733300
Vildagliptin,phase 4 complete,DB04876,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N,Agents causing angioedema / Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cycloparaffins / DPP-IV Inhibitors / Drugs Used in Diabetes / Enzyme Inhibitors / Glucagon-Like Peptide 1 / Nitriles / Protease Inhibitors / Pyrrolidines,I6B4B2U96P,274901-16-5,,6918537.0,5293734.0,11695.0,596554.0,135285.0,CHEMBL142703,,PA165958346,
Enoximone,phase 4 complete,DB04880,CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1,"Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiotonic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Imidazoles / Phosphodiesterase 3 Inhibitors / Phosphodiesterase Inhibitors / Photosensitizing Agents / Protective Agents / Vasodilating Agents",C7Z4ITI7L7,77671-31-9,D04004,53708.0,48492.0,50241379.0,49626.0,135010.0,CHEMBL249856,DAP000611,PA164768794,ZINC000009225358
Bepotastine,phase 4 complete,DB04890,OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,Anti-Allergic Agents / Drugs that are Mainly Renally Excreted / Histamine Antagonists / Histamine H1 Antagonists / Mast Cell Stabilizers,HYD2U48IAS,125602-71-3,D01654,2350.0,2260.0,,863035.0,71204.0,CHEMBL1201758,DCL000719,PA164781356,
Milnacipran,phase 4 complete,DB04896,CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1,"Adrenergic Agents / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Analgesics / Analgesics, Non-Narcotic / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cyclopropanes / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Norepinephrine Uptake Inhibitors / Peripheral Nervous System Agents / Psychoanaleptics / Psychotropic Drugs / Selective Serotonin Reuptake Inhibitors / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin and Noradrenaline Reuptake Inhibitors / Serotonin Modulators",G56VK1HF36,92623-85-3,D08222,65833.0,9797657.0,86420.0,588250.0,135005.0,CHEMBL259209,DAP001155,PA164752812,
Ximelagatran,phase 4 complete,DB04898,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1,Amines / Anticoagulants / Antithrombins / Azetines / Benzene Derivatives / Benzyl Compounds / Blood and Blood Forming Organs / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Hematologic Agents / Protease Inhibitors / Serine Protease Inhibitors,49HFB70472,192939-46-1,,9574101.0,7848559.0,,,65172.0,CHEMBL522038,DAP001218,PA161748474,ZINC000012504524
Ticagrelor,phase 4 complete,DB08816 (DB04902),CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1,"Anticoagulants / Antiplatelet agents / Blood and Blood Forming Organs / Carbohydrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Platelet Aggregation / Glycosides / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / P-glycoprotein inhibitors / P-glycoprotein substrates / P2Y12 Platelet Inhibitor / Phenylalanine Hydroxylase Activators / Platelet Aggregation Inhibitors Excl. Heparin / Purine Nucleosides / Purinergic Agents / Purinergic Antagonists / Purinergic P2 Receptor Antagonists / Purinergic P2Y Receptor Antagonists / Purines / Ribonucleosides",GLH0314RVC,274693-27-5,D09017,9871419.0,8047109.0,50397205.0,1116632.0,68558.0,CHEMBL398435,,PA165374673,ZINC000028957444
Flibanserin,phase 4 complete,DB04908,FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1,"Agents that produce hypertension / Antidepressive Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Miscellaneous Central Nervous System Agents / P-glycoprotein inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Agonists / Serotonin Receptor Antagonists",37JK4STR6Z,167933-07-5,D02577,6918248.0,5293454.0,,1665509.0,90865.0,CHEMBL231068,,PA166153431,ZINC000052716421
Oritavancin,phase 4 complete,DB04911,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,"Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Glycoconjugates / Glycopeptide Antibacterials / Glycopeptides / Lipids / Lipoglycopeptide Antibacterial / Lipopeptides / Peptides",PUG62FRZ2E,171099-57-3,,16136912.0,17286443.0,,1547611.0,82699.0,CHEMBL1688530,,,
Ceftobiprole,phase 4 complete,DB04918,[H][C@@]1(NC(=O)C(=N/O)\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\C=C1/CCN(C1=O)[C@]1([H])CCNC1,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Sulfur Compounds / Thiazines",5T97333YZK,209467-52-7,D08885,12993649.0,23350302.0,,,140407.0,CHEMBL520642,,,ZINC000004424091
Clevidipine,phase 4 complete,DB04920,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,Agents causing hyperkalemia / Antiarrhythmic agents / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium Channel Blockers (Dihydropyridine) / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cholinesterase substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Dihydropyridines / Drugs that are Mainly Renally Excreted / Hypotensive Agents / Membrane Transport Modulators / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,19O2GP3B7Q,167221-71-8,D08892,153994.0,135722.0,50088387.0,233603.0,135738.0,CHEMBL1237132,,,
Gabapentin enacarbil,phase 4 complete,DB08872 (DB04922),CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1,"Acids, Acyclic / Amino Acids / Amino Acids, Peptides, and Proteins / Aminobutyrates / Anti-epileptic Agent / Butyrates / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Fatty Acids / Fatty Acids, Volatile / Gabapentin and Prodrugs / Lipids",75OCL1SPBQ,478296-72-9,D09539,9883933.0,8059607.0,,1101333.0,68840.0,CHEMBL1628502,,,
Permethrin,phase 4 complete,DB04930,CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1,"Agrochemicals / Antiparasitic Products, Insecticides and Repellents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Ectoparasiticides, Incl. Scabicides / Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents / Enzyme Inhibitors / Insecticides / Monoterpenes / Pesticides / Pyrethrines, Incl. Synthetic Compounds / Pyrethrins / Scabicides and Pediculicides / Terpenes / Toxic Actions",509F88P9SZ,52645-53-1,D05443,40326.0,36845.0,,33199.0,34911.0,CHEMBL1525,DAP001235,PA164743137,
Afamelanotide,phase 4 complete,DB04931,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O,"Amino Acids, Peptides, and Proteins / Compounds used in a research, industrial, or household setting / Dermatologicals / Hormones, Hormone Substitutes, and Hormone Antagonists / Indicators and Reagents / Laboratory Chemicals / Melanocyte-Stimulating Hormones / Peptide Hormones / Peptides / Protective Agents / Protectives Against UV-Radiation / Protectives Against UV-Radiation for Systemic Use / Proteins",QW68W3J66U,75921-69-6,,16197727.0,17310725.0,82411.0,2262250.0,,CHEMBL441738,,,
Ospemifene,phase 4 complete,DB04938,OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,Benzene Derivatives / Benzylidene Compounds / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Estrogen Agonist/Antagonist / Genito Urinary System and Sex Hormones / Selective Estrogen Receptor Modulators / Sex Hormones and Modulators of the Genital System / Stilbenes,B0P231ILBK,128607-22-7,D08958,3036505.0,2300501.0,,1370971.0,73275.0,CHEMBL2105395,,,ZINC000001550766
Eribulin,phase 4 complete,DB08871 (DB04940),[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@H]7O[C@@]8(C[C@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Immunosuppressive Agents / Microtubule Inhibition / Microtubule Inhibitors / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Potential QTc-Prolonging Agents / QTc Prolonging Agents,LR24G6354G,253128-41-5,D08914,73425383.0,24721813.0,,1045453.0,63587.0,CHEMBL1683590,,,ZINC000169344691
Crofelemer,phase 4 complete,DB04941,,"Alimentary Tract and Metabolism / Antidiarrheals / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Benzopyrans / Biopolymers / Chromans / Chromones / Compounds used in a research, industrial, or household setting / Flavonoids / Heterocyclic Compounds, Fused-Ring / Macromolecular Substances / Polymers / Pyrans / Tannins",PY79D6C8RX,148465-45-6,D03605,,,,1364449.0,,CHEMBL2108184,,,
Iloperidone,phase 4 complete,DB04946,COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O,Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Highest Risk QTc-Prolonging Agents / Histamine Antagonists / Histamine H1 Antagonists / Hyperglycemia-Associated Agents / Nervous System / Neurotoxic agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Schizophrenia / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents,VPO7KJ050N,133454-47-4,D02666,71360.0,64459.0,50034043.0,73178.0,65173.0,CHEMBL14376,,PA161199368,ZINC000001548097
Lofexidine,phase 4 complete,DB04948,CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1,Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Antidepressive Agents / Antihypertensive Agents / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Drugs Used in Addictive Disorders / Drugs Used in Opioid Dependence / Hypotensive Agents / Imidazoles / Imidazolines / MATE 1 Inhibitors / MATE inhibitors / Moderate Risk QTc-Prolonging Agents / Nervous System / Neurotransmitter Agents / Peripheral Nervous System Agents / QTc Prolonging Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Agonists / Serotonin Agents / Serotonin Receptor Agonists,UI82K0T627,31036-80-3,,30668.0,28460.0,50019646.0,28863.0,51368.0,CHEMBL17860,DAP000064,PA164744510,
Pirfenidone,phase 4 complete,DB04951,CC1=CN(C(=O)C=C1)C1=CC=CC=C1,"Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Antifibrotic Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Antirheumatic Agents / Central Nervous System Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Immunosuppressive Agents / Peripheral Nervous System Agents / Pyridines / Pyridones / Sensory System Agents",D7NLD2JX7U,53179-13-8,,40632.0,37115.0,50005201.0,1592254.0,32016.0,CHEMBL1256391,,,ZINC000000001958
Ezogabine,phase 4 complete,DB04953,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1,"Acids, Acyclic / Amines / Aniline Compounds / Anticonvulsants / Central Nervous System Agents / Central Nervous System Depressants / Diamines / Drugs that are Mainly Renally Excreted / Membrane Transport Modulators / Nervous System / Polyamines / Potassium Channel Opener / Potassium Channel Openers / Potential QTc-Prolonging Agents / QTc Prolonging Agents / UGT1A1 Substrates / UGT1A3 substrates / UGT1A4 substrates / UGT1A9 Substrates",12G01I6BBU,150812-12-7,D09569,121892.0,108740.0,50143558.0,1112990.0,68584.0,CHEMBL41355,,PA144997862,ZINC000000016154
Ingenol mebutate,phase 4 complete,DB05013,[H][C@@]12C[C@@H](C)[C@]34C=C(C)[C@H](OC(=O)C(\C)=C/C)[C@@]3(O)[C@H](O)C(CO)=C[C@@]([H])(C4=O)[C@]1([H])C2(C)C,Cell Death Inducer / Dermatologicals / Increased Cellular Death / Misc. Skin and Mucous Membrane Agents / Terpenes,7686S50JAH,75567-37-2,D09393,6918670.0,28533061.0,,1242806.0,66913.0,CHEMBL1863513,,,ZINC000056898854
Belinostat,phase 4 complete,DB05015,ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1,Amides / Amines / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (weak) / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Histone Deacetylase Inhibitors / Hydroxy Acids / Hydroxylamines / Immunosuppressive Agents / Myelosuppressive Agents / P-glycoprotein substrates / Sulfones / Sulfur Compounds / UGT1A1 Substrates / UGT1A1 substrates with narrow therapeutic index,F4H96P17NZ,866323-14-0,,6918638.0,5293831.0,25150.0,1543543.0,61076.0,CHEMBL408513,,,ZINC000003818726
Ataluren,phase 4 complete,DB05016,OC(=O)C1=CC=CC(=C1)C1=NOC(=N1)C1=CC=CC=C1F,Musculo-Skeletal System / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B3 inhibitors / Oxazoles / UGT1A9 Substrates,K16AME9I3V,775304-57-9,D09323,11219835.0,9394889.0,,,94805.0,CHEMBL256997,,PA166151864,ZINC000013831791
Migalastat,phase 4 complete,DB05018,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O,Alimentary Tract and Metabolism / Alkaloids / Carbohydrates / Drugs that are Mainly Renally Excreted / Imines / Imino Pyranoses / Imino Sugars / Other Miscellaneous Therapeutic Agents / Piperidines / UGT1A1 Substrates / Various Alimentary Tract and Metabolism Products,C4XNY919FW,108147-54-2,,176077.0,153388.0,50163440.0,2054252.0,135923.0,CHEMBL110458,,,ZINC000001636704
Indacaterol,phase 4 complete,DB05039,CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1,"Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Heterocyclic Compounds, Fused-Ring / Indenes / P-glycoprotein substrates / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quinolines / Selective Beta 2-adrenergic Agonists / UGT1A1 Substrates",8OR09251MQ,312753-06-3,D09318,6918554.0,5293751.0,50318159.0,1114326.0,68575.0,CHEMBL1095777,,PA165958348,ZINC000035801098
Erdosteine,phase 4 complete,DB05057,OC(=O)CSCC(=O)NC1CCSC1=O,"Acetates / Acids, Acyclic / Cough and Cold Preparations / Expectorants / Fatty Acids / Fatty Acids, Volatile / Lipids / Respiratory System Agents / Sulfhydryl Compounds / Sulfur Compounds",76J0853EKA,84611-23-4,,65632.0,59073.0,,24305.0,135014.0,CHEMBL1697744,,,
Tavaborole,phase 4 complete,DB09041 (DB05058),OB1OCC2=CC(F)=CC=C12,Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Dermatologicals / Oxaborole Antifungal / Protein Synthesis Inhibitors,K124A4EUQ3,174671-46-6,D10169,11499245.0,9674047.0,50370987.0,1543173.0,77942.0,CHEMBL443052,,,ZINC000169990691
Rilpivirine,phase 4 complete,"DB08864 (DB08592, DB05083)",CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1,Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor / Nitriles / Non-Nucleoside Reverse Transcriptase Inhibitors / Nonnucleoside Reverse Transcriptase Inhibitors / Nucleic Acid Synthesis Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / Potential QTc-Prolonging Agents / Pyrimidines / QTc Prolonging Agents / Reverse Transcriptase Inhibitors,FI96A8X663,500287-72-9,D09720,6451164.0,4953643.0,222178.0,1102270.0,68606.0,CHEMBL175691,,,ZINC000001554274
Enzalutamide,phase 4 complete,DB08899 (DB05094),CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F,"Androgen Receptor Antagonists / Androgen Receptor Inhibitor / Antiandrogens / Antiandrogens, non-steroidal / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (moderate) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (moderate) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strong) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Endocrine Therapy / Hormone Antagonists and Related Agents / Hydantoins / Imidazoles / Imidazolidines / P-glycoprotein inhibitors / Thyroxine-binding globulin substrates",93T0T9GKNU,915087-33-1,D10218,15951529.0,13093347.0,50425732.0,1307298.0,68534.0,CHEMBL1082407,,,ZINC000034806477
Trabectedin,phase 4 complete,DB05109,[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31,"Agents Causing Muscle Toxicity / Alkylating Activity / Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Dioxoles / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Isoquinolines / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Noxae / Tetrahydroisoquinolines / Toxic Actions",ID0YZQ2TCP,114899-77-3,,108150.0,97236.0,,1716278.0,84050.0,CHEMBL450449,,PA165958349,ZINC000150338708
Cabozantinib,phase 4 complete,DB08875 (DB05153),COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2,"Amides / Amines / Aniline Compounds / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Kinase Inhibitor / Protein Kinase Inhibitors / Receptor Protein-Tyrosine Kinases, antagonists & inhibitors / Tyrosine Kinase Inhibitors",1C39JW444G,849217-68-1,D10062,25102847.0,25948202.0,50021574.0,1363268.0,72317.0,CHEMBL2105717,,,ZINC000070466416
Pretomanid,phase 4 complete,DB05154,[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC1=CC=C(OC(F)(F)F)C=C1,Antituberculosis Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Imidazoles / Nitro Compounds / OAT3/SLC22A8 Inhibitors,2XOI31YC4N,187235-37-6,,456199.0,401693.0,50363237.0,2198359.0,,CHEMBL227875,,,ZINC000003821675
Crisaborole,phase 4 complete,DB05219,OB1OCC2=C1C=CC(OC1=CC=C(C=C1)C#N)=C2,"Agents for Dermatitis, Excluding Corticosteroids / Anti-Inflammatory Agents / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (weak) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Phosphodiesterase 4 Inhibitors / Phosphodiesterase Inhibitors",Q2R47HGR7P,906673-24-3,D10873,44591583.0,24701949.0,50277665.0,1865953.0,134677.0,CHEMBL484785,,,ZINC000169748244
Vemurafenib,phase 4 complete,DB08881 (DB05238),CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,"Amides / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Indoles / Kinase Inhibitor / Narrow Therapeutic Index Drugs / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Photosensitizing Agents / Protein Kinase Inhibitors / QTc Prolonging Agents / Sulfonamides / Sulfones / Sulfur Compounds / Tyrosine Kinase Inhibitors",207SMY3FQT,918504-65-1,D09996,42611257.0,24747352.0,50396483.0,1147220.0,63637.0,CHEMBL1229517,,PA165946873,ZINC000052509366
Cobimetinib,phase 4 complete,DB05239,OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Azetines / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Kinase Inhibitor / MAP Kinase Kinase 1, antagonists & inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / OATP1B3 substrates / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Photosensitizing Agents / Protein Kinase Inhibitors",ER29L26N1X,934660-93-2,D10405,16222096.0,17349374.0,50391802.0,1722365.0,90851.0,CHEMBL2146883,,PA166160044,ZINC000060325170
Silver sulfadiazine,phase 4 complete,DB05245,[Ag+].NC1=CC=C(C=C1)S(=O)(=O)[N-]C1=NC=CC=N1,"Amides / Amines / Aniline Compounds / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Local / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Miscellaneous Local Anti-infectives / Sulfanilamides / Sulfonamide Antibacterial / Sulfonamides / Sulfones / Sulfur Compounds",W46JY43EJR,22199-08-2,D00433,441244.0,390017.0,,9793.0,9142.0,CHEMBL1382627,DAP001321,PA164744951,
Methsuximide,phase 4 complete,DB05246,CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1,Agents causing hyperkalemia / Anti-epileptic Agent / Antiarrhythmic agents / Anticonvulsants / Bradycardia-Causing Agents / Calcium Channel Blockers / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Imides / Nervous System / Potential QTc-Prolonging Agents / Pyrrolidines / Pyrrolidinones / QTc Prolonging Agents / Succinimide Derivatives,0G76K8X6C0,77-41-8,D00404,6476.0,6231.0,,47858.0,6846.0,CHEMBL697,DAP001253,PA164743145,
Iodine,phase 4 complete,DB05382 (DB05247),II,"Anti-Infective Agents / Anti-Infective Agents, Local / Antiseptics and Disinfectants / Dermatologicals / Diet, Food, and Nutrition / Elements / Food / Food and Beverages / Growth Substances / Halogens / Herbs and Natural Products / Iodine Products / Micronutrients / Minerals / Miscellaneous Local Anti-infectives / Trace Elements",9679TC07X4,7553-56-2,D00108,807.0,785.0,,5933.0,17606.0,CHEMBL1201225,,,
Gallium nitrate,phase 4 complete,DB05260,[Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O,"Antineoplastic Agents / Bone Resorption Inhibition / Calcium Resorption Inhibitor / Calcium-Regulating Hormones and Agents / Elements / Immunosuppressive Agents / Metals / Metals, Heavy",Y2V2R4W9TQ,13494-90-1,,61635.0,55543.0,,25544.0,,CHEMBL1200983,DAP001096,PA164781198,
Activated charcoal,phase 4 complete,DB09278 (DB05269),[C],"Adsorption / Alimentary Tract and Metabolism / Anions / Antacids and Adsorbents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antidotes / Antifoaming Agents / Carbon / Charcoal Preparations / Compounds used in a research, industrial, or household setting / Electrolytes / Elements / Intestinal Adsorbents / Ions / Microspheres / Oxygen Compounds / Protective Agents",4XYU5U00C4,64365-11-3,D03251,297.0,4575370.0,,272.0,27594.0,CHEMBL2106049,,,
Rotigotine,phase 4 complete,DB05271,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1,Agents that produce hypertension / Anti-Parkinson Agents (Dopamine Agonist) / Anti-Parkinson Drugs / Antidepressive Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Agonists / Hypotensive Agents / Naphthalenes / Nervous System / Neurotransmitter Agents / Nonergot-derivative Dopamine Receptor Agonists / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin Agents / Serotonin Receptor Agonists / Sulfur Compounds,87T4T8BO2E,99755-59-6,D05768,59227.0,53406.0,50123626.0,616739.0,135351.0,CHEMBL1303,,PA166165149,ZINC000000004028
Samarium (153Sm) lexidronam,phase 4 complete,DB05273,[153Sm+3].OP(O)(=O)CN(CCN(CP(O)([O-])=O)CP(O)([O-])=O)CP(O)([O-])=O,"Analgesics / Analgesics, Non-Narcotic / Central Nervous System Agents / Pain Palliation (Bone Seeking Agents) / Peripheral Nervous System Agents / Radioactive Therapeutic Agent / Radioisotopes / Radiopharmaceutical Activity / Sensory System Agents / Therapeutic Radiopharmaceuticals / Various Pain Palliation Radiopharmaceuticals",745X144DZY,122575-21-7,,76962714.0,143933.0,,177906.0,,,,,
Fospropofol,phase 4 complete,DB06716 (DB05279),CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O,"Agents that reduce seizure threshold / Anesthetics / Anesthetics, General / Benzene Derivatives / Central Nervous System Agents / Central Nervous System Depressants / Hypnotics and Sedatives / Phenols",LZ257RZP7K,258516-89-1,D04257,3038498.0,2302062.0,,828682.0,135193.0,CHEMBL1201766,,PA165958389,ZINC000002519740
Vandetanib,phase 4 complete,DB05294 (DB08764),COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Kinase Inhibitor / Narrow Therapeutic Index Drugs / OCT2 Inhibitors / P-glycoprotein inhibitors / Photosensitizing Agents / Protein Kinase Inhibitors / QTc Prolonging Agents / Tyrosine Kinase Inhibitors",YO460OQ37K,443913-73-3,D06407,3081361.0,2338979.0,21.0,1098413.0,49960.0,CHEMBL24828,,PA166118341,ZINC000053683345
Pimavanserin,phase 4 complete,DB05316,CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1,Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Agents / Central Nervous System Depressants / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents,JZ963P0DIK,706779-91-1,,10071196.0,8246736.0,139370.0,1791685.0,133017.0,CHEMBL2111101,,,ZINC000016159083
Capsaicin,phase 4 complete,"DB06774 (DB05674, DB05318)",COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1,"Alkaloids / Alkenes / Alkynes / Amides / Anesthetics / Anesthetics, Local / Antipruritics / Basic Lotions and Liniments / Benzene Derivatives / Capsaicin and Similar Agents / Capsaicin, antagonists & inhibitors / Catechols / Cholinesterase Inhibitors / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Fatty Acids / Fatty Acids, Monounsaturated / Fatty Acids, Unsaturated / Hydrocarbons, Acyclic / Lipids / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Musculo-Skeletal System / Nervous System / Peripheral Nervous System Agents / Phenols / Polyunsaturated Alkamides / Sensory System Agents / Solanaceous Alkaloids / Topical Products for Joint and Muscular Pain",S07O44R1ZM,404-86-4,D00250,1548943.0,1265957.0,20461.0,1992.0,3374.0,CHEMBL294199,,,ZINC000001530575
Dexlansoprazole,phase 4 complete,DB05351,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,"2-Pyridinylmethylsulfinylbenzimidazoles / Acid Reducers / Alimentary Tract and Metabolism / Anti-Ulcer Agents / Benzimidazoles / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Enzyme Inhibitors / Gastric Acid Lowering Agents / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Proton Pump Inhibitors / Proton-pump Inhibitors / Pyridines / Sulfoxides / Sulfur Compounds",UYE4T5I70X,138530-94-6,,9578005.0,7852369.0,,816346.0,135931.0,CHEMBL1201863,,PA166110257,ZINC000003830986
Raltegravir,phase 4 complete,DB06817 (DB05355),CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1,Agents Causing Muscle Toxicity / Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Direct Acting Antivirals / Enzyme Inhibitors / HIV Integrase Inhibitors / Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor / Integrase Inhibitors / Pyrrolidines / Pyrrolidinones / UGT1A1 Substrates,22VKV8053U,518048-05-0,D06676,54671008.0,16445111.0,25351.0,719872.0,,CHEMBL254316,,,ZINC000013831130
Azilsartan medoxomil,phase 4 complete,DB08822 (DB05358),CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1,"Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Angiotensin 2 Receptor Blocker / Angiotensin II receptor blockers (ARBs) and diuretics / Angiotensin II receptor blockers (ARBs), plain / Angiotensin II Type 1 Receptor Blockers / Angiotensin Receptor Antagonists / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Decreased Blood Pressure / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Oxazoles",LL0G25K7I2,863031-21-4,D08865,11238823.0,9413866.0,,1294597.0,68845.0,CHEMBL2028661,,,ZINC000014210642
Tasimelteon,phase 4 complete,DB09071 (DB05359),CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2,"Central Nervous System Depressants / Cycloparaffins / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Melatonin Receptor Agonists / Nervous System / Psycholeptics / Receptors, Melatonin, agonists",SHS4PU80D9,609799-22-6,D09388,10220503.0,8395995.0,,1490468.0,79042.0,CHEMBL2103822,,,ZINC000004392649
Ulipristal,phase 4 complete,DB08867 (DB05366),CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12,"Adrenal Cortex Hormones / Contraceptive Agents, Female / Contraceptives, Postcoital / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Norpregnanes / Norsteroids / Progesterone Agonist/Antagonist / Progesterone Receptor Modulators / Reproductive Control Agents / Selective Progesterone Receptor Modulators / Sex Hormones and Modulators of the Genital System / Steroids",6J5J15Q2X8,159811-51-5,D09567,13559281.0,19349271.0,,1005921.0,71025.0,CHEMBL2103846,,,ZINC000034089131
Rifamycin,phase 4 complete,DB11753 (DB05378),CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antiinfectives for Systemic Use / Antimycobacterials / Antirheumatic Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strong) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Drugs for Treatment of Tuberculosis / Heterocyclic Compounds, Fused-Ring / Lactams / Lactams, Macrocyclic / MATE 1 Inhibitors / MATE inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Ophthalmologicals / Otologicals / P-glycoprotein inhibitors / P-glycoprotein substrates / Rifamycins / Sensory Organs",DU69T8ZZPA,6998-60-3,D02549,,16735998.0,50391000.0,35616.0,29673.0,CHEMBL437765,,,ZINC000169633673
Tetrachlorodecaoxide,phase 4 complete,DB05389,,"Anions / Compounds used in a research, industrial, or household setting / Electrolytes / Elements / Gases / Halogens / Ions / Oxygen Compounds / Protective Agents / Radiation-Protective Agents",549BT7IE1Q,92047-76-2,,3000391.0,2272021.0,,,,CHEMBL3707387,,,
Perflubutane,phase 4 complete,DB12821 (DB05392),FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F,"Anions / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Electrolytes / Elements / Hydrocarbons, Fluorinated / Hydrocarbons, Halogenated / Ions / Iron Compounds / Metals / Metals, Heavy / Organometallic Compounds / Oxygen Compounds / Transition Elements",SE4TWR0K2C,355-25-9,,9638.0,13862701.0,,,134964.0,CHEMBL2104979,,,ZINC000056897668
Uridine triacetate,phase 4 complete,DB09144 (DB05425),CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)N1C=CC(=O)NC1=O,"Acids, Acyclic / Alimentary Tract and Metabolism / Carbohydrates / Fatty Acids / Fatty Acids, Volatile / Glycosides / Lipids / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / Pyrimidine Analog / Pyrimidine Nucleosides / Pyrimidines / Ribonucleosides / Various Alimentary Tract and Metabolism Products",2WP61F175M,4105-38-8,D09985,20058.0,18897.0,,1665222.0,90914.0,CHEMBL2107381,,,ZINC000003843198
Acetylcysteine,phase 4 complete,DB06151 (DB05436),CC(=O)N[C@@H](CS)C(O)=O,"Amino Acids / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Amino Acids, Sulfur / Anti-Infective Agents / Antidote for Acetaminophen Overdose / Antidotes / Antioxidants / Compounds used in a research, industrial, or household setting / Cough and Cold Preparations / Cysteine / Decreased Respiratory Secretion Viscosity / Expectorants / Free Radical Scavengers / Increased Glutathione Concentration / OATP1B1/SLCO1B1 Inhibitors / Ophthalmologicals / Protective Agents / Reduction Activity / Respiratory System Agents / Sensory Organs / Sulfhydryl Compounds / Sulfur Compounds",WYQ7N0BPYC,616-91-1,D00221,12035.0,11540.0,50420190.0,197.0,28939.0,CHEMBL600,DNC000981,PA448033,ZINC000003589203
Telaprevir,phase 4 complete,DB05521,[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,"Amino Acids, Peptides, and Proteins / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / HCV NS3/4A Protease Inhibitors / NS3/4A Protease Inhibitors / OATP1B1/SLCO1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Organic Anion Transporting Polypeptide 2B1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Peptides / Protease Inhibitors",655M5O3W0U,402957-28-2,D09012,3010818.0,2279948.0,50326056.0,1102261.0,68595.0,CHEMBL231813,,PA165958354,ZINC000003992480
Pralatrexate,phase 4 complete,DB06813 (DB05527),NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1,"Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Biological Factors / Drugs that are Mainly Renally Excreted / Folic Acid Analogues / Folic Acid Antagonists / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Narrow Therapeutic Index Drugs / Pigments, Biological / Pteridines / Pterins",A8Q8I19Q20,146464-95-1,D05589,148121.0,130578.0,,662019.0,71223.0,CHEMBL1201746,,,
Mipomersen,phase 4 complete,DB05528,COCCO[C@@H]1[C@H](O)[C@@H](COP(S)(=O)O[C@@H]2[C@@H](COP(S)(=O)O[C@@H]3[C@@H](COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]5[C@@H](COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@@H]6[C@@H](COP(S)(=O)O[C@@H]7[C@@H](COP(S)(=O)O[C@@H]8[C@@H](COP(S)(=O)O[C@@H]9[C@@H](COP(S)(=O)O[C@@H]%10[C@@H](CO)O[C@H]([C@@H]%10OCCOC)N%10C=NC%11=C%10N=C(N)NC%11=O)O[C@H]([C@@H]9OCCOC)N9C=C(C)C(N)=NC9=O)O[C@H]([C@@H]8OCCOC)N8C=C(C)C(N)=NC8=O)O[C@H]([C@@H]7OCCOC)N7C=C(C)C(=O)NC7=O)O[C@H]([C@@H]6OCCOC)N6C=C(C)C(N)=NC6=O)N6C=NC7=C6N=CN=C7N)N6C=NC7=C6N=C(N)NC7=O)N6C=C(C)C(=O)NC6=O)N6C=C(C)C(N)=NC6=O)N6C=C(C)C(=O)NC6=O)N6C=NC7=C6N=C(N)NC7=O)N6C=C(C)C(N)=NC6=O)N6C=C(C)C(=O)NC6=O)N6C=C(C)C(=O)NC6=O)N6C=C(C)C(N)=NC6=O)O[C@H]([C@@H]5OCCOC)N5C=NC6=C5N=C(N)NC6=O)O[C@H]([C@@H]4OCCOC)N4C=C(C)C(N)=NC4=O)O[C@H]([C@@H]3OCCOC)N3C=NC4=C3N=CN=C4N)O[C@H]([C@@H]2OCCOC)N2C=C(C)C(N)=NC2=O)O[C@H]1N1C=C(C)C(N)=NC1=O,"Anticholesteremic Agents / Antisense Elements (Genetics) / Apolipoprotein B-100 Synthesis Inhibitor / Carbohydrates / Compounds used in a research, industrial, or household setting / Decreased Protein Synthesis / Diagnostic Uses of Chemicals / DNA / DNA, Antisense / Glycosides / Hepatotoxic Agents / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Laboratory Chemicals / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Molecular Probes / Noxae / Nucleic Acid Probes / Nucleic Acids / Nucleic Acids, Nucleotides, and Nucleosides / Nucleotides / Oligodeoxyribonucleotides, Antisense / Oligonucleotides / Oligonucleotides, Antisense / Polynucleotides / Toxic Actions",9GJ8S4GU0M,1000120-98-8,D08946,131704297.0,34983392.0,,1367839.0,,CHEMBL502097,,,
Sinapultide,phase 4 complete,DB11332 (DB05534),CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O,"Amino Acids, Peptides, and Proteins / Pulmonary Surfactants",040X3AX99T,138531-07-4,,,16742247.0,,1440288.0,,CHEMBL2103901,,,
Brivaracetam,phase 4 complete,DB05541,CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1,Anticonvulsants / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Epoxide Hydrolase Inhibitors / Miscellaneous Anticonvulsants / Nervous System / Pyrrolidines,U863JGG2IA,357336-20-0,D08879,9837243.0,8012964.0,50422531.0,1739745.0,133013.0,CHEMBL607400,,PA166153491,ZINC000003979899
Linaclotide,phase 4 complete,DB08890 (DB05566),[H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,"Alimentary Tract and Metabolism / Amino Acids, Peptides, and Proteins / Drugs for Constipation / Enzyme Activators / Gastrointestinal Agents / Guanylate Cyclase Activators / Guanylate Cyclase-C Agonist / Guanylyl Cyclase C Agonists / Laxatives / Miscellaneous GI Drugs",N0TXR0XR5X,851199-59-2,D09355,16158208.0,17314504.0,,1307404.0,68551.0,CHEMBL3301675,,,
Elvitegravir,phase 4 complete,DB09101 (DB05618),[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2,"Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Heterocyclic Compounds, Fused-Ring / HIV Integrase / HIV Integrase Inhibitors / Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor / Quinolines / UGT1A1 Substrates",4GDQ854U53,697761-98-1,,5277135.0,4441060.0,50183273.0,1306286.0,72289.0,CHEMBL204656,,,ZINC000013682481
Sodium stibogluconate,phase 4 complete,DB05630,O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[H][C@@]1(O[Sb]2(O)(O[Sb]34([O-])O[C@@H](C([O-])=O)[C@@]([H])(O3)[C@]([H])(O4)[C@H](O)CO)O[C@@H](C([O-])=O)[C@@]1([H])O2)[C@H](O)CO,"Acids, Acyclic / Agents Against Leishmaniasis and Trypanosomiasis / Anti-Infective Agents / Antimony Compounds / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiplatyhelmintic Agents / Antiprotozoals / Carbohydrates / Gluconates / Hydroxy Acids / Organometallic Compounds / Schistosomicides / Sugar Acids",APJ6285Y89,16037-91-5,D00582,56927674.0,27471272.0,,8010.0,28148.0,CHEMBL2079699,DCL000001,PA164743129,
Boceprevir,phase 4 complete,DB08873 (DB05665),[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C,"Acids, Acyclic / Amino Acids / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strong) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / HCV NS3/4A Protease Inhibitors / Imines / Imino Acids / NS3/4A Protease Inhibitors / P-glycoprotein inhibitors / Protease Inhibitors",89BT58KELH,394730-60-0,D08876,10324367.0,8499830.0,12311.0,1102129.0,68621.0,CHEMBL218394,,PA165948902,
Apremilast,phase 4 complete,DB05676,CCOC1=CC(=CC=C1OC)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O,"Agents reducing cytokine levels / Anti-Inflammatory Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Disease-modifying Antirheumatic Agents / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Isoindoles / P-glycoprotein substrates / Phosphodiesterase 4 Inhibitors / Phosphodiesterase Inhibitors / Phthalimides / Selective Immunosuppressants",UP7QBP99PN,608141-41-9,D08860,11561674.0,9736448.0,50248919.0,1492727.0,78540.0,CHEMBL514800,,,ZINC000030691736
Radium Ra 223 dichloride,phase 4 complete,"DB08913 (DB05677, DB09566)",[Cl-].[Cl-].[223Ra++],"Antineoplastic Agents / Elements / Elements, Radioactive / Isotopes / Metals / Metals, Alkaline Earth / Metals, Heavy / Radioactive alpha-Particle Emitting Therapeutic Agent / Radioisotopes",RJ00KV3VTG,444811-40-9,D10398,,28528370.0,,1424174.0,74895.0,CHEMBL2107816,,,
Vorapaxar,phase 4 complete,DB09030 (DB05692),[H][C@@]12C[C@]3([H])C[C@@H](CC[C@@]3([H])[C@H](\C=C\C3=CC=C(C=N3)C3=CC(F)=CC=C3)[C@]1([H])[C@@H](C)OC2=O)NC(=O)OCC,"Anticoagulants / Antiplatelet agents / Blood and Blood Forming Organs / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Hematologic Agents / P-glycoprotein inhibitors / Platelet Aggregation Inhibitors Excl. Heparin / Protease-activated Receptor-1 Antagonist / Protease-activated Receptor-1 Antagonists / Receptor, PAR-1, antagonists & inhibitors / Receptors, Thrombin, antagonists & inhibitors",ZCE93644N2,618385-01-6,D09765,10077130.0,8252668.0,50261110.0,1537034.0,82702.0,CHEMBL493982,,,ZINC000003925861
Elagolix,phase 4 complete,DB11979 (DB05694),COC1=CC=CC(=C1F)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O,"Antigonadotropins and Similar Agents / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Gonadotropin-releasing Hormone Antagonists / Hydrocarbons, Halogenated / OATP1B1/SLCO1B1 Substrates / P-glycoprotein inhibitors / P-glycoprotein substrates / UGT1A1 Substrates",5B2546MB5Z,834153-87-6,,11250647.0,9425680.0,,2049846.0,,CHEMBL1208155,,,ZINC000049888891
Vortioxetine,phase 4 complete,DB09068 (DB05700),CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1,Agents that produce hypertension / Anti-Anxiety Agents / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Piperazines / Psychoanaleptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT3 Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists / Serotonin Receptor Antagonists / Tranquilizing Agents,3O2K1S3WQV,508233-74-7,D10184,71768094.0,8141643.0,50400902.0,1455099.0,76016.0,CHEMBL2104993,,PA166122595,ZINC000034051848
Mirabegron,phase 4 complete,DB08893 (DB05702),NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1,Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-3 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Amides / Amines / Anilides / Aniline Compounds / Cholinesterase substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Urinary Frequency and Incontinence / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Neurotransmitter Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Selective Beta 3-adrenergic Agonists / Sulfur Compounds / Urological Agents / Urologicals,MVR3JL3B2V,223673-61-8,D09535,9865528.0,8041219.0,,1300786.0,65349.0,CHEMBL2095212,,,ZINC000001996784
Isosorbide,phase 4 complete,DB09401 (DB05707),[H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H],"Adrenal Cortex Hormones / Alcohols / Antianginal Agents / Carbohydrates / Cardiovascular Agents / Contraceptive Agents, Male / Diuretics / Diuretics, Osmotic / Hormonal Contraceptives for Systemic Use / Natriuretic Agents / Noxae / Organic Nitrates / Reproductive Control Agents / Sesquiterpenes / Sugar Alcohols / Terpenes / Toxic Actions / Vasodilating Agents",WXR179L51S,652-67-5,,,12077.0,,6057.0,6060.0,CHEMBL1200660,,,ZINC000018284778
Eliglustat,phase 4 complete,DB09039 (DB05715),CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1,Alimentary Tract and Metabolism / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Gaucher Disease / Glucosylceramide Synthase Inhibitor / Glucosylceramide Synthase Inhibitors / Highest Risk QTc-Prolonging Agents / Other Miscellaneous Therapeutic Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / QTc Prolonging Agents / Various Alimentary Tract and Metabolism Products,DR40J4WA67,491833-29-5,D09893,23652731.0,28475348.0,,1547220.0,82752.0,CHEMBL2110588,,PA166123486,ZINC000072267023
Cetylpyridinium,phase 4 complete,DB11073 (DB05748),CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1,"Anti-Infective Agents / Anti-Infective Agents, Local / Antiseptics and Disinfectants / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Compounds used in a research, industrial, or household setting / Dermatologicals / Detergents / Household Products / Irrigating Solutions / Medicated Dressings / Medicated Dressings With Antiinfectives / Miscellaneous Anti-infectives / Mouthwashes and Gargles / Pyridines / Pyridinium Compounds / Quaternary Ammonium Compounds / Surface-Active Agents / Throat Preparations",CUB7JI0JV3,7773-52-6,,2683.0,2582.0,80992.0,2286.0,32914.0,CHEMBL305906,,,ZINC000006845963
Levosalbutamol,phase 4 complete,DB13139 (DB05761),CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1,Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Alcohols / Amines / Amino Alcohols / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Ethanolamines / Ethylamines / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / Phenethylamines,EDN2NBH5SS,34391-04-3,D08124,123600.0,110192.0,50361247.0,237159.0,8746.0,CHEMBL1002,,,ZINC000000007601
Solriamfetol,phase 4 complete,DB14754 (DB05795),N[C@@H](COC(N)=O)CC1=CC=CC=C1,"Acids, Acyclic / Adrenergic Agents / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Agents that produce hypertension / Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Dopamine Agents / Dopamine Uptake Inhibitors / Drugs that are Mainly Renally Excreted / MATE 1 Substrates / MATE substrates / Norepinephrine Reuptake Inhibitor / OCT2 Substrates",939U7C91AI,178429-62-4,,,8305853.0,,2121751.0,,CHEMBL4297620,,,ZINC000034278783
Abiraterone,phase 4 complete,DB05812,[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C,"Androstanes / Androstenes / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Cytochrome P450 17A1 Inhibitors / Endocrine Therapy / Enzyme Inhibitors / Fused-Ring Compounds / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Steroid Synthesis Inhibitors / Steroids",G819A456D0,154229-19-3,D09701,132971.0,117349.0,25458.0,1100072.0,68642.0,CHEMBL254328,,PA166123407,ZINC000003797541
Besifloxacin,phase 4 complete,DB06771 (DB05862),N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O,"Anti-Bacterial Agents / Anti-Infective Agents / Antineoplastic Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Moderate Risk QTc-Prolonging Agents / Ophthalmologicals / QTc Prolonging Agents / Quinolines / Quinolone Antimicrobial / Quinolones / Sensory Organs / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",BFE2NBZ7NX,141388-76-3,D08872,10178705.0,8354210.0,,819911.0,135622.0,CHEMBL1201760,,,ZINC000003787097
Macimorelin,phase 4 complete,"DB13074 (DB06066, DB05917)",CC(C)(N)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)NC=O,"Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Diagnostic Agents / Growth Hormone Secretagogue Receptor Agonist / Growth Hormone Secretagogue Receptor Agonists / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / QTc Prolonging Agents / Tests for Pituitary Function",8680B21W73,381231-18-1,D10563,,7980698.0,50125886.0,1999420.0,,CHEMBL278623,,,ZINC000001554197
Olaparib,phase 4 complete,DB09074 (DB05940),FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Immunosuppressive Agents / Myelosuppressive Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Poly(ADP-ribose) Polymerase Inhibitors / Pyridazines,WOH1JD9AR8,763113-22-0,D09730,,23343272.0,27566.0,1597582.0,83766.0,CHEMBL521686,,,ZINC000040430143
Binimetinib,phase 4 complete,DB11967 (DB05985),CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / MAP Kinase Kinase 1, antagonists & inhibitors / MAP Kinase Kinase 2, antagonists & inhibitors / P-glycoprotein substrates with narrow therapeutic index / Protein Kinase Inhibitors / UGT1A1 Substrates / UGT1A1 substrates with narrow therapeutic index",181R97MR71,606143-89-9,,10288191.0,8463660.0,,,145371.0,CHEMBL3187723,,PA166179867,ZINC000038460704
Ivacaftor,phase 4 complete,DB08820 (DB05989),CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C,"Amines / Aniline Compounds / Benzene Derivatives / Chloride Channel Activation Potentiators / Chloride Channel Agonists / Cystic Fibrosis Transmembrane Conductance Regulator Potentiators / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Membrane Transport Modulators / P-glycoprotein inhibitors / Phenols / Quinolines",1Y740ILL1Z,873054-44-5,D09916,16220172.0,17347474.0,50032693.0,1243041.0,66901.0,CHEMBL2010601,,PA165950341,ZINC000052509463
Obeticholic acid,phase 4 complete,DB05990,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,Alimentary Tract and Metabolism / Bile Acid Preparations / Bile acids and derivatives / Bile Acids and Salts / Bile and Liver Therapy / Bile Therapy / BSEP/ABCB11 inducers / BSEP/ABCB11 Inhibitors / Cholanes / Cholic Acids / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Farnesoid X Receptor Agonist / Farnesoid X Receptor Agonists / Fused-Ring Compounds / Miscellaneous GI Drugs,0462Z4S4OZ,459789-99-2,D09360,447715.0,394730.0,21675.0,1798288.0,43602.0,CHEMBL566315,,,ZINC000014164617
Tecovirimat,phase 4 complete,DB12020 (DB06000),FC(F)(F)C1=CC=C(C=C1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O,"Acids, Carbocyclic / Amides / Antiviral Agents / Benzene Derivatives / Benzoates / Heterocyclic Compounds, Fused-Ring / UGT1A1 Substrates / UGT1A4 substrates",F925RR824R,869572-92-9,,16124688.0,17281586.0,,,,CHEMBL1257073,,,ZINC000035323125
Cariprazine,phase 4 complete,DB06016,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1,Agents that produce hypertension / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Histamine Antagonists / Histamine H1 Antagonists / Nervous System / Neurotoxic agents / Psycholeptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Agonists / Serotonin Receptor Antagonists / Tranquilizing Agents,F6RJL8B278,839712-12-8,D09997,11154555.0,25999972.0,50443101.0,1667655.0,90933.0,CHEMBL2028019,,,ZINC000100907004
Favipiravir,phase 4 complete,"DB12466 (DB06046, DB15625)",NC(=O)C1=NC(F)=CN=C1O,Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Experimental Unapproved Treatments for COVID-19 / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / P-glycoprotein inhibitors,EW5GL2X7E0,259793-96-9,,492405.0,431002.0,,,134722.0,CHEMBL221722,,,ZINC000013915654
Lumateperone,phase 4 complete,DB06077,[H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C,Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dopamine Agonists / Dopamine Antagonists / Dopamine D2 Receptor Agonists / Neurotoxic agents / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / UGT1A1 Substrates / UGT1A4 substrates,70BSQ12069,313368-91-1,,21302490.0,19328801.0,,2275602.0,,CHEMBL3306803,,,ZINC000116262036
Cenobamate,phase 4 complete,DB06119,NC(=O)O[C@@H](CN1N=CN=N1)C1=C(Cl)C=CC=C1,Anticonvulsants / Central Nervous System Depressants / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / GABA Modulators / UGT2B7 substrates / Voltage-Gated Sodium Channel Blockers,P85X70RZWS,913088-80-9,,,10136642.0,,2265690.0,,CHEMBL3989949,,,
Tucatinib,phase 4 complete,DB11652 (DB06142),CC1=CC(NC2=NC=NC3=CC=C(NC4=NC(C)(C)CO4)C=C23)=CC=C1OC1=CC2=NC=NN2C=C1,BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Substrates / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / Tyrosine Kinase Inhibitors,234248D0HH,937263-43-9,,51039094.0,34995558.0,,2361285.0,,CHEMBL3989868,,,ZINC000068250462
Sertindole,phase 4 complete,DB06144,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2,"Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Indole Derivatives / Nervous System / Neurotoxic agents / Psycholeptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents",GVV4Z879SP,106516-24-9,D00561,60149.0,54229.0,50001786.0,41996.0,9122.0,CHEMBL12713,DAP000832,PA164784002,ZINC000000538337
Spiramycin,phase 4 complete,DB06145,CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Antiparasitic Agents / Antiprotozoals / Carbohydrates / Coccidiostats / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Glycosides / Lactones / Leucomycins / Macrolides / Macrolides, Lincosamides and Streptogramins / Polyketides",033ECH6IFG,24916-50-5,,6440717.0,4944970.0,,9991.0,85260.0,CHEMBL1908369,,,
Methenamine,phase 4 complete,DB06799 (DB06146),C1N2CN3CN1CN(C2)C3,"Acids, Carbocyclic / Amides / Amines / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Benzene Derivatives / Benzoates / Cycloparaffins / Hydroxy Acids / Keto Acids / Polyamines / Renal Agents / Urinary Acidifying Agents",J50OIX95QV,100-97-0,D00393,4101.0,3959.0,,6832.0,6824.0,CHEMBL1201270,,,ZINC000086040406
Sulfathiazole,phase 4 complete,DB06147,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1,Amides / Amines / Aniline Compounds / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Short-Acting Sulfonamides / Sulfanilamides / Sulfathiazoles / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds / Thiazoles,Y7FKS2XWQH,72-14-0,D01047,5340.0,5148.0,50027796.0,10193.0,9337.0,CHEMBL437,,PA165958356,ZINC000000121458
Mianserin,phase 4 complete,DB06148,CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21,"Adrenergic Agents / Agents that produce hypertension / Antidepressive Agents / Antidepressive Agents, Second-Generation / Antidepressive Agents, Tetracyclic / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dibenzazepines / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Nervous System / Neurotransmitter Agents / Psychoanaleptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists",250PJI13LM,24219-97-4,,4184.0,4040.0,50222218.0,6929.0,51137.0,CHEMBL6437,DAP000293,PA134687937,
Teicoplanin,phase 4 complete,DB06149,,"Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Glycoconjugates / Glycopeptide Antibacterials / Glycopeptides / Lipids / Lipoglycopeptides / Lipopeptides / Peptides",4U3D3YY81M,61036-62-2,D02142,,,,57021.0,29687.0,,,PA164746244,
Sulfadimethoxine,phase 4 complete,DB06150,COC1=NC(OC)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1,Amides / Amines / Aniline Compounds / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Long-Acting Sulfonamides / Sulfanilamides / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds,30CPC5LDEX,122-11-2,D01142,5323.0,5132.0,50238669.0,10172.0,32161.0,CHEMBL62193,,PA165958357,ZINC000013233295
Nylidrin,phase 4 complete,DB06152,CC(CCC1=CC=CC=C1)NC(C)C(O)C1=CC=C(O)C=C1,"2-Amino-1-Phenylethanol Derivatives / Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-Agonists / Agents causing hyperkalemia / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Antiarrhythmic agents / Autonomic Agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Ethylamines / Genito Urinary System and Sex Hormones / Miscellaneous Vasodilatating Agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Peripheral Vasodilators / Phenethylamines / Propanolamines / Propanols / Reproductive Control Agents / Sympathomimetics / Sympathomimetics, Labour Repressants / Tocolytic Agents / Vasodilating Agents",695DKH33EI,447-41-6,,4567.0,4407.0,50240096.0,7595.0,91656.0,CHEMBL114655,,,
Pizotifen,phase 4 complete,DB06153,CN1CCC(CC1)=C1C2=C(CCC3=CC=CC=C13)SC=C2,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anticholinergic Agents / Antidepressive Agents / Antimigraine Agents, Miscellaneous / Antimigraine Preparations / Central Nervous System Agents / Central Nervous System Depressants / Histamine Antagonists / Histamine H1 Antagonists / Muscarinic Antagonists / Nervous System / Neurotransmitter Agents / Peripheral Nervous System Agents / Psychotropic Drugs / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT1D Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Thiophenes",0BY8440V3N,15574-96-6,,27400.0,25497.0,82088.0,8373.0,50212.0,CHEMBL294951,,,ZINC000000001968
Pentaerythritol tetranitrate,phase 4 complete,DB06154,[O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O,Alcohols / Antianginal Agents / Carbohydrates / Cardiac Therapy / Cardiovascular Agents / Drugs that are Mainly Renally Excreted / Fibrin Modulating Agents / Glycols / Hematologic Agents / Organic Nitrates / Polysaccharides / Propylene Glycols / Vasodilating Agents / Vasodilators Used in Cardiac Diseases,10L39TRG1Z,78-11-5,D01721,6518.0,6271.0,,7992.0,25879.0,CHEMBL466659,,,ZINC000008101167
Rimonabant,phase 4 complete,DB06155,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1,"Agents producing tachycardia / Alimentary Tract and Metabolism / Anti-Obesity Agents / Antiobesity Preparations, Excl. Diet Products / Cannabinoid Receptor Antagonists / Cannabinoids and similars / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Neurotransmitter Agents / Piperidines / Pyrazoles / Receptor, Cannabinoid, CB1, antagonists & inhibitors",RML78EN3XE,168273-06-1,D05731,104850.0,94641.0,21278.0,,34967.0,CHEMBL111,DNC001371,PA152407999,ZINC000001540228
Ruxolitinib,phase 4 complete,DB08877 (DB06164),N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Immunosuppressive Agents / Janus Kinases, antagonists & inhibitors / Kinase Inhibitor / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Protein Kinase Inhibitors / Tyrosine Kinase Inhibitors",82S8X8XX8H,941678-49-5,D09959,25126798.0,25027389.0,50355501.0,1193326.0,66919.0,CHEMBL1789941,,PA166123386,ZINC000043207851
Fedratinib,phase 4 complete,DB12500 (DB06165),CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C,Amides / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Sulfones / Sulfur Compounds / Tyrosine Kinase Inhibitors,6L1XP550I6,936091-26-8,,16722836.0,17626393.0,50332294.0,2197490.0,91408.0,CHEMBL1287853,,,ZINC000019862646
Glycerol phenylbutyrate,phase 4 complete,DB08909 (DB06170),O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1,"Acids, Carbocyclic / Alcohols / Alimentary Tract and Metabolism / Carbohydrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Nitrogen Binding Agent / Sugar Alcohols / Triose Sugar Alcohols / Urea Cycle Disorder Agents / Various Alimentary Tract and Metabolism Products",ZH6F1VCV7B,611168-24-2,D10127,10482134.0,8657541.0,,1368451.0,134745.0,CHEMBL2105745,,,
Noscapine,phase 4 complete,DB06174,[H][C@@]1(OC(=O)C2=C1C=CC(OC)=C2OC)[C@]1([H])N(C)CCC2=CC3=C(OCO3)C(OC)=C12,"Alkaloids / Antitussive Agents / Central Nervous System Agents / Cough and Cold Preparations / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Opiate Alkaloids / Opium Alkaloids and Derivatives / Respiratory System Agents",8V32U4AOQU,128-62-1,,,242139.0,50424716.0,7533.0,73237.0,CHEMBL364713,,,ZINC000019418974
Romidepsin,phase 4 complete,DB06176,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,"Amino Acids, Peptides, and Proteins / Antibiotics, Antineoplastic / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Highest Risk QTc-Prolonging Agents / Histone Deacetylase Inhibitors / Narrow Therapeutic Index Drugs / OATP1B3 substrates / P-glycoprotein substrates / Peptides / Peptides, Cyclic / QTc Prolonging Agents",CX3T89XQBK,128517-07-7,D06637,57515973.0,10122002.0,19151.0,877510.0,61080.0,CHEMBL343448,,PA166161306,ZINC000003935130
Pixantrone,phase 4 complete,DB06193,NCCNC1=CC=C(NCCN)C2=C1C(=O)C1=C(C=NC=C1)C2=O,"Anthracyclines and Related Substances / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytotoxic Antibiotics and Related Substances / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",F5SXN2KNMR,144510-96-3,,134019.0,118174.0,,,135945.0,CHEMBL167731,,,ZINC000001535903
Icatibant,phase 4 complete,DB06196,[H][C@]12C[C@]([H])(N(C(=O)[C@@]3([H])CC4=C(CN3C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)[C@]3([H])C[C@@H](O)CN3C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C=CC=C4)[C@@]1([H])CCCC2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O,"Agents causing angioedema / Amino Acids, Peptides, and Proteins / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Antirheumatic Agents / Autacoids / Biological Factors / Blood and Blood Forming Organs / Bradykinin B2 Receptor Antagonists / Bradykinin Receptor Antagonists / Central Nervous System Agents / Complement Inactivating Agents / Drugs that are Mainly Renally Excreted / Drugs Used in Hereditary Angioedema / Immunologic Factors / Inflammation Mediators / Intercellular Signaling Peptides and Proteins / Kinins / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptides / Peripheral Nervous System Agents / Proteins / Sensory System Agents",7PG89G35Q7,130308-48-4,D04492,71364.0,5293384.0,50406750.0,1148138.0,68556.0,CHEMBL2028850,DCL000131,PA164749185,
Rufinamide,phase 4 complete,DB06201,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1,Anticonvulsants / Carboxamide Derivatives / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (weak) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Membrane Transport Modulators / Miscellaneous Anticonvulsants / Nervous System / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers,WFW942PR79,106308-44-5,D05775,129228.0,114471.0,,69036.0,134966.0,CHEMBL1201754,,PA166131606,ZINC000000007782
Lasofoxifene,phase 4 complete,DB06202,[H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1,Genito Urinary System and Sex Hormones / Naphthalenes / Selective Estrogen Receptor Modulators / Sex Hormones and Modulators of the Genital System,337G83N988,180916-16-9,D04672,216416.0,187585.0,20606.0,,,CHEMBL328190,,,ZINC000003918428
Alogliptin,phase 4 complete,DB06203,CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O,"Agents causing angioedema / Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / DPP-IV Inhibitors / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Enzyme Inhibitors / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Incretins / Protease Inhibitors / Pyrimidines / Pyrimidinones",JHC049LO86,850649-61-5,D06553,11450633.0,9625485.0,16285.0,1368001.0,72323.0,CHEMBL376359,,,ZINC000014961096
Tapentadol,phase 4 complete,DB06204,CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1,Adrenergic Agents / Adrenergic Uptake Inhibitors / Analgesics / Antidepressive Agents / Benzene Derivatives / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Membrane Transport Modulators / Narcotics / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Opiate Agonists / Opioid Agonist / Opioids / Peripheral Nervous System Agents / Phenols / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / UGT1A9 Substrates / UGT2B7 substrates,H8A007M585,175591-23-8,D06007,9838022.0,8013742.0,50386381.0,787390.0,135935.0,CHEMBL1201776,,PA166179720,ZINC000000020783
Sugammadex,phase 4 complete,DB06206,O[C@@H]1[C@@H](O)[C@@H]2O[C@H]3O[C@H](CSCCC(O)=O)[C@@H](O[C@H]4O[C@H](CSCCC(O)=O)[C@@H](O[C@H]5O[C@H](CSCCC(O)=O)[C@@H](O[C@H]6O[C@H](CSCCC(O)=O)[C@@H](O[C@H]7O[C@H](CSCCC(O)=O)[C@@H](O[C@H]8O[C@H](CSCCC(O)=O)[C@@H](O[C@H]9O[C@H](CSCCC(O)=O)[C@@H](O[C@H]1O[C@@H]2CSCCC(O)=O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,"Antidotes / Biopolymers / Carbohydrates / Compounds used in a research, industrial, or household setting / Cyclodextrins / Dextrins / Diet, Food, and Nutrition / Dietary Carbohydrates / Food / Food and Beverages / gamma-Cyclodextrins / Glucans / Macromolecular Substances / Physiological Phenomena / Polymers / Polysaccharides / Starch",361LPM2T56,343306-71-8,D05940,6918585.0,32689915.0,,1726988.0,90953.0,CHEMBL2111107,,,
Silodosin,phase 4 complete,DB06207,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F,"Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs Used in Benign Prostatic Hypertrophy / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / P-glycoprotein substrates / Peripheral alpha-1 blockers / Selective Alfa-1-adrenergic Blocking Agents / UGT2B7 substrates / Urological Agents / Urologicals",CUZ39LUY82,160970-54-7,D01965,5312125.0,4471557.0,50160154.0,720825.0,135929.0,CHEMBL24778,,PA165291889,ZINC000003806063
Prasugrel,phase 4 complete,DB06209,CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1,Anticoagulants / Antiplatelet agents / Blood and Blood Forming Organs / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Decreased Platelet Aggregation / Drugs that are Mainly Renally Excreted / Hematologic Agents / P2Y12 Platelet Inhibitor / Piperazines / Platelet Aggregation Inhibitors Excl. Heparin / Purinergic P2Y Receptor Antagonists / Sulfur Compounds / Thiophenes,34K66TBT99,150322-43-3,D05597,6918456.0,5293653.0,,613391.0,87723.0,CHEMBL1201772,,PA154410481,
Eltrombopag,phase 4 complete,DB06210,CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1,"Acids, Carbocyclic / BCRP/ABCG2 Inhibitors / Benzene Derivatives / Blood and Blood Forming Organs / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hematinics / Hemostatics / Increased Megakaryocyte Maturation / Increased Platelet Production / OATP1B1/SLCO1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Thrombopoietin Receptor Agonist / Thrombopoietin Receptor Agonists / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT1A3 Inhibitors / UGT1A3 substrates / UGT1A4 Inhibitors / UGT1A6 Inhibitors / UGT1A9 Inhibitors / UGT2B15 Inhibitors / UGT2B7 Inhibitors",S56D65XJ9G,496775-61-2,D03978,9846180.0,19879943.0,,711942.0,85010.0,CHEMBL461101,,,ZINC000011679756
Doripenem,phase 4 complete,DB06211,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Carbapenems / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / OAT3/SLC22A8 Substrates / Penem Antibacterial / Sulfur Compounds",BHV525JOBH,148016-81-3,D03895,73303.0,66040.0,50088382.0,119771.0,135928.0,CHEMBL491571,,,ZINC000003922770
Tolvaptan,phase 4 complete,DB06212,CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2,"Agents causing hyperkalemia / Antidiuretic Hormone Receptor Antagonists / Benzazepines / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Diuretics / Heterocyclic Compounds, Fused-Ring / Natriuretic Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Vasopressin V2 Receptor Antagonist / Vasopressin V2 Receptor Antagonists",1E2497LPNY,150683-30-0,D01213,443894.0,391976.0,,358257.0,,CHEMBL344159,,,ZINC000000538658
Regadenoson,phase 4 complete,DB06213,CNC(=O)C1=CN(N=C1)C1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(N)=N1,"Adenosine A2 Receptor Agonists / Cardiac Therapy / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / Purinergic Agents / Purinergic Agonists / Purinergic P1 Receptor Agonists",7AXV542LZ4,313348-27-5,D05711,219024.0,189859.0,50119132.0,1546015.0,135613.0,CHEMBL317052,,PA166129536,ZINC000013818943
Ferumoxytol,phase 4 complete,DB06215,[O--].[O--].[O--].[O--].[Fe++].[Fe+3].[Fe+3],"Compounds used in a research, industrial, or household setting / Ferric Compounds / Ferrous Compounds / Hematinics / Hematologic Agents / Iron Compounds / Magnetic Resonance Contrast Activity / Minerals / Organometallic Compounds / Paramagnetic Contrast Agent / Parenteral Iron Replacement / Parenteral Nutrition Solutions / Pharmaceutical Preparations / Pharmaceutical Solutions / Solutions",G6N3J05W84,722492-56-0,D04177,16211978.0,4937312.0,,473387.0,50821.0,,,,
Asenapine,phase 4 complete,DB06216,OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1,"Acid Reducers / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diazepines, Oxazepines, Thiazepines and Oxepines / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H2 Antagonists / Hyperglycemia-Associated Agents / Nervous System / Neurotoxic agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Agonists / Serotonin Receptor Antagonists / Tranquilizing Agents / UGT1A4 substrates",JKZ19V908O,65576-45-6,D02995,11954293.0,10128588.0,,784649.0,71253.0,CHEMBL3544974,,,
Vernakalant,phase 4 complete,DB06217,COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1,"Antiarrhythmic agents / Antiarrhythmics, Class III / Benzene Derivatives / Cardiac Therapy / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Ethers / Methyl Ethers / Phenols / Phenyl Ethers / Potential QTc-Prolonging Agents / QTc Prolonging Agents",9G468C8B13,794466-70-9,D06665,9930049.0,8105680.0,,,135956.0,CHEMBL2111112,,,ZINC000022010910
Lacosamide,phase 4 complete,DB06218,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,"Acetamides / Acetates / Acids, Acyclic / Alkanes / Amides / Anti-epileptic Agent / Anticonvulsants / Bradycardia-Causing Agents / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Decreased Central Nervous System Disorganized Electrical Activity / Fatty Acids / Fatty Acids, Volatile / Hydrocarbons, Acyclic / Lipids / Membrane Transport Modulators / Miscellaneous Anticonvulsants / Nervous System / Sodium Channel Blockers / Voltage-Gated Sodium Channel Blockers",563KS2PQY5,175481-36-4,D07299,219078.0,189902.0,50300204.0,623400.0,135939.0,CHEMBL58323,,PA166160048,ZINC000000007673
Dalbavancin,phase 4 complete,DB06219,,"Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Glycoconjugates / Glycopeptide Antibacterials / Glycopeptides / Lipids / Lipoglycopeptide Antibacterial / Lipoglycopeptides / Lipopeptides / Peptides",808UI9MS5K,171500-79-1,D03640,23724878.0,30791917.0,,1539239.0,82721.0,CHEMBL3301669,,,
Rivaroxaban,phase 4 complete,DB06228 (DB08477),ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Anticoagulants / Antithrombins / BCRP/ABCG2 Substrates / Blood and Blood Forming Organs / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Factor Xa Inhibitors / Hematologic Agents / Morpholines / Oxazines / P-glycoprotein substrates / Protease Inhibitors / Serine Protease Inhibitors / Sulfur Compounds / Thiophenes,9NDF7JZ4M3,366789-02-8,D07086,9875401.0,8051086.0,7840.0,1114195.0,68579.0,CHEMBL198362,,,ZINC000003964126
Nalmefene,phase 4 complete,DB06230,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C,"Alkaloids / Antipruritics / Appetite Depressants / Central Nervous System Agents / Drugs that are Mainly Renally Excreted / Drugs Used in Addictive Disorders / Drugs Used in Alcohol Dependence / Heterocyclic Compounds, Fused-Ring / Morphinans / Nervous System / Neuroprotective Agents / Opiate Alkaloids / Opioid Antagonists / Peripheral Nervous System Agents / Phenanthrenes / Sensory System Agents / UGT1A3 substrates / UGT2B7 substrates",TOV02TDP9I,55096-26-9,D05111,,4447642.0,50045776.0,31479.0,7457.0,CHEMBL982,,,ZINC000000403529
Avanafil,phase 4 complete,DB06237,COC1=C(Cl)C=C(CNC2=C(C=NC(=N2)N2CCC[C@H]2CO)C(=O)NCC2=NC=CC=N2)C=C1,"Cyclic Nucleotide Phosphodiesterases, Type 5 / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs Used in Erectile Dysfunction / Genito Urinary System and Sex Hormones / Phosphodiesterase 5 Inhibitors / Urologicals / Vasodilating Agents",DR5S136IVO,330784-47-9,D03217,9869929.0,8045620.0,235766.0,1291301.0,66876.0,CHEMBL1963681,,,ZINC000011677857
Eflornithine,phase 4 complete,DB06243,NCCCC(N)(C(F)F)C(O)=O,"Agents Against Leishmaniasis and Trypanosomiasis / Amino Acids / Amino Acids, Basic / Amino Acids, Diamino / Amino Acids, Peptides, and Proteins / Anti-Infective Agents / Antineoplastic Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Decarboxylase Inhibitor / Decarboxylase Inhibitors / Dermatologicals / Enzyme Inhibitors / Misc. Skin and Mucous Membrane Agents / Ornithine Decarboxylase Inhibitors / Trypanocidal Agents",ZQN1G5V6SR,70052-12-9,D07883,3009.0,2902.0,50028197.0,569.0,41948.0,CHEMBL830,,,
Arzoxifene,phase 4 complete,DB06249,COC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,Sulfur Compounds,E569WG6E60,182133-25-1,,,156104.0,19442.0,,,CHEMBL226267,,,ZINC000001544683
Hexaminolevulinate,phase 4 complete,DB06261,[H]N([H])CC(=O)CCC(=O)OCCCCCC,"Amino Acids / Amino Acids, Peptides, and Proteins / Carbon Radioisotopes / Keto Acids / Levulinic Acids / Other Diagnostics / Photosensitizing Agents",G7H20TKI67,140898-97-1,D04436,6433083.0,4938272.0,,1426872.0,134892.0,CHEMBL1201784,,,ZINC000001554392
Droxidopa,phase 4 complete,DB06262,N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O,"Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic and Dopaminergic Agents / Adrenergic beta-1 Receptor Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-3 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Acids / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Amino Alcohols / Anti-Dyskinesia Agents / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Catecholamines / Catechols / Central Nervous System Agents / Drugs that are Mainly Renally Excreted / Epinephrine and similars / Ethanolamines / Increased Blood Pressure / Phenols",J7A92W69L7,23651-95-8,D01277,92974.0,83927.0,50103611.0,1489913.0,31524.0,CHEMBL2103827,,PA164748386,ZINC000001482049
Udenafil,phase 4 complete,DB06267,CCCOC1=C(C=C(C=C1)S(=O)(=O)NCCC1CCCN1C)C1=NC(=O)C2=C(N1)C(CCC)=NN2C,Amides / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs Used in Erectile Dysfunction / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Phosphodiesterase 5 Inhibitors / Phosphodiesterase Inhibitors / Sulfones / Sulfur Compounds / Urologicals / Vasodilating Agents,L5IB4XLY36,268203-93-6,D10027,6918523.0,5293720.0,,,135926.0,CHEMBL2103849,DAP000960,PA164776753,
Sitaxentan,phase 4 complete,DB06268,CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl,Antihypertensive Agents / Antihypertensives for Pulmonary Arterial Hypertension / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Endothelin Receptor Antagonists / Sulfur Compounds,J9QH779MEM,184036-34-8,D07171,216235.0,187436.0,50058126.0,,135736.0,CHEMBL282724,,PA165958361,ZINC000001481831
Alvimopan,phase 4 complete,DB06274,C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1,"Alimentary Tract and Metabolism / Drugs for Constipation / Gastrointestinal Agents / Opioid Antagonists / Peripheral Opioid Receptor Antagonists / Receptors, Opioid, mu, antagonists & inhibitors",Q153V49P3Z,156053-89-3,D02878,5488548.0,4589864.0,50088381.0,480639.0,135686.0,CHEMBL270190,DAP001140,PA164754864,ZINC000003802417
Levocetirizine,phase 4 complete,DB06282,OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1,"Antihistamines for Systemic Use / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Neurotransmitter Agents / Piperazine Derivatives / Piperazines / Potential QTc-Prolonging Agents / QTc Prolonging Agents",6U5EA9RT2O,130018-77-8,D07402,1549000.0,1266001.0,85030.0,356887.0,94559.0,CHEMBL1201191,,,ZINC000019364230
Ziconotide,phase 4 complete,DB06283,,"Analgesics / Analgesics, Non-Narcotic / Antiarrhythmic agents / Calcium Channel Blockers / Calcium Channels, N-Type / Calcium-Regulating Hormones and Agents / Central Nervous System Agents / Central Nervous System Depressants / Complex Mixtures / Compounds used in a research, industrial, or household setting / Conotoxins / Fluids and Secretions / Marine Toxins / Membrane Transport Modulators / Mollusk Venoms / N-Calcium Channel Receptor Antagonists / Narrow Therapeutic Index Drugs / Nervous System / Neuroprotective Agents / Peripheral Nervous System Agents / Protective Agents / Sensory System Agents / Toxins, Biological / Vasodilating Agents / Venoms",7I64C51O16,107452-89-1,D06363,,,,68503.0,,CHEMBL2103752,,,
Temsirolimus,phase 4 complete,DB06287,OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC,Agents causing angioedema / Anti-Bacterial Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Kinase Inhibitor / Lactones / Macrolides / mTOR Inhibitors / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Polyketides / Protein Kinase Inhibitors / Sirolimus and Prodrugs,624KN6GM2T,162635-04-3,D06068,23724530.0,21468899.0,50343413.0,657797.0,79699.0,CHEMBL1201182,DAP001222,PA164746890,
Amisulpride,phase 4 complete,DB06288,CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC,"Acids, Carbocyclic / Amides / Antidepressive Agents / Antidepressive Agents, Second-Generation / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Potential QTc-Prolonging Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents",8110R61I4U,71675-85-9,D07310,2159.0,2074.0,81790.0,46303.0,64045.0,CHEMBL243712,DAP000848,PA162565877,
Simeprevir,phase 4 complete,DB06290,[H][C@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C1C=CC(OC)=C2C)C1=NC(=CS1)C(C)C)C(=O)NS(=O)(=O)C1CC1,"Amides / Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / BSEP/ABCB11 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / HCV NS3/4A Protease Inhibitors / HCV Protease Inhibitors / Heterocyclic Compounds, Fused-Ring / NS3/4A Protease Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / OATP1B3 substrates / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B3 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Photosensitizing Agents / Protease Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds",9WS5RD66HZ,923604-59-5,D10081,24873435.0,23331536.0,50336504.0,1482790.0,134743.0,CHEMBL501849,,,ZINC000085540268
Icosapent ethyl,phase 4 complete,DB08887 (DB06291),CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC,"Antiplatelet agents / Autacoids / Biological Factors / Diet, Food, and Nutrition / Dietary Fats / Dietary Fats, Unsaturated / Eicosanoids / Fats / Fatty Acids / Fatty Acids, Omega-3 / Fatty Acids, Unsaturated / Fish Oils / Food / Food and Beverages / Hematologic Agents / Hypolipidemic Agents / Inflammation Mediators / Lipids / Miscellaneous Antilipemic Agents / Oils / Physiological Phenomena",6GC8A4PAYH,86227-47-6,D01892,9831415.0,8007147.0,,1304974.0,84883.0,CHEMBL2095209,,,ZINC000003785276
Dapagliflozin,phase 4 complete,DB06292,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1,"Alimentary Tract and Metabolism / Benzene Derivatives / Blood Glucose Lowering Agents / Carbohydrates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Diuretics / Drugs Used in Diabetes / Glycosides / Hypotensive Agents / P-glycoprotein substrates / Sodium-glucose co-transporter 2 (SGLT2) inhibitors / Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors / Sodium-Glucose Transport Proteins, antagonists & inhibitors / Sodium-Glucose Transporter 2 Inhibitors / UGT1A9 Substrates / UGT2B7 substrates",1ULL0QJ8UC,461432-26-8,D08897,9887712.0,8063384.0,20880.0,1488564.0,85078.0,CHEMBL429910,,,ZINC000003819138
Ponatinib,phase 4 complete,DB08901 (DB06300),CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Hepatotoxic Agents / Immunosuppressive Agents / Kinase Inhibitor / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors / Tyrosine Kinase Inhibitors,4340891KFS,943319-70-8,D09950,24826799.0,24747381.0,50322535.0,1364347.0,78543.0,CHEMBL1171837,,PA165980594,ZINC000036701290
Saxagliptin,phase 4 complete,DB06335,[H][C@@]12C[C@]1([H])N([C@@H](C2)C#N)C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,"Agents causing angioedema / Alimentary Tract and Metabolism / Amino Acids, Peptides, and Proteins / Blood Glucose Lowering Agents / Cycloparaffins / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / DPP-IV Inhibitors / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Enzyme Inhibitors / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypoglycemia-Associated Agents / Incretins / OAT3/SLC22A8 Substrates / Oligopeptides / Peptides / Protease Inhibitors",8I7IO46IVQ,361442-04-8,D08996,11243969.0,9419005.0,50225074.0,1546030.0,71272.0,CHEMBL385517,,PA165958362,
Plecanatide,phase 4 complete,DB13170 (DB06377),[H][C@@]12CSSC[C@H](NC(=O)CNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O,"Alimentary Tract and Metabolism / Amino Acids, Peptides, and Proteins / Drugs for Constipation / Enzyme Activators / Gastrointestinal Agents / Guanylate Cyclase Activators / Guanylate Cyclase-C Agonist / Guanylyl Cyclase C Agonists / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Laxatives / Peptide Hormones / Peptides / Receptors, Guanylate Cyclase-Coupled, agonists",7IK8Z952OK,467426-54-6,,70693500.0,28530494.0,,1873752.0,,CHEMBL2103867,,,
Bazedoxifene,phase 4 complete,DB06401,CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1,"Bone Density Conservation Agents / Estrogen Agonist/Antagonist / Estrogen Receptor Modulators / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Selective Estrogen Receptor Modulators / Sex Hormones and Modulators of the Genital System / UGT1A1 Substrates",Q16TT9C5BK,198481-32-2,D03062,154257.0,135921.0,50099585.0,1441386.0,135947.0,CHEMBL46740,,,ZINC000001895505
Telavancin,phase 4 complete,DB06402,CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2=C3OC4=CC=C(C=C4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]4C(C=C2OC2=C(Cl)C=C(C=C2)[C@@H](O)[C@@H]2NC(=O)[C@H](NC4=O)C4=CC(=C(O)C=C4)C4=C(O)C(CNCP(O)(O)=O)=C(O)C=C4[C@H](NC2=O)C(O)=O)=C3)O[C@@H](C)[C@H]1O,"Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Drugs that are Mainly Renally Excreted / Glycoconjugates / Glycopeptide Antibacterials / Glycopeptides / Glycosides / Lipids / Lipoglycopeptide Antibacterial / Lipopeptides / Moderate Risk QTc-Prolonging Agents / Peptides / QTc Prolonging Agents",XK134822Z0,372151-71-8,,3081362.0,2338980.0,,473837.0,71229.0,CHEMBL507870,,,
Ambrisentan,phase 4 complete,DB06403,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1,"Acids, Carbocyclic / Antihypertensive Agents / Antihypertensives for Pulmonary Arterial Hypertension / Cardiovascular Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Endothelin Receptor Antagonists / Hypertension, Pulmonary / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / UGT1A3 substrates / UGT1A9 Substrates / UGT2B7 substrates / Vasodilating Agents",HW6NV07QEC,177036-94-1,,6918493.0,5293690.0,50146710.0,358274.0,135949.0,CHEMBL1111,,PA165860521,ZINC000000538627
Doxercalciferol,phase 4 complete,DB06410,[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\[C@H](C)C(C)C,"Anti-Parathyroid Agents / Bone Density Conservation Agents / Calcium Homeostasis / Cholestanes / Cholestenes / Diet, Food, and Nutrition / Food / Food and Beverages / Fused-Ring Compounds / Growth Substances / Lipids / Membrane Lipids / Micronutrients / Physiological Phenomena / Secosteroids / Steroids / Sterols / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Vitamin D and Analogues / Vitamins / Vitamins (Fat Soluble)",3DIZ9LF5Y9,54573-75-0,D01009,46705423.0,4444554.0,,11516.0,4712.0,CHEMBL1200810,,,ZINC000004641374
Oxymetholone,phase 4 complete,DB06412,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O,"Alimentary Tract and Metabolism / Anabolic Agents / Anabolic Agents for Systemic Use / Anabolic Steroids / Androgens / Androstan Derivatives / Androstanes / Androstanols / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Steroids / Thyroxine-binding globulin inhibitors",L76T0ZCA8K,434-07-1,D00490,5281034.0,4444502.0,,7813.0,7864.0,CHEMBL1200585,,,ZINC000118912450
Armodafinil,phase 4 complete,DB06413,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1,"Benzene Derivatives / Benzhydryl Compounds / Central Nervous System Agents / Central Nervous System Stimulants / Centrally Acting Sympathomimetics / Chemically-Induced Disorders / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Nervous System / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Wakefulness-Promoting Agents",V63XWA605I,112111-43-0,D03215,9690109.0,7962943.0,50336892.0,641465.0,77590.0,CHEMBL1201192,,,ZINC000003831139
Etravirine,phase 4 complete,DB06414 (DB07191),CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N,Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor / Non-Nucleoside Reverse Transcriptase Inhibitors / Nonnucleoside Reverse Transcriptase Inhibitors / Nucleic Acid Synthesis Inhibitors / P-glycoprotein inducers / Reverse Transcriptase Inhibitors,0C50HW4FO1,269055-15-4,D04112,193962.0,168313.0,50103642.0,475969.0,63589.0,CHEMBL308954,,PA166014703,ZINC000000602632
Calfactant,phase 4 complete,DB06415,,Alveolar Surface Tension Reduction / Bradycardia-Causing Agents / Complex Mixtures / Pulmonary Surfactants / Respiratory System Agents / Surface-Active Agents / Surfactant Activity,Q4K217VGA9,183325-78-2,D03317,,,,232539.0,,CHEMBL1201447,,,
Tyloxapol,phase 4 complete,DB06439,,"Alcohols / Compounds used in a research, industrial, or household setting / Cough and Cold Preparations / Detergents / Ethylene Glycols / Expectorants / Glycols / Household Products / Macromolecular Substances / Polymers / Surface-Active Agents",Y27PUL9H56,25301-02-4,D03261,,26330335.0,,38998.0,,CHEMBL1201548,DCL000254,PA164743726,
Cangrelor,phase 4 complete,DB06441,CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1,"Adenine Nucleotides / Anticoagulants / Antiplatelet agents / Blood and Blood Forming Organs / Carbohydrates / Decreased Platelet Aggregation / Glycosides / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / Nucleic Acids, Nucleotides, and Nucleosides / Nucleotides / P2Y12 Platelet Inhibitor / Platelet Aggregation Inhibitors Excl. Heparin / Purine Nucleotides / Purinergic Agents / Purinergic Antagonists / Purinergic P2 Receptor Antagonists / Purinergic P2Y Receptor Antagonists / Purines / Ribonucleotides",6AQ1Y404U7,163706-06-7,D03359,9854012.0,8029718.0,50118225.0,1656052.0,90841.0,CHEMBL334966,,PA165945763,ZINC000085537017
Prucalopride,phase 4 complete,DB06480,COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1,"Alimentary Tract and Metabolism / Antidepressive Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Drugs for Constipation / Drugs that are Mainly Renally Excreted / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Laxatives / Miscellaneous GI Drugs / Neurotransmitter Agents / P-glycoprotein substrates / Serotonin Agents",0A09IUW5TP,179474-81-8,,3052762.0,2314539.0,50122872.0,2107310.0,135552.0,CHEMBL117287,,,ZINC000001891034
Pitavastatin,phase 4 complete,DB08860 (DB06514),O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O,"Agents Causing Muscle Toxicity / Anticholesteremic Agents / BCRP/ABCG2 Substrates / BSEP/ABCB11 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / Toxic Actions / UGT1A3 substrates / UGT2B7 substrates",M5681Q5F9P,147511-69-1,D01862,5282452.0,4445604.0,86707.0,861634.0,32020.0,CHEMBL1201753,,PA142650384,ZINC000001534965
Vilanterol,phase 4 complete,DB09082 (DB06577),OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl,"Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Alcohols / Benzene Derivatives / Benzyl Compounds / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Drugs that are Mainly Renally Excreted / Hydrocarbons, Chlorinated / Hydrocarbons, Halogenated / Immunosuppressive Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents",028LZY775B,503068-34-6,D09696,10184665.0,8360167.0,50416060.0,1424884.0,75037.0,CHEMBL1198857,,,ZINC000003991624
Pazopanib,phase 4 complete,DB06589,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1,"Amides / Angiogenesis Inhibitors / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hepatotoxic Agents / Immunosuppressive Agents / Kinase Inhibitor / Moderate Risk QTc-Prolonging Agents / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors / QTc Prolonging Agents / Receptors, Vascular Endothelial Growth Factor, antagonists & inhibitors / Sulfones / Sulfur Compounds / Tyrosine Kinase Inhibitors / UGT1A1 Inhibitors",7RN5DR86CK,444731-52-6,D05380,10113978.0,8289501.0,26474.0,714438.0,71219.0,CHEMBL477772,,,ZINC000011617039
Ceftaroline fosamil,phase 4 complete,DB06590,[H][C@]12SCC(SC3=NC(=CS3)C3=CC=[N+](C)C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC)\C1=NSC(NP(O)(O)=O)=N1)C([O-])=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Sulfur Compounds / Thiazines",7P6FQA5D21,229016-73-3,D08884,9852981.0,8028692.0,,1040004.0,70718.0,CHEMBL501122,,,
Agomelatine,phase 4 complete,DB06594,COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1,"Acetates / Acids, Acyclic / Amides / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Fatty Acids / Fatty Acids, Volatile / Lipids / Melatonin, agonists / Nervous System / Psychoanaleptics / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists",137R1N49AD,138112-76-2,D02578,82148.0,74141.0,50035179.0,,134990.0,CHEMBL10878,,PA165958363,ZINC000000005608
Midostaurin,phase 4 complete,DB06595,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1,"Alkaloids / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Carbazoles / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strong) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strong) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 CYP3A7 Inducers / Cytochrome P-450 CYP3A7 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Indole Alkaloids / Indoles / Kinase Inhibitor / Protein Kinase C, antagonists & inhibitors / Protein Kinase Inhibitors / Receptor Tyrosine Kinase Inhibitors / Tyrosine Kinase Inhibitors",ID912S5VON,120685-11-2,D05029,9829523.0,8005258.0,50326053.0,1919083.0,63452.0,CHEMBL608533,,,ZINC000100013130
Betrixaban,phase 4 complete,DB12364 (DB06601),COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1,"Acids, Carbocyclic / Amides / Anticoagulants / Antithrombins / Benzene Derivatives / Benzoates / Enzyme Inhibitors / Factor Xa Inhibitors / Hematologic Agents / P-glycoprotein substrates / Protease Inhibitors / Serine Protease Inhibitors",74RWP7W0J9,330942-05-7,,10275777.0,18981107.0,50249298.0,1927851.0,140421.0,CHEMBL512351,,,ZINC000030691754
Panobinostat,phase 4 complete,DB06603,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1,"Amines / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Histone Deacetylase Inhibitors / Hydroxamic Acids / Hydroxy Acids / Hydroxylamines / Immunosuppressive Agents / Indoles / Moderate Risk QTc-Prolonging Agents / P-glycoprotein substrates / QTc Prolonging Agents",9647FM7Y3Z,404950-80-7,D10019,6918837.0,5294028.0,29589.0,1603350.0,85990.0,CHEMBL483254,,PA166161307,ZINC000022010649
Apixaban,phase 4 complete,DB06605 (DB07828),COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O,Anticoagulants / Antithrombins / BCRP/ABCG2 Substrates / Blood and Blood Forming Organs / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Factor Xa Inhibitors / Hematologic Agents / P-glycoprotein substrates / Protease Inhibitors / Pyridines / Serine Protease Inhibitors,3Z9Y7UWC1J,503612-47-3,D03213,10182969.0,8358471.0,19023.0,1364430.0,72296.0,CHEMBL231779,,PA166163740,ZINC000011677837
Tafenoquine,phase 4 complete,DB06608,COC1=CC(C)=C2C(OC3=CC=CC(=C3)C(F)(F)F)=C(OC)C=C(NC(C)CCCN)C2=N1,"Aminoquinolines / Anti-Infective Agents / Antimalarials / Antiparasitic Agents / Antiprotozoals / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / OCT2 Inhibitors / Quinolines",262P8GS9L9,106635-80-7,,,103196.0,,2054023.0,141487.0,CHEMBL298470,,PA166115580,
Bosutinib,phase 4 complete,DB06616,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,"Amines / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Kinase Inhibitor / Myelosuppressive Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Protein Kinase Inhibitors / Tyrosine Kinase Inhibitors",5018V4AEZ0,380843-75-4,D03252,5328940.0,4486102.0,4552.0,1307619.0,39112.0,CHEMBL288441,,,ZINC000022448983
Axitinib,phase 4 complete,DB06626,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1,"Acids, Carbocyclic / Amides / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Indazoles / Kinase Inhibitor / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors / Pyrazoles / Receptor Tyrosine Kinase Inhibitors / Tyrosine Kinase Inhibitors / UGT1A1 Substrates",C9LVQ0YUXG,319460-85-0,D03218,6450551.0,4953153.0,25117.0,1242999.0,66910.0,CHEMBL1289926,,PA164924493,ZINC000003816287
Isavuconazonium,phase 4 complete,DB06636,[H]C(C)(OC(=O)N(C)C1=C(COC(=O)CNC)C=CC=N1)[N+]1=CN(C[C@](O)(C2=C(F)C=CC(F)=C2)[C@@]([H])(C)C2=NC(=CS2)C2=CC=C(C=C2)C#N)N=C1,Anti-Infective Agents / Antifungal Agents / Azole Antifungals / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Isavuconazole and Prodrugs / P-glycoprotein inhibitors,VH2L779W8Q,742049-41-8,D10643,6918606.0,5293801.0,,1608322.0,85978.0,CHEMBL1183349,,,
Dalfampridine,phase 4 complete,DB06637,NC1=CC=NC=C1,Amines / Aminopyridines / Cardiovascular Agents / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Membrane Transport Modulators / Nervous System / OCT2 Substrates / OCT2 substrates with narrow therapeutic index / Other Miscellaneous Therapeutic Agents / Potassium Channel Antagonists / Potassium Channel Blockers / Pyridines,BH3B64OKL9,504-24-5,D04127,1727.0,1664.0,10458.0,897018.0,34385.0,CHEMBL284348,,PA166123389,ZINC000000599985
Safinamide,phase 4 complete,DB06654,C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O,"Agents that produce hypertension / Agents that reduce seizure threshold / Amines / Amino Acids / Amino Acids, Peptides, and Proteins / Anti-Parkinson Drugs / Antidepressive Agents / BCRP/ABCG2 Inhibitors / Benzene Derivatives / Benzyl Compounds / Breast Cancer Resistance Protein Inhibitors / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dopamine Agents / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Monoamine Oxidase B Inhibitors / Monoamine Oxidase Inhibitors / Nervous System / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",90ENL74SIG,133865-89-1,,131682.0,116349.0,50078694.0,1922448.0,134718.0,CHEMBL396778,,,ZINC000053084692
Pasireotide,phase 4 complete,DB06663,NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1,"Amino Acids, Peptides, and Proteins / Bradycardia-Causing Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Hypoglycemia-Associated Agents / Hypothalamic Hormones / Nerve Tissue Proteins / Neuropeptides / Pancreatic Hormones / Peptide Hormones / Peptides / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormone Release Inhibiting Hormones / Potential QTc-Prolonging Agents / Proteins / QTc Prolonging Agents / Somatostatin Agonists / Somatostatin and Analogues / Somatostatin Receptor Agonists / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",98H1T17066,396091-73-9,D10147,9941444.0,8117062.0,,1364105.0,72312.0,CHEMBL3349607,,,
Vilazodone,phase 4 complete,DB06684,NC(=O)C1=CC2=CC(=CC=C2O1)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1,"Agents that produce hypertension / Antidepressive Agents / Benzofurans / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Indoles / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Piperazines / Psychoanaleptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Agonists",S239O2OOV3,163521-12-8,D09698,6918314.0,5293518.0,50151982.0,1086769.0,70707.0,CHEMBL439849,,,ZINC000001542113
Ethanolamine oleate,phase 4 complete,DB06689,NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O,"Antivaricose Therapy / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Fatty Acids / Fatty Acids, Monounsaturated / Fatty Acids, Unsaturated / Lipids / Pharmaceutical Preparations / Pharmaceutical Solutions / Sclerosing Agents for Local Injection / Sclerosing Solutions / Solutions / Vasoprotectives",U4RY8MRX7C,2272-11-9,D02276,5282489.0,4445632.0,,24460.0,,CHEMBL3989529,,PA164746758,
Nitrous oxide,phase 4 complete,DB06690,[N-]=[N+]=O,"Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anesthetics / Anesthetics, General / Anesthetics, Inhalation / Anions / Central Nervous System Agents / Central Nervous System Depressants / Electrolytes / Gases / Ions / Methemoglobinemia Associated Agents / Nervous System / Nitrogen Compounds / Nitrogen Oxides / Oxides / Oxygen Compounds / Peripheral Nervous System Agents / Sensory System Agents",K50XQU1029,10024-97-2,D00102,948.0,923.0,,7486.0,17045.0,CHEMBL1234579,,PA450645,
Mepyramine,phase 4 complete,DB06691,COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1,"Amines / Aminopyridines / Anti-Allergic Agents / Antihistamines for Systemic Use / Antihistamines for Topical Use / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Hypnotics and Sedatives / Neurotransmitter Agents / Potential QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents / Sleep Aids, Pharmaceutical / Substituted Ethylene Diamines",HPE317O9TL,91-84-9,D08183,4992.0,4818.0,22567.0,9009.0,6762.0,CHEMBL511,,PA165817939,ZINC000019144216
Xylometazoline,phase 4 complete,DB06694,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C,"Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Antiarrhythmic agents / Antihistamine Drugs / Calcium Channel Blockers / Cardiovascular Agents / Decongestants and Antiallergics / Nasal Decongestants / Nasal Preparations / Ophthalmologicals / Respiratory System Agents / Sensory Organs / Sympathomimetics Used as Decongestants / Sympathomimetics, Plain / Vasoconstrictor Agents / Vasodilating Agents",WPY40FTH8K,526-36-3,D08684,5709.0,5507.0,30703.0,39841.0,10082.0,CHEMBL312448,,PA165958368,ZINC000000057534
Dabigatran etexilate,phase 4 complete,DB06695,CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1,"Anticoagulants / Antithrombins / Benzimidazoles / Blood and Blood Forming Organs / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hematologic Agents / Heterocyclic Compounds, Fused-Ring / P-glycoprotein substrates / Protease Inhibitors / Pyridines / Serine Protease Inhibitors / UGT1A9 Substrates / UGT2B7 substrates",2E18WX195X,211915-06-9,D07144,6445226.0,4948999.0,50432209.0,1037042.0,70746.0,CHEMBL539697,,PA165958369,ZINC000003943279
Artemether,phase 4 complete,DB06697,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OC)[C@@H]2C)O4,"Anions / Anti-Infective Agents / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Artemisinin and Derivatives, Plain / Artemisinins / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (weak) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Electrolytes / Free Radicals / Highest Risk QTc-Prolonging Agents / Ions / Oxides / Oxygen Compounds / Peroxides / QTc Prolonging Agents / Reactive Oxygen Species / Sesquiterpenes / Terpenes",C7D6T3H22J,71963-77-4,D02483,68911.0,62138.0,50022886.0,18343.0,195280.0,CHEMBL566534,,PA165111698,ZINC000014263142
Betahistine,phase 4 complete,DB06698,CNCCC1=CC=CC=N1,Antivertigo Preparations / Cardiovascular Agents / Histamine Agents / Histamine Agonists / Histamine Antagonists / Miscellaneous Central Nervous System Agents / Miscellaneous Therapeutic Agents / Nervous System / Neurotransmitter Agents / Pyridines / Vasodilating Agents,X32KK4201D,5638-76-6,D07522,2366.0,2276.0,96589.0,1511.0,35677.0,CHEMBL24441,,PA165958372,ZINC000001675415
Degarelix,phase 4 complete,DB06699,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,"Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Endocrine Therapy / Gonadotropin-releasing Hormone Antagonists / Gonadotropin-Releasing Hormone, antagonists & inhibitors / Hormone Antagonists and Related Agents / Peptides / Potential QTc-Prolonging Agents / QTc Prolonging Agents",SX0XJI3A11,214766-78-6,D08901,16136245.0,17292756.0,50102450.0,475230.0,135961.0,CHEMBL415606,,PA165958373,
Desvenlafaxine,phase 4 complete,DB06700,CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1,Agents producing tachycardia / Agents that reduce seizure threshold / Alcohols / Antidepressive Agents / Benzene Derivatives / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cyclohexanes / Cyclohexanols / Cycloparaffins / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fatty Alcohols / Hexanols / Hypoglycemia-Associated Agents / Lipids / Membrane Transport Modulators / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Norepinephrine Uptake Inhibitors / Phenols / Psychoanaleptics / Psychotropic Drugs / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin and Noradrenaline Reuptake Inhibitors / Serotonin Modulators,NG99554ANW,93413-62-8,D07793,125017.0,111300.0,86748.0,734064.0,83527.0,CHEMBL1118,,PA165958374,
Dexmethylphenidate,phase 4 complete,DB06701,[H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1,"Agents that produce hypertension / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Central Nervous System Stimulants / Central Nervous System Stimulation / Centrally Acting Sympathomimetics / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Dopamine Agents / Dopamine Uptake Inhibitors / Membrane Transport Modulators / Methylphenidate and isomer / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Phenylacetates / Piperidines / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators",M32RH9MFGP,40431-64-9,,154101.0,135807.0,50062915.0,352372.0,51860.0,CHEMBL827,,PA10054,ZINC000000896711
Fesoterodine,phase 4 complete,DB06702,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C,Agents producing tachycardia / Anticholinergic Agents / Benzene Derivatives / Cholinergic Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Urinary Frequency and Incontinence / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Muscarinic Antagonists / Neurotransmitter Agents / P-glycoprotein substrates / Urological Agents / Urologicals,621G617227,286930-02-7,D07226,6918558.0,5293755.0,,797195.0,135920.0,CHEMBL1201764,,PA165958376,ZINC000001552908
Gadobutrol,phase 4 complete,DB06703,OC[C@H](O)[C@H](CO)[N+]12CC[N+]3(CC([O-])=O)CC[N+]4(CC([O-])=O)CC[N+](CC([O-])=O)(CC1)[Gd-]234,"Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Gadolinium-based Contrast Agent / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / Other Diagnostics / Paramagnetic Contrast Media",1BJ477IO2L,770691-21-9,D07420,70678987.0,28533281.0,,84990.0,68841.0,CHEMBL2218860,,PA165958377,
Iobenguane,phase 4 complete,DB06704 (DB09497),NC(N)=NCC1=CC(I)=CC=C1,"Amidines / Benzene Derivatives / Compounds used in a research, industrial, or household setting / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Enzyme Inhibitors / Guanidines / Hydrocarbons, Halogenated / Hydrocarbons, Iodinated / Indicators and Reagents / Iodine (131I) Compounds / Iodobenzenes / Laboratory Chemicals / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Therapeutic Radiopharmaceuticals / Tumour Detection",35MRW7B4AD,80663-95-2,D04559,60860.0,54847.0,,14448.0,92769.0,CHEMBL818,,,ZINC000001538318
Gadofosveset trisodium,phase 4 complete,DB06705,[Na+].[Na+].[Na+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC(COP([O-])(=O)OC1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1)N(CC([O-])=O)CC([O-])=O,"Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Elements / Gadolinium-based Contrast Agent / Lanthanoid Series Elements / Magnetic Resonance Angiography / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / Metals / Metals, Rare Earth / Paramagnetic Contrast Agent / Paramagnetic Contrast Media",9430ZR8ZAN,193901-90-5,D04286,73049652.0,58829621.0,,1364289.0,,CHEMBL1908362,,PA165958378,
Isometheptene,phase 4 complete,DB06706,CNC(C)CCC=C(C)C,Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alimentary Tract and Metabolism / Amines / Drugs for Functional Gastrointestinal Disorders / Methemoglobinemia Associated Agents,Y7L24THH6T,503-01-5,,22297.0,21106328.0,,27946.0,134765.0,CHEMBL1697841,,PA165958379,
Levonordefrin,phase 4 complete,DB06707,C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1,Adrenergic Agonists / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Cardiovascular Agents / Catecholamines / Catechols / Epinephrine and similars / Ethanolamines / Phenols / Vasoconstrictor Agents,V008L6478D,829-74-3,D02388,164739.0,144416.0,50223426.0,132889.0,10304.0,CHEMBL677,,PA165958380,ZINC000000034157
Lumefantrine,phase 4 complete,DB06708,CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1,"Anti-Infective Agents / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Fluorenes / Highest Risk QTc-Prolonging Agents / QTc Prolonging Agents",F38R0JR742,82186-77-4,D03821,6437380.0,4941944.0,50238630.0,847728.0,156095.0,CHEMBL38827,,PA165111722,
Methacholine,phase 4 complete,DB06709,CC(C[N+](C)(C)C)OC(C)=O,Amines / Ammonium Compounds / Autonomic Agents / Bronchoconstrictor Agents / Cholinergic Agents / Cholinergic Agonists / Cholinergic Receptor Agonist / Methacholine Compounds / Miotics / Muscarinic Agonists / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Other Diagnostics / Parasympathomimetics / Peripheral Nervous System Agents / Quaternary Ammonium Compounds / Respiratory System Agents / Trimethyl Ammonium Compounds,03V657ZD3V,55-92-5,,1993.0,1916.0,48918.0,155080.0,6804.0,CHEMBL978,,PA165958382,
Methyltestosterone,phase 4 complete,DB06710,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"3-Oxoandrosten (4) Derivatives / Anabolic Agents / Androgens / Androgens and Estrogens / Androstanes / Androstenes / Androstenols / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OAT3/SLC22A8 Inducers / Sex Hormones and Modulators of the Genital System / Steroids / Testosterone Congeners / Thyroxine-binding globulin inhibitors",V9EFU16ZIF,58-18-4,D00408,6010.0,5788.0,50410531.0,6904.0,27436.0,CHEMBL1395,,PA165958383,ZINC000003814422
Naphazoline,phase 4 complete,DB06711,C(C1=NCCN1)C1=CC=CC2=CC=CC=C12,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Cardiovascular Agents / Decongestants and Antiallergics / Imidazoles / Nasal Decongestants / Nasal Preparations / Neurotransmitter Agents / Ophthalmologicals / Respiratory System Agents / Sensory Organs / Sympathomimetics Used as Decongestants / Sympathomimetics, Plain / Vasoconstrictor Agents",H231GF11BV,835-31-4,D08253,4436.0,4283.0,50001922.0,7247.0,93363.0,CHEMBL761,,PA165958384,ZINC000000119717
Nilvadipine,phase 4 complete,DB06712,COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N,Agents causing hyperkalemia / Antiarrhythmic agents / Antihypertensive Agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Dihydropyridines / Hypotensive Agents / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,0214FUT37J,75530-68-6,D01908,4494.0,4338.0,50103634.0,53692.0,31911.0,CHEMBL517427,,PA165958385,
Norelgestromin,phase 4 complete,DB06713,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NO,"Adrenal Cortex Hormones / Amines / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hydroxylamines / Norpregnanes / Norpregnenes / Norsteroids / Pharmaceutical Preparations / Progestins / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",R0TAY3X631,53016-31-2,D05205,62930.0,56648.0,,326374.0,135398.0,CHEMBL1200807,,,ZINC000410428674
Propylhexedrine,phase 4 complete,DB06714,CNC(C)CC1CCCCC1,Amines,LQU92IU8LL,101-40-6,D05637,7558.0,7277.0,,8792.0,134783.0,CHEMBL2105275,,PA165958387,
Potassium Iodide,phase 4 complete,DB06715,[K+].[I-],Anions / Antidotes / Antithyroid agents / Cough and Cold Preparations / Electrolytes / Expectorants / Iodides / Iodine Compounds / Ions / Minerals / Ophthalmologicals / Potassium Compounds / Potassium Salt / Sensory Organs / Thyroid Products,1C4QK22F9J,7681-11-0,D01016,4875.0,4709.0,,8597.0,8346.0,CHEMBL1141,,PA451060,
Fosaprepitant,phase 4 complete,DB06717,C[C@@H](O[C@H]1OCCN(CC2=NC(=O)N(N2)P(O)(O)=O)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,Antiemetics / Aprepitant and Prodrugs / Autonomic Agents / Central Nervous System Agents / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Gastrointestinal Agents / Miscellaneous Antiemetics / Morpholines / Neurokinin 1 Antagonists / Neurokinin-1 Receptor Antagonists / Neurotransmitter Agents / Oxazines / Peripheral Nervous System Agents / Substance P/Neurokinin-1 Receptor Antagonist,6L8OF9XRDC,172673-20-0,D06597,219090.0,189912.0,,1731071.0,64321.0,CHEMBL1199324,,PA165958390,ZINC000003939013
Stanozolol,phase 4 complete,DB06718,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C,"Alimentary Tract and Metabolism / Anabolic Agents / Anabolic Agents for Systemic Use / Anabolic Steroids / Androgens / Androstan Derivatives / Androstanes / Androstanols / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Steroids / Thyroxine-binding globulin inhibitors",4R1VB9P8V3,10418-03-8,D00444,25249.0,23582.0,,10032.0,9249.0,CHEMBL2079587,,PA165958391,ZINC000004097376
Aluminum hydroxide,phase 4 complete,DB06723,[OH-].[OH-].[OH-].[Al+3],"Acids / Acids, Noncarboxylic / Adjuvants, Immunologic / Alimentary Tract and Metabolism / Alkalies / Aluminium Compounds / Aluminum and magnesium containing antacids / Anions / Antacids / Antacids and Adsorbents / Carbon Compounds, Inorganic / Carbonic Acid / Drugs for Acid Related Disorders / Electrolytes / Gastric Acid Lowering Agents / Gastrointestinal Agents / Hydroxides / Immunologic Factors / Ions / Metal cations / Metal divalent cations / Miscellaneous Local Anti-infectives",5QB0T2IUN0,21645-51-2,,10176082.0,8351587.0,,81948.0,33130.0,CHEMBL1200706,,,
Calcium carbonate,phase 4 complete,DB06724,[Ca++].[O-]C([O-])=O,"Acids / Acids, Noncarboxylic / Alimentary Tract and Metabolism / Alkalies / Anions / Antacids / Antacids and Adsorbents / Blood Coagulation Factors / Calcium Compounds / Calcium Salts / Carbon Compounds, Inorganic / Carbonates / Carbonic Acid / Drugs for Acid Related Disorders / Electrolytes / Gastric Acid Lowering Agents / Gastrointestinal Agents / Ions / Mineral Supplements / Minerals / Phosphate Binder / Polyvalent cation containing laxatives, antacids, oral supplements / Replacement Preparations",H0G9379FGK,471-34-1,D00932,10112.0,9708.0,,1897.0,3311.0,CHEMBL1200539,,PA448726,
Lornoxicam,phase 4 complete,DB06725,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Oxicams / Peripheral Nervous System Agents / Sensory System Agents / Sulfur Compounds / Thiazines",ER09126G7A,70374-39-9,D01866,54690031.0,10442760.0,92331.0,20890.0,31783.0,CHEMBL1569487,,PA165958395,ZINC000100015491
Sulfaphenazole,phase 4 complete,DB06729,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1,Amides / Amines / Aniline Compounds / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Intermediate-Acting Sulfonamides / Long-Acting Sulfonamides / Ophthalmologicals / Pyrazoles / Sensory Organs / Sulfanilamides / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds,0J8L4V3F81,526-08-9,D01954,5335.0,5144.0,50090677.0,,77780.0,CHEMBL1109,,PA130231310,ZINC000000057490
Aceclofenac,phase 4 complete,DB06736,OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,"Acetic Acid Derivatives and Related Substances / Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antirheumatic Agents / Central Nervous System Agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Musculo-Skeletal System / Nephrotoxic agents / Peripheral Nervous System Agents / Phenylacetates / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory System Agents / Topical Products for Joint and Muscular Pain",RPK779R03H,89796-99-6,D01545,71771.0,64809.0,50109016.0,16689.0,31159.0,CHEMBL93645,,PA166049185,ZINC000003805798
Ambroxol,phase 4 complete,DB06742,NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1,Adrenergics for Systemic Use / Amines / Aniline Compounds / Cough and Cold Preparations / Cyclohexanes / Cyclohexylamines / Cycloparaffins / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Expectorants / Respiratory System Agents / Selective Beta 2-adrenergic Agonists,200168S0CL,18683-91-5,,2132.0,10276826.0,50395322.0,625.0,135590.0,CHEMBL153479,,,ZINC000100070274
Drotaverine,phase 4 complete,DB06751,CCOC1=C(OCC)C=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1,"Alimentary Tract and Metabolism / Alkaloids / Analgesics / Autonomic Agents / Benzylisoquinolines / Cardiovascular Agents / Central Nervous System Agents / Drugs for Functional Gastrointestinal Disorders / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Opiate Alkaloids / Papaverine and Derivatives / Parasympatholytics / Peripheral Nervous System Agents / Sensory System Agents / Vasodilating Agents",98QS4N58TW,14009-24-6,,1712095.0,1361582.0,50237620.0,23684.0,135630.0,CHEMBL551978,,PA165958398,ZINC000100011979
Triclofos,phase 4 complete,DB06753,OP(O)(=O)OCC(Cl)(Cl)Cl,Central Nervous System Depressants / Hypnotics and Sedatives / Nervous System / Organophosphorus Compounds / Psycholeptics,J712EO9048,306-52-5,D08634,,5362.0,,38610.0,9695.0,CHEMBL1201317,,,ZINC000003831574
Danaparoid,phase 4 complete,DB06754,,Agents causing hyperkalemia / Anticoagulants / Blood and Blood Forming Organs / Carbohydrates / Cardiovascular Agents / Chondroitin / Fibrin Modulating Agents / Fibrinolytic Agents / Glycosaminoglycans / Hematologic Agents / Heparin and similars / Heparinoids / Polysaccharides,BI6GY4U9CW,308068-55-5,,,,,78484.0,,,,,
Beta carotene,phase 4 complete,DB06755,C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C,"Alimentary Tract and Metabolism / Alkenes / Biological Factors / Carotenoids / Cyclohexanes / Cyclohexenes / Cycloparaffins / Dermatologicals / Diet, Food, and Nutrition / Emollients and Protectives / Food / Food and Beverages / Growth Substances / Hydrocarbons, Acyclic / Micronutrients / Physiological Phenomena / Pigments, Biological / Polyenes / Protectives Against UV-Radiation / Protectives Against UV-Radiation for Systemic Use / Provitamins / Terpenes / Vitamin A / Vitamins / Vitamins (Fat Soluble)",01YAE03M7J,7235-40-7,D03101,5280489.0,4444129.0,54988.0,19143.0,17579.0,CHEMBL1293,,,ZINC000006845076
Glycine betaine,phase 4 complete,DB06756,C[N+](C)(C)CC([O-])=O,"Acid Preparations / Alimentary Tract and Metabolism / Amines / Amino Acids and Derivatives / Ammonium Compounds / Cholinesterase Inhibitors / Digestives, Incl. Enzymes / Gastrointestinal Agents / Hypolipidemic Agents / Lipid Regulating Agents / Lipotropic Agents / Methylating Activity / Methylating Agent / Nitrogen Compounds / Noxae / Onium Compounds / Other Miscellaneous Therapeutic Agents / Quaternary Ammonium Compounds / Toxic Actions / Trimethyl Ammonium Compounds",3SCV180C9W,107-43-7,D07523,247.0,242.0,50103520.0,1512.0,17750.0,CHEMBL1182,,,
Manganese,phase 4 complete,DB06757,[Mn++],"Acids / Acids, Noncarboxylic / Anions / Chlorine Compounds / Diet, Food, and Nutrition / Electrolytes / Elements / Food / Food and Beverages / Growth Substances / Ions / Magnetic Resonance Contrast Activity / Metals / Metals, Heavy / Micronutrients / Minerals / Paramagnetic Contrast Agent / Physiological Phenomena / Replacement Preparations / Sulfur Acids / Sulfur Compounds / Sulfuric Acids / Trace Elements / Transition Elements",H6EP7W5457,7439-96-5,D04854,27854.0,25916.0,,6623.0,29035.0,CHEMBL2103742,,,
Pinacidil,phase 4 complete,DB06762,CC(N\C(NC#N)=N\C1=CC=NC=C1)C(C)(C)C,"Amidines / Antihypertensive Agents / Arteriolar Smooth Muscle, Agents Acting On / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Guanidine Derivatives / Guanidines / Membrane Transport Modulators / Vasodilating Agents",BB4UGO5K0D,60560-33-0,,,4660.0,50240750.0,33717.0,91706.0,CHEMBL1159,,,
Tetryzoline,phase 4 complete,DB06764,C1CN=C(N1)C1CCCC2=CC=CC=C12,"Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Autonomic Agents / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Decongestants and Antiallergics / Nasal Decongestants / Nasal Preparations / Ophthalmic Solutions / Ophthalmologicals / Peripheral Nervous System Agents / Pharmaceutical Preparations / Pharmaceutical Solutions / Respiratory System Agents / Sensory Organs / Solutions / Sympathomimetics / Sympathomimetics Used as Decongestants / Sympathomimetics, Plain / Vasoconstrictor Agents",S9U025Y077,84-22-0,D08578,5419.0,5226.0,96559.0,37935.0,28674.0,CHEMBL1266,,,
Alcaftadine,phase 4 complete,DB06766,CN1CCC(CC1)=C1C2=NC=C(C=O)N2CCC2=CC=CC=C12,"Decongestants and Antiallergics / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Neurotransmitter Agents / Ophthalmologicals / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Sensory Organs",7Z8O94ECSX,147084-10-4,D06552,19371515.0,14201635.0,,1000082.0,71023.0,CHEMBL1201747,,PA165958399,ZINC000011726211
Ammonium chloride,phase 4 complete,DB06767,[NH4+].[Cl-],"Acidifiers / Acidifying Agents / Acids / Acids, Noncarboxylic / Agents causing hyperkalemia / Ammonium Compounds / Anions / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Chlorides / Chlorine Compounds / Drugs that are Mainly Renally Excreted / Electrolyte Solutions / Electrolytes / Genito Urinary System and Sex Hormones / I.V. Solution Additives / Ions / Nitrogen Compounds / Urinary Acidifying Agents / Urologicals",01Q9PC255D,12125-02-9,,25517.0,23807.0,,712.0,31206.0,CHEMBL1200939,,PA448392,
Ammonium lactate,phase 4 complete,DB06768,[NH4+].CC(O)C([O-])=O,alpha-Hydroxy Acid,67M901L9NQ,515-98-0,D02920,62358.0,56149.0,,215247.0,,CHEMBL1200747,,PA165958400,
Bendamustine,phase 4 complete,DB06769,CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl,"Acids, Acyclic / Alkylating Activity / Alkylating Drugs / Antineoplastic Agents / Antineoplastic Agents, Alkylating / Antineoplastic and Immunomodulating Agents / Benzimidazoles / Butyrates / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Fatty Acids / Fatty Acids, Volatile / Heterocyclic Compounds, Fused-Ring / Hydrocarbons, Halogenated / Immunosuppressive Agents / Lipids / Mustard Compounds / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Nitrogen Mustard Analogues / Nitrogen Mustard Compounds / Noxae / P-glycoprotein substrates with narrow therapeutic index / Toxic Actions",9266D9P3PQ,16506-27-7,D07085,65628.0,59069.0,173621.0,134547.0,135515.0,CHEMBL487253,,,ZINC000004214955
Benzyl alcohol,phase 4 complete,DB06770,OCC1=CC=CC=C1,"Alcohols / Anesthetics / Anesthetics, Local / Antiparasitic Products, Insecticides and Repellents / Benzene Derivatives / Benzyl Alcohols / Benzyl Compounds / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 Substrates / Ectoparasiticides, Incl. Scabicides / Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents / Pediculicides / Peripheral Nervous System Agents / Sensory System Agents",LKG8494WBH,100-51-6,D00077,244.0,13860335.0,,1426.0,17987.0,CHEMBL720,,PA448594,ZINC000000895302
Cabazitaxel,phase 4 complete,DB06772,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / Cardiotoxic antineoplastic agents / Cyclodecanes / Cycloparaffins / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Diterpenes / Immunosuppressive Agents / Microtubule Inhibition / Microtubule Inhibitors / Myelosuppressive Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Taxane Derivatives / Taxoids / Terpenes,51F690397J,183133-96-2,D09755,9854073.0,8029779.0,,996051.0,63584.0,CHEMBL1201748,,PA165958401,ZINC000085536932
Carglumic acid,phase 4 complete,DB06775,NC(=O)N[C@@H](CCC(O)=O)C(O)=O,"Alimentary Tract and Metabolism / Amino Acids / Amino Acids and Derivatives / Amino Acids, Acidic / Amino Acids, Dicarboxylic / Amino Acids, Peptides, and Proteins / Ammonia Detoxicants / Carbamoyl Phosphate Synthetase 1 Activator / Carbamoyl Phosphate Synthetase 1 Activators",5L0HB4V1EW,1188-38-1,D07130,121396.0,108351.0,,401713.0,71028.0,CHEMBL1201780,,PA165958402,ZINC000001530283
Sodium cellulose phosphate,phase 4 complete,DB06776,,"Biopolymers / Calcium Binder / Calcium Chelating Activity / Carbohydrates / Cation Exchange Resins / Compounds used in a research, industrial, or household setting / Drugs for Treatment of Hypercalcemia / Glucans / Macromolecular Substances / Polymers / Polysaccharides",E6S1NJ4Y5Q,9038-41-9,,,,,342965.0,,CHEMBL1201457,,,
Chenodeoxycholic acid,phase 4 complete,DB06777,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,Alimentary Tract and Metabolism / Bile Acid Preparations / Bile acids and derivatives / Bile Acids and Salts / Bile and Liver Therapy / Bile Therapy / Cholanes / Cholic Acids / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Gastrointestinal Agents / Steroids / UGT2B7 Inhibitors,0GEI24LG0J,474-25-9,D00163,10133.0,9728.0,21674.0,2323.0,16755.0,CHEMBL240597,,PA165958403,ZINC000003914808
Cupric sulfate,phase 4 complete,DB06778,[Cu++].[O-]S([O-])(=O)=O,"Acids / Acids, Noncarboxylic / Anions / Antidotes / Autonomic Agents / Central Nervous System Agents / Compounds used in a research, industrial, or household setting / Copper-containing Intrauterine Device / Electrolytes / Emetics / Gastrointestinal Agents / Ions / Peripheral Nervous System Agents / Protective Agents / Sulfates / Sulfur Acids / Sulfur Compounds / Sulfuric Acids",KUW2Q3U1VV,7758-98-7,,24462.0,22870.0,,21579.0,23414.0,CHEMBL604,,,
Dalteparin,phase 4 complete,DB06779,,Agents causing hyperkalemia / Anticoagulants / Blood and Blood Forming Organs / Carbohydrates / Cardiovascular Agents / Fibrin Modulating Agents / Fibrinolytic Agents / Glycosaminoglycans / Hematologic Agents / Heparin (Low Molecular Weight) / Heparin and similars / Polysaccharides,S79O08V79F,9005-49-6,D03353,,,,67109.0,,,,,
Desoxycorticosterone acetate,phase 4 complete,DB06780,[H][C@@]12CC[C@H](C(=O)COC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"Adrenal Cortex Hormones / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Desoxycorticosterone / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydroxycorticosteroids / Mineralocorticoids / Pregnanes / Pregnenediones / Pregnenes / Steroids",6E0A168OB8,56-47-3,D03698,,5737.0,,258333.0,34671.0,CHEMBL1200542,,,ZINC000004428527
Difluprednate,phase 4 complete,DB06781,[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids / Steroids, Fluorinated",S8A06QG2QE,23674-86-4,D01266,443936.0,391990.0,,23043.0,31485.0,CHEMBL1201749,,PA165958405,ZINC000004212945
Dimercaprol,phase 4 complete,DB06782,OCC(S)CS,"Antidotes / Chelating Agents / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Heavy Metal Antagonists / Metal Chelating Activity / Metal Chelator / Sequestering Agents / Sulfhydryl Compounds / Sulfur Compounds",0CPP32S55X,59-52-9,D00167,3080.0,2971.0,50103608.0,3445.0,64198.0,CHEMBL1597,,PA165958406,
Prussian blue,phase 4 complete,DB06783 (DB09538),[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N.N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N.N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N,"Acids / Acids, Noncarboxylic / Anions / Antidotes / Chelating Activity / Coloring Agents / Compounds used in a research, industrial, or household setting / Cyanides / Decorporation Agent / Electrolytes / Ferrous Compounds / Hydrogen Cyanide / Ion Exchange Activity / Ions / Iron Compounds / Nitrogen Compounds / Organometallic Compounds / Protective Agents",TLE294X33A,14038-43-8,,2724251.0,20074656.0,,24902.0,30069.0,,,,
Gallium citrate Ga-67,phase 4 complete,DB06784 (DB09412),[67Ga+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,Gallium / Gallium Radioisotopes / Radioactive Diagnostic Agent / Radiopharmaceutical Activity,4LJK511Z86,41183-64-6,,65430.0,58893.0,,272758.0,31645.0,CHEMBL1200994,,,
Ganirelix,phase 4 complete,DB06785,CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,"Amino Acids, Peptides, and Proteins / Anti-Gonadotropin-Releasing Hormones / Decreased GnRH Secretion / Gonadotropin Releasing Hormone Receptor Antagonists / Gonadotropin-releasing Hormone Antagonists / Gonadotropin-Releasing Hormone, antagonists & inhibitors / Hormone Antagonists / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypothalamic Hormones / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormone-Releasing Hormones / Proteins / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",IX503L9WN0,124904-93-4,D08010,16130957.0,17287671.0,50102454.0,35825.0,135910.0,CHEMBL1251,,,
Halcinonide,phase 4 complete,DB06786,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Very Potent (Group IV) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Immunosuppressive Agents / Pregnanes / Pregnenediones / Pregnenes / Steroids",SI86V6QNEG,3093-35-4,D01308,443943.0,391997.0,50240097.0,5084.0,31663.0,CHEMBL1200845,,,ZINC000004213474
Hexocyclium,phase 4 complete,DB06787,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,"Agents producing tachycardia / Alimentary Tract and Metabolism / Anticholinergic Agents / Drugs for Functional Gastrointestinal Disorders / Muscarinic Antagonists / Synthetic Anticholinergics, Quaternary Ammonium Compounds",LL3147PI1T,6004-98-4,,24199.0,22621.0,81959.0,26867.0,5707.0,CHEMBL1201325,,,
Histrelin,phase 4 complete,DB06788,CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CN(CC2=CC=CC=C2)C=N1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1,"Adrenal Cortex Hormones / Amino Acids, Peptides, and Proteins / Antineoplastic and Immunomodulating Agents / Endocrine Therapy / Gonadotropin Releasing Hormone Receptor Agonist / Gonadotropin Releasing Hormone Receptor Agonists / Gonadotropin-releasing hormone agonist / Hormones / Hormones and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Hypothalamic Hormones / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary Hormone-Releasing Hormones / Potential QTc-Prolonging Agents / Proteins / QTc Prolonging Agents",QMG7HLD1ZE,76712-82-8,D02369,56927879.0,26606349.0,,50975.0,63530.0,CHEMBL1201255,,,
Hydroxyprogesterone caproate,phase 4 complete,DB06789,[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"Adrenal Cortex Hormones / Antineoplastic Agents / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Corpus Luteum Hormones / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Estrogen Antagonists / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormone Antagonists / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydroxyprogesterones / Hyperglycemia-Associated Agents / Pregnanes / Pregnenediones / Pregnenes / Progesterone and Derivatives / Progesterone Congeners / Progestin Contraceptives / Progestins / Steroids",276F2O42F5,630-56-8,D00949,169870.0,148552.0,70293.0,12488.0,5812.0,CHEMBL1200848,,,ZINC000004083606
Iron sucrose,phase 4 complete,DB09146 (DB06790),O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,"Acids, Acyclic / Carbohydrates / Disaccharides / Drugs for Treatment of Hyperkalemia and Hyperphosphatemia / Ferric Compounds / Hydroxy Acids / Iron Compounds / Iron Preparations / Iron Trivalent, Oral Preparations / Oligosaccharides / Organometallic Compounds / Pharmaceutical Preparations / Phosphate Binder / Phosphate-removing Agents / Polysaccharides / Sugar Acids",FZ7NYF5N8L,8047-67-4,,91663255.0,32699616.0,,1484283.0,,CHEMBL1200823,,,
Lanreotide,phase 4 complete,DB06791,[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H],"Acromegaly / Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Bradycardia-Causing Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Hypoglycemia-Associated Agents / Hypothalamic Hormones / Nerve Tissue Proteins / Neuropeptides / Other Miscellaneous Therapeutic Agents / Pancreatic Hormones / Peptide Hormones / Peptides / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormone Release Inhibiting Hormones / Proteins / Somatostatin and Analogues / Somatostatin Receptor Agonists / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",0G3DE8943Y,108736-35-2,D04666,71349.0,64450.0,,68092.0,,CHEMBL1201185,,,
Lanthanum carbonate,phase 4 complete,DB06792,[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O,"Drugs for Treatment of Hyperkalemia and Hyperphosphatemia / Elements / Kidney Failure, Chronic / Lanthanoid Series Elements / Metal cations / Metals / Metals, Rare Earth / Phosphate Binder / Phosphate-removing Agents",0M78EU4V9H,587-26-8,,168924.0,147758.0,,1311070.0,,CHEMBL2096647,,,
Lodoxamide,phase 4 complete,DB06794,OC(=O)C(=O)NC1=CC(=CC(NC(=O)C(O)=O)=C1Cl)C#N,"Acids, Aldehydic / Alcohols / Amino Acids / Amino Acids, Peptides, and Proteins / Anti-Allergic Agents / Antioxidants / Decongestants and Antiallergics / Decreased Histamine Release / Glycols / Glyoxylates / Histamine Agents / Mast Cell Stabilizers / Neurotransmitter Agents / Ophthalmologicals / Propylene Glycols / Sensory Organs",SPU695OD73,53882-12-5,D04762,44564.0,40543.0,50259889.0,52151.0,135333.0,CHEMBL1201266,,,ZINC000002000707
Mafenide,phase 4 complete,DB06795,NCC1=CC=C(C=C1)S(N)(=O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Local / Dermatologicals / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Methemoglobinemia Associated Agents / Sulfonamide Antibacterial / Sulfonamides / Sulfones / Sulfur Compounds",58447S8P4L,138-39-6,D02351,3998.0,3858.0,10860.0,6572.0,6633.0,CHEMBL419,,,ZINC000000001644
Mangafodipir,phase 4 complete,DB06796,[Mn++].CC1=C(O)C(CN(CCN(CC([O-])=O)CC2=CC(COP(O)(O)=O)=NC(C)=C2O)CC([O-])=O)=CC(COP(O)(O)=O)=N1,"Acetates / Acids, Acyclic / Amines / Coenzymes / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Diamines / Drugs that are Mainly Renally Excreted / Enzymes and Coenzymes / Ethylenediamines / Fatty Acids / Fatty Acids, Volatile / Lipids / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / Paramagnetic Contrast Agent / Paramagnetic Contrast Media / Picolines / Polyamines / Pyridines",N02W67RKJS,155319-91-8,,131704299.0,32700460.0,,236987.0,,,,,
Mebutamate,phase 4 complete,DB06797,CCC(C)C(C)(COC(N)=O)COC(N)=O,Anti-Anxiety Agents / Carbamates / Central Nervous System Depressants / Nervous System / Psycholeptics,5H8F175RER,64-55-1,D01807,,5919.0,,,31804.0,CHEMBL1200922,,,
Methylnaltrexone,phase 4 complete,DB06800,C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35,"Alimentary Tract and Metabolism / Alkaloids / Amines / Ammonium Compounds / Central Nervous System Agents / Drugs for Constipation / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Miscellaneous GI Drugs / Morphinans / Narcotics / Nitrogen Compounds / Onium Compounds / Opiate Alkaloids / Opioid Antagonists / Peripheral Nervous System Agents / Peripheral Opioid Receptor Antagonists / Phenanthrenes / Sensory System Agents",0RK7M7IABE,916055-93-1,D06618,16089915.0,17248532.0,,29899.0,,CHEMBL1186579,,,ZINC000245204949
Nepafenac,phase 4 complete,DB06802,NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N,"Acetamides / Acetates / Acids, Acyclic / Acids, Carbocyclic / Agents causing hyperkalemia / Amides / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antirheumatic Agents / Benzene Derivatives / Central Nervous System Agents / Cyclooxygenase Inhibitors / Fatty Acids / Fatty Acids, Volatile / Lipids / Nephrotoxic agents / Ophthalmologicals / Peripheral Nervous System Agents / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory Organs / Sensory System Agents",0J9L7J6V8C,78281-72-8,D05143,151075.0,133160.0,50228731.0,298665.0,75922.0,CHEMBL1021,,PA165958407,ZINC000005162311
Niclosamide,phase 4 complete,DB06803,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O,"Agrochemicals / Amides / Amines / Anilides / Aniline Compounds / Anthelmintics / Anti-Infective Agents / Anticestodal Agents / Anticestodals / Antinematodal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiplatyhelmintic Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Molluscacides / Pesticides / Salicylamides / Salicylanilides / Salicylic Acid Derivatives / Toxic Actions",8KK8CQ2K8G,50-65-7,D00436,4477.0,4322.0,11242.0,7402.0,7553.0,CHEMBL1448,,PA165958408,ZINC000003874496
Nonoxynol-9,phase 4 complete,DB06804,CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1,"Adrenal Cortex Hormones / Alcohols / Antispermatogenic Agents / Compounds used in a research, industrial, or household setting / Contraceptive Agents, Female / Contraceptive Agents, Male / Ethylene Glycols / Glycols / Hormonal Contraceptives for Systemic Use / Macromolecular Substances / Noxae / Polyethylene Glycols / Polymers / Reproductive Control Agents / Spermatocidal Agents / Surface-Active Agents / Toxic Actions",48Q180SH9T,26027-38-3,D06490,72385.0,65319.0,50442874.0,53750.0,53775.0,CHEMBL1410,,PA450648,ZINC000008214629
Phenyl aminosalicylate,phase 4 complete,DB06807,NC1=CC(O)=C(C=C1)C(=O)OC1=CC=CC=C1,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Hydroxy Acids / Hydroxybenzoates / Phenols / Salicylates",52936SIP7V,133-11-9,,,8290.0,,,114203.0,CHEMBL1200868,,,ZINC000000119905
Plerixafor,phase 4 complete,DB06809,C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1,"Adjuvants, Immunologic / Anti-HIV Agents / Anti-Infective Agents / Antineoplastic and Immunomodulating Agents / Drugs that are Mainly Renally Excreted / Hematinics / Hematopoietic Stem Cell Mobilizer / Increased Hematopoietic Stem Cell Mobilization",S915P5499N,110078-46-1,D08971,65015.0,58531.0,50035696.0,733003.0,125354.0,CHEMBL18442,,PA165958410,ZINC000022443609
Plicamycin,phase 4 complete,DB06810,CO[C@@H]([C@@H]1CC2=CC3=CC(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)=C(C)C(O)=C3C(O)=C2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O,"Anthracyclines / Antibiotics, Antineoplastic / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Calcium-Regulating Hormones and Agents / Carbohydrates / Coloring Agents / Compounds used in a research, industrial, or household setting / Cytotoxic Antibiotics and Related Substances / Enzyme Inhibitors / Fluorescent Dyes / Glycosides / Indicators and Reagents / Laboratory Chemicals / Luminescent Agents / Naphthacenes / Nucleic Acid Synthesis Inhibitors / Protein Synthesis Inhibitors",NIJ123W41V,18378-89-7,D00468,163659.0,143544.0,,6995.0,31856.0,CHEMBL1237054,,PA165958411,
Polidocanol,phase 4 complete,DB06811,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,"Alcohols / Antivaricose Therapy / Cardiovascular Agents / Compounds used in a research, industrial, or household setting / Detergents / Ethylene Glycols / Glycols / Household Products / Macromolecular Substances / Pegylated agents / Pharmaceutical Preparations / Pharmaceutical Solutions / Polyethylene Glycols / Polymers / Sclerosing Activity / Sclerosing Agents for Local Injection / Sclerosing Solutions / Solutions / Surface-Active Agents / Vascular Sclerosing Activity / Vasoprotectives",0AWH8BFG9A,9002-92-0,D01993,656641.0,570993.0,,968170.0,46859.0,CHEMBL1231723,,,ZINC000008214662
Povidone-iodine,phase 4 complete,DB06812,,"Alkenes / Anti-Infective Agents / Anti-Infective Agents, Local / Antifungal Agents (Vaginal) / Antiseptics and Disinfectants / Compounds used in a research, industrial, or household setting / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Hydrocarbons, Acyclic / Iodine Compounds / Iodine Products / Iodophors / Irrigating Solutions / Macromolecular Substances / Medicated Dressings / Medicated Dressings With Antiinfectives / Medicated Shampoos / Miscellaneous Local Anti-infectives / Ophthalmologicals / Plastics / Polyenes / Polymers / Polyvinyls / Pyrrolidines / Pyrrolidinones / Sensory Organs / Throat Preparations / Vinyl Compounds",85H0HZU99M,25655-41-8,D00863,,,,8611.0,8347.0,CHEMBL1201724,,,
Protokylol,phase 4 complete,DB06814,CC(CC1=CC=C2OCOC2=C1)NCC(O)C1=CC=C(O)C(O)=C1,Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents to Treat Airway Disease / Alcohols / Amines / Amino Alcohols / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Catecholamines / Catechols / Dioxoles / Epinephrine and similars / Ethanolamines / Phenols,8Y5Y4EEO2V,136-70-9,,,4798.0,,,135413.0,CHEMBL1201273,,,
Pyrithione,phase 4 complete,DB06815,[O-][N+]1=C(S)C=CC=C1,Anti-Infective Agents / Antifungal Agents / Dermatologicals / Drugs that are Mainly Renally Excreted / Gallium Radioisotopes / Indium Radioisotopes / Keratolytic Agents / Miscellaneous Local Anti-infectives / Radiopharmaceuticals / Sulfur Compounds,6GK82EC25D,1121-31-9,,26041.0,10446934.0,50366038.0,35100.0,36584.0,CHEMBL1356238,,,ZINC000000156822
Pyrvinium,phase 4 complete,DB06816,CN(C)C1=CC2=C(C=C1)[N+](C)=C(\C=C\C1=C(C)N(C(C)=C1)C1=CC=CC=C1)C=C2,"Anthelmintics / Anti-Infective Agents / Antinematodal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Heterocyclic Compounds, Fused-Ring / Quinolines / Quinolinium Compounds",6B9991FLU3,7187-62-4,,5281035.0,21125.0,,35163.0,8687.0,CHEMBL1201303,,,ZINC000003831401
Sulconazole,phase 4 complete,DB06820,ClC1=CC=C(CSC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Azole Antifungals / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Imidazole and Triazole Derivatives,5D9HAA5Q5S,61318-90-9,D08535,5318.0,5127.0,31770.0,37319.0,77776.0,CHEMBL1221,,,
Sulfameter,phase 4 complete,DB06821,COC1=CN=C(NS(=O)(=O)C2=CC=C(N)C=C2)N=C1,"Amides / Amines / Aniline Compounds / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Leprostatic Agents / Long-Acting Sulfonamides / Renal Agents / Sulfanilamides / Sulfonamide Antibacterial / Sulfonamides / SULFONAMIDES AND TRIMETHOPRIM / Sulfones / Sulfur Compounds",3L179F09D6,651-06-9,D02517,,5135.0,,,53727.0,CHEMBL1200359,,,ZINC000000049142
Tinzaparin,phase 4 complete,DB06822,,Agents causing hyperkalemia / Anticoagulants / Blood and Blood Forming Organs / Carbohydrates / Cardiovascular Agents / Fibrin Modulating Agents / Fibrinolytic Agents / Glycosaminoglycans / Hematologic Agents / Heparin (Low Molecular Weight) / Heparin and similars / Polysaccharides,7UQ7X4Y489,9041-08-1,D06398,,,,104466.0,,,,,
Tiopronin,phase 4 complete,DB06823,CC(S)C(=O)NCC(O)=O,"Amino Acids / Amino Acids, Peptides, and Proteins / Amino Acids, Sulfur / Cystine Disulfide Reduction / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / N-substituted Glycines / Peptides / Peptoids / Reducing and Complexing Thiol / Sulfur Compounds / Urologicals",C5W04GO61S,1953-02-2,D01430,5483.0,5283.0,50020805.0,6765.0,32229.0,CHEMBL1314,,,
Triethylenetetramine,phase 4 complete,DB06824,NCCNCCNCCN,"Alimentary Tract and Metabolism / Amines / Chelating Agents / Compounds used in a research, industrial, or household setting / Diamines / Drugs that are Mainly Renally Excreted / Ethylenediamines / Metal Chelating Activity / Metal Chelator / Polyamines / Sequestering Agents / Various Alimentary Tract and Metabolism Products",SJ76Y07H5F,112-24-3,,5565.0,21106175.0,50323751.0,10798.0,39501.0,CHEMBL609,,,ZINC000019364225
Triptorelin,phase 4 complete,DB06825,CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,"Adrenal Cortex Hormones / Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Antineoplastic and Immunomodulating Agents / Endocrine Therapy / Gonadotropin Releasing Hormone Receptor Agonist / Gonadotropin Releasing Hormone Receptor Agonists / Gonadotropin-releasing hormone agonist / Hormones / Hormones and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Hypothalamic Hormones / Luteolytic Agents / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary Hormone-Releasing Hormones / Potential QTc-Prolonging Agents / Proteins / QTc Prolonging Agents / Reproductive Control Agents",9081Y98W2V,57773-63-4,D06247,25074470.0,17290424.0,,38782.0,63633.0,CHEMBL1201334,,,
Unoprostone,phase 4 complete,DB06826,CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,"Antiglaucoma Preparations and Miotics / Antihypertensive Agents / Autacoids / Biological Factors / Cardiovascular Agents / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Inflammation Mediators / Lipids / Ophthalmologicals / Prostaglandins / Prostaglandins F / Prostaglandins, Synthetic / Sensory Organs",6X4F561V3W,120373-36-6,,5311236.0,4470755.0,,1546408.0,39455.0,CHEMBL1201407,,,ZINC000008214703
Viomycin,phase 4 complete,DB06827,[H][C@@]1(C[C@H](O)NC(=N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC1=O)NC(=O)C[C@@H](N)CCCN)=C\NC(N)=O,"Agents that produce neuromuscular block (indirect) / Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Antibiotics, Antitubercular / Antituberculosis Agents / Enzyme Inhibitors / Neurotoxic agents / Peptides / Peptides, Cyclic / Protein Synthesis Inhibitors",YVU35998K5,32988-50-4,,3037981.0,2301596.0,,,15782.0,CHEMBL3085436,,,ZINC000049799668
Chloramphenicol succinate,phase 4 complete,DB07565,O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O,Alcohols / Anti-Bacterial Agents / Anti-Infective Agents / Benzene Derivatives / Glycols / Narrow Therapeutic Index Drugs / Nitro Compounds / Nitrobenzenes / P-glycoprotein substrates / Propylene Glycols,ZCX619U9A1,3544-94-3,,656580.0,570947.0,,20769.0,3606.0,CHEMBL1201281,,,ZINC000001532336
Flavone,phase 4 complete,DB07776 (DB11139),O=C1C=C(OC2=CC=CC=C12)C1=CC=CC=C1,"Benzopyrans / Chromones / Flavones / Flavonoids / Heterocyclic Compounds, Fused-Ring / Pyrans",S2V45N7G3B,525-82-6,,10680.0,10230.0,50028962.0,1536070.0,42491.0,CHEMBL275638,,,ZINC000000057674
Tofacitinib,phase 4 complete,DB08895 (DB08183),[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,"Antineoplastic and Immunomodulating Agents / Antirheumatic Agents / Biologics for Rheumatoid Arthritis Treatment / Bradycardia-Causing Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Disease-modifying Antirheumatic Agents / Enzyme Inhibitors / Immunosuppressive Agents / Janus Kinase 3, antagonists & inhibitors / Janus Kinase Inhibitor / Janus Kinase Inhibitors / Myelosuppressive Agents / Protein Kinase Inhibitors / Selective Immunosuppressants",87LA6FU830,477600-75-2,D09970,9926791.0,8102425.0,50193995.0,1357536.0,71200.0,CHEMBL221959,,,ZINC000003818808
Parecoxib,phase 4 complete,DB08439,CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / COX-2 Inhibitors / Cyclooxygenase Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Peripheral Nervous System Agents / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) / Sensory System Agents",9TUW81Y3CE,198470-84-7,D02709,119828.0,106990.0,,279950.0,73038.0,CHEMBL1206690,,PA166049193,ZINC000005761797
Triclosan,phase 4 complete,DB08604,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,"Anti-Infective Agents / Anti-Infective Agents, Local / Antiseptics and Disinfectants / Benzene Derivatives / Dermatologicals / Ethers / Fatty Acid Synthesis Inhibitors / Hypolipidemic Agents / Lipid Regulating Agents / Medicated Dressings / Medicated Dressings With Antiinfectives / Miscellaneous Local Anti-infectives / Noxae / Phenol and Derivatives / Phenols / Phenyl Ethers / Toxic Actions",4NM5039Y5X,3380-34-5,D06226,5564.0,5363.0,8726.0,10795.0,164200.0,CHEMBL849,,,ZINC000000002216
Crizotinib,phase 4 complete,DB08865 (DB08700),C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl,Amines / Aminopyridines / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Bradycardia-Causing Agents / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Kinase Inhibitor / Moderate Risk QTc-Prolonging Agents / OCT2 Inhibitors / Organic Cation Transporter 1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Piperidines / Protein Kinase Inhibitors / Pyridines / QTc Prolonging Agents / Receptor Tyrosine Kinase Inhibitors / Tyrosine Kinase Inhibitors,53AH36668S,877399-52-5,D09731,11626560.0,9801307.0,50306682.0,1148495.0,64310.0,CHEMBL601719,,PA165946122,ZINC000035902489
Salicylamide,phase 4 complete,DB08797,NC(=O)C1=CC=CC=C1O,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Amides / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antirheumatic Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Cyclooxygenase Inhibitors / Ligands / Nephrotoxic agents / Nervous System / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Salicylic Acid and Derivatives / Sensory System Agents",EM8BM710ZC,65-45-2,D01811,5147.0,4963.0,50056900.0,9518.0,32114.0,CHEMBL27577,,,ZINC000000002055
Antazoline,phase 4 complete,DB08799,C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1,"Anti-Allergic Agents / Antiallergic Agents, Excl. Corticosteroids / Antihistamines for Systemic Use / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Imidazoles / Moderate Risk QTc-Prolonging Agents / Nasal Preparations / Neurotransmitter Agents / QTc Prolonging Agents",DHA8014SS1,91-75-8,D07458,2200.0,2115.0,76862.0,865.0,84115.0,CHEMBL1305,,PA165958418,ZINC000000057204
Dimetindene,phase 4 complete,DB08801,CC(C1=C(CCN(C)C)CC2=CC=CC=C12)C1=CC=CC=N1,"Agents producing tachycardia / Anti-Allergic Agents / Anticholinergic Agents / Antihistamines for Systemic Use / Antihistamines for Topical Use / Antipruritics / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Dermatologicals / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Indenes / Muscarinic Antagonists / Neurotransmitter Agents / Pyridines / Substituted Alkylamines",661FH77Z3P,5636-83-9,D07853,21855.0,20541.0,81452.0,3449.0,135222.0,CHEMBL22108,,PA165958420,
Nandrolone decanoate,phase 4 complete,DB08804,[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],"Anabolic Agents / Androgens / Bone Density Conservation Agents / Estranes / Estrenes / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Nandrolone and esters / Steroids / Testosterone Congeners / Thyroxine-binding globulin inhibitors",H45187T098,360-70-3,D00955,9677.0,9296.0,,31494.0,7467.0,CHEMBL1200946,DAP000903,PA165958423,ZINC000008214619
Dichloroacetic acid,phase 4 complete,DB08809,OC(=O)C(Cl)Cl,"Acetates / Acids, Acyclic / Chloroacetates / Fatty Acids / Fatty Acids, Volatile / Hydrocarbons, Chlorinated / Hydrocarbons, Halogenated / Lipids",9LSH52S3LQ,79-43-6,,6597.0,10771217.0,227588.0,155021.0,36386.0,CHEMBL13960,,PA165947835,ZINC000003830689
Nadroparin,phase 4 complete,DB08813,,Agents causing hyperkalemia / Anticoagulants / Blood and Blood Forming Organs / Carbohydrates / Cardiovascular Agents / Fibrin Modulating Agents / Glycosaminoglycans / Hematologic Agents / Heparin (Low Molecular Weight) / Heparin and similars / Polysaccharides,1K5KDI46KZ,,,,,,67031.0,,,,,
Triflusal,phase 4 complete,DB08814,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O,"Acids, Carbocyclic / Anticoagulants / Antiplatelet agents / Benzene Derivatives / Benzoates / Blood and Blood Forming Organs / Hematologic Agents / Hydroxy Acids / Hydroxybenzoates / Phenols / Platelet Aggregation Inhibitors Excl. Heparin",1Z0YFI05OO,322-79-2,,9458.0,9086.0,,38655.0,94721.0,CHEMBL1332032,,,ZINC000000002220
Lurasidone,phase 4 complete,DB08815,[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O,"Adrenergic Agents / Adrenergic alpha-2 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Indole Derivatives / Isoindoles / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Potential QTc-Prolonging Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Thiazoles / Tranquilizing Agents",22IC88528T,367514-87-2,D04820,213046.0,184739.0,85222.0,1040028.0,70735.0,CHEMBL1237021,,PA166129557,ZINC000003927822
Hyaluronic acid,phase 4 complete,DB08818,CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O,"Adjuvants, Immunologic / Carbohydrates / Cicatrizants / Compounds used in a research, industrial, or household setting / Dermatologicals / Glycosaminoglycans / Immunologic Factors / Lubricants / Musculo-Skeletal System / Nasal Preparations / Ophthalmologicals / Polysaccharides / Preparations for Treatment of Wounds and Ulcers / Protective Agents / Sensory Organs / Surgical Aids / Viscoelastic Substances / Viscosupplements",S270N0TRQY,9004-61-9,D08043,24759.0,23145.0,,5463.0,,,,PA165958431,
Tafluprost,phase 4 complete,DB08819,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1,"Antiglaucoma Preparations and Miotics / Autacoids / Biological Factors / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Increased Prostaglandin Activity / Inflammation Mediators / Lipids / Ophthalmics / Ophthalmologicals / Prostaglandin analogs reducing intraocular pressure (IOP) / Prostaglandin Receptor Agonists / Prostaglandins / Prostaglandins, Synthetic / Sensory Organs",1O6WQ6T7G3,209860-87-7,D06274,9868491.0,8044182.0,,1244607.0,66899.0,CHEMBL1963683,,PA165958432,ZINC000013912394
Spinosad,phase 4 complete,DB08823,[H][C@]1(C[C@@]2([H])C=C[C@@]3([H])[C@]4([H])CC(=O)O[C@@]([H])(CC)CCC[C@]([H])(O[C@@]5([H])CC[C@]([H])(N(C)C)[C@@]([H])(C)O5)[C@@]([H])(C)C(=O)C4=C[C@@]3([H])[C@]2([H])C1)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(OC)[C@@]([H])(OC)[C@@]1([H])OC.[H][C@]1(C[C@@]2([H])C(C)=C[C@@]3([H])[C@]4([H])CC(=O)O[C@@]([H])(CC)CCC[C@]([H])(O[C@@]5([H])CC[C@]([H])(N(C)C)[C@@]([H])(C)O5)[C@@]([H])(C)C(=O)C4=C[C@@]3([H])[C@]2([H])C1)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(OC)[C@@]([H])(OC)[C@@]1([H])OC,"Agrochemicals / Compounds used in a research, industrial, or household setting / Insecticides / Lactones / Pediculicides / Pesticides / Pharmaceutical Preparations / Polyketides / Toxic Actions",XPA88EAP6V,168316-95-8,D09384,17754356.0,16736513.0,,299081.0,39211.0,CHEMBL2040681,,,
Ioflupane I-123,phase 4 complete,DB08824 (DB09548),[H][C@]12CC[C@]([H])([C@H]([C@H](C1)C1=CC=C([123I])C=C1)C(=O)OC)N2CCCF,Alkaloids / Aza Compounds / Azabicyclo Compounds / Carbon Radioisotopes / Central Nervous System / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Fluorine Radioisotopes / Iodine (123I) Compounds / Iodine Radioisotopes / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Tropanes,3MM99T8R5Q,155798-07-5,D10014,3086674.0,2343241.0,,1426874.0,68855.0,CHEMBL3989517,,,ZINC000100091991
Deferiprone,phase 4 complete,DB08826,CN1C=CC(=O)C(O)=C1C,"Chelating Agents / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Heavy Metal Antagonists / Iron Chelating Activity / Iron Chelating Agents / Pyridines / Pyridones / Sequestering Agents / UGT1A6 substrate",2BTY8KH53L,30652-11-0,D07416,2972.0,2866.0,,11645.0,68554.0,CHEMBL70927,,PA166118041,ZINC000000006226
Lomitapide,phase 4 complete,DB08827,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12,"Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hepatotoxic Agents / Heterocyclic Compounds, Fused-Ring / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Microsomal Triglyceride Transfer Protein Inhibitor / Microsomal Triglyceride Transfer Protein Inhibitors / Miscellaneous Antilipemic Agents / P-glycoprotein inhibitors",82KUB0583F,182431-12-5,D09637,9853053.0,8028764.0,50098320.0,1364479.0,72297.0,CHEMBL354541,,PA166114922,ZINC000027990463
Vismodegib,phase 4 complete,DB08828,CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1,Amides / Amines / Aniline Compounds / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hedgehog Pathway Inhibitor / P-glycoprotein substrates / Smoothened Receptor Antagonists,25X868M3DS,879085-55-9,D09992,24776445.0,23337846.0,50249522.0,1242987.0,66903.0,CHEMBL473417,,PA166048558,ZINC000040899447
Acetylcarnitine,phase 4 complete,DB08842,CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C,"Amines / Ammonium Compounds / Central Nervous System Agents / Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Micronutrients / Nervous System / Nitrogen Compounds / Nootropic Agents / Onium Compounds / Physiological Phenomena / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Quaternary Ammonium Compounds / Trimethyl Ammonium Compounds",6DH1W9VH8Q,3040-38-8,,7045767.0,5406074.0,,193.0,57589.0,CHEMBL1697733,,,
Cholecystokinin,phase 4 complete,DB08862,,"Amino Acids, Peptides, and Proteins / Cholagogues and Choleretics / Cholecystokinin, agonists / Cholecystokinin, antagonists & inhibitors / Diagnostic Agents / Gastrointestinal Agents / Gastrointestinal Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / Peptides / Tests for Pancreatic Function",00XI8W60QF,9011-97-6,,,,,2420.0,,,,,
Fingolimod,phase 4 complete,DB08868,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Alcohols / Amines / Amino Alcohols / Antineoplastic and Immunomodulating Agents / Bradycardia-Causing Agents / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 Substrates / Experimental Unapproved Treatments for COVID-19 / Glycols / Immunologic Factors / Immunomodulatory Agents / Immunosuppressive Agents / P-glycoprotein inducers / P-glycoprotein inhibitors / Propylene Glycols / QTc Prolonging Agents / Selective Immunosuppressants / Sphingosine 1-phosphate Receptor Modulator,3QN8BYN5QF,162359-55-9,D10001,107970.0,97087.0,50158336.0,1012892.0,63115.0,CHEMBL314854,,,ZINC000001542002
Tesamorelin,phase 4 complete,DB08869,CC\C=C\CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O,"Amino Acids, Peptides, and Proteins / Anterior Pituitary Lobe Hormones and Analogues / Growth Hormone Releasing Factor Analog / Growth Hormone-Releasing Hormone / Growth Substances / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypothalamic Hormones / Increased GHRH Activity / Lipodystrophy / Nerve Tissue Proteins / Neuropeptides / Peptide Hormones / Peptides / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormone-Releasing Hormones / Proteins / Somatotropin Agonists / Somatropin and Somatropin Agonists / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",MQG94M5EEO,218949-48-5,D09015,56928011.0,34999256.0,,1044584.0,63626.0,CHEMBL1237026,,,
Fidaxomicin,phase 4 complete,DB08874,[H][C@@]1(O[C@@H]2[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]3O[C@H](C)[C@@H](OC(=O)C4=C(CC)C(Cl)=C(O)C(Cl)=C4O)[C@H](O)[C@@H]3OC)\C(=O)O[C@@H](C\C=C(/C)\C=C2/C)[C@@H](C)O)OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O,"Alimentary Tract and Metabolism / Anti-Bacterial Agents / Anti-Infective Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Carbohydrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Intestinal Antiinfectives / Lactones / Macrolide Antibacterial / Macrolides / Other Macrolides / P-glycoprotein substrates / Polyketides",Z5N076G8YQ,873857-62-6,D09394,70678896.0,8209640.0,,1111103.0,68590.0,CHEMBL1255800,,,
Linagliptin,phase 4 complete,DB08882,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1,"Agents causing angioedema / Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / DPP-IV Inhibitors / Drugs Used in Diabetes / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Incretins / OCT1 inhibitors / OCT2 Inhibitors / OCT2 Substrates / P-glycoprotein inhibitors / P-glycoprotein substrates / Protease Inhibitors / Purines / Quinazolines",3X29ZEJ4R2,668270-12-0,D09566,10096344.0,8271879.0,50228403.0,1100699.0,68610.0,CHEMBL237500,,,ZINC000003820029
Perampanel,phase 4 complete,DB08883,O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1,"AMPA Receptor Antagonists / Anticonvulsants / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (weak) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Miscellaneous Anticonvulsants / Nervous System / Noncompetitive AMPA Glutamate Receptor Antagonist / Pyridines / Receptors, AMPA, antagonists & inhibitors",H821664NPK,380917-97-5,D08964,9924495.0,8100130.0,50184410.0,1356552.0,71013.0,CHEMBL1214124,,,ZINC000030691797
Gadoxetic acid,phase 4 complete,DB08884,[Gd+3].[H][C@@](CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)(CC1=CC=C(OCC)C=C1)N(CC(O)=O)CC(O)=O,"Acetates / Acids, Acyclic / Amines / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Fatty Acids / Fatty Acids, Volatile / Gadolinium-based Contrast Agent / Lipids / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / Organometallic Compounds / Other Diagnostics / Paramagnetic Contrast Agent / Paramagnetic Contrast Media / Polyamines",3QJA87N40S,135326-11-3,D04288,131704314.0,189907.0,,802624.0,,CHEMBL1201768,,PA165985534,
Carfilzomib,phase 4 complete,DB08889,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,"Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Immunosuppressive Agents / Myelosuppressive Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Peptides / Proteasome Inhibitors",72X6E3J5AR,868540-17-4,D08880,11556711.0,9731489.0,50277889.0,1302966.0,65347.0,CHEMBL451887,,PA166165203,ZINC000049841054
Regorafenib,phase 4 complete,DB08896,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / Benzene Derivatives / Bradycardia-Causing Agents / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hepatotoxic Agents / Kinase Inhibitor / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors / Tyrosine Kinase Inhibitors / UGT1A1 Inhibitors / UGT1A9 Inhibitors / UGT1A9 Substrates,24T2A1DOYB,755037-03-7,D10138,11167602.0,9342697.0,50363397.0,1312397.0,68647.0,CHEMBL1946170,,,ZINC000006745272
Aclidinium,phase 4 complete,DB08897,OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1,"Adrenergics, Inhalants / Agents producing tachycardia / Agents to Treat Airway Disease / Alkaloids / Anticholinergic Agents / Antimuscarinics Antispasmodics / Aza Compounds / Azabicyclo Compounds / Cholinesterase substrates / Drugs for Obstructive Airway Diseases / Drugs that are Mainly Renally Excreted / Muscarinic Antagonists",K17VY42F6C,727649-81-2,D08837,11434515.0,9609381.0,50296331.0,1303098.0,65346.0,CHEMBL1194325,,,ZINC000030691727
Bedaquiline,phase 4 complete,DB08903,COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2,"Anti-Bacterial Agents / Anti-Infective Agents / Antiinfectives for Systemic Use / Antimycobacterials / Antituberculosis Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Diarylquinoline Antimycobacterial / Drugs for Treatment of Tuberculosis / Heterocyclic Compounds, Fused-Ring / Moderate Risk QTc-Prolonging Agents / Mycobacterium tuberculosis / QTc Prolonging Agents / Quinolines",78846I289Y,843663-66-1,D09872,5388906.0,4534966.0,50063995.0,1364504.0,72292.0,CHEMBL376488,,,ZINC000004655029
Formestane,phase 4 complete,DB08905,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C,"17-Ketosteroids / Adrenal Cortex Hormones / Androstanes / Androstenes / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Aromatase Inhibitors / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Drugs that are Mainly Renally Excreted / Endocrine Therapy / Enzyme Inhibitors / Estrogen Antagonists / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormone Antagonists / Hormone Antagonists and Related Agents / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Ketosteroids / Steroid Synthesis Inhibitors / Steroids / Testosterone Congeners",PUB9T8T355,566-48-3,D07260,11273.0,10799.0,225704.0,15070.0,75172.0,CHEMBL132530,,,ZINC000003919580
Fluticasone furoate,phase 4 complete,DB08906,[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Adrenal Cortex Hormones / Agents to Treat Airway Disease / Androstanes / Androstenes / Corticosteroids / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Fused-Ring Compounds / Glucocorticoids / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Nasal Preparations / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein substrates / Steroids / Thyroxine-binding globulin inhibitors,JS86977WNV,397864-44-7,D06315,9854489.0,8030195.0,50354851.0,705022.0,74899.0,CHEMBL1676,,,ZINC000003992105
Canagliflozin,phase 4 complete,DB08907,[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1,Agents causing hyperkalemia / Alimentary Tract and Metabolism / Blood Glucose Lowering Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Diuretics / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Glucosides / Hypotensive Agents / P-glycoprotein inhibitors / P-glycoprotein substrates / Sodium-glucose co-transporter 2 (SGLT2) inhibitors / Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors / Sulfur Compounds / Thiophenes / UGT1A9 Substrates,6S49DGR869,842133-18-0,D09592,24812758.0,26333259.0,50386885.0,1373458.0,73274.0,CHEMBL2048484,,,ZINC000043207238
Dimethyl fumarate,phase 4 complete,DB08908,[H]\C(=C(\[H])C(=O)OC)C(=O)OC,"Acids, Acyclic / Antineoplastic and Immunomodulating Agents / Dermatologicals / Dicarboxylic Acids / Fumarates / Immunologic Factors / Immunosuppressive Agents / Miscellaneous Central Nervous System Agents / Radiation-Sensitizing Agents",FO2303MNI2,624-49-7,D03846,637568.0,553171.0,,1373478.0,76004.0,CHEMBL2107333,,PA166152838,ZINC000003843378
Pomalidomide,phase 4 complete,DB08910,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,"Acids, Carbocyclic / Angiogenesis Inhibitors / Angiogenesis Modulating Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Growth Inhibitors / Growth Substances / Heterocyclic Compounds, Fused-Ring / Imides / Immunologic Factors / Immunosuppressive Agents / Isoindoles / Myelosuppressive Agents / P-glycoprotein substrates / Phthalic Acids / Phthalimides / Piperidines / Piperidones / Thalidomide Analog",D2UX06XLB5,19171-19-8,D08976,134780.0,118785.0,65456.0,1369713.0,72690.0,CHEMBL43452,,,
Trametinib,phase 4 complete,DB08911,CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Kinase Inhibitor / MAP Kinase Kinase 1, antagonists & inhibitors / MAP Kinase Kinase 2, antagonists & inhibitors / Narrow Therapeutic Index Drugs / Protein Kinase Inhibitors / Pyridines / Pyrimidines",33E86K87QN,871700-17-3,D10175,11707110.0,9881833.0,,1425099.0,75998.0,CHEMBL2103875,,PA166115364,ZINC000043100709
Dabrafenib,phase 4 complete,DB08912,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1,"Amines / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (weak) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strong) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (moderate) / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Enzyme Inhibitors / Hydroxylamines / Hyperglycemia-Associated Agents / Kinase Inhibitor / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Organic Anion Transporter 1 Inhibitors / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B3 Inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Photosensitizing Agents / Potential QTc-Prolonging Agents / Protein Kinase Inhibitors / Proto-Oncogene Proteins B-raf, antagonists & inhibitors / QTc Prolonging Agents",QGP4HA4G1B,1195765-45-7,D10064,44462760.0,25948204.0,50428286.0,1424911.0,75045.0,CHEMBL2028663,,,ZINC000068153186
Afatinib,phase 4 complete,DB08916,CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1,"Amides / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Kinase Inhibitor / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors / Quinazolines / Tyrosine Kinase Inhibitors",41UD74L59M,850140-72-6,D09724,10184653.0,8360155.0,50322823.0,1430438.0,61390.0,CHEMBL1173655,,PA165981154,ZINC000003976838
Ferric carboxymaltose,phase 4 complete,DB08917,,"Biopolymers / Carbohydrates / Compounds used in a research, industrial, or household setting / Disaccharides / Glucans / Iron Compounds / Macromolecular Substances / Oligosaccharides / Organometallic Compounds / Parenteral Iron Replacement / Phosphate Binder / Polymers / Polysaccharides",6897GXD6OE,9007-72-1,D08920,,,,1433693.0,,CHEMBL2108597,,,
Levomilnacipran,phase 4 complete,DB08918,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1,Adrenergic Uptake Inhibitors / Agents producing tachycardia / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cycloparaffins / Cyclopropanes / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Hypoglycemia-Associated Agents / Membrane Transport Modulators / Miscellaneous Antidepressants / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Norepinephrine Uptake Inhibitors / P-glycoprotein substrates / Psychotropic Drugs / Selective Serotonin Reuptake Inhibitors / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin and Noradrenaline Reuptake Inhibitors / Serotonin Modulators,UGM0326TXX,96847-54-0,D10072,6917779.0,5293005.0,50032379.0,1433212.0,136040.0,CHEMBL99946,,,ZINC000000000506
Dolutegravir,phase 4 complete,DB08930,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2,"Anti-HIV Agents / Anti-Infective Agents / Anti-Retroviral Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BCRP/ABCG2 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / HIV Integrase Inhibitors / Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor / Integrase Inhibitors / Miscellaneous Antiretrovirals* / Multidrug and Toxin Extrusion Transporter 1 Inhibitors / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / UGT1A1 Substrates / UGT1A3 substrates / UGT1A9 Substrates",DKO1W9H7M1,1051375-16-6,D10066,54726191.0,25051637.0,50062551.0,1433868.0,76010.0,CHEMBL1229211,,PA166114961,ZINC000058581064
Riociguat,phase 4 complete,DB08931,COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2,Antihypertensive Agents / Antihypertensives for Pulmonary Arterial Hypertension / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Enzyme Activators / Guanylate Cyclase / Guanylate Cyclase Stimulators / Hypotensive Agents / Soluble Guanylate Cyclase Stimulator / Vasodilating Agents,RU3FE2Y4XI,625115-55-1,D09572,11304743.0,9479719.0,,1439816.0,76018.0,CHEMBL2107834,,,ZINC000003819392
Macitentan,phase 4 complete,DB08932,CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1,Amides / Antihypertensive Agents / Antihypertensives for Pulmonary Arterial Hypertension / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Endothelin A Receptor Antagonists / Endothelin B Receptor Antagonists / Endothelin Receptor Antagonists / Sulfones / Sulfur Compounds / Vasodilating Agents,Z9K9Y9WMVL,441798-33-0,D10135,16004692.0,13134960.0,50395626.0,1442132.0,76607.0,CHEMBL2103873,,,ZINC000043202140
Luliconazole,phase 4 complete,DB08933,ClC1=CC(Cl)=C(C=C1)[C@@H]1CS\C(S1)=C(\C#N)N1C=CN=C1,Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Azole Antifungals / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 Enzyme Inhibitors / Dermatologicals / Imidazole and Triazole Derivatives,RE91AN4S8G,187164-19-8,D01980,3003141.0,2273807.0,,1482680.0,34825.0,CHEMBL2105689,,,ZINC000003929486
Sofosbuvir,phase 4 complete,DB08934,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / BCRP/ABCG2 Substrates / Carbohydrates / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Glycosides / Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / Nucleotides / P-glycoprotein substrates / Pyrimidine Nucleosides / Pyrimidine Nucleotides / Pyrimidines / Ribonucleosides / Ribonucleotides / RNA Replicase Inhibitors / Uracil Nucleotides",WJ6CA3ZU8B,1190307-88-0,D10366,45375808.0,26286922.0,50239940.0,1484911.0,85083.0,CHEMBL1259059,,PA166122593,ZINC000100074252
Chlorcyclizine,phase 4 complete,DB08936,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Antihistamines for Systemic Use / Histamine Antagonists / Histamine H1 Antagonists / Piperazine Derivatives / Potential QTc-Prolonging Agents / QTc Prolonging Agents,M26C4IP44P,82-93-9,,2710.0,2609.0,50329371.0,2354.0,94402.0,CHEMBL22150,,,
Magaldrate,phase 4 complete,DB08938,O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O,Alimentary Tract and Metabolism / Alkalies / Aluminium Compounds / Aluminum and magnesium containing antacids / Anions / Antacids / Antacids With Antiflatulents / Drugs for Acid Related Disorders / Electrolytes / Gastric Acid Lowering Agents / Gastrointestinal Agents / Hydroxides / Ions / Magnesium Compounds / Metal cations / Metal divalent cations,6V88E24N5T,74978-16-8,D04832,3086011.0,,,29151.0,,CHEMBL3833350,,,
Isoxsuprine,phase 4 complete,DB08941,C[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C1=CC=C(O)C=C1,2-Amino-1-Phenylethanol Derivatives / Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Autonomic Agents / Cardiovascular Agents / Ethylamines / Hypotensive Agents / Neurotransmitter Agents / Peripheral Nervous System Agents / Peripheral Vasodilators / Phenethylamines / Propanolamines / Propanols / Reproductive Control Agents / Sympathomimetics / Tocolytic Agents / Vasodilating Agents,R15UI3245N,395-28-8,,11779629.0,9954311.0,,6066.0,,,,,ZINC000009302317
Isoxicam,phase 4 complete,DB08942,CN1C(C(=O)NC2=NOC(C)=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antirheumatic Agents / Central Nervous System Agents / Nephrotoxic agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Sensory System Agents / Sulfur Compounds / Thiazines",8XU734C4NG,34552-84-6,D04639,54677972.0,10442695.0,,,76163.0,CHEMBL53292,,PA166049183,ZINC000049538599
Isoconazole,phase 4 complete,DB08943,ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=C(Cl)C=CC=C1Cl,Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Azole Antifungals / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Imidazole and Triazole Derivatives / Imidazole Derivatives / Imidazoles / Ointments,GRI7WFR424,27523-40-6,D04624,3760.0,3629.0,31771.0,27901.0,83667.0,CHEMBL1571863,,,
Isoaminile,phase 4 complete,DB08944,CC(C)[C@@](C[C@H](C)N(C)C)(C#N)C1=CC=CC=C1,Antitussive Agents / Central Nervous System Agents / Cough and Cold Preparations / Nitriles / Respiratory System Agents,R4823W2PQL,77-51-0,D08088,12162152.0,64873333.0,,27866.0,,,,,
Iopanoic acid,phase 4 complete,DB08946,CCC(CC1=C(I)C(N)=C(I)C=C1I)C(O)=O,"Benzene Derivatives / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Hydrocarbons, Halogenated / Hydrocarbons, Iodinated / Iodobenzenes / Watersoluble, Hepatotropic X-Ray Contrast Media / X-Ray Contrast Media, Iodinated",FE9794P71J,96-83-3,,3735.0,3604.0,,5967.0,5951.0,CHEMBL867,,,
Iopamidol,phase 4 complete,DB08947,C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Iodinated Contrast Agents / Iodobenzoates / Radiographic Contrast Agent / Roentgenography / Triiodobenzoic Acids / Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media / X-Ray Contrast Activity / X-Ray Contrast Media, Iodinated",JR13W81H44,60166-93-0,D01797,65492.0,58940.0,,5966.0,31711.0,CHEMBL1200932,,,ZINC000003830947
Inositol nicotinate,phase 4 complete,DB08949,O=C(O[C@H]1[C@H](OC(=O)C2=CC=CN=C2)[C@@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@@H]1OC(=O)C1=CC=CN=C1)C1=CC=CN=C1,Cardiovascular Agents / Nicotinic Acid and Derivatives / Other Nutritional Agents / Peripheral Vasodilators / Pyridines / Vasodilating Agents / Vitamin B Complex / Vitamins,A99MK953KZ,6556-11-2,D01813,3720.0,16736141.0,,27604.0,31699.0,CHEMBL1094982,,,ZINC000150338506
Indoramin,phase 4 complete,DB08950,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1,"Acids, Carbocyclic / Adrenergic Agents / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Amides / Antiadrenergic Agents, Peripherally Acting / Antihypertensive Agents / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Cardiovascular Agents / Heterocyclic Compounds, Fused-Ring / Hypotensive Agents / Indoles / Neurotransmitter Agents / Peripheral alpha-1 blockers / Piperidines",0Z802HMY7H,26844-12-2,D04531,33625.0,31014.0,50033113.0,5784.0,135470.0,CHEMBL279516,,,ZINC000000001567
Ifenprodil,phase 4 complete,DB08954,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1,"Adrenergic Agents / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Anti-Parkinson Drugs / Anticonvulsants / Cardiovascular Agents / Central Nervous System Depressants / Excitatory Amino Acid Agents / Excitatory Amino Acid Antagonists / Neurotransmitter Agents / NMDA Receptor Antagonists / Peripheral Vasodilators / Receptors, N-Methyl-D-Aspartate / Vasodilating Agents",R8OE3P6O5S,23210-56-2,D08064,3689.0,3561.0,50083351.0,27403.0,93829.0,CHEMBL305187,,,
Hexetidine,phase 4 complete,DB08958,CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1,"Alimentary Tract and Metabolism / Anti-Infective Agents / Anti-Infective Agents, Local / Antifungal Agents / Antiinfectives and Antiseptics for Local Oral Treatment / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Pyrimidines / Stomatological Preparations",852A84Y8LS,141-94-6,D07068,3607.0,3481.0,,5301.0,94339.0,CHEMBL144673,,,
Gemeprost,phase 4 complete,DB08964,CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC,"Abortifacient Agents / Abortifacient Agents, Nonsteroidal / Autacoids / Biological Factors / Drugs that are Mainly Renally Excreted / Eicosanoids / Fatty Acids / Fatty Acids, Monounsaturated / Fatty Acids, Unsaturated / Genito Urinary System and Sex Hormones / Inflammation Mediators / Lipids / Prostaglandins / Prostaglandins E / Prostaglandins E, Synthetic / Reproductive Control Agents / Uterotonic agents",45KZB1FOLS,64318-79-2,D02073,5282237.0,4445416.0,,12449.0,135626.0,CHEMBL1908315,,,ZINC000004216393
Fusafungine,phase 4 complete,DB08965,[H]C1(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C1=O)C(C)C)C(C)C)C(C)C,"Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Peptides / Peptides, Cyclic / Throat Preparations",65DD690W0C,1393-87-9,,3084092.0,2341206.0,,25437.0,,,,,
Fursultiamine,phase 4 complete,DB08966,C\C(N(CC1=C(N)N=C(C)N=C1)C=O)=C(\CCO)SSCC1CCCO1,"Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Micronutrients / Physiological Phenomena / Pyrimidines / Sulfur Compounds / Thiazoles / Vitamin B Complex / Vitamins",05J61265PX,804-30-8,,3002119.0,2273321.0,,4604.0,135636.0,CHEMBL1740659,,,
Dimetotiazine,phase 4 complete,DB08967,CC(CN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(=O)(=O)N(C)C)N(C)C,"Analgesics / Antimigraine Preparations / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Nervous System / Neurotransmitter Agents / Sulfur Compounds",1FTA475ZDB,7456-24-8,,3089.0,2979.0,,50138.0,135616.0,CHEMBL346977,,,
Fluocortolone,phase 4 complete,DB08971,[H][C@@]1(C)C[C@@]2([H])[C@]3([H])C[C@]([H])(F)C4=CC(=O)C=C[C@]4(C)[C@@]3([H])[C@@]([H])(O)C[C@]2(C)[C@@]1([H])C(=O)CO,"Adrenal Cortex Hormones / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Anti-Inflammatory Agents / Corticosteroids / Corticosteroids for Systemic Use, Plain / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Ophthalmologicals / Pregnadienediols / Pregnadienes / Pregnanes / Sensory Organs / Steroids / Steroids, Fluorinated / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Vasoprotectives",65VXC1MH0J,152-97-6,,9053.0,8701.0,,4463.0,135581.0,CHEMBL251634,,,ZINC000004213353
Fluclorolone acetonide,phase 4 complete,DB08973,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,Fused-Ring Compounds / Pregnadienes / Pregnanes / Steroids,MG258KTA37,3693-39-8,,20054914.0,16735814.0,,103447.0,135787.0,CHEMBL461332,,,ZINC000004213332
Floctafenine,phase 4 complete,DB08976,OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C=CC=C12)C(F)(F)F,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Aminobenzoates / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antirheumatic Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Miscellaneous Analgesics and Antipyretics / Nephrotoxic agents / Nervous System / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Sensory System Agents",O04HVX6A9Q,23779-99-9,,76958517.0,3243.0,,4444.0,31612.0,CHEMBL2105075,,,
Fenbufen,phase 4 complete,DB08981,OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / Cyclooxygenase Inhibitors / Enzyme Inhibitors / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Propionates / Sensory System Agents",9815R1WR9B,36330-85-5,D01344,3335.0,3218.0,50240374.0,24830.0,31599.0,CHEMBL277522,,PA166049176,ZINC000000001427
Etidocaine,phase 4 complete,DB08987,CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C,"Acetanilides / Amides / Amines / Anesthetics / Anesthetics, Local / Anilides / Aniline Compounds / Central Nervous System Agents / Central Nervous System Depressants / Local Anesthetics (Amide) / Nervous System / Peripheral Nervous System Agents / Sensory System Agents",I6CQM0F31V,36637-18-0,D04095,37497.0,34400.0,50225497.0,4171.0,4904.0,CHEMBL492,,,
Ethoheptazine,phase 4 complete,DB08988,CCOC(=O)C1(CCCN(C)CC1)C1=CC=CC=C1,,3A4G3A848U,77-15-6,D01435,6469.0,6225.0,,24484.0,135074.0,CHEMBL170797,,,
Diosmin,phase 4 complete,DB08995,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)C=C2O1,"Benzopyrans / Capillary Stabilizing Agents / Chromones / Flavones / Flavonoids / Heterocyclic Compounds, Fused-Ring / Pyrans / Vasoprotectives",7QM776WJ5N,520-27-4,D07858,5281613.0,4444932.0,153267.0,3489.0,4631.0,CHEMBL231884,,,ZINC000004098512
Articaine,phase 4 complete,DB09009,CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC,"Amides / Anesthetics / Anesthetics, Local / Central Nervous System Agents / Hyperglycemia-Associated Agents / Local Anesthesia / Local Anesthetics (Amide) / Nervous System / Peripheral Nervous System Agents / Sensory System Agents / Sulfur Compounds / Thiophenes",D3SQ406G9X,23964-58-1,D07468,32170.0,29837.0,50225496.0,592464.0,91834.0,CHEMBL1093,,,
Canrenoic acid,phase 4 complete,DB09015,[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C,"Agents causing hyperkalemia / Cardiovascular Agents / Diuretics / Fused-Ring Compounds / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Mineralocorticoid Receptor Antagonists / Natriuretic Agents / Potassium-Sparing Diuretics / Pregnadienes / Pregnanes / Steroids",87UG89VA9K,4138-96-9,,656615.0,570976.0,,81971.0,50156.0,CHEMBL1616951,,,ZINC000003938750
Butriptyline,phase 4 complete,DB09016,,"Agents that produce hypertension / Agents that reduce seizure threshold / Anti-Anxiety Agents / Antidepressive Agents / Antidepressive Agents, Tricyclic / Benzocycloheptenes / Central Nervous System Agents / Central Nervous System Depressants / Histamine Antagonists / Histamine H1 Antagonists / Moderate Risk QTc-Prolonging Agents / Narrow Therapeutic Index Drugs / Nervous System / Neurotoxic agents / Non-Selective Monoamine Reuptake Inhibitors / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tertiary amine tricyclic antidepressants / Tranquilizing Agents",Z22441975X,35941-65-2,D07601,21772.0,,,19895.0,,CHEMBL2110816,,,
Bromhexine,phase 4 complete,DB09019,CN(CC1=CC(Br)=CC(Br)=C1N)C1CCCCC1,Amines / Aniline Compounds / Cough and Cold Preparations / Cyclohexanes / Cyclohexylamines / Cycloparaffins / Expectorants / Respiratory System Agents,Q1J152VB1P,3572-43-8,D07542,2442.0,2348.0,50239965.0,1753.0,77032.0,CHEMBL253376,,,ZINC000000608220
Bisacodyl,phase 4 complete,DB09020,CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1,Alimentary Tract and Metabolism / Benzene Derivatives / Contact Laxatives / Cresols / Drugs for Constipation / Enemas / Gastrointestinal Agents / Increased Large Intestinal Motility / Laxatives / Phenols / Stimulation Large Intestine Fluid/Electrolyte Secretion,10X0709Y6I,603-50-9,D00245,2391.0,2299.0,61400.0,1596.0,3125.0,CHEMBL942,,,ZINC000003830321
Ledipasvir,phase 4 complete,DB09027,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C1=NC(=CN1)C1=CC=C2C3=CC=C(C=C3C(F)(F)C2=C1)C1=CC=C2NC(=NC2=C1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / Breast Cancer Resistance Protein Inhibitors / Direct Acting Antivirals / Drugs that are Mainly Renally Excreted / Hepatitis C Virus NS5A Inhibitor / Heterocyclic Compounds, Fused-Ring / P-glycoprotein inhibitors / P-glycoprotein substrates",013TE6E4WV,1256388-51-8,D10442,67505836.0,29271894.0,,1591922.0,85089.0,CHEMBL2374220,,PA166128166,ZINC000150338819
Miltefosine,phase 4 complete,DB09031,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C,Alcohols / Amines / Amino Alcohols / Ammonium Compounds / Anti-Infective Agents / Antifungal Agents / Antileishmanial / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Antiparasitic Agents / Antiprotozoals / Ethanolamines / Narrow Therapeutic Index Drugs / Nitrogen Compounds / Onium Compounds / Quaternary Ammonium Compounds / Trimethyl Ammonium Compounds,53EY29W7EC,58066-85-6,D02494,3599.0,3473.0,50034220.0,1494066.0,75283.0,CHEMBL125,,,
Suvorexant,phase 4 complete,DB09034,[H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2,"Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hypnotics and Sedatives / Miscellaneous Anxiolytics Sedatives and Hypnotics / Nervous System / Neurotransmitter Agents / Orexin Receptor Antagonists / P-glycoprotein inhibitors / Psycholeptics / Sleep Aids, Pharmaceutical",081L192FO9,1030377-33-3,D10082,24965990.0,24662178.0,50318701.0,1547099.0,82698.0,CHEMBL1083659,,,ZINC000049036447
Empagliflozin,phase 4 complete,DB09038,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C1,Alimentary Tract and Metabolism / BCRP/ABCG2 Substrates / Benzene Derivatives / Blood Glucose Lowering Agents / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / Glycosides / Hypotensive Agents / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / Sodium-glucose co-transporter 2 (SGLT2) inhibitors / Sodium-Glucose Transporter 2 Inhibitors / UGT1A3 substrates / UGT1A9 Substrates / UGT2B7 substrates,HDC1R2M35U,864070-44-0,D10459,11949646.0,10123957.0,150162.0,1545653.0,82720.0,CHEMBL2107830,,PA166163327,ZINC000036520252
Efinaconazole,phase 4 complete,DB09040,C[C@@H](N1CCC(=C)CC1)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Azole Antifungals / Dermatologicals / Imidazole and Triazole Derivatives,J82SB7FXWB,164650-44-6,D10021,489181.0,428538.0,,1539753.0,82718.0,CHEMBL2103877,,,ZINC000000006251
Tedizolid phosphate,phase 4 complete,DB09042,CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[C@H](COP(O)(O)=O)OC1=O,Anti-Bacterial Agents / Anti-Infective Agents / Antidepressive Agents / Central Nervous System Depressants / Immunosuppressive Agents / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Myelosuppressive Agents / Organophosphorus Compounds / Oxazolidinone Antibacterial / Oxazolidinones / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators,O7DRJ6R4DW,856867-55-5,D09686,11476460.0,9651289.0,50017198.0,1540824.0,83326.0,CHEMBL2105669,,,ZINC000043100953
Finafloxacin,phase 4 complete,DB09047,[H][C@]12CN(C[C@]1([H])OCCN2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1C#N)C(O)=O,"Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Urinary / Antineoplastic Agents / Enzyme Inhibitors / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Quinolines / Quinolone Antimicrobial / Quinolones / Renal Agents / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",D26OSN9Q4R,209342-40-5,D10575,11567473.0,9742243.0,,1598641.0,85176.0,CHEMBL1908370,,,ZINC000003985346
Netupitant,phase 4 complete,DB09048,CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CCN(C)CC1,Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Netupitant and prodrug / Neurokinin 1 Antagonists / P-glycoprotein inhibitors / Substance P/Neurokinin-1 Receptor Antagonist,7732P08TIR,290297-26-6,D10572,6451149.0,4953629.0,50178574.0,1552337.0,85155.0,CHEMBL206253,,,ZINC000011681563
Naloxegol,phase 4 complete,DB09049,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5,"Alcohols / Alimentary Tract and Metabolism / Alkaloids / Central Nervous System Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Constipation / Ethylene Glycols / Glycols / Heterocyclic Compounds, Fused-Ring / Macromolecular Substances / Miscellaneous GI Drugs / Narcotics / Opiate Alkaloids / Opioid Antagonists / Peripheral Nervous System Agents / Peripheral Opioid Receptor Antagonists / Phenanthrenes / Polymers / Sensory System Agents",44T7335BKE,854601-70-0,D10479,56959087.0,28651656.0,,1551777.0,82975.0,CHEMBL2219418,,,ZINC000095564694
Ceftolozane,phase 4 complete,DB09050,CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=NSC(N)=N1)C2=O)C([O-])=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Aza Compounds / Azabicyclo Compounds / beta-Lactams / Cephalosporins / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Sulfur Compounds / Thiazines",37A4IES95Q,689293-68-3,D10097,53234134.0,25999973.0,,1597609.0,134719.0,CHEMBL2103872,,,
Ibrutinib,phase 4 complete,DB09053,NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Immunosuppressive Agents / Kinase Inhibitor / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / Protein Kinase Inhibitors / Tyrosine Kinase Inhibitors,1X70OSD4VX,936563-96-1,D10223,24821094.0,26637187.0,50357312.0,1442981.0,76612.0,CHEMBL1873475,,PA166121346,ZINC000035328014
Idelalisib,phase 4 complete,DB09054,[H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Hepatotoxic Agents / Heterocyclic Compounds, Fused-Ring / Immunosuppressive Agents / Kinase Inhibitor / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Quinazolines / UGT1A4 Inhibitors / UGT1A4 substrates",YG57I8T5M0,870281-82-6,D10560,11625818.0,9800565.0,150175.0,1544460.0,82701.0,CHEMBL2216870,,,ZINC000013986658
Acipimox,phase 4 complete,DB09055,CC1=[N+]([O-])C=C(N=C1)C(O)=O,"Agents Causing Muscle Toxicity / Hypolipidemic Agents / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Nicotinic Acid and Derivatives / Noxae / Toxic Actions",K9AY9IR2SD,51037-30-0,D07190,5310993.0,4470534.0,50208130.0,16817.0,94688.0,CHEMBL345714,,,ZINC000001481960
Amorolfine,phase 4 complete,DB09056,[H]C(C)(CN1C[C@]([H])(C)O[C@]([H])(C)C1)CC1=CC=C(C=C1)C(C)(C)CC,Anti-Infective Agents / Antifungal Agents / Antifungals for Dermatological Use / Antifungals for Topical Use / Dermatologicals / Oxazines,AB0BHP2FH0,78613-35-1,,,49010.0,,17804.0,599440.0,CHEMBL489411,,,
Atosiban,phase 4 complete,DB09059,[H][C@]1(NC(=O)[C@@]([H])(NC(=O)[C@@H](CC2=CC=C(OCC)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)[C@@H](C)CC)[C@@H](C)O,"Amino Acids, Peptides, and Proteins / Genito Urinary System and Sex Hormones / Hormone Antagonists / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Peptide Hormones / Peptides / Pituitary Hormones / Pituitary Hormones, Posterior / Reproductive Control Agents / Tocolytic Agents",081D12SI0Z,90779-69-4,D03008,,4470550.0,50177595.0,59639.0,135899.0,CHEMBL382301,,,ZINC000169362009
Avibactam,phase 4 complete,DB09060,NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O,Anti-Infective Agents / Aza Compounds / beta-Lactamase Inhibitors / Enzyme Inhibitors / OAT3/SLC22A8 Substrates,7352665165,1192500-31-4,,9835049.0,8010770.0,50339145.0,1603834.0,85984.0,CHEMBL1689063,,,ZINC000009302239
Cannabidiol,phase 4 complete,DB09061,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1,Agents producing tachycardia / Agents that produce hypertension / Anticonvulsants / Antidepressive Agents / BCRP/ABCG2 Inhibitors / Cannabinoids and similars / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Nervous System / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin 5-HT2 Receptor Agonists / Serotonin Agents / Serotonin Receptor Agonists / Terpenes,19GBJ60SN5,13956-29-1,,644019.0,559095.0,50121429.0,2045371.0,69478.0,CHEMBL190461,,,ZINC000004097406
Ceritinib,phase 4 complete,DB09063,CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Bradycardia-Causing Agents / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Hyperglycemia-Associated Agents / Kinase Inhibitor / Moderate Risk QTc-Prolonging Agents / Narrow Therapeutic Index Drugs / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Protein Kinase Inhibitors / QTc Prolonging Agents / Receptor Protein-Tyrosine Kinases, antagonists & inhibitors / Sulfur Compounds / Tyrosine Kinase Inhibitors",K418KG2GET,1032900-25-6,D10551,57379345.0,29315053.0,50436850.0,1535457.0,78432.0,CHEMBL2403108,,,ZINC000096272772
Ciprofibrate,phase 4 complete,DB09064,CC(C)(OC1=CC=C(C=C1)C1CC1(Cl)Cl)C(O)=O,"Acids, Acyclic / Agents Causing Muscle Toxicity / Benzene Derivatives / Butyrates / Carcinogens / Ethers / Fatty Acids / Fatty Acids, Volatile / Fibric Acids / Hypolipidemic Agents / Isobutyrates / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Lipids / Noxae / Peroxisome Proliferators / Phenols / Phenyl Ethers / Toxic Actions",F8252JGO9S,52214-84-3,D03521,,2661.0,50371235.0,21149.0,50867.0,CHEMBL557555,,,
Cobicistat,phase 4 complete,DB09065,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1,"Acids, Acyclic / Anti-HIV Agents / Anti-Infective Agents / Antiinfectives for Systemic Use / BCRP/ABCG2 Inhibitors / Breast Cancer Resistance Protein Inhibitors / Carbamates / Chemically-Induced Disorders / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strong) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strong) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B3 Inhibitors / Other Miscellaneous Therapeutic Agents / P-glycoprotein inhibitors / Sulfur Compounds / Thiazoles",LW2E03M5PG,1004316-88-4,D09881,25151504.0,25084912.0,50447471.0,1306284.0,72291.0,CHEMBL2095208,,PA166165092,ZINC000085537014
Corticorelin ovine triflutate,phase 4 complete,DB09067,CC[C@H](C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](C)C(N)=O,"Amino Acids, Peptides, and Proteins / Diagnostic Agents / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypothalamic Hormones / Nerve Tissue Proteins / Neuropeptides / Peptide Hormones / Peptides / Pituitary Hormone-Releasing Hormones / Proteins / Tests for Pituitary Function",56X54T817Q,121249-14-7,D03592,16132344.0,17289003.0,,74671.0,65307.0,CHEMBL1201591,,,
Trimetazidine,phase 4 complete,DB09069,COC1=C(OC)C(OC)=C(CN2CCNCC2)C=C1,Cardiac Therapy / Cardiovascular Agents / Piperazines / Vasodilating Agents,N9A0A0R9S8,5011-34-7,D01606,21109.0,19853.0,80613.0,10826.0,94789.0,CHEMBL203266,,,ZINC000019358638
Tibolone,phase 4 complete,DB09070,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC(=O)CC3)C[C@@]([H])(C)[C@@]21[H],"Anabolic Agents / Antineoplastic Agents, Hormonal / Cardiovascular Agents / Estrogen Receptor Modulators / Estrogens / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormone Antagonists / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Norpregnanes / Norsteroids / Sex Hormones and Modulators of the Genital System / Steroids",FF9X0205V2,5630-53-5,D01639,444008.0,392038.0,,38260.0,32223.0,CHEMBL2103774,,,ZINC000003812889
Sodium oxybate,phase 4 complete,DB09072,[Na+].OCCCC([O-])=O,"Acids, Acyclic / Adjuvants, Anesthesia / Anesthetics / Anesthetics, General / Anesthetics, Intravenous / Butyrates / Central Nervous System Agents / Central Nervous System Depressants / Fatty Acids / Fatty Acids, Volatile / Hydroxy Acids / Hydroxybutyrates / Lipids / Miscellaneous Central Nervous System Agents / Nervous System",7G33012534,502-85-2,,23663870.0,9983.0,,9899.0,,CHEMBL1200682,,,
Palbociclib,phase 4 complete,DB09073,CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cyclin-Dependent Kinases, antagonists & inhibitors / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Immunosuppressive Agents / Kinase Inhibitor / Myelosuppressive Agents / Narrow Therapeutic Index Drugs / OCT1 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors",G9ZF61LE7G,571190-30-2,D10372,5330286.0,4487437.0,6309.0,1601374.0,85993.0,CHEMBL189963,,PA166153469,ZINC000003938686
Edoxaban,phase 4 complete,DB09075,CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1,Anticoagulants / Antithrombins / Blood and Blood Forming Organs / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Factor Xa Inhibitors / Fibrinolytic Agents / Hematologic Agents / P-glycoprotein substrates / Protease Inhibitors / Serine Protease Inhibitors / Sulfur Compounds,NDU3J18APO,480449-70-5,D09546,10280735.0,8456212.0,50328731.0,1599538.0,85973.0,CHEMBL1269025,,PA166128806,ZINC000043200832
Umeclidinium,phase 4 complete,DB09076,OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2,"Adrenergics, Inhalants / Agents producing tachycardia / Agents to Treat Airway Disease / Anticholinergic Agents / Antimuscarinics Antispasmodics / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Muscarinic Antagonists / P-glycoprotein substrates / Pulmonary Disease, Chronic Obstructive, drug therapy",GE2T1418SV,869185-19-3,D10180,11519070.0,9693858.0,50267614.0,1487514.0,79041.0,CHEMBL1187833,,,ZINC000034608502
Lenvatinib,phase 4 complete,DB09078,COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Benzene Derivatives / BSEP/ABCB11 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Kinase Inhibitor / Moderate Risk QTc-Prolonging Agents / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors / QTc Prolonging Agents / Receptor Tyrosine Kinase Inhibitors / Tyrosine Kinase Inhibitors",EE083865G2,417716-92-8,D09919,9823820.0,7999567.0,50331094.0,1603296.0,85994.0,CHEMBL1289601,,PA166153472,ZINC000003816292
Nintedanib,phase 4 complete,DB09079,COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1,"Antifibrotic Agents / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Kinase Inhibitor / OCT1 inhibitors / OCT1 substrates / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors / Tyrosine Kinase Inhibitors / UGT1A1 Substrates",G6HRD2P839,656247-17-5,D10481,9809715.0,7985471.0,50026612.0,1592737.0,85164.0,CHEMBL502835,,,ZINC000100014909
Olodaterol,phase 4 complete,DB09080,COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1,"Adrenergic Agonists / Adrenergic beta-1 Receptor Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Adrenergics, Inhalants / Agents producing tachycardia / Agents that produce hypertension / Agents to Treat Airway Disease / Anti-Asthmatic Agents / Autonomic Agents / Bronchodilator Agents / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Drugs for Obstructive Airway Diseases / Heterocyclic Compounds, Fused-Ring / Oxazines / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Respiratory System Agents / Selective Beta 2-adrenergic Agonists",VD2YSN1AFD,868049-49-4,D10145,11504295.0,9679097.0,,1546059.0,82700.0,CHEMBL605846,,,ZINC000034636383
Idebenone,phase 4 complete,DB09081,COC1=C(OC)C(=O)C(CCCCCCCCCCCCO)=C(C)C1=O,"Antioxidants / Benzoquinones / Coenzymes / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Enzymes and Coenzymes / Nervous System / Protective Agents / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Quinones",,58186-27-9,D01750,12881464.0,14944546.0,,51296.0,31687.0,CHEMBL252556,,,
Ivabradine,phase 4 complete,DB09083,COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1,"Benzazepines / Bradycardia-Causing Agents / Cardiac Therapy / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists / Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker / Miscellaneous Cardiac Drugs / QTc Prolonging Agents",3H48L0LPZQ,155974-00-8,D07165,132999.0,117373.0,50326992.0,1649480.0,85966.0,CHEMBL471737,,PA166123415,ZINC000003805768
Benzydamine,phase 4 complete,DB09084,CN(C)CCCOC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12,"Agents causing hyperkalemia / Agents that produce hypertension / Alimentary Tract and Metabolism / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antiinflammatory Products for Vaginal Administration / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Indazoles / Mouthwashes and Gargles / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Pyrazoles / Stomatological Preparations / Throat Preparations / Topical Products for Joint and Muscular Pain",4O21U048EF,642-72-8,,12555.0,12036.0,50103598.0,1425.0,94563.0,CHEMBL12610,,,ZINC000002020083
Tetracaine,phase 4 complete,DB09085,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,"Acids, Carbocyclic / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Aminobenzoates / Anesthetics / Anesthetics for Topical Use / Anesthetics, General / Anesthetics, Local / Antipruritics and Local Anesthetics / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Benzene Derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Dental Agents / Dermatologicals / Esters of Aminobenzoic Acid / Local Anesthesia / Local Anesthetics (Ester) / Nervous System / Ophthalmologicals / para-Aminobenzoates / Peripheral Nervous System Agents / Sensory Organs / Sensory System Agents / Vasoprotectives",0619F35CGV,94-24-6,D00551,5411.0,5218.0,50017659.0,10391.0,9468.0,CHEMBL698,,PA451638,ZINC000001530811
Eugenol,phase 4 complete,DB09086,COC1=C(O)C=CC(CC=C)=C1,"Acids, Carbocyclic / Anti-Infective Agents / Caffeic Acids / Cell-mediated Immunity / Cinnamates / Compounds used in a research, industrial, or household setting / Increased Histamine Release / Solvents / Standardized Chemical Allergen",3T8H1794QW,97-53-0,,3314.0,13876103.0,50164168.0,4186.0,4917.0,CHEMBL42710,,,ZINC000000001411
Potassium alum,phase 4 complete,DB09087,[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O,"Acids / Acids, Noncarboxylic / Adjuvants, Immunologic / Aluminium Compounds / Anions / Electrolytes / Immunologic Factors / Ions / Metal cations / Metal divalent cations / Potassium Salt / Sulfates / Sulfur Acids / Sulfur Compounds / Sulfuric Acids",09OXB01F3O,10043-67-1,,24856.0,23239.0,,54989.0,86463.0,,,,
Amylocaine,phase 4 complete,DB09088,CCC(C)(CN(C)C)OC(=O)C1=CC=CC=C1,"Acids, Carbocyclic / Benzene Derivatives",QRW683O56T,644-26-8,D07454,10767.0,10312.0,,40660.0,34981.0,CHEMBL1740065,,,
Trimebutine,phase 4 complete,DB09089,CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents producing tachycardia / Alimentary Tract and Metabolism / Antiarrhythmic agents / Anticholinergic Agents / Antimuscarinics Antispasmodics / Autonomic Agents / Benzene Derivatives / Benzoates / Bradycardia-Causing Agents / Calcium Channel Blockers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Functional Gastrointestinal Disorders / Drugs that are Mainly Renally Excreted / Ethers / Gastrointestinal Agents / Hydroxy Acids / Hydroxybenzoate Ethers / Hydroxybenzoates / Muscarinic Antagonists / Parasympatholytics / Peripheral Nervous System Agents / Phenols / Phenyl Ethers / Potential QTc-Prolonging Agents / Prokinetic Agents / QTc Prolonging Agents / Synthetic Anticholinergics, Esters With Tertiary Amino Group",QZ1OJ92E5R,39133-31-8,,5573.0,5372.0,83417.0,10819.0,94458.0,CHEMBL190044,,,
Pinaverium,phase 4 complete,DB09090,COC1=C(OC)C=C(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)C(Br)=C1,Agents causing hyperkalemia / Alimentary Tract and Metabolism / Antiarrhythmic agents / Autonomic Agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Functional Gastrointestinal Disorders / Membrane Transport Modulators / Miscellaneous GI Drugs / Oxazines / Parasympatholytics / Peripheral Nervous System Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Vasodilating Agents,U2368VVE7O,59995-65-2,,40704.0,37182.0,50101975.0,33724.0,135811.0,CHEMBL1909324,,,
Tixocortol,phase 4 complete,DB09091,[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"11-Hydroxycorticosteroids / 17-Hydroxycorticosteroids / Adrenal Cortex Hormones / Alimentary Tract and Metabolism / Anti-Allergic Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Cell-mediated Immunity / Corticosteroids / Corticosteroids Acting Locally / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydroxycorticosteroids / Immunosuppressive Agents / Increased Histamine Release / Intestinal Antiinflammatory Agents / Nasal Preparations / Pregnanes / Pregnenediones / Pregnenes / Standardized Chemical Allergen / Steroids",ZX3KEK657Z,61951-99-3,,162955.0,143053.0,,57257.0,63560.0,,,,ZINC000005138848
Xanthinol,phase 4 complete,DB09092,CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C,"Alkaloids / Cardiovascular Agents / Heterocyclic Compounds, Fused-Ring / Nicotinic Acids / Peripheral Vasodilators / Purine Derivatives / Purines / Purinones / Pyridines / Vasodilating Agents",TN1B5910V2,2530-97-4,,9913.0,9526.0,,89795.0,94314.0,CHEMBL1624126,,,
Chlortetracycline,phase 4 complete,DB09093,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC(Cl)=C1[C@@]3(C)O,Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antibiotics for Topical Use / Antiinfectives and Antiseptics for Local Oral Treatment / Antiinfectives for Systemic Use / Antiparasitic Agents / Antiprotozoals / Dermatologicals / Enzyme Inhibitors / Naphthacenes / Ophthalmologicals / Protein Synthesis Inhibitors / Sensory Organs / Stomatological Preparations / Tetracyclines,WCK1KIQ23Q,57-62-5,D07689,54708735.0,10469370.0,,2408.0,27644.0,CHEMBL404520,,,ZINC000019701769
Podophyllin,phase 4 complete,DB09094,COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O,"Antineoplastic Agents / Antineoplastic Agents, Phytogenic / Biological Products / Caustics / Complex Mixtures / Compounds used in a research, industrial, or household setting / Dermatologicals / Keratolytic Agents / Misc. Skin and Mucous Membrane Agents / Noxae / Pharmaceutical Preparations / Plant Extracts / Plant Preparations / Toxic Actions",16902YVY2B,9000-55-9,,11979494.0,10152781.0,,8462.0,,,,,
Difluocortolone,phase 4 complete,DB09095,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Pregnadienediols / Pregnadienes / Pregnanes / Steroids / Steroids, Fluorinated",K253365DXI,2607-06-9,,11954369.0,10128664.0,,3392.0,135624.0,CHEMBL509924,,,ZINC000004212939
Benzoyl peroxide,phase 4 complete,DB09096,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,"Acids, Carbocyclic / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Benzene Derivatives / Benzoates / Dermatologicals / Keratolytic Agents / Nitrogen Binding Agent / Peroxides",W9WZN9A0GM,94-36-0,D03093,7187.0,6919.0,,1418.0,82405.0,CHEMBL1200370,,,ZINC000000001016
Quinagolide,phase 4 complete,DB09097,[H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC,"Dopamine Agents / Dopamine Agonists / Dopamine D2 Receptor Agonists / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Miscellaneous Therapeutic Agents / Neurotransmitter Agents / Prolactine Inhibitors / Quinolines",80Q9QWN15M,87056-78-8,,3086401.0,2343034.0,50225362.0,76887.0,135627.0,CHEMBL290962,,,ZINC000003778441
Somatostatin,phase 4 complete,DB09099,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O,"Amino Acids, Peptides, and Proteins / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypothalamic Hormones / Nerve Tissue Proteins / Neuropeptides / P-glycoprotein substrates / Pancreatic Hormones / Peptide Hormones / Peptides / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormone Release Inhibiting Hormones / Proteins / Somatostatin and Analogues / Somatostatin, agonists / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",6E20216Q0L,38916-34-6,D07431,16129681.0,17286507.0,81767.0,9939.0,64628.0,CHEMBL1823872,,,
Daclatasvir,phase 4 complete,DB09102,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / BCRP/ABCG2 Inhibitors / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Direct Acting Antivirals / HCV Replication Complex Inhibitors / Hepatitis C Virus NS5A Inhibitor / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B3 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates,LI2427F9CI,1009119-64-5,D10105,25154714.0,24609522.0,50387084.0,1606218.0,82977.0,CHEMBL2023898,,PA166128167,ZINC000068204830
Magnesium hydroxide,phase 4 complete,DB09104,[OH-].[OH-].[Mg++],"Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Alkalies / Aluminum and magnesium containing antacids / Anions / Antacids / Antacids and Adsorbents / Basic Ointments and Protectants / Calculi Dissolution Agent / Drugs for Acid Related Disorders / Drugs that are Mainly Renally Excreted / Electrolytes / Emollients Demulcents and Protectants / Gastric Acid Lowering Agents / Gastrointestinal Agents / Genito Urinary System and Sex Hormones / Hydroxides / Ions / Laxatives / Laxatives, magnesium containing / Magnesium Compounds / Magnesium Salts / Metal cations / Metal divalent cations / Osmotic Laxatives / Urologicals",NBZ3QY004S,1309-42-8,,73981.0,14107.0,,6581.0,6637.0,CHEMBL1200718,,,
Hydroxyethyl Starch,phase 4 complete,DB09106,,"Biomimetic Materials / Biopolymers / Blood and Blood Forming Organs / Blood and Related Products / Blood Substitutes / Blood Substitutes and Perfusion Solutions / Blood Substitutes and Plasma Protein Fractions / Carbohydrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Dietary Carbohydrates / Drugs that are Mainly Renally Excreted / Food / Food and Beverages / Glucans / Hematologic Agents / Increased Intravascular Volume / Macromolecular Substances / Osmotic Activity / Physiological Phenomena / Plasma Substitutes / Polymers / Polysaccharides / Replacement Preparations / Starch",875Y4127EA,9005-27-0,D03335,,,,5531.0,,CHEMBL2108448,,,
Coenzyme M,phase 4 complete,DB09110,OS(=O)(=O)CCS,"Acids / Acids, Noncarboxylic / Alkanes / Alkanesulfonates / Alkanesulfonic Acids / Compounds used in a research, industrial, or household setting / Cough and Cold Preparations / Cytoprotective Agent / Detoxifying Agents for Antineoplastic Treatment / Expectorants / Hydrocarbons, Acyclic / Mesna / Protective Agents / Sulfhydryl Compounds / Sulfonic Acids / Sulfur Acids / Sulfur Compounds",VHD28S0H7F,3375-50-6,,598.0,578.0,,1546354.0,17905.0,CHEMBL1098319,,,ZINC000003831040
Pentastarch,phase 4 complete,DB09111,,"Biomimetic Materials / Biopolymers / Blood Substitutes / Carbohydrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Dietary Carbohydrates / Drugs that are Mainly Renally Excreted / Food / Food and Beverages / Glucans / Hematologic Agents / Increased Intravascular Volume / Macromolecular Substances / Osmotic Activity / Physiological Phenomena / Plasma Substitutes / Polymers / Polysaccharides / Starch",MOQ3RNM0SV,9005-27-0,,,,,816249.0,,,,,
Nitrous acid,phase 4 complete,DB09112,ON=O,"Acids / Acids, Noncarboxylic / Anions / Antidotes / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Electrolytes / Food / Food Additives / Food and Beverages / Food Ingredients / Food Preservatives / Hypotensive Agents / Indicators and Reagents / Ions / Laboratory Chemicals / Nitrites / Nitrogen Compounds / Physiological Phenomena / Sodium Compounds",T2I5UM75DN,7782-77-6,,23668193.0,22936.0,50147619.0,,25567.0,CHEMBL1161681,,PA166115361,
Colfosceril palmitate,phase 4 complete,DB09114,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,Alcohols / Carbohydrates / Glycerophosphates / Glycerophospholipids / Lipids / Lung Surfactants / Membrane Lipids / Phosphatidic Acids / Phosphatidylcholines / Phospholipids / Pulmonary Surfactants / Sugar Alcohols / Sugar Phosphates / Triose Sugar Alcohols,319X2NFW0A,63-89-8,,452110.0,398235.0,,69782.0,72999.0,CHEMBL1200737,,,
Diiodohydroxyquinoline,phase 4 complete,DB09115,OC1=C2N=CC=CC2=C(I)C=C1I,"Amebicides / Anti-Infective Agents / Antiparasitic Agents / Antiprotozoals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hydroxyquinolines / Quinoline Derivatives / Quinolines",63W7IE88K8,83-73-8,D00581,3728.0,3597.0,66035.0,3435.0,5950.0,CHEMBL86754,,,ZINC000003830942
Calcium carbimide,phase 4 complete,DB09116,[Ca++].[N-]=C=[N-],Drugs Used in Addictive Disorders / Drugs Used in Alcohol Dependence / Nervous System,ZLR270912W,156-62-7,D03288,56955933.0,21106503.0,,1902.0,64301.0,CHEMBL3301667,,,
Paraldehyde,phase 4 complete,DB09117,CC1OC(C)OC(C)O1,Acetaldehyde / Anticonvulsants / Central Nervous System Agents / Central Nervous System Depressants / Hypnotics and Sedatives / Nervous System / Psycholeptics,S6M3YBG8QA,123-63-7,,31264.0,21106173.0,,7909.0,27909.0,CHEMBL1410743,,,ZINC000000001886
Stiripentol,phase 4 complete,DB09118,CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1,Anticonvulsants / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (strong) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dioxoles / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Miscellaneous Anticonvulsants / Nervous System / Photosensitizing Agents,R02XOT8V8I,49763-96-4,,5311454.0,4470940.0,,2054968.0,,CHEMBL1983350,,,
Eslicarbazepine acetate,phase 4 complete,DB09119,CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12,"Anticonvulsants / Carboxamide Derivatives / Cardiovascular Agents / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (moderate) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Eslicarbazepine and prodrugs / Heterocyclic Compounds, Fused-Ring / Membrane Transport Modulators / Nervous System / Sodium Channel Blockers / UGT1A1 Substrates / Voltage-Gated Sodium Channel Blockers",BEA68ZVB2K,236395-14-5,D09612,179344.0,156110.0,50240669.0,1482501.0,87016.0,CHEMBL87992,,,ZINC000000007295
Zucapsaicin,phase 4 complete,DB09120,COC1=C(O)C=CC(CNC(=O)CCCC\C=C/C(C)C)=C1,"Alkaloids / Alkenes / Alkynes / Amides / Benzene Derivatives / Capsaicin and Similar Agents / Catechols / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Fatty Acids / Fatty Acids, Monounsaturated / Fatty Acids, Unsaturated / Hydrocarbons, Acyclic / Lipids / Musculo-Skeletal System / Other Nonsteroidal Anti-inflammatory Agents / Phenols / Polyunsaturated Alkamides / Solanaceous Alkaloids / Topical Products for Joint and Muscular Pain",15OX67P384,25775-90-0,,1548942.0,1265956.0,,,135952.0,CHEMBL313971,,,ZINC000004468952
Aurothioglucose,phase 4 complete,DB09121,OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O,Antiinflammatory and Antirheumatic Products / Antirheumatic Agents / Drugs that are Mainly Renally Excreted / Gold Preparations / Musculo-Skeletal System / Organogold Compounds / Organometallic Compounds / Specific Antirheumatic Agents,2P2V9Q0E78,12192-57-3,D00991,6104.0,5879.0,,4980.0,2930.0,,,,
Dienogest,phase 4 complete,DB09123,[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H],"Adrenal Cortex Hormones / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptive Agents, Male / Contraceptives, Oral / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Estranes / Estrenes / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormone Antagonists / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Pregnadien Derivatives / Progestin Contraceptives / Progestins / Progestogens and Estrogens, Sequential Preparations / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids / Testosterone Congeners",46M3EV8HHE,65928-58-7,,68861.0,62093.0,,22968.0,70708.0,CHEMBL1201864,,,ZINC000004215629
Medrogestone,phase 4 complete,DB09124,[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,"Adrenal Cortex Hormones / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Pregnadien Derivatives / Pregnadienes / Pregnanes / Progestins / Progestogens and Estrogens, Sequential Preparations / Sex Hormones and Modulators of the Genital System / Steroids",077DN93G5B,977-79-7,,9949848.0,8125459.0,,6690.0,135446.0,CHEMBL2106825,,,ZINC000004216820
Potassium citrate,phase 4 complete,DB09125,[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,"Acids, Acyclic / Agents causing hyperkalemia / Alimentary Tract and Metabolism / Alkalinizing Activity / Anticoagulants / Calculi Dissolution Agent / Cardiovascular Agents / Citrates / Citric Acid Derivatives / Diuretics / Expectorants / Metabolic Alkalinizer / Mineral Supplements / Natriuretic Agents / Potassium Salt / Replacement Preparations / Respiratory System Agents / Tricarboxylic Acids / Urinary Alkalinisers",86R1NVR0HW,866-84-2,,13344.0,12775.0,,54993.0,64733.0,CHEMBL1200458,,,
"Sodium phosphate, monobasic",phase 4 complete,"DB09449 (DB09127, DB11083, DB09524, DB09542, DB09468, DB11084, DB09482, DB09469, DB09525, DBSALT001969)",[Na+].OP(O)([O-])=O,"Acids / Acids, Noncarboxylic / Agents that reduce seizure threshold / Anions / Electrolytes / Ions / Laxatives / Osmotic Laxatives / Phosphate salts / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds / Potassium Salt / Urinary Acidifying Agents",KH7I04HPUU,7558-80-7,,23672064.0,22626.0,,,37585.0,CHEMBL1368,,,
Brexpiprazole,phase 4 complete,DB09128,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Agonists / Dopamine D2 Receptor Agonists / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Psycholeptics / Quinolines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Agonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Agonists / Serotonin Receptor Antagonists / Sulfur Compounds",2J3YBM1K8C,913611-97-9,D10309,11978813.0,10152155.0,194780.0,1658314.0,134716.0,CHEMBL2105760,,PA166160053,ZINC000084758479
Chromic chloride,phase 4 complete,DB09129,[Cl-].[Cl-].[Cl-].[Cr+3],"Acids / Acids, Noncarboxylic / Anions / Antioxidants / Chlorine Compounds / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Electrolytes / Ions / Minerals / Protective Agents / Replacement Preparations",Z310X5O5RP,10025-73-7,,6452300.0,23193.0,,21009.0,53351.0,,,,
Copper,phase 4 complete,DB09130,[Cu],"Copper-containing Intrauterine Device / Decreased Embryonic Implantation / Decreased Sperm Motility / Diet, Food, and Nutrition / Elements / Food / Food and Beverages / Growth Substances / Inhibit Ovum Fertilization / Metals / Metals, Heavy / Micronutrients / Minerals / Physiological Phenomena / Replacement Preparations / Trace Elements / Transition Elements",789U1901C5,7440-50-8,,23978.0,22414.0,,2837.0,28694.0,,,PA449114,
Cupric Chloride,phase 4 complete,DB09131,Cl[Cu]Cl,"Elements / Metals / Metals, Heavy / Transition Elements",P484053J2Y,7447-39-4,,24014.0,22447.0,,150596.0,49553.0,CHEMBL1200553,,,
Gadoteric acid,phase 4 complete,DB09132,[Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,"Alcohols / Amino Sugars / Carbohydrates / Chelating Agents / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Gadolinium-based Contrast Agent / Hexosamines / Magnetic Resonance Imaging Contrast Media / Paramagnetic Contrast Media / Roentgenography / Sequestering Agents / Sugar Alcohols",QVF9Y6955W,72573-82-1,D08007,158536.0,139460.0,,,73732.0,CHEMBL3833326,,,
Iothalamic acid,phase 4 complete,DB09133,CNC(=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I,"Acids, Carbocyclic / Alcohols / Amino Sugars / Benzene Derivatives / Benzoates / Carbohydrates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Hexosamines / Iodobenzoates / Radiographic Contrast Agent / Roentgenography / Sugar Alcohols / Triiodobenzoic Acids / Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media / X-Ray Contrast Activity / X-Ray Contrast Media, Iodinated",16CHD79MIX,2276-90-6,D01258,3737.0,3606.0,,1546451.0,31713.0,CHEMBL1201300,,,ZINC000003830961
Ioversol,phase 4 complete,DB09134,OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Iodinated Contrast Agents / Iodobenzoates / Radiographic Contrast Agent / Roentgenography / Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media / X-Ray Contrast Activity / X-Ray Contrast Media, Iodinated",N3RIB7X24K,87771-40-2,D01555,3741.0,3610.0,,27792.0,31717.0,CHEMBL1200614,,,
Ioxilan,phase 4 complete,DB09135,CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Iodinated Contrast Agents / Iodobenzoates / Radiographic Contrast Agent / Triiodobenzoic Acids / Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media / X-Ray Contrast Activity / X-Ray Contrast Media, Iodinated",A4YJ7J11TG,107793-72-6,D02161,3743.0,3612.0,,27793.0,135884.0,CHEMBL1201075,,,
Isosulfan blue,phase 4 complete,DB09136,CCN(CC)C1=CC=C(C=C1)C(=C1C=CC(C=C1)=[N+](CC)CC)C1=CC(=CC=C1S(O)(=O)=O)S(O)(=O)=O,"Amines / Aniline Compounds / Coloring Agents / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted",NS6Q291771,748080-29-7,,50108.0,4533.0,,1546453.0,,CHEMBL1615783,,,ZINC000003873832
Technetium Tc-99m mebrofenin,phase 4 complete,DB09137,[99Tc].[H]OC(=O)C([H])([H])N(C([H])([H])C(=O)O[H])C([H])([H])C(=O)N([H])C1=C(C(Br)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H],"Acids, Acyclic / Amino Acids / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Compounds used in a research, industrial, or household setting / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Hepatic and Reticulo Endothelial System / Imines / Indicators and Reagents / Laboratory Chemicals / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / Organometallic Compounds / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Technetium (99Mtc) Compounds",F2NQ468L52,1415247-71-0,D06037,11431716.0,,,1311500.0,,CHEMBL2110555,,,
Technetium Tc-99m medronate,phase 4 complete,DB09138,O.O.[98Tc+4].[O-]P([O-])(=O)CP([O-])([O-])=O,"Compounds used in a research, industrial, or household setting / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Indicators and Reagents / Laboratory Chemicals / Organometallic Compounds / Organophosphonates / Organophosphorus Compounds / Organotechnetium Compounds / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Skeleton / Technetium (99Mtc) Compounds",X89XV46R07,121524-79-6,D02029,131704315.0,34995234.0,,1488818.0,32186.0,CHEMBL2110576,,,
Technetium Tc-99m oxidronate,phase 4 complete,DB09139,[99Tc].OC(P(O)(O)=O)P(O)(O)=O,Diagnostic Radiopharmaceuticals / Drugs that are Mainly Renally Excreted / Organometallic Compounds / Organophosphonates / Organophosphorus Compounds / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Skeleton / Technetium (99Mtc) Compounds,MG4KI49HHJ,72945-61-0,D06041,123801.0,,,,,,,,
Oxygen,phase 4 complete,DB09140,O=O,Chalcogens / Elements / Gases / Medical Gases / Miscellaneous Therapeutic Agents / Other Miscellaneous Therapeutic Agents,S88TT14065,7782-44-7,D00003,977.0,952.0,,7806.0,27140.0,CHEMBL1234886,,PA450744,
Sincalide,phase 4 complete,DB09142,CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,"Amino Acids, Peptides, and Proteins / Cholecystokinin Analog / Diagnostic Agents / Gallbladder Function / Gastrointestinal Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OATP1B3 substrates / Peptides / Tests for Bile Duct Patency",M03GIQ7Z6P,25126-32-3,D05845,9833444.0,8009168.0,21147.0,9800.0,135946.0,CHEMBL1121,,,
Sonidegib,phase 4 complete,DB09143,[H][C@]1(C)CN(C[C@@]([H])(C)O1)C1=CC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=N1,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Benzene Derivatives / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Hedgehog Pathway Inhibitor / Narrow Therapeutic Index Drugs / Smoothened Receptor Antagonists,0RLU3VTK5M,956697-53-3,D10119,24775005.0,25027390.0,50394562.0,1659191.0,90863.0,CHEMBL2105737,,,ZINC000068202099
Water,phase 4 complete,DB09145,O,"Diluents / EENT Drugs, Miscellaneous / Irrigating Solutions / Other Miscellaneous Therapeutic Agents / Oxygen Compounds",059QF0KO0R,7732-18-5,D00001,962.0,937.0,,107129.0,15377.0,CHEMBL1098659,,,
Florbetaben (18F),phase 4 complete,DB09148,CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCC[18F])C=C2)C=C1,Amines / Benzene Derivatives / Benzylidene Compounds / Central Nervous System / Diagnostic Radiopharmaceuticals / Drugs that are Mainly Renally Excreted / Fluorine Radioisotopes / Positron Emitting Activity / Radioactive Diagnostic Agent,TLA7312TOI,902143-01-5,D10002,11501341.0,9676143.0,,1492940.0,79033.0,CHEMBL566752,,,ZINC000100529288
Florbetapir (18F),phase 4 complete,DB09149,[H]N(C1=C([H])C([H])=C(\C([H])=C(/[H])C2=C([H])N=C(OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])[18F])C([H])=C2[H])C([H])=C1[H])C([H])([H])[H],Alcohols / Amines / Central Nervous System / Diagnostic Radiopharmaceuticals / Drugs that are Mainly Renally Excreted / Fluorine Radioisotopes / Glycols / Positron Emitting Activity / Radioactive Diagnostic Agent,6W15Z5R0RU,956103-76-7,D09617,24822371.0,26348452.0,,1427224.0,66880.0,CHEMBL1774461,,,ZINC000100090643
Fludeoxyglucose (18F),phase 4 complete,DB09502 (DB09150),[H]C(=O)[C@H]([18F])[C@@H](O)[C@H](O)[C@H](O)CO,"Carbohydrates / Compounds used in a research, industrial, or household setting / Deoxy Sugars / Deoxyglucose / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Indicators and Reagents / Laboratory Chemicals / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Tumour Detection",0Z5B2CJX4D,63503-12-8,,68614.0,61878.0,,1362737.0,49136.0,CHEMBL1808698,,,ZINC000100079041
Flutemetamol (18F),phase 4 complete,DB09151,CNC1=C([18F])C=C(C=C1)C1=NC2=CC=C(O)C=C2S1,"Amines / Central Nervous System / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Heterocyclic Compounds, Fused-Ring / Indicators and Reagents / Laboratory Chemicals / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Sulfur Compounds / Thiazoles",L49M066S0O,765922-62-1,D10231,15950376.0,13092196.0,,1486025.0,76611.0,CHEMBL2042122,,,ZINC000100096928
Nitrogen,phase 4 complete,DB09152,N#N,Elements / Gases / Medical Gases / Miscellaneous Therapeutic Agents / Other Miscellaneous Therapeutic Agents,N762921K75,7727-37-9,D00083,947.0,922.0,,7456.0,17997.0,CHEMBL142438,,,
Sodium chloride,phase 4 complete,DB09153,[Na+].[Cl-],"Acids / Acids, Noncarboxylic / Alimentary Tract and Metabolism / Anions / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Chlorides / Chlorine Compounds / Diluents / EENT Drugs, Miscellaneous / Electrolyte Solutions / Electrolytes / I.V. Solution Additives / Ions / Irrigating Solutions / Mineral Supplements / Miscellaneous Therapeutic Agents / Other Miscellaneous Therapeutic Agents / Replacement Preparations / Respiratory Agents, Miscellaneous / Salt Solutions / Sodium / Sodium Compounds",451W47IQ8X,7647-14-5,D02056,5234.0,5044.0,50098543.0,9863.0,26710.0,CHEMBL1200574,,PA451382,
Sodium citrate,phase 4 complete,DB09154 (DB09159),[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,"Acids, Acyclic / Antacids and Adsorbents / Anticoagulants / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Buffers / Calculi Dissolution Agent / Citrates / Citric Acid Derivatives / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Food / Food Additives / Food and Beverages / Food Ingredients / Food Preservatives / Hematologic Agents / Irrigating Solutions / Laboratory Chemicals / Miscellaneous Anticoagulants / Miscellaneous GI Drugs / Neurotoxic agents / Physiological Phenomena / Salt Solutions / Tricarboxylic Acids / Urinary Alkalinisers",RS7A450LGA,68-04-2,D05855,6224.0,5989.0,,56466.0,53258.0,CHEMBL1355,,,
Helium,phase 4 complete,DB09155,[He],Elements / Gases / Medical Gases / Miscellaneous Therapeutic Agents / Noble Gases / Other Miscellaneous Therapeutic Agents,206GF3GB41,7440-59-7,D04420,23987.0,22423.0,,5140.0,33681.0,CHEMBL1796997,,PA449848,
Iopromide,phase 4 complete,DB09156,COCC(=O)NC1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Iodinated Contrast Agents / Iodobenzoates / Radiographic Contrast Agent / Roentgenography / Triiodobenzoic Acids / Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media / X-Ray Contrast Activity / X-Ray Contrast Media, Iodinated",712BAC33MZ,73334-07-3,D01893,3736.0,3605.0,,27781.0,63578.0,CHEMBL1725,,,
Carbon dioxide,phase 4 complete,DB09157,O=C=O,"Anions / Carbon Compounds, Inorganic / Electrolytes / Gases / Ions / Medical Gases / Miscellaneous Therapeutic Agents / Other Diagnostics / Other Miscellaneous Therapeutic Agents / Oxides / Oxygen Compounds / Radiographic Contrast Agent / X-Ray Contrast Activity",142M471B3J,124-38-9,D00004,280.0,274.0,,2034.0,16526.0,CHEMBL1231871,,PA448801,
Trypan blue free acidCommonly known or available as Trypan blue,phase 4 complete,DB09158,CC1=CC(=CC=C1\N=N\C1=C(C=C2C=C(C=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C=C(C=C2C=C1S(O)(=O)=O)S(O)(=O)=O,"Acids / Acids, Noncarboxylic / Arylsulfonates / Arylsulfonic Acids / Azo Compounds / Coloring Agents / Compounds used in a research, industrial, or household setting / Diagnostic Dye / Naphthalenes / Naphthalenesulfonates / Ocular Disorders / Sulfonic Acids / Sulfur Acids / Sulfur Compounds",768N7QO4KH,2538-83-2,,9562061.0,14833963.0,,1726081.0,78900.0,CHEMBL1089641,,,ZINC000169289767
Technetium Tc-99m tetrofosmin,phase 4 complete,DB09160 (DB09505),O.O.[98Tc].CCOCCP(CCOCC)CCP(CCOCC)CCOCC.CCOCCP(CCOCC)CCP(CCOCC)CCOCC,"Compounds used in a research, industrial, or household setting / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Indicators and Reagents / Laboratory Chemicals / Organometallic Compounds / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Technetium (99Mtc) Compounds",42FOP1YX93,127455-27-0,D06050,131704316.0,,,,,,,,
Technetium Tc-99m sestamibi,phase 4 complete,DB09161,[Tc+].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-],"Compounds used in a research, industrial, or household setting / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Indicators and Reagents / Laboratory Chemicals / Nitriles / Organometallic Compounds / Organotechnetium Compounds / P-glycoprotein substrates / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Technetium (99Mtc) Compounds",971Z4W1S09,109581-73-9,D01060,22617237.0,58829659.0,,1482913.0,9423.0,CHEMBL2074398,,,
Technetium Tc-99m exametazime,phase 4 complete,DB09163,,"Amines / Central Nervous System / Compounds used in a research, industrial, or household setting / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Hydroxylamines / Indicators and Reagents / Laboratory Chemicals / Organometallic Compounds / Organotechnetium Compounds / Oximes / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Technetium (99Mtc) Compounds",3B744AG22N,99944-78-2,D02284,,,,1431726.0,,CHEMBL2111018,,,
Technetium Tc-99m disofenin,phase 4 complete,DB09164,[99Tc].CC(C)C1=CC=CC(C(C)C)=C1NC(=O)CN(CC(O)=O)CC(O)=O,"Amino Acids / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Compounds used in a research, industrial, or household setting / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Drugs that are Mainly Renally Excreted / Hepatic and Reticulo Endothelial System / Imines / Imino Acids / Indicators and Reagents / Laboratory Chemicals / Organometallic Compounds / Organotechnetium Compounds / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Technetium (99Mtc) Compounds",QTJ2VIW97T,,,11430828.0,,,37665.0,,,,,
Technetium Tc-99m pyrophosphate,phase 4 complete,DB09165 (DB09417),[99Tc+4].[O-]P([O-])(=O)OP([O-])([O-])=O,"Acids / Acids, Noncarboxylic / Anions / Compounds used in a research, industrial, or household setting / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Diphosphates / Drugs that are Mainly Renally Excreted / Electrolytes / Indicators and Reagents / Ions / Laboratory Chemicals / Phosphate salts / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds / Polyphosphates / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Skeleton / Technetium (99Mtc) Compounds / Technetium Compounds",5L76I61H2B,52997-54-3,,6452753.0,,,1488368.0,,,,,
Dosulepin,phase 4 complete,DB09167,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12,"Adrenergic Agents / Adrenergic Uptake Inhibitors / Agents producing tachycardia / Agents that produce hypertension / Agents that reduce seizure threshold / Anticholinergic Agents / Antidepressive Agents / Antidepressive Agents, Tricyclic / Central Nervous System Agents / Central Nervous System Depressants / Combined Inhibitors of Serotonin/Norepinephrine Reuptake / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dibenzothiepins / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Membrane Transport Modulators / Muscarinic Antagonists / Narrow Therapeutic Index Drugs / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Non-Selective Monoamine Reuptake Inhibitors / Potential QTc-Prolonging Agents / Psychoanaleptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT1 Receptor Antagonists / Serotonin 5-HT1A Receptor Antagonists / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists / Sulfur Compounds / Tertiary amine tricyclic antidepressants / Thiepins",W13O82Z7HL,113-53-1,D07872,5284550.0,4447605.0,,3634.0,36803.0,CHEMBL1492500,,,ZINC000000020249
Dasabuvir,phase 4 complete,DB09183,COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C,Amides / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / BCRP/ABCG2 Inhibitors / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Direct Acting Antivirals / Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor / P-glycoprotein substrates / Pyrimidines / Pyrimidinones / RNA Replicase Inhibitors / Sulfones / Sulfur Compounds / UGT1A1 Inhibitors,DE54EQW8T1,1132935-63-7,D10582,56640146.0,29776744.0,,1597381.0,85182.0,CHEMBL3137312,,PA166163411,ZINC000095616937
Viloxazine,phase 4 complete,DB09185,CCOC1=CC=CC=C1OCC1CNCCO1,"Adrenergic Agents / Adrenergic Uptake Inhibitors / Antidepressive Agents / Antidepressive Agents, Second-Generation / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Drugs that are Mainly Renally Excreted / Membrane Transport Modulators / Morpholines / Nervous System / Neurotransmitter Agents / Neurotransmitter Uptake Inhibitors / Oxazines / Psychoanaleptics / Psychotropic Drugs",5I5Y2789ZF,46817-91-8,D08673,5666.0,5464.0,50025691.0,11196.0,94405.0,CHEMBL306700,,,
Lorpiprazole,phase 4 complete,DB09195,[H][C@@]12CCC[C@]1([H])C1=NN=C(CCN3CCN(CC3)C3=CC=CC(=C3)C(F)(F)F)N1C2,Antidepressive Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin 5-HT2C Receptor Antagonists / Serotonin Agents / Serotonin Modulators / Serotonin Receptor Antagonists,0M14O7T47Q,108785-69-9,,20055414.0,16736802.0,,,,,,,ZINC000000537940
Moxisylyte,phase 4 complete,DB09205,CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1,Adrenergic Agents / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Amines / Autonomic Agents / Cardiovascular Agents / Cholinesterase substrates / Dimethylamines / Drugs that are Mainly Renally Excreted / Drugs Used in Erectile Dysfunction / Genito Urinary System and Sex Hormones / Methylamines / Miotics / Neurotransmitter Agents / Peripheral Nervous System Agents / Peripheral Vasodilators / Sympatholytics / Urologicals / Vasodilating Agents,PW8QYA7KI0,54-32-0,D08239,4260.0,4110.0,50452139.0,10561.0,94754.0,CHEMBL159226,,,ZINC000000057401
Pholcodine,phase 4 complete,DB09209,[H][C@@]12OC3=C(OCCN4CCOCC4)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,"Alkaloids / Analgesics / Antitussive Agents / Central Nervous System Agents / Cough and Cold Preparations / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Morphinans / Morphine Derivatives / Opiate Alkaloids / Opium Alkaloids and Derivatives / Oxazines / Peripheral Nervous System Agents / Phenanthrenes / Respiratory System Agents / Sensory System Agents",LPP64AWZ7L,509-67-1,D07385,5311356.0,4470854.0,,33431.0,53579.0,CHEMBL2105224,,,ZINC000004217287
Piracetam,phase 4 complete,DB09210,NC(=O)CN1CCCC1=O,"Acetamides / Acetates / Acids, Acyclic / Amides / Central Nervous System Agents / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Fatty Acids / Fatty Acids, Volatile / Lipids / Nervous System / Neuroprotective Agents / Nootropic Agents / Protective Agents / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics / Pyrrolidines / Pyrrolidinones",ZH516LNZ10,7491-74-9,,,4677.0,62877.0,8351.0,32010.0,CHEMBL36715,,,ZINC000003812874
Loxoprofen,phase 4 complete,DB09212,CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antirheumatic Agents / Central Nervous System Agents / Nephrotoxic agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Sensory System Agents / UGT2B7 substrates",3583H0GZAP,68767-14-6,D08149,3965.0,3828.0,50140320.0,28908.0,76172.0,CHEMBL19299,,PA166049180,
Dexibuprofen,phase 4 complete,DB09213,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 Substrates / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Phenylpropionates / Propionates / UGT1A1 Substrates / UGT1A3 substrates / UGT1A9 Substrates / UGT2B7 substrates",671DKG7P5S,51146-56-6,D03715,39912.0,36498.0,50169047.0,,43415.0,CHEMBL175,,PA166049174,ZINC000000002647
Dexketoprofen,phase 4 complete,DB09214,[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Alcohols / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antirheumatic Agents / Central Nervous System Agents / Drugs that are Mainly Renally Excreted / Glycols / Musculo-Skeletal System / Nephrotoxic agents / Nervous System / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Phenylpropionates / Propionates / Propylene Glycols / Sensory System Agents / Topical Products for Joint and Muscular Pain",6KD9E78X68,22161-81-5,D07269,667550.0,580922.0,50088570.0,237162.0,76128.0,CHEMBL75435,,PA166049175,ZINC000000005560
Tolfenamic acid,phase 4 complete,DB09216,CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Aminobenzoates / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiarrhythmic agents / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Benzene Derivatives / Benzoates / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Central Nervous System Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fenamates / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Membrane Transport Modulators / Migraine Disorders, drug therapy / Musculo-Skeletal System / Nephrotoxic agents / Neurotransmitter Agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Prostaglandin Antagonists / Sensory System Agents",3G943U18KM,13710-19-5,D01183,610479.0,530683.0,35905.0,38377.0,32243.0,CHEMBL121626,,PA166049189,ZINC000000002188
Bisoxatin,phase 4 complete,DB09219,OC1=CC=C(C=C1)C1(OC2=CC=CC=C2NC1=O)C1=CC=C(O)C=C1,Alimentary Tract and Metabolism / Contact Laxatives / Drugs for Constipation / Drugs that are Mainly Renally Excreted / Laxatives,7C75N0L7FP,17692-24-9,,28689.0,26684.0,,,135955.0,,,,ZINC000002017901
Nicorandil,phase 4 complete,DB09220,[O-][N+](=O)OCCNC(=O)C1=CC=CN=C1,"Acids / Acids, Noncarboxylic / Agents causing hyperkalemia / Anions / Antiarrhythmic agents / Antihypertensive Agents / Cardiac Therapy / Cardiovascular Agents / Diet, Food, and Nutrition / Drugs that are Mainly Renally Excreted / Electrolytes / Food / Food and Beverages / Growth Substances / Ions / Micronutrients / Nicotinic Acids / Nitrates / Nitric Acid / Nitrogen Compounds / Physiological Phenomena / Pyridines / Vasodilating Agents / Vasodilators Used in Cardiac Diseases",260456HAM0,65141-46-0,D01810,47528.0,43240.0,,31748.0,31905.0,CHEMBL284906,,,ZINC000001533102
Zotepine,phase 4 complete,DB09225,CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,"Antidepressive Agents / Antipsychotic Agents / Antipsychotic Agents (Second Generation [Atypical]) / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dopamine Antagonists / Dopamine D2 Receptor Antagonists / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotoxic agents / Psycholeptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Sulfur Compounds / Thiepins / Tranquilizing Agents",U29O83JAZW,26615-21-4,D01321,5736.0,5534.0,35255.0,40003.0,32316.0,CHEMBL285802,,,ZINC000000002264
Lacidipine,phase 4 complete,DB09236,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC,Agents causing hyperkalemia / Antiarrhythmic agents / Antihypertensive Agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Hypotensive Agents / Membrane Transport Modulators / Mutagens / Potential QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,260080034N,103890-78-4,D04657,5311217.0,4470736.0,,28382.0,135737.0,CHEMBL460291,,,ZINC000100015470
Levamlodipine,phase 4 complete,DB09237,CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC,Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Nicotinic Acids / P-glycoprotein substrates / Pyridines,0P6NLP6806,103129-82-4,,9822750.0,7998499.0,,,53796.0,CHEMBL2111097,,,ZINC000100001964
Manidipine,phase 4 complete,DB09238,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,ACE Inhibitors and Calcium Channel Blockers / Agents causing hyperkalemia / Antiarrhythmic agents / Antihypertensive Agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (weak) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dihydropyridine Derivatives / Membrane Transport Modulators / Pyridines / Selective Calcium Channel Blockers With Mainly Vascular Effects / Vasodilating Agents,6O4754US88,89226-50-6,,4008.0,3868.0,,29275.0,135849.0,CHEMBL1085699,,,
Methylene blue,phase 4 complete,DB09241,[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1,"Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Antidotes / Antipsychotic Agents / Central Nervous System Depressants / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Diagnostic Agents / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Gastric Function / Heterocyclic Compounds, Fused-Ring / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Miscellaneous Therapeutic Agents / Monoamine Oxidase Inhibitors / Neurotoxic agents / OCT2 Inhibitors / Oxidation-Reduction Agent / P-glycoprotein inhibitors / P-glycoprotein substrates / Phenothiazines / Photosensitizing Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sulfur Compounds / Tests for Gastric Secretion / UGT1A4 Inhibitors / UGT1A9 Inhibitors",8NAP7826UB,61-73-4,,6099.0,5874.0,,6878.0,6872.0,CHEMBL405110,,,
Moxonidine,phase 4 complete,DB09242,COC1=NC(C)=NC(Cl)=C1NC1=NCCN1,"Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Antiadrenergic Agents, Centrally Acting / Antihypertensive Agents / Cardiovascular Agents / Hypotensive Agents / Imidazoline Receptor Agonists / Sympatholytics",CC6X0L40GW,75438-57-2,D05087,4810.0,4645.0,50050093.0,30257.0,7009.0,CHEMBL19236,,,ZINC000001854466
Dextran,phase 4 complete,DB09255,,"Anticoagulants / Biomimetic Materials / Biopolymers / Blood and Blood Forming Organs / Blood and Related Products / Blood Substitutes / Blood Substitutes and Perfusion Solutions / Blood Substitutes and Plasma Protein Fractions / Carbohydrates / Compounds used in a research, industrial, or household setting / Dextrans / Drugs that are Mainly Renally Excreted / Glucans / Hematologic Agents / Increased Intravascular Volume / Macromolecular Substances / Osmotic Activity / Plasma Substitutes / Polymers / Polysaccharides",,9004-54-0,D00060,,,,42635.0,,,,,
Tegafur,phase 4 complete,DB09256,FC1=CN(C2CCCO2)C(=O)NC1=O,Antimetabolites / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fluoropyrimidines / Fluorouracil and prodrugs / Narrow Therapeutic Index Drugs / Noxae / Pyrimidine Analogues / Pyrimidines / Pyrimidinones / Thyroxine-binding globulin inducers / Toxic Actions,1548R74NSZ,17902-23-7,D01244,5386.0,5193.0,,4582.0,32188.0,CHEMBL20883,,,
Gimeracil,phase 4 complete,DB09257,OC1=CC(=O)NC=C1Cl,Drugs that are Mainly Renally Excreted,UA8SE1325T,103766-25-2,D01846,54679224.0,3353.0,,,31652.0,CHEMBL1730601,,,ZINC000013831809
Bemiparin,phase 4 complete,DB09258,,Agents causing hyperkalemia / Anticoagulants / Blood and Blood Forming Organs / Carbohydrates / Glycosaminoglycans / Hematologic Agents / Heparin (Low Molecular Weight) / Heparin and similars / Polysaccharides,PUE0TO3XDR,91449-79-5,,,,,280611.0,,,,,
Reviparin,phase 4 complete,DB09259,,Agents causing hyperkalemia / Anticoagulants / Blood and Blood Forming Organs / Carbohydrates / Cardiovascular Agents / Fibrin Modulating Agents / Glycosaminoglycans / Hematologic Agents / Heparin (Low Molecular Weight) / Heparin and similars / Polysaccharides,5XQ9UBJ16W,9041-08-1,D03337,,,,75960.0,,,,,
Parnaparin,phase 4 complete,DB09260,,Agents causing hyperkalemia / Anticoagulants / Blood and Blood Forming Organs / Carbohydrates / Cardiovascular Agents / Fibrin Modulating Agents / Glycosaminoglycans / Hematologic Agents / Heparin (Low Molecular Weight) / Heparin and similars / Polysaccharides,U6K360XMIU,9005-49-6,,,,,69528.0,,,,,
Certoparin,phase 4 complete,DB09261,,Agents causing hyperkalemia / Anticoagulants / Carbohydrates / Glycosaminoglycans / Hematologic Agents / Heparin (Low Molecular Weight) / Heparin and similars / Polysaccharides,V72OT3K19I,,,,,,152610.0,,,,,
Patiromer,phase 4 complete,DB09263,,"Compounds used in a research, industrial, or household setting / Macromolecular Substances / Potassium Binder / Potassium Ion Binding Activity / Potassium-removing Agents",1FQ2RY5YHH,1260643-52-4,D10148,,,,1716203.0,,CHEMBL2107875,,,
Lixisenatide,phase 4 complete,DB09265,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O,"Alimentary Tract and Metabolism / Amino Acids, Peptides, and Proteins / Blood Glucose Lowering Agents / Drugs that are Mainly Renally Excreted / Drugs Used in Diabetes / GLP-1 Agonists / Glucagon-like Peptide-1 (GLP-1) Agonists / Glucagon-like peptide-1 (GLP-1) analogues / Incretin Mimetics",74O62BB01U,320367-13-3,D09729,131704317.0,17295846.0,,1440051.0,85662.0,CHEMBL2108336,,,
Technetium Tc-99m tilmanocept,phase 4 complete,DB09266,,Diagnostic Radiopharmaceuticals / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Technetium (99Mtc) Compounds / Tumour Detection,8IHI69PQTC,1262984-82-6,,,,,1373391.0,,,,,
Strontium ranelate,phase 4 complete,DB09267,[Sr++].[Sr++].[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O,Bone Density Conservation Agents / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Musculo-Skeletal System / Strontium / Sulfur Compounds,04NQ160FRU,135459-87-9,,6918182.0,5293393.0,50248156.0,,,CHEMBL3707306,,,
Picosulfuric acid,phase 4 complete,DB09268,OS(=O)(=O)OC1=CC=C(C=C1)C(C1=CC=C(OS(O)(=O)=O)C=C1)C1=CC=CC=N1,"Acids, Acyclic / Alimentary Tract and Metabolism / Contact Laxatives / Drugs for Constipation / Drugs that are Mainly Renally Excreted / Gastrointestinal Agents / Laxatives / Pyridines / Tricarboxylic Acids",95D580798S,10040-34-3,,5243.0,5053.0,,1546457.0,,CHEMBL1741134,,,ZINC000003873921
Phenylacetic acid,phase 4 complete,DB09269,OC(=O)CC1=CC=CC=C1,"Acids, Carbocyclic / Ammonium Ion Binding Activity / Nitrogen Binding Agent / Noxae / Toxic Actions / Urea Cycle Disorder Agents",ER5I1W795A,103-82-2,,999.0,10181341.0,16419.0,33332.0,30745.0,CHEMBL1044,,,ZINC000000388462
Ubidecarenone,phase 4 complete,DB09270,COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O,"Agents Causing Muscle Toxicity / Benzoquinones / Cardiac Therapy / Coenzymes / Diet, Food, and Nutrition / Electron Transport Chain Complex Proteins / Enzymes and Coenzymes / Food / Food and Beverages / Growth Substances / Hypoglycemia-Associated Agents / Micronutrients / Other Nutritional Agents / P-glycoprotein substrates / Physiological Phenomena / Quinones / Vitamins",EJ27X76M46,303-98-0,D01065,5281915.0,4445197.0,,21406.0,46245.0,CHEMBL454801,,,ZINC000085427689
Eluxadoline,phase 4 complete,DB09272,COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O,"Alimentary Tract and Metabolism / Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antipropulsives / Gastrointestinal Agents / Miscellaneous GI Drugs / Mixed Agonist / Antagonist Opioids / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / Opioid Antagonists / Opioids / Receptors, Opioid, delta, antagonists & inhibitors / Receptors, Opioid, mu, agonists / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",45TPJ4MBQ1,864821-90-9,D10403,11250029.0,9425062.0,50393720.0,1653781.0,85980.0,CHEMBL2159122,,,ZINC000014210876
Artesunate,phase 4 complete,DB09274,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4,"Acids, Acyclic / Anions / Anthelmintics / Anti-Infective Agents / Antimalarials / Antineoplastic Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiplatyhelmintic Agents / Antiprotozoals / Antiviral Agents / Artemisinin and Derivatives, Plain / Artemisinins / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 Substrates / Dicarboxylic Acids / Electrolytes / Free Radicals / Ions / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / Oxides / Oxygen Compounds / P-glycoprotein substrates / Peroxides / Reactive Oxygen Species / Schistosomicides / Terpenes / UGT1A9 Substrates / UGT2B7 substrates",60W3249T9M,88495-63-0,D02482,6917864.0,5293084.0,,18346.0,63918.0,CHEMBL361497,,,ZINC000014096305
Bismuth subcitrate potassium,phase 4 complete,DB09275 (DBSALT001961),[K+].[K+].[K+].[K+].[K+].[Bi+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O,Bismuth containing drugs / Neurotoxic agents,BQE6KE1T4H,880149-29-1,,118987133.0,34989447.0,,,,,,,
Sodium aurothiomalate,phase 4 complete,DB09276,[Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O,"Acids, Acyclic / Antiinflammatory and Antirheumatic Products / Antirheumatic Agents / Dicarboxylic Acids / Drugs that are Mainly Renally Excreted / Gold Compounds / Gold Preparations / Hydroxy Acids / Malates / Musculo-Skeletal System / Organogold Compounds / Organometallic Compounds / Specific Antirheumatic Agents / Sulfhydryl Compounds / Sulfur Compounds / Thiomalates / UGT1A1 Inhibitors",E4768ZY6GM,12244-57-4,,16760302.0,20946.0,,4981.0,35864.0,,,,
Choline C 11,phase 4 complete,DB09277,[Cl-].C[N+](C)([11CH3])CCO,Drugs that are Mainly Renally Excreted,381E0BTR5Q,87591-54-6,,14989482.0,28514887.0,,,72321.0,CHEMBL2095207,,,
Lumacaftor,phase 4 complete,DB09280,CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O,"Amines / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Dioxoles / Heterocyclic Compounds, Fused-Ring / P-glycoprotein inducers / P-glycoprotein inhibitors / Pyridines",EGP8L81APK,936727-05-8,D10134,16678941.0,17611836.0,,1655922.0,90951.0,CHEMBL2103870,,PA166114483,ZINC000064033452
Magnesium trisilicate,phase 4 complete,DB09281,[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O,"Acids / Acids, Noncarboxylic / Agents that produce neuromuscular block (indirect) / Aluminum and magnesium containing antacids / Anions / Antacids / Calculi Dissolution Agent / Drugs that are Mainly Renally Excreted / Electrolytes / Gastric Acid Lowering Agents / Gastrointestinal Agents / Ions / Laxatives / Magnesium Compounds / Metal cations / Metal divalent cations / Minerals / Osmotic Laxatives / Oxides / Oxygen Compounds / Silicates / Silicon Compounds",FML8G1U0Y3,14987-04-3,D03271,5311266.0,4470779.0,,29170.0,,CHEMBL2096633,,,
Molsidomine,phase 4 complete,DB09282,CCOC(=O)[N-]C1=C[N+](=NO1)N1CCOCC1,Cardiac Therapy / Cardiovascular Agents / Morpholines / Nitric Oxide Donors / Oxadiazoles / Oxazines / Oxazoles / Sydnones / Vasodilating Agents / Vasodilators Used in Cardiac Diseases,D46583G77X,25717-80-0,D01320,5353788.0,4090.0,39912.0,7023.0,92623.0,CHEMBL1329455,,,
Polyethylene glycol,phase 4 complete,DB09287,,"Alcohols / Alimentary Tract and Metabolism / Compounds used in a research, industrial, or household setting / Drug Delivery Systems / Drugs for Constipation / Electrolytes / Ethylene Glycols / Excipients / Gastrointestinal Agents / Glycols / Laxatives / Macromolecular Substances / Osmotic Activity / Osmotic Laxatives / P-glycoprotein inhibitors / Pegylated agents / Pharmaceutic Aids / Pharmaceutical Preparations / Pharmaceutical Vehicles / Polyethylene Glycols / Polymers / Solvents / Stimulation Large Intestine Fluid/Electrolyte Secretion / Surface-Active Agents",3WJQ0SDW1A,25322-68-3,D03370,,,,1310594.0,,CHEMBL1201478,,,
Rolapitant,phase 4 complete,DB09291,C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,Alimentary Tract and Metabolism / Antiemetics and Antinauseants / BCRP/ABCG2 Inhibitors / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Neurokinin 1 Antagonists / Neurokinin-1 Receptor Antagonists / Neurotransmitter Agents / P-glycoprotein inhibitors / Substance P/Neurokinin-1 Receptor Antagonist,NLE429IZUC,552292-08-7,D10742,10311306.0,8486772.0,,1665496.0,90908.0,CHEMBL3707331,,,ZINC000003816514
Sacubitril,phase 4 complete,DB09292,CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C1=CC=CC=C1)NC(=O)CCC(O)=O,"Acids, Acyclic / Agents causing angioedema / Amino Acids / Amino Acids, Peptides, and Proteins / Butyrates / Drugs that are Mainly Renally Excreted / Fatty Acids / Fatty Acids, Volatile / Hypotensive Agents / Lipids / Neprilysin Inhibitor / Neprilysin, antagonists & inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors",17ERJ0MKGI,149709-62-6,D10225,9811834.0,7987587.0,,1656328.0,134714.0,CHEMBL3137301,,PA166131580,ZINC000003792417
Iodide I-131,phase 4 complete,DB09293 (DB12217),[131I-],Diagnostic Radiopharmaceuticals / Iodine (131I) Compounds / Radioactive Therapeutic Agent / Radiopharmaceutical Activity / Therapeutic Radiopharmaceuticals / Thyroid Diagnostic Radiopharmaceuticals,4GC1FOQ22U,14914-30-8,D02259,167195.0,146281.0,,1546394.0,,CHEMBL1201084,,,
Ombitasvir,phase 4 complete,DB09296,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1,"Acids, Acyclic / Amides / Amines / Aniline Compounds / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 Substrates / Direct Acting Antivirals / Hepatitis C Virus NS5A Inhibitor / P-glycoprotein substrates / UGT1A1 Inhibitors",2302768XJ8,1258226-87-7,D10745,54767916.0,31136214.0,,1597371.0,85183.0,CHEMBL3127326,,PA166163409,ZINC000150601177
Paritaprevir,phase 4 complete,DB09297,[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1,Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / BCRP/ABCG2 Inhibitors / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Direct Acting Antivirals / HCV NS3/4A Protease Inhibitors / NS3/4A Protease Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / OATP1B3 substrates / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B3 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / UGT1A1 Inhibitors,OU2YM37K86,1216941-48-8,D10580,68498031.0,32700634.0,,1597373.0,85188.0,CHEMBL3391662,,PA166163410,ZINC000197964623
Tenofovir alafenamide,phase 4 complete,DB09299,CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1,"Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Direct Acting Antivirals / Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Heterocyclic Compounds, Fused-Ring / Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor / Nephrotoxic agents / Nucleoside and Nucleotide Reverse Transcriptase Inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / Purines / Tenofovir and prodrugs",J4414G3BUK,379270-37-8,D10428,9574768.0,7849225.0,,1721603.0,90926.0,CHEMBL2107825,,,ZINC000100055899
Butylscopolamine,phase 4 complete,DB09300 (DB11535),CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,"Agents producing tachycardia / Alimentary Tract and Metabolism / Alkaloids / Amines / Ammonium Compounds / Anticholinergic Agents / Antimuscarinics Antispasmodics / Autonomic Agents / Aza Compounds / Azabicyclo Compounds / Belladonna Alkaloids, Semisynthetic, Quaternary Ammonium Compounds / Belladonna and Derivatives, Plain / Cholinergic Agents / Drugs for Functional Gastrointestinal Disorders / Muscarinic Antagonists / Neurotransmitter Agents / Nitrogen Compounds / Onium Compounds / Parasympatholytics / Peripheral Nervous System Agents / Quaternary Ammonium Compounds / Scopolamine Derivatives / Tropanes",2Z3E1OF81V,7182-53-8,D01451,6852391.0,21782131.0,,1085787.0,145701.0,CHEMBL1618102,,,ZINC000100047075
Chondroitin sulfate,phase 4 complete,"DB09301 (DB11353, DB11339)",,"Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Carbohydrates / Chondroitin / Drugs that are Mainly Renally Excreted / Glycosaminoglycans / Musculo-Skeletal System / Polysaccharides",,24967-93-9,D00080,,,,2473.0,,,,,
Ioxaglic acid,phase 4 complete,DB09313,CNC(=O)C1=C(I)C(C(=O)NCC(=O)NC2=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C2I)=C(I)C(N(C)C(C)=O)=C1I,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Iodobenzoates / Radiographic Contrast Agent / Triiodobenzoic Acids / Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media / X-Ray Contrast Activity / X-Ray Contrast Media, Iodinated",Z40X7EI2AF,59017-64-0,D01761,3742.0,3611.0,,1426458.0,31718.0,CHEMBL1201291,,,
Technetium Tc-99m pertechnetate,phase 4 complete,DB09314 (DB13043),O.O.O.O.[98Tc-],"Compounds used in a research, industrial, or household setting / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Indicators and Reagents / Laboratory Chemicals / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Technetium Compounds / Thyroid Diagnostic Radiopharmaceuticals",PPP8783IQ1,23288-61-1,D08761,131709156.0,,,1489762.0,,CHEMBL2109884,,,
Xenon-133,phase 4 complete,DB09315,[133Xe],Diagnostic Radiopharmaceuticals / Elements / Gases / Inhalation Diagnostic Agent / Isotopes / Noble Gases / Radioisotopes / Radiopharmaceutical Activity / Xenon / Xenon Isotopes,X3P9A5HNYF,14932-42-4,,66376.0,59751.0,,259282.0,,CHEMBL1200685,,,
Thallous Chloride,phase 4 complete,DB09316,[Cl-].[Tl+],"Elements / Metals / Metals, Heavy / Radioactive Diagnostic Agent",37CB58V15B,7791-12-0,,24642.0,23044.0,,91588.0,37117.0,CHEMBL2110567,,,
"Synthetic Conjugated Estrogens, A",phase 4 complete,DB09317,,"Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Estrogens / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Thyroxine-binding globulin inducers",JM2621P2LS,,,,,,253166.0,,CHEMBL1201649,,,
"Synthetic Conjugated Estrogens, B",phase 4 complete,DB09318,,"Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Estrogens / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Thyroxine-binding globulin inducers",8L6LAK9BTR,746658-13-9,D05987,,,,618365.0,,CHEMBL1201467,,,
Carindacillin,phase 4 complete,DB09319,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(=O)OC1=CC2=C(CCC2)C=C1)C1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillin G / Penicillins / Penicillins With Extended Spectrum / Sulfur Compounds",5V278481KE,35531-88-5,,,84127.0,,,52015.0,CHEMBL1596,,,
Procaine benzylpenicillin,phase 4 complete,DB09320,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,"Acids, Carbocyclic / Amides / Aminobenzoates / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Benzene Derivatives / Benzoates / Beta-Lactam Antibacterials / Beta-Lactamase Sensitive Penicillins / beta-Lactams / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / para-Aminobenzoates / Penicillin G / Penicillins / Sulfur Compounds",1LW5K9CIR1,54-35-3,,5903.0,5692.0,,7983.0,52154.0,CHEMBL1628385,,,
Zinc oxide,phase 4 complete,DB09321,O=[Zn],"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Anions / Basic Ointments and Protectants / Basic Powders and Demulcents / Compounds used in a research, industrial, or household setting / Copper Absorption Inhibitor / Cosmetics / Dermatologicals / Electrolytes / Household Products / Ions / Metal cations / Metal divalent cations / Oxides / Oxygen Compounds / Protective Agents / Radiation-Protective Agents / Sunscreen Agents / Vasoprotectives / Zinc Compounds",SOI2LOH54Z,1314-13-2,D01170,14806.0,14122.0,,11423.0,36560.0,CHEMBL1201128,,,
Zinc sulfate,phase 4 complete,DB09322,[Zn++].[O-]S([O-])(=O)=O,"Acids / Acids, Noncarboxylic / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Alimentary Tract and Metabolism / Anions / Astringents / Copper Absorption Inhibitor / Dermatologicals / Electrolytes / Ions / Metal cations / Metal divalent cations / Mineral Supplements / Minerals / Misc. Skin and Mucous Membrane Agents / Sulfates / Sulfur Acids / Sulfur Compounds / Sulfuric Acids / Vasoprotectives / Zinc Compounds",0J6Z13X3WO,7733-02-0,,24424.0,22833.0,,39954.0,35176.0,CHEMBL1200929,,PA451971,
Sulbactam,phase 4 complete,DB09324,[H][C@@]12CC(=O)N1[C@@]([H])(C(O)=O)C(C)(C)S2(=O)=O,"Amides / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactamase Inhibitors / beta-Lactams / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Lactams / Sulfur Compounds",S4TF6I2330,68373-14-8,D02223,130313.0,115306.0,50021954.0,10167.0,9321.0,CHEMBL403,,,ZINC000000897244
Sodium fluoride,phase 4 complete,DB09325,[F-].[Na+],"Alimentary Tract and Metabolism / Anions / Caries Prophylactic Agents / Cariostatic Agents / Compounds used in a research, industrial, or household setting / Dental Agents / Drugs that are Mainly Renally Excreted / Fluorides / Fluorine Compounds / Ions / Mineral Supplements / Miscellaneous Therapeutic Agents / Mouthwashes and Gargles / Protective Agents / Sodium Compounds / Stomatological Preparations",8ZYQ1474W7,7681-49-4,,5235.0,5045.0,50209223.0,9873.0,28741.0,CHEMBL1528,,PA451388,
Ammonia N-13,phase 4 complete,DB09326,[13NH3],Radioactive Diagnostic Agent / Radiopharmaceutical Activity,9OQO0E343Z,34819-78-8,,119432.0,106665.0,,1305558.0,135980.0,CHEMBL1201189,,,
Tegafur-uracil,phase 4 complete,DB09327,O=C1NC=CC(=O)N1.FC1=CN(C2CCCO2)C(=O)NC1=O,Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 Substrates,HMI5GR78FR,74578-38-4,,104747.0,94558.0,,,,,,,
Osimertinib,phase 4 complete,DB09330,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,"Acids, Acyclic / Acrylates / Amides / Amines / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Kinase Inhibitor / Narrow Therapeutic Index Drugs / P-glycoprotein substrates / Protein Kinase Inhibitors / Tyrosine Kinase Inhibitors",3C06JJ0Z2O,1421373-65-0,,71496458.0,31042598.0,50029668.0,1721560.0,90943.0,CHEMBL3353410,,PA166131626,ZINC000098023177
Kappadione,phase 4 complete,DB09332,[Na+].[Na+].[Na+].[Na+].CC1=C(OP([O-])([O-])=O)C2=CC=CC=C2C(OP([O-])([O-])=O)=C1,,R2L46WE615,131-13-5,,8555.0,8237.0,,,,,,,
Iopodic acid,phase 4 complete,DB09333,CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I,"Benzene Derivatives / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Hydrocarbons, Halogenated / Hydrocarbons, Iodinated / Iodobenzenes / Watersoluble, Hepatotropic X-Ray Contrast Media / X-Ray Contrast Media, Iodinated",F604ZKI910,5587-89-3,,5241.0,20473670.0,,5976.0,,CHEMBL3306201,,,
Alatrofloxacin,phase 4 complete,DB09335,[H][C@@]12CN(C[C@]1([H])[C@H]2NC(=O)[C@H](C)NC(=O)[C@H](C)N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=CC=C(F)C=C1F)C(O)=O,"Anti-Infective Agents / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Quinolines / Quinolones / Topoisomerase II Inhibitors / Topoisomerase Inhibitors",7QVV6I50DT,146961-76-4,,3086677.0,21243647.0,,141440.0,135829.0,CHEMBL1201197,,,ZINC000100067477
Technetium Tc-99m nofetumomab merpentan,phase 4 complete,DB09336,,,9UFH75HT7S,165942-79-0,,,,,,,,,,
Medical air,phase 4 complete,DB09337,,Medical Gases / Other Miscellaneous Therapeutic Agents,K21NZZ5Y0B,132259-10-0,,,,,411.0,,,,,
Tyropanoic acid,phase 4 complete,DB09340,CCCC(=O)NC1=C(I)C=C(I)C(CC(CC)C(O)=O)=C1I,"Compounds used in a research, industrial, or household setting / Contrast Media / Watersoluble, Hepatotropic X-Ray Contrast Media / X-Ray Contrast Media, Iodinated",4F05V145YR,27293-82-9,,5611.0,5409.0,,,135862.0,CHEMBL1201261,,,
"Dextrose, unspecified formCommonly known or available as Glucose",phase 4 complete,DB09341,,"Caloric Agents / Cardiac Function / Compounds used in a research, industrial, or household setting / Diabetes Mellitus / Hemodialysis Solution / Miscellaneous Therapeutic Agents",IY9XDZ35W2,,,,,,,,,,,
Propoxycaine,phase 4 complete,DB09342,CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC,"Acids, Carbocyclic / Aminobenzoates / Anesthetics / Anesthetics, Local / Benzene Derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Ethers / Hydroxy Acids / Hydroxybenzoate Ethers / Hydroxybenzoates / para-Aminobenzoates / Peripheral Nervous System Agents / Phenols / Phenyl Ethers / Sensory System Agents",EPD1EH7F53,86-43-1,,6843.0,6582.0,50225492.0,,8496.0,CHEMBL1195,,,ZINC000001530942
Tipiracil,phase 4 complete,DB09343,ClC1=C(CN2CCCC2=N)NC(=O)NC1=O,MATE 1 Substrates / MATE substrates / OCT2 Substrates / OCT2 substrates with narrow therapeutic index / Pyrimidines / Pyrimidinones / Thymidine Phosphorylase Inhibitor,NGO10K751P,183204-74-2,,6323266.0,13243748.0,20079.0,1670304.0,90879.0,CHEMBL235668,,,ZINC000100032379
Pramocaine,phase 4 complete,DB09345,CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Anesthetics / Anesthetics for Topical Use / Anesthetics, Local / Antipruritics and Local Anesthetics / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Central Nervous System Agents / Central Nervous System Depressants / Dermatologicals / Oxazines / Peripheral Nervous System Agents / Sensory System Agents / Vasoprotectives",068X84E056,140-65-8,,4886.0,4717.0,50225493.0,34347.0,8357.0,CHEMBL1198,,,ZINC000019594594
Metrizoic acid,phase 4 complete,DB09346,CN(C(C)=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Iodobenzoates / Radiographic Contrast Agent / Triiodobenzoic Acids / Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media / X-Ray Contrast Activity / X-Ray Contrast Media, Iodinated",CM1N99QR1M,1949-45-7,,2528.0,2433.0,,,34847.0,CHEMBL1736,,,ZINC000003831116
Propiolactone,phase 4 complete,DB09348,O=C1CCO1,"Anti-Infective Agents / Compounds used in a research, industrial, or household setting / Disinfectants / Lactones",6RC3ZT4HB0,57-57-8,D05630,2365.0,2275.0,,1311565.0,49073.0,CHEMBL1200627,,,ZINC000001482154
Piperonyl butoxide,phase 4 complete,DB09350,CCCCOCCOCCOCC1=CC2=C(OCO2)C=C1CCC,"Agrochemicals / Benzodioxoles / Compounds used in a research, industrial, or household setting / Dioxoles / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Pesticide Synergists / Pesticides / Toxic Actions",LWK91TU9AH,51-03-6,D08383,5794.0,5590.0,181115.0,8345.0,32687.0,CHEMBL1201131,,,ZINC000003875342
Levobetaxolol,phase 4 complete,DB09351,CC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1,Adrenergic Antagonists / Adrenergic beta-Antagonists / Agents causing hyperkalemia / Bradycardia-Causing Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates,75O9XHA4TU,93221-48-8,,60657.0,54669.0,25752.0,353497.0,59254.0,CHEMBL1201274,,,ZINC000001530567
Hydroxyamphetamine,phase 4 complete,DB09352,CC(N)CC1=CC=C(O)C=C1,Adrenergic Agonists / Amines / Amphetamines / Autonomic Agents / Ethylamines / Mydriatics / Peripheral Nervous System Agents / Phenethylamines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sympathomimetics,FQR280JW2N,103-86-6,,3651.0,3525.0,81459.0,7839.0,103855.0,CHEMBL1546,,,
OctasulfurCommonly known or available as Sulfur,phase 4 complete,DB09353,S1SSSSSSS1,Chalcogens / Elements / Keratolytic Agents,70FD1KFU70,10544-50-0,,66348.0,59726.0,,,29385.0,,,,
Sulfabenzamide,phase 4 complete,DB09355,NC1=CC=C(C=C1)S(=O)(=O)NC(=O)C1=CC=CC=C1,Amides / Sulfones / Sulfur Compounds,G58F8OPL4I,127-71-9,,,5128.0,,37320.0,94677.0,CHEMBL1243,,,ZINC000005421253
Dexpanthenol,phase 4 complete,DB09357,CC(C)(CO)[C@@H](O)C(=O)NCCCO,"Alanine / Alimentary Tract and Metabolism / Amino Acids / Amino Acids, Peptides, and Proteins / Cicatrizants / Dermatologicals / Drugs that are Mainly Renally Excreted / Imides / Ophthalmologicals / Preparations for Treatment of Wounds and Ulcers / Sensory Organs / Vitamin B Complex / Vitamins / Wound Healing",1O6C93RI7Z,81-13-0,D00193,131204.0,115991.0,,22701.0,,CHEMBL1200979,,,ZINC000001530303
Procaine merethoxylline,phase 4 complete,DB09364,O.[Hg+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[CH2]C(CN=C(O)C1=CC=CC=C1OCC([O-])=O)OCCOC,,O77D636VYN,60064-28-0,,,21243345.0,,,,,,,
Propyliodone,phase 4 complete,DB09366,CCCOC(=O)CN1C=C(I)C(=O)C(I)=C1,"Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Iodopyridones / Non-Watersoluble X-Ray Contrast Media / Pyridines / Pyridones / X-Ray Contrast Media, Iodinated",5NPJ6BPX36,587-61-1,D01755,,4780.0,,8793.0,32064.0,CHEMBL1200821,,,ZINC000003831392
Polyestradiol phosphate,phase 4 complete,DB09369,,"Antineoplastic and Immunomodulating Agents / Endocrine Therapy / Estradiol Congeners / Estranes / Estrenes / Estrogens / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones and Related Agents / Hormones, Hormone Substitutes, and Hormone Antagonists / Steroids",P14877CDX2,28014-46-2,D07434,,,,34120.0,,CHEMBL1201477,,,
Sodium phosphate P 32,phase 4 complete,DB09370,[Na+].[Na+].O[32P]([O-])([O-])=O,Antineoplastic Agents / Diagnostic Agents / Narrow Therapeutic Index Drugs / Radioactive Diagnostic Agent / Therapeutic Radiopharmaceuticals / Various Therapeutic Radiopharmaceuticals,O181101B5G,7635-46-3,,,64319.0,,91559.0,,CHEMBL2107525,,,
Norethynodrel,phase 4 complete,DB09371,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3,"Adrenal Cortex Hormones / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptives, Oral / Contraceptives, Oral, Synthetic / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Norpregnanes / Norpregnenes / Norsteroids / Progestin Contraceptives / Progestins / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",88181ACA0M,68-23-5,D05207,,5995.0,50410507.0,7515.0,34895.0,CHEMBL1387,,,ZINC000118913164
Tannic acid,phase 4 complete,DB09372,OC1=CC(=CC(O)=C1O)C(=O)OC1=C(O)C(O)=CC(=C1)C(=O)OC[C@H]1OC(OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H]1OC(=O)C1=CC(OC(=O)C2=CC(O)=C(O)C(O)=C2)=C(O)C(O)=C1,"Compounds used in a research, industrial, or household setting",28F9E0DJY6,1401-55-4,,,17288010.0,,10328.0,75211.0,,,,
Trolamine polypeptide oleate condensate,phase 4 complete,DB09373,,,,,,,,,,,,,,
Indocyanine green acid formCommonly known or available as Indocyanine green,phase 4 complete,DB09374,CC1(C)\C(=C\C=C\C=C\C=C\C2=[N+](CCCCS(O)(=O)=O)C3=C(C4=CC=CC=C4C=C3)C2(C)C)N(CCCCS(O)(=O)=O)C2=C1C1=CC=CC=C1C=C2,"BSEP/ABCB11 Substrates / Cardiac Function / Coloring Agents / Compounds used in a research, industrial, or household setting / Diagnostic Dye / Liver Function / Roentgenography",C4V974V932,28782-33-4,D01342,11967809.0,18109.0,,2199577.0,31696.0,CHEMBL1615807,,,ZINC000008101127
Chymotrypsin,phase 4 complete,DB09375,,"Blood and Blood Forming Organs / Chymotrypsin, antagonists & inhibitors / Endopeptidases / Enzymes / Enzymes and Coenzymes / Hydrolases / Ophthalmologicals / Peptide Hydrolases / Sensory Organs / Serine Endopeptidases / Serine Proteases / Surgical Aids",BVS505O332,9004-07-3,D03484,,,,2530.0,,CHEMBL1201465,,,
Lapyrium,phase 4 complete,DB09376,CCCCCCCCCCCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1,Pyridines,5172AI8LRR,109260-82-4,,22660.0,21241.0,,28456.0,135534.0,CHEMBL1201786,,,ZINC000008214591
Undecoylium chloride iodine complex,phase 4 complete,DB09377,[Cl-].CCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1,,O4CEK7FP0D,1338-54-1,,,14224.0,,,,,,,
Fluprednisolone,phase 4 complete,DB09378,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroids / Corticosteroids for Systemic Use / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids / Steroids, Fluorinated",9H05937G3X,53-34-9,D04227,,5665.0,,4497.0,34474.0,CHEMBL1200774,,,ZINC000003875362
Sodium chromate Cr-51,phase 4 complete,DB09380,[Na+].[Na+].[O-][51Cr]([O-])(=O)=O,Radioactive Diagnostic Agent,XI776WYU0N,10039-53-9,,,2338409.0,,91510.0,,,,,
Esterified estrogens,phase 4 complete,DB09381,,Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Estrogens / Thyroxine-binding globulin inducers,3ASP8Q3768,,,,,,214549.0,,,,,
Iodohippurate sodium I-131,phase 4 complete,DB09382,[Na+].[O-]C(=O)CNC(=O)C1=C([131I])C=CC=C1,Diagnostic Radiopharmaceuticals / Renal System,9BRV734R3E,881-17-4,,,64825.0,,91540.0,134740.0,CHEMBL1200763,,,
Meprednisone,phase 4 complete,DB09383,[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO,"Adrenal Cortex Hormones / Corticosteroids / Corticosteroids for Systemic Use / Corticosteroids for Systemic Use, Plain / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Glucocorticoids / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Pregnadienediols / Pregnadienes / Pregnanes / Steroids / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Thyroxine-binding globulin inhibitors",67U96J8P35,1247-42-3,,,4447637.0,,29523.0,135573.0,CHEMBL1201148,,,ZINC000004216862
Cyanocobalamin Co-57,phase 4 complete,DB09385,[57Co+3].[C-]#N.C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)C2[N-]\C1=C(C)/C1=N/C(=C\C3=N\C(=C(C)/C4=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)\[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)/C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=[NH]C2=C1C=C(C)C(C)=C2,Radioactive Diagnostic Agent / Radiopharmaceutical Activity,025P9I542Y,13115-03-2,,,,,91516.0,,,,,
Norgestrel,phase 4 complete,DB09389,CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C,"Adrenal Cortex Hormones / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptives, Oral / Contraceptives, Oral, Synthetic / Contraceptives, Postcoital / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Norpregnanes / Norpregnenes / Norsteroids / Progestin Contraceptives / Progestins / Progestogens and Estrogens, Sequential Preparations / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",3J8Q1747Z2,6533-00-2,D00954,4542.0,4383.0,,7518.0,7630.0,CHEMBL2107797,,,
Phosphoric acid,phase 4 complete,DB09394,OP(O)(O)=O,"Acid Etching, Dental / Acids / Acids, Noncarboxylic / Compounds used in a research, industrial, or household setting / Dental Materials / Drugs that are Mainly Renally Excreted / Phosphorus Acids / Phosphorus Compounds",E4GA8884NN,7664-38-2,,1004.0,979.0,14671.0,8259.0,26078.0,CHEMBL1187,,,
Sodium acetate,phase 4 complete,DB09395 (DB09470),[Na+].CC([O-])=O,"Acetates / Acids, Acyclic / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Drugs that are Mainly Renally Excreted / Electrolyte Solutions / Fatty Acids / Fatty Acids, Volatile / I.V. Solution Additives / Lipids / Replacement Preparations",NVG71ZZ7P0,127-09-3,,517045.0,29105.0,,267453.0,32954.0,CHEMBL1354,,PA451369,
Technetium Tc-99m sulfur colloid,phase 4 complete,DB09397,[99Tc].S1SSSSSSS1,"Compounds used in a research, industrial, or household setting / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Hepatic and Reticulo Endothelial System / Indicators and Reagents / Laboratory Chemicals / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Radiopharmaceuticals / Sulfur Compounds / Technetium (99Mtc), Particles and Colloids / Technetium Compounds",556Q0P6PB1,,D06048,76957057.0,,,1423270.0,,CHEMBL1201529,,,
Fluoride ion F-18,phase 4 complete,DB09398,[18F-],Diagnostic Radiopharmaceuticals / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Tumour Detection,4M4WE5N2GE,67862-54-8,,23690531.0,8373100.0,,1546273.0,,CHEMBL1248,,,
Selenomethionine Se-75,phase 4 complete,DB09400,C[75Se]CC[C@H](N)C(O)=O,Selenium Compounds,P6708E7555,1187-56-0,,,59637.0,,9133.0,,CHEMBL1201054,,,
Iocetamic acid,phase 4 complete,DB09403,CC(CN(C(C)=O)C1=C(I)C=C(I)C(N)=C1I)C(O)=O,"Benzene Derivatives / Contrast Media / Hydrocarbons, Halogenated / Hydrocarbons, Iodinated / Watersoluble, Hepatotropic X-Ray Contrast Media / X-Ray Contrast Media, Iodinated",FA675Q0E3E,16034-77-8,,,25724.0,,183830.0,91662.0,CHEMBL1200770,,,
Magnesium chloride,phase 4 complete,DB09407,[Mg++].[Cl-].[Cl-],"Acids / Acids, Noncarboxylic / Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Anions / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Calculi Dissolution Agent / Chlorides / Chlorine Compounds / Drugs that are Mainly Renally Excreted / Electrolyte Solutions / Electrolytes / Hemodialysis Solution / I.V. Solution Additives / Ions / Magnesium Compounds / Metal cations / Metal divalent cations / Mineral Supplements / Minerals",59XN63C8VM,7786-30-3,,5360315.0,22987.0,,1311539.0,6636.0,CHEMBL2219642,,,
Gluconic Acid,phase 4 complete,DB13180 (DB09408),OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O,"Acids, Acyclic / Carbohydrates / Chelating Agents / Hydroxy Acids / Laxatives / Osmotic Laxatives / Sugar Acids",R4R8J0Q44B,526-95-4,,10690.0,10240.0,,,33198.0,CHEMBL464345,,PA449770,ZINC000001531008
Magnesium acetate tetrahydrate,phase 4 complete,DB09409,O.O.O.O.[Mg++].CC([O-])=O.CC([O-])=O,Agents that produce neuromuscular block (indirect) / Calculi Dissolution Agent / Laxatives / Osmotic Laxatives,I01G0EJC3B,16674-78-5,,134717.0,118734.0,,317246.0,,CHEMBL3989858,,,
Monopotassium phosphate,phase 4 complete,DB09413,[K+].OP(O)([O-])=O,"Acids / Acids, Noncarboxylic / Anions / Buffers / Cariostatic Agents / Compounds used in a research, industrial, or household setting / Dental Materials / Electrolytes / Ions / Laboratory Chemicals / Laxatives / Osmotic Laxatives / Phosphate salts / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds / Potassium Salt / Protective Agents / Replacement Preparations",4J9FJ0HL51,7778-77-0,,516951.0,22914.0,50004328.0,34322.0,63036.0,CHEMBL1200925,,,
Dipotassium phosphate,phase 4 complete,DB09414,[K+].[K+].OP([O-])([O-])=O,"Acids / Acids, Noncarboxylic / Anions / Buffers / Cariostatic Agents / Compounds used in a research, industrial, or household setting / Dental Materials / Electrolytes / Ions / Laboratory Chemicals / Laxatives / Osmotic Laxatives / Phosphate salts / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds / Potassium Salt / Protective Agents",CI71S98N1Z,7758-11-4,,24450.0,22858.0,,55018.0,131527.0,CHEMBL1200459,,,
Potassium perchlorate,phase 4 complete,DB09418,[K+].[O-][Cl](=O)(=O)=O,"Acids / Acids, Noncarboxylic / Antithyroid agents / Chlorine Compounds / Drugs that are Mainly Renally Excreted / Perchlorates / Potassium Salt / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Thyroid Products",42255P5X4D,7778-74-7,,516900.0,22913.0,,34318.0,,CHEMBL1200696,,,
Xylose,phase 4 complete,DB09419,OC[C@@H](O)[C@H](O)[C@@H](O)C=O,Carbohydrates / Monosaccharides / Pentoses,A1TA934AKO,58-86-6,,644160.0,559198.0,,11378.0,15936.0,,,,ZINC000018168715
Iodide I-123,phase 4 complete,DB09420 (DB11240),[123I-],Diagnostic Radiopharmaceuticals / Elements / Halogens / Iodine Isotopes / Isotopes / Radioactive Diagnostic Agent / Radioisotopes / Radiopharmaceutical Activity / Thyroid Diagnostic Radiopharmaceuticals,98QPV8670C,69239-56-1,,135300.0,119193.0,,1361657.0,,CHEMBL1249,,,
Protirelin,phase 4 complete,DB09421,[H][C@@](CC1=CN=CN1)(NC(=O)[C@]1([H])CCC(=O)N1)C(=O)N1CCC[C@@]1([H])C(N)=O,"Amino Acids, Peptides, and Proteins / Diagnostic Agents / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypothalamic Hormones / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary Hormone-Releasing Hormones / Proteins / Tests for Thyreoidea Function / Thyroid Products / Thyrotropin-Releasing Hormone",5Y5F15120W,24305-27-9,D00176,638678.0,554166.0,50072394.0,10580.0,35940.0,CHEMBL1472,,,ZINC000004096261
Technetium Tc-99m polyphosphate,phase 4 complete,DB09423,,"Acids / Acids, Noncarboxylic / Anions / Electrolytes / Ions / Phosphate salts / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds",,,,,,,,,,,,
Indium In-111 pentetate,phase 4 complete,DB09425,[111In+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)CC(O)=O,Central Nervous System / Diagnostic Radiopharmaceuticals / Lead Chelator / Radioactive Diagnostic Agent / Radiopharmaceutical Activity,5K3UP561AX,135998-32-2,D04527,131704319.0,25048228.0,,,,,,,
Krypton Kr 81m,phase 4 complete,DB09443,[81Kr],Diagnostic Radiopharmaceuticals,68QN45K12N,15678-91-8,,,59755.0,,,136002.0,CHEMBL1201096,,,
Sodium carbonate,phase 4 complete,DB09460,[Na+].[Na+].[O-]C([O-])=O,"Acids / Acids, Noncarboxylic / Alkalies / Anions / Carbon Compounds, Inorganic / Carbonic Acid / Electrolytes / Ions",45P3261C7T,497-19-8,,10340.0,9916.0,,36685.0,29377.0,CHEMBL186314,,,
Xenon Xe-127,phase 4 complete,DB09461,[127Xe],Elements / Gases / Inhalation Diagnostic Agent / Isotopes / Noble Gases / Radioactive Diagnostic Agent / Radioisotopes / Radiopharmaceutical Activity / Xenon / Xenon Isotopes,H95KBR1GDB,13994-19-9,,,146100.0,,,,CHEMBL1200673,,,
Sodium sulfate,phase 4 complete,DB09472 (DB09476),[Na+].[Na+].[O-]S([O-])(=O)=O,"Acids / Acids, Noncarboxylic / Alimentary Tract and Metabolism / Anions / Drugs for Constipation / Drugs that are Mainly Renally Excreted / Electrolytes / Gastrointestinal Agents / Ions / Laxatives / Mineral Supplements / Osmotic Laxatives / Sodium / Sulfur Acids / Sulfur Compounds / Sulfuric Acids",36KCS0R750,7757-82-6,D01732,24436.0,22844.0,50101993.0,1299926.0,32149.0,CHEMBL233406,,,
Indium In-111 oxyquinoline,phase 4 complete,DB09473,[111In+3].[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2,Radioactive Diagnostic Agent / Radiopharmaceutical Activity,LGX9OL562T,65389-08-4,D04526,119117.0,106429.0,,1314372.0,,,,,
Enalaprilat,phase 4 complete,DB09477,[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@@]1([H])C(O)=O,"Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Amino Acids, Peptides, and Proteins / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Antihypertensive Agents Indicated for Hypertension / Cardiovascular Agents / Decreased Blood Pressure / Dipeptides / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hypotensive Agents / Oligopeptides / Peptides / Photosensitizing Agents / Protease Inhibitors",Q508Q118JM,76420-72-9,D03769,5462501.0,4575429.0,50367254.0,3829.0,4786.0,CHEMBL577,,,ZINC000003812851
Rubidium Rb-82Commonly known or available as Rubidium chloride Rb-82,phase 4 complete,DB09479,[82Rb+],Radioactive Diagnostic Agent / Radiopharmaceutical Activity,550Z839889,,,71357.0,8351588.0,,1546434.0,,CHEMBL1200727,,,
Iofetamine I-123,phase 4 complete,DB09480,CC(C)NC(C)CC1=CC=C([123I])C=C1,"Agents producing tachycardia / Agents that produce hypertension / Amines / Amphetamines / Central Nervous System / Compounds used in a research, industrial, or household setting / Diagnostic Radiopharmaceuticals / Diagnostic Uses of Chemicals / Ethylamines / Indicators and Reagents / Iodine (123I) Compounds / Laboratory Chemicals / Phenethylamines / Radiopharmaceuticals / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sympathomimetics",LV23B78IJC,75917-92-9,,,137706.0,,,31708.0,,,,
Magnesium carbonate,phase 4 complete,DB09481,[Mg++].[O-]C([O-])=O,"Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Aluminum and magnesium containing antacids / Antacids / Bleaching Agents / Calculi Dissolution Agent / Compounds used in a research, industrial, or household setting / Drugs for Acid Related Disorders / Drugs for Constipation / Drugs for Treatment of Hyperkalemia and Hyperphosphatemia / Drugs that are Mainly Renally Excreted / Elements / Gastric Acid Lowering Agents / Hygroscopic Agents / Laxatives / Laxatives, magnesium containing / Magnesium Compounds / Metal cations / Metal divalent cations / Metals / Metals, Alkaline Earth / Metals, Light / Noxae / Osmotic Laxatives / Oxidants / Toxic Actions",0IHC698356,546-93-0,,11029.0,10563.0,,29155.0,31793.0,CHEMBL1200736,,,
Potassium lactate,phase 4 complete,DB09483,[K+].CC(O)C([O-])=O,Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Electrolyte Solutions / I.V. Solution Additives / Laxatives / Potassium Salt,276897E67U,996-31-6,,,55189.0,,314797.0,,CHEMBL1200664,,,
Sodium fluorophosphate,phase 4 complete,DB09484,[Na+].[Na+].[O-]P([O-])(F)=O,"Acids / Acids, Noncarboxylic / Alimentary Tract and Metabolism / Anions / Caries Prophylactic Agents / Cariostatic Agents / Compounds used in a research, industrial, or household setting / Dental Agents / Electrolytes / Fluorides / Fluorine Compounds / Hydrofluoric Acid / Ions / Laxatives / Mineral Supplements / Osmotic Laxatives / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds / Protective Agents / Stomatological Preparations / Toothpastes",C810JCZ56Q,10163-15-2,D05864,,22686.0,,56501.0,86431.0,CHEMBL1908359,,,
Iotrolan,phase 4 complete,DB09487,CN(C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Iodobenzoates / Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media / X-Ray Contrast Media, Iodinated",16FL47B687,79770-24-4,D01714,,3607.0,,51474.0,31715.0,CHEMBL1200555,,,
Acrivastine,phase 4 complete,DB09488,[H]\C(CN1CCCC1)=C(\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\[H])=C(/[H])C(O)=O,"Antihistamines for Systemic Use / Drugs that are Mainly Renally Excreted / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Neurotransmitter Agents / Potential QTc-Prolonging Agents / Pyridines / QTc Prolonging Agents",A20F9XAI7W,87848-99-5,D02760,5284514.0,4447574.0,,19959.0,83168.0,CHEMBL1224,,,ZINC000003776633
Indium In-111 chloride,phase 4 complete,DB09490,Cl[111In](Cl)Cl,Radioactive Diagnostic Agent / Radiopharmaceutical Activity,58TD96H03I,50800-85-6,,49800058.0,4954694.0,,42987.0,,,,,
Cetyl alcohol,phase 4 complete,DB09494,CCCCCCCCCCCCCCCCO,Alcohols / Drugs that are Mainly Renally Excreted / Lipids,936JST6JCN,36653-82-4,,2682.0,2581.0,,20615.0,16125.0,CHEMBL706,,,ZINC000008214519
Avobenzone,phase 4 complete,DB09495,COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C,"Compounds used in a research, industrial, or household setting / Cosmetics / Dermatologicals / Household Products / Ketones / Protective Agents / Radiation-Protective Agents / Sunscreen Agents",G63QQF2NOX,70356-09-1,,51040.0,46261.0,,45045.0,134751.0,CHEMBL1200522,,,ZINC000000000973
Octinoxate,phase 4 complete,DB09496,[H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC,"Acids, Carbocyclic / Compounds used in a research, industrial, or household setting / Cosmetics / Dermatologicals / Drugs that are Mainly Renally Excreted / Emollients and Protectives / Household Products / Protective Agents / Protectives Against UV-Radiation / Protectives Against UV-Radiation for Topical Use / Radiation-Protective Agents / Sunscreen Agents",4Y5P7MUD51,5466-77-3,D05225,5355130.0,4511170.0,,13369.0,88667.0,CHEMBL1200608,,,
Strontium chloride Sr-89,phase 4 complete,DB09498 (DB12546),[Cl-].[Cl-].[89Sr++],"Elements / Metals / Metals, Alkaline Earth / Metals, Heavy / Pain Palliation (Bone Seeking Agents) / Radioactive Therapeutic Agent / Strontium Radioisotopes / Therapeutic Radiopharmaceuticals / Various Pain Palliation Radiopharmaceuticals",5R78837D4A,38270-90-5,,5362485.0,64523.0,,281890.0,36383.0,CHEMBL1200625,,,
Thiosulfuric acid,phase 4 complete,DB09499,OS(O)(=O)=S,"Acids / Acids, Noncarboxylic / Anions / Anti-Infective Agents / Antidotes / Antioxidants / Antituberculosis Agents / Chelating Agents / Compounds used in a research, industrial, or household setting / Electrolytes / Ions / Minerals / Protective Agents / Sequestering Agents / Sulfates / Sulfur Acids / Sulfur Compounds / Sulfuric Acids",7K79Y2EKKP,13686-28-7,,24478.0,22886.0,,,29279.0,CHEMBL1208642,,,ZINC000008214573
Ferric ammonium citrate,phase 4 complete,DB09501,N.[Fe+3].OC(=O)CC(O)(CC(O)=O)C(O)=O,Amines / Ammonium Compounds / Contrast Media / Iron Compounds / Magnetic Resonance Imaging Contrast Media / Nitrogen Compounds / Onium Compounds / Organometallic Compounds / Paramagnetic Contrast Media,UVP74NG1C5,1185-57-5,,,2006378.0,,24897.0,,,,,
Indium In-111 pentetreotide,phase 4 complete,DB11835 (DB09503),[111In+3].CC(O)C(CO)N=C(O)C1CSSCC(N=C(O)C(CC2=CC=CC=C2)N=C([O-])CN(CCN(CCC(C(O)=O)C(O)=O)CC([O-])=O)CC([O-])=O)C(O)=NC(CC2=CC=CC=C2)C(O)=NC(CC2=CNC3=CC=CC=C23)C(O)=NC(CCCCN)C([O-])=NC(C(C)O)C(O)=N1,"Amino Acids, Peptides, and Proteins / Diagnostic Radiopharmaceuticals / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypothalamic Hormones / Indium (111In) Compounds / Indium Radioisotopes / Nerve Tissue Proteins / Neuropeptides / Pancreatic Hormones / Peptide Hormones / Peptides / Pituitary Hormone Release Inhibiting Hormones / Proteins / Radioactive Diagnostic Agent / Radiopharmaceutical Activity / Tumour Detection",M312JJ6Z32,139096-04-1,,131704321.0,,,1724429.0,,,,,
Ferumoxsil,phase 4 complete,DB09507,,"Colloids / Complex Mixtures / Compounds used in a research, industrial, or household setting / Contrast Media / Ferric Compounds / Ferrosoferric Oxide / Ferrous Compounds / Investigative Techniques / Iron Compounds / Macromolecular Substances / Magnetic Resonance Imaging Contrast Media / Magnets / Metal Nanoparticles / Minerals / Nanoparticles / Nanostructures / Organometallic Compounds / Organosilicon Compounds / Pharmaceutical Preparations / Polymers / Silicon Compounds / Superparamagnetic Contrast Media",6HJV9H13XS,171544-35-7,,,,,77754.0,,,,,
Ferumoxides,phase 4 complete,DB09508,,"Biopolymers / Carbohydrates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Ferric Compounds / Ferrosoferric Oxide / Ferrous Compounds / Glucans / Iron Compounds / Macromolecular Substances / Magnets / Metal Nanoparticles / Minerals / Nanoparticles / Nanostructures / Organometallic Compounds / Polymers / Polysaccharides / Suspensions",,,,,,,72901.0,,,,,
Urea C-13,phase 4 complete,DB09510,N[13C](N)=O,Helicobacter pylori Diagnostic,W6KX9E6D8X,58069-82-2,D01749,636363.0,552162.0,,226724.0,32285.0,CHEMBL2096648,,,
Talc,phase 4 complete,DB09511,,"Acids / Acids, Noncarboxylic / Anions / Antiperspirants / Compounds used in a research, industrial, or household setting / Cosmetics / Electrolytes / Household Products / Ions / Magnesium Compounds / Metal cations / Metal divalent cations / Minerals / Oxides / Oxygen Compounds / Silicates / Silicon Compounds",7SEV7J4R1U,,,,,,10323.0,,,,,
Simethicone,phase 4 complete,DB09512,O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C,"Antifoaming Agents / Compounds used in a research, industrial, or household setting / Dermatologicals / Dimethylpolysiloxanes / Emollients / Macromolecular Substances / Organosilicon Compounds / Polymers / Silicon Compounds / Silicones / Siloxanes / Surface-Active Agents",,8050-81-5,,,4938661.0,,9796.0,,CHEMBL1200838,,,
Urea C-14,phase 4 complete,DB09513,N[14C](N)=O,,WBZ6M63TEE,594-05-8,,11457650.0,9632491.0,,253158.0,134711.0,CHEMBL2096635,,,
Mequinol,phase 4 complete,DB09516,COC1=CC=C(O)C=C1,"Antioxidants / Benzene Derivatives / Compounds used in a research, industrial, or household setting / Depigmenting Activity / Dermatologicals / Ethers / Lentigo / Melanin Synthesis Inhibitors / Methyl Ethers / Phenols / Phenyl Ethers / Protective Agents / Skin Lightening Agent",6HT8U7K3AM,150-76-5,,9015.0,8665.0,,15080.0,69441.0,CHEMBL544,,,ZINC000000001684
Sodium ferric gluconate complex,phase 4 complete,DB09517,[O--].[O--].[O--].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,Iron Preparations / Parenteral Iron Replacement / Phosphate Binder,CC9149U2QX,34089-81-1,,76968835.0,34989638.0,,261435.0,,,,,
Petrolatum,phase 4 complete,DB11058 (DB09520),,"Basic Ointments and Protectants / Compounds used in a research, industrial, or household setting / Dermatologicals / Emollients / Ointment Bases / Pharmaceutic Aids / Pharmaceutical Preparations",4T6H12BN9U,8009-03-8,D05304,,,,8091.0,,,,,
Hydroquinone,phase 4 complete,DB09526,OC1=CC=C(O)C=C1,"Antioxidants / Benzene Derivatives / Compounds used in a research, industrial, or household setting / Depigmenting Activity / Depigmenting Agents / Dermatologicals / Melanin Synthesis Inhibitor / Melanin Synthesis Inhibitors / Mutagens / Noxae / Phenols / Protective Agents / Radiation-Protective Agents / Toxic Actions",XV74C1N1AE,123-31-9,D00073,785.0,764.0,26190.0,5509.0,17594.0,CHEMBL537,,PA449924,ZINC000005133378
Perflexane,phase 4 complete,DB09531,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,"Diagnostic Agents / Hydrocarbons, Fluorinated / Hydrocarbons, Halogenated / Ultrasound Contrast Activity / Ultrasound Contrast Media",FX3WJ41CMX,355-42-0,,,9262.0,,1540828.0,39427.0,CHEMBL1200607,,,ZINC000006827705
Ecamsule,phase 4 complete,DB09534,CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC1=CC=C(C=C2C3CCC(CS(O)(=O)=O)(C2=O)C3(C)C)C=C1,"Acids / Acids, Noncarboxylic / Compounds used in a research, industrial, or household setting / Cosmetics / Dermatologicals / Household Products / Monoterpenes / Norbornanes / Protective Agents / Radiation-Protective Agents / Sulfur Acids / Sulfur Compounds / Sunscreen Agents / Terpenes",M94R1PM439,92761-26-7,,9915879.0,28534218.0,,1544124.0,135830.0,CHEMBL3989850,,,
Octocrylene,phase 4 complete,DB09535,,"Acids, Acyclic / Sunscreen Agents",5A68WGF6WM,6197-30-4,,,,,77674.0,,,,,
Titanium dioxide,phase 4 complete,DB09536,O=[Ti]=O,"Astringents and Deodorants / Biocompatible Materials / Coloring Agents / Compounds used in a research, industrial, or household setting / Cosmetics / Dermatologicals / Elements / Household Products / Metals / Metals, Light / Photosensitizing Agents / Protective Agents / Radiation-Protective Agents / Radiation-Sensitizing Agents / Sunscreen Agents / Transition Elements / Water Pollutants, Chemical",15FIX9V2JP,13463-67-7,,26042.0,24256.0,,38323.0,32234.0,,,,
Iodine povacrylex,phase 4 complete,DB09537,,,6E43AWY083,845736-10-9,,,,,692863.0,,,,,
Omega-3-acid ethyl esters,phase 4 complete,DB09539 (DB09540),,"Autacoids / Biological Factors / Diet, Food, and Nutrition / Dietary Fats / Dietary Fats, Unsaturated / Eicosanoids / Fats / Fatty Acids / Fatty Acids, Omega-3 / Fatty Acids, Unsaturated / Fish Oils / Food / Food and Beverages / Inflammation Mediators / Lipids / Nootropic Agents / Oils / Pharmaceutical Preparations / Physiological Phenomena",D87YGH4Z0Q,308081-97-2,,,,,484348.0,,,,,
Methyl salicylate,phase 4 complete,DB09543,COC(=O)C1=CC=CC=C1O,"Acids, Carbocyclic / Antirheumatic Agents / Benzene Derivatives / Benzoates / Betula / Biological Products / Complex Mixtures / Compounds used in a research, industrial, or household setting / Fixatives / Gaultheria / Hydroxy Acids / Hydroxybenzoates / Lipids / Oils / Pharmaceutical Preparations / Phenols / Plant Preparations / Salicylates",LAV5U5022Y,119-36-8,D01087,4133.0,13848808.0,,29787.0,31832.0,CHEMBL108545,,,ZINC000000000490
Iobenguane sulfate I-123,phase 4 complete,DB09546,OS(O)(=O)=O.NC(=N)NCC1=CC([123I])=CC=C1.NC(=N)NCC1=CC([123I])=CC=C1,Drugs that are Mainly Renally Excreted / Radioactive Diagnostic Agent / Radiopharmaceutical Activity,23X1185WBO,80663-95-2,,56840904.0,32701571.0,,1427223.0,,CHEMBL3989523,,,
Thonzonium,phase 4 complete,DB09552,CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C1=NC=CC=N1,Amines / Ammonium Compounds / Nitrogen Compounds / Onium Compounds,Z05ZE98FV8,25466-36-8,,5456.0,5257.0,59083.0,237058.0,94514.0,CHEMBL1201322,,,ZINC000008035268
Dexchlorpheniramine maleate,phase 4 complete,DB09555,OC(=O)\C=C/C(O)=O.CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1,Agents that reduce seizure threshold / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / OCT1 inhibitors / OCT1 substrates / OCT2 Inhibitors / Pyridines / QTc Prolonging Agents / Stereoisomerism,B10YD955QW,2438-32-6,,5281070.0,4444527.0,,54828.0,4465.0,CHEMBL1200927,,,
Sodium glycerophosphate,phase 4 complete,DB09561 (DBSALT001586),[Na+].[Na+].OCC(O)COP([O-])([O-])=O,Alcohols / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Carbohydrates / Electrolyte Solutions / I.V. Solution Additives / Lipids / Membrane Lipids / Phosphate salts / Phospholipids / Sugar Alcohols / Sugar Phosphates / Triose Sugar Alcohols,YP1H63LJ2K,1334-74-3,,22251426.0,14071.0,,1595589.0,,CHEMBL3040581,,,
Choline C-11,phase 4 complete,DB09563,C[N+](C)([11CH3])CCO,Radioactive Diagnostic Agent / Radiopharmaceutical Activity,M4AS4XGD4Q,94793-58-5,,449688.0,396147.0,,1425419.0,72322.0,,,,
Olive oil,phase 4 complete,DB09567,,"Biological Products / Complex Mixtures / Diet, Food, and Nutrition / Dietary Fats / Dietary Fats, Unsaturated / Fats / Fats, Unsaturated / Food / Food and Beverages / Lipid Emulsion / Lipids / Oils / Physiological Phenomena / Plant Oils / Plant Preparations",6UYK2W1W1E,8001-25-0,,,,,1309250.0,,,,,
Omega-3-carboxylic acids,phase 4 complete,DB09568,,"Fatty Acids, Omega-3",F85N2YHE4E,,,,,,1652071.0,,,,,
Ixazomib,phase 4 complete,DB09570,CC(C)C[C@H](NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl)B(O)O,"Amino Acids / Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Protease Inhibitors / Proteasome Inhibitors",71050168A2,1072833-77-2,D10130,25183872.0,25027391.0,50398609.0,1723735.0,90942.0,CHEMBL2141296,,,ZINC000169946773
Levmetamfetamine,phase 4 complete,DB09571,CN[C@H](C)CC1=CC=CC=C1,,Y24T9BT2Q2,33817-09-3,,36604.0,33634.0,50359500.0,1314416.0,136013.0,CHEMBL1927030,,,ZINC000008466459
Calcium Phosphate,phase 4 complete,"DB11348 (DB11052, DB11053)",[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O,"Acids / Acids, Noncarboxylic / Alimentary Tract and Metabolism / Anions / Biocompatible Materials / Blood Coagulation Factors / Calcium Compounds / Calcium Salts / Ceramics / Compounds used in a research, industrial, or household setting / Electrolytes / Ions / Mineral Supplements / Phosphate salts / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds",K4C08XP666,10103-46-5,,24456.0,22864.0,,1919.0,9679.0,CHEMBL2106566,,,
Stannous chloride,phase 4 complete,DB11056,[Cl-].[Cl-].[Sn++],,R30H55TN67,7772-99-8,,,22887.0,,314853.0,78067.0,,,,
Mineral oil,phase 4 complete,DB11057,,"Alimentary Tract and Metabolism / Basic Ointments and Protectants / Dermatologicals / Drugs for Constipation / Emollients / Laxatives / Softener and Emollient Laxatives / Softeners, Emollients",T5L8T28FGP,8042-47-5,,,,,258439.0,,,,,
Carboxymethylcellulose,phase 4 complete,DB11059,,"Anorexigenic Agents & Respiratory and CNS Stimulants / Artificial Tears / Biopolymers / Bulk-Forming Laxatives / Carbohydrates / Carboxymethylcellulose Sodium / Cellulose / Compounds used in a research, industrial, or household setting / EENT Drugs, Miscellaneous / Gastrointestinal Agents / Glucans / Laxatives / Macromolecular Substances / Polymers / Polysaccharides",05JZI7B19X,9000-11-7,,,,,2062.0,,CHEMBL1909054,,,
Polyvinyl alcohol,phase 4 complete,DB11060,,"Alcohols / Alkenes / Artificial Tears / Compounds used in a research, industrial, or household setting / EENT Drugs, Miscellaneous / Hydrocarbons, Acyclic / Macromolecular Substances / Plastics / Polyenes / Polymers / Polyvinyls / Vinyl Compounds",532B59J990,9002-89-5,,,,,8570.0,,,,,
Povidone,phase 4 complete,DB11061,,"Alkenes / Artificial Tears / Biomimetic Materials / Blood Substitutes / Compounds used in a research, industrial, or household setting / Hematologic Agents / Hydrocarbons, Acyclic / Macromolecular Substances / Pharmaceutic Aids / Pharmaceutical Preparations / Plasma Substitutes / Plastics / Polyenes / Polymers / Polyvinyls / Pyrrolidines / Pyrrolidinones / Vinyl Compounds",FZ989GH94E,9003-39-8,D02295,,,,8610.0,,,,,
Octisalate,phase 4 complete,DB11062,CCCCC(CC)COC(=O)C1=C(O)C=CC=C1,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Cosmetics / Dermatologicals / Household Products / Hydroxy Acids / Hydroxybenzoates / Phenols / Protective Agents / Radiation-Protective Agents / Sunscreen Agents",4X49Y0596W,118-60-5,,,8061.0,,91327.0,88639.0,CHEMBL1329203,,,
Polysorbate 80,phase 4 complete,DB11063,,"Alcohols / Artificial Tears / Compounds used in a research, industrial, or household setting / Drug Delivery Systems / Ethylene Glycols / Excipients / Glycols / Macromolecular Substances / Pharmaceutic Aids / Pharmaceutical Preparations / Pharmaceutical Vehicles / Polyethylene Glycols / Polymers / Surface-Active Agents",6OZP39ZG8H,9005-65-6,,,,,8560.0,,,,,
Homosalate,phase 4 complete,DB11064,CC1CC(CC(C)(C)C1)OC(=O)C1=C(O)C=CC=C1,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Cosmetics / Dermatologicals / Household Products / Hydroxy Acids / Hydroxybenzoates / Phenols / Protective Agents / Radiation-Protective Agents / Sunscreen Agents",V06SV4M95S,118-56-9,,,8059.0,,91326.0,91642.0,CHEMBL1377575,,,
Selenic acid,phase 4 complete,DB11068,O[Se](O)(=O)=O,"Alimentary Tract and Metabolism / Antioxidants / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Micronutrients / Mineral Supplements / Physiological Phenomena / Protective Agents / Selenium Compounds / Trace Elements",HV0Y51NC4J,7783-08-6,,1089.0,1058.0,50147596.0,,18170.0,CHEMBL2097002,,,
Phenyl salicylate,phase 4 complete,DB11071,OC1=CC=CC=C1C(=O)OC1=CC=CC=C1,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Genito Urinary System and Sex Hormones / Hydroxy Acids / Hydroxybenzoates / Phenols / Urologicals",28A37T47QO,118-55-8,,8361.0,8058.0,,36122.0,34918.0,CHEMBL1339216,,,ZINC000000038545
Hydrogen fluoride,phase 4 complete,DB11072,F,"Acids / Acids, Noncarboxylic / Dental Agents / Fluorine Compounds",RGL5YE86CZ,7664-39-3,,14917.0,14214.0,,5496.0,29228.0,CHEMBL1232767,,,
Dimethicone,phase 4 complete,DB11074,,"Antifoaming Agents / Basic Ointments and Protectants / Compounds used in a research, industrial, or household setting / Macromolecular Substances / Misc. Skin and Mucous Membrane Agents / Organosilicon Compounds / Polymers / Scabicides and Pediculicides / Silicon Compounds / Silicones / Siloxanes / Skin Barrier Activity",92RU3N3Y1O,63148-62-9,,,,,324072.0,,,,,
Hypromellose,phase 4 complete,DB11075,,"Artificial Tears / Biopolymers / Carbohydrates / Cellulose / Compounds used in a research, industrial, or household setting / EENT Drugs, Miscellaneous / Glucans / Macromolecular Substances / Ophthalmologicals / Other Diagnostics / Polymers / Polysaccharides / Sensory Organs / Surgical Aids / Viscoelastic Substances",3NXW29V3WO,9004-65-3,,,,,1363586.0,,,,,
Trolamine salicylate,phase 4 complete,DB11079,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,"Acids, Carbocyclic / Agents causing hyperkalemia / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Benzene Derivatives / Benzoates / Hydroxy Acids / Hydroxybenzoates / Nephrotoxic agents / Non COX-2 selective NSAIDS / Phenols / Salicylates / Sunscreen Agents",H8O4040BHD,2174-16-5,,25213.0,23549.0,,38866.0,,CHEMBL2107288,,,
Silver nitrate,phase 4 complete,DB11080,[Ag+].[O-]N(=O)=O,"Acids / Acids, Noncarboxylic / Anions / Anti-Infective Agents / Anti-Infective Agents, Local / Antiseptics and Disinfectants / Dermatologicals / Electrolytes / Ions / Nitrates / Nitric Acid / Nitrogen Compounds / Silver Compounds",95IT3W8JZE,7761-88-8,D01730,516904.0,22878.0,,9789.0,32130.0,CHEMBL177367,,,
Aluminum chloride,phase 4 complete,DB11081,Cl[Al](Cl)Cl,"Acids / Acids, Noncarboxylic / Aluminium Compounds / Anions / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Antiperspirants / Astringents and Deodorants / Chlorides / Chlorine Compounds / Compounds used in a research, industrial, or household setting / Cosmetics / Dental Agents / Dermatologicals / Electrolytes / Household Products / Ions / Metal cations / Metal divalent cations",LIF1N9568Y,7446-70-0,,24012.0,22445.0,,46241.0,30114.0,CHEMBL3833401,,,
Coal tar,phase 4 complete,DB11082,,Complex Mixtures / Dermatologicals / Keratolytic Agents / Keratoplastic Agents / Tars,R533ESO2EC,8007-45-2,,,,,2635.0,,,,,
Resorcinol,phase 4 complete,DB11085,OC1=CC(O)=CC=C1,Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Anti-Infective Agents / Benzene Derivatives / Dermatologicals / Drugs that are Mainly Renally Excreted / Ophthalmologicals / Phenols / Root Canal Filling Materials / Sensory Organs,YUL4LO94HK,108-46-3,D00133,5054.0,4878.0,26189.0,35382.0,27810.0,CHEMBL24147,,,ZINC000000002028
Docusate,phase 4 complete,DB11089,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(O)(=O)=O,"Alimentary Tract and Metabolism / Drugs for Constipation / Enemas / Laxatives / Softener and Emollient Laxatives / Softeners, Emollients / Succinates / Surface-Active Agents",M7P27195AG,10041-19-7,D00305,,10862.0,,82003.0,534.0,CHEMBL1477036,,,
Potassium nitrate,phase 4 complete,DB11090,[K+].[O-][N+]([O-])=O,"Acids / Acids, Noncarboxylic / Anions / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Electrolytes / Explosive Agents / Ions / Nitric Acid / Nitrogen Compounds / Potassium Salt",RU45X2JN0Z,7757-79-1,,24434.0,22843.0,,34316.0,63043.0,CHEMBL1644029,,,
Hydrogen peroxide,phase 4 complete,DB11091,OO,"Alimentary Tract and Metabolism / Anions / Anti-Infective Agents / Anti-Infective Agents, Local / Antifibrinolytic Agents / Antiinfectives and Antiseptics for Local Oral Treatment / Antiseptics and Disinfectants / Compounds used in a research, industrial, or household setting / Dermatologicals / Electrolytes / Free Radicals / Ions / Noxae / Otologicals / Oxidants / Oxides / Oxygen Compounds / Peroxides / Reactive Oxygen Species / Sensory Organs / Stomatological Preparations / Toxic Actions",BBX060AN9V,7722-84-1,,784.0,763.0,,5499.0,16240.0,CHEMBL71595,,,
Stannous fluoride,phase 4 complete,DB11092,F[Sn]F,"Alimentary Tract and Metabolism / Caries Prophylactic Agents / Compounds used in a research, industrial, or household setting / Stomatological Preparations",3FTR44B32Q,7783-47-3,D05919,24550.0,22956.0,,10030.0,135933.0,CHEMBL1909079,,,
Calcium citrate,phase 4 complete,DB11093,[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,"Acids, Acyclic / Alimentary Tract and Metabolism / Blood Coagulation Factors / Calcium Compounds / Calcium Salts / Citrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Food / Food Additives / Food and Beverages / Food Ingredients / Mineral Supplements / Phosphate Binder / Physiological Phenomena / Polyvalent cation containing laxatives, antacids, oral supplements / Tricarboxylic Acids",86117BWO7P,813-94-5,,13136.0,12584.0,,47613.0,,CHEMBL2106123,,,
Vitamin D,phase 4 complete,DB11094,,"Bone Density Conservation Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Diet, Food, and Nutrition / Food / Food and Beverages / Fused-Ring Compounds / Growth Substances / Micronutrients / Physiological Phenomena / Secosteroids / Steroids / Vitamin D and Analogues / Vitamins / Vitamins (Fat Soluble)",9VU1KI44GP,1406-16-2,,,,,11253.0,,,,,
Meradimate,phase 4 complete,DB11096,CC(C)C1CCC(C)CC1OC(=O)C1=CC=CC=C1N,"Acids, Carbocyclic / Aminobenzoates / Benzene Derivatives / Benzoates / Sunscreen Agents",J9QGD60OUZ,134-09-8,,,8312.0,,91324.0,135974.0,CHEMBL1597075,,,
Potassium bicarbonate,phase 4 complete,DB11098,[K+].OC([O-])=O,"Acids / Acids, Noncarboxylic / Agents causing hyperkalemia / Alimentary Tract and Metabolism / Alkalies / Anions / Carbon Compounds, Inorganic / Carbonates / Carbonic Acid / Drugs that are Mainly Renally Excreted / Electrolytes / Ions / Mineral Supplements / Potassium Salt",HM5Z15LEBN,298-14-6,,516893.0,55053.0,,34296.0,81862.0,CHEMBL2106975,,,
Allantoin,phase 4 complete,DB11100,NC(=O)NC1NC(=O)NC1=O,Basic Ointments and Protectants / Dermatologicals / Herbs and Natural Products / Hydantoins / Imidazoles / Imidazolidines / Thyroxine-binding globulin substrates,344S277G0Z,97-59-6,D00121,,199.0,,508.0,15676.0,CHEMBL593429,,,
N-acetyltyrosine,phase 4 complete,DB11102,CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,"Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Drugs that are Mainly Renally Excreted",DA8G610ZO5,537-55-3,,68310.0,61606.0,50043802.0,31005.0,21563.0,CHEMBL65543,,,ZINC000000156395
Sulfur hexafluoride,phase 4 complete,DB11104,FS(F)(F)(F)(F)F,"Acids / Acids, Noncarboxylic / Anions / Contrast Media / Electrolytes / Fluorides / Fluorine Compounds / Gases / Hydrofluoric Acid / Ions / Other Diagnostics / Sulfur Compounds / Ultrasound Contrast Activity / Ultrasound Contrast Media",WS7LR3I1D6,2551-62-4,D05962,17358.0,16425.0,,1599276.0,30496.0,CHEMBL1796998,,,ZINC000245224194
Benzalkonium,phase 4 complete,DB11105,,"Amines / Ammonium Compounds / Anti-Infective Agents / Anti-Infective Agents, Local / Antiseptics and Disinfectants / Benzalkonium Compounds / Benzylammonium Compounds / Compounds used in a research, industrial, or household setting / Dermatologicals / Detergents / Household Products / Medicated Dressings / Medicated Dressings With Antiinfectives / Miscellaneous Local Anti-infectives / Nitrogen Compounds / Onium Compounds / Pharmaceutic Aids / Pharmaceutical Preparations / Preservatives, Pharmaceutical / Quaternary Ammonium Compounds / Surface-Active Agents / Throat Preparations",7N6JUD5X6Y,,,,,,1378.0,,,,,
Aluminum sesquichlorohydrate,phase 4 complete,DB11108,,"Acids / Acids, Noncarboxylic / Alkalies / Aluminium Compounds / Anions / Chlorine Compounds / Electrolytes / Hydroxides / Ions / Metal cations / Metal divalent cations",UCN889409V,,,,,,543375.0,,,,,
Magnesium citrate,phase 4 complete,DB11110,[Mg++].[Mg++].[Mg++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,"Acids, Acyclic / Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Calculi Dissolution Agent / Citrates / Drugs for Constipation / Gastrointestinal Agents / Irrigating Solutions / Laxatives / Laxatives, magnesium containing / Magnesium Compounds / Metal cations / Metal divalent cations / Mineral Supplements / Osmotic Laxatives / Salt Solutions / Tricarboxylic Acids",RHO26O1T9V,3344-18-1,,6099959.0,2925651.0,,52356.0,131391.0,CHEMBL3989480,,,
Lanolin,phase 4 complete,DB11112,,"Basic Ointments and Protectants / Compounds used in a research, industrial, or household setting / Cosmetics / Household Products / Lipids / Waxes",7EV65EAW6H,8006-54-0,,,,,6227.0,,,,,
Eucalyptus oil,phase 4 complete,DB11114,,Biological Products / Complex Mixtures / Drugs that are Mainly Renally Excreted / Lipids / Oils / Other Cold and Cough Preparations / Plant Oils / Plant Preparations,2R04ONI662,8000-48-4,,,,,59087.0,,,,,
Ensulizole,phase 4 complete,DB11115,OS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C1=CC=CC=C1,"Acids / Acids, Noncarboxylic / Heterocyclic Compounds, Fused-Ring / Sulfur Acids / Sulfur Compounds / Sunscreen Agents",9YQ9DI1W42,27503-81-7,,33919.0,31267.0,181124.0,13714.0,135132.0,CHEMBL1987518,,,ZINC000006467621
Aluminum zirconium trichlorohydrex gly,phase 4 complete,DB11116,,,,134375-99-8,,,,,1370425.0,,,,,
Undecylenic acid,phase 4 complete,DB11117 (DBSALT001514),OC(=O)CCCCCCCCC=C,"Antifungals for Dermatological Use / Antifungals for Topical Use / Dermatologicals / Fatty Acids / Fatty Acids, Monounsaturated / Fatty Acids, Unsaturated / Lipids",K3D86KJ24N,112-38-9,,,10771160.0,50248304.0,314881.0,35045.0,CHEMBL1276010,,,ZINC000001577120
Ammonia,phase 4 complete,DB11118,,Gases / Nitrogen Compounds,,7664-41-7,,,,,1299884.0,,,,,
Sodium iodide,phase 4 complete,DB11119,[Na+].[I-],Anions / Electrolytes / Iodides / Iodine Compounds / Ions / Replacement Preparations / Sodium Compounds / Thyroid Diagnostic Radiopharmaceuticals,F5WR8N145C,7681-82-5,,5238.0,5048.0,50098561.0,9884.0,33167.0,CHEMBL1644695,,,
Turpentine,phase 4 complete,DB11120,,"Biological Products / Biopolymers / Complex Mixtures / Compounds used in a research, industrial, or household setting / Irritants / Lipids / Macromolecular Substances / Noxae / Oils / Oils, Volatile / Plant Exudates / Polymers / Resins, Plant / Solvents / Toxic Actions",XJ6RUH0O4G,9005-90-7,,,,,10938.0,,,,,
Chloroxylenol,phase 4 complete,DB11121,CC1=CC(O)=CC(C)=C1Cl,"Anti-Infective Agents / Anti-Infective Agents, Local / Antiparasitic Agents / Antiplatyhelmintic Agents / Antiseptics and Disinfectants / Benzene Derivatives / Compounds used in a research, industrial, or household setting / Dermatologicals / Disinfectants / Drugs that are Mainly Renally Excreted / Miscellaneous Local Anti-infectives / Phenol and Derivatives / Schistosomicides",0F32U78V2Q,88-04-0,D03473,2723.0,21106017.0,50238619.0,20877.0,34393.0,CHEMBL398440,,,ZINC000000001132
Hypochlorite,phase 4 complete,DB11123,[O-]Cl,"Acids / Acids, Noncarboxylic / Anions / Anti-Infective Agents / Antiseptics and Disinfectants / Chlorine Compounds / Compounds used in a research, industrial, or household setting / Dermatologicals / Disinfectants / Electrolytes / Free Radicals / Ions / Miscellaneous Local Anti-infectives / Noxae / Oxidants / Oxides / Oxygen Compounds / Reactive Oxygen Species / Sodium Compounds / Toxic Actions",T5UM7HB19N,14380-61-1,,61739.0,55632.0,,1483317.0,29222.0,,,,
Racepinephrine,phase 4 complete,DB11124,,Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-1 Receptor Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Adrenergic beta-1 Receptor Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-3 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Alpha-and Beta-adrenergic Agonists / Amines / Amino Alcohols / Anti-Asthmatic Agents / Autonomic Agents / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Bronchodilator Agents / Cardiovascular Agents / Catecholamines / Catechols / Epinephrine and similars / Ethanolamines / Mydriatics / Neurotransmitter Agents / Peripheral Nervous System Agents / Phenols / Respiratory System Agents / Sympathomimetics / Vasoconstrictor Agents,GR0L9S3J0F,329-65-7,,,,,66887.0,,,,,
Benzethonium,phase 4 complete,DB11125,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1,"Amines / Ammonium Compounds / Anti-Infective Agents / Anti-Infective Agents, Local / Antiseptics and Disinfectants / Benzylammonium Compounds / Dermatologicals / Miscellaneous Local Anti-infectives / Nitrogen Compounds / Onium Compounds / Quaternary Ammonium Compounds / Throat Preparations",1VU15B70BP,10172-60-8,,2335.0,2245.0,50203812.0,1390.0,94725.0,CHEMBL1182210,,,ZINC000001571009
Calcium gluconate,phase 4 complete,DB11126,[Ca++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,"Acids, Acyclic / Alimentary Tract and Metabolism / Blood Coagulation Factors / Calcium Salts / Carbohydrates / Dermatologicals / Gluconates / Hydroxy Acids / Mineral Supplements / Minerals / Phosphate Binder / Replacement Preparations / Sugar Acids",SQE6VB453K,299-28-5,,9290.0,8932.0,,1908.0,3309.0,CHEMBL2106119,,,
Selenious acid,phase 4 complete,DB11127,O[Se](O)=O,"Alimentary Tract and Metabolism / Diet, Food, and Nutrition / Drugs that are Mainly Renally Excreted / Food / Food and Beverages / Growth Substances / Micronutrients / Mineral Supplements / Minerals / Physiological Phenomena / Replacement Preparations / Selenium Compounds / Sodium Compounds / Trace Elements",F6A27P4Q4R,7783-00-8,,1091.0,1060.0,,36344.0,26642.0,CHEMBL2009089,,,
Carbamide peroxide,phase 4 complete,DB11129,OO.NC(N)=O,"Anions / Anti-Infective Agents / Anti-Infective Agents, Local / Bleaching Agents / Compounds used in a research, industrial, or household setting / Electrolytes / Free Radicals / Ions / Noxae / Oxidants / Oxides / Oxygen Compounds / Peroxides / Reactive Oxygen Species / Tooth Bleaching Agents / Toxic Actions",31PZ2VAU81,124-43-6,,31294.0,29034.0,,47686.0,75178.0,CHEMBL3184026,,,
Opium,phase 4 complete,DB11130,,"Alimentary Tract and Metabolism / Analgesics / Antidiarrheals / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antipropulsives / Antitussive Agents / Biological Products / Central Nervous System Agents / Central Nervous System Depressants / Complex Mixtures / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Gastrointestinal Agents / Narcotics / Natural Opium Alkaloids / Nervous System / Opiate Agonists / Opioids / Peripheral Nervous System Agents / Pharmaceutical Preparations / Plant Extracts / Plant Preparations / Respiratory System Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",37M3MZ001L,8008-60-4,,,,,7676.0,,,,,
Silicon dioxide,phase 4 complete,DB11132,O=[Si]=O,"Acids / Acids, Noncarboxylic / Anions / Colloids / Complex Mixtures / Compounds used in a research, industrial, or household setting / Dental Casting Investment / Electrolytes / Hygroscopic Agents / Investigative Techniques / Ions / Minerals / Oxides / Oxygen Compounds / Pharmaceutical Preparations / Silicon Compounds",ETJ7Z6XBU4,7631-86-9,,22644374.0,22683.0,,314826.0,30563.0,CHEMBL3188292,,,
Omega-3 fatty acids,phase 4 complete,DB11133,,"Diet, Food, and Nutrition / Dietary Fats / Dietary Fats, Unsaturated / Fats / Fatty Acids / Fatty Acids, Omega-3 / Fatty Acids, Unsaturated / Fish Oils / Food / Food and Beverages / Lipids / Membrane Lipids / Oils / Phospholipids / Physiological Phenomena",71M78END5S,329042-31-1,,,,,4301.0,,,,,
Cupric oxide,phase 4 complete,DB11134,[O--].[Cu++],"Copper-containing Intrauterine Device / Diet, Food, and Nutrition / Elements / Food / Food and Beverages / Growth Substances / Metals / Metals, Heavy / Micronutrients / Physiological Phenomena / Trace Elements / Transition Elements",V1XJQ704R4,1317-38-0,,164827.0,144499.0,,21837.0,75955.0,CHEMBL1909057,,,
Selenium,phase 4 complete,DB11135,[Se],"Alimentary Tract and Metabolism / Antioxidants / Chalcogens / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Drugs that are Mainly Renally Excreted / Elements / Food / Food and Beverages / Growth Substances / Micronutrients / Mineral Supplements / Minerals / Physiological Phenomena / Polyvalent cation containing laxatives, antacids, oral supplements / Protective Agents / Selenium Compounds / Trace Elements",H6241UJ22B,7782-49-2,,6326970.0,4885617.0,,9641.0,27568.0,,,,
Chromium,phase 4 complete,DB11136,[Cr],"Cell-mediated Immunity / Chromium / Diet, Food, and Nutrition / Drugs that are Mainly Renally Excreted / Elements / Food / Food and Beverages / Growth Substances / Increased Histamine Release / Metals / Metals, Heavy / Micronutrients / Minerals / Physiological Phenomena / Standardized Chemical Allergen / Trace Elements / Transition Elements",0R0008Q3JB,7440-47-3,,23976.0,22412.0,,2496.0,28073.0,,,,
Molybdenum,phase 4 complete,DB11137,[Mo],"Diet, Food, and Nutrition / Elements / Food / Food and Beverages / Growth Substances / Metals / Metals, Heavy / Micronutrients / Physiological Phenomena / Trace Elements / Transition Elements",81AH48963U,7439-98-7,,23932.0,22374.0,,7024.0,28685.0,,,,
Chromium Cr-51,phase 4 complete,DB11140,[51Cr],"Chromium / Chromium Isotopes / Elements / Isotopes / Metals / Metals, Heavy / Radioisotopes / Transition Elements",9QAU17N705,14392-02-0,,104786.0,94591.0,,1306065.0,50076.0,,,,
Manganese gluconate,phase 4 complete,DB11141,[Mn++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,"Acids, Acyclic / Carbohydrates / Hydroxy Acids / Paramagnetic Contrast Agent / Sugar Acids",7G09WJ8QIR,6485-39-8,,,21514.0,,52403.0,,,,,
Selenomethionine,phase 4 complete,DB11142,C[Se]CC[C@H](N)C(O)=O,"Amino Acids / Amino Acids, Essential / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Amino Acids, Sulfur / Organoselenium Compounds / Selenium Compounds / Sulfur Compounds",964MRK2PEL,3211-76-5,,105024.0,94765.0,,9644.0,62621.0,CHEMBL113178,,,
Cresol,phase 4 complete,DB11143,,Benzene Derivatives / Drugs that are Mainly Renally Excreted / Phenols / Standardized Chemical Allergen,GF3CGH8D7Z,1319-77-3,,,,,62130.0,,,,,
Oxyquinoline,phase 4 complete,DB11145,OC1=CC=CC2=C1N=CC=C2,"Alimentary Tract and Metabolism / Anti-Infective Agents, Local / Antiinfectives and Antiseptics for Local Oral Treatment / Antiseptics and Disinfectants / Dermatologicals / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hydroxyquinolines / Quinoline Derivatives / Quinolines / Stomatological Preparations / Throat Preparations",5UTX5635HP,148-24-3,,1923.0,1847.0,32203.0,110.0,48981.0,CHEMBL310555,,,ZINC000000008492
Aluminum zirconium pentachlorohydrate,phase 4 complete,DB11147,,,15K31617MU,173762-83-9,,,,,1306097.0,,,,,
Butamben,phase 4 complete,DB11148,CCCCOC(=O)C1=CC=C(N)C=C1,"Acids, Carbocyclic / Aminobenzoates / Anesthetics / Anesthetics, Local / Benzene Derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Cholinesterase substrates / Drugs that are Mainly Renally Excreted / para-Aminobenzoates / Peripheral Nervous System Agents / Sensory System Agents",EFW857872Q,94-25-7,,2482.0,2388.0,50240094.0,19861.0,3231.0,CHEMBL127516,,,ZINC000001530937
Aluminum zirconium tetrachlorohydrex gly,phase 4 complete,DB11149,,,,90604-80-1,,,,,1305896.0,,,,,
Barium sulfate,phase 4 complete,DB11150,[Ba++].[O-]S([O-])(=O)=O,"Acids / Acids, Noncarboxylic / Anions / Barium Compounds / Barium Sulfate Containing X-Ray Contrast Media / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Electrolytes / Ions / Radiographic Contrast Agent / Sulfates / Sulfur Acids / Sulfur Compounds / Sulfuric Acids / X-Ray Contrast Activity / X-Ray Contrast Media, Non-Iodinated",25BB7EKE2E,7727-43-7,,24414.0,22823.0,,1331.0,133326.0,CHEMBL2105897,,,
Sodium hydroxide,phase 4 complete,DB11151,[OH-].[Na+],"Alkalies / Anions / Caustics / Compounds used in a research, industrial, or household setting / Electrolytes / Hydroxides / Ions / Noxae / Sodium Compounds / Toxic Actions",55X04QC32I,1310-73-2,,14798.0,14114.0,,9880.0,32145.0,CHEMBL2105794,,,
Trichloroacetate,phase 4 complete,DB11152,,"Acetates / Acids, Acyclic / Caustics / Chloroacetates / Compounds used in a research, industrial, or household setting / Fatty Acids / Fatty Acids, Volatile / Hydrocarbons, Chlorinated / Hydrocarbons, Halogenated / Lipids / Noxae / Toxic Actions / Trichloroacetic Acid",,76-03-9,,,,,618564.0,,,,,
Potassium hydroxide,phase 4 complete,DB11153,[OH-].[K+],"Alkalies / Anions / Compounds used in a research, industrial, or household setting / Electrolytes / Indicators and Reagents / Ions / Laboratory Chemicals / Potassium Salt",WZH3C48M4T,1310-58-3,D01168,14797.0,14113.0,,34311.0,32035.0,CHEMBL2103983,,,
Triclocarban,phase 4 complete,DB11155,ClC1=CC=C(NC(=O)NC2=CC(Cl)=C(Cl)C=C2)C=C1,"Amides / Amines / Anilides / Aniline Compounds / Anti-Infective Agents / Anti-Infective Agents, Local / Benzene Derivatives / Environmental Pollutants / Miscellaneous Local Anti-infectives / Phenylurea Compounds / Toxic Actions / Water Pollutants / Water Pollutants, Chemical",BGG1Y1ED0Y,101-20-2,D06223,7547.0,7266.0,25730.0,38609.0,48347.0,CHEMBL1076347,,,ZINC000000121480
Pyrantel,phase 4 complete,DB11156,[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1,"Anthelmintics / Anti-Infective Agents / Antinematodal Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular Depolarizing Agents / Peripheral Nervous System Agents / Pyrimidines / Sulfur Compounds / Tetrahydropyrimidine Derivatives / Thiophenes",4QIH0N49E7,15686-83-6,D08451,708857.0,618121.0,,8984.0,8654.0,CHEMBL1626223,,,ZINC000000097996
Anthralin,phase 4 complete,DB11157,OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2,Anthracenes / Antipsoriatics / Antipsoriatics for Topical Use / Antracen Derivatives / Dermatologicals,U8CJK0JH5M,1143-38-0,,2202.0,2117.0,50041802.0,873.0,37510.0,CHEMBL46469,,,ZINC000000001322
Pectin,phase 4 complete,DB11158,,"Alimentary Tract and Metabolism / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Biological Products / Biopolymers / Carbohydrates / Complex Mixtures / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Food / Food Additives / Food and Beverages / Food Ingredients / Intestinal Adsorbents / Macromolecular Substances / Pharmaceutical Preparations / Physiological Phenomena / Plant Extracts / Plant Preparations / Polymers / Polysaccharides",89NA02M4RX,9000-69-5,,,,,32987.0,,,,,
Sodium sulfide,phase 4 complete,DB11159,[Na+].[Na+].[S--],"Acids / Acids, Noncarboxylic / Anions / Electrolytes / Gases / Hydrogen Sulfide / Ions / Sulfur Compounds",YGR27ZW0Y7,1313-82-2,,14804.0,14120.0,,1293719.0,76208.0,CHEMBL2107611,,,
Phenyltoloxamine,phase 4 complete,DB11160,CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1,Benzene Derivatives,K65LB6598J,92-12-6,,7077.0,6810.0,50151046.0,33408.0,135047.0,CHEMBL186720,,,ZINC000000001931
Polyethylene glycol 300,phase 4 complete,DB11161,,"Alcohols / Compounds used in a research, industrial, or household setting / Ethylene Glycols / Glycols / Macromolecular Substances / Polymers",5655G9Y8AQ,25322-68-3,,,,,8513.0,,,,,
Bicisate,phase 4 complete,DB11164,CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC,Diagnostic Agents / Drugs that are Mainly Renally Excreted,3JXF0Z0XOI,121251-02-3,,72048.0,65035.0,,1306100.0,,,,,ZINC000022593510
Calcium threonate,phase 4 complete,DB11168,[Ca++].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O,"Acids, Acyclic / Blood Coagulation Factors / Fatty Acids / Fatty Acids, Volatile / Lipids",HBB4YPO93U,70753-61-6,,13388558.0,9337769.0,,273888.0,,,,,
Ferrous asparto glycinate,phase 4 complete,DB11169,,,H7426RGB3L,,,,,,644718.0,,,,,
Ferric sulfate,phase 4 complete,DB11171,O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O,Hematinics / Iron Compounds / Organometallic Compounds / Parenteral Iron Replacement / Phosphate Binder,3HWS7HF5XD,10028-22-5,,23443659.0,11640309.0,,24913.0,,,,,
Zeaxanthin,phase 4 complete,DB11176,C\C(\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,"Alkenes / Biological Factors / Carotenoids / Cyclohexanes / Cyclohexenes / Cycloparaffins / Hydrocarbons, Acyclic / Pigments, Biological / Polyenes / Terpenes / Xanthophylls",CV0IB81ORO,144-68-3,,5280899.0,4444421.0,,39918.0,27547.0,CHEMBL2359248,,,ZINC000008220175
Polysorbate 20,phase 4 complete,DB11178,,"Alcohols / Compounds used in a research, industrial, or household setting / Drug Delivery Systems / Ethylene Glycols / Excipients / Glycols / Macromolecular Substances / Pharmaceutic Aids / Pharmaceutical Preparations / Pharmaceutical Vehicles / Polyethylene Glycols / Polymers / Surface-Active Agents",7T1F30V5YH,9005-64-5,,,,,8559.0,,,,,
Exametazime,phase 4 complete,DB11179,,Ketones,G29272NCKL,105613-48-7,,,,,62153.0,,,,,
Tetrofosmin,phase 4 complete,DB11180,CCOCCP(CCOCC)CCP(CCOCC)CCOCC,,3J0KPB596Q,127502-06-1,,4274.0,4124.0,,1311569.0,135598.0,CHEMBL1615784,,,ZINC000003780929
Homatropine,phase 4 complete,DB11181,[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)C1=CC=CC=C1)N2C,Alkaloids / Anticholinergic Agents / Autonomic Agents / Aza Compounds / Azabicyclo Compounds / Muscarinic Agonists / Muscarinic Antagonists / Mydriatics and Cycloplegics / Ophthalmologicals / Parasympatholytics / Peripheral Nervous System Agents / Sensory Organs,8QS6WCL55Z,87-00-3,,,16498795.0,50240066.0,27084.0,5747.0,CHEMBL1618018,,,
Rose bengal,phase 4 complete,DB11182,OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12,"Coloring Agents / Colouring Agents / Compounds used in a research, industrial, or household setting / Diagnostic Agents / Fluoresceins / Fluorescent Dyes / Heterocyclic Compounds, Fused-Ring / Indicators and Reagents / Laboratory Chemicals / Luminescent Agents / Ophthalmologicals / Other Diagnostics / Sensory Organs / Spiro Compounds / Xanthenes",,,,,23774.0,,9471.0,87202.0,CHEMBL1208422,,,ZINC000150338646
Light green SF yellowish,phase 4 complete,DB11183,[Na+].[Na+].CCN(CC1=CC(=CC=C1)S([O-])(=O)=O)C1=CC=C(C=C1)C(C1=CC=C(C=C1)S([O-])(=O)=O)=C1C=CC(C=C1)=[N+](CC)CC1=CC(=CC=C1)S([O-])(=O)=O,"Acids / Acids, Noncarboxylic / Amines / Ammonium Compounds / Arylsulfonates / Arylsulfonic Acids / Nitrogen Compounds / Onium Compounds / Quaternary Ammonium Compounds / Sulfonic Acids / Sulfur Acids / Sulfur Compounds",3F7BHA64Z0,5141-20-8,,21223.0,19952.0,,1305579.0,87065.0,,,,
Oftasceine,phase 4 complete,DB11184,OC(=O)CN(CC(O)=O)CC1=CC2=C(OC3=CC(O)=C(CN(CC(O)=O)CC(O)=O)C=C3C22OC(=O)C3=CC=CC=C23)C=C1O,,V0YM2B16TS,1461-15-0,,65079.0,58589.0,,1367088.0,51903.0,CHEMBL1973733,,,ZINC000004217203
Pentoxyverine,phase 4 complete,DB11186,CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1,Antitussive Agents / Central Nervous System Agents / Cough and Cold Preparations / Cycloparaffins / Respiratory System Agents,32C726X12W,77-23-6,,2562.0,2464.0,94507.0,20217.0,94484.0,CHEMBL73234,,,ZINC000003830375
Magnesium glycinate,phase 4 complete,DB11189,[Mg++].NCC([O-])=O.NCC([O-])=O,Agents that produce neuromuscular block (indirect) / Calculi Dissolution Agent / Laxatives / Osmotic Laxatives,IFN18A4Y6B,14783-68-7,,84645.0,76358.0,,476818.0,,,,,
Pantethine,phase 4 complete,DB11190,CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO,Alimentary Tract and Metabolism / Sulfhydryl Compounds / Sulfur Compounds / Vitamin B Complex / Vitamins,7K81IL792L,16816-67-4,D01234,452306.0,398402.0,,32863.0,31959.0,CHEMBL2104786,,,ZINC000003874604
Cobamamide,phase 4 complete,DB11191,[C@H]1(C[Co-3]2345[N+]6=C7C(C)=C8N2[C@]([H])([C@H](CC(=O)N)[C@]8(CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@@H]2[C@@H](CO)O[C@H](N8C=[N+]3C3=CC(C)=C(C)C=C83)[C@@H]2O)C)[C@@]2(C)[C@@](CC(=O)N)([C@H](CCC(=O)N)C(C(C)=C3[N+]4=C(C=C6C([C@@H]7CCC(=O)N)(C)C)[C@@H](CCC(=O)N)[C@@]3(CC(=O)N)C)=[N+]52)C)O[C@@H](N2C3=C(N=C2)C(=NC=N3)N)[C@H](O)[C@@H]1O,"Antianemic Preparations / Blood and Blood Forming Organs / Coenzymes / Corrinoids / Enzymes and Coenzymes / Heterocyclic Compounds, Fused-Ring / Vitamin B Complex / VITAMIN B12 AND FOLIC ACID / Vitamins",F0R1QK73KB,13870-90-1,D00042,,21864853.0,,21373.0,18408.0,CHEMBL3833359,,,
Papain,phase 4 complete,DB11193,,"Cysteine Endopeptidases / Cysteine Proteases / Endopeptidases / Enzymes / Enzymes and Coenzymes / Gastrointestinal Agents / Hydrolases / Papain, antagonists & inhibitors / Peptide Hydrolases",A236A06Y32,9001-73-4,,,,,7892.0,,,,,
Inositol,phase 4 complete,DB13178 (DB11196),O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O,"Alcohols / Alimentary Tract and Metabolism / Carbohydrates / Diet, Food, and Nutrition / Drugs that are Mainly Renally Excreted / Food / Food and Beverages / Growth Substances / Micronutrients / Other Nutritional Agents / Physiological Phenomena / Sugar Alcohols / Vitamin B Complex / Vitamins",4L6452S749,87-89-8,D08079,,10239179.0,,5833.0,17268.0,CHEMBL1222251,,,ZINC000100018867
Ferrous cysteine glycinate,phase 4 complete,DB11197,[Fe++].NCC(O)=O.[H][C@](N)(CS)C(O)=O.[H][C@](N)(C[S-])C([O-])=O,,8B4OP7RK5N,,,,34987810.0,,1490797.0,,,,,
Aluminum zirconium octachlorohydrex gly,phase 4 complete,DB11200,O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O,,P9D3YP29MY,174514-58-0,,,32698594.0,,1306096.0,,,,,
Menthyl salicylate,phase 4 complete,DB11201,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1O,,43XOA705ZD,89-46-3,,,16736426.0,,1368207.0,135976.0,,,,ZINC000000002060
N-alkyl ethylbenzyl dimethyl ammonium (C12-C14),phase 4 complete,DB11202,,,85440928RV,,,,,,1422066.0,,,,,
Panthenol,phase 4 complete,DB11204,,"Alanine / Amino Acids / Amino Acids, Peptides, and Proteins / Imides / Vitamin B Complex / Vitamins / Wound Healing",WV9CM0O67Z,16485-10-2,D03726,,,,1044977.0,27373.0,CHEMBL1371937,,,
Alcloxa,phase 4 complete,DB11205,[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-].NC(=O)NC1NC(=O)[N-]C1=O,,18B8O9DQA2,1317-25-5,,,32698939.0,,1305554.0,,,,,
Bemotrizinol,phase 4 complete,DB11206,CCCCC(CC)COC1=CC(O)=C(C=C1)C1=NC(=NC(=N1)C1=CC=C(OC)C=C1)C1=C(O)C=C(OCC(CC)CCCC)C=C1,Benzene Derivatives / Sunscreen Agents,PWZ1720CBH,187393-00-6,,,10645286.0,,1306115.0,135857.0,CHEMBL2104956,,,
Amiloxate,phase 4 complete,DB11207,COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1,"Acids, Carbocyclic / Sunscreen Agents",376KTP06K8,71617-10-2,,,1266578.0,,1426854.0,,CHEMBL1476782,,,ZINC000001600509
Aluminum chlorohydrex propylene glycol,phase 4 complete,DB11208,,,PGG6VG42HP,53026-85-0,,,,,1313224.0,,,,,
Iron protein succinylate,phase 4 complete,DB11209,,"Acids, Acyclic / Amino Acids, Peptides, and Proteins / Anemia, Hypochromic, drug therapy / Dicarboxylic Acids / Ferric Compounds / Hematinics / Hematologic Agents / Proteins",VBJ9L90P4L,250705-13-6,,,,,27823.0,,,,,
Ferrous bisglycinate,phase 4 complete,DB11210,[Fe++].NCC([O-])=O.NCC([O-])=O,"Amino Acids / Amino Acids, Peptides, and Proteins / Iron Compounds / Organometallic Compounds",SFW1D987QV,20150-34-9,,9837124.0,8012845.0,,1102188.0,,,,,
Arbutin,phase 4 complete,DB11217,OC[C@H]1O[C@@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O,Carbohydrates / Glucosides / Glycosides,C5INA23HXF,497-76-7,,440936.0,389765.0,50219502.0,1367175.0,18305.0,CHEMBL232202,,,ZINC000000518554
Enzacamene,phase 4 complete,DB11219,CC1=CC=C(\C=C2/C3CCC(C)(C2=O)C3(C)C)C=C1,Bornanes / Ketones / Monoterpenes / Norbornanes / Sunscreen Agents / Terpenes,8I3XWY40L9,36861-47-9,,7019255.0,4939160.0,50103609.0,1311507.0,135937.0,CHEMBL2104261,,,
Dioxybenzone,phase 4 complete,DB11221,COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1O,Benzene Derivatives / Ketones / Sunscreen Agents,B762XZ551X,131-53-3,D03853,,8251.0,,23350.0,34208.0,CHEMBL1326877,,,ZINC000000037293
Peg-100 stearate,phase 4 complete,DB11225,,Pegylated agents,YD01N1999R,9004-99-3,,,,,1367120.0,,,,,
Ethylhexyl methoxycrylene,phase 4 complete,DB11226,CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C1=CC=C(OC)C=C1,,S3KFG6Q5X8,947753-66-4,,,52085894.0,,1311616.0,,,,,
Methylcellulose,phase 4 complete,DB11228,,"Alimentary Tract and Metabolism / Biopolymers / Bulk-Forming Laxatives / Carbohydrates / Cellulose / Compounds used in a research, industrial, or household setting / Drugs for Constipation / EENT Drugs, Miscellaneous / Glucans / Laxatives / Macromolecular Substances / Polymers / Polysaccharides",Z944H5SN0H,9004-67-5,D04996,,23107149.0,,6873.0,53448.0,,,,
Magnesium Aluminum Silicate,phase 4 complete,DB11230,,"Acids / Acids, Noncarboxylic / Agents that produce neuromuscular block (indirect) / Anions / Electrolytes / Ions / Minerals / Oxides / Oxygen Compounds / Pharmaceutic Aids / Silicon Compounds",6M3P64V0NC,1327-43-1,,,,,17614.0,,,,,
Lycopene,phase 4 complete,DB11231,CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C,"Alkenes / Anti-Inflammatory Agents / Anticarcinogenic Agents / Antioxidants / Biological Factors / Carotenoids / Compounds used in a research, industrial, or household setting / Cyclohexanes / Cyclohexenes / Cycloparaffins / Hydrocarbons, Acyclic / Pigments, Biological / Polyenes / Protective Agents / Radiation-Protective Agents / Terpenes",SB0N2N0WV6,502-65-8,,446925.0,394156.0,,29008.0,15948.0,CHEMBL501174,,,ZINC000008214943
Saccharide isomerate,phase 4 complete,DB11232,,,W8K377W98I,100843-69-4,,,,,1314278.0,,,,,
Thonzylamine,phase 4 complete,DB11235,COC1=CC=C(CN(CCN(C)C)C2=NC=CC=N2)C=C1,"Agents producing tachycardia / Antiallergic Agents, Excl. Corticosteroids / Anticholinergic Agents / Antihistamines for Systemic Use / Antihistamines for Topical Use / Antipruritics, Incl. Antihistamines, Anesthetics, Etc. / Dermatologicals / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Muscarinic Antagonists / Nasal Preparations / Neurotransmitter Agents / Substituted Ethylene Diamines",R79646H5Z8,91-85-0,,5457.0,5258.0,,1360721.0,104017.0,CHEMBL1623738,,,ZINC000000057513
Trypsin,phase 4 complete,DB11237,,Blood and Blood Forming Organs / Dermatologicals / Endopeptidases / Enzymes / Enzymes and Coenzymes / Hydrolases / Musculo-Skeletal System / Peptide Hydrolases / Preparations for Treatment of Wounds and Ulcers / Serine Endopeptidases / Serine Proteases,GV54A213NN,9002-07-7,,,,,10890.0,,,,,
Borage oil,phase 4 complete,DB11238,,"Agents that reduce seizure threshold / Antirheumatic Agents / Biological Products / Complex Mixtures / Dietary Fats, Unsaturated / Fatty Acids / Fatty Acids, Essential / Fatty Acids, Omega-6 / Fatty Acids, Unsaturated / Linolenic Acids / Lipids / Oils / Plant Preparations",F8XAG1755S,,,,,,68905.0,,,,,
Aluminum sulfate,phase 4 complete,DB11239,[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O,"Acids / Acids, Noncarboxylic / Adjuvants, Immunologic / Aluminium Compounds / Anions / Electrolytes / Immunologic Factors / Ions / Metal cations / Metal divalent cations / Sulfates / Sulfur Acids / Sulfur Compounds / Sulfuric Acids",I7T908772F,10043-01-3,,24850.0,23233.0,,17621.0,74768.0,CHEMBL3833402,,,
Gelatin,phase 4 complete,DB11242,,"Amino Acids, Peptides, and Proteins / Proteins / Scleroproteins",2G86QN327L,9000-70-8,,,,,4716.0,,,,,
Ethyl macadamiate,phase 4 complete,DB11243,,,ANA2NCS6V1,,,,,,1314358.0,,,,,
Copper gluconate,phase 4 complete,DB11246,[Cu++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,Copper-containing Intrauterine Device,RV823G6G67,527-09-3,,10692.0,10242.0,,2839.0,31431.0,,,,
Zinc gluconate,phase 4 complete,DB11248,[Zn++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,"Acids, Acyclic / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Alimentary Tract and Metabolism / Carbohydrates / Copper Absorption Inhibitor / Hydroxy Acids / Metal cations / Metal divalent cations / Mineral Supplements / Sugar Acids / Vasoprotectives / Zinc Compounds",U6WSN5SQ1Z,4468-02-4,,443445.0,391659.0,,58300.0,29708.0,CHEMBL3833377,,,
Tocopherol,phase 4 complete,DB11251,,"Alimentary Tract and Metabolism / Antioxidants / Benzopyrans / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Diet, Food, and Nutrition / Drugs that are Mainly Renally Excreted / Food / Food and Beverages / Growth Substances / Heterocyclic Compounds, Fused-Ring / Micronutrients / Physiological Phenomena / Protective Agents / Pyrans / Vitamin E / Vitamins / Vitamins (Fat Soluble)",R0ZB2556P8,1406-66-2,,,,,1236136.0,,,,,
Xanthan gum,phase 4 complete,DB11253,,"Antigens / Antigens, Bacterial / Biological Factors / Carbohydrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Drug Carriers / Food / Food Additives / Food and Beverages / Food Ingredients / Physiological Phenomena / Polysaccharides",TTV12P4NEE,11138-66-2,,,,,1307815.0,,,,,
Hexylresorcinol,phase 4 complete,DB11254,CCCCCCC1=C(O)C=C(O)C=C1,"Anthelmintics / Anti-Infective Agents / Anti-Infective Agents, Local / Antiparasitic Agents / Benzene Derivatives / Miscellaneous Anti-infectives / Phenols / Resorcinols / Throat Preparations",R9QTB5E82N,136-77-6,,3610.0,21106121.0,50292636.0,5321.0,93749.0,CHEMBL443605,,,ZINC000001576892
Chromium picolinate,phase 4 complete,DB11255,[Cr+3].[O-]C(=O)C1=NC=CC=C1.[O-]C(=O)C1=NC=CC=C1.[O-]C(=O)C1=NC=CC=C1,"Compounds used in a research, industrial, or household setting / Iron Chelating Agents / Pyridines / Sequestering Agents / Standardized Chemical Allergen",S71T8B8Z6P,14639-25-9,,625469.0,133913.0,,59308.0,50369.0,,,,
Levomefolic acid,phase 4 complete,DB11256,CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)N=C(N)N2,"Amino Acids / Amino Acids, Acidic / Amino Acids, Dicarboxylic / Amino Acids, Peptides, and Proteins / Biological Factors / Coenzymes / Enzymes and Coenzymes / Folic Acid and Derivatives / Heterocyclic Compounds, Fused-Ring / Pigments, Biological / Pteridines / Pterins / Vitamin B Complex / Vitamins",8S95DH25XC,31690-09-2,,444412.0,392351.0,50391007.0,1025342.0,15641.0,CHEMBL1231574,,PA166129561,ZINC000002005305
Fluoride ion,phase 4 complete,DB11257,[F-],,Q80VPU408O,16984-48-8,,28179.0,26214.0,26978.0,196213.0,17051.0,CHEMBL1362,,,
Diacetyl benzoyl lathyrol,phase 4 complete,DB11260,C[C@H]1C[C@@]2(OC(C)=O)[C@H]([C@H]1OC(=O)C1=CC=CC=C1)[C@@H](OC(C)=O)C(=C)CC[C@H]1[C@@H](\C=C(C)\C2=O)C1(C)C,,8986760I2S,218916-52-0,,10577938.0,8753322.0,,1426391.0,136008.0,CHEMBL552128,,,ZINC000096903163
Atractylodes japonica root,phase 4 complete,DB11261,,,,,,,,,1307719.0,,,,,
Bisoctrizole,phase 4 complete,DB11262,CC(C)(C)CC(C)(C)C1=CC(CC2=C(O)C(=CC(=C2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)=C(O)C(=C1)N1N=C2C=CC=CC2=N1,Sunscreen Agents,8NT850T0YS,103597-45-1,,,2808671.0,,1310510.0,135865.0,CHEMBL2104957,,,ZINC000011677911
Polydatin,phase 4 complete,DB11263,OC[C@H]1O[C@@H](OC2=CC(\C=C\C3=CC=C(O)C=C3)=CC(O)=C2)[C@H](O)[C@@H](O)[C@@H]1O,"Benzene Derivatives / Benzylidene Compounds / Carbohydrates / Drugs, Chinese Herbal / Glycosides",XM261C37CQ,27208-80-6,,5281718.0,4445034.0,60919.0,1364277.0,8198.0,CHEMBL142652,,,ZINC000004098633
Calcium glycerophosphate,phase 4 complete,DB11264 (DBSALT002553),[Ca++].OCC(CO)OP([O-])([O-])=O,,Y56W30YB7O,27214-00-2,D01488,,56554.0,,1909.0,31336.0,CHEMBL3707206,,,
Sea salt,phase 4 complete,DB11266,,,87GE52P74G,,,,,,1311499.0,,,,,
Diethylamino hydroxybenzoyl hexyl benzoate,phase 4 complete,DB11269,CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(C=C1O)N(CC)CC,Amines / Aniline Compounds / Benzene Derivatives / Ketones / Phenols / Sunscreen Agents,ANQ870JD20,302776-68-7,,,8286957.0,,1426392.0,136006.0,,,,ZINC000034230491
Atractylodes japonica root oil,phase 4 complete,DB11270,,,,,,,,,1305643.0,,,,,
Polysilicone-15,phase 4 complete,DB11271,,Sunscreen Agents,F8DRP5BB29,207574-74-1,,,,,1367142.0,,,,,
Dihydroergocornine,phase 4 complete,DB11273,[H][C@@]12CCCN1C(=O)[C@H](C(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,"Agents that produce hypertension / Alkaloids / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Dopamine Agents / Dopamine Agonists / Ergot Alkaloids and Derivatives / Ergot-derivative Dopamine Receptor Agonists / Ergotamines / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents",IK4C1OC8NE,25447-65-8,,,147720.0,,3415.0,59909.0,CHEMBL2365712,,,ZINC000004215648
Dihydro-alpha-ergocryptine,phase 4 complete,DB11274,[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates,202229IR8Y,25447-66-9,,,102887.0,81453.0,91170.0,59919.0,CHEMBL1743263,,,ZINC000003929793
Epicriptine,phase 4 complete,DB11275,[H][C@@]12CCCN1C(=O)[C@]([H])([C@H](C)CC)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,Alkaloids,5M64643B5U,88660-47-3,,,59102.0,,91171.0,135927.0,CHEMBL2106411,,,ZINC000004215812
Aluminum zirconium pentachlorohydrex gly,phase 4 complete,DB11277,,,,,,,,,1305899.0,,,,,
DL-Methylephedrine,phase 4 complete,DB11278,C[C@@H]([C@H](O)C1=CC=CC=C1)N(C)C,Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Drugs that are Mainly Renally Excreted,60VH42A1KJ,1201-56-5,,,58315.0,,1546444.0,113556.0,CHEMBL445001,,,ZINC000000000491
Brilliant green cationCommonly known or available as Brilliant green,phase 4 complete,DB11279,CCN(CC)C1=CC=C(C=C1)C(C1=CC=CC=C1)=C1C=CC(C=C1)=[N+](CC)CC,"Amines / Ammonium Compounds / Anti-Infective Agents / Anti-Infective Agents, Local / Coloring Agents / Compounds used in a research, industrial, or household setting / Nitrogen Compounds / Onium Compounds",S85JD8CLBH,18198-35-1,,12449.0,11942.0,81263.0,1546367.0,88176.0,CHEMBL1589793,,,ZINC000004235575
Diethyltoluamide,phase 4 complete,DB11282,CCN(CC)C(=O)C1=CC(C)=CC=C1,"Acids, Carbocyclic / Agrochemicals / Amides / Antiparasitic Products, Insecticides and Repellents / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents / Insect Repellents / Insecticides and Repellents / Pesticides / Protective Agents / Toxic Actions",FB0C1XZV4Y,134-62-3,D02379,,4133.0,,3129.0,7071.0,CHEMBL1453317,,,ZINC000000001291
DL-dimyristoylphosphatidylcholine,phase 4 complete,DB11283 (DBSALT001574),CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC,"Alcohols / Carbohydrates / Compounds used in a research, industrial, or household setting / Glycerophosphates / Glycerophospholipids / Indicators and Reagents / Laboratory Chemicals / Lipids / Membrane Lipids / Phosphatidic Acids / Phosphatidylcholines / Phospholipids / Sugar Alcohols / Sugar Phosphates / Triose Sugar Alcohols",U86ZGC74V5,18656-38-7,,,24408.0,,1362902.0,241349.0,CHEMBL316257,,,
DL-dimyristoylphosphatidylglycerol,phase 4 complete,DB11284 (DBSALT001575),CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC,Alcohols / Carbohydrates / Glycerophosphates / Glycerophospholipids / Lipids / Membrane Lipids / Phosphatidic Acids / Phospholipids / Sugar Alcohols / Sugar Phosphates / Triose Sugar Alcohols,BI71WT9P3R,61361-72-6,,,96926.0,,1427048.0,,,,,
Ethyl ferulate,phase 4 complete,DB11285,[H]\C(=C(\[H])C1=CC(OC)=C(O)C=C1)C(=O)OCC,"Acids, Carbocyclic / Cinnamates",5B8915UELW,4046-02-0,,,643791.0,50297424.0,1420983.0,,CHEMBL286796,,,ZINC000000160496
Rice bran oil,phase 4 complete,DB11293,,Biological Products / Complex Mixtures / Lipids / Oils / Plant Oils / Plant Preparations,LZO6K1506A,,,,,,1309223.0,,,,,
Trichophyton verrucosum,phase 4 complete,DB11295,,,JA74887EHM,,,,,,1310905.0,,,,,
Thioredoxin,phase 4 complete,DB11298,,"Amino Acids, Peptides, and Proteins / Proteins / Thioredoxins / Thioredoxins, antagonists & inhibitors",XJZ418133Z,52500-60-4,,,,,1314275.0,,,,,
Vanillyl butyl ether,phase 4 complete,DB11299,CCCCOCC1=CC(OC)=C(O)C=C1,,S2ULN37C9R,82654-98-6,,5084146.0,4260417.0,,1313189.0,,,,,ZINC000002561203
Curcuma aromatica root oil,phase 4 complete,DB11301,,,Q68H9P4S4J,94349-73-2,,,,,1482794.0,,,,,
Phenoxyethanol,phase 4 complete,DB11304,,"Alcohols / Anesthetics / Anti-Infective Agents / Anti-Infective Agents, Local / Central Nervous System Agents / Drugs that are Mainly Renally Excreted / Glycols",HIE492ZZ3T,122-99-6,,31236.0,13848467.0,,89552.0,64275.0,CHEMBL1229846,,,ZINC000001577061
Bentonite,phase 4 complete,DB11306,,"Acids / Acids, Noncarboxylic / Aluminium Compounds / Aluminum Silicates / Anions / Antidotes / Compounds used in a research, industrial, or household setting / Electrolytes / Ions / Metal cations / Metal divalent cations / Minerals / Oxides / Oxygen Compounds / Protective Agents / Silicates / Silicon Compounds",,,,,,,1375.0,,,,,
Methscopolamine,phase 4 complete,DB11315,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,"Agents producing tachycardia / Alimentary Tract and Metabolism / Alkaloids / Anticholinergic Agents / Autonomic Agents / Aza Compounds / Azabicyclo Compounds / Belladonna Alkaloids, Semisynthetic, Quaternary Ammonium Compounds / Belladonna and Derivatives, Plain / Drugs for Functional Gastrointestinal Disorders / Muscarinic Antagonists / Mydriatics and Cycloplegics / Ophthalmologicals / Parasympatholytics / Peripheral Nervous System Agents / Scopolamine Derivatives / Sensory Organs / Synthetic Anticholinergics, Quaternary Ammonium Compounds / Tropanes",VDR09VTQ8U,13265-10-6,,71183.0,21106347.0,50241132.0,89785.0,135361.0,CHEMBL376897,,,ZINC000100047524
Pentetic acid,phase 4 complete,"DB14007 (DB11322, DBSALT001589)",OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O,"Acetates / Acids, Acyclic / Amines / Antidotes / Chelating Agents / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Fatty Acids / Fatty Acids, Volatile / Iron Chelating Agents / Lead Chelating Activity / Lead Chelator / Lipids / Polyamines / Protective Agents / Sequestering Agents",7A314HQM0I,67-43-6,,,2945.0,,3690.0,35739.0,CHEMBL780,,,ZINC000019419017
Glycol salicylate,phase 4 complete,DB11323,OCCOC(=O)C1=CC=CC=C1O,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Hydroxy Acids / Hydroxybenzoates / Phenols",3I1VBB7AXH,87-28-5,,6880.0,6616.0,,26051.0,86541.0,CHEMBL173562,,,ZINC000001698306
Boric acid,phase 4 complete,DB11326,OB(O)O,"Acids / Acids, Noncarboxylic / Agrochemicals / Anti-Infective Agents / Boron Compounds / Compounds used in a research, industrial, or household setting / Insecticides / Otologicals / Pesticides / Sensory Organs / Toxic Actions",R57ZHV85D4,10043-35-3,,7628.0,7346.0,39817.0,1700.0,33118.0,CHEMBL42403,,,ZINC000245189278
Dipyrithione,phase 4 complete,DB11327,[O-][N+]1=CC=CC=C1SSC1=CC=CC=[N+]1[O-],,9L87N86R9A,3696-28-4,,,2998.0,,1362743.0,136010.0,CHEMBL549473,,,ZINC000001751811
Tetradecyl hydrogen sulfate (ester),phase 4 complete,DB11328,CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O,Drugs that are Mainly Renally Excreted,6326W0DRHY,300-52-7,,,8441.0,,1370424.0,75275.0,CHEMBL1201345,,,
C11-12 isoparaffin,phase 4 complete,DB11329,,,OIY0J17X7Z,246538-76-1,,,,,1609072.0,,,,,
1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)),phase 4 complete,DB11331 (DB14095),CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC,,F72017VPR7,185435-28-3,,,4446626.0,,1440971.0,34080.0,,,,
Poloxamer 188,phase 4 complete,DB11333,,"Alcohols / Compounds used in a research, industrial, or household setting / Drug Delivery Systems / Ethylene Glycols / Excipients / Glycols / Macromolecular Substances / Pharmaceutic Aids / Pharmaceutical Preparations / Pharmaceutical Vehicles / Polyethylene Glycols / Polymers / Surface-Active Agents",LQA7B6G8JG,691397-13-4,,,,,155152.0,,CHEMBL2108134,,,
Kinetin,phase 4 complete,DB11336,C(NC1=NC=NC2=C1NC=N2)C1=CC=CO1,"Cytokinins / Growth Substances / Heterocyclic Compounds, Fused-Ring / Plant Growth Regulators / Purines",P39Y9652YJ,525-79-1,,3830.0,3698.0,181147.0,16054.0,27407.0,CHEMBL228792,,,ZINC000000001601
Ubiquinol,phase 4 complete,DB11340,COC1=C(OC)C(O)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(C)=C1O,Benzoquinones / Coenzymes / Enzymes and Coenzymes / Quinones,M9NL0C577Y,992-78-9,,9962735.0,8138335.0,,39085.0,64183.0,,,,ZINC000085574641
Ichthammol,phase 4 complete,DB11341,,Amines / Ammonium Compounds / Dermatologicals / Nitrogen Compounds / Onium Compounds,NQ14646378,8029-68-3,,,,,5645.0,,,,,
Aluminum oxide,phase 4 complete,DB11342,[O--].[O--].[O--].[Al+3].[Al+3],Aluminium Compounds / Aluminum Oxides / Anions / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Dermatologicals / Electrolytes / Ions / Metal cations / Metal divalent cations / Oxides / Oxygen Compounds,LMI26O6933,1344-28-1,,9989226.0,8164808.0,,615.0,,CHEMBL3707210,,,
Silanol,phase 4 complete,DB11343,O[SiH3],Organosilicon Compounds / Silicon Compounds,079V3J9O3X,70131-67-8,,6327522.0,125395.0,,1601667.0,37173.0,,,,
Rubidium,phase 4 complete,DB11346,[Rb],"Elements / Metals / Metals, Alkali / Metals, Heavy",MLT4718TJW,7440-17-7,,,4512975.0,,1311489.0,33322.0,,,,
Ascorbyl phosphate,phase 4 complete,DB11352,,Vitamin C and analogues / Vitamins,,,,,,,1370605.0,,,,,
Propolis wax,phase 4 complete,DB11355,,,6Y8XYV2NOF,,,,,,1311659.0,,,,,
Polyquaternium-10 (400 cps at 2%),phase 4 complete,DB11356,,,HB1401PQFS,81859-24-7,,,,,1367143.0,,,,,
Linseed oil,phase 4 complete,DB11357,,"Biological Products / Complex Mixtures / Fats / Fats, Unsaturated / Lipids / Oils / Plant Oils / Plant Preparations",84XB4DV00W,66071-03-2,,,,,6404.0,,,,,
Guaiacol,phase 4 complete,DB11359,COC1=C(O)C=CC=C1,Benzene Derivatives / Catechols / Ethers / Methyl Ethers / Phenols / Phenyl Ethers,6JKA7MAH9C,90-05-1,D00117,460.0,447.0,50240369.0,5031.0,28591.0,CHEMBL13766,,,ZINC000013512224
Lactobacillus plantarum,phase 4 complete,DB11360,,,QFC21096ON,,,,,,1673942.0,,,,,
Selexipag,phase 4 complete,DB11362,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1,"Acetates / Acids, Acyclic / Amides / Antihypertensive Agents / Blood and Blood Forming Organs / Cardiovascular Agents / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fatty Acids / Fatty Acids, Volatile / Lipids / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / Platelet Aggregation Inhibitors Excl. Heparin / Prodrugs / Prostacyclin Receptor Agonist / Prostacyclin Receptor Agonists / Receptors, Prostaglandin, agonists / Vasodilating Agents",5EXC0E384L,475086-01-2,D09994,9913767.0,8089417.0,50235383.0,1729002.0,90844.0,CHEMBL238804,,,ZINC000003990451
Alectinib,phase 4 complete,DB11363,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Indoles / Kinase Inhibitor / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors / Tyrosine Kinase Inhibitors",LIJ4CT1Z3Y,1256580-46-7,D10542,49806720.0,26326738.0,50362781.0,1727455.0,90936.0,CHEMBL1738797,,PA166160050,ZINC000066166864
Chlorobutanol,phase 4 complete,DB11386,CC(C)(O)C(Cl)(Cl)Cl,"Alcohols / Alimentary Tract and Metabolism / Antiemetics and Antinauseants / Butanols / Chlorohydrins / Compounds used in a research, industrial, or household setting / Fatty Alcohols / Lipids / Pharmaceutic Aids / Pharmaceutical Preparations / Preservatives, Pharmaceutical",HM4YQM8WRC,57-15-8,D01942,5977.0,13842993.0,50417941.0,2378.0,134813.0,CHEMBL1439973,,,ZINC000001482005
Chloroform,phase 4 complete,DB11387,ClC(Cl)Cl,"Anesthetics / Anesthetics, General / Compounds used in a research, industrial, or household setting / Hydrocarbons, Chlorinated / Hydrocarbons, Halogenated / Nervous System / Solvents / Trihalomethanes",7V31YC746X,67-66-3,,,5977.0,,1362698.0,35255.0,CHEMBL44618,,,ZINC000008214524
Moxidectin,phase 4 complete,DB11431,[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O,"Agrochemicals / Anthelmintics / Anti-Infective Agents / Antinematodal Agents / Antiparasitic Agents / Compounds used in a research, industrial, or household setting / Insecticides / Lactones / Pesticides / Polyketides / Toxic Actions",NGU5H31YO9,113507-06-5,D05084,,22901017.0,,1047072.0,,CHEMBL2104415,,,ZINC000169649308
2-mercaptobenzothiazole,phase 4 complete,DB11496,S=C1NC2=C(S1)C=CC=C2,"Anti-Infective Agents / Cell-mediated Immunity / Heterocyclic Compounds, Fused-Ring / Increased Histamine Release / Standardized Chemical Allergen / Sulfur Compounds / Thiazoles",5RLR54Z22K,149-30-4,,,608157.0,50444459.0,1358845.0,34292.0,CHEMBL111654,,,ZINC000018098783
Dihydrostreptomycin,phase 4 complete,DB11512,CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO,Agents that produce neuromuscular block (indirect) / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Glycosides / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Ophthalmologicals / Sensory Organs,P2I6R8W6UA,128-46-1,D07840,,388489.0,,1549540.0,38291.0,CHEMBL1950576,,,ZINC000008216695
Lesinurad,phase 4 complete,DB11560,OC(=O)CSC1=NN=C(Br)N1C1=CC=C(C2CC2)C2=C1C=CC=C2,"Acetates / Acids, Acyclic / Antigout Preparations / Antirheumatic Agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fatty Acids / Fatty Acids, Volatile / Lipids / Musculo-Skeletal System / Preparations Increasing Uric Acid Excretion / Renal Agents / Sulfhydryl Compounds / Sulfur Compounds / Urate Transporter 1 Inhibitor / Urate Transporter 1 Inhibitors / Uricosuric Agents",09ERP08I3W,878672-00-5,D09921,53465279.0,28527877.0,37953.0,1731031.0,90929.0,CHEMBL2105720,,PA166160006,ZINC000084757007
Padimate O,phase 4 complete,DB11570,CCCCC(CC)COC(=O)C1=CC=C(C=C1)N(C)C,"Acids, Carbocyclic / Aminobenzoates / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Cosmetics / Dermatologicals / Household Products / Protective Agents / Radiation-Protective Agents / Sunscreen Agents",Z11006CMUZ,21245-02-3,D05335,30541.0,28343.0,,32786.0,135932.0,CHEMBL1323699,,,
Aluminum chlorohydrate,phase 4 complete,DB11573,O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-],Astringents and Deodorants / Dermatologicals / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Medicated Dressings / Medicated Dressings With Antiinfectives / Musculo-Skeletal System,HPN8MZW13M,12359-72-7,,71586946.0,32699791.0,,17610.0,,,,,
Elbasvir,phase 4 complete,DB11574,[H][C@]1(CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=NC=C(N1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CN=C(N3)[C@]3([H])CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1,"Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Experimental Unapproved Treatments for COVID-19 / Hepatitis C Virus NS5A Inhibitor / Heterocyclic Compounds, Fused-Ring / P-glycoprotein inhibitors / P-glycoprotein substrates",632L571YDK,1370468-36-2,D10625,71661251.0,30843797.0,,1734628.0,132967.0,CHEMBL3039514,,PA166163436,ZINC000150588351
Grazoprevir,phase 4 complete,DB11575,COC1=CC2=NC3=C(CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)O3)C(C)(C)C)N=C2C=C1,"Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / HCV NS3/4A Protease Inhibitors / Heterocyclic Compounds, Fused-Ring / NS3/4A Protease Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates",8YE81R1X1J,1350514-68-9,D10639,44603531.0,28506694.0,,1734630.0,132975.0,CHEMBL2063090,,PA166163437,ZINC000095551509
Indigotindisulfonic acid,phase 4 complete,DB11577,OS(=O)(=O)C1=CC2=C(N\C(C2=O)=C2\NC3=C(C=C(C=C3)S(O)(=O)=O)C2=O)C=C1,"Coloring Agents / Compounds used in a research, industrial, or household setting / Diagnostic Agents / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Indoles / Kidney Function / Tests for Renal Function and Ureteral Injuries",X7OI7JF73P,483-20-5,,5282430.0,4445584.0,,1546441.0,90117.0,CHEMBL1091250,,,ZINC000100005073
Hard fat,phase 4 complete,DB11578,,Pharmaceutical Vehicles / Suppositories,8334LX7S21,,,,,,1368196.0,,,,,
Light Mineral Oil,phase 4 complete,DB11579,,Basic Ointments and Protectants,N6K5787QVP,92062-35-6,,,,,577312.0,,,,,
Venetoclax,phase 4 complete,DB11581,CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1,Amides / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCL-2 Inhibitor / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Increased Cellular Death / Narrow Therapeutic Index Drugs / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Sulfones / Sulfur Compounds,N54AIC43PW,1257044-40-8,D10679,49846579.0,29315017.0,60828.0,1747556.0,133021.0,CHEMBL3137309,,PA166153473,ZINC000150338755
Cetalkonium,phase 4 complete,DB11583,CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1,"Alcohols / Amines / Ammonium Compounds / Anti-Infective Agents / Anti-Infective Agents, Local / Compounds used in a research, industrial, or household setting / Lipids / Nitrogen Compounds / Onium Compounds / Surface-Active Agents",FHG725432Z,10328-34-4,,31203.0,28944.0,,,135523.0,CHEMBL1624075,,,ZINC000014233334
Pipradrol,phase 4 complete,DB11584,[H]N1CCCCC1C(O)(C1=CC=CC=C1)C1=CC=CC=C1,"Nervous System / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics",S6I030E0DA,467-60-7,,,9681.0,,,135101.0,CHEMBL2110938,,,
Drometrizole trisiloxane,phase 4 complete,DB11585,CC(CC1=C(O)C(=CC(C)=C1)N1N=C2C=CC=CC2=N1)C[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C,"Compounds used in a research, industrial, or household setting / Macromolecular Substances / Organosilicon Compounds / Polymers / Silicon Compounds",HC22845I1X,155633-54-8,,,8024601.0,,1992874.0,,,,,
Asunaprevir,phase 4 complete,DB11586,COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2,"Amides / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / Cytochrome P-450 CYP2A6 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (weak) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / HCV Protease Inhibitors / Heterocyclic Compounds, Fused-Ring / HIV Protease Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Protease Inhibitors / Sulfones / Sulfur Compounds",S9X0KRJ00S,630420-16-5,,16076883.0,17235944.0,,1652103.0,134723.0,CHEMBL2105735,,PA166128168,ZINC000085540202
Etafedrine,phase 4 complete,DB11587,CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1,Adrenergic Agonists / Adrenergic beta-2 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Drugs that are Mainly Renally Excreted / Ethylamines / Phenethylamines / Propanolamines / Propanols,2Y6VQU63E8,48141-64-6,,,85308.0,,,,,,,ZINC000001846418
Carbon monoxide,phase 4 complete,DB11588,,"Anions / Carbon Compounds, Inorganic / Electrolytes / Gases / Gasotransmitters / Ions / Neurotransmitter Agents / Noxae / Oxides / Oxygen Compounds / Toxic Actions",7U1EE4V452,630-08-0,D09706,281.0,275.0,,2037.0,17245.0,CHEMBL1231840,,,
Neon,phase 4 complete,DB11589,[Ne],Elements / Gases / Noble Gases,4VB4Y46AHD,7440-01-9,,23935.0,22377.0,,7301.0,33310.0,,,,
Thimerosal,phase 4 complete,DB11590,[Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O,"Alkylmercury Compounds / Antiseptics and Disinfectants / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Dermatologicals / Ethylmercury Compounds / Increased Histamine Release / Mercurial Products / Organomercury Compounds / Organometallic Compounds / Pharmaceutic Aids / Pharmaceutical Preparations / Preservatives, Pharmaceutical / Standardized Chemical Allergen",2225PI3MOV,54-64-8,D00864,16684434.0,5697.0,,10472.0,9546.0,CHEMBL508338,,,
Bilastine,phase 4 complete,DB11591,CCOCCN1C(=NC2=CC=CC=C12)C1CCN(CCC2=CC=C(C=C2)C(C)(C)C(O)=O)CC1,"Antihistamines for Systemic Use / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Potential QTc-Prolonging Agents / QTc Prolonging Agents",PA1123N395,202189-78-4,,185460.0,161234.0,,,135954.0,CHEMBL1742423,,,ZINC000003822702
Domiphen,phase 4 complete,DB11594,CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1,Alimentary Tract and Metabolism / Amines / Ammonium Compounds / Antiinfectives and Antiseptics for Local Oral Treatment / Miscellaneous Anti-infectives / Miscellaneous Local Anti-infectives / Nitrogen Compounds / Onium Compounds / Stomatological Preparations,4AZL56CU0F,13900-14-6,,3149.0,3037.0,,23623.0,135978.0,CHEMBL1187011,,,ZINC000006845992
Levoleucovorin,phase 4 complete,DB11596,NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1,"Antidotes / Biological Factors / Coenzymes / Compounds used in a research, industrial, or household setting / Detoxifying Agents for Antineoplastic Treatment / Enzymes and Coenzymes / Folate Analog / Folic Acid Analogues / Folic Acid and Derivatives / Formyltetrahydrofolates / Heterocyclic Compounds, Fused-Ring / Pigments, Biological / Protective Agents / Pteridines / Pterins / Tetrahydrofolates / Vitamin B Complex / Vitamins",990S25980Y,68538-85-2,D04715,149436.0,131714.0,286.0,877015.0,63606.0,CHEMBL1908841,,PA450198,ZINC000009212427
"Starch, corn",phase 4 complete,DB11599,,"Biopolymers / Carbohydrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Dietary Carbohydrates / Food / Food and Beverages / Glucans / Macromolecular Substances / Physiological Phenomena / Polymers / Polysaccharides / Starch",O8232NY3SJ,9005-25-8,,,,,1039062.0,,,,,
Hydroxyethyl cellulose,phase 4 complete,DB11602,CC(O)COCC1OC(OC2C(COCC(C)O)OC(OCC(C)O)C(OCC(C)O)C2OCC(C)O)C(OCC(C)O)C(OCC(C)O)C1OCC(C)O,"Biopolymers / Carbohydrates / Compounds used in a research, industrial, or household setting / Glucans / Macromolecular Substances / Ophthalmic Solutions / Polymers / Polysaccharides / Saliva, Artificial",T4V6TWG28D,9004-62-0,D04474,4327536.0,3532118.0,,27244.0,85249.0,CHEMBL2109076,,,
Myrrh,phase 4 complete,DB11605,,,JC71GJ1F3L,9000-45-7,,,,,67257.0,,,,,
Normethadone,phase 4 complete,DB11609,CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,Analgesics / Antitussive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cough and Cold Preparations / Ketones / Narcotics / Opioids / Opium Alkaloids and Derivatives / Peripheral Nervous System Agents / Respiratory System Agents / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome,KR2L2A68XL,467-85-6,D07384,10090.0,9687.0,,32009.0,135242.0,CHEMBL346331,,,ZINC000001847280
Oxilofrine,phase 4 complete,DB11610,[H][C@@](C)(NC)[C@]([H])(O)C1=CC=C(O)C=C1,Alcohols / Amines / Amino Alcohols / Ethylamines / Phenethylamines / Propanolamines / Propanols,F49638UBDR,365-26-4,D08314,688009.0,599505.0,,32639.0,134822.0,CHEMBL1160695,,,ZINC000000056399
Lifitegrast,phase 4 complete,DB11611,CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C3=CC=C4C=COC4=C3)C=C2Cl)C(O)=O)=CC=C1,"Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Anti-Inflammatory Agents / Anti-inflammatory Agents, Miscellaneous / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Lymphocyte Function-Associated Antigen-1 / Lymphocyte Function-Associated Antigen-1 Antagonist / Lymphocyte Function-Associated Antigen-1 Antagonists / Ophthalmic Solutions / Ophthalmologicals / Pharmaceutical Preparations / Pharmaceutical Solutions / Sensory Organs / Solutions / Sulfur Compounds",038E5L962W,1025967-78-5,D10374,11965427.0,10139520.0,50386331.0,1801820.0,133023.0,CHEMBL2048028,,,ZINC000084668739
Velpatasvir,phase 4 complete,DB11613,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC=C(N1)C1=CC=C2C(COC3=CC4=C(C=CC5=C4NC(=N5)[C@@H]4CC[C@H](C)N4C(=O)[C@@H](NC(=O)OC)C(C)C)C=C23)=C1,"Acids, Acyclic / Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Direct Acting Antivirals / Hepatitis C Virus NS5A Inhibitor / Heterocyclic Compounds, Fused-Ring / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B3 Inhibitors / Organic Anion Transporting Polypeptide 2B1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates",KCU0C7RS7Z,1377049-84-7,D10806,67683363.0,34501056.0,,1799206.0,133009.0,CHEMBL3545062,,PA166163415,ZINC000203686879
Rupatadine,phase 4 complete,DB11614,CC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1,"Antihistamines for Systemic Use / Benzocycloheptenes / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dibenzocycloheptenes / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Piperidines / Platelet Activating Factor, antagonists & inhibitors / Potential QTc-Prolonging Agents / QTc Prolonging Agents",2AE8M83G3E,158876-82-5,,133017.0,117388.0,50036935.0,,135673.0,CHEMBL91397,,PA165107052,ZINC000000598829
Gestrinone,phase 4 complete,DB11619,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H],"Adrenal Cortex Hormones / Antigonadotropins and Similar Agents / Contraceptive Agents, Female / Contraceptives, Oral / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Norpregnanes / Norpregnatrienes / Norsteroids / Progestin Contraceptives / Progestins / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",1421533RCM,16320-04-0,D04317,27812.0,25877.0,50423515.0,4792.0,89642.0,CHEMBL1868702,,,ZINC000003938633
Dehydrocholic acid,phase 4 complete,DB11622,[H][C@@]1(CC[C@@]2([H])[C@]3([H])C(=O)C[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC(=O)[C@]12C)[C@H](C)CCC(O)=O,Bile Acids and Salts / Cholagogues and Choleretics / Cholanes / Cholic Acids / Fused-Ring Compounds / Gastrointestinal Agents / Laxatives / Steroids,NH5000009I,81-23-2,D01693,6674.0,6422.0,,42625.0,31459.0,CHEMBL514446,,,ZINC000003860869
Laropiprant,phase 4 complete,DB11629,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1,"Heterocyclic Compounds, Fused-Ring",G7N11T8O78,571170-77-9,,,8043333.0,50205275.0,,135942.0,CHEMBL426559,,PA166129564,ZINC000003961849
Temoporfin,phase 4 complete,DB11630,OC1=CC=CC(=C1)C-1=C2\CCC(=N2)\C(=C2/N\C(\C=C2)=C(/C2=N/C(/C=C2)=C(\C2=CC=C\-1N2)C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Biological Factors / Dermatologicals / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / Photosensitizing Agents / Pigments, Biological / Porphyrins / Radiation-Sensitizing Agents / Sensitizers Used in Photodynamic/radiation Therapy",FU21S769PF,122341-38-2,D06066,,54754.0,,115243.0,9437.0,CHEMBL500576,,,
Opicapone,phase 4 complete,DB11632,CC1=C(C2=NOC(=N2)C2=CC(=C(O)C(O)=C2)[N+]([O-])=O)C(Cl)=[N+]([O-])C(C)=C1Cl,Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Central Nervous System Agents / COMT Inhibitors / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Dopamine Agents / Enzyme Inhibitors / Nervous System / Oxazoles,Y5929UIJ5N,923287-50-7,,,24667564.0,50019329.0,2362167.0,134699.0,CHEMBL1089318,,,ZINC000034602275
Isavuconazole,phase 4 complete,DB11633,C[C@@H](C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1,Anti-Infective Agents / Antifungal Agents / Antiinfectives for Systemic Use / Antimycotics for Systemic Use / Azole Antifungals / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (weak) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (moderate) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Isavuconazole and Prodrugs / OCT2 Inhibitors / P-glycoprotein inhibitors / Triazole Derivatives / UGT1A9 Inhibitors,60UTO373KE,241479-67-4,,,5293682.0,,1720882.0,85979.0,CHEMBL409153,,,ZINC000001485935
Colestilan chloride,phase 4 complete,DB11634,,Drugs for Treatment of Hyperkalemia and Hyperphosphatemia / Fused-Ring Compounds / Steroids,VSI302RYSR,95522-45-5,,,,,,,,,,
Tocofersolan,phase 4 complete,DB11635,,"Alimentary Tract and Metabolism / Benzopyrans / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drug Carriers / Heterocyclic Compounds, Fused-Ring / Pyrans / Vitamin E / Vitamins / Vitamins (Fat Soluble)",O03S90U1F2,9002-96-4,,,,,159151.0,,,,,
Nomegestrol,phase 4 complete,DB11636,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,"Adrenal Cortex Hormones / Antineoplastic Agents, Hormonal / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Pregnadien Derivatives / Pregnadienes / Pregnanes / Progesterone Congeners / Progestins / Progestogens and Estrogens, Sequential Preparations / Sex Hormones and Modulators of the Genital System / Steroids",10F89177CO,58691-88-6,D07222,,62024.0,,31930.0,135993.0,CHEMBL2105722,,,ZINC000004217164
Delamanid,phase 4 complete,DB11637,C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)[N+]([O-])=O,Antiinfectives for Systemic Use / Antimycobacterials / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Treatment of Tuberculosis / Imidazoles / Moderate Risk QTc-Prolonging Agents / Nitro Compounds / QTc Prolonging Agents,8OOT6M1PC7,681492-22-8,,,4981055.0,,,134742.0,CHEMBL218650,,,ZINC000043100810
Amifampridine,phase 4 complete,DB11640,NC1=CC=NC=C1N,Amines / Aminopyridines / Cardiovascular Agents / Iodine Radioisotopes / Membrane Transport Modulators / Moderate Risk QTc-Prolonging Agents / Nervous System / Peripheral Nervous System Agents / Potassium Channel Antagonists / Potassium Channel Blockers / Pyridines / QTc Prolonging Agents,RU4S6E2G0J,54-96-6,,,5705.0,50416493.0,2106338.0,135948.0,CHEMBL354077,,,ZINC000000164000
Vinflunine,phase 4 complete,DB11641,CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC,"Alkaloids / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Indole Alkaloids / Indoles / Narrow Therapeutic Index Drugs / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Secologanin Tryptamine Alkaloids / Vinca Alkaloids",5BF646324K,162652-95-1,,,8804619.0,,,90241.0,CHEMBL2110725,,,ZINC000085537078
Pitolisant,phase 4 complete,DB11642,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1,"Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs causing inadvertant photosensitivity / Drugs that are Mainly Renally Excreted / Histamine Antagonists / Moderate Risk QTc-Prolonging Agents / Nervous System / OCT1 inhibitors / Photosensitizing Agents / QTc Prolonging Agents / Receptors, Histamine H3",4BC83L4PIY,362665-56-3,,,8123714.0,50247053.0,2197878.0,134709.0,CHEMBL462605,,,ZINC000034045468
Tafamidis,phase 4 complete,DB11644,OC(=O)C1=CC=C2N=C(OC2=C1)C1=CC(Cl)=CC(Cl)=C1,"Anti-Inflammatory Agents / BCRP/ABCG2 Inhibitors / Fused-Ring Compounds / Heterocyclic Compounds, Fused-Ring / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunologic Factors / Miscellaneous Cardiac Drugs / Nervous System / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors",8FG9H9D31J,594839-88-0,D09673,11001318.0,9176510.0,50197883.0,1545063.0,78538.0,CHEMBL2103837,,,ZINC000043206271
Bremelanotide,phase 4 complete,DB11653,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O,"Amino Acids, Peptides, and Proteins / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypothalamic Hormones / Melanocortins / Melanocyte-Stimulating Hormones / Nerve Tissue Proteins / Neuropeptides / Peptide Hormones / Peptides / Pituitary Hormones / Pituitary Hormones, Anterior / Pro-Opiomelanocortin / Protein Precursors / Proteins / Receptor, Melanocortin, Type 3, agonists / Receptor, Melanocortin, Type 4, agonists",6Y24O4F92S,189691-06-3,,9941379.0,8116997.0,50389769.0,2176312.0,,CHEMBL2070241,,,
Latanoprostene bunod,phase 4 complete,DB11660,O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1,"Autacoids / Biological Factors / Drugs that are Mainly Renally Excreted / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Inflammation Mediators / Lipids / Prostaglandin analogs reducing intraocular pressure (IOP) / Prostaglandins / Prostaglandins, Synthetic",I6393O0922,860005-21-6,,11156438.0,9331546.0,,1988390.0,,CHEMBL2364612,,,ZINC000095598449
Curcumin,phase 4 complete,DB11672,COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O,"Alkanes / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Antineoplastic Agents / Antirheumatic Agents / Benzene Derivatives / Catechols / Central Nervous System Agents / Coloring Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (moderate) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 Enzyme Inhibitors / Diarylheptanoids / Enzyme Inhibitors / Heptanes / Hydrocarbons, Acyclic / P-glycoprotein inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / Phenols / Sensory System Agents",IT942ZTH98,458-37-7,,969516.0,839564.0,50140172.0,2955.0,3962.0,CHEMBL140,,,ZINC000000899824
Triheptanoin,phase 4 complete,DB11677,CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC,Glycerides / Lipids / Triglycerides,2P6O7CFW5K,620-67-7,,69286.0,62497.0,,1313234.0,,CHEMBL4297585,,,ZINC000004521897
Selumetinib,phase 4 complete,DB11689,CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO,"BCRP/ABCG2 Substrates / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / P-glycoprotein substrates / Tyrosine Kinase Inhibitors / UGT1A1 Substrates",6UH91I579U,606143-52-6,D09666,10127622.0,8303141.0,50355497.0,2289380.0,90227.0,CHEMBL1614701,,PA166129529,ZINC000031773258
Naldemedine,phase 4 complete,DB11691,[H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CC6)CC[C@@]14[C@@]5(O)CC(C(=O)NC(C)(C)C1=NC(=NO1)C1=CC=CC=C1)=C2O)=CC=C3O,"Alimentary Tract and Metabolism / Alkaloids / Drugs for Constipation / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Morphinans / Opiate Alkaloids / Opioid Antagonists / Peripheral Opioid Receptor Antagonists / Phenanthrenes / UGT1A3 substrates",03KSI6WLXH,916072-89-4,,54732242.0,28530803.0,,1876597.0,,CHEMBL2105755,,,
Tropisetron,phase 4 complete,DB11699,[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C1=CNC3=CC=CC=C13)N2C,"Alimentary Tract and Metabolism / Antiarrhythmic agents / Antidepressive Agents / Antiemetics / Antiemetics and Antinauseants / Autonomic Agents / Central Nervous System Agents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Indoles / Neurotransmitter Agents / Peripheral Nervous System Agents / Serotonin 5-HT3 Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists",6I819NIK1W,89565-68-4,,656665.0,16736476.0,50108392.0,27392.0,32269.0,CHEMBL56564,,,ZINC000100019233
Acalabrutinib,phase 4 complete,DB11703,CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1,"Acids, Carbocyclic / Amides / Antineoplastic Agents / Benzene Derivatives / Benzoates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Kinase Inhibitor / Tyrosine Kinase Inhibitors",I42748ELQW,1420477-60-6,,71226662.0,36764951.0,50175583.0,1986808.0,,CHEMBL3707348,,,ZINC000208774715
Iomeprol,phase 4 complete,DB11705,CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Iodobenzoates / Triiodobenzoic Acids / Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media / X-Ray Contrast Media, Iodinated",17E17JBP8L,78649-41-9,D01719,3731.0,3600.0,,,31710.0,CHEMBL2107214,,,
Tezacaftor,phase 4 complete,DB11712,CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO,"BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Dioxoles / Heterocyclic Compounds, Fused-Ring / P-glycoprotein inhibitors / P-glycoprotein substrates",8RW88Y506K,1152311-62-0,D11041,46199646.0,28637762.0,281054.0,1999382.0,,CHEMBL3544914,,,ZINC000068206930
Encorafenib,phase 4 complete,DB11718,COC(=O)N[C@@H](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=CC(Cl)=CC(NS(C)(=O)=O)=C1F)C(C)C,"Acids, Acyclic / Amides / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Moderate Risk QTc-Prolonging Agents / Protein Kinase Inhibitors / QTc Prolonging Agents / Sulfones / Sulfur Compounds",8L7891MRB6,1269440-17-6,,50922675.0,28536139.0,221688.0,2049106.0,,CHEMBL3301612,,PA166179872,ZINC000068249103
Ribociclib,phase 4 complete,DB11730,CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1,"Amines / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / Kinase Inhibitor / Protein Kinase Inhibitors / Pyridines / QTc Prolonging Agents",TK8ERE8P56,1211441-98-3,D10883,44631912.0,30798107.0,148264.0,1873916.0,,CHEMBL3545110,,PA166153470,ZINC000072316335
Lasmiditan,phase 4 complete,DB11732,CN1CCC(CC1)C(=O)C1=CC=CC(NC(=O)C2=C(F)C=C(F)C=C2F)=N1,Amides / BCRP/ABCG2 Inhibitors / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / OCT1 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome,760I9WM792,439239-90-4,,11610526.0,9785281.0,,2256930.0,,CHEMBL3039520,,,ZINC000003818355
Galactose,phase 4 complete,DB11735,[H]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO,Carbohydrates / Contrast Media / Diagnostic Agents / Hexoses / Monosaccharides / Tests for Liver Functional Capacity / Ultrasound Contrast Media,X2RN3Q8DNE,59-23-4,,3037556.0,2301265.0,,4626.0,17118.0,,,,ZINC000100008403
Rilmenidine,phase 4 complete,DB11738,C1CC1C(NC1=NCCO1)C1CC1,"Adrenergic Agents / Adrenergic Agonists / Adrenergic alpha-2 Receptor Agonists / Adrenergic alpha-Agonists / Agents producing tachycardia / Agents that produce hypertension / Antiadrenergic Agents, Centrally Acting / Antihypertensive Agents / Autonomic Agents / Cardiovascular Agents / Imidazoline Receptor Agonists / Neurotransmitter Agents / Oxazoles / Peripheral Nervous System Agents / Sympatholytics",P67IM25ID8,54187-04-1,,68712.0,61963.0,50070328.0,55679.0,8862.0,CHEMBL289480,,,ZINC000000009708
Ebastine,phase 4 complete,DB11742,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1,Antihistamines for Systemic Use / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Ketones / Neurotransmitter Agents / Potential QTc-Prolonging Agents / QTc Prolonging Agents,TQD7Q784P1,90729-43-4,,3191.0,3079.0,22873.0,23796.0,31528.0,CHEMBL305660,,,ZINC000003781952
Benfotiamine,phase 4 complete,DB11748,C\C(N(CC1=CN=C(C)N=C1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)C1=CC=CC=C1,"Adjuvants, Immunologic / Alimentary Tract and Metabolism / Compounds used in a research, industrial, or household setting / Immunologic Factors / Pyrimidines / Sequestering Agents / Sulfur Compounds / Thiazoles / Vitamin B Complex / Vitamins",Y92OUS2H9B,22457-89-2,,3032771.0,2297665.0,,18891.0,41039.0,CHEMBL3183549,,,ZINC000002015559
Clobetasol,phase 4 complete,DB11750,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Very Potent (Group IV) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids / Steroids, Fluorinated / Thyroxine-binding globulin inhibitors",ADN79D536H,25122-41-2,,5311051.0,4470588.0,,2590.0,205919.0,CHEMBL1201362,,,ZINC000026892643
Istradefylline,phase 4 complete,DB11757,[H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC,"Adenosine A2 Receptor Antagonists / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C18 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Neurotransmitter Agents / OAT1/SLC22A6 inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / Purinergic Agents / Purinergic Antagonists / Purinergic P1 Receptor Antagonists",2GZ0LIK7T4,155270-99-8,,5311037.0,4470574.0,50176050.0,2199015.0,134726.0,CHEMBL431770,,,ZINC000003803921
Talazoparib,phase 4 complete,DB11760,CN1N=CN=C1[C@@H]1[C@H](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Enzyme Inhibitors / Narrow Therapeutic Index Drugs / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Poly(ADP-ribose) Polymerase Inhibitors / Pyridazines,9QHX048FRV,1207456-01-6,,44819241.0,28637772.0,50084621.0,2099704.0,,CHEMBL3137320,,,ZINC000072318110
Tenapanor,phase 4 complete,DB11761,CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2,"Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Sulfur Compounds",WYD79216A6,1234423-95-0,,71587953.0,32056950.0,,2199674.0,,CHEMBL3304485,,,
Zytron,phase 4 complete,DB11768,COP(=S)(NC(C)C)OC1=CC=C(Cl)C=C1Cl,Amines / Organophosphorus Compounds / Sulfur Compounds,IK51552IFH,299-85-4,,9299.0,8940.0,,,,,,,
Capmatinib,phase 4 complete,DB11791,CNC(=O)C1=C(F)C=C(C=C1)C1=NN2C(CC3=CC4=C(C=C3)N=CC=C4)=CN=C2N=C1,"Acids, Carbocyclic / Amides / Antineoplastic Agents / BCRP/ABCG2 Inhibitors / Benzene Derivatives / Benzoates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / P-glycoprotein substrates / Tyrosine Kinase Inhibitors",TY34L4F9OZ,1029712-80-8,,25145656.0,25069712.0,50146167.0,2362165.0,,CHEMBL3188267,,,ZINC000043195321
Niraparib,phase 4 complete,DB11793,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / Poly(ADP-ribose) Polymerase Inhibitors / Pyrazoles",HMC2H89N35,1038915-60-4,,24958200.0,24531930.0,50316226.0,1918231.0,,CHEMBL1094636,,PA166131610,ZINC000043206370
Bictegravir,phase 4 complete,DB11799,OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC2=C(F)C=C(F)C=C2F)C1=O,"Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Direct Acting Antivirals / Heterocyclic Compounds, Fused-Ring / MATE 1 Inhibitors / MATE inhibitors / UGT1A1 Substrates",8GB79LOJ07,1611493-60-7,,90311989.0,44208822.0,330048.0,1999660.0,,CHEMBL3989866,,,
Tilarginine,phase 4 complete,DB11815,CNC(=N)NCCC[C@H](N)C(O)=O,"Amino Acids / Amino Acids, Basic / Amino Acids, Diamino / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Arginine / Enzyme Inhibitors / Nitric Oxide Synthase, antagonists & inhibitors",27JT06E6GR,17035-90-4,,132862.0,117259.0,92900.0,,60257.0,CHEMBL256147,,,ZINC000001529776
Baricitinib,phase 4 complete,DB11817,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,Amides / Antineoplastic and Immunomodulating Agents / Azetines / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Immunosuppressive Agents / Janus Kinase Inhibitor / Janus Kinase Inhibitors / MATE 2 Inhibitors / MATE 2 Substrates / MATE 2 Substrates with a Narrow Therapeutic Index / MATE inhibitors / MATE substrates / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OAT3/SLC22A8 Substrates / OATP1B3 inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / Selective Immunosuppressants / Sulfones / Sulfur Compounds,ISP4442I3Y,1187594-09-7,D10308,44205240.0,26373084.0,50021656.0,2047232.0,95341.0,CHEMBL2105759,,,ZINC000073069247
Esketamine,phase 4 complete,DB11823,CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl,"Agents producing tachycardia / Anesthetics / Anesthetics, General / Antidepressive Agents / Central Nervous System Agents / Central Nervous System Depressants / Cyclohexanes / Cycloparaffins / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (weak) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Nervous System / Psychotropic Drugs",50LFG02TXD,33643-46-8,D07283,182137.0,158414.0,,2119365.0,60799.0,CHEMBL395091,,,ZINC000035999642
Ertugliflozin,phase 4 complete,DB11827,CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1,Alimentary Tract and Metabolism / BCRP/ABCG2 Substrates / Blood Glucose Lowering Agents / Diuretics / Drugs Used in Diabetes / P-glycoprotein substrates / Sodium-glucose co-transporter 2 (SGLT2) inhibitors / Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors / Sodium-Glucose Transporter 2 Inhibitors / UGT1A1 Inhibitors / UGT1A4 Inhibitors / UGT1A9 Substrates / UGT2B7 substrates,6C282481IP,1210344-57-2,,44814423.0,26340533.0,50342885.0,1992672.0,,CHEMBL1770248,,,ZINC000068197809
Neratinib,phase 4 complete,DB11828,CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Kinase Inhibitor / P-glycoprotein inhibitors / Protein Kinase Inhibitors / Tyrosine Kinase Inhibitors",JJH94R3PWB,698387-09-6,,9915743.0,8091392.0,50161957.0,1940643.0,61397.0,CHEMBL180022,,,ZINC000003916214
Osilodrostat,phase 4 complete,DB11837,FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12,"Cytochrome P-450 CYP11B2, antagonists & inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (moderate) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / MATE 1 Inhibitors / MATE inhibitors / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / OCT2 Inhibitors / UGT1A4 substrates / UGT2B7 substrates",5YL4IQ1078,928134-65-0,,44139752.0,29340911.0,50444549.0,2286252.0,,CHEMBL3099695,,,ZINC000072318114
Angiotensin II,phase 4 complete,DB11842,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O,"Amino Acids, Peptides, and Proteins / Angiotensin II, antagonists & inhibitors / Angiotensins / Autacoids / Biological Factors / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiovascular Agents / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Inflammation Mediators / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Proteins / Vasoconstriction / Vasoconstrictor Agents",M089EFU921,4474-91-3,,172198.0,150504.0,50236697.0,1999003.0,58506.0,CHEMBL408403,,,ZINC000169676920
Revefenacin,phase 4 complete,DB11855,CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1,Amides / Anticholinergic Agents / BCRP/ABCG2 Substrates / Benzene Derivatives / Bronchodilator Agents / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 Substrates / Muscarinic Antagonists / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates,G2AE2VE07O,864750-70-9,,11753673.0,9928376.0,,2102775.0,,CHEMBL3833319,,,
Brexanolone,phase 4 complete,DB11859,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O,"Anesthetics / Anticonvulsants / Biopolymers / Carbohydrates / Central Nervous System Agents / Central Nervous System Depressants / Compounds used in a research, industrial, or household setting / Corpus Luteum Hormones / Cyclodextrins / Dextrins / Diet, Food, and Nutrition / Dietary Carbohydrates / Food / Food and Beverages / Fused-Ring Compounds / GABA Modulators / Glucans / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Macromolecular Substances / Pharmaceutical Preparations / Physiological Phenomena / Polymers / Polysaccharides / Pregnanes / Pregnenediones / Pregnenes / Progesterone Congeners / Starch / Steroids",S39XZ5QV8Y,516-54-1,,92786.0,83760.0,50191342.0,2121777.0,50169.0,CHEMBL207538,,,ZINC000004081043
Apalutamide,phase 4 complete,DB11901,CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F,"Antiandrogens / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inducers / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strong) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (weak) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inducers (strong) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strong) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Endocrine Therapy / Hormone Antagonists and Related Agents / Imidazoles / Imidazolidines / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inducers / OCT2 Inhibitors / P-glycoprotein inducers / Prostatic Neoplasms, drug therapy",4T36H88UA7,956104-40-8,,24872560.0,28424131.0,50094975.0,1999574.0,,CHEMBL3183409,,,ZINC000043174901
Valbenazine,phase 4 complete,DB11915,COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1,"Amino Acids / Amino Acids, Branched-Chain / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Nervous System / Quinolizines / Vesicular Monoamine Transporter 2 Inhibitor / Vesicular Monoamine Transporter 2 Inhibitors",54K37P50KH,1025504-45-3,,24795069.0,28536134.0,,1918219.0,,CHEMBL2364639,,,ZINC000043195697
Deflazacort,phase 4 complete,DB11921,[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@]([H])(O)C[C@]3(C)[C@@]1(N=C(C)O2)C(=O)COC(C)=O,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids for Systemic Use / Corticosteroids for Systemic Use, Plain / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Glucocorticoids / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Steroids / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",KR5YZ6AE4B,14484-47-0,D03671,189821.0,164861.0,,22396.0,135720.0,CHEMBL1201891,,,ZINC000004212809
Bempedoic acid,phase 4 complete,DB11936,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,"Acids, Acyclic / Enzyme Inhibitors / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Lipid Regulating Agents / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / OATP1B3 substrates / UGT2B7 substrates",1EJ6Z6Q368,738606-46-7,,10472693.0,8648104.0,,2282403.0,,CHEMBL3545313,,,ZINC000003948738
Selinexor,phase 4 complete,DB11942,FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F,Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / OATP1B3 inhibitors,31TZ62FO8F,1393477-72-9,,71481097.0,32701989.0,,2178390.0,,CHEMBL3545185,,,ZINC000096170454
Delafloxacin,phase 4 complete,DB11943,NC1=NC(N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23)=C(F)C=C1F,"Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (weak) / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (weak) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 Enzyme Inducers / Drugs that are Mainly Renally Excreted / Fluoroquinolone Antibacterial / Fluoroquinolones / Heterocyclic Compounds, Fused-Ring / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Quinolines / Quinolones / UGT1A1 Substrates / UGT1A3 substrates",6315412YVF,189279-58-1,,487101.0,427049.0,,1927663.0,,CHEMBL2105637,,,ZINC000003827556
Lemborexant,phase 4 complete,DB11951,CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC2=NC=C(F)C=C2)C2=CC=CC(F)=C2)C(C)=N1,"Central Nervous System Depressants / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Orexin Receptor Antagonists / P-glycoprotein substrates / Sleep Aids, Pharmaceutical / Sleep Initiation and Maintenance Disorders",0K5743G68X,1369764-02-2,,56944144.0,34500836.0,50093793.0,2272403.0,,CHEMBL3545367,,,ZINC000118073503
Duvelisib,phase 4 complete,DB11952,C[C@H](NC1=C2N=CNC2=NC=N1)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1,"BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / P-glycoprotein substrates / Phosphatidylinositol 3-Kinases, antagonists & inhibitors",610V23S0JI,1201438-56-3,D10555,50905713.0,28637766.0,50193013.0,2058509.0,131169.0,CHEMBL3039502,,,ZINC000088346058
Dacomitinib,phase 4 complete,DB11963,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strong) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / OCT1 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Protein Kinase Inhibitors / Quinazolines / Tyrosine Kinase Inhibitors / UGT1A1 Inhibitors",2XJX250C20,1110813-31-4,D09883,11511120.0,9685914.0,112499.0,2058848.0,132268.0,CHEMBL2110732,,,ZINC000072266312
Glasdegib,phase 4 complete,DB11978,CN1CC[C@H](C[C@@H]1C1=NC2=CC=CC=C2N1)NC(=O)NC1=CC=C(C=C1)C#N,"Antineoplastic Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Benzene Derivatives / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Hedgehog Pathway Inhibitor / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / QTc Prolonging Agents / Smoothened Receptor Antagonists / UGT1A9 Substrates",K673DMO5H9,1095173-27-5,,25166913.0,28518072.0,50385635.0,2105845.0,145428.0,CHEMBL2043437,,,ZINC000068251434
Entrectinib,phase 4 complete,DB11986,CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)C(NC2CCOCC2)=C1,"Amides / Antineoplastic Agents / Benzene Derivatives / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Protein Kinase Inhibitors / Pyrazoles / QTc Prolonging Agents / Tyrosine Kinase Inhibitors",L5ORF0AN1I,1108743-60-7,,25141092.0,24808589.0,158154.0,2197862.0,,CHEMBL1983268,,,ZINC000043204146
Benznidazole,phase 4 complete,DB11989,[O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1,"Agents Against Leishmaniasis and Trypanosomiasis / Anti-Infective Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Drugs that are Mainly Renally Excreted / Imidazoles / Immunologic Factors / Mutagens / Nitro Compounds / Nitroimidazole Derivatives / Noxae / Toxic Actions / Trypanocidal Agents",YC42NRJ1ZD,22994-85-0,D02489,31593.0,29299.0,50089916.0,18994.0,133833.0,CHEMBL110,,,ZINC000000056949
Diacerein,phase 4 complete,DB11994,CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O,"Anthracenes / Anti-Inflammatory Agents / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2E1 Inhibitors / Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Musculo-Skeletal System / Quinones",4HU6J11EL5,13739-02-1,,26248.0,24456.0,32018.0,22759.0,94708.0,CHEMBL41286,,,ZINC000003812842
Avatrombopag,phase 4 complete,DB11995,OC(=O)C1CCN(CC1)C1=C(Cl)C=C(C=N1)C(=O)NC1=NC(C2=CC(Cl)=CS2)=C(S1)N1CCN(CC1)C1CCCCC1,"BCRP/ABCG2 Inhibitors / Blood and Blood Forming Organs / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (weak) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (weak) / Cytochrome P-450 Enzyme Inducers / Hemostatics / OAT3/SLC22A8 Inhibitors / P-glycoprotein substrates / Receptors, Thrombopoietin, agonists / Sulfur Compounds",3H8GSZ4SQL,570406-98-3,,9852519.0,8028230.0,,2045726.0,,CHEMBL2103883,,,ZINC000072190218
Abemaciclib,phase 4 complete,DB12001,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1,"Amines / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Kinase Inhibitor / MATE 1 Inhibitors / MATE 1 Substrates / MATE 1 Substrates with a Narrow Therapeutic Index / MATE 2 Inhibitors / MATE inhibitors / MATE substrates / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors / Pyridines",60UAB198HK,1231929-97-7,,46220502.0,29340700.0,50110183.0,1946825.0,,CHEMBL3301610,,PA166153471,ZINC000072318121
Fostamatinib,phase 4 complete,DB12010,COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC,BCRP/ABCG2 Inhibitors / Blood and Blood Forming Organs / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hemostatics / Phosphodiesterase 5 Inhibitors / Tyrosine Kinase Inhibitors / UGT1A1 Inhibitors / UGT1A9 Substrates / Vasodilating Agents,SQ8A3S5101,901119-35-5,,11671467.0,9846198.0,50431381.0,2044896.0,,CHEMBL2103830,,,ZINC000043131420
Alpelisib,phase 4 complete,DB12015,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F,"Antineoplastic Agents / BCRP/ABCG2 Substrates / Breast Cancer Resistance Protein Inhibitors / Breast Neoplasms / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (moderate) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (moderate) / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / P-glycoprotein inhibitors / Phosphatidylinositol 3-Kinases, antagonists & inhibitors / Sulfur Compounds",08W5N2C97Q,1217486-61-7,,56649450.0,28424123.0,50436459.0,2169285.0,93752.0,CHEMBL2396661,,,ZINC000068198368
Voxilaprevir,phase 4 complete,DB12026,CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(F)(F)C1=C(O2)N=C2C=C(OC)C=CC2=N1)C(C)(C)C,Amides / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Direct Acting Antivirals / HCV NS3/4A Protease Inhibitors / NS3/4A Protease Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / OATP1B3 substrates / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B3 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Sulfones / Sulfur Compounds,0570F37359,1535212-07-7,,89921642.0,44209500.0,,1939323.0,,CHEMBL3707372,,,
Sarecycline,phase 4 complete,DB12035,[H][C@@]12CC3=C(CN(C)OC)C=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,Anti-Acne Preparations / Anti-Acne Preparations for Systemic Use / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Dermatologicals / Naphthacenes / P-glycoprotein inhibitors / Tetracyclines,94O110CX2E,1035654-66-0,,54681908.0,28540486.0,,2059018.0,,CHEMBL2364632,,,ZINC000072319783
Letermovir,phase 4 complete,DB12070,COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[C@H](CC(O)=O)N1C1=CC(=CC=C1OC)C(F)(F)F,"Acids, Acyclic / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / BCRP/ABCG2 Inhibitors / BSEP/ABCB11 Inhibitors / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (moderate) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Cytomegalovirus DNA Terminase Complex Inhibitor / Direct Acting Antivirals / DNA Terminase Complex Inhibitors / Fatty Acids / Fatty Acids, Volatile / Heterocyclic Compounds, Fused-Ring / Lipids / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B3 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / UGT1A1 Substrates / UGT1A3 substrates",1H09Y5WO1F,917389-32-3,,,26352849.0,,1988648.0,,CHEMBL1241951,,,ZINC000100369359
Gadolinium,phase 4 complete,DB12091,[Gd],"Anti-Inflammatory Agents / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Elements / Lanthanoid Series Elements / Metals / Metals, Rare Earth",AU0V1LM3JT,7440-54-2,,23982.0,22418.0,,1310171.0,33375.0,,,,
Telotristat ethyl,phase 4 complete,DB12095,CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C1=NC(N)=NC(O[C@H](C2=CC=C(Cl)C=C2N2C=CC(C)=N2)C(F)(F)F)=C1,"Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Antidiarrheals / Tryptophan Hydroxylase Inhibitor",8G388563M7,1033805-22-9,,25025298.0,28189674.0,,1872441.0,,CHEMBL2105695,,,ZINC000043205655
Mannitol busulfan,phase 4 complete,DB12097,CS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COS(C)(=O)=O,Agents causing hyperkalemia,6STO1P091F,1187-00-4,,142775.0,125962.0,,,,,,,ZINC000008214535
Vaborbactam,phase 4 complete,DB12107,OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1,"Acids / Acids, Noncarboxylic / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactamase Inhibitors / Boron Compounds / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors",1C75676F8V,1360457-46-0,,56649692.0,35035409.0,50089084.0,1945213.0,,CHEMBL3317857,,,
Sultamicillin,phase 4 complete,DB12127,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@@]2([H])S(=O)(=O)C1(C)C,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillin G / Penicillins / Sulfur Compounds",65DT0ML581,76497-13-7,,444022.0,392048.0,,,51770.0,CHEMBL506110,,,ZINC000042834847
Lorlatinib,phase 4 complete,DB12130,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2,Amides / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Kinase Inhibitor / Lactams / Protein Kinase Inhibitors / UGT1A3 substrates,OSP71S83EU,1454846-35-5,,71731823.0,32813339.0,50018830.0,2103164.0,143117.0,CHEMBL3286830,,,ZINC000098208524
Gilteritinib,phase 4 complete,DB12141,CCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O,Amines / Antineoplastic Agents / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / MATE 1 Inhibitors / MATE inhibitors / Moderate Risk QTc-Prolonging Agents / OCT1 inhibitors / P-glycoprotein substrates / QTc Prolonging Agents / Tyrosine Kinase Inhibitors,66D92MGC8M,1254053-43-4,,49803313.0,32055842.0,144315.0,2105806.0,145372.0,CHEMBL3301622,,,ZINC000113476229
Erdafitinib,phase 4 complete,DB12147,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1,"Antineoplastic Agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Receptors, Fibroblast Growth Factor, antagonists & inhibitors / Tumor Suppressor Proteins / Tyrosine Kinase Inhibitors",890E37NHMV,1346242-81-6,,67462786.0,35308353.0,,2123125.0,,CHEMBL3545376,,,ZINC000168520308
Deutetrabenazine,phase 4 complete,DB12161,[2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2,"Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Highest Risk QTc-Prolonging Agents / QTc Prolonging Agents / Quinolizines",P341G6W9NB,1392826-25-3,,73442840.0,32700662.0,,1876905.0,,,,,
Iron isomaltoside 1000,phase 4 complete,DB12208,,Carbohydrates / Hematinics / Hematologic Agents / Iron Compounds / Oligosaccharides / Organometallic Compounds / Polysaccharides,3M6325NY1R,1370654-58-2,,,,,,,,,,
Edaravone,phase 4 complete,DB12243,CC1=NN(C(=O)C1)C1=CC=CC=C1,"Antioxidants / Central Nervous System Agents / Compounds used in a research, industrial, or household setting / Free Radical Scavengers / Miscellaneous Central Nervous System Agents / Nervous System / Neuroprotective Agents / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / Protective Agents / Pyrazoles / Pyrazolones",S798V6YJRP,89-25-8,D01552,4021.0,3881.0,50200541.0,1921877.0,31530.0,CHEMBL290916,,,ZINC000018203737
Triclabendazole,phase 4 complete,DB12245,CSC1=NC2=C(N1)C=C(Cl)C(OC1=CC=CC(Cl)=C1Cl)=C2,"Anthelmintics / Anti-Infective Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiplatyhelmintic Agents / Antitrematodals / Benzimidazoles / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Potential QTc-Prolonging Agents / QTc Prolonging Agents",4784C8E03O,68786-66-3,D07364,50248.0,45565.0,58491.0,2118525.0,94759.0,CHEMBL1086440,,,ZINC000001444556
Brigatinib,phase 4 complete,DB12267,COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1,Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Kinase Inhibitor / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Protein Kinase Inhibitors / Tyrosine Kinase Inhibitors,HYW8DB273J,1197953-54-0,,68165256.0,34982928.0,50185140.0,1921217.0,,CHEMBL3545311,,PA166163482,ZINC000148723177
Polihexanide,phase 4 complete,DB12277,,"Amidines / Anti-Infective Agents / Antiseptics and Disinfectants / Biguanides and Amidines / Compounds used in a research, industrial, or household setting / Dermatologicals / Disinfectants / Guanidines",322U039GMF,28757-47-3,,,,,1373041.0,,,,,
Propiverine,phase 4 complete,DB12278,CCCOC(C(=O)OC1CCN(C)CC1)(C1=CC=CC=C1)C1=CC=CC=C1,"Acids, Carbocyclic / Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents producing tachycardia / Agents that produce hypertension / Anticholinergic Agents / Autonomic Agents / Cholinergic Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Diphenylacetic Acids / Drugs for Urinary Frequency and Incontinence / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Hydroxy Acids / Muscarinic Antagonists / Neurotransmitter Agents / Parasympatholytics / Peripheral Nervous System Agents / Phenylacetates / Urological Agents / Urologicals",468GE2241L,60569-19-9,D08441,4942.0,4773.0,,55175.0,8493.0,CHEMBL1078261,,,ZINC000001530934
Nefopam,phase 4 complete,DB12293,CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1,"Analgesics / Analgesics, Non-Narcotic / Azocines / Central Nervous System Agents / Nervous System / Oxazocines / Peripheral Nervous System Agents / Sensory System Agents",4UP8060B7J,13669-70-0,,4450.0,4295.0,50237616.0,7285.0,88318.0,CHEMBL465026,,,
P-nitrobiphenyl,phase 4 complete,DB12300,O=N(=O)C1=CC=C(C=C1)C1=CC=CC=C1,,QM80NUW6WZ,92-93-3,,7114.0,21109008.0,,,82504.0,CHEMBL352531,,,ZINC000001591846
Doravirine,phase 4 complete,DB12301,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F,Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Direct Acting Antivirals / Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor / Non-Nucleoside Reverse Transcriptase Inhibitors / Nonnucleoside Reverse Transcriptase Inhibitors / Pyridines,913P6LK81M,1338225-97-0,,58460047.0,28424197.0,,2055755.0,,CHEMBL2364608,,,ZINC000072317283
Dopexamine,phase 4 complete,DB12313,OC1=C(O)C=C(CCNCCCCCCNCCC2=CC=CC=C2)C=C1,Adrenergic Agents / Adrenergic Agonists / Adrenergic and Dopaminergic Agents / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Amines / Benzene Derivatives / Biogenic Amines / Biogenic Monoamines / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Cardiovascular Agents / Catecholamines / Catechols / Dopamine Agents / Dopamine Agonists / Neurotransmitter Agents / Nonergot-derivative Dopamine Receptor Agonists / Phenols / Vasodilating Agents,398E7Z7JB5,86197-47-9,,55483.0,50102.0,50239997.0,23638.0,135507.0,CHEMBL77622,,,ZINC000003798745
Cantharidin,phase 4 complete,DB12328,[H][C@]12CC[C@]([H])(O1)[C@]1(C)C(=O)OC(=O)[C@]21C,"Benzofurans / Compounds used in a research, industrial, or household setting / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Irritants / Noxae / Toxic Actions",IGL471WQ8P,56-25-7,,5944.0,5731.0,50090505.0,1984.0,64213.0,CHEMBL48449,,,ZINC000017611186
Eravacycline,phase 4 complete,DB12329,[H][C@@]12CC3=C(F)C=C(NC(=O)CN4CCCC4)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,Anti-Bacterial Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Monoamine Oxidase A Substrates / Naphthacenes / Tetracyclines,07896928ZC,1207283-85-9,,54726192.0,28495485.0,,2055906.0,,CHEMBL1951095,,,
Rucaparib,phase 4 complete,DB12332,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (moderate) / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (weak) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (moderate) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A7 Inhibitors / Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / OCT1 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Poly(ADP-ribose) Polymerase Inhibitors / UGT1A1 Inhibitors",8237F3U7EH,283173-50-2,D10079,9931954.0,8107584.0,50446130.0,1862579.0,134689.0,CHEMBL1173055,,PA166163418,ZINC000000025958
Temocillin,phase 4 complete,DB12343,CO[C@]1(NC(=O)C(C(O)=O)C2=CSC=C2)[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / beta-Lactams / Heterocyclic Compounds, Fused-Ring / Lactams / Penicillins / Penicillins With Extended Spectrum / Sulfur Compounds",03QB156W6I,66148-78-5,,171758.0,150149.0,,37775.0,51817.0,CHEMBL1276310,,,
Diaminopropanol tetraacetic acid,phase 4 complete,DB12362,OC(CN(CC(O)=O)CC(O)=O)CN(CC(O)=O)CC(O)=O,,949B9ZMO7M,3148-72-9,,18465.0,17441.0,,1659205.0,,,,,ZINC000003861209
Siponimod,phase 4 complete,DB12371,CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\C)=N\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F,"Agents that produce hypertension / Azetines / Benzene Derivatives / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Immunomodulatory Agents / Immunosuppressive Agents / Receptors, Lysosphingolipid, antagonists & inhibitors",RR6P8L282I,1230487-00-9,,44599207.0,29315058.0,50428142.0,2121085.0,,CHEMBL2336071,,,ZINC000006717453
Relebactam,phase 4 complete,DB12377,OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O,Aza Compounds / beta-Lactamase Inhibitors / Enzyme Inhibitors / MATE 1 Substrates / MATE 2 Substrates / MATE substrates / OAT3/SLC22A8 Substrates,1OQF7TT3PF,1174018-99-5,,44129647.0,31137585.0,1858.0,2268500.0,,CHEMBL3112741,,,ZINC000043206319
Bromperidol,phase 4 complete,DB12401,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1,Antipsychotic Agents / Butyrophenone Derivatives / Butyrophenones / Central Nervous System Agents / Central Nervous System Depressants / Ketones / Nervous System / Neurotoxic agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents,LYH6F7I22E,10457-90-6,,2448.0,2354.0,81484.0,19777.0,31305.0,CHEMBL28218,,,ZINC000000601270
Remimazolam,phase 4 complete,DB12404,COC(=O)CC[C@@H]1N=C(C2=CC=CC=N2)C2=CC(Br)=CC=C2N2C(C)=CN=C12,"Benzazepines / Benzodiazepine hypnotics and sedatives / Benzodiazepines and benzodiazepine derivatives / Central Nervous System Depressants / GABA Agents / GABA Modulators / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Tranquilizing Agents",7V4A8U16MB,308242-62-8,,9867812.0,8043503.0,,,,CHEMBL4297526,,,ZINC000003927450
Iobitridol,phase 4 complete,DB12407,CN(CC(O)CO)C(=O)C1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(NC(=O)C(CO)CO)=C1I,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Iodobenzoates / Triiodobenzoic Acids / Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media / X-Ray Contrast Media, Iodinated",182ECH14UH,136949-58-1,D01181,65985.0,59379.0,,87639.0,31701.0,CHEMBL2107212,,,
Lefamulin,phase 4 complete,DB12825 (DB12430),[H][C@@]12C(=O)CC[C@]11CCC(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O,Acetates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / P-glycoprotein substrates / QTc Prolonging Agents / Sulfur Compounds,21904A5386,1061337-51-6,,25185057.0,,50019649.0,2198944.0,,CHEMBL3291398,,,
Steviolbioside,phase 4 complete,DB12434,C[C@@]12CCC[C@](C)([C@H]1CC[C@@]13CC(=C)[C@@](C1)(CC[C@@H]23)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(O)=O,"Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Diterpenes / Flavoring Agents / Food / Food Additives / Food and Beverages / Food Ingredients / Pharmaceutic Aids / Pharmaceutical Preparations / Physiological Phenomena / Stevia / Sweetening Agents / Terpenes",07GV37SOFN,41093-60-1,,16401639.0,10209449.0,,,145030.0,,,,
Omadacycline,phase 4 complete,DB12455,[H][C@@]12CC3=C(C=C(CNCC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C,Anti-Bacterial Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Naphthacenes / P-glycoprotein substrates / Tetracyclines,090IP5RV8F,389139-89-3,,54697325.0,20131003.0,,2059269.0,,CHEMBL1689772,,,ZINC000004836283
Rimegepant,phase 4 complete,DB12457,N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)N2C(=O)NC3=NC=CC=C23)C2=C1C=CC=N2)C1=C(F)C(F)=CC=C1,Antimigraine Preparations / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / MATE 1 Inhibitors / MATE inhibitors / Migraine Disorders / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / OCT2 Inhibitors / P-glycoprotein substrates,997WVV895X,1289023-67-1,,51049968.0,27289072.0,50400098.0,2282307.0,,CHEMBL2178422,,,ZINC000068267814
Taurolidine,phase 4 complete,DB12473,O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1,"Acids / Acids, Noncarboxylic / Alkanes / Alkanesulfonic Acids / Anti-Infective Agents / Anti-Infective Agents, Local / Antineoplastic Agents / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Hydrocarbons, Acyclic / Irrigating Solutions / Sulfonic Acids / Sulfur Acids / Sulfur Compounds / Thiazines",8OBZ1M4V3V,19388-87-5,,29566.0,27486.0,,,135173.0,CHEMBL2105420,,,ZINC000019322537
Lynestrenol,phase 4 complete,DB12474,C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,"Adrenal Cortex Hormones / Combination Contraceptives (with Estrogen and derivatives) / Contraceptive Agents, Female / Contraceptives, Oral / Contraceptives, Oral, Synthetic / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Estren Derivatives / Fused-Ring Compounds / Genito Urinary System and Sex Hormones / Hormonal Contraceptives for Systemic Use / Norpregnanes / Norpregnenes / Norsteroids / Progestin Contraceptives / Progestins / Progestogens and Estrogens, Sequential Preparations / Reproductive Control Agents / Sex Hormones and Modulators of the Genital System / Steroids",N2Z8ALG4U5,52-76-6,,5857.0,5648.0,,6529.0,31790.0,CHEMBL2107431,,,ZINC000003875355
Copanlisib,phase 4 complete,DB12483,COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21,"Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Kinase Inhibitor / MATE 2 Inhibitors / MATE inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index",WI6V529FZ9,1032568-63-0,,24989044.0,25069683.0,50204093.0,1945077.0,,CHEMBL3218576,,,ZINC000068247389
Piritramide,phase 4 complete,DB12492,NC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)N1CCCCC1,Analgesics / Central Nervous System Agents / Central Nervous System Depressants / Diphenylpropylamine Derivatives / Isonipecotic Acids / Narcotics / Nervous System / Opioids / Peripheral Nervous System Agents / Piperidines / Sensory System Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome,4RP92LYZ2F,302-41-0,,9331.0,8967.0,,8354.0,135699.0,CHEMBL559288,,,ZINC000000538198
Mizolastine,phase 4 complete,DB12523,CN(C1CCN(CC1)C1=NC2=C(C=CC=C2)N1CC1=CC=C(F)C=C1)C1=NC=CC(=O)N1,"Antihistamines for Systemic Use / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / QTc Prolonging Agents",244O1F90NA,108612-45-9,,65906.0,59315.0,22877.0,61455.0,31857.0,CHEMBL94454,,PA166129535,ZINC000013831810
Nitrite,phase 4 complete,DB12529,[O-]N=O,,J39976L608,14797-65-0,,946.0,921.0,26989.0,1546424.0,16301.0,,,,
Oxetacaine,phase 4 complete,DB12532,CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1=CC=CC=C1)C(C)(C)CC1=CC=CC=C1,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Anesthetics / Anesthetics, Local / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Vasoprotectives",IP8QT76V17,126-27-2,,4621.0,4460.0,50017672.0,,31947.0,CHEMBL127592,,,ZINC000003874585
Benzodiazepine,phase 4 complete,DB12537,N1N=CC=CC2=CC=CC=C12,"Benzazepines / Benzodiazepines and benzodiazepine derivatives / Benzodiazepines, antagonists & inhibitors / Central Nervous System Depressants / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring",M0Q7802G2B,12794-10-4,,134664.0,118687.0,,,,CHEMBL4297264,,,
Mebeverine,phase 4 complete,DB12554,CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC1=CC=C(OC)C=C1,"Agents Causing Muscle Toxicity / Agents producing tachycardia / Alimentary Tract and Metabolism / Amines / Anticholinergic Agents / Autonomic Agents / Central Nervous System Agents / Drugs for Functional Gastrointestinal Disorders / Ethylamines / Muscarinic Antagonists / Parasympatholytics / Peripheral Nervous System Agents / Synthetic Anticholinergics, Esters With Tertiary Amino Group",7F80CC3NNV,3625-06-7,,4031.0,3891.0,,29410.0,91514.0,CHEMBL282121,,,
Pentetreotide,phase 4 complete,DB12602,C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN(CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC2=CNC3=CC=CC=C23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1,"Acetates / Acids, Acyclic / Amines / Amino Acids, Peptides, and Proteins / Compounds used in a research, industrial, or household setting / Diagnostic Uses of Chemicals / Fatty Acids / Fatty Acids, Volatile / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hypothalamic Hormones / Indicators and Reagents / Indium Radioisotopes / Laboratory Chemicals / Lipids / Nerve Tissue Proteins / Neuropeptides / Pancreatic Hormones / Peptide Hormones / Peptides / Peptides, Cyclic / Pituitary Hormone Release Inhibiting Hormones / Polyamines / Proteins / Radiopharmaceuticals / Terbium",G083B71P98,138661-02-6,,72128.0,65105.0,,69893.0,,,,,
Ozanimod,phase 4 complete,DB12612,CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N,Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Immunosuppressive Agents / Indenes / Oxazoles / P-glycoprotein substrates / Selective Immunosuppressants,Z80293URPV,1306760-87-1,,52938427.0,34979946.0,,2288236.0,,CHEMBL3707247,,,ZINC000116109867
Plazomicin,phase 4 complete,DB12615,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H]2O)NC(=O)[C@@H](O)CCN)OC[C@]1(C)O,Agents that produce neuromuscular block (indirect) / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Gentamicins / Glycosides / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Narrow Therapeutic Index Drugs / Nephrotoxic agents,LYO9XZ250J,1154757-24-0,,42613186.0,26390008.0,,2049549.0,,CHEMBL1650559,,,ZINC000068150640
Protionamide,phase 4 complete,DB12667,CCCC1=CC(=CC=N1)C(N)=S,Anti-Bacterial Agents / Anti-Infective Agents / Antiinfectives for Systemic Use / Antimycobacterials / Antituberculosis Agents / Drugs for Treatment of Tuberculosis / Isonicotinic Acids / Pyridines / Thiocarbamide Derivatives,76YOO33643,14222-60-7,D01195,666418.0,579891.0,,8871.0,32066.0,CHEMBL1378024,,,ZINC000003874803
Lurbinectedin,phase 4 complete,DB12674,[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4NC4=CC=C(OC)C=C54)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@@]2([H])N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31,"Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Indoles / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / OCT1 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Pyridines",2CN60TN6ZS,497871-47-3,,57327016.0,32701856.0,,,,CHEMBL4297516,,,
Perazine,phase 4 complete,DB12710,CN1CCN(CCCN2C3=CC=CC=C3SC3=CC=CC=C23)CC1,"Antipsychotic Agents / Central Nervous System Agents / Central Nervous System Depressants / Dopamine Agents / Dopamine Antagonists / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Phenothiazines / Phenothiazines With Piperazine Structure / Psycholeptics / Psychotropic Drugs / Sulfur Compounds / Tranquilizing Agents",8915147A2B,84-97-9,,4744.0,4582.0,260166.0,8042.0,59118.0,CHEMBL1697766,,PA162565876,ZINC000019362664
Fenpropidin,phase 4 complete,DB12728,CC(CN1CCCCC1)CC1=CC=C(C=C1)C(C)(C)C,"Agrochemicals / Compounds used in a research, industrial, or household setting / Fungicides, Industrial / Pesticides / Toxic Actions",845XW54F31,67306-00-7,,91694.0,82797.0,,,83291.0,CHEMBL1889041,,,
Iodide,phase 4 complete,DB12754,[I-],,09G4I6V86Q,20461-54-5,,30165.0,28015.0,26981.0,1546275.0,16382.0,CHEMBL185537,,,
Gaxilose,phase 4 complete,DB12767,OC[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C=O,Carbohydrates / Oligosaccharides / Polysaccharides,A571S2B3JE,14087-31-1,,3082054.0,2339540.0,,,,,,,
Benserazide,phase 4 complete,DB12783,NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1,Anti-Dyskinesia Agents / Anti-Parkinson Drugs / Aromatic L-amino Acid Decarboxylase Inhibitors / Central Nervous System Agents / Dopamine Agents / Drugs that are Mainly Renally Excreted / Enzyme Inhibitors / Hydrazines / Neurotransmitter Agents,762OS3ZEJU,322-35-0,D03082,2327.0,2237.0,49122.0,1374.0,64187.0,CHEMBL1096979,,PA165360203,
Dinoprost,phase 4 complete,DB12789,[H]\C(CCCC(O)=O)=C(/[H])C[C@@]1([H])[C@@]([H])(O)C[C@@]([H])(O)[C@]1([H])C(\[H])=C(/[H])[C@@]([H])(O)CCCCC,"Abortifacient Agents / Abortifacient Agents, Nonsteroidal / Autacoids / Biological Factors / Eicosanoids / Fatty Acids / Fatty Acids, Unsaturated / Genito Urinary System and Sex Hormones / Inflammation Mediators / Lipids / Prostaglandins / Prostaglandins F / Reproductive Control Agents / Uterotonic agents",B7IN85G1HY,551-11-1,,5280363.0,4444062.0,50035622.0,3477.0,15553.0,CHEMBL815,,,ZINC000003830709
Boscalid,phase 4 complete,DB12792,ClC1=CC=C(C=C1)C1=C(NC(=O)C2=C(Cl)N=CC=C2)C=CC=C1,Benzene Derivatives / Nicotinic Acids / Pyridines,32MS8ZRD1V,188425-85-6,,213013.0,184713.0,,1735163.0,81822.0,CHEMBL1076544,,,ZINC000003612929
Trifarotene,phase 4 complete,DB12808,CC(C)(C)C1=CC(=CC=C1N1CCCC1)C1=CC(=CC=C1OCCO)C1=CC=C(C=C1)C(O)=O,Alkenes / Anti-Acne Preparations / Anti-Acne Preparations for Topical Use / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Misc. Skin and Mucous Membrane Agents / Polyenes / Retinoids for Topical Use in Acne,0J8RN2W0HK,895542-09-3,,11518241.0,9693029.0,,2205637.0,,CHEMBL3707313,,,
Secnidazole,phase 4 complete,DB12834,CC(O)CN1C(C)=NC=C1N(=O)=O,"Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Imidazoles / Nitro Compounds / Nitroimidazole Antimicrobial / Nitroimidazole Derivatives / Nitroimidazoles",R3459K699K,3366-95-8,,71815.0,64839.0,50349330.0,36314.0,94433.0,CHEMBL498847,,,
Pegvaliase,phase 4 complete,DB12839,COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O,"Amino Acids, Peptides, and Proteins / Ammonia-Lyases / Carbon-Nitrogen Lyases / Enzymes / Enzymes and Coenzymes / Lyases / Pegylated agents / Proteins",N6UAH27EUV,1585984-95-7,,86278362.0,58172730.0,,2046360.0,,,,,
Etelcalcetide,phase 4 complete,DB12865,C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O,"Amino Acids, Peptides, and Proteins / Anti-Parathyroid Agents / Calcium Homeostasis / Calcium-sensing Receptor Agonist / Increased Calcium-sensing Receptor Sensitivity / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins",60ME133FJB,1262780-97-1,D10676,71511839.0,32697932.0,,1876119.0,134700.0,CHEMBL3545184,,,
Benperidol,phase 4 complete,DB12867,OC1=NC2=CC=CC=C2N1C1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1,Antipsychotic Agents / Butyrophenone Derivatives / Butyrophenones / Central Nervous System Agents / Central Nervous System Depressants / Dopamine Agents / Dopamine Antagonists / Ketones / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / Tranquilizing Agents,97O6X78C53,2062-84-2,,16363.0,15521.0,81492.0,1373.0,93403.0,CHEMBL297302,,,ZINC000009232411
Oxatomide,phase 4 complete,DB12877,O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,Anti-Allergic Agents / Anti-Asthmatic Agents / Antihistamines for Systemic Use / Histamine Agents / Histamine Antagonists / Histamine H1 Antagonists / Moderate Risk QTc-Prolonging Agents / Neurotransmitter Agents / Piperazine Derivatives / QTc Prolonging Agents / Respiratory System Agents,J31IL9Z2EE,60607-34-3,D01773,4615.0,4454.0,76863.0,54236.0,31943.0,CHEMBL13828,,PA163522137,ZINC000019632896
Tazemetostat,phase 4 complete,DB12887,CCN(C1CCOCC1)C1=C(C)C(=CC(=C1)C1=CC=C(CN2CCOCC2)C=C1)C(=O)NCC1=C(C)C=C(C)NC1=O,Amides / BCRP/ABCG2 Substrates / Benzene Derivatives / Benzoates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / P-glycoprotein substrates / Pyridines,Q40W93WPE1,1403254-99-8,,66558664.0,30208713.0,172038.0,2274378.0,,CHEMBL3414621,,,ZINC000100285161
Nicoboxil,phase 4 complete,DB12911,CCCCOCCOC(=O)C1=CN=CC=C1,Drugs that are Mainly Renally Excreted / Pyridines,GSD5B9US0W,13912-80-6,D01677,14866.0,14176.0,,235788.0,32322.0,CHEMBL2105161,,,ZINC000002020020
Ozenoxacin,phase 4 complete,DB12924,CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O,"Amines / Anti-Bacterial Agents / Antibiotics for Topical Use / Dermatologicals / Heterocyclic Compounds, Fused-Ring / Pyridines / Quinolines / Quinolone Antimicrobial",V0LH498RFO,245765-41-7,,9863827.0,8039521.0,,1994739.0,136050.0,CHEMBL3990047,,,ZINC000001483896
Isoxaflutole,phase 4 complete,DB12938,[H]C1=NOC(=C1C(=O)C1=C(C([H])=C(C([H])=C1[H])C(F)(F)F)S(=O)(=O)C([H])([H])[H])C1([H])C([H])([H])C1([H])[H],"Amino Acids, Peptides, and Proteins / Membrane Proteins / Neoplasm Proteins / Proteins / Tumor Suppressor Proteins",0T9R0O0EYT,141112-29-0,,84098.0,75869.0,,1371313.0,141213.0,CHEMBL1887147,,,ZINC000002384341
Darolutamide,phase 4 complete,DB12941,C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O,"Antiandrogens / Antiandrogens, non-steroidal / Antineoplastic Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein substrates / UGT1A1 Substrates / UGT1A9 Substrates",X05U0N2RCO,1297538-32-9,,67171867.0,38772320.0,309979.0,2180325.0,,CHEMBL4297185,,,
Lactitol,phase 4 complete,DB12942,OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,"Alcohols / Alimentary Tract and Metabolism / Carbohydrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Drugs for Constipation / Flavoring Agents / Food / Food Additives / Food and Beverages / Food Ingredients / Gastrointestinal Agents / Laxatives / Osmotic Laxatives / Pharmaceutic Aids / Pharmaceutical Preparations / Sweetening Agents",L2B0WJF7ZY,585-86-4,D08266,157355.0,138481.0,50240023.0,28395.0,75323.0,CHEMBL1661,,,ZINC000005225520
Dihydralazine,phase 4 complete,DB12945,NNC1=C2C=CC=CC2=C(NN)N=N1,"Antihypertensive Agents / Arteriolar Smooth Muscle, Agents Acting On / Cardiovascular Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hydrazinophthalazine Derivatives / Hydrazinophthalazine Derivatives and Diuretics / Phthalazines / Pyridazines",PCU411F5L6,484-23-1,,10230.0,9813.0,50088433.0,3409.0,134841.0,CHEMBL35505,,,ZINC000004474539
Methylprednisone,phase 4 complete,DB12952,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(=O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates,621XR2W6OP,91523-05-6,,124653.0,110996.0,,,,,,,ZINC000004744090
Terizidone,phase 4 complete,DB12954,O=C1NOCC1\N=C\C1=CC=C(\C=N\C2CONC2=O)C=C1,Antiinfectives for Systemic Use / Antimycobacterials / Drugs for Treatment of Tuberculosis / Oxazoles,1199LEX5N8,25683-71-0,,65720.0,59144.0,,57047.0,135278.0,CHEMBL2107553,,,
Silver,phase 4 complete,DB12965,[Ag],"Antiseptics and Disinfectants / Dermatologicals / Elements / Metals / Metals, Heavy / Silver Compounds / Transition Elements",3M4G523W1G,7440-22-4,,23954.0,22394.0,,9785.0,9141.0,,,,
Pexidartinib,phase 4 complete,DB12978,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,Amines / Antineoplastic Agents / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hepatotoxic Agents / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Narrow Therapeutic Index Drugs / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Pyridines / Tyrosine Kinase Inhibitors / UGT1A1 Inhibitors / UGT1A4 substrates,6783M2LV5X,1029044-16-3,,25151352.0,35308322.0,50177716.0,2183102.0,145373.0,CHEMBL3813873,,,ZINC000115705166
Silicon,phase 4 complete,DB12982,[Si],"Diet, Food, and Nutrition / Elements / Food / Food and Beverages / Growth Substances / Metalloids / Micronutrients / Minerals / Physiological Phenomena / Trace Elements",Z4152N8IUI,7440-21-3,,5461123.0,4574465.0,,9774.0,27573.0,,,,
Parthenolide,phase 4 complete,DB13063,C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,"Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Antirheumatic Agents / Asteraceae / Cell-mediated Immunity / Central Nervous System Agents / Increased Histamine Release / Magnoliaceae / NF-kappa B, antagonists & inhibitors / Peripheral Nervous System Agents / Sensory System Agents / Standardized Chemical Allergen / Terpenes",2RDB26I5ZB,20554-84-1,,6473881.0,20126246.0,50433441.0,32941.0,,CHEMBL540445,,,ZINC000030726283
Yttrium Y-90,phase 4 complete,DB13076,[90Y],"Acids, Acyclic / Anti-Inflammatory Agents / Elements / Isotopes / Metals / Metals, Rare Earth / Radioisotopes / Therapeutic Radiopharmaceuticals / Transition Elements / Tricarboxylic Acids / Yttrium / Yttrium (90Y) Compounds / Yttrium Isotopes / Yttrium Radioisotopes",1K8M7UR6O1,10098-91-6,,104760.0,94570.0,,,,,,,
Riamet,phase 4 complete,DB13085,,,5T2U51A0MW,141204-94-6,,,,,,,,,,
Biguanide,phase 4 complete,DB13100,NC(=N)NC(N)=N,,FB4Q52I9K2,56-03-1,,5939.0,5726.0,,1918319.0,3095.0,,,,ZINC000004097424
Amitriptylinoxide,phase 4 complete,DB13114,CN(C)(=O)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,"Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Antidepressive Agents, Tricyclic / Benzocycloheptenes / Central Nervous System Depressants / Dibenzocycloheptenes / Narrow Therapeutic Index Drugs / Neurotoxic agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",TYR2U59WMA,4317-14-0,,20313.0,19137.0,112778.0,,135224.0,CHEMBL627,,,ZINC000001481969
Norflurane,phase 4 complete,DB13116,FCC(F)(F)F,"Aerosol Propellants / Aerosols / Anesthetics / Central Nervous System Agents / Central Nervous System Depressants / Colloids / Complex Mixtures / Hydrocarbons, Halogenated / Investigative Techniques / Pharmaceutical Preparations",DH9E53K1Y8,811-97-2,D05208,13129.0,12577.0,,1311560.0,,CHEMBL2104432,,,ZINC000008214630
Pentafluoropropane,phase 4 complete,DB13117,FC(F)CC(F)(F)F,"Hydrocarbons, Halogenated",TA9UOF49CY,460-73-1,,68030.0,61345.0,,1591891.0,,,,,ZINC000001847395
Lusutrombopag,phase 4 complete,DB13125,CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C1=CSC(NC(=O)C2=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C2)=N1,"Acids, Carbocyclic / BCRP/ABCG2 Substrates / Blood and Blood Forming Organs / Hemostatics / P-glycoprotein substrates / Sulfur Compounds",6LL5JFU42F,1110766-97-6,,49843517.0,28529616.0,,2054984.0,136051.0,CHEMBL2107831,,,ZINC000084759273
Fluindione,phase 4 complete,DB13136,FC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O,Anticoagulants / Blood and Blood Forming Organs / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Hematologic Agents / Indans / Indenes / Narrow Therapeutic Index Drugs / Vitamin K Antagonists,EQ35YMS20Q,957-56-2,,68942.0,62167.0,50280156.0,50097.0,134975.0,CHEMBL24924,,,ZINC000100091724
Calcium glubionate anhydrousCommonly known or available as Calcium glubionate,phase 4 complete,DB13142,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Ca]OC(=O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,Alimentary Tract and Metabolism / Calcium Salts / Carbohydrates / Infant Food / Mineral Supplements / Oligosaccharides / Polysaccharides,93H20IU3DN,97635-31-9,,131704325.0,58310.0,,,,CHEMBL2219740,,,
Nedaplatin,phase 4 complete,DB13145,[H][N]([H])([H])[Pt]1(OCC(=O)O1)[N]([H])([H])[H],Antineoplastic Agents / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Organometallic Compounds / Platinum Compounds,8UQ3W6JXAN,95734-82-0,D01416,9548889.0,7972206.0,,,31898.0,,,,
Fluciclovine (18F),phase 4 complete,DB13146,N[C@]1(C[C@H]([18F])C1)C(O)=O,Cycloparaffins / Diagnostic Radiopharmaceuticals / Positron Emitting Activity / Radioactive Diagnostic Agent / Tumour Detection,38R1Q0L1ZE,222727-39-1,,450601.0,23313216.0,,1796118.0,134703.0,CHEMBL254468,,,ZINC000101525552
Levomenol,phase 4 complete,DB13153,[H][C@@]1(CCC(C)=CC1)[C@@](C)(O)CCC=C(C)C,Biological Products / Complex Mixtures / Lipids / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / Oils / Pharmaceutical Preparations / Plant Preparations / Terpenes,24WE03BX2T,23089-26-1,,442343.0,390796.0,50382730.0,19461.0,125.0,CHEMBL1096927,,,ZINC000001849759
Parachlorophenol,phase 4 complete,DB13154,OC1=CC=C(Cl)C=C1,"Anti-Infective Agents / Anti-Infective Agents, Local / Benzene Derivatives / Chlorobenzenes / Drugs that are Mainly Renally Excreted / Hydrocarbons, Chlorinated / Hydrocarbons, Halogenated / OATP1B3 substrates / Phenols",3DLC36A01X,106-48-9,D00149,4684.0,13875219.0,,14982.0,28078.0,CHEMBL57053,,,ZINC000000001885
Esculin,phase 4 complete,DB13155,OC[C@H]1O[C@@H](OC2=C(O)C=C3OC(=O)C=CC3=C2)[C@H](O)[C@@H](O)[C@@H]1O,"Benzopyrans / Carbohydrates / Coumarins / Glucosides / Glycosides / Heterocyclic Compounds, Fused-Ring / Pyrans",1Y1L18LQAF,531-75-9,,5281417.0,4444765.0,,1314351.0,4853.0,CHEMBL482581,,,ZINC000003860441
Inosine pranobex,phase 4 complete,DB13156,C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CNC2=O,"Acetanilides / Adjuvants, Immunologic / Amides / Amines / Anilides / Aniline Compounds / Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Carbohydrates / Drugs that are Mainly Renally Excreted / Glycosides / Heterocyclic Compounds, Fused-Ring / Immunologic Factors / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / Purine Nucleosides / Purines / Ribonucleosides",W1SO0V223F,36703-88-5,D01995,131704326.0,58829622.0,,6048.0,,,,,
Sodium lauryl sulfoacetate,phase 4 complete,DB13157,[Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O,Alimentary Tract and Metabolism / Drugs for Constipation / Enemas,D0Y70F2B9J,1847-58-1,,23668827.0,15024.0,,314832.0,,,,,
Clobetasone,phase 4 complete,DB13158,[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]2(C)[C@@]1(O)C(=O)CCl,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Moderately Potent (Group II) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Dermatologicals / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Immunosuppressive Agents / Ointments / Ophthalmologicals / Pregnadienes / Pregnadienetriols / Pregnanes / Sensory Organs / Steroids / Steroids, Fluorinated",LT69WY1J6D,54063-32-0,D07717,71387.0,64482.0,,108074.0,,,,,ZINC000005752185
Terpin hydrate,phase 4 complete,DB13163,O.CC(C)(O)[C@H]1CC[C@@](C)(O)CC1,Alcohols / Cyclohexanes / Cyclohexanols / Cycloparaffins / Expectorants / Fatty Alcohols / Hexanols / Lipids / Monoterpenes / Respiratory System Agents / Terpenes,S3V868548T,2451-01-6,,17141.0,16736914.0,,89916.0,,,,,
Zofenopril,phase 4 complete,DB13166,C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1,"ACE Inhibitors and Diuretics / Acids, Acyclic / Agents Acting on the Renin-Angiotensin System / Agents causing angioedema / Agents causing hyperkalemia / Amino Acids / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / Angiotensin-Converting Enzyme Inhibitors / Antihypertensive Agents / Cardiovascular Agents / Enzyme Inhibitors / Imines / Imino Acids / Protease Inhibitors",290ZY759PI,81872-10-8,D08688,92400.0,83422.0,50084629.0,39990.0,78539.0,CHEMBL331378,,,ZINC000003775162
Alclofenac,phase 4 complete,DB13167,OC(=O)CC1=CC(Cl)=C(OCC=C)C=C1,"Acetic Acid Derivatives and Related Substances / Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / Drugs that are Mainly Renally Excreted / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Sensory System Agents",M9CP5H21N8,22131-79-9,D01252,30951.0,28714.0,,,31183.0,CHEMBL94081,,,ZINC000002014875
Bismuth subnitrate,phase 4 complete,DB13209,[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O--].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O,"Alimentary Tract and Metabolism / Antacids / Bismuth containing drugs / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Elements / Elements, Radioactive / Gastric Acid Lowering Agents / Gastrointestinal Agents / Isotopes / Metals / Metals, Heavy / Neurotoxic agents / Radioisotopes",H19J064BA5,1304-85-4,D01642,,32699716.0,,19477.0,31293.0,,,,
Guanoxan,phase 4 complete,DB13211,NC(=N)NCC1COC2=C(O1)C=CC=C2,"Amidines / Antiadrenergic Agents, Peripherally Acting / Antihypertensive Agents / Guanidine Derivatives",9V0MRL0R5Y,2165-19-7,,,15704.0,,,134871.0,CHEMBL76725,,,
Butaperazine,phase 4 complete,DB13213,CCCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1,"Antipsychotic Agents / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotoxic agents / Phenothiazines / Phenothiazines With Piperazine Structure / Psycholeptics / Sulfur Compounds",TXP4T9106S,653-03-2,,,12078.0,,,135663.0,CHEMBL1697826,,,ZINC000022446639
Oxolamine,phase 4 complete,DB13216,CCN(CC)CCC1=NC(=NO1)C1=CC=CC=C1,Antitussive Agents / Central Nervous System Agents / Cough and Cold Preparations / Oxazoles / Respiratory System Agents,90BEA145GY,959-14-8,,,13143.0,,32658.0,94607.0,CHEMBL1620875,,,ZINC000000001874
Mandelic acid,phase 4 complete,DB13218,OC(C(O)=O)C1=CC=CC=C1,"Acids, Carbocyclic / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Hydroxy Acids / Irrigating Solutions",NH496X0UJX,90-64-2,,,1253.0,92715.0,29256.0,35825.0,CHEMBL1609,,,
Medifoxamine,phase 4 complete,DB13219,CN(C)CC(OC1=CC=CC=C1)OC1=CC=CC=C1,Amines / Antidepressive Agents / Central Nervous System Depressants / Nervous System / Psychoanaleptics,KWU7C2A1NT,32359-34-5,,,33212.0,,29434.0,135061.0,CHEMBL85231,,,ZINC000038605999
Apronalide,phase 4 complete,DB13221,CC(C)C(CC=C)C(=O)NC(N)=O,Central Nervous System Depressants / Hypnotics and Sedatives / Nervous System / Psycholeptics,V18J24E25E,528-92-7,,,10264.0,,,134827.0,CHEMBL509282,,,
Tilbroquinol,phase 4 complete,DB13222,CC1=C2C=CC=NC2=C(O)C(Br)=C1,"Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Heterocyclic Compounds, Fused-Ring / Hydroxyquinoline Derivatives / Hydroxyquinolines / Quinolines",P6SB125NHA,7175-09-9,,,59034.0,,166718.0,134965.0,CHEMBL1788385,,,ZINC000000002170
Dibenzepin,phase 4 complete,DB13225,CN(C)CCN1C2=CC=CC=C2N(C)C2=CC=CC=C2C1=O,"Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Antidepressive Agents, Tricyclic / Central Nervous System Agents / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / Nervous System / Neurotoxic agents / Non-Selective Monoamine Reuptake Inhibitors / Psychoanaleptics / Psychotropic Drugs / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",510SJZ1Y6L,4498-32-2,,,9048.0,50101814.0,3332.0,93394.0,CHEMBL1442422,,,ZINC000000001275
Flosequinan,phase 4 complete,DB13228,CN1C=C(C(=O)C2=C1C=C(F)C=C2)S(C)=O,"Cardiac Therapy / Cardiovascular Agents / Heterocyclic Compounds, Fused-Ring / Quinolone Vasodilators / Vasodilating Agents / Vasodilators Used in Cardiac Diseases",6NB119DLU7,76568-02-0,,,3672315.0,,25089.0,134972.0,CHEMBL1908307,,,
Calcium lactate,phase 4 complete,DB13231,[Ca++].CC(O)C([O-])=O.CC(O)C([O-])=O,Alimentary Tract and Metabolism / Calcium Salts / Hydroxy Acids / Mineral Supplements,2URQ2N32W3,814-80-2,,13144.0,12592.0,,47622.0,,CHEMBL2106111,,,
Perboric acid,phase 4 complete,DB13235,OOB=O,"Acids / Acids, Noncarboxylic / Alimentary Tract and Metabolism / Anions / Antiinfectives and Antiseptics for Local Oral Treatment / Boric Acids / Boron Compounds / Electrolytes / Ions / Stomatological Preparations / Tooth Bleaching",HC4C3M1FO2,14034-78-7,,,102872.0,,,30175.0,CHEMBL3707334,,,ZINC000256057132
Thiram,phase 4 complete,DB13245,CN(C)C(=S)SSC(=S)N(C)C,"Acids, Acyclic / Agrochemicals / Antiparasitic Products, Insecticides and Repellents / Carbamates / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Dimethyldithiocarbamate / Ectoparasiticides, Incl. Scabicides / Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents / Fungicides, Industrial / Increased Histamine Release / Mutagens / Noxae / Pesticides / Standardized Chemical Allergen / Sulfur Compounds / Sulfur Containing Products / Thiocarbamates / Toxic Actions",0D771IS0FH,137-26-8,D06114,,5256.0,43362.0,10517.0,9495.0,CHEMBL120563,,,ZINC000001532176
Quinupramine,phase 4 complete,DB13246,C1CN2CCC1C(C2)N1C2=CC=CC=C2CCC2=CC=CC=C12,"Agents that produce hypertension / Agents that reduce seizure threshold / Antidepressive Agents / Antidepressive Agents, Tricyclic / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Narrow Therapeutic Index Drugs / Nervous System / Neurotoxic agents / Non-Selective Monoamine Reuptake Inhibitors / Psychoanaleptics / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",29O61HFF4L,31721-17-2,,,84098.0,,35242.0,135292.0,CHEMBL107360,,,
Pramiracetam,phase 4 complete,DB13247,CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C,"Nervous System / Psychoanaleptics / Psychostimulants, Agents Used for Adhd and Nootropics",4449F8I3LE,68497-62-1,,,46801.0,,,135110.0,CHEMBL159776,,,ZINC000001856108
Phthalylsulfathiazole,phase 4 complete,DB13248,OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1,"Alimentary Tract and Metabolism / Amides / Amines / Aniline Compounds / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Intestinal Antiinfectives / Sulfanilamides / Sulfonamides / Sulfones / Sulfur Compounds / Thiazoles",6875L5852V,85-73-4,,,4641.0,,33632.0,9336.0,CHEMBL1524273,,,ZINC000001530877
Magnesium silicate,phase 4 complete,DB13249,[O--].[O--].[O--].[Mg++].[Si+4],"Acids / Acids, Noncarboxylic / Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Aluminum and magnesium containing antacids / Anions / Antacids / Drugs for Acid Related Disorders / Electrolytes / Gastric Acid Lowering Agents / Ions / Magnesium Compounds / Metal cations / Metal divalent cations / Minerals / Oxides / Oxygen Compounds / Silicates / Silicon Compounds",9B9691B2N9,1343-88-0,,,32698785.0,,1310566.0,,,,,
Proxibarbal,phase 4 complete,DB13253,CC(O)CC1(CC=C)C(=O)NC(=O)NC1=O,"Barbiturates, Plain / Central Nervous System Agents / Central Nervous System Depressants / Hypnotics and Sedatives / Nervous System / Psycholeptics / Pyrimidines / Pyrimidinones",F97OMS297F,2537-29-3,,,16406.0,,83885.0,134928.0,CHEMBL2105233,,,
Clothiapine,phase 4 complete,DB13256,CN1CCN(CC1)C1=NC2=CC=CC=C2SC2=C1C=C(Cl)C=C2,"Antipsychotic Agents / Azepines / Central Nervous System Agents / Central Nervous System Depressants / Diazepines, Oxazepines, Thiazepines and Oxepines / Heterocyclic Compounds, Fused-Ring / Nervous System / Neurotoxic agents / Psycholeptics / Psychotropic Drugs / Sulfur Compounds / Thiazepines / Thiepins / Tranquilizing Agents",Z05HCY0X1T,2058-52-8,,,15510.0,50040237.0,2620.0,31424.0,CHEMBL304902,,,ZINC000026185346
Ferrous sulfate anhydrousCommonly known or available as Ferrous sulfate,phase 4 complete,DB13257 (DBSALT000084),[Fe++].[O-]S([O-])(=O)=O,"Anemia, Iron-Deficiency / Delayed-Action Preparations / Hematinics / Iron Compounds / Iron Preparations / Minerals / Organometallic Compounds / Pharmaceutical Preparations / Polyvalent cation containing laxatives, antacids, oral supplements",2IDP3X9OUD,7720-78-7,,62662.0,22804.0,,,75832.0,CHEMBL1200830,,,
Etofamide,phase 4 complete,DB13258,CCOCCN(CC1=CC=C(OC2=CC=C(C=C2)[N+]([O-])=O)C=C1)C(=O)C(Cl)Cl,"Acetates / Acids, Acyclic / Amebicides / Amides / Anti-Infective Agents / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Dichloroacetamide Derivatives / Fatty Acids / Fatty Acids, Volatile / Lipids",03F36JH21U,25287-60-9,,,59142.0,,24607.0,135692.0,CHEMBL1788393,,,ZINC000002019951
Ethyl chloride,phase 4 complete,DB13259,CCCl,"Anesthetics / Anesthetics, Local / Central Nervous System Agents / Central Nervous System Depressants / Hydrocarbons, Chlorinated / Hydrocarbons, Halogenated / Nervous System / Peripheral Nervous System Agents / Sensory System Agents",46U771ERWK,75-00-3,,6337.0,6097.0,,4141.0,47554.0,CHEMBL46058,,,
Aceclidine,phase 4 complete,DB13262,CC(=O)OC1CN2CCC1CC2,Antiglaucoma Preparations and Miotics / Autonomic Agents / Miotics / Ophthalmologicals / Parasympathomimetics / Peripheral Nervous System Agents / Sensory Organs,0578K3ELIO,827-61-2,,,1902.0,50034625.0,,93847.0,CHEMBL20835,,,
Hexobendine,phase 4 complete,DB13265,COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN(C)CCN(C)CCCOC(=O)C1=CC(OC)=C(OC)C(OC)=C1,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Cardiac Therapy / Cardiovascular Agents / Ethers / Hydroxy Acids / Hydroxybenzoate Ethers / Hydroxybenzoates / Phenols / Phenyl Ethers / Vasodilating Agents / Vasodilators Used in Cardiac Diseases",B6X4SYR93B,54-03-5,,,5573.0,50225480.0,5303.0,135843.0,CHEMBL127300,,,ZINC000022463202
Ritiometan,phase 4 complete,DB13267,OC(=O)CSC(SCC(O)=O)SCC(O)=O,Nasal Preparations,J89LM8QVEE,34914-39-1,,,59206.0,,,136023.0,CHEMBL2105322,,,ZINC000002019920
Acetarsol,phase 4 complete,DB13268,CC(=O)NC1=CC(=CC=C1O)[As](O)(O)=O,"Agents Against Leishmaniasis and Trypanosomiasis / Alimentary Tract and Metabolism / Anti-Infective Agents / Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Arsenicals / Drugs that are Mainly Renally Excreted / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Intestinal Antiinfectives / Organometallic Compounds",806529YU1N,97-44-9,,,1908.0,50240028.0,,135135.0,CHEMBL1330792,,,
Dichlorobenzyl alcohol,phase 4 complete,DB13269,OCC1=C(Cl)C=C(Cl)C=C1,"Alcohols / Anti-Infective Agents, Local / Benzene Derivatives / Benzyl Compounds / Drugs that are Mainly Renally Excreted / Throat Preparations",1NKX3648J9,1777-82-8,,,14918.0,,22906.0,48220.0,CHEMBL3184437,,,ZINC000000157458
Dibekacin,phase 4 complete,DB13270,NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1,Agents that produce neuromuscular block (indirect) / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Glycosides / Narrow Therapeutic Index Drugs / Nephrotoxic agents,45ZFO9E525,34493-98-6,D07811,,413666.0,,3328.0,37945.0,CHEMBL560976,,,ZINC000008214383
Sultopride,phase 4 complete,DB13273,CCN1CCCC1CNC(=O)C1=CC(=CC=C1OC)S(=O)(=O)CC,"Acids, Carbocyclic / Amides / Antidepressive Agents / Antidepressive Agents, Second-Generation / Antipsychotic Agents / Benzamides and benzamide derivatives / Benzene Derivatives / Benzoates / Central Nervous System Agents / Central Nervous System Depressants / Dopamine Agents / Dopamine Antagonists / Moderate Risk QTc-Prolonging Agents / Nervous System / Neurotoxic agents / Neurotransmitter Agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Tranquilizing Agents",AA0G3TW31W,53583-79-2,,,5164.0,86720.0,37416.0,9356.0,CHEMBL277945,,,
Micronomicin,phase 4 complete,DB13274,CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1,Agents that produce neuromuscular block (indirect) / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Anti-Infective Agents / Benzalkonium Compounds / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Glycosides / Irritants / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Ophthalmic Solutions / Ophthalmologicals / Sensory Organs,S9AZ0R40QV,52093-21-7,,,2301017.0,,29996.0,81283.0,CHEMBL373081,,,ZINC000008214612
Benziodarone,phase 4 complete,DB13277,CCC1=C(C(=O)C2=CC(I)=C(O)C(I)=C2)C2=CC=CC=C2O1,"Antigout Preparations / Antirheumatic Agents / Cardiac Therapy / Heterocyclic Compounds, Fused-Ring / Renal Agents / Uricosuric Agents / Vasodilators Used in Cardiac Diseases",75CL65GTYR,68-90-6,,,6001.0,50209206.0,,135814.0,CHEMBL232201,,,ZINC000003875456
Bucetin,phase 4 complete,DB13278,CCOC1=CC=C(NC(=O)CC(C)O)C=C1,Amines / Aminophenols / Analgesics / Anilides / Aniline Compounds / Benzene Derivatives / Ethers / Ethyl Ethers / Nervous System / Phenols / Phenyl Ethers,6M7CVQ8PF8,1083-57-4,,,13507.0,,,31311.0,CHEMBL1697856,,,
Carbocromen,phase 4 complete,DB13279,CCOC(=O)COC1=CC2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2,"Benzopyrans / Cardiac Therapy / Cardiovascular Agents / Coumarins / Heterocyclic Compounds, Fused-Ring / Pyrans / Vasodilating Agents / Vasodilators Used in Cardiac Diseases",R0C9NIE5JJ,804-10-4,,,12084.0,,2508.0,135525.0,CHEMBL163672,,,ZINC000004215319
Benzododecinium,phase 4 complete,DB13282,CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1,"Amines / Ammonium Compounds / Anti-Infective Agents / Anti-Infective Agents, Local / Benzylammonium Compounds / Compounds used in a research, industrial, or household setting / Dermatologicals / Disinfectants / Medicated Dressings / Medicated Dressings With Antiinfectives / Nitrogen Compounds / Onium Compounds / Quaternary Ammonium Compounds",N0BN0O8CSL,10328-35-5,,,8424.0,,1311593.0,135611.0,CHEMBL1907001,,,ZINC000038141462
Meticrane,phase 4 complete,DB13284,CC1=CC2=C(C=C1S(N)(=O)=O)S(=O)(=O)CCC2,"Diuretics / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Low-Ceiling Diuretics, Excl. Thiazides / Sulfonamides",I7EKN1924Q,1084-65-7,,,4021.0,,,31839.0,CHEMBL1318341,,,ZINC000000001718
Bumadizone,phase 4 complete,DB13286,CCCCC(C(O)=O)C(=O)N(NC1=CC=CC=C1)C1=CC=CC=C1,"Acetic Acid Derivatives and Related Substances / Acids, Acyclic / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / Dicarboxylic Acids / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Sensory System Agents",ATD81G944M,3583-64-0,,,18080.0,,19847.0,76119.0,CHEMBL2105456,,,
Tromantadine,phase 4 complete,DB13288,CN(C)CCOCC(=O)NC12CC3CC(CC(C3)C1)C2,Anti-Infective Agents / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Cyclic Amines / Cycloparaffins / Dermatologicals / Direct Acting Antivirals,H191JFG8WA,53783-83-8,,,57947.0,,38868.0,135163.0,CHEMBL3989506,,,ZINC000004214578
Pimethixene,phase 4 complete,DB13292,CN1CCC(CC1)=C1C2=CC=CC=C2SC2=CC=CC=C12,"Antihistamines for Systemic Use / Heterocyclic Compounds, Fused-Ring / Sulfur Compounds / Xanthenes",T46J20J26F,314-03-4,,,4656.0,50097224.0,33712.0,94787.0,CHEMBL152408,,,ZINC000000000627
Ipecac,phase 4 complete,DB13293,,Agents Causing Muscle Toxicity / Antidotes / Autonomic Agents / Biological Products / Central Nervous System Agents / Complex Mixtures / Cough and Cold Preparations / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Emetics / Expectorants / Gastrointestinal Agents / Peripheral Nervous System Agents / Pharmaceutical Preparations / Plant Extracts / Plant Preparations,62I3C8233L,8012-96-2,,,,,5975.0,,CHEMBL2108372,,,
Atracurium,phase 4 complete,DB13295,,"Alkaloids / Anticholinergic Agents / Benzylisoquinolines / Central Nervous System Depressants / Cholinergic Agents / Heterocyclic Compounds, Fused-Ring / Isoquinolines / Muscle Relaxants / Muscle Relaxants, Peripherally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Neuromuscular Blocking Agents / Neuromuscular Nondepolarizing Blockade / Neuromuscular-Blocking Agents (Nondepolarizing) / Neurotransmitter Agents / Nicotinic Antagonists / Peripheral Nervous System Agents",2GQ1IRY63P,64228-79-1,,,,,1218.0,,,,,
Chlorquinaldol,phase 4 complete,DB13306,CC1=NC2=C(C=C1)C(Cl)=CC(Cl)=C2O,"Anti-Infective Agents / Anti-Infective Agents, Local / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Antiseptics and Disinfectants / Cell-mediated Immunity / Chloroquinolinols / Dermatologicals / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hydroxyquinoline Derivatives / Hydroxyquinolines / Increased Histamine Release / Quinoline Derivatives / Quinolines / Standardized Chemical Allergen / Throat Preparations",D6VHC87LLS,72-80-0,D07208,,6062.0,76302.0,2407.0,74500.0,CHEMBL224325,,,ZINC000000119403
Hydrotalcite,phase 4 complete,DB13322,O.O.O.O.O.O.O.O.O.O.O.O.[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[O-]C([O-])=O,Alimentary Tract and Metabolism / Alkalies / Aluminium Compounds / Aluminum and magnesium containing antacids / Anions / Antacids / Drugs for Acid Related Disorders / Electrolytes / Gastric Acid Lowering Agents / Gastrointestinal Agents / Hydroxides / Ions / Magnesium Compounds / Metal cations / Metal divalent cations,17432CG1KU,12304-65-3,,,32698917.0,,27221.0,,,,,
Trichloroethylene,phase 4 complete,DB13323,ClC=C(Cl)Cl,"Agents that produce hypertension / Anesthetics / Anesthetics, General / Anesthetics, Inhalation / Central Nervous System Agents / Central Nervous System Depressants / Compounds used in a research, industrial, or household setting / Hydrocarbons, Chlorinated / Hydrocarbons, Halogenated / Nervous System / Solvents",290YE8AR51,79-01-6,,,13837280.0,,,16602.0,CHEMBL279816,,PA166115521,ZINC000008214699
Pheneticillin,phase 4 complete,DB13337,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C)OC1=CC=CC=C1)C(O)=O,Anti-Bacterial Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Beta-Lactam Antibacterials / Beta-Lactamase Sensitive Penicillins / beta-Lactams / Penicillins,EFA30X554H,147-55-7,,,240055.0,50240064.0,33277.0,52427.0,CHEMBL1614637,,,
Dihydroergocristine,phase 4 complete,DB13345,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,"Adrenergic Agents / Adrenergic Antagonists / Agents that produce hypertension / Alkaloids / BSEP/ABCB11 Substrates / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 Substrates / Ergot Alkaloids and Derivatives / Ergotamines / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / Peripheral Vasodilators / Vasodilating Agents",05D48LUM4Z,17479-19-5,D07834,,96884.0,50390992.0,3416.0,59912.0,CHEMBL601773,,,ZINC000003995616
Bufexamac,phase 4 complete,DB13346,CCCCOC1=CC=C(CC(=O)NO)C=C1,"Acetamides / Acetates / Acetic Acid Derivatives and Related Substances / Acids, Acyclic / Agents causing hyperkalemia / Amides / Amines / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antineoplastic Agents / Antirheumatic Agents / Benzene Derivatives / Benzeneacetamides / Central Nervous System Agents / Fatty Acids / Fatty Acids, Volatile / Histone Deacetylase Inhibitors / Hydroxamic Acids / Hydroxy Acids / Hydroxylamines / Lipids / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Sensory System Agents / Topical Products for Joint and Muscular Pain",4T3C38J78L,2438-72-4,D01271,2466.0,2372.0,50015144.0,1796.0,31317.0,CHEMBL94394,,,ZINC000003871797
Calcium alginate,phase 4 complete,DB13372,,"Blood and Blood Forming Organs / Compounds used in a research, industrial, or household setting / Hemostatics / Local Hemostatics",8P20S56HZI,9005-35-0,,,,,47610.0,,,,,
Sodium feredetate,phase 4 complete,DB13381,[Na+].[O-]C(=O)C[N+]12CC[N+]34CC(=O)O[Fe--]13(OC(=O)C2)OC(=O)C4,"Acetates / Acids, Acyclic / Amines / Antianemic Preparations / Blood and Blood Forming Organs / Compounds used in a research, industrial, or household setting / Diamines / Ethylenediamines / Fatty Acids / Fatty Acids, Volatile / Iron Chelating Agents / Iron Compounds / Iron Preparations / Iron Trivalent, Oral Preparations / Organometallic Compounds / Parenteral Iron Replacement / Polyamines / Sequestering Agents",403J23EMFA,15708-41-5,D07145,,25555.0,,105673.0,78292.0,CHEMBL1705709,,,
Edoxudine,phase 4 complete,DB13421,CCC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O,"Anti-Infective Agents / Antiviral Agents / Carbohydrates / Deoxyribonucleosides / Dermatologicals / Glycosides / Nucleic Acids, Nucleotides, and Nucleosides / Nucleosides / Pyrimidine Nucleosides / Pyrimidines / Ribonucleosides",15ZQM81Y3R,15176-29-1,,66377.0,59752.0,50132292.0,49428.0,135051.0,CHEMBL318153,,,ZINC000003956771
Ioxitalamic acid,phase 4 complete,DB13444,CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C1I,"Acids, Carbocyclic / Alcohols / Amino Sugars / Benzene Derivatives / Benzoates / Carbohydrates / Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Hexosamines / Iodobenzoates / Sugar Alcohols / Triiodobenzoic Acids / Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media / X-Ray Contrast Media, Iodinated",967RDI7Z6K,28179-44-4,D07418,,31782.0,,,83517.0,CHEMBL2107239,,,ZINC000004216615
Bendazac,phase 4 complete,DB13501,OC(=O)COC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12,"Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antiinflammatory Preparations, Non-Steroids for Topical Use / Antirheumatic Agents / Central Nervous System Agents / Heterocyclic Compounds, Fused-Ring / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Ophthalmologicals / Peripheral Nervous System Agents / Pyrazoles / Sensory Organs / Sensory System Agents / Topical Products for Joint and Muscular Pain",G4AG71204O,20187-55-7,,,2223.0,,,31257.0,CHEMBL1089221,,,ZINC000000001000
Tyrothricin,phase 4 complete,DB13503,,"Amino Acids, Peptides, and Proteins / Anti-Bacterial Agents / Anti-Infective Agents / Anti-Infective Agents, Local / Antibiotics for Topical Use / Cholinesterase Inhibitors / Dermatologicals / Ophthalmologicals / Peptides / Peptides, Cyclic / Sensory Organs / Throat Preparations",877376V2XW,1404-88-2,,,398608.0,,10968.0,,CHEMBL577736,,,
Alginic acid,phase 4 complete,DB13518,,"Acids, Acyclic / Acids, Aldehydic / Alginates / Alimentary Tract and Metabolism / Carbohydrates / Compounds used in a research, industrial, or household setting / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Glucuronates / Hexuronic Acids / Hydroxy Acids / Polysaccharides / Sugar Acids / Uronic Acids",8C3Z4148WZ,9005-32-7,D02324,131704328.0,,,17305.0,17548.0,,,,
Metergoline,phase 4 complete,DB13520,[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@@]1([H])C[C@@H](CNC(=O)OCC1=CC=CC=C1)CN2C,"Agents that produce hypertension / Alkaloids / Antidepressive Agents / Central Nervous System Depressants / Dopamine Agents / Dopamine Agonists / Ergolines / Ergot Alkaloids and Derivatives / Ergot-derivative Dopamine Receptor Agonists / Genito Urinary System and Sex Hormones / Heterocyclic Compounds, Fused-Ring / Neurotransmitter Agents / Prolactine Inhibitors / Serotonin Agents / Serotonin Receptor Agonists / Serotonin Receptor Antagonists",1501393LY5,17692-51-2,D07218,28693.0,26687.0,30704.0,6834.0,64216.0,CHEMBL19215,,,ZINC000003812975
Cyclopenthiazide,phase 4 complete,DB13532,NS(=O)(=O)C1=CC2=C(NC(CC3CCCC3)NS2(=O)=O)C=C1Cl,"Amides / Antihypertensive Agents / Benzothiadiazines / Cardiovascular Agents / Diuretics / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Heterocyclic Compounds, Fused-Ring / Hyperglycemia-Associated Agents / Low-Ceiling Diuretics and Potassium-Sparing Agents / Membrane Transport Modulators / Natriuretic Agents / Sodium Chloride Symporter Inhibitors / Sulfonamides / Sulfones / Sulfur Compounds / Thiazides",VX4S2N85F5,742-20-1,,2904.0,2801.0,,3000.0,91686.0,CHEMBL1373254,,,
Mephenesin,phase 4 complete,DB13583,CC1=CC=CC=C1OCC(O)CO,"Alcohols / Central Nervous System Agents / Central Nervous System Depressants / Glycols / Muscle Relaxants / Muscle Relaxants, Centrally Acting Agents / Musculo-Skeletal System / Neuromuscular Agents / Peripheral Nervous System Agents / Propylene Glycols",7B8PIR2954,59-47-2,,,3919.0,50238673.0,6755.0,94398.0,CHEMBL229128,,,
Almasilate,phase 4 complete,DB13595,O.[Mg++].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-],"Acids / Acids, Noncarboxylic / Alimentary Tract and Metabolism / Aluminum and magnesium containing antacids / Anions / Antacids / Drugs for Acid Related Disorders / Drugs that are Mainly Renally Excreted / Electrolytes / Gastric Acid Lowering Agents / Ions / Minerals / Oxides / Oxygen Compounds / Pharmaceutic Aids / Silicon Compounds",,71205-22-6,D07419,131704329.0,32700646.0,,,,,,,
Mifamurtide,phase 4 complete,DB13615,O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC,"Acids, Acyclic / Adjuvants, Immunologic / Alcohols / Amino Acids, Peptides, and Proteins / Amino Sugars / Antineoplastic and Immunomodulating Agents / Carbohydrates / Glycerophosphates / Glycerophospholipids / Glycoconjugates / Glycopeptides / Hydroxy Acids / Immunologic Factors / Lipids / Membrane Lipids / Muramic Acids / Peptides / Phosphatidic Acids / Phospholipids / Sugar Acids / Sugar Alcohols / Sugar Phosphates / Triose Sugar Alcohols",1LM890Q4FY,838853-48-8,,,32700228.0,,,,,,,
Potassium gluconate,phase 4 complete,DB13620,[K+].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,Alimentary Tract and Metabolism / Mineral Supplements / Potassium Salt,12H3K5QKN9,299-27-4,D01298,16760467.0,8931.0,,89903.0,32032.0,CHEMBL2106978,,,
Methoxyphenamine,phase 4 complete,DB13624,CNC(C)CC1=CC=CC=C1OC,Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-Agonists / Adrenergics for Systemic Use / Agents producing tachycardia / Agents that produce hypertension / Amines / Amphetamines / Drugs for Obstructive Airway Diseases / Ethylamines / Neurotransmitter Agents / Non-selective Beta-adrenergic Agonists / Phenethylamines / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Sympathomimetics,J3Z5SRI26Z,93-30-1,,,3974.0,,29704.0,134817.0,CHEMBL2010507,,,
Ethyl hydroxybenzoate,phase 4 complete,DB13628,CCOC(=O)C1=CC=C(O)C=C1,"Acids, Carbocyclic / Antifungals for Dermatological Use / Antifungals for Topical Use / Benzene Derivatives / Benzoates / Cell-mediated Immunity / Dermatologicals / Hydroxy Acids / Hydroxybenzoates / Increased Histamine Release / Phenols / Standardized Chemical Allergen",14255EXE39,120-47-8,D01647,,13846749.0,50428380.0,1362892.0,31575.0,CHEMBL15841,,,ZINC000000001392
Benorilate,phase 4 complete,DB13657,CC(=O)NC1=CC=C(OC(=O)C2=CC=CC=C2OC(C)=O)C=C1,"Acids, Carbocyclic / Agents causing hyperkalemia / Agents that produce hypertension / Amides / Amines / Analgesics / Analgesics, Non-Narcotic / Anilides / Aniline Compounds / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antirheumatic Agents / Benzene Derivatives / Benzoates / Central Nervous System Agents / Hydroxy Acids / Hydroxybenzoates / Nephrotoxic agents / Nervous System / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Phenols / Salicylic Acid and Derivatives / Sensory System Agents",W1QX9DV96G,5003-48-5,,,19846.0,,1372.0,135340.0,CHEMBL162036,,,ZINC000000001003
Naftazone,phase 4 complete,DB13680,NC(=O)N\N=C1/C=CC2=CC=CC=C2C1=O,Capillary Stabilizing Agents / Coagulants / Hematologic Agents / Hemostatics / Naphthalenes / Quinones / Vasoprotectives,15B0523P5L,15687-37-3,,,4698034.0,,31475.0,134890.0,CHEMBL2106794,,,ZINC000018163569
Cefpirome,phase 4 complete,DB13682,[H][C@]12SCC(C[N+]3=C4CCCC4=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C([O-])=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / beta-Lactams / Cephalosporins / Fourth-Generation Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Nephrotoxic agents / Sulfur Compounds / Thiazines",S72Q2F09HY,84957-29-9,D07649,,4586396.0,,27130.0,3503.0,CHEMBL65794,,,
Sodium tartrate,phase 4 complete,DB13707,[Na+].[Na+].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O,"Acids, Acyclic / Alimentary Tract and Metabolism / Carbohydrates / Dicarboxylic Acids / Drugs for Constipation / Hydroxy Acids / Laxatives / Osmotic Laxatives / Sugar Acids",QTO9JB4MDD,868-18-8,,162637.0,142788.0,,56524.0,63017.0,CHEMBL2107781,,,
Tritoqualine,phase 4 complete,DB13711,CCOC1=C(OCC)C(OCC)=C(N)C2=C1C(OC2=O)C1N(C)CCC2=CC3=C(OCO3)C(OC)=C12,"Antihistamines for Systemic Use / Cholagogues and Choleretics / Heterocyclic Compounds, Fused-Ring / Histamine Agents / Histamine Antagonists / Neurotransmitter Agents",F4MW5166YH,14504-73-5,,,65119.0,,38810.0,135802.0,CHEMBL2104445,,,
Diphemanil,phase 4 complete,DB13720,C[N+]1(C)CCC(CC1)=C(C1=CC=CC=C1)C1=CC=CC=C1,"Agents producing tachycardia / Alimentary Tract and Metabolism / Anti-Asthmatic Agents / Anticholinergic Agents / Autonomic Agents / Bronchodilator Agents / Drugs for Functional Gastrointestinal Disorders / Muscarinic Antagonists / Parasympatholytics / Peripheral Nervous System Agents / Respiratory System Agents / Synthetic Anticholinergics, Quaternary Ammonium Compounds",Q26TX1UD0W,15394-62-4,,,5897.0,74260.0,89782.0,93636.0,CHEMBL1201340,,,ZINC000001482039
Sodium aurotiosulfate,phase 4 complete,DB13743,O.O.[Na+].[Na+].[Na+].[Au+].[O-]S([S-])(=O)=O.[O-]S([S-])(=O)=O,"Acids / Acids, Noncarboxylic / Anions / Antiinflammatory and Antirheumatic Products / Antirheumatic Agents / Electrolytes / Gold Compounds / Gold Preparations / Ions / Laxatives / Musculo-Skeletal System / Osmotic Laxatives / Sodium Compounds / Specific Antirheumatic Agents / Sulfates / Sulfur Acids / Sulfur Compounds / Sulfuric Acids / Thiosulfates",CKS1YQ9W1J,33614-49-2,,,142087.0,,9876.0,,CHEMBL3833379,,,
Bioallethrin,phase 4 complete,DB13746,,"Agents causing hyperkalemia / Agrochemicals / Antiarrhythmic agents / Antiparasitic Products, Insecticides and Repellents / Bradycardia-Causing Agents / Calcium Channel Blockers / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Ectoparasiticides, Incl. Scabicides / Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents / Insecticides / Monoterpenes / Pesticides / Pyrethrines, Incl. Synthetic Compounds / Pyrethrins / Stereoisomerism / Terpenes / Toxic Actions",0X03II877M,584-79-2,,15558638.0,18923353.0,,19338.0,39118.0,CHEMBL1788403,,,
Trolamine,phase 4 complete,DB13747,OCCN(CCO)CCO,Alcohols / Amines / Amino Alcohols / Cicatrizants / Dermatologicals / Drugs that are Mainly Renally Excreted / Preparations for Treatment of Wounds and Ulcers,9O3K93S3TK,102-71-6,D00215,7618.0,13835630.0,,38623.0,28621.0,CHEMBL446061,,,ZINC000000896409
Magnesium gluconate,phase 4 complete,DB13749,O.O.[Mg++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,"Acids, Acyclic / Agents that produce neuromuscular block (indirect) / Alimentary Tract and Metabolism / Carbohydrates / Hydroxy Acids / Magnesium Compounds / Metal cations / Metal divalent cations / Mineral Supplements / Sugar Acids",T42NAD2KHC,59625-89-7,,71587201.0,28295928.0,,52358.0,,CHEMBL3989640,,,
Glycyrrhizic acid,phase 4 complete,DB13751,[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O,"Alimentary Tract and Metabolism / Anti-Inflammatory Agents / Bile and Liver Therapy / BSEP/ABCB11 Substrates / Liver Therapy / Liver Therapy, Lipotropics / Pentacyclic Triterpenes / Terpenes / Triterpenes",6FO62043WK,1405-86-3,D00157,,14263.0,50185127.0,26143.0,15939.0,CHEMBL441687,,,ZINC000096015174
Lidoflazine,phase 4 complete,DB13766,CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1,Agents causing hyperkalemia / Antiarrhythmic agents / Bradycardia-Causing Agents / Calcium Channel Blockers / Calcium-Regulating Hormones and Agents / Cardiovascular Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Membrane Transport Modulators / Non-Selective Calcium Channel Blockers / Piperazines / Potential QTc-Prolonging Agents / QTc Prolonging Agents / Vasodilating Agents,J4ZHN3HBTE,3416-26-0,,,3789.0,23619.0,6390.0,93095.0,CHEMBL92870,,PA165818137,ZINC000022034381
Xamoterol,phase 4 complete,DB13781,OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1,Adrenergic Agents / Adrenergic Agonists / Adrenergic beta-1 Receptor Agonists / Adrenergic beta-Agonists / Agents producing tachycardia / Agents that produce hypertension / Alcohols / Amines / Amino Alcohols / Cardiac Stimulants Excl. Cardiac Glycosides / Cardiac Therapy / Morpholines / Neurotransmitter Agents / Oxazines / Phenoxypropanolamines / Propanolamines / Propanols,7HE0JQL703,81801-12-9,D06328,155774.0,137213.0,,39801.0,10055.0,CHEMBL75753,,,
Acemetacin,phase 4 complete,DB13783,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O,"Acetic Acid Derivatives and Related Substances / Agents causing hyperkalemia / Agents that produce hypertension / Analgesics / Analgesics, Non-Narcotic / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Antigout Preparations / Antiinflammatory and Antirheumatic Products / Antiinflammatory and Antirheumatic Products, Non-Steroids / Antirheumatic Agents / Central Nervous System Agents / Heterocyclic Compounds, Fused-Ring / Indoles / Musculo-Skeletal System / Nephrotoxic agents / Non COX-2 selective NSAIDS / Peripheral Nervous System Agents / Sensory System Agents / UGT2B7 substrates",5V141XK28X,53164-05-9,D01582,1981.0,1904.0,50336272.0,16695.0,31162.0,CHEMBL189171,,PA166049184,ZINC000000601272
Calcium levulinate,phase 4 complete,DB13800,[Ca++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O,Alimentary Tract and Metabolism / Calcium Salts / Enzyme Inhibitors / Keto Acids / Mineral Supplements,LLQ966USIL,591-64-0,,,11090.0,,47624.0,81717.0,,,,
Muzolimine,phase 4 complete,DB13801,CC(N1N=C(N)CC1=O)C1=CC(Cl)=C(Cl)C=C1,Antihypertensive Agents / Cardiovascular Agents / Diuretics / High-Ceiling Diuretics / Natriuretic Agents / Pyrazoles / Pyrazolone Derivatives,07Z36289ZX,55294-15-0,,,37766.0,,,135124.0,CHEMBL1697760,,,
Iodoform,phase 4 complete,DB13813,[H]C(I)(I)I,"Dermatologicals / Hydrocarbons, Halogenated / Medicated Dressings / Medicated Dressings With Antiinfectives / Miscellaneous Local Anti-infectives",KXI2J76489,75-47-8,D01910,6374.0,6134.0,,27748.0,37758.0,CHEMBL1451116,,,ZINC000006827595
Noxytiolin,phase 4 complete,DB13838,CNC(=S)NCO,"Anti-Infective Agents / Anti-Infective Agents, Local / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Irrigating Solutions / Sulfur Compounds / Thiourea",4DN3AF1FU6,15599-39-0,,,4418329.0,,7543.0,134756.0,CHEMBL2106441,,,ZINC000001482128
Fluorodopa (18F),phase 4 complete,DB13848,N[C@@H](CC1=CC(O)=C(O)C=C1[18F])C(O)=O,"Amines / Amino Acids / Amino Acids, Aromatic / Amino Acids, Cyclic / Amino Acids, Essential / Amino Acids, Peptides, and Proteins / Benzene Derivatives / Catecholamines / Catechols / Diagnostic Radiopharmaceuticals / Fluorine Radioisotopes / Phenols / Phenylalanine",2C598205QX,92812-82-3,,,50970.0,,,49166.0,CHEMBL3400972,,,ZINC000100079068
Artemotil,phase 4 complete,DB13851,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OCC)[C@@H]2C)O4,"Amebicides / Anions / Anti-Infective Agents / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiplatyhelmintic Agents / Antiprotozoals / Artemisinin and Derivatives, Plain / Electrolytes / Free Radicals / Ions / Oxides / Oxygen Compounds / Peroxides / Reactive Oxygen Species / Schistosomicides / Sesquiterpenes / Terpenes",XGL7GFB9YI,75887-54-6,,,2272064.0,50426305.0,,135335.0,CHEMBL301267,,,ZINC000008214360
Anethole trithione,phase 4 complete,DB13853,COC1=CC=C(C=C1)C1=CC(=S)SS1,"Alimentary Tract and Metabolism / Anisoles / Benzene Derivatives / EENT Drugs, Miscellaneous / Ethers / Gastrointestinal Agents / Methyl Ethers / Phenols / Phenyl Ethers / Sulfur Compounds / Thiones / Various Alimentary Tract and Metabolism Products",QUY32964DJ,532-11-6,D01584,2194.0,2109.0,,820.0,31221.0,CHEMBL178862,,,ZINC000000000949
Gamolenic acid,phase 4 complete,DB13854,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O,"Agents that reduce seizure threshold / Dermatologicals / Fatty Acids / Fatty Acids, Essential / Fatty Acids, Omega-6 / Fatty Acids, Unsaturated / Linolenic Acids / Lipids",78YC2MAX4O,506-26-3,D07213,,4444436.0,50269532.0,25605.0,28661.0,CHEMBL464982,,,ZINC000003777423
Dimazole,phase 4 complete,DB13858,CCN(CC)CCOC1=CC2=C(C=C1)N=C(S2)N(C)C,Antifungals for Dermatological Use / Antifungals for Topical Use / Dermatologicals / Sulfur Compounds,2KL01R8ZV1,95-27-2,,,8384.0,,,103934.0,CHEMBL1184360,,,ZINC000000001271
Fluticasone,phase 4 complete,DB13867,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Androstadienes / Androstanes / Androstenes / Anti-Allergic Agents / Anti-Asthmatic Agents / Anti-Inflammatory Agents / Autonomic Agents / Bronchodilator Agents / Corticosteroid Hormone Receptor Agonists / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Drugs for Obstructive Airway Diseases / Fused-Ring Compounds / Glucocorticoids / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Nasal Preparations / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein substrates / Peripheral Nervous System Agents / Respiratory System Agents / Steroids / Thyroxine-binding globulin inhibitors",CUT2W21N7U,90566-53-3,D07981,,4470631.0,,41126.0,5134.0,CHEMBL1201396,,,ZINC000004097438
Lormetazepam,phase 4 complete,DB13872,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1Cl,"Benzazepines / Benzodiazepines and benzodiazepine derivatives / Benzodiazepinones / Central Nervous System Agents / Central Nervous System Depressants / Heterocyclic Compounds, Fused-Ring / Hypnotics and Sedatives / Nervous System / Psycholeptics",GU56C842ZA,848-75-9,,13314.0,12750.0,,28894.0,52993.0,CHEMBL22097,,,
Fenofibric acid,phase 4 complete,DB13873,CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O,"Acids, Acyclic / Agents Causing Muscle Toxicity / Anticholesteremic Agents / Benzene Derivatives / Benzophenones / Butyrates / Drugs that are Mainly Renally Excreted / Ethers / Fatty Acids / Fatty Acids, Volatile / Fibric Acids / Hypolipidemic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / Isobutyrates / Ketones / Lipid Modifying Agents / Lipid Modifying Agents, Plain / Lipid Regulating Agents / Lipids / Noxae / Peroxisome Proliferator Receptor alpha Agonist / Phenols / Phenyl Ethers / Toxic Actions",BGF9MN2HU1,42017-89-0,,64929.0,58457.0,28700.0,24852.0,83469.0,CHEMBL981,,,ZINC000000001984
Enasidenib,phase 4 complete,DB13874,CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=NC(=CC=C1)C(F)(F)F,Amines / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Isocitrate Dehydrogenase 2 Inhibitor / Isocitrate Dehydrogenase 2 Inhibitors / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / Pyridines / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT1A1 substrates with narrow therapeutic index / UGT1A3 substrates / UGT1A3 substrates with narrow therapeutic index / UGT1A4 substrates / UGT1A9 Substrates / UGT1A9 substrates with narrow therapeutic index / UGT2B7 substrates / UGT2B7 substrates with narrow therapeutic index,3T1SS4E7AG,1446502-11-9,,89683805.0,38772329.0,,1940332.0,145374.0,CHEMBL3989908,,,ZINC000222731806
Pibrentasvir,phase 4 complete,DB13878,CO[C@H](C)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1=NC2=C(N1)C=C(F)C(=C2)[C@H]1CC[C@@H](N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)C=C1F,"Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 Enzyme Inhibitors / Direct Acting Antivirals / Hepatitis C Virus NS5A Inhibitor / Heterocyclic Compounds, Fused-Ring / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B3 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / UGT1A1 Inhibitors",2WU922TK3L,1353900-92-1,,58031952.0,35013016.0,,1940636.0,,CHEMBL3545123,,,
Glecaprevir,phase 4 complete,DB13879,[H][C@@]12CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC\C=C\C(F)(F)C3=NC4=C(C=CC=C4)N=C3O1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1,"Amides / Antiinfectives for Systemic Use / Antiviral Agents / Antivirals for Systemic Use / Antivirals for treatment of HCV infections / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Breast Cancer Resistance Protein Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Direct Acting Antivirals / HCV NS3/4A Protease Inhibitors / Heterocyclic Compounds, Fused-Ring / NS3/4A Protease Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / OATP1B3 substrates / Organic Anion Transporting Polypeptide 1B1 Inhibitors / Organic Anion Transporting Polypeptide 1B3 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Sulfones / Sulfur Compounds / UGT1A1 Inhibitors",K6BUU8J72P,1365970-03-1,D10814,66828839.0,35013015.0,,1940635.0,,CHEMBL3545363,,,ZINC000164528615
Methyl nicotinate,phase 4 complete,DB13882,COC(=O)C1=CN=CC=C1,Anti-Inflammatory Agents / Erythema / Inflammation / Nicotinic Acids / Pyridines,7B1AVU9DJN,93-60-7,,7151.0,21111785.0,,29900.0,134761.0,CHEMBL379845,,,ZINC000000001706
Ferric subsulfate,phase 4 complete,DB13885,,"Acids / Acids, Noncarboxylic / Anions / Coagulants / Electrolytes / Hematologic Agents / Hemostatics / Ions / Iron Compounds / Organometallic Compounds / Parenteral Iron Replacement / Phosphate Binder / Sulfur Acids / Sulfur Compounds / Sulfuric Acids",3QJ8WS6V8H,1310-45-8,,,,,24912.0,,,,,
Amylmetacresol,phase 4 complete,DB13908,CCCCCC1=CC=C(C)C=C1O,Benzene Derivatives / Miscellaneous Anti-infectives / Phenols,05W904P57F,1300-94-3,,,14076.0,,236248.0,48213.0,CHEMBL1512677,,,ZINC000002039651
Bismuth subgallate,phase 4 complete,DB13909,O[Bi]1OC2=CC(=CC(O)=C2O1)C(O)=O,"Acids, Carbocyclic / Antacids and Adsorbents / Anti-Infective Agents / Antidiarrheals / Benzene Derivatives / Benzoates / Bismuth containing drugs / Coagulants / Drugs that are Mainly Renally Excreted / Hematologic Agents / Hemostatics / Hydroxy Acids / Hydroxybenzoates / Neurotoxic agents / Phenols",YIW503MI7V,99-26-3,D01398,,10607905.0,,19476.0,31292.0,CHEMBL1592101,,,
Valproate bismuth,phase 4 complete,DB13910,[Bi+3].CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O,"Bismuth containing drugs / EENT Drugs, Miscellaneous / Neurotoxic agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",87PTX621FI,60364-28-5,,,20137751.0,,324003.0,,,,,
Phloxine BCommonly known or available as Phloxine,phase 4 complete,DB13911,[Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C1C=C(Br)C([O-])=C2Br,"Coloring Agents / Compounds used in a research, industrial, or household setting / Dental Agents / Fluoresceins / Fluorescent Dyes / Heterocyclic Compounds, Fused-Ring / Indicators and Reagents / Laboratory Chemicals / Luminescent Agents / Spiro Compounds / Xanthenes",767IP0Y5NH,18472-87-2,,,2006228.0,,1310707.0,87192.0,CHEMBL61441,,,
Dotatate gallium Ga-68,phase 4 complete,DB13925,[68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,"Amino Acids, Peptides, and Proteins / Gallium Radioisotopes / Peptides / Peptides, Cyclic / Positron Emitting Activity / Radioactive Diagnostic Agent",9L17Y0H71P,1027785-90-5,,,58828606.0,,676679.0,,,,,
Semaglutide,phase 4 complete,DB13928,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O,"Alimentary Tract and Metabolism / Amino Acids, Peptides, and Proteins / Blood Glucose Lowering Agents / Drugs Used in Diabetes / Gastrointestinal Hormones / GLP-1 Agonists / Glucagon-like Peptide-1 (GLP-1) Agonists / Glucagon-like peptide-1 (GLP-1) analogues / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Incretin Mimetics / Pancreatic Hormones / Peptide Hormones / Peptides / Proteins",53AXN4NNHX,910463-68-2,,,34985066.0,50121400.0,1991302.0,,CHEMBL3616752,,,
Netarsudil,phase 4 complete,DB13931,CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1,"Acids, Carbocyclic / Alanine / Amino Acids / Amino Acids, Peptides, and Proteins / Antiglaucoma Preparations and Miotics / Benzene Derivatives / Ophthalmologicals / Rho Kinase Inhibitor / Rho Kinase Inhibitors / Sensory Organs",W6I5QDT7QI,1254032-66-0,,,34980598.0,,1992864.0,,,,,ZINC000113149554
Testosterone cypionate,phase 4 complete,DB13943 (DBSALT001298),C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,"Anabolic Agents / Androgens / Androstanes / Androstenes / Androstenols / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Delayed-Action Preparations / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OAT3/SLC22A8 Inducers / P-glycoprotein inhibitors / Steroids / Testosterone and derivatives / Testosterone Congeners / Thyroxine-binding globulin inhibitors",M0XW1UBI14,58-20-8,D00957,,390140.0,,,9463.0,CHEMBL1201101,,,ZINC000004097468
Testosterone enanthate,phase 4 complete,"DB13944 (DBSALT001030, DBSALT001031, DB13945)",[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"Adrenal Cortex Hormones / Androgens / Androstanes / Androstenes / Androstenols / BCRP/ABCG2 Substrates / Contraceptive Agents, Male / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OAT3/SLC22A8 Inducers / P-glycoprotein inhibitors / Steroids / Testosterone and derivatives / Testosterone Congeners / Thyroxine-binding globulin inhibitors",7Z6522T8N9,315-37-7,,,9045.0,,,9464.0,CHEMBL1200335,,,ZINC000003876080
Testosterone undecanoate,phase 4 complete,DB13946 (DBSALT001033),CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,"Androgens / Androstanes / Androstenes / Androstenols / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OAT3/SLC22A8 Inducers / P-glycoprotein inhibitors / Steroids / Testosterone and derivatives / Testosterone Congeners / Thyroxine-binding globulin inhibitors",H16A5VCT9C,5949-44-0,,,58664.0,,,135741.0,CHEMBL2107067,,,ZINC000008214690
Testosterone enantate benzilic acid hydrazone,phase 4 complete,DB13947 (DBSALT002571),[H]N(N=C1CC[C@@]2(C)C(CC[C@@]3([H])[C@]4([H])CC[C@H](OC(=O)CCCCCC)[C@@]4(C)CC[C@]23[H])=C1)C(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,"Androstanes / Androstenes / Androstenols / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Steroids / Testosterone and derivatives / Testosterone Congeners",X8Z8A2G2Y4,18625-33-7,,,34995240.0,,,,,,,ZINC000299888598
Ferric cation,phase 4 complete,DB13949,[Fe+3],"Iron Compounds / Parenteral Iron Replacement / Phosphate Binder / Phosphate Chelating Activity / Polyvalent cation containing laxatives, antacids, oral supplements",91O4LML611,20074-52-6,,,27815.0,,1546357.0,29034.0,,,,
Estradiol acetate,phase 4 complete,DB13952 (DBSALT000065),[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(C)=O)C=C3CC[C@@]21[H],BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Estrogens / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / Thyroxine-binding globulin inducers / UGT1A1 Substrates,5R97F5H93P,4245-41-4,D04061,9818306.0,7994056.0,,,135981.0,CHEMBL1200430,,,
Estradiol benzoate,phase 4 complete,DB13953 (DBSALT000066),[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)C5=CC=CC=C5)=CC=C4[C@@]3([H])CC[C@]12C,"Adrenal Cortex Hormones / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Estradiol Congeners / Estranes / Estrenes / Estrogens / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / Reproductive Control Agents / Steroids / UGT1A1 Substrates",1S4CJB5ZGN,50-50-0,,222757.0,193412.0,56905.0,,77006.0,CHEMBL282575,,,ZINC000003881345
Estradiol cypionate,phase 4 complete,DB13954 (DBSALT000067),[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,"Adrenal Cortex Hormones / BCRP/ABCG2 Inhibitors / Contraceptive Agents, Female / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Estradiol Congeners / Estranes / Estrenes / Estrogen Contraceptives / Estrogens / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / Reproductive Control Agents / Steroids / Thyroxine-binding globulin inducers / UGT1A1 Substrates",7E1DV054LO,313-06-4,D04063,9403.0,9033.0,,,34745.0,CHEMBL1200973,,,ZINC000003876078
Estradiol dienanthate,phase 4 complete,DB13955 (DBSALT002570),CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(OC(=O)CCCCCC)=CC=C4[C@H]3CC[C@]12C,"BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Estradiol Congeners / Estranes / Estrenes / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / Steroids / UGT1A1 Substrates",65C72P1860,7732-97-0,,,145199.0,,,,,,,ZINC000031476880
Estradiol valerate,phase 4 complete,DB13956 (DBSALT000068),[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,"Adrenal Cortex Hormones / BCRP/ABCG2 Inhibitors / Contraceptive Agents, Female / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Estradiol Congeners / Estradiol, agonists / Estranes / Estrenes / Estrogen Contraceptives / Estrogens / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormonal Contraceptives for Systemic Use / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / OCT2 Inhibitors / P-glycoprotein substrates / Steroids / Thyroxine-binding globulin inducers / UGT1A1 Substrates",OKG364O896,979-32-8,,13791.0,13194.0,,,31561.0,CHEMBL1511,,,ZINC000003881556
Medium-chain triglycerides,phase 4 complete,DB13959,,,C9H2L21V7U,438544-49-1,,,,,1310578.0,,,,,
Bronopol,phase 4 complete,DB13960,OCC(Br)(CO)[N+]([O-])=O,"Alcohols / Anti-Infective Agents / Anti-Infective Agents, Local / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Glycols / Increased Histamine Release / Indicators and Reagents / Laboratory Chemicals / Preservatives, Pharmaceutical / Standardized Chemical Allergen",6PU1E16C9W,52-51-7,D01577,,2356.0,50248122.0,1114345.0,31306.0,CHEMBL1408862,,,ZINC000001088216
Calcium saccharate,phase 4 complete,DB13962,[Ca++].[H][C@](O)(C([O-])=O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)C([O-])=O,Replacement Preparations,SST07NLK7J,5793-88-4,,,136477.0,,1907.0,,CHEMBL2104217,,,
Isopropyl myristate,phase 4 complete,DB13966,CCCCCCCCCCCCCC(=O)OC(C)C,Fatty Acids / Lipids / Myristic Acids / Scabicides and Pediculicides,0RE8K4LNJS,110-27-0,,,7751.0,,27985.0,90027.0,CHEMBL207602,,,ZINC000008214588
Patent Blue,phase 4 complete,DB13967,CCN(CC)C1=CC=C(C=C1)C(=C1C=CC(C=C1)=[N+](CC)CC)C1=C(C=C(C(O)=C1)S(O)(=O)=O)S(O)(=O)=O,"Amines / Aniline Compounds / Coloring Agents / Compounds used in a research, industrial, or household setting / Drugs that are Mainly Renally Excreted / Other Diagnostics",D4RJJ6R97N,25305-77-5,,,69520.0,,32950.0,59601.0,,,,ZINC000004365621
Dioctyldimonium,phase 4 complete,DB13970,CCCCCCCC[N+](C)(C)CCCCCCCC,Amines / Ammonium Compounds / Nitrogen Compounds / Onium Compounds,3535D7RPGW,20256-55-7,,,56344.0,,,,CHEMBL2366023,,,ZINC000038141918
Vanadium,phase 4 complete,DB13971,[V],"Diet, Food, and Nutrition / Elements / Food / Food and Beverages / Growth Substances / Metals / Metals, Heavy / Micronutrients / Physiological Phenomena / Trace Elements / Transition Elements",00J9J9XKDE,7440-62-2,,,22426.0,,11121.0,27698.0,,,,
Racemethionine,phase 4 complete,DB13972,CSCCC(N)C(O)=O,"Amino Acids / Amino Acids, Essential / Amino Acids, Neutral / Amino Acids, Peptides, and Proteins / Amino Acids, Sulfur / Sulfur Compounds",73JWT2K6T3,59-51-8,D04983,,853.0,86195.0,9100.0,16811.0,CHEMBL274119,,,
Potassium carbonate,phase 4 complete,DB13977,[K+].[K+].[O-]C([O-])=O,"Acids / Acids, Noncarboxylic / Alkalies / Anions / Carbon Compounds, Inorganic / Carbonic Acid / Electrolytes / Elements / Ions / Metals / Metals, Alkali / Metals, Light / Potassium Salt",BQN1B9B9HA,584-08-7,D02038,,10949.0,,34300.0,131526.0,CHEMBL2105894,,,
Copper Cu-64,phase 4 complete,DB13980,,,2MK2L64N0S,13981-25-4,,,,,2200143.0,,,,,
Lutetium Lu-177,phase 4 complete,DB13982,[177Lu],"Elements / Isotopes / Lanthanoid Series Elements / Metals / Metals, Rare Earth / Transition Elements",BRH40Y9V1Q,14265-75-9,,,141480.0,,,,,,,
Lutetium Lu 177 dotatate,phase 4 complete,DB13985,[177Lu+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,"Amino Acids, Peptides, and Proteins / Lutetium / Organometallic Compounds / Peptides / Peptides, Cyclic",AE221IM3BB,437608-50-9,,,32699095.0,,1999335.0,,,,,
Strontium chloride,phase 4 complete,DB13987,[Cl-].[Cl-].[Sr++],"Drugs that are Mainly Renally Excreted / Elements / Metals / Metals, Alkaline Earth / Metals, Heavy / Strontium Radioisotopes",EKE8PS9J6Z,10476-85-4,,,55440.0,,37175.0,,CHEMBL2219640,,,
Ferric pyrophosphate citrate,phase 4 complete,DB13995 (DBSALT001314),[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O.OP([O-])(=O)OP([O-])([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,Enzymes / Enzymes and Coenzymes / Hydrolases / Parenteral Iron Replacement / Peptide Hydrolases / Phosphate Binder / Phosphate salts,UBY79OCO9G,1802359-96-1,,,34994433.0,,,,CHEMBL3833317,,,
Magnesium acetate,phase 4 complete,DB13996 (DBSALT001426),[Mg++].CC([O-])=O.CC([O-])=O,Agents that produce neuromuscular block (indirect) / Calculi Dissolution Agent / Laxatives / Osmotic Laxatives,0E95JZY48K,142-72-3,,,8556.0,,,62964.0,CHEMBL1200691,,,
Baloxavir marboxil,phase 4 complete,DB13997,[H][C@@]12COCCN1C(=O)C1=C(OCOC(=O)OC)C(=O)C=CN1N2[C@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C12,Anti-Infective Agents / Antiviral Agents / Antivirals for Systemic Use / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Direct Acting Antivirals / Enzyme Inhibitors / Sulfur Compounds / UGT1A3 substrates,505CXM6OHG,1985606-14-1,D11021,,59718643.0,,2099995.0,,CHEMBL4297503,,,
alpha-Tocopherol succinate,phase 4 complete,DB14001 (DBSALT001494),[H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@]1(C)CCC2=C(C)C(OC(=O)CCC(O)=O)=C(C)C(C)=C2O1,"Antioxidants / Benzopyrans / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Heterocyclic Compounds, Fused-Ring / Micronutrients / Physiological Phenomena / Protective Agents / Pyrans / Tocopherols / Vitamin E / Vitamins / Vitamins (Fat Soluble)",LU4B53JYVE,4345-03-3,,,19171.0,,,135821.0,CHEMBL81421,,,ZINC000004214779
D-alpha-Tocopherol acetate,phase 4 complete,DB14002 (DBSALT001457),CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(C)C(OC(C)=O)=C(C)C(C)=C2O1,"Compounds used in a research, industrial, or household setting / Tocopherols / Vitamin E / Vitamins / Vitamins (Fat Soluble)",A7E6112E4N,58-95-7,D01735,,77987.0,,1441649.0,32321.0,CHEMBL1047,,,ZINC000004172337
alpha-Tocopherol acetate,phase 4 complete,DB14003,,"Antioxidants / Benzopyrans / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Heterocyclic Compounds, Fused-Ring / Micronutrients / P-glycoprotein substrates / Physiological Phenomena / Protective Agents / Pyrans / Tocopherols / Vitamin E / Vitamins / Vitamins (Fat Soluble)",9E8X80D2L0,7695-91-2,,,,,39625.0,,,,,
Dimethicone 410,phase 4 complete,DB14005 (DBSALT001568),,,TYU5GP6XGE,9006-65-9,,,,,,,,,,
Choline salicylate,phase 4 complete,DB14006 (DBSALT001576),C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O,"Acids, Carbocyclic / Alcohols / Amines / Amino Alcohols / Ammonium Compounds / Analgesics / Benzene Derivatives / Benzoates / Drugs that are Mainly Renally Excreted / Ethanolamines / Hydroxy Acids / Hydroxybenzoates / Nervous System / Nitrogen Compounds / OCT1 inhibitors / OCT1 substrates / OCT2 Inhibitors / OCT2 Substrates / Onium Compounds / Pharmaceutical Preparations / Phenols / Quaternary Ammonium Compounds / Salicylates / Salicylic Acid and Derivatives / Trimethyl Ammonium Compounds",KD510K1IQW,2016-36-6,D00810,,15385.0,,,3668.0,CHEMBL2104095,,,
Sodium bisulfite,phase 4 complete,DB14015,[Na+].OS([O-])=O,"Anions / Anti-Infective Agents / Anti-Infective Agents, Local / Antioxidants / Compounds used in a research, industrial, or household setting / Electrolytes / Ions / Mutagens / Noxae / Protective Agents / Sulfur Compounds / Toxic Actions",TZX5469Z6I,7631-90-5,,,571016.0,,36679.0,26709.0,CHEMBL1689285,,,
Bromotheophylline,phase 4 complete,DB14018,CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O,"Alcohols / Alkaloids / Amines / Amino Alcohols / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 Substrates / Diuretics / Drugs for Obstructive Airway Diseases / Heterocyclic Compounds, Fused-Ring / Pharmaceutical Preparations / Propanols / Purines / Purinones / Xanthine derivatives",FZG87K1MQ6,10381-75-6,,,11315.0,50045345.0,1546386.0,,CHEMBL316160,,,ZINC000100005670
Fosnetupitant,phase 4 complete,DB14019,CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CC[N+](C)(COP(O)([O-])=O)CC1,Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (moderate) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Netupitant and prodrug / Substance P/Neurokinin-1 Receptor Antagonist,T672P80L2S,1703748-89-3,,,44208829.0,,2044417.0,,CHEMBL3989917,,,
Benzoin,phase 4 complete,DB14020,OC(C(=O)C1=CC=CC=C1)C1=CC=CC=C1,Acetophenones / Ketones,L7J6A1NE81,119-53-9,,,8093.0,22728.0,,17682.0,CHEMBL190677,,,
Acetyl sulfisoxazole,phase 4 complete,DB14033 (DBSALT000856),CC(=O)N(C1=C(C)C(C)=NO1)S(=O)(=O)C1=CC=C(N)C=C1,Amides / Amines / Aniline Compounds / Anti-Bacterial Agents / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 Enzyme Inhibitors / Genito Urinary System and Sex Hormones / Gynecological Antiinfectives and Antiseptics / Sulfanilamides / Sulfonamide Antibacterial / Sulfonamides / Sulfones / Sulfur Compounds,WBT5QH3KED,80-74-0,,6662.0,6410.0,,,135975.0,CHEMBL1200910,,,ZINC000000002114
Dichlorobenzene,phase 4 complete,DB14046,,Benzene Derivatives / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 Substrates,F56X88UAJQ,25321-22-6,,,,,89548.0,,,,,
Sodium zirconium cyclosilicate,phase 4 complete,DB14048,[Na+].[Na+].[Zr].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1,"Acids / Acids, Noncarboxylic / Anions / Drugs for Treatment of Hyperkalemia and Hyperphosphatemia / Electrolytes / Gastric Acid Lowering Agents / Ions / Minerals / Oxides / Oxygen Compounds / Potassium Binder / Potassium-removing Agents / Silicon Compounds",D652ZWF066,17141-74-1,D10727,,,,2047628.0,,,,,
Imidurea,phase 4 complete,DB14075,OCN1C(NC(=O)NCNC(=O)NC2N(CO)C(=O)NC2=O)C(=O)NC1=O,"Cell-mediated Immunity / Increased Histamine Release / Pharmaceutic Aids / Preservatives, Pharmaceutical / Standardized Chemical Allergen",M629807ATL,39236-46-9,,,35067.0,66981.0,1368885.0,51805.0,CHEMBL65433,,,
Medronic acid,phase 4 complete,DB14078,OP(O)(=O)CP(O)(O)=O,,73OS0QIN3O,1984-15-2,D04887,,15308.0,50162816.0,1314368.0,43945.0,CHEMBL180570,,,ZINC000008015016
Betiatide,phase 4 complete,DB14082,OC(=O)CNC(=O)CNC(=O)CNC(=O)CSC(=O)C1=CC=CC=C1,,9NV2SR34P8,103725-47-9,,,161231.0,,194098.0,136015.0,CHEMBL3183117,,,ZINC000006095847
Bisphenol A diglycidyl ether,phase 4 complete,DB14083,CC(C)(C1=CC=C(OCC2CO2)C=C1)C1=CC=C(OCC2CO2)C=C1,"Benzene Derivatives / Carcinogens / Cell-mediated Immunity / Ethers / Ethers, Cyclic / Increased Histamine Release / Noxae / Standardized Chemical Allergen / Toxic Actions",F3XRM1NX4H,1675-54-3,,,2199.0,50241439.0,1368138.0,34578.0,CHEMBL258558,,,
Butylparaben,phase 4 complete,DB14084,CCCCOC(=O)C1=CC=C(O)C=C1,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Cell-mediated Immunity / Hydroxy Acids / Hydroxybenzoates / Increased Histamine Release / Phenols / Standardized Chemical Allergen",3QPI1U3FV8,94-26-8,D01420,,6916.0,23448.0,1306937.0,88542.0,CHEMBL459008,,,ZINC000001586769
Cianidanol,phase 4 complete,DB14086,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C(O)=C1,"Benzopyrans / Catechin / Chromans / Chromones / Flavonoids / Heterocyclic Compounds, Fused-Ring / Pyrans",8R1V1STN48,154-23-4,,,8711.0,60836.0,1367177.0,15600.0,CHEMBL311498,,,ZINC000000119983
Dimercaptosuccinic acid,phase 4 complete,DB14089,OC(=O)C(S)C(S)C(O)=O,"Chelating Agents / Compounds used in a research, industrial, or household setting / Metal Chelator",4S9JU7XF01,2418-14-6,,,8988.0,60868.0,,,CHEMBL28721,,PA451521,
"1,2-icosapentoyl-sn-glycero-3-phosphoserine",phase 4 complete,DB14096,[H]C(N)(COP(O)(=O)OCC([H])(COC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(=O)CCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(O)=O,,C3019D8IIA,,,,32699258.0,,1549117.0,,,,,
"1,2-Distearoyllecithin",phase 4 complete,DB14099,CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,Alcohols / Carbohydrates / Glycerophosphates / Glycerophospholipids / Lipids / Membrane Lipids / Phosphatidic Acids / Phospholipids / Sugar Alcohols / Sugar Phosphates / Triose Sugar Alcohols,EAG959U971,4539-70-2,,,58655.0,,1426932.0,,CHEMBL113644,,,
Soy isoflavones,phase 4 complete,DB14101,,,71B37NR06D,,,,,,,,,,,
Linoleic acid,phase 4 complete,DB14104,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O,"Fatty Acids / Fatty Acids, Essential / Fatty Acids, Omega-6 / Fatty Acids, Unsaturated / Linoleic Acids / Lipids",9KJL21T0QJ,60-33-3,,,4444105.0,22231.0,6400.0,17351.0,CHEMBL267476,,,ZINC000004474613
"Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)",phase 4 complete,DB14105,[Na+].[H][C@@](COC(=O)CCCCCCCCCCCCCCC)(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC,,841B886EJ7,200880-41-7,,,29763754.0,,1599275.0,,,,,
Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborateCommonly known or available as Cardio-spect,phase 4 complete,DB14106,[Cu+].F[B-](F)(F)F.COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-],,N6OU7HJ70P,103694-84-4,,,58827688.0,,1306061.0,,,,,
alpha-Arbutin,phase 4 complete,DB14109,OC[C@H]1O[C@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O,,72VUP07IT5,84380-01-8,,,139552.0,,1363429.0,29710.0,CHEMBL226495,,,ZINC000004102324
Butylene glycol,phase 4 complete,DB14110,CC(O)CCO,Alcohols / Glycols,3XUS85K0RA,107-88-0,,,13837670.0,,1310542.0,52683.0,CHEMBL3186475,,,
Silodrate,phase 4 complete,DB14116,O.[O--].[O--].[Mg++].[Mg++].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O,,9T3UU8T0QK,12408-47-8,,,32699010.0,,236730.0,,,,,
Phenylethyl resorcinol,phase 4 complete,DB14120,CC(C1=CC=CC=C1)C1=CC=C(O)C=C1O,Benzene Derivatives / Phenols,G37UFG162O,85-27-8,,,9346995.0,240731.0,1313724.0,,CHEMBL3961037,,,
Racementhol,phase 4 complete,DB14123,,,YS08XHA860,89-78-1,,,,,1430390.0,,,,,
Hydroxyethyl ethylcellulose,phase 4 complete,DB14139,,"Biopolymers / Carbohydrates / Compounds used in a research, industrial, or household setting / Glucans / Macromolecular Substances / Polymers / Polysaccharides",ZDN57Z154K,9004-58-4,,,,,1722035.0,,,,,
p-Phenylenediamine,phase 4 complete,DB14141,NC1=CC=C(N)C=C1,"Amines / Aniline Compounds / Antigens / Antigens, Bacterial / Azo Compounds / Biological Factors / Cell-mediated Immunity / Coloring Agents / Compounds used in a research, industrial, or household setting / Diamines / Increased Histamine Release / Indicators and Reagents / Laboratory Chemicals / Polyamines / Standardized Chemical Allergen / Tuberculin",U770QIT64J,106-50-3,,,13835179.0,,1362740.0,51403.0,CHEMBL403741,,,ZINC000008294962
Distearyldimonium,phase 4 complete,DB14143,CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC,"Adjuvants, Immunologic / Amines / Ammonium Compounds / Anti-Infective Agents / Compounds used in a research, industrial, or household setting / Immunologic Factors / Nitrogen Compounds / Onium Compounds / Surface-Active Agents",251IW5I21C,14357-21-2,,,7592.0,,1311550.0,,,,,ZINC000059993772
Chloric acid,phase 4 complete,DB14150,[H]O[Cl](=O)=O,"Agrochemicals / Anions / Chlorine Compounds / Compounds used in a research, industrial, or household setting / Electrolytes / Herbicides / Ions / Pesticides / Toxic Actions",Z0V9L75H3K,7790-93-4,,,18513.0,,1546391.0,17322.0,CHEMBL1161633,,,
Phosphorus,phase 4 complete,DB14151,[P],Elements / Phosphorus,27YLU75U4W,7723-14-0,,,4575369.0,,8263.0,30207.0,,,,
Synthetic camphor,phase 4 complete,DB14156,CC1(C)C2CCC1(C)C(=O)C2,,5TJD82A1ET,76-22-2,,,2441.0,,1371994.0,36773.0,CHEMBL15768,,,
Microcrystalline cellulose,phase 4 complete,DB14158,,"Biopolymers / Carbohydrates / Cellulose / Compounds used in a research, industrial, or household setting / Drug Delivery Systems / Excipients / Glucans / Macromolecular Substances / Pharmaceutic Aids / Pharmaceutical Preparations / Pharmaceutical Vehicles / Polymers / Polysaccharides",SMD1X3XO9M,9004-34-6,,,,,2221.0,,,,,
Oxidronic acid,phase 4 complete,DB14159,OC(P(O)(O)=O)P(O)(O)=O,Organophosphonates / Organophosphorus Compounds,71MR4V32TI,15468-10-7,,,25412.0,,1546448.0,134844.0,CHEMBL1615775,,,ZINC000024740492
Diazolidinylurea,phase 4 complete,DB14173,OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O,Cell-mediated Immunity / Increased Histamine Release / Standardized Chemical Allergen,H5RIZ3MPW4,78491-02-8,,,56078.0,,1310602.0,136014.0,CHEMBL3187032,,,
Dipentamethylenethiuram disulfide,phase 4 complete,DB14174,S=C(SSC(=S)N1CCCCC1)N1CCCCC1,Cell-mediated Immunity / Increased Histamine Release / Standardized Chemical Allergen,CR113982E5,94-37-1,,,6920.0,50414948.0,1426773.0,,CHEMBL121516,,,ZINC000001606736
alpha-Amyl cinnamaldehyde,phase 4 complete,DB14175,CCCCC\C(C=O)=C\C1=CC=CC=C1,Cell-mediated Immunity / Increased Histamine Release / Perfume / Standardized Chemical Allergen,06T2G22P2C,122-40-7,,,1361549.0,,1311606.0,32318.0,CHEMBL1611291,,,ZINC000001874357
Benzylparaben,phase 4 complete,DB14176,OC1=CC=C(C=C1)C(=O)OCC1=CC=CC=C1,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Cell-mediated Immunity / Hydroxy Acids / Hydroxybenzoates / Increased Histamine Release / Phenols / Standardized Chemical Allergen",8Y41DYV4VG,94-18-8,D07518,,6912.0,,19075.0,34571.0,CHEMBL447861,,,ZINC000000388756
Propylparaben,phase 4 complete,DB14177,CCCOC(=O)C1=CC=C(O)C=C1,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Hydroxy Acids / Hydroxybenzoates / Increased Histamine Release / Pharmaceutic Aids / Pharmaceutical Preparations / Phenols / Preservatives, Pharmaceutical / Standardized Chemical Allergen",Z8IX2SC1OH,94-13-3,D01422,,6907.0,70190.0,34706.0,32063.0,CHEMBL194014,,,ZINC000001586788
Tetramethylthiuram monosulfide,phase 4 complete,DB14178,CN(C)C(=S)SC(=S)N(C)C,"Acids, Acyclic / Carbamates / Cell-mediated Immunity / Dimethyldithiocarbamate / Increased Histamine Release / Standardized Chemical Allergen / Sulfur Compounds / Thiocarbamates",01W430XXSQ,97-74-5,,,7070.0,50414949.0,1363713.0,,CHEMBL571700,,,ZINC000001666745
Nickel sulfate,phase 4 complete,DB14180,[Ni++].[O-]S([O-])(=O)=O,"Compounds used in a research, industrial, or household setting / Elements / Irritants / Metals / Metals, Heavy / Noxae / Toxic Actions / Transition Elements",4FLT4T3WUN,7786-81-4,,,22989.0,,31738.0,53001.0,CHEMBL3990696,,,
Lanolin alcohols,phase 4 complete,DB14181,,Cell-mediated Immunity / Increased Histamine Release / Standardized Chemical Allergen,884C3FA9HE,8027-33-6,,,,,1426478.0,,,,,
Dichromate,phase 4 complete,DB14182,[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O,"Anions / Caustics / Chromates / Chromium Compounds / Coloring Agents / Compounds used in a research, industrial, or household setting / Electrolytes / Ions / Noxae / Toxic Actions",9LKY4BFN2V,13907-47-6,,,22911.0,,1313336.0,33141.0,,,,
Geraniol,phase 4 complete,DB14183,CC(C)=CCC\C(C)=C\CO,Cell-mediated Immunity / Increased Histamine Release / Standardized Chemical Allergen,L837108USY,106-24-1,,,13849989.0,50037023.0,1368875.0,17447.0,CHEMBL25719,,,ZINC000001529210
Cinnamaldehyde,phase 4 complete,DB14184,O=C\C=C\C1=CC=CC=C1,"Aldehydes / Antimutagenic Agents / Antineoplastic Agents / Antineoplastic Agents, Phytogenic / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Drugs that are Mainly Renally Excreted / Flavoring Agents / Food / Food Additives / Food and Beverages / Food Ingredients / Increased Histamine Release / Pharmaceutic Aids / Pharmaceutical Preparations / Physiological Phenomena / Protective Agents / Standardized Chemical Allergen",SR60A3XG0F,14371-10-9,,,553117.0,50203065.0,1368153.0,16731.0,CHEMBL293492,,,ZINC000001532777
Aripiprazole lauroxil,phase 4 complete,DB14185 (DBSALT001351),CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12,"Adrenergic alpha-1 Receptor Antagonists / Adrenergic alpha-Antagonists / Adrenergic Antagonists / Agents that produce hypertension / Antidepressive Agents / Antipsychotic Agents / Aripiprazole and prodrugs / Central Nervous System Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Histamine Antagonists / Histamine H1 Antagonists / Neurotoxic agents / Piperazines / Potential QTc-Prolonging Agents / Psychotropic Drugs / QTc Prolonging Agents / Quinolines / Quinolones / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin 5-HT2 Receptor Antagonists / Serotonin 5-HT2A Receptor Antagonists / Serotonin Agents / Serotonin Receptor Antagonists / Tranquilizing Agents",B786J7A343,1259305-29-7,D10364,,28651973.0,,,90930.0,CHEMBL2219425,,PA166161216,ZINC000095564895
Cinnamyl alcohol,phase 4 complete,DB14186,OC\C=C\C1=CC=CC=C1,Alcohols / Cell-mediated Immunity / Drugs that are Mainly Renally Excreted / Increased Histamine Release / Standardized Chemical Allergen,SS8YOP444F,4407-36-7,,,21105870.0,50310446.0,1362889.0,33227.0,CHEMBL324794,,,ZINC000001529427
Hydroxycitronellal,phase 4 complete,DB14187,[H]C(=O)CC(C)CCCC(C)(C)O,Cell-mediated Immunity / Increased Histamine Release / Perfume / Standardized Chemical Allergen,8SQ0VA4YUR,107-75-5,,,7600.0,,1362893.0,53459.0,CHEMBL3186027,,,
Isoeugenol,phase 4 complete,DB14188,COC1=CC(C=CC)=CC=C1O,"Acids, Carbocyclic / Caffeic Acids / Cell-mediated Immunity / Cinnamates / Increased Histamine Release / Standardized Chemical Allergen",5M0MWY797U,97-54-1,,,7061.0,,1363706.0,18224.0,CHEMBL2135887,,,
Ethylenediamine,phase 4 complete,DB14189,NCCN,"Allergens / Amines / Cell-mediated Immunity / Dermatitis, Contact / Diamines / Increased Histamine Release / Polyamines / Standardized Chemical Allergen",60V9STC53F,107-15-3,D01114,,13835550.0,7972.0,4158.0,30347.0,CHEMBL816,,,ZINC000037253587
P-Tert-Butylphenol-Formaldehyde Resin (Low Molecular Weight),phase 4 complete,DB14190,,Cell-mediated Immunity / Increased Histamine Release / Standardized Chemical Allergen,Q51LPW21CH,,,,,,1427189.0,,,,,
Diphenylguanidine,phase 4 complete,DB14191,N=C(NC1=CC=CC=C1)NC1=CC=CC=C1,Amidines / Cell-mediated Immunity / Increased Histamine Release / Standardized Chemical Allergen,6MRZ85RNHQ,102-06-7,,,7313.0,50010769.0,1368170.0,144319.0,CHEMBL77675,,,ZINC000018208503
"N,N'-diphenyl-1,4-phenylenediamine",phase 4 complete,DB14192,,"Amines / Aniline Compounds / Antioxidants / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Diamines / Increased Histamine Release / Polyamines / Protective Agents / Standardized Chemical Allergen",DD517SCM92,74-31-7,,,,,1363709.0,,,,,
Ditiocarb zinc,phase 4 complete,DB14193,[Zn++].CCN(CC)C([S-])=S.CCN(CC)C([S-])=S,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Allergens / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Increased Histamine Release / Metal cations / Metal divalent cations / Standardized Chemical Allergen / Vasoprotectives / Zinc Compounds",ICW4708Z8G,14324-55-1,,,24810.0,,1427192.0,144351.0,CHEMBL3182813,,,
Zinc dibutyldithiocarbamate,phase 4 complete,DB14194,[Zn++].CCCCN(CCCC)C([S-])=S.CCCCN(CCCC)C([S-])=S,"Acids, Acyclic / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Carbamates / Cell-mediated Immunity / Increased Histamine Release / Metal cations / Metal divalent cations / Standardized Chemical Allergen / Sulfur Compounds / Vasoprotectives / Zinc Compounds",HNM5J934VP,136-23-2,,,8360.0,,1426942.0,144323.0,CHEMBL2373108,,,
4-(Isopropylamino)diphenylamine,phase 4 complete,DB14195,CC(C)NC1=CC=C(NC2=CC=CC=C2)C=C1,"Amines / Aniline Compounds / Antioxidants / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Diamines / Increased Histamine Release / Polyamines / Protective Agents / Standardized Chemical Allergen",0M7PSL4100,101-72-4,,,7292.0,,1363710.0,63569.0,CHEMBL1449018,,,ZINC000000393922
"N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine",phase 4 complete,DB14196,C1CCC(CC1)NC1=CC=C(NC2=CC=CC=C2)C=C1,Amines / Aniline Compounds / Cell-mediated Immunity / Diamines / Increased Histamine Release / Polyamines / Standardized Chemical Allergen,T29JGK5V4R,101-87-1,,,83143.0,,1427136.0,,,,,ZINC000002507992
Methylchloroisothiazolinone,phase 4 complete,DB14197,CN1SC(Cl)=CC1=O,"Anti-Infective Agents / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Disinfectants / Increased Histamine Release / Preservatives, Pharmaceutical / Standardized Chemical Allergen / Sulfur Compounds",DEL7T5QRPN,26172-55-4,,,30800.0,,1367119.0,53621.0,CHEMBL1738962,,,ZINC000002002061
Quaternium-15,phase 4 complete,DB14198,[Cl-].[H]C(Cl)=C([H])C[N+]12CN3CN(CN(C3)C1)C2,"Amines / Cell-mediated Immunity / Cycloparaffins / Increased Histamine Release / Polyamines / Preservatives, Pharmaceutical / Standardized Chemical Allergen",E40U03LEM0,4080-31-3,,,23621565.0,,283678.0,59607.0,,,,
Bromothalonil,phase 4 complete,DB14199,BrCC(Br)(CCC#N)C#N,"Allergens / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Increased Histamine Release / Pharmaceutic Aids / Pharmaceutical Preparations / Preservatives, Pharmaceutical / Standardized Chemical Allergen",YX089CPS05,35691-65-7,,,55806.0,,1307044.0,62823.0,CHEMBL3188084,,,
Thiohexam,phase 4 complete,DB14200,C1CCC(CC1)NSC1=NC2=CC=CC=C2S1,"Cell-mediated Immunity / Heterocyclic Compounds, Fused-Ring / Increased Histamine Release / Standardized Chemical Allergen / Sulfur Compounds / Thiazoles",UCA53G94EV,95-33-0,,,6962.0,,1306886.0,,CHEMBL1591074,,,ZINC000001680410
"2,2'-Dibenzothiazyl disulfide",phase 4 complete,DB14201,S(SC1=NC2=CC=CC=C2S1)C1=NC2=CC=CC=C2S1,"Cell-mediated Immunity / Heterocyclic Compounds, Fused-Ring / Increased Histamine Release / Latex Hypersensitivity / Standardized Chemical Allergen / Sulfur Compounds / Thiazoles",6OK753033Z,120-78-5,,,8139.0,50444458.0,1306112.0,53239.0,CHEMBL508112,,,ZINC000001555224
Morpholinylmercaptobenzothiazole,phase 4 complete,DB14202,C1CN(CCO1)SC1=NC2=CC=CC=C2S1,"Cell-mediated Immunity / Heterocyclic Compounds, Fused-Ring / Increased Histamine Release / Oxazines / Standardized Chemical Allergen / Sulfur Compounds / Thiazoles",VCD7623F3K,102-77-2,,,7337.0,,1363711.0,,CHEMBL1530581,,,ZINC000000393947
Disperse Blue 106,phase 4 complete,DB14203,CCN(CCO)C1=CC=C(\N=N\C2=NC=C(S2)N(=O)=O)C(C)=C1,Allergens / Cell-mediated Immunity / Increased Histamine Release / Standardized Chemical Allergen,C48O4QYD6N,68516-81-4,,,97163.0,,1368171.0,,,,,ZINC000005139570
Cobalt chloride,phase 4 complete,DB14206,[Cl-].[Cl-].[Co++],"Antimutagenic Agents / Compounds used in a research, industrial, or household setting / Elements / Metals / Metals, Heavy / Protective Agents / Transition Elements",EVS87XF13W,7646-79-9,,,22708.0,,1426884.0,35696.0,,,,
Methylparaben,phase 4 complete,DB14212,COC(=O)C1=CC=C(O)C=C1,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Cell-mediated Immunity / Compounds used in a research, industrial, or household setting / Hydroxy Acids / Hydroxybenzoates / Increased Histamine Release / Pharmaceutic Aids / Pharmaceutical Preparations / Phenols / Preservatives, Pharmaceutical / Standardized Chemical Allergen",A2I8C7HI9T,99-76-3,D01400,,7176.0,50209100.0,29903.0,31835.0,CHEMBL325372,,,ZINC000000001712
DL-alpha-Tocopherol,phase 4 complete,DB14476,CC(C)CCCC(C)CCCC(C)CCCC1(C)CCC2=C(C)C(O)=C(C)C(C)=C2O1,Vitamin E / Vitamins / Vitamins (Fat Soluble),7QWA1RIO01,10191-41-0,,,2032.0,50436220.0,220893.0,93909.0,CHEMBL49563,,,
DL-alpha tocopheryl acetate,phase 4 complete,DB14477,,,WR1WPI7EW8,52225-20-4,,,,,317841.0,,,,,
Povidone K30,phase 4 complete,DB14478 (DBSALT001581),,,U725QWY32X,9003-39-8,,,,,,,,,,
Calcium phosphate dihydrate,phase 4 complete,DB14481 (DBSALT001593),O.O.[Ca++].OP([O-])([O-])=O,"Acids / Acids, Noncarboxylic / Anions / Calcium Compounds / Electrolytes / Ions / Phosphate salts / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds",O7TSZ97GEP,7789-77-7,,,94606.0,,1310463.0,4496.0,,,,
Sodium ascorbate,phase 4 complete,DB14482 (DBSALT001764),[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,"Compounds used in a research, industrial, or household setting / Laxatives / Osmotic Laxatives / Urinary Acidifying Agents / Vitamin C and analogues / Vitamins",S033EH8359,134-03-2,D05853,,16736174.0,,,113451.0,CHEMBL591665,,PA166163262,
Calcium ascorbate,phase 4 complete,DB14483 (DBSALT002425),[Ca++].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-],"Acids, Acyclic / Antioxidants / Carbohydrates / Compounds used in a research, industrial, or household setting / Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Hydroxy Acids / Micronutrients / Physiological Phenomena / Protective Agents / Sugar Acids / Urinary Acidifying Agents / Vitamin C and analogues / Vitamins",J96U0ZD4Y6,5743-27-1,,,22900989.0,,,,CHEMBL2146095,,,
Magnesium ascorbate,phase 4 complete,DB14484 (DBSALT002423),[Mg++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,"Compounds used in a research, industrial, or household setting / Urinary Acidifying Agents",0N1G678593,15431-40-0,,,17339241.0,,,,,,,
Zinc ascorbate,phase 4 complete,DB14485 (DBSALT002424),[Zn++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Metal cations / Metal divalent cations / Polyvalent cation containing laxatives, antacids, oral supplements / Urinary Acidifying Agents / Vasoprotectives / Vitamin C and analogues / Vitamins / Zinc Compounds",9TI35313XW,331242-75-2,,,34988958.0,,,,,,,
Niacinamide ascorbate,phase 4 complete,DB14486 (DBSALT002426),NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O,Urinary Acidifying Agents / Vitamin C and analogues / Vitamins,JTL8B7TVW7,1987-71-9,,,18895044.0,,,,,,,
Zinc acetate,phase 4 complete,DB14487 (DBSALT001308),[Zn++].CC([O-])=O.CC([O-])=O,"Acetates / Acids, Acyclic / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Alimentary Tract and Metabolism / Copper Absorption Inhibitor / Fatty Acids / Fatty Acids, Volatile / Lipids / Metal cations / Metal divalent cations / Various Alimentary Tract and Metabolism Products / Vasoprotectives / Zinc Compounds",H2ZEY72PME,557-34-6,,,10719.0,,1299637.0,62984.0,CHEMBL1200928,,,
Ferrous gluconate,phase 4 complete,DB14488 (DBSALT000080),[Fe++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,"Anemia, Iron-Deficiency / Antianemia Drugs / Antianemic Preparations / Blood and Blood Forming Organs / Hematinics / Hematologic Agents / Iron Bivalent, Oral Preparations / Iron Compounds / Iron Preparations / Minerals / Organometallic Compounds / Polyvalent cation containing laxatives, antacids, oral supplements",781E2AXH0K,299-29-6,,9291.0,19953133.0,,,,,,,
Ferrous succinate,phase 4 complete,DB14489 (DBSALT000083),[Fe++].[O-]C(=O)CCC([O-])=O,"Antianemic Preparations / Blood and Blood Forming Organs / Hematinics / Hematologic Agents / Iron Bivalent, Oral Preparations / Iron Compounds / Iron Preparations / Organometallic Compounds",818ZYK7N91,10030-90-7,,159252.0,8640173.0,,,,,,,
Ferrous ascorbate,phase 4 complete,DB14490 (DBSALT000075),[Fe++].[H][C@](O)(CO)[C@@]1([H])OC(=O)C(O)=C1O.[H][C@](O)(CO)[C@@]1([H])OC(=O)C([O-])=C1[O-],"Antianemic Preparations / Blood and Blood Forming Organs / Compounds used in a research, industrial, or household setting / Iron Bivalent, Oral Preparations / Iron Preparations / Polyvalent cation containing laxatives, antacids, oral supplements / Urinary Acidifying Agents",DI3477D0PI,24808-52-4,,54710214.0,21169558.0,,,,,,,
Ferrous fumarate,phase 4 complete,DB14491 (DBSALT000079),[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O,"Antianemic Preparations / Blood and Blood Forming Organs / Diet, Food, and Nutrition / Food / Food and Beverages / Growth Substances / Iron Bivalent, Oral Preparations / Iron Compounds / Iron Preparations / Micronutrients / Minerals / Organometallic Compounds / Physiological Phenomena / Trace Elements",R5L488RY0Q,141-01-5,,6433164.0,10607713.0,,,31607.0,CHEMBL1200640,,,
Sodium molybdate,phase 4 complete,DB14496,[Na+].[Na+].[O-][Mo]([O-])(=O)=O,"Elements / Metals / Metals, Heavy / Transition Elements",948QAQ08I1,7631-95-0,,,55350.0,,36699.0,75215.0,,,,
Potassium acetate,phase 4 complete,DB14498 (DBSALT001427),[K+].CC([O-])=O,"Acetates / Acids, Acyclic / Agents causing hyperkalemia / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Drugs that are Mainly Renally Excreted / Electrolyte Solutions / Fatty Acids / Fatty Acids, Volatile / I.V. Solution Additives / Lipids / Potassium Compounds / Potassium Salt / Replacement Preparations",M911911U02,127-08-2,,,29104.0,,,32029.0,CHEMBL1201058,,,
Potassium sulfate,phase 4 complete,DB14499 (DBSALT001465),[K+].[K+].[O-]S([O-])(=O)=O,"Acids / Acids, Noncarboxylic / Anions / Drugs that are Mainly Renally Excreted / Electrolytes / Ions / Laxatives / Osmotic Laxatives / Potassium Salt / Sulfur Acids / Sulfur Compounds / Sulfuric Acids",1K573LC5TV,7778-80-5,,,22915.0,,,32036.0,CHEMBL2021424,,,
Potassium,phase 4 complete,DB14500,[KH],"Agents causing hyperkalemia / Diuretics / Elements / High-Ceiling Diuretics / Low-Ceiling Diuretics, Excl. Thiazides / Metals / Metals, Alkali / Metals, Light / Minerals / Potassium Salt / Replacement Preparations",RWP5GA015D,7440-09-7,,,16787786.0,,8588.0,32589.0,,,,
Ferrous glycine sulfate,phase 4 complete,DB14501 (DBSALT000081),[Fe++].NCC([O-])=O.NCC([O-])=O.OS(O)(=O)=O,"Antianemic Preparations / Blood and Blood Forming Organs / Iron Bivalent, Oral Preparations / Iron Preparations",56PS9HY5XI,14729-84-1,,167159.0,146251.0,,,,CHEMBL3707208,,,
"Sodium phosphate, dibasic",phase 4 complete,DB14502 (DBSALT001976),[Na+].[Na+].OP([O-])([O-])=O,"Acids / Acids, Noncarboxylic / Anions / Electrolytes / Ions / Laxatives / Osmotic Laxatives / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds / Urinary Acidifying Agents",22ADO53M6F,7558-79-4,,,22625.0,,,34683.0,CHEMBL1060,,,
"Sodium phosphate, monobasic, unspecified form",phase 4 complete,DB14503 (DBSALT001972),,Laxatives / Osmotic Laxatives,3980JIH2SW,,,,,,,,,,,
"Sodium phosphate, dibasic, unspecified form",phase 4 complete,DB14504,,Laxatives / Osmotic Laxatives,GR686LBA74,10140-65-5,,,,,,,,,,
Sodium borate,phase 4 complete,DB14505 (DBSALT002513),[Na+].[Na+].[O-]B1OB2OB([O-])OB(O1)O2,"Acids / Acids, Noncarboxylic / Anions / Anti-Infective Agents / Boric Acids / Boron Compounds / Electrolytes / Ions / Ophthalmologicals / Sensory Organs",8191EN8ZMD,1330-43-4,,,8395345.0,,,,,,,
Lithium hydroxide,phase 4 complete,DB14506,[Li+].[OH-],Drugs that are Mainly Renally Excreted / Lithium Compounds,903YL31JAS,1310-65-2,,,3802.0,,1546375.0,33979.0,,,,
Lithium citrate,phase 4 complete,DB14507 (DBSALT001430),[Li+].[Li+].[Li+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,"Acids, Acyclic / Antidepressive Agents / Antimanic Agents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Lithium Compounds / Mood Stabilizer / Nephrotoxic agents / Neurotoxic agents / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / Tricarboxylic Acids",3655633623,919-16-4,,,12932.0,,,64735.0,CHEMBL1201170,,,
Lithium carbonate,phase 4 complete,DB14509 (DBSALT001075),[Li+].[Li+].[O-]C([O-])=O,"Acids / Acids, Noncarboxylic / Alkalies / Anions / Antidepressive Agents / Antimanic Agents / Carbon Compounds, Inorganic / Carbonates / Carbonic Acid / Central Nervous System Agents / Central Nervous System Depressants / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index / Electrolytes / Enzyme Inhibitors / Ions / Lithium Compounds / Mood Stabilizer / Narrow Therapeutic Index Drugs / Nephrotoxic agents / Nervous System / Neurotoxic agents / Psycholeptics / Psychotropic Drugs / QTc Prolonging Agents / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin Agents / Serotonin Modulators / Tranquilizing Agents",2BMD2GNA4V,554-13-2,,,10654.0,,,6504.0,CHEMBL1200826,,,
Mometasone furoate,phase 4 complete,DB14512 (DBSALT002454),[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Adrenals / Adrenergics, Inhalants / Anti-Allergic Agents / Anti-Inflammatory Agents / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors (strong) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dermatologicals / Drugs for Obstructive Airway Diseases / Fused-Ring Compounds / Glucocorticoids / Hyperglycemia-Associated Agents / Immunosuppressive Agents / Nasal Preparations / Pregnadienes / Steroids / Thyroxine-binding globulin inhibitors",04201GDN4R,83919-23-7,D00690,,390091.0,50148733.0,,47564.0,CHEMBL1161,,,ZINC000003938677
Magnesium,phase 4 complete,DB14513,[MgH2],"Calculi Dissolution Agent / Elements / Laxatives / Magnesium Compounds / Metal cations / Metal divalent cations / Metals / Metals, Alkaline Earth / Metals, Light / Minerals / Osmotic Laxatives",I38ZP9992A,7439-95-4,,,16787263.0,,6574.0,,CHEMBL2146125,,,
Aluminium phosphate,phase 4 complete,DB14517 (DBSALT002422),[Al+3].[O-]P([O-])([O-])=O,"Acids / Acids, Noncarboxylic / Adjuvants, Immunologic / Alimentary Tract and Metabolism / Aluminium Compounds / Aluminum and magnesium containing antacids / Anions / Antacids / Drugs for Acid Related Disorders / Electrolytes / Gastric Acid Lowering Agents / Gastrointestinal Agents / Immunologic Factors / Ions / Metal cations / Metal divalent cations / Phosphoric Acids / Phosphorus Acids / Phosphorus Compounds",F92V3S521O,7784-30-7,,,58204.0,,,,CHEMBL3833315,,,
Aluminum acetate,phase 4 complete,DB14518 (DBSALT001466),[Al+3].CC([O-])=O.CC([O-])=O.CC([O-])=O,"Acids, Acyclic / Fatty Acids / Fatty Acids, Volatile / Lipids",80EHD8I43D,139-12-8,,,8427.0,,,,CHEMBL1201015,,,
Tetraferric tricitrate decahydrateCommonly known or available as Ferric citrate,phase 4 complete,DB14520 (DBSALT002619),O.O.O.O.O.O.O.O.O.O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O,"Anemia, Iron-Deficiency / Drugs for Treatment of Hyperkalemia and Hyperphosphatemia / Iron Compounds / Organometallic Compounds / Phosphate Binder",Q91187K011,,,,34993203.0,,,,CHEMBL3301597,,,
Chromic nitrate,phase 4 complete,DB14527 (DBSALT002353),[Cr+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O,"Acids / Acids, Noncarboxylic / Anions / Drugs that are Mainly Renally Excreted / Electrolytes / Ions / Nitric Acid / Nitrogen Compounds",C6H0RE016B,13548-38-4,,,23000.0,,,86204.0,,,,
Chromium gluconate,phase 4 complete,DB14528 (DBSALT002356),[Cr+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,Drugs that are Mainly Renally Excreted,V236ZVR3RL,33661-40-4,,,32701256.0,,,,,,,
Chromium nicotinate,phase 4 complete,DB14529 (DBSALT001747),[Cr+3].[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1,Drugs that are Mainly Renally Excreted / Nicotinic Acids,A150AY412V,64452-96-6,,,8085563.0,,,50368.0,,,,
Chromous sulfate,phase 4 complete,DB14530 (DBSALT002355),[Cr++].[O-]S([O-])(=O)=O,Drugs that are Mainly Renally Excreted,TR64E2WM7Z,13825-86-0,,,55589.0,,,,,,,
Zinc chloride,phase 4 complete,DB14533 (DBSALT001307),[Cl-].[Cl-].[Zn++],"Acids / Acids, Noncarboxylic / Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Anions / Basic Ointments and Protectants / Blood and Blood Forming Organs / Blood Substitutes and Perfusion Solutions / Chlorine Compounds / Compounds used in a research, industrial, or household setting / Copper Absorption Inhibitor / Cosmetics / Dental Agents / EENT Drugs, Miscellaneous / Electrolyte Solutions / Electrolytes / Household Products / I.V. Solution Additives / Ions / Metal cations / Metal divalent cations / Mouthwashes / Skin Ulcer, drug therapy / Vasoprotectives / Zinc Compounds",86Q357L16B,7646-85-7,,,5525.0,,,49976.0,CHEMBL1200679,,,
Hydrocortisone acetate,phase 4 complete,DB14539 (DBSALT000369),[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"11-Hydroxycorticosteroids / 17-Hydroxycorticosteroids / Administration, Topical / Adrenal Cortex Hormones / Aerosols / Anti-Inflammatory Agents / Corticosteroids / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydrocortisone and derivatives / Hydroxycorticosteroids / Immunosuppressive Agents / Pregnanes / Pregnenediones / Pregnenes / Steroids",3X7931PO74,50-03-3,D00165,5744.0,5542.0,,,17609.0,CHEMBL1091,,,ZINC000003875333
Hydrocortisone butyrate,phase 4 complete,DB14540 (DBSALT001234),[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"11-Hydroxycorticosteroids / 17-Hydroxycorticosteroids / Administration, Topical / Adrenal Cortex Hormones / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Moderately Potent (Group II) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydrocortisone and derivatives / Hydroxycorticosteroids / Immunosuppressive Agents / Pregnanes / Pregnenediones / Pregnenes / Steroids",05RMF7YPWN,13609-67-1,D01619,,24344.0,323672.0,,31674.0,CHEMBL1683,,,ZINC000003977794
Hydrocortisone cypionate,phase 4 complete,DB14541 (DBSALT001388),[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC3CCCC3)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"11-Hydroxycorticosteroids / 17-Hydroxycorticosteroids / Adrenal Cortex Hormones / Corticosteroids / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydrocortisone and derivatives / Hydroxycorticosteroids / Pregnanes / Pregnenediones / Pregnenes / Steroids",4XDY25L70B,508-99-6,D00976,,193884.0,50371265.0,,5783.0,CHEMBL1549,,,ZINC000004097470
Hydrocortisone phosphate,phase 4 complete,DB14542 (DBSALT002214),[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"11-Hydroxycorticosteroids / 17-Hydroxycorticosteroids / Adrenal Cortex Hormones / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydrocortisone and derivatives / Hydroxycorticosteroids / Pregnanes / Pregnenediones / Pregnenes / Steroids",2Y87E22X71,3863-59-0,,,390143.0,,,68634.0,CHEMBL1641,,,ZINC000004097471
Hydrocortisone probutate,phase 4 complete,DB14543 (DBSALT000783),[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"11-Hydroxycorticosteroids / 17-Hydroxycorticosteroids / Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Moderately Potent (Group II) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Dermatologicals / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydrocortisone and derivatives / Hydroxycorticosteroids / Immunosuppressive Agents / Pregnanes / Pregnenediones / Pregnenes / Steroids",O6550D6K3A,72590-77-3,D01886,636398.0,552186.0,,,31675.0,CHEMBL1200953,,,ZINC000004213519
Hydrocortisone valerate,phase 4 complete,DB14544 (DBSALT000782),[H][C@@]12CC[C@](OC(=O)CCCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"11-Hydroxycorticosteroids / 17-Hydroxycorticosteroids / Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroids / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydrocortisone and derivatives / Hydroxycorticosteroids / Immunosuppressive Agents / Pregnanes / Pregnenediones / Pregnenes / Steroids",68717P8FUZ,57524-89-7,,5282494.0,4445635.0,,,50865.0,CHEMBL1200562,,,ZINC000004213520
Hydrocortisone succinate,phase 4 complete,DB14545,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"11-Hydroxycorticosteroids / 17-Hydroxycorticosteroids / Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroids / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Hydrocortisone and derivatives / Hydroxycorticosteroids / Immunosuppressive Agents / Pregnanes / Pregnenediones / Pregnenes / Steroids",IHV1VP592V,2203-97-6,D01442,,15760.0,50016931.0,21651.0,31677.0,CHEMBL977,,,ZINC000004097472
"Zinc sulfate, unspecified form",phase 4 complete,DB14548,,Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use / Copper Absorption Inhibitor / Metal cations / Metal divalent cations / Vasoprotectives / Zinc Compounds,89DS0H96TB,,,,,,,,,,,
Gallium chloride Ga-67,phase 4 complete,DB14550,[Cl-].[Cl-].[Cl-].[67Ga+3],,A04B19O2B0,,,,32699043.0,,314639.0,,,,,
Dotatate,phase 4 complete,DB14554,C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,Radioactive Diagnostic Agent,MRL3739G66,177943-88-3,,,9345959.0,50165166.0,1797118.0,,CHEMBL441920,,,
Brown iron oxide,phase 4 complete,DB14567,,,1N032N7MFO,52357-70-7,,,,,1306946.0,,,,,
Ivosidenib,phase 4 complete,DB14568,[H][C@@](N(C(=O)[C@]1([H])CCC(=O)N1C1=NC=CC(=C1)C#N)C1=CC(F)=CN=C1)(C(=O)NC1CC(F)(F)C1)C1=C(Cl)C=CC=C1,"Amino Acids / Amino Acids, Peptides, and Proteins / Antineoplastic Agents / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Enzyme Inhibitors / Moderate Risk QTc-Prolonging Agents / OAT3/SLC22A8 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / P-glycoprotein substrates with narrow therapeutic index / QTc Prolonging Agents",Q2PCN8MAM6,1448347-49-6,,,38772333.0,,2049873.0,145430.0,CHEMBL3989958,,,ZINC000205136523
Tedizolid,phase 4 complete,DB14569,CN1N=NC(=N1)C1=NC=C(C=C1)C1=C(F)C=C(C=C1)N1C[C@H](CO)OC1=O,Anti-Bacterial Agents / Anti-Infective Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Breast Cancer Resistance Protein Inhibitors / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / Oxazoles / Oxazolidinone Antibacterial,97HLQ82NGL,856866-72-3,D09685,,9409096.0,,1540825.0,82717.0,CHEMBL1257051,,,ZINC000043100956
Cobalt,phase 4 complete,DB14574,[Co],"Cell-mediated Immunity / Cobalt / Diet, Food, and Nutrition / Elements / Food / Food and Beverages / Growth Substances / Increased Histamine Release / Metals / Metals, Heavy / Micronutrients / Physiological Phenomena / Standardized Chemical Allergen / Trace Elements / Transition Elements",3G0H8C9362,7440-48-4,,,94547.0,,1310300.0,27638.0,,,,
Eslicarbazepine,phase 4 complete,DB14575,NC(=O)N1C2=C(C[C@H](O)C3=C1C=CC=C3)C=CC=C2,"Anticonvulsants / Carboxamide Derivatives / Cardiovascular Agents / Central Nervous System Depressants / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Eslicarbazepine and prodrugs / Heterocyclic Compounds, Fused-Ring / Membrane Transport Modulators / Nervous System / Sodium Channel Blockers / UGT1A1 Substrates / Voltage-Gated Sodium Channel Blockers",S5VXA428R4,104746-04-5,,,8057180.0,,1482502.0,,CHEMBL315985,,,ZINC000000896938
Segesterone acetate,phase 4 complete,DB14583,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],"Adrenal Cortex Hormones / Contraceptive Agents, Female / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drug Implants / Fused-Ring Compounds / Hormonal Contraceptives for Systemic Use / Intravaginal Contraceptives / Norpregnanes / Norpregnenes / Norsteroids / Reproductive Control Agents / Steroids",9AMX4Q13CC,7759-35-5,,,97161.0,,2055977.0,135563.0,CHEMBL3707377,,,ZINC000005167230
Citrus bioflavonoids,phase 4 complete,DB14586,,"Benzopyrans / Chromones / Flavonoids / Heterocyclic Compounds, Fused-Ring / Pyrans",BD70459I50,12002-36-7,,,,,314661.0,,,,,
Loteprednol etabonate,phase 4 complete,DB14596 (DBSALT000930),[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Adrenal Cortex Hormones / Androstadienes / Androstanes / Androstenes / Anti-Allergic Agents / Corticosteroids / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fused-Ring Compounds / Immunosuppressive Agents / Steroids,YEH1EZ96K6,82034-46-6,D01689,9865442.0,392049.0,,,31784.0,CHEMBL1200865,DAP001045,PA164764569,ZINC000003920673
Edetate calcium disodium anhydrousCommonly known or available as Edetate calcium disodium,phase 4 complete,DB14598 (DBSALT000837),[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,"Anticoagulants / Calcium Chelating Activity / Calcium Chelating Agents / Chelating Activity / Chelating Agents / Compounds used in a research, industrial, or household setting / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Iron Chelating Activity / Iron Chelating Agents / Lead Chelating Activity / Lead Chelator / Metal Chelating Activity / Metal Chelator",8U5D034955,62-33-9,,6109.0,5883.0,,,4757.0,CHEMBL1200375,,,
Edetate disodium anhydrousCommonly known or available as Edetate disodium,phase 4 complete,DB14600 (DBSALT000838),[Na+].[Na+].OC(=O)CN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O,Anticoagulants / Calcium Chelating Activity / Calcium Chelating Agents / Chelating Activity / Chelating Agents / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / Iron Chelating Agents / Lead Chelator / Metal Chelator,8NLQ36F6MM,139-33-3,D03945,8759.0,8429.0,,,64734.0,CHEMBL1749,,,
Oxyphenisatin acetate,phase 4 complete,DB14627 (DBSALT002242),CC(=O)OC1=CC=C(C=C1)C1(C(=O)NC2=CC=CC=C12)C1=CC=C(OC(C)=O)C=C1,"Gastrointestinal Agents / Heterocyclic Compounds, Fused-Ring / Indoles / Laxatives",U0Y1YAL65X,115-33-3,,,7971.0,,,135638.0,CHEMBL1402684,,,ZINC000003831258
Prednisolone phosphate,phase 4 complete,DB14631 (DBSALT002204),[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroids / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OAT3/SLC22A8 Substrates / P-glycoprotein inducers / P-glycoprotein substrates / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids",752SY38R6C,302-25-0,,,65064.0,,,145705.0,CHEMBL1201231,,,ZINC000004097473
Prednisolone tebutate,phase 4 complete,"DB14632 (DBSALT000786, DBSALT001635)",[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Fused-Ring Compounds / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids,1V7A1U282K,7681-14-3,D00982,93055.0,84007.0,,,8381.0,CHEMBL1200909,,,ZINC000004097474
Diloxanide furoate,phase 4 complete,DB14638 (DBSALT001813),CN(C(=O)C(Cl)Cl)C1=CC=C(OC(=O)C2=CC=CO2)C=C1,Amebicides / Anti-Infective Agents / Antiparasitic Agents / Antiprotozoals,YP4N72IW34,3736-81-0,D02480,,18400.0,70295.0,,4601.0,CHEMBL1334860,,,ZINC000000001300
Lypressin,phase 4 complete,DB14642 (DBSALT002465),[H]N([H])C(=O)C[C@]1([H])NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC1=O)C(=O)N1CCC[C@H]1C(=O)NC([H])(CCCCN)C(=O)NCC(N)=O,"Amino Acids, Peptides, and Proteins / Antidiuretic Agents / Cardiovascular Agents / Coagulants / Hematologic Agents / Hemostatics / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Natriuretic Agents / Nerve Tissue Proteins / Neuropeptides / Oligopeptides / Peptide Hormones / Peptides / Pituitary and Hypothalamic Hormones and Analogues / Pituitary Hormones / Pituitary Hormones, Posterior / Posterior Pituitary Lobe Hormones / Proteins / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Vasoconstrictor Agents / Vasopressin and Analogues / Vasopressins",7CZF3L922Y,50-57-7,,,559125.0,,,94802.0,CHEMBL1200690,,,
Methylprednisolone aceponate,phase 4 complete,DB14643 (DBSALT002468),[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroids / Corticosteroids, Dermatological Preparations / Corticosteroids, Potent (Group III) / Dermatologicals / Fused-Ring Compounds / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids",ET54W9J4U2,86401-95-8,,,56717.0,,,135762.0,CHEMBL1697782,,,ZINC000004213828
Methylprednisolone hemisuccinate,phase 4 complete,DB14644,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Central Nervous System Agents / Compounds used in a research, industrial, or household setting / Corticosteroids / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Neuroprotective Agents / Pregnadienes / Pregnadienetriols / Pregnanes / Protective Agents / Steroids",5GMR90S4KN,2921-57-5,,,16034.0,,,135765.0,CHEMBL1201265,,,ZINC000003977781
Prednisone acetate,phase 4 complete,DB14646 (DBSALT002337),[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Anti-Inflammatory Agents / Antineoplastic Agents / Antineoplastic Agents, Hormonal / Corticosteroids / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Pregnadienediols / Pregnadienes / Pregnanes / Steroids / Thyroxine-binding globulin inhibitors",OU93QEL83U,125-10-0,D08416,,82567.0,,,34655.0,CHEMBL1507567,,,ZINC000003881638
Dexamethasone acetate,phase 4 complete,DB14649 (DBSALT000383),[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Anti-Inflammatory Agents / BCRP/ABCG2 Inhibitors / BSEP/ABCB11 inducers / Cytochrome P-450 CYP2A6 Inducers / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2E1 Inducers / Cytochrome P-450 CYP2E1 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (moderate) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (moderate) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Inducers / Cytochrome P-450 CYP3A7 Inducers (strength unknown) / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Fused-Ring Compounds / OAT3/SLC22A8 Substrates / P-glycoprotein inducers / P-glycoprotein inhibitors / P-glycoprotein substrates / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids / Steroids, Fluorinated",K7V8P532WP,1177-87-3,D07796,236702.0,206624.0,50103620.0,,4463.0,CHEMBL1530428,,,ZINC000003882068
Menadiol diphosphate,phase 4 complete,DB14650 (DBSALT000878),CC1=C(OP(O)(O)=O)C2=CC=CC=C2C(OP(O)(O)=O)=C1,Diterpenes / Naphthalenes / Naphthoquinones / Phytol / Quinones / Terpenes,GRL65FEU3T,84-98-0,,8556.0,8238.0,,,134713.0,CHEMBL1201348,,,ZINC000001542933
Drostanolone propionate,phase 4 complete,DB14655 (DBSALT001342),[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C,Androstanes / Fused-Ring Compounds / Steroids / Testosterone and derivatives,X20UZ57G4O,521-12-0,D01534,,194604.0,,,31523.0,CHEMBL1201048,,PA164760855,ZINC000004213057
Chlorphenesin carbamate,phase 4 complete,DB14656 (DBSALT001343),NC(=O)OCC(O)COC1=CC=C(Cl)C=C1,Alcohols / Glycols / Propylene Glycols,57U5YI11WP,886-74-8,D00770,,2623.0,,,3643.0,CHEMBL607710,,,
Paramethasone acetate,phase 4 complete,DB14657 (DBSALT001420),[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Fused-Ring Compounds / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids / Steroids, Fluorinated",8X50N88ZDP,1597-82-6,D01229,,391984.0,,,31963.0,CHEMBL1200342,,,ZINC000004214095
Chloramphenicol palmitate,phase 4 complete,DB14658 (DBSALT001468),CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,Alcohols / Benzene Derivatives / Glycols / Nitro Compounds / Nitrobenzenes / Propylene Glycols,43VU4207NW,530-43-8,D01072,,391613.0,,,3605.0,CHEMBL1506,,,ZINC000008214521
Betamethasone phosphate,phase 4 complete,DB14669 (DBSALT002245),[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Adrenal Cortex Hormones / Corticosteroids / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / Glucocorticoids / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OAT3/SLC22A8 Substrates / P-glycoprotein inducers / P-glycoprotein substrates / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids / Steroids, Fluorinated",YJO1F9W10R,360-63-4,,,96937.0,,,68603.0,CHEMBL1201207,,,ZINC000004097469
Estramustine phosphate,phase 4 complete,DB14674 (DBSALT002563),[H][C@@]12CC[C@H](OP(O)(O)=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC(=O)N(CCCl)CCCl)C=C3,,MUZ9585Y7B,4891-15-0,,,227633.0,50333645.0,,68643.0,CHEMBL1756,,,ZINC000003938713
Gestonorone caproate,phase 4 complete,DB14677,[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],Fused-Ring Compounds / Norpregnanes / Norpregnenes / Norsteroids / Pregnanes / Pregnenediones / Pregnenes / Steroids,U38E620NS6,1253-28-7,,,391969.0,,4791.0,31650.0,CHEMBL2107389,,,ZINC000004216396
Calcium polycarbophil,phase 4 complete,DB14684 (DBSALT002736),,"Alimentary Tract and Metabolism / Antidiarrheals / Bulk-Forming Laxatives / Calcium Salts / Compounds used in a research, industrial, or household setting / Dental Materials / Drug Carriers / Drugs for Constipation / Gastrointestinal Agents / Laxatives / Macromolecular Substances / Phosphate Binder / Plastics / Polymers / Resins, Synthetic",8F049NKY49,126040-58-2,,,,,,,,,,
Sodium metavanadate,phase 4 complete,DB14702,[Na+].[O-][V](=O)=O,Vanadates,252S9L5606,13718-26-8,,,24427.0,,,75221.0,CHEMBL294467,,,
Dexamethasone metasulfobenzoate,phase 4 complete,DB14703,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=CC(=C3)S(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Fused-Ring Compounds / Pregnadienes / Pregnadienetriols / Pregnanes / Steroids / Steroids, Fluorinated",C67221CB9Q,16978-57-7,,,56740.0,,,,CHEMBL3305965,,,ZINC000004212887
Larotrectinib,phase 4 complete,DB14723,O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1,Antineoplastic Agents / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / P-glycoprotein substrates / Tyrosine Kinase Inhibitors,PF9462I9HX,1223403-58-4,,,44210503.0,136597.0,2105628.0,,CHEMBL3889654,,,ZINC000118399834
Cefamandole nafate,phase 4 complete,DB14725,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](OC=O)C1=CC=CC=C1)C(O)=O,"Amides / Anti-Bacterial Agents / Anti-Infective Agents / beta-Lactams / Cephalosporins / Heterocyclic Compounds, Fused-Ring / Lactams / Sulfur Compounds / Thiazines",,57268-80-1,,,4447585.0,,20473.0,53654.0,CHEMBL1201218,,,ZINC000003830397
Racephedrine,phase 4 complete,DB14752,,Adrenergic Agonists / Alpha-and Beta-adrenergic Agonists / Herbs and Natural Products / Sympathomimetic (Adrenergic) Agents,03VRY66076,90-81-3,,,,,,,,,,
Hydroxystilbamidine,phase 4 complete,DB14753,NC(=N)C1=CC=C(\C=C\C2=C(O)C=C(C=C2)C(N)=N)C=C1,Amidines / Benzene Derivatives / Benzylidene Compounds / Stilbenes,39J262E49W,495-99-8,,,10612853.0,,,,CHEMBL1301,,PA164745514,ZINC000000001547
Cycloguanil,phase 4 complete,DB14763,CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1,"Amidines / Anti-Infective Agents / Antimalarials / Antiparasitic Agents / Antiparasitic Products, Insecticides and Repellents / Antiprotozoals / Biguanides / Enzyme Inhibitors / Folic Acid Antagonists / Guanidines",26RM326WVN,516-21-2,,,8697.0,18792.0,,135029.0,CHEMBL747,,,ZINC000000001233
Diroximel fumarate,phase 4 complete,DB14783,COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O,Fumarates / Hepatotoxic Agents,K0N0Z40J3W,1577222-14-0,,,57423290.0,,2261783.0,,CHEMBL3989944,,,ZINC000215286156
Ripretinib,phase 4 complete,DB14840,CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1,BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP2E1 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / MATE 1 Inhibitors / MATE inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors,9XW757O13D,1442472-39-0,,,67886378.0,,2369389.0,,CHEMBL4216467,,,
Cefiderocol,phase 4 complete,DB14879,[H][C@]12SCC(C[N+]3(CCNC(=O)C4=C(Cl)C(O)=C(O)C=C4)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O,"Amides / Anti-Bacterial Agents / beta-Lactams / Cephalosporins / Drugs that are Mainly Renally Excreted / Heterocyclic Compounds, Fused-Ring / Lactams / Sulfur Compounds",SZ34OMG6E8,1225208-94-5,,,52084902.0,,2265702.0,,CHEMBL3989974,,,
Flortaucipir F-18,phase 4 complete,DB14914,[18F]C1=CC=C(C=N1)C1=CC=C2C(NC3=C2C=NC=C3)=C1,"Compounds used in a research, industrial, or household setting / Contrast Media / Diagnostic Uses of Chemicals / Heterocyclic Compounds, Fused-Ring / Indoles / Pyridines",T1JP1KYU9O,1522051-90-6,,,32701063.0,,,,CHEMBL3545253,,,
Voxelotor,phase 4 complete,DB14975,CC(C)N1N=CC=C1C1=C(COC2=CC=CC(O)=C2C=O)C=CC=N1,Aldehydes / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Hematologic Agents,3ZO554A4Q8,1446321-46-5,,,37999268.0,50235297.0,2265678.0,,CHEMBL4101807,,,ZINC000145969085
Zanubrutinib,phase 4 complete,DB15035,NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1,Antineoplastic Agents / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Enzyme Inhibitors / Hematologic Agents / Narrow Therapeutic Index Drugs / P-glycoprotein substrates / Protein Kinase Inhibitors / Teratogens,AG9MHG098Z,1691249-45-2,,,64835237.0,250082.0,2262435.0,,CHEMBL3936761,,,ZINC000584641430
Upadacitinib,phase 4 complete,DB15091,CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F,"Antirheumatic Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Disease-modifying Antirheumatic Agents / Enzyme Inhibitors / Heterocyclic Compounds, Fused-Ring / Janus Kinase Inhibitors / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Protein Kinase Inhibitors",4RA0KN46E0,1310726-60-3,,,44210449.0,,2196092.0,,CHEMBL3622821,,,
Pemigatinib,phase 4 complete,DB15102,CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F,"Antineoplastic Agents / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fibroblast Growth Factor 2, antagonists & inhibitors / Kinase Inhibitor / MATE 1 Inhibitors / MATE inhibitors / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors / Receptors, Fibroblast Growth Factor, antagonists & inhibitors",Y6BX7BL23K,1513857-77-6,,,68007304.0,301310.0,2359268.0,,CHEMBL4297522,,,
Avapritinib,phase 4 complete,DB15233,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1,Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Protein Kinase Inhibitors,513P80B4YJ,1703793-34-3,,,58828673.0,,2272107.0,,CHEMBL4204794,,,
Ubrogepant,phase 4 complete,DB15328,C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC2=NC=CC=C42)C(=O)N1CC(F)(F)F)C1=CC=CC=C1,Antimigraine Preparations / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 Inhibitors (weak) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (weak) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (weak) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / OATP1B3 substrates / OCT2 Inhibitors / P-glycoprotein substrates / UGT1A1 Inhibitors,AD0O8X2QJR,1374248-77-7,,,28536135.0,,2268216.0,,CHEMBL2364638,,,ZINC000095598454
Elexacaftor,phase 4 complete,DB15444,C[C@@H]1CN(C2=NC(=CC=C2C(=O)NS(=O)(=O)C2=CN(C)N=C2C)N2C=CC(OCC(C)(C)C(F)(F)F)=N2)C(C)(C)C1,Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Membrane Transport Modulators / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates,RRN67GMB0V,2216712-66-0,,,75531299.0,,2256951.0,,CHEMBL4298128,,,
Benzhydrocodone,phase 4 complete,DB15465,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC=C2OC(=O)C1=CC=CC=C1,Opioids,75MS0AAZ9I,1259440-61-3,,,34222482.0,,2001352.0,,CHEMBL3137321,,,ZINC000103297957
Cinoxate,phase 4 complete,DB15467,CCOCCOC(=O)\C=C\C1=CC=C(OC)C=C1,"Acids, Carbocyclic / Sunscreen Agents",5437O7N5BH,104-28-9,,,4523729.0,,288262.0,,CHEMBL2104045,,,ZINC000002041136
Alloin,phase 4 complete,DB15477,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(CO)C=C2O,Anthracenes / Anthraquinones / Biological Products / Cascara / Complex Mixtures / Gastrointestinal Agents / Laxatives / Pharmaceutical Preparations / Plant Extracts / Plant Preparations / Quinones,W41H6S09F4,8015-61-0,,,8042387.0,50269016.0,17354.0,73222.0,CHEMBL497001,,,
Zirconium chloride hydroxide,phase 4 complete,DB15479,O[Zr]Cl,,R7EF6G80G1,10119-31-0,,,13432518.0,,,,,,,
Resorcinol monoacetate,phase 4 complete,DB15480,CC(=O)OC1=CC(O)=CC=C1,Benzene Derivatives / Phenols,YL6O37RD1S,102-29-4,,,4879.0,,2106739.0,29672.0,CHEMBL1593874,,,ZINC000000002029
Edotreotide gallium Ga-68,phase 4 complete,DB15494,[68Ga+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1,Diagnostic Radiopharmaceuticals / Gallium Radioisotopes / Radiopharmaceuticals / Tumour Detection,Y68179SY2L,,,,52083916.0,,2199391.0,,,,,
Colchiceine,phase 4 complete,DB15534,COC1=C(OC)C(OC)=C2C(CCC(NC(C)=O)C3=CC(=O)C(O)=CC=C23)=C1,Alkaloids / Colchicine Derivatives / Tubulin Inhibiting Agent,HJ30158L57,477-27-0,,,9750.0,66784.0,2174385.0,,CHEMBL323668,,,
Prednisolone acetate,phase 4 complete,DB15566 (DBSALT000254),[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Adrenal Cortex Hormones / Anti-Inflammatory Agents / Corticosteroids / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Fused-Ring Compounds / P-glycoprotein substrates / Pregnadienes / Pregnadienetriols / Pregnanes / Prodrugs / Steroids,8B2807733D,52-21-1,,5834.0,5629.0,,,8380.0,CHEMBL1152,,,ZINC000003875348
Ethyl salicylate,phase 4 complete,DB15576,CCOC(=O)C1=CC=CC=C1O,"Acids, Carbocyclic / Benzene Derivatives / Benzoates / Hydroxy Acids / Hydroxybenzoates / Phenols",555U6TZ2MV,118-61-6,,,21105897.0,,1546423.0,88839.0,CHEMBL2251610,,,ZINC000000157490
Brilliant blue G,phase 4 complete,DB15594,[Na+].CCOC1=CC=C(NC2=CC=C(C=C2)C(=C2\C=C/C(/C=C2C)=[N+](/CC)CC2=CC(=CC=C2)S([O-])(=O)=O)\C2=C(C)C=C(C=C2)N(CC)CC2=CC(=CC=C2)S([O-])(=O)=O)C=C1,"Amines / Aniline Compounds / Compounds used in a research, industrial, or household setting / Indicators and Reagents / Laboratory Chemicals",M1ZRX790SI,6104-58-1,,,4884338.0,,1998867.0,,CHEMBL4173394,,,
Ferric maltol,phase 4 complete,DB15598,[Fe+3].CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1,"Antianemic Preparations / Blood and Blood Forming Organs / Hematinics / Hematologic Agents / Iron Compounds / Iron Preparations / Iron Trivalent, Oral Preparations / Organometallic Compounds / Pyrans / UGT1A6 substrate",MA10QYF1Z0,33725-54-1,,,148265.0,,,,,,,
Ferric derisomaltose,phase 4 complete,DB15617,[Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,"Anemia, Iron-Deficiency / Antianemia Drugs / Antianemic Preparations / Iron Compounds / Parenteral Iron Replacement",AHU547PI9H,1345510-43-1,,,,,2274394.0,,,,,
Calcium undecylenate,phase 4 complete,DB15678,[Ca++].[O-]C(=O)CCCCCCCCC=C.[O-]C(=O)CCCCCCCCC=C,,77YW1RTU8V,1322-14-1,,,14175.0,,89746.0,,CHEMBL2104130,,,
Aluminum subacetate,phase 4 complete,DB15679,CC(=O)O[Al](O)OC(C)=O,Astringents,FGL8577C9S,142-03-0,,,8373332.0,,235461.0,,CHEMBL1532734,,,
Selpercatinib,phase 4 complete,DB15685,COC1=NC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(OCC(C)(C)O)=CN3N=CC(C#N)=C23)C=C1,Agents that produce hypertension / Antineoplastic Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hepatotoxic Agents / MATE 1 Inhibitors / MATE inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / QTc Prolonging Agents / Tyrosine Kinase Inhibitors,CEGM9YBNGD,2152628-33-4,,,72379991.0,,2370147.0,,,,,
Fluoroestradiol F-18,phase 4 complete,DB15690,[H][C@@]12C[C@@H]([18F])[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,"Estradiol Congeners / Estranes / Estrogens / Estrogens, agonists / Fluorine Radioisotopes / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Steroids",T32277KB09,94153-53-4,,,9045262.0,,2372221.0,,,,,ZINC000100657549
